	ARTICLE	ARTICLE DATE	SENTENCE NUM	SENTENCE	IGNORANCE CATEGORIES	NUM IGNORANCE CATEGORIES	OBO ID (LABEL)
S52-BMJ_2008_Nov_7_337_a2001	BMJ_2008_Nov_7_337_a2001	11/2008	S52-BMJ_2008_Nov_7_337_a2001	['the multiple Micronutrient supplements were formulated to contain approximately the who/unicef RECOMMENDED dietary allowances for each of 15 Minerals or Vitamins as follows: 30 mg iron, 400 µg Folate, 15.0 mg zinc, 2.0 mg copper, 65.0 µg Selenium, 150.0 µg Iodine, 800.0 µg Vitamin A, 1.4 mg Vitamin B-1 (Thiamine), 1.4 mg Vitamin B-2 (riboflavin), 1.9 mg Vitamin B-6, 2.6 µg Vitamin B-12, 5.0 µg Vitamin D, 70.0 mg Vitamin C, 10.0 mg Vitamin E, and 18.0 mg niacin.12iron-Folic Acid supplements contained 60 mg iron (twice the amount of elemental iron in the multiple Micronutrients) and 400 µg Folic Acid.']	[('FUTURE_WORK', 95)]	1	[('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 13, 'micronutrient'), ('CHEBI_46751', 'quinolizidine', 141, 'minerals'), ('CHEBI_33277', 'gamma-tocotrienol', 153, 'vitamins'), ('CHEBI_30863', '5-azaorotic acid', 193, 'folate'), ('CHEBI_27568', 'selenium atom', 238, 'selenium'), ('CHEBI_24859', 'iodine atom', 257, 'iodine'), ('CHEBI_27300', 'vitamin D', 274, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 282, 'A'), ('CHEBI_27300', 'vitamin D', 292, 'vitamin B'), ('PR_000004480', 'V-type proton ATPase catalytic subunit A', 292, 'vitamin B-1'), ('CHEBI_26948', 'vitamin B1', 305, 'thiamine'), ('CHEBI_27300', 'vitamin D', 323, 'vitamin B'), ('PR_000000037', 'BMP receptor type-2', 331, 'B'), ('PR_000010222', 'muscleblind-like protein 2', 333, '2'), ('CHEBI_27300', 'vitamin D', 356, 'vitamin B'), ('CHEBI_27300', 'vitamin D', 376, 'vitamin B'), ('PR_000000037', 'BMP receptor type-2', 384, 'B'), ('CHEBI_37983', 'sulfur-35 atom', 386, '12'), ('CHEBI_27300', 'vitamin D', 397, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 416, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 435, 'vitamin E'), ('CHEBI_30751', 'formic acid', 472, 'folic acid'), ('CHEBI_33839', 'macromolecule', 568, 'micronutrients'), ('CHEBI_30751', 'formic acid', 595, 'folic acid')]
S180-BMJ_2008_Nov_7_337_a2001	BMJ_2008_Nov_7_337_a2001	11/2008	S180-BMJ_2008_Nov_7_337_a2001	['the Vitamin C in the multiple Micronutrient supplements MIGHT have enhanced the absorption of iron and also CONTRIBUTED TO reducing the difference in the absolute amount of iron absorbed.']	[('INCOMPLETE_EVIDENCE', 56), ('SUPERFICIAL_RELATIONSHIP', 108)]	2	[('CHEBI_27300', 'vitamin D', 4, 'vitamin C'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 30, 'micronutrient')]
S18-BMJ_2010_Apr_29_340_c1640	BMJ_2010_Apr_29_340_c1640	4/2010	S18-BMJ_2010_Apr_29_340_c1640	['this EVIDENCE comes from both case-control and cohort studies and INDICATES that age of operation for such a PROTECTIVE EFFECT MIGHT include both childhood and early Adulthood.67891011\nexposure to ultraviolet radiation in early Life has NOT YET been formally examined but MIGHT be LINKED to excess risk of multiple sclerosis at Birth through seasonal deficiency in maternal Vitamin D concentrations.12A study of half siblings with multiple sclerosis has ALSO SHOWN that risk CAN be maternally MEDIATED.13pregnancy is a vulnerable time for Vitamin d deficiency BECAUSE of increased physiological needs and reduced maternal outdoor activity.14experimental data on Animal Fetal Development INDICATE that Cerebral White Matter is responsive to Vitamin D and that Oligodendrocytes in the Brain and Spinal Cord have Vitamin D Receptors.1516furthermore, maternal Vitamin D depletion alters Neurogenesis in the developing Rat Brain,17with subsequent altered Gene Expression in Adult Life.18a RECENT Genetic STUDY in Humans has FURTHER IMPLICATED Vitamin D as a strong environmental CANDIDATE by SHOWING direct functional INTERACTION with the major locus that determines susceptibility to multiple sclerosis.19ALTHOUGH Human EVIDENCE pertaining to fetal development HAS BEEN DIFFICULT to obtain, the body of RELATED EVIDENCE to date has led SOME to RECOMMEND Antenatal supplementation with Vitamin D to prevent multiple sclerosis.14\nAS an indicator of POSSIBLE Perinatal environmental exposures, such as ultraviolet radiation, individual studies in the northern hemisphere have examined month of Birth and risk of multiple sclerosis with VARIED results.2021222324a large RECENT pooled analysis of Births in the northern hemisphere, HOWEVER, SHOWED an excess of multiple sclerosis among People Born in may and a relative deficit among those Born in november; these results were stronger in familial cases and SUGGESTED INTERACTIONS between Genes and environment that are RELATED to climate and that MIGHT act during Gestation or shortly after Birth.12we EXAMINED month of Birth and risk of multiple sclerosis in australia.']	[('INCOMPLETE_EVIDENCE', 5), ('INCOMPLETE_EVIDENCE', 66), ('SUPERFICIAL_RELATIONSHIP', 109), ('SUPERFICIAL_RELATIONSHIP', 120), ('INCOMPLETE_EVIDENCE', 127), ('FULL_UNKNOWN', 237), ('INCOMPLETE_EVIDENCE', 272), ('SUPERFICIAL_RELATIONSHIP', 281), ('INCOMPLETE_EVIDENCE', 399), ('INCOMPLETE_EVIDENCE', 454), ('INCOMPLETE_EVIDENCE', 475), ('SUPERFICIAL_RELATIONSHIP', 493), ('PROBABLE_UNDERSTANDING', 560), ('INCOMPLETE_EVIDENCE', 687), ('INCOMPLETE_EVIDENCE', 984), ('INCOMPLETE_EVIDENCE', 1019), ('SUPERFICIAL_RELATIONSHIP', 1027), ('INCOMPLETE_EVIDENCE', 1074), ('INCOMPLETE_EVIDENCE', 1087), ('SUPERFICIAL_RELATIONSHIP', 1113), ('ANOMALY_CURIOUS_FINDING', 1199), ('ANOMALY_CURIOUS_FINDING', 1199), ('INCOMPLETE_EVIDENCE', 1216), ('INCOMPLETE_EVIDENCE', 1257), ('DIFFICULT_TASK', 1266), ('INCOMPLETE_EVIDENCE', 1299), ('SUPERFICIAL_RELATIONSHIP', 1299), ('INCOMPLETE_EVIDENCE', 1332), ('FUTURE_WORK', 1340), ('PROBABLE_UNDERSTANDING', 1424), ('INCOMPLETE_EVIDENCE', 1443), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1629), ('INCOMPLETE_EVIDENCE', 1662), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1723), ('INCOMPLETE_EVIDENCE', 1732), ('INCOMPLETE_EVIDENCE', 1899), ('SUPERFICIAL_RELATIONSHIP', 1909), ('SUPERFICIAL_RELATIONSHIP', 1961), ('INCOMPLETE_EVIDENCE', 1989), ('QUESTION_ANSWERED_BY_THIS_WORK', 2044)]	40	[('UBERON_0000113', 'post-juvenile adult stage', 166, 'adulthood'), ('UBERON_0000104', 'life cycle', 228, 'life'), ('GO_0007567', 'parturition', 328, 'birth'), ('CHEBI_27300', 'vitamin D', 374, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 539, 'vitamin'), ('NCBITaxon_33208', 'Metazoa', 662, 'animal'), ('GO_0002065', 'columnar/cuboidal epithelial cell differentiation', 669, 'fetal development'), ('UBERON_0002437', 'cerebral hemisphere white matter', 701, 'cerebral white matter'), ('CHEBI_27300', 'vitamin D', 740, 'vitamin D'), ('CL_0000128', 'oligodendrocyte', 759, 'oligodendrocytes'), ('UBERON_0000955', 'brain', 783, 'brain'), ('UBERON_0002240', 'spinal cord', 793, 'spinal cord'), ('CHEBI_27300', 'vitamin D', 810, 'vitamin D'), ('PR_000001708', 'sphingosine 1-phosphate receptor 3', 810, 'vitamin D receptors'), ('CHEBI_27300', 'vitamin D', 856, 'vitamin D'), ('GO_0022008', 'neurogenesis', 883, 'neurogenesis'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 914, 'rat'), ('UBERON_0000955', 'brain', 918, 'brain'), ('GO_0010467', 'gene expression', 950, 'gene expression'), ('SO_0000704', 'gene', 950, 'gene'), ('UBERON_0000113', 'post-juvenile adult stage', 969, 'adult life'), ('SO_0000704', 'gene', 991, 'genetic'), ('NCBITaxon_9606', 'Homo sapiens', 1008, 'humans'), ('CHEBI_27300', 'vitamin D', 1038, 'vitamin D'), ('NCBITaxon_9606', 'Homo sapiens', 1210, 'human'), ('GO_0007567', 'parturition', 1350, 'antenatal'), ('CHEBI_27300', 'vitamin D', 1381, 'vitamin D'), ('GO_0036268', 'swimming', 1452, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 1452, 'perinatal'), ('GO_0007567', 'parturition', 1587, 'birth'), ('GO_0007567', 'parturition', 1688, 'births'), ('NCBITaxon_10088', 'Mus <genus>', 1777, 'people'), ('GO_0007567', 'parturition', 1784, 'born'), ('GO_0007567', 'parturition', 1831, 'born'), ('SO_0000704', 'gene', 1930, 'genes'), ('GO_0007565', 'female pregnancy', 2006, 'gestation'), ('GO_0007567', 'parturition', 2033, 'birth'), ('GO_0007567', 'parturition', 2062, 'birth')]
S96-BMJ_2010_Apr_29_340_c1640	BMJ_2010_Apr_29_340_c1640	4/2010	S96-BMJ_2010_Apr_29_340_c1640	['by the time of Delivery, maternal and infant Cord Serum 25-Hydroxyvitamin d3concentrations are highly CORRELATED.37UNFORTUNATELY, much REMAINS UNKNOWN, leading to large international variations in maternal Vitamin D monitoring and supplementation during Pregnancy.353839\na maternal EFFECT operating Antenatally would also be CONSISTENT with the stronger maternal than paternal “parent of origin” EFFECT in familial multiple sclerosis.1340it HAS BEEN PREVIOUSLY PROPOSED14THAT maternal Vitamin D deficiency, a PROBLEM for SOME dark skinned women migrating to regions with low ambient ultraviolet radiation, such as the uk, MIGHT EXPLAIN the increase in incidence of disease SEEN among second generation migrants in such locations.41our FINDINGS are CONSISTENT with this EXPLANATION.']	[('SUPERFICIAL_RELATIONSHIP', 102), ('ANOMALY_CURIOUS_FINDING', 113), ('ANOMALY_CURIOUS_FINDING', 113), ('FULL_UNKNOWN', 135), ('SUPERFICIAL_RELATIONSHIP', 282), ('INCOMPLETE_EVIDENCE', 325), ('SUPERFICIAL_RELATIONSHIP', 396), ('INCOMPLETE_EVIDENCE', 441), ('INCOMPLETE_EVIDENCE', 450), ('INCOMPLETE_EVIDENCE', 461), ('IMPORTANT_CONSIDERATION', 509), ('INCOMPLETE_EVIDENCE', 521), ('INCOMPLETE_EVIDENCE', 622), ('PROBABLE_UNDERSTANDING', 628), ('INCOMPLETE_EVIDENCE', 673), ('INCOMPLETE_EVIDENCE', 735), ('INCOMPLETE_EVIDENCE', 748), ('PROBABLE_UNDERSTANDING', 769)]	18	[('GO_0007567', 'parturition', 15, 'delivery'), ('UBERON_0002240', 'spinal cord', 45, 'cord'), ('UBERON_0001977', 'blood serum', 50, 'serum'), ('CHEBI_67376', 'dihydrooroxylin A', 56, '25-hydroxyvitamin'), ('CHEBI_27300', 'vitamin D', 206, 'vitamin D'), ('GO_0007565', 'female pregnancy', 254, 'pregnancy'), ('GO_0007288', 'sperm axoneme assembly', 299, 'antenatally'), ('CHEBI_27300', 'vitamin D', 485, 'vitamin D')]
S103-BMJ_2010_Apr_29_340_c1640	BMJ_2010_Apr_29_340_c1640	4/2010	S103-BMJ_2010_Apr_29_340_c1640	['overall, epidemiological studies SUPPORT a PROTECTIVE ROLE for Vitamin D in Autoimmune disease, PARTICULARLY in childhood and Adolescence, and Vitamin D supplementation in early Adulthood EFFECTIVELY reduces the risk of multiple sclerosis; THEREFORE, supplementation of adolescents and young Adults COULD BE effectively used for PREVENTION.6the FINDINGS HERE provide the FIRST population BASED evidence beyond month of Birth PATTERNS to INDICATE that Vitamin D supplementation for the PREVENTION of multiple sclerosis MIGHT also NEED to be CONSIDERED during in utero development.14they are CONSISTENT with a multi-hit causal cascade for multiple sclerosis, with PUTATIVE adverse environmental FACTORS, such as low Vitamin D concentrations, acting at more than one stage of Life.53\n\nwhat is already known on this topic\nin the northern hemisphere, there are more cases of multiple sclerosis in People Born in may and fewer in those Born in november\nmaternal exposure to ambient ultraviolet radiation in Pregnancy can be used as an instrumental variable for Vitamin D status during Pregnancy\nlow Vitamin D concentrations HAVE BEEN ASSOCIATED with a higher risk of multiple sclerosis\n\nwhat THIS STUDY adds\nin australia there is a reciprocal PATTERN of month of Birth and risk of multiple sclerosis, with a higher risk for those Born in november-december compared with may-june\nthis PATTERN was accounted FOR by maternal exposure to ambient ultraviolet radiation in the first trimester\nlow maternal exposure to Ultraviolet Radiation in the first trimester was inversely RELATED to risk of multiple sclerosis in the offspring after adjustment for either month of Birth or place of Birth\n\npubmed central:']	[('INCOMPLETE_EVIDENCE', 33), ('SUPERFICIAL_RELATIONSHIP', 43), ('SUPERFICIAL_RELATIONSHIP', 54), ('IMPORTANT_CONSIDERATION', 96), ('IMPORTANT_CONSIDERATION', 188), ('PROBABLE_UNDERSTANDING', 240), ('INCOMPLETE_EVIDENCE', 299), ('SUPERFICIAL_RELATIONSHIP', 329), ('INCOMPLETE_EVIDENCE', 345), ('QUESTION_ANSWERED_BY_THIS_WORK', 354), ('INCOMPLETE_EVIDENCE', 371), ('QUESTION_ANSWERED_BY_THIS_WORK', 388), ('SUPERFICIAL_RELATIONSHIP', 425), ('INCOMPLETE_EVIDENCE', 437), ('SUPERFICIAL_RELATIONSHIP', 485), ('INCOMPLETE_EVIDENCE', 518), ('FUTURE_WORK', 529), ('IMPORTANT_CONSIDERATION', 529), ('FUTURE_WORK', 540), ('IMPORTANT_CONSIDERATION', 540), ('INCOMPLETE_EVIDENCE', 590), ('SUPERFICIAL_RELATIONSHIP', 590), ('PROBABLE_UNDERSTANDING', 662), ('SUPERFICIAL_RELATIONSHIP', 693), ('INCOMPLETE_EVIDENCE', 1118), ('SUPERFICIAL_RELATIONSHIP', 1128), ('QUESTION_ANSWERED_BY_THIS_WORK', 1186), ('SUPERFICIAL_RELATIONSHIP', 1237), ('SUPERFICIAL_RELATIONSHIP', 1378), ('QUESTION_ANSWERED_BY_THIS_WORK', 1400), ('SUPERFICIAL_RELATIONSHIP', 1565)]	31	[('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('UBERON_0001442', 'skeleton of manus', 76, 'autoimmune'), ('GO_0048848', 'neurohypophysis morphogenesis', 126, 'adolescence'), ('CHEBI_27300', 'vitamin D', 143, 'vitamin D'), ('UBERON_0000113', 'post-juvenile adult stage', 178, 'adulthood'), ('UBERON_0007023', 'adult organism', 292, 'adults'), ('GO_0007567', 'parturition', 419, 'birth'), ('CHEBI_27300', 'vitamin D', 451, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 714, 'vitamin D'), ('UBERON_0000104', 'life cycle', 773, 'life'), ('NCBITaxon_10088', 'Mus <genus>', 892, 'people'), ('GO_0007567', 'parturition', 899, 'born'), ('GO_0007567', 'parturition', 930, 'born'), ('GO_0007565', 'female pregnancy', 1001, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 1055, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1079, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 1093, 'vitamin D'), ('GO_0007567', 'parturition', 1257, 'birth'), ('GO_0007567', 'parturition', 1324, 'born'), ('CHEBI_52927', 'To-Pro-1(2+)', 1506, 'ultraviolet radiation'), ('GO_0007567', 'parturition', 1657, 'birth'), ('GO_0007567', 'parturition', 1675, 'birth')]
S34-PMC1481554	PMC1481554	4/2006	S34-PMC1481554	['d (Cholecalciferol)ε250 iu250 iu5 μg* Calcium 300 mg250 mg1000–1300 mg* Biotin 030 μg- chromium 025 μg29–30 μg* manganese 05 mg2 mg* Molybdenum 025 μg50 μg Selenium 025 μg60 μg pill size smalllarge\n* adequate intake\n** applies only to pregvit®\nψvit a – 1 international unit (iu) of Retinol is equivalent to 0.3 μg Retinol (750 μg of Retinol is 2,500 iu of Retinol)\n2 μg of supplemental β-Carotene is equivalent to 1 μg Retinol3 (page 92 & 565)\nξvit e – 1 international unite (iu) is equivalent to 0.67 μg of Α-Tocopherol (15 mg is equivalent to 22,388 iu)\nHOWEVER, DIFFERENT conversion factors are used for DIFFERENT forms of Vitamin E\nε vit d – 1 iu is equivalent to 0.025 μg of Cholecalciferol (5 μg is equivalent to 200 iu)\n*** please note : since the completion of this study a new formulation of materna was introduced containing 27 mg of elemental iron.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 556), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 565), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 607)]	3	[('CHEBI_52550', 'theopalauamide', 3, 'cholecalciferol'), ('CHEBI_31341', 'calcium dihydroxide', 38, 'Calcium'), ('CHEBI_15956', 'biotin', 72, 'Biotin'), ('UBERON_0002150', 'superior cerebellar peduncle', 133, 'Molybdenum'), ('CHEBI_27568', 'selenium atom', 156, 'Selenium'), ('CHEBI_26536', 'retinoic acid', 282, 'retinol'), ('CHEBI_26536', 'retinoic acid', 314, 'retinol'), ('CHEBI_26536', 'retinoic acid', 333, 'retinol'), ('CHEBI_26536', 'retinoic acid', 356, 'retinol'), ('CHEBI_23042', 'carotene', 388, 'carotene'), ('CHEBI_69514', 'rubinaphthin A methyl ester', 419, 'retinol3'), ('CHEBI_27725', 'butin', 508, 'α-tocopherol'), ('CHEBI_27300', 'vitamin D', 626, 'vitamin E'), ('CHEBI_52550', 'theopalauamide', 680, 'cholecalciferol')]
S9-PMC1533075	PMC1533075	6/1998	S9-PMC1533075	['mothers also took individual Micronutrient supplements (e.g., Vitamin C tablets), but most mothers who took these also took multivitamins, making it IMPOSSIBLE to determine POTENTIAL independent EFFECTS of these Micronutrients.']	[('DIFFICULT_TASK', 149), ('INCOMPLETE_EVIDENCE', 173), ('SUPERFICIAL_RELATIONSHIP', 195)]	3	[('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 29, 'micronutrient'), ('CHEBI_27300', 'vitamin D', 62, 'vitamin C'), ('PR_000004900', 'complement C3', 70, 'C'), ('CHEBI_33839', 'macromolecule', 212, 'micronutrients')]
S40-PMC1544352	PMC1544352	6/2006	S40-PMC1544352	['(2001), usa [19]survey, self completed questionnaire150 women in 1stto 3rdtrimesters (24% response rate)13% used Dietary Supplement during Pregnancy45 herbs used, most common: echinacea, Pregnancy tea**, ginger, Vitamin B6*, Vitamin C*, multivitamin with herbs, raspberry leaf studies specifically CONCERNED with nausea hollyer et al.']	[('IMPORTANT_CONSIDERATION', 298)]	1	[('CHEBI_23888', 'drug', 113, 'dietary'), ('CHEBI_16158', 'steroid sulfate', 121, 'supplement'), ('GO_0007565', 'female pregnancy', 139, 'pregnancy45'), ('GO_0007565', 'female pregnancy', 187, 'pregnancy'), ('CHEBI_33237', 'vitamin D4', 212, 'vitamin B6'), ('CHEBI_27300', 'vitamin D', 225, 'vitamin C')]
S46-PMC1888711	PMC1888711	5/2007	S46-PMC1888711	"['beneficial EFFECTS on Birth weight and the risk of Postpartum endometritis were SEEN for high-risk women"" [22].moderatedietary Vitamin A deficiencyvitamin a supplementation""further EVIDENCE on biologically PLAUSIBLE mechanisms of morbidity reduction such as reduced incidence of sepsis and/or reduced MARKERS of inflammation ARE NEEDED"" [60].lowdietary Micronutrient deficienciesmultiple Micronutrient supplementationone trial in tanzania showed no additional effect on markers of infection (C-Reactive Protein) compared with Iron and Folic Acid [15].lowanemia p. falciparum infectionanti-malarial Drugs""Drugs given routinely for malaria during Pregnancy reduce SEVERE Antenatal anaemia in the mother, and are ASSOCIATED with higher Birth weight in the baby and PROBABLY fewer Perinatal deaths.']"	[('SUPERFICIAL_RELATIONSHIP', 11), ('INCOMPLETE_EVIDENCE', 80), ('INCOMPLETE_EVIDENCE', 181), ('INCOMPLETE_EVIDENCE', 206), ('SUPERFICIAL_RELATIONSHIP', 301), ('FUTURE_WORK', 325), ('IMPORTANT_CONSIDERATION', 662), ('SUPERFICIAL_RELATIONSHIP', 710), ('PROBABLE_UNDERSTANDING', 762)]	9	[('GO_0007567', 'parturition', 22, 'birth'), ('GO_0007565', 'female pregnancy', 51, 'postpartum'), ('CHEBI_27300', 'vitamin D', 127, 'vitamin A'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 353, 'micronutrient'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 388, 'micronutrient'), ('PR_000005890', 'crooked neck-like protein 1', 492, 'C-reactive protein'), ('CHEBI_24870', 'ion', 526, 'iron'), ('CHEBI_30751', 'formic acid', 535, 'folic acid'), ('CHEBI_23888', 'drug', 598, 'drugs'), ('CHEBI_23888', 'drug', 604, 'Drugs'), ('GO_0007565', 'female pregnancy', 645, 'pregnancy'), ('GO_0007567', 'parturition', 669, 'antenatal'), ('GO_0007567', 'parturition', 733, 'birth'), ('GO_0036268', 'swimming', 777, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 777, 'perinatal')]
S48-PMC1888711	PMC1888711	5/2007	S48-PMC1888711	"['routine daily or weekly Antenatal iron or iron plus Folic Acid supplementation MAY BE of benefit, especially where pre-Gestational iron deficiency and anaemia are prevalent"" [26].moderatedietary Vitamin A deficiencyvitamin A supplementation""FURTHER EVIDENCE on the effectiveness of adding Vitamin A to Iron and Folic Acid for treatment of anaemia IS NEEDED"" [60].']"	[('INCOMPLETE_EVIDENCE', 79), ('INCOMPLETE_EVIDENCE', 241), ('FUTURE_WORK', 347)]	3	[('GO_0007567', 'parturition', 24, 'antenatal'), ('CHEBI_30751', 'formic acid', 52, 'folic acid'), ('GO_0007565', 'female pregnancy', 119, 'gestational'), ('CHEBI_27300', 'vitamin D', 195, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 223, 'A'), ('CHEBI_27300', 'vitamin D', 289, 'vitamin A'), ('CHEBI_24870', 'ion', 302, 'iron'), ('CHEBI_30751', 'formic acid', 311, 'folic acid')]
S107-PMC1888711	PMC1888711	5/2007	S107-PMC1888711	['supplementation with Vitamins C and E HAS BEEN SHOWN to have no effect on eclampsia, ALBEIT among well-nourished women [34,35].']	[('INCOMPLETE_EVIDENCE', 38), ('ANOMALY_CURIOUS_FINDING', 85)]	2	[('CHEBI_27300', 'vitamin D', 21, 'vitamins C'), ('PR_000004900', 'complement C3', 30, 'C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 36, 'E')]
S123-PMC1888711	PMC1888711	5/2007	S123-PMC1888711	['Albendazole HAS BEEN SHOWN to reduce the decline in haemoglobin during Pregnancy, but there is NO CONCLUSIVE EVIDENCE for an EFFECT of Vitamin A or other Micronutrients on anemia during Pregnancy, PARTICULARLY when compared with Iron and Folate supplementation [60,61].']	[('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 95), ('SUPERFICIAL_RELATIONSHIP', 125), ('ANOMALY_CURIOUS_FINDING', 197)]	4	[('CHEBI_16664', 'albendazole', 0, 'Albendazole'), ('GO_0007565', 'female pregnancy', 71, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 135, 'vitamin A'), ('CHEBI_33839', 'macromolecule', 154, 'micronutrients'), ('GO_0007565', 'female pregnancy', 186, 'pregnancy'), ('CHEBI_24870', 'ion', 229, 'iron'), ('CHEBI_30863', '5-azaorotic acid', 238, 'folate')]
S76-PMC2290997	PMC2290997	4/2008	S76-PMC2290997	['“NEVERTHELESS, considering the SAFETY of Vitamin D EVEN in high doses, there is NO CLEAR contraindication, and BECAUSE Vitamin D deficiency is very PREVALENT, especially among ms patients, taking Vitamin D supplements and getting moderate sun exposure is more LIKELY to be beneficial than not.”\nas with ms, there APPEARS TO be a latitudinal gradient for type 1 diabetes, with a higher incidence at higher latitudes.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 1), ('IMPORTANT_CONSIDERATION', 31), ('ANOMALY_CURIOUS_FINDING', 51), ('FULL_UNKNOWN', 80), ('PROBABLE_UNDERSTANDING', 111), ('IMPORTANT_CONSIDERATION', 148), ('PROBABLE_UNDERSTANDING', 260), ('ANOMALY_CURIOUS_FINDING', 313)]	8	[('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 119, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 196, 'vitamin D')]
S101-PMC2290997	PMC2290997	4/2008	S101-PMC2290997	['NEVERTHELESS, given the epidemiologic backdrop DESCRIBED above, there are now CALLS to rethink sun exposure policy OR to promote Vitamin D supplementation in HIGHER-RISK populations.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 47), ('IMPORTANT_CONSIDERATION', 78), ('IMPORTANT_CONSIDERATION', 78), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 115), ('IMPORTANT_CONSIDERATION', 158)]	6	[('CHEBI_27300', 'vitamin D', 129, 'vitamin D')]
S131-PMC2290997	PMC2290997	4/2008	S131-PMC2290997	['gilchrest says the american academy of dermatology and MOST dermatologists currently SUGGEST sun protection in combination with Vitamin D supplementation AS a means of minimizing the RISK of both skin cancer and internal cancers.']	[('PROBABLE_UNDERSTANDING', 55), ('INCOMPLETE_EVIDENCE', 85), ('PROBABLE_UNDERSTANDING', 154), ('IMPORTANT_CONSIDERATION', 183)]	4	[('CHEBI_27300', 'vitamin D', 128, 'vitamin D')]
S192-PMC2290997	PMC2290997	4/2008	S192-PMC2290997	['in short, there is no real specificity for ambient uvr.”\nresearchers also ASSESS history of time in the sun at various ages, history of sunburns, dietary and supplemental Vitamin D intake, and OTHER PROXY measures.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 74), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 193), ('SUPERFICIAL_RELATIONSHIP', 199)]	3	[('CHEBI_27300', 'vitamin D', 171, 'vitamin D')]
S13-PMC2405769	PMC2405769	5/2008	S13-PMC2405769	['background\nmultivitamin-Mineral supplementation is RECOMMENDED before and during Pregnancy to ensure adequate intake of several KEY Nutrients including Folate, iron, and more RECENTLY Vitamin D – all of which have IMPORTANCE among Pregnant women, women of Childbearing age, and during Fetal Development [1-6].']	[('FUTURE_WORK', 51), ('IMPORTANT_CONSIDERATION', 128), ('INCOMPLETE_EVIDENCE', 175), ('IMPORTANT_CONSIDERATION', 214)]	4	[('CHEBI_46662', 'mineral', 24, 'mineral'), ('GO_0007565', 'female pregnancy', 81, 'pregnancy'), ('CHEBI_33284', 'nutrient', 132, 'nutrients'), ('CHEBI_30863', '5-azaorotic acid', 152, 'folate'), ('CHEBI_27300', 'vitamin D', 184, 'vitamin D'), ('GO_0007565', 'female pregnancy', 231, 'pregnant'), ('GO_0007129', 'homologous chromosome pairing at meiosis', 256, 'childbearing'), ('GO_0002065', 'columnar/cuboidal epithelial cell differentiation', 285, 'fetal development')]
S0-PMC2581757	PMC2581757	11/2008	S0-PMC2581757	['ROLE of Vitamins C and e in Regulating antioxidant and pro-oxidant markers in Preeclampsia\n\nabstract\nwe compared three groups of Pregnant women: placebo with normotensive women, group a which included preeclamptics, and group b which comprised preeclamptics who were supplemented their diets with Vitamins C and e. Mda increased from 6.22\xa0±\xa02.8 (Placebo) to 8.48\xa0±\xa01.2 (a) and 8.02\xa0±\xa01.8\xa0nmol/ghb (b).']	[('SUPERFICIAL_RELATIONSHIP', 0)]	1	[('CHEBI_27306', 'vitamin B6', 8, 'Vitamins C'), ('PR_000027594', 'histone H3', 8, 'Vitamins C'), ('GO_0065007', 'biological regulation', 28, 'Regulating'), ('GO_0007128', 'meiotic prophase I', 78, 'Preeclampsia'), ('GO_0007565', 'female pregnancy', 129, 'pregnant'), ('CHEBI_27300', 'vitamin D', 297, 'vitamins C'), ('CHEBI_34840', 'methyl methacrylate', 315, 'MDA'), ('CHEBI_26130', 'biological pigment', 346, 'placebo')]
S6-PMC2581757	PMC2581757	11/2008	S6-PMC2581757	['a significant reduction in the incidence of Preeclampsia was FOUND in women AT RISK who were taking Vitamins C and E supplements [1].']	[('INCOMPLETE_EVIDENCE', 61), ('IMPORTANT_CONSIDERATION', 76)]	2	[('GO_0007128', 'meiotic prophase I', 44, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 100, 'vitamins C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 115, 'E')]
S13-PMC2581757	PMC2581757	11/2008	S13-PMC2581757	['HOWEVER, in a recent review, antioxidant therapy HAS BEEN SUGGESTED and that the prophylactic supplementation of Vitamins C and E to Pregnant women is ASSOCIATED with reduced incidence of preeclampsia and decreased Placental and Endothelial dysfunction [9].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 49), ('SUPERFICIAL_RELATIONSHIP', 151)]	3	[('CHEBI_27300', 'vitamin D', 113, 'vitamins C'), ('PR_000004900', 'complement C3', 122, 'C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 128, 'E'), ('GO_0007565', 'female pregnancy', 133, 'pregnant'), ('UBERON_0001987', 'placenta', 215, 'placental'), ('UBERON_0001986', 'endothelium', 229, 'endothelial')]
S45-PMC2581757	PMC2581757	11/2008	S45-PMC2581757	['group b initially consisted of a high number of patients who were viewed as being at an INCREASED RISK of preeclampsia BECAUSE of FACTORS such as preeclampsia in a preceding Pregnancy, hellp syndrome, or eclampsia in any past Pregnancy at any Gestational stage, and who were taking additional Vitamin supplement (1000\xa0mg Vitamin C plus 400\xa0iu Vitamin E per day) from the second Trimester of Pregnancy to Delivery as mentioned for the controls (placebo).']	[('IMPORTANT_CONSIDERATION', 88), ('PROBLEM_COMPLICATION', 119), ('SUPERFICIAL_RELATIONSHIP', 130)]	3	[('GO_0007565', 'female pregnancy', 174, 'pregnancy'), ('GO_0007565', 'female pregnancy', 226, 'pregnancy'), ('GO_0007565', 'female pregnancy', 243, 'gestational'), ('CHEBI_33229', 'vitamin (role)', 293, 'vitamin'), ('CHEBI_27300', 'vitamin D', 321, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 343, 'vitamin E'), ('GO_0009294', 'DNA mediated transformation', 378, 'trimester'), ('GO_0007565', 'female pregnancy', 391, 'pregnancy'), ('GO_0007567', 'parturition', 404, 'delivery')]
S187-PMC2581757	PMC2581757	11/2008	S187-PMC2581757	['[1] HAVE REPORTED that a significant reduction in the incidence of Preeclampsia was FOUND in women AT RISK who were taking a Vitamins C and E supplements.']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 84), ('IMPORTANT_CONSIDERATION', 99)]	3	[('GO_0007128', 'meiotic prophase I', 67, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 125, 'vitamins C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 140, 'E')]
S195-PMC2581757	PMC2581757	11/2008	S195-PMC2581757	['we FOUND that the patients supplemented with Vitamin C 1000\xa0mg plus Vitamin E 400\xa0iu daily from the second Trimester of Pregnancy until Delivery showed improvements in certain biochemical indices during the Development Of Preeclampsia.']	[('INCOMPLETE_EVIDENCE', 3)]	1	[('CHEBI_27300', 'vitamin D', 45, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 68, 'vitamin E'), ('GO_0009294', 'DNA mediated transformation', 107, 'trimester'), ('GO_0007565', 'female pregnancy', 120, 'pregnancy'), ('GO_0007567', 'parturition', 136, 'delivery'), ('GO_0070483', 'detection of hypoxia', 207, 'development of preeclampsia')]
S84-PMC2582131	PMC2582131	11/2008	S84-PMC2582131	['the MAJOR sources of Vitamin D in the body are dietary Vitamin D intake and supplementation as well as Endogenous Production Of Vitamin D in the skin exposed to sunlight.']	[('IMPORTANT_CONSIDERATION', 4)]	1	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 55, 'vitamin D'), ('GO_0009790', 'embryo development', 103, 'endogenous'), ('GO_0018240', 'protein S-linked glycosylation via cysteine', 114, 'production of vitamin D'), ('CHEBI_27300', 'vitamin D', 128, 'vitamin D')]
S125-PMC2582131	PMC2582131	11/2008	S125-PMC2582131	['intervention studies[14],[40]–[44]assessing the EFFECT of Vitamin D and Calcium supplements on Glucose Metabolism among non-Pregnant Individuals have yielded MIXED results, which is AT LEAST PARTLY DUE TO VARIATIONS in the dose of supplementation and the duration of follow up.']	[('SUPERFICIAL_RELATIONSHIP', 48), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 158), ('PROBABLE_UNDERSTANDING', 182), ('INCOMPLETE_EVIDENCE', 191), ('PROBLEM_COMPLICATION', 198), ('DIFFICULT_TASK', 205)]	6	[('CHEBI_27300', 'vitamin D', 58, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 72, 'calcium'), ('CHEBI_17234', 'glucose', 95, 'glucose'), ('GO_0006006', 'glucose metabolic process', 95, 'glucose metabolism'), ('GO_0007565', 'female pregnancy', 124, 'pregnant'), ('NCBITaxon_1', 'root', 133, 'individuals')]
S126-PMC2582131	PMC2582131	11/2008	S126-PMC2582131	['optimizing the effective dose of Vitamin D supplement continues to be a CHALLENGE.']	[('DIFFICULT_TASK', 72)]	1	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D')]
S127-PMC2582131	PMC2582131	11/2008	S127-PMC2582131	['IF CONFIRMED, our data RAISE the POSSIBILITY that treating Vitamin D deficiency in Pregnancy, via supplementation OR lifestyle measures, CAN CONTRIBUTE to the PREVENTION of gdm.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 3), ('EXPLICIT_QUESTION', 23), ('INCOMPLETE_EVIDENCE', 33), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 114), ('INCOMPLETE_EVIDENCE', 137), ('SUPERFICIAL_RELATIONSHIP', 141), ('SUPERFICIAL_RELATIONSHIP', 159)]	8	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('GO_0007565', 'female pregnancy', 83, 'pregnancy')]
S214-PMC2671168	PMC2671168	5/2009	S214-PMC2671168	['IN FACT, supplementation with some Micronutrients, such as Vitamins C and e, was ASSOCIATED with INCREASED RISK of low Birth weight[55].']	[('ANOMALY_CURIOUS_FINDING', 0), ('SUPERFICIAL_RELATIONSHIP', 81), ('IMPORTANT_CONSIDERATION', 97)]	3	[('CHEBI_33839', 'macromolecule', 35, 'micronutrients'), ('CHEBI_27300', 'vitamin D', 59, 'vitamins C'), ('PR_000004900', 'complement C3', 68, 'C'), ('GO_0007567', 'parturition', 119, 'birth')]
S477-PMC2679409	PMC2679409	5/2009	S477-PMC2679409	['given the POTENTIAL Teratogenic EFFECT and toxicity of high-dose Vitamin A, a variety of Vitamin A INTERVENTIONS (daily supplementation with either low-dose Vitamin A or Β-Carotene) HAVE BEEN evaluated with assessment of SAFETY and IMPACT on maternal, newborn and infant outcomes.']	[('INCOMPLETE_EVIDENCE', 10), ('SUPERFICIAL_RELATIONSHIP', 32), ('SUPERFICIAL_RELATIONSHIP', 99), ('INCOMPLETE_EVIDENCE', 182), ('IMPORTANT_CONSIDERATION', 221), ('SUPERFICIAL_RELATIONSHIP', 232)]	6	[('CHEBI_50905', 'teratogenic agent', 20, 'teratogenic'), ('CHEBI_27300', 'vitamin D', 65, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 89, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 157, 'vitamin A'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 170, 'β-carotene')]
S488-PMC2679409	PMC2679409	5/2009	S488-PMC2679409	['[87] yielded SIMILAR FINDINGS on the risk of stillbirth ASSOCIATED with Vitamin A supplementation (rr = 1.26, 95% ci: 0.53, 3.01) [loe: 1++] (additional file13).']	[('INCOMPLETE_EVIDENCE', 13), ('SUPERFICIAL_RELATIONSHIP', 56)]	2	[('CHEBI_27300', 'vitamin D', 72, 'vitamin A')]
S491-PMC2679409	PMC2679409	5/2009	S491-PMC2679409	['3 rcts included.assessed the IMPACT on Pregnancy outcomes of Vitamin A supplementation +/- multivitamins (intervention #1), compared to supplementation with placebo +/- multivitamins (controls).']	[('SUPERFICIAL_RELATIONSHIP', 29)]	1	[('GO_0007565', 'female pregnancy', 39, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 61, 'vitamin A')]
S492-PMC2679409	PMC2679409	5/2009	S492-PMC2679409	['also assessed the IMPACT of Vitamin A + iron + Folate (intervention #2) vs. iron + Folate (controls).sbr: rr = 1.04 (95% ci: 0.60–1.79) [ns] in those supplemented with Vitamin A (+/- multivitamins) vs. those supplemented with Placebo (+/- multivitamins)[1 rct, n = 11723 women]sbr: rr = 1.26 (95% ci: 0.53–3.01) [ns] in those supplemented with Vitamin A + iron + Folate vs. those supplemented with Iron + Folate [2 rcts, n = 940 women]van den broek et al.']	[('SUPERFICIAL_RELATIONSHIP', 18)]	1	[('CHEBI_27300', 'vitamin D', 28, 'vitamin A'), ('CHEBI_30863', '5-azaorotic acid', 47, 'folate'), ('CHEBI_30863', '5-azaorotic acid', 83, 'folate'), ('CHEBI_27300', 'vitamin D', 168, 'vitamin A'), ('CHEBI_26130', 'biological pigment', 226, 'placebo'), ('CHEBI_27300', 'vitamin D', 344, 'vitamin A'), ('CHEBI_30863', '5-azaorotic acid', 363, 'folate'), ('CHEBI_24870', 'ion', 398, 'iron'), ('CHEBI_30863', '5-azaorotic acid', 405, 'folate')]
S494-PMC2679409	PMC2679409	5/2009	S494-PMC2679409	['1 rct included.assessed the IMPACT on Pregnancy outcomes of Vitamin A (intervention #1) and/or Β-Carotene (intervention #2) supplementation vs. placebo (controls).Fetal death: rr = 1.04 (95% ci: 0.92–1.17) [ns] in women receiving Vitamin A vs. controls, respectively.Fetal death: rr = 1.03 (95% ci: 0.91–1.16) [ns] in women receiving Β-Carotene vs. controls, respectively.wiysonge et al.']	[('SUPERFICIAL_RELATIONSHIP', 28)]	1	[('GO_0007565', 'female pregnancy', 38, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 60, 'vitamin A'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 95, 'β-carotene'), ('GO_0008618', '7-methylguanosine metabolic process', 163, 'Fetal'), ('CHEBI_27300', 'vitamin D', 230, 'vitamin A'), ('GO_0008618', '7-methylguanosine metabolic process', 267, 'Fetal'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 334, 'β-carotene')]
S496-PMC2679409	PMC2679409	5/2009	S496-PMC2679409	['4 rcts included.compared the IMPACT on Pregnancy outcomes of Vitamin A supplementation (intervention) vs. no Vitamin A supplementation (controls).sbr: or = 0.99 (95% ci: 0.67–1.46) [ns] .']	[('SUPERFICIAL_RELATIONSHIP', 29)]	1	[('GO_0007565', 'female pregnancy', 39, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 61, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 109, 'vitamin A')]
S500-PMC2679409	PMC2679409	5/2009	S500-PMC2679409	['ANY FUTURE STUDIES of Vitamin A supplementation MUST FOCUS on HIGH-RISK women, assess the most APPROPRIATE Vitamin type and dosage, and show that the intervention is both SAFE for the mother and fetus, and EFFECTIVE.']	[('IMPORTANT_CONSIDERATION', 0), ('FUTURE_WORK', 4), ('IMPORTANT_CONSIDERATION', 48), ('IMPORTANT_CONSIDERATION', 53), ('IMPORTANT_CONSIDERATION', 62), ('IMPORTANT_CONSIDERATION', 95), ('IMPORTANT_CONSIDERATION', 171), ('SUPERFICIAL_RELATIONSHIP', 206)]	8	[('CHEBI_27300', 'vitamin D', 22, 'vitamin A'), ('CHEBI_33229', 'vitamin (role)', 107, 'vitamin')]
S697-PMC2679409	PMC2679409	5/2009	S697-PMC2679409	['2005 meta-analysis: IMPACT of Vitamin A supplementation on Stillbirth and Perinatal mortality .']	[('SUPERFICIAL_RELATIONSHIP', 20)]	1	[('CHEBI_27300', 'vitamin D', 30, 'vitamin A'), ('GO_0001966', 'thigmotaxis', 59, 'stillbirth'), ('GO_0036268', 'swimming', 74, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 74, 'perinatal')]
S702-PMC2679409	PMC2679409	5/2009	S702-PMC2679409	['2002 review: IMPACT of Vitamin A supplementation on Stillbirth and Perinatal mortality .']	[('SUPERFICIAL_RELATIONSHIP', 13)]	1	[('CHEBI_27300', 'vitamin D', 23, 'vitamin A'), ('GO_0001966', 'thigmotaxis', 52, 'stillbirth'), ('GO_0036268', 'swimming', 67, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 67, 'perinatal')]
S707-PMC2679409	PMC2679409	5/2009	S707-PMC2679409	['2005 meta-analysis: IMPACT of Vitamin A supplementation on Stillbirth and Perinatal mortality .']	[('SUPERFICIAL_RELATIONSHIP', 20)]	1	[('CHEBI_27300', 'vitamin D', 30, 'vitamin A'), ('GO_0001966', 'thigmotaxis', 59, 'stillbirth'), ('GO_0036268', 'swimming', 74, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 74, 'perinatal')]
S13-PMC2685863	PMC2685863	5/2009	S13-PMC2685863	['the authors PROPOSE that Vitamin D supplementation at CRITICAL periods during Pregnancy and early childhood MIGHT reduce the RISK for developing ms—a VIEW endorsed by bruce hollis, a nutritional biochemist and professor of pediatrics at the medical university of south carolina.']	[('INCOMPLETE_EVIDENCE', 12), ('IMPORTANT_CONSIDERATION', 54), ('INCOMPLETE_EVIDENCE', 108), ('IMPORTANT_CONSIDERATION', 125), ('INCOMPLETE_EVIDENCE', 150)]	5	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('GO_0007565', 'female pregnancy', 78, 'pregnancy')]
S122-PMC2722583	PMC2722583	1/2009	S122-PMC2722583	['for example, the fact that Prenatal Folate supplementation substantially reduces the risk of Neural Tube defect ONLY IF it is taken Preconceptually is WELL KNOWN BUT improving Vitamin A status before Pregnancy HAS also BEEN SHOWN to have a dramatic and AS YET UNEXPLAINED EFFECT on maternal morbidity and mortality (west et al 1999).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 112), ('INCOMPLETE_EVIDENCE', 151), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 162), ('INCOMPLETE_EVIDENCE', 210), ('INCOMPLETE_EVIDENCE', 224), ('INCOMPLETE_EVIDENCE', 253), ('INCOMPLETE_EVIDENCE', 260), ('SUPERFICIAL_RELATIONSHIP', 272)]	8	[('GO_0007565', 'female pregnancy', 27, 'prenatal'), ('CHEBI_30863', '5-azaorotic acid', 36, 'folate'), ('UBERON_0001049', 'neural tube', 93, 'neural tube'), ('GO_0007608', 'sensory perception of smell', 132, 'preconceptually'), ('CHEBI_27300', 'vitamin D', 176, 'vitamin A'), ('GO_0007565', 'female pregnancy', 200, 'pregnancy')]
S129-PMC2722583	PMC2722583	1/2009	S129-PMC2722583	['in indonesia, the haemoglobin concentration of adolescent girls improved on supplementation with combinations of Iron, Folic Acid, Retinol and Vitamin C, over placebo BUT did not respond better to daily rather that weekly supplementation, ALTHOUGH Serum ferritin increased more in the daily supplemented group (angeles-agdeppa et al 1997).']	[('ANOMALY_CURIOUS_FINDING', 167), ('ANOMALY_CURIOUS_FINDING', 239)]	2	[('CHEBI_24870', 'ion', 113, 'iron'), ('CHEBI_30751', 'formic acid', 119, 'folic acid'), ('CHEBI_26536', 'retinoic acid', 131, 'retinol'), ('CHEBI_27300', 'vitamin D', 143, 'vitamin C'), ('UBERON_0001977', 'blood serum', 248, 'serum')]
S42-PMC2779500	PMC2779500	11/2009	S42-PMC2779500	['for example, ALTHOUGH reduced mortality HAS BEEN SHOWN in hiv-positive children receiving Vitamin A supplementation [30], the administration of Vitamin A supplements to women has BEEN IMPLICATED in increased Vaginal Viral shedding (no effect on risk was observed from Vitamins B, C, and E) [31], a heightened risk of Mother-To-Child Hiv Transmission [32], and hastened progression of child mortality [30].']	[('ANOMALY_CURIOUS_FINDING', 13), ('INCOMPLETE_EVIDENCE', 40), ('ANOMALY_CURIOUS_FINDING', 179), ('SUPERFICIAL_RELATIONSHIP', 184)]	4	[('CHEBI_27300', 'vitamin D', 90, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin A'), ('UBERON_0001987', 'placenta', 208, 'vaginal'), ('NCBITaxon_1', 'root', 216, 'viral'), ('CHEBI_27300', 'vitamin D', 268, 'vitamins B'), ('PR_000000037', 'BMP receptor type-2', 277, 'B'), ('CHEBI_18245', 'carboxylato group', 280, 'C'), ('PR_000004900', 'complement C3', 280, 'C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 287, 'E'), ('GO_0048870', 'cell motility', 317, 'mother-to-child'), ('GO_0007228', 'positive regulation of hh target transcription factor activity', 333, 'HIV transmission')]
S43-PMC2779500	PMC2779500	11/2009	S43-PMC2779500	['in addition, high doses of Vitamin C supplementation HAVE BEEN SHOWN to reduce the bioavailability of the protease Inhibitor, Indinavir [33].']	[('INCOMPLETE_EVIDENCE', 53)]	1	[('CHEBI_27300', 'vitamin D', 27, 'vitamin C'), ('CHEBI_35222', 'inhibitor', 115, 'inhibitor'), ('CHEBI_44032', 'indinavir', 126, 'indinavir')]
S44-PMC2779500	PMC2779500	11/2009	S44-PMC2779500	['THESE FINDINGS, among others, UNDOUBTEDLY necessitate CONCERN, and have led authors to QUESTION the benefits of universal Vitamin A supplementation for women in hiv-endemic areas [30,31].']	[('INCOMPLETE_EVIDENCE', 0), ('PROBABLE_UNDERSTANDING', 30), ('IMPORTANT_CONSIDERATION', 54), ('PROBLEM_COMPLICATION', 54), ('EXPLICIT_QUESTION', 87)]	5	[('CHEBI_27300', 'vitamin D', 122, 'vitamin A')]
S46-PMC2779500	PMC2779500	11/2009	S46-PMC2779500	['[31] maintain that Prenatal supplementation of Vitamins B, C, and e SHOULD BE continued DUE TO their MANY REPORTED positive EFFECTS on maternal and fetal health.']	[('FUTURE_WORK', 68), ('PROBABLE_UNDERSTANDING', 88), ('PROBLEM_COMPLICATION', 88), ('INCOMPLETE_EVIDENCE', 101), ('INCOMPLETE_EVIDENCE', 106), ('SUPERFICIAL_RELATIONSHIP', 124)]	6	[('GO_0007565', 'female pregnancy', 19, 'prenatal'), ('CHEBI_27300', 'vitamin D', 47, 'vitamins B'), ('PR_000004480', 'V-type proton ATPase catalytic subunit A', 47, 'vitamins B'), ('CHEBI_18245', 'carboxylato group', 59, 'C'), ('PR_000004900', 'complement C3', 59, 'C')]
S175-PMC2779500	PMC2779500	11/2009	S175-PMC2779500	['we include the unstable equilibrium point of the hiv(+)v group at a total Vitamin C supplementation level of APPROXIMATELY 116 mg/day.']	[('INCOMPLETE_EVIDENCE', 109)]	1	[('CHEBI_27300', 'vitamin D', 74, 'vitamin C')]
S194-PMC2779500	PMC2779500	11/2009	S194-PMC2779500	['in (b), a periodic cycle APPEARS when α = 4.0 × 1013molecules/( μ l day), corresponding to 116 mg of daily Vitamin C supplementation.']	[('ANOMALY_CURIOUS_FINDING', 25)]	1	[('CHEBI_27300', 'vitamin D', 107, 'vitamin C'), ('PR_000004900', 'complement C3', 115, 'C')]
S1-PMC2798111	PMC2798111	12/2010	S1-PMC2798111	['TO EXAMINE the EFFECTIVENESS of oral Vitamin D3(400\u2009iu) supplementation on the nutritional Vitamin D status of breastfeeding infants.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('SUPERFICIAL_RELATIONSHIP', 15)]	2	[('CHEBI_33279', 'vitamin D5', 37, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 37, 'vitamin D3'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin D')]
S17-PMC2798111	PMC2798111	12/2010	S17-PMC2798111	['THEREFORE, Oral supplementation or sufficient sun exposure is NECESSARY to ensure adequate Vitamin D status for proper calcium absorption and bone mineralization [3–6].RECENT RESEARCH has also LINKED Vitamin D to Innate Immunity [7–9].']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 62), ('INCOMPLETE_EVIDENCE', 168), ('SUPERFICIAL_RELATIONSHIP', 193)]	4	[('UBERON_0000165', 'mouth', 11, 'oral'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 200, 'vitamin D'), ('GO_0045087', 'innate immune response', 213, 'innate immunity')]
S19-PMC2798111	PMC2798111	12/2010	S19-PMC2798111	['with THIS KNOWLEDGE, IT IS CLEAR that Vitamin D supplementation of the breastfedinfant is NECESSARY and RECOMMENDED by the american academy of pediatrics and the canadian pediatrics society [5,25].']	[('PROBABLE_UNDERSTANDING', 5), ('PROBABLE_UNDERSTANDING', 21), ('IMPORTANT_CONSIDERATION', 90), ('FUTURE_WORK', 104)]	4	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D')]
S23-PMC2798111	PMC2798111	12/2010	S23-PMC2798111	['as part of an ongoing Vitamin D supplementation trial of fully Lactating women and their infants, we SOUGHT TO DETERMINE WHETHER a dosing regimen that utilizes an oil emulsion of one drop per day to Deliver 400\u2009iu/day is effective in raising infant 25(Oh)D levels from baseline.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 101), ('QUESTION_ANSWERED_BY_THIS_WORK', 108), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 121)]	3	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('GO_0007594', 'puparial adhesion', 63, 'lactating'), ('GO_0007567', 'parturition', 199, 'deliver'), ('CHEBI_71657', 'versiconol acetate', 249, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 249, '25(OH)D')]
S43-PMC2798111	PMC2798111	12/2010	S43-PMC2798111	['use of formula\nbecause of the POTENTIAL CONFOUNDER of proprietary formulas that contain 400\u2009iu/l Vitamin D, each mother was given up to six 4-oz bottles per month of Vitamin D-free formula with the instructions to avoid use of any formula but if there was a need to supplement, the Vitamin D-free formula prepared by mead-johnson, evansville, in was used.']	[('INCOMPLETE_EVIDENCE', 30), ('PROBLEM_COMPLICATION', 40)]	2	[('CHEBI_27300', 'vitamin D', 97, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 166, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 282, 'vitamin D')]
S45-PMC2798111	PMC2798111	12/2010	S45-PMC2798111	['THEREFORE, the dietary source of Vitamin D in these infants came from the Vitamin D supplement provided.']	[('PROBABLE_UNDERSTANDING', 0)]	1	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 74, 'vitamin D')]
S90-PMC2798111	PMC2798111	12/2010	S90-PMC2798111	['discussion\nbecause the PRELIMINARY results of this arm of the trial are IMPORTANT for decision-making in the current clinical environment, we report HERE the interim results of an ONGOING Vitamin D supplementation TRIAL of Lactating women and their infants.']	[('INCOMPLETE_EVIDENCE', 23), ('IMPORTANT_CONSIDERATION', 72), ('QUESTION_ANSWERED_BY_THIS_WORK', 149), ('IMPORTANT_CONSIDERATION', 180), ('INCOMPLETE_EVIDENCE', 214)]	5	[('CHEBI_27300', 'vitamin D', 188, 'vitamin D'), ('GO_0007594', 'puparial adhesion', 223, 'lactating')]
S95-PMC2798111	PMC2798111	12/2010	S95-PMC2798111	['WHILE not powered to assess SAFETY at this juncture, it is IMPORTANT TO NOTE that, thus FAR, there HAVE BEEN no increased rates of infection in the infants or adverse health EFFECTS that COULD BE ATTRIBUTED to Vitamin D supplementation in this cohort.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('IMPORTANT_CONSIDERATION', 28), ('IMPORTANT_CONSIDERATION', 59), ('ANOMALY_CURIOUS_FINDING', 88), ('INCOMPLETE_EVIDENCE', 99), ('SUPERFICIAL_RELATIONSHIP', 174), ('INCOMPLETE_EVIDENCE', 187), ('SUPERFICIAL_RELATIONSHIP', 196)]	8	[('CHEBI_27300', 'vitamin D', 210, 'vitamin D')]
S98-PMC2798111	PMC2798111	12/2010	S98-PMC2798111	['UNTIL it can be determined WHAT amount of Vitamin D supplementation in mothers will effectively and SAFELY increase and/or maintain the Vitamin D status in her breastfed infant, we MUST rely on Vitamin D supplementation of the infant to prevent deficiency.']	[('FUTURE_WORK', 0), ('EXPLICIT_QUESTION', 27), ('IMPORTANT_CONSIDERATION', 100), ('IMPORTANT_CONSIDERATION', 181)]	4	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 194, 'vitamin D')]
S99-PMC2798111	PMC2798111	12/2010	S99-PMC2798111	['THUS, OUR FINDINGS in THIS STUDY and our earlier studies [4,32] SUPPORT the RECENT aap RECOMMENDATION of starting Vitamin D supplementation in all breastfed infants within the first few days after Delivery [26].']	[('PROBABLE_UNDERSTANDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 6), ('QUESTION_ANSWERED_BY_THIS_WORK', 22), ('INCOMPLETE_EVIDENCE', 64), ('INCOMPLETE_EVIDENCE', 76), ('FUTURE_WORK', 87)]	6	[('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('GO_0007567', 'parturition', 197, 'delivery')]
S104-PMC2798111	PMC2798111	12/2010	S104-PMC2798111	['OUR FINDINGS SUPPORT the PREMISE that an oil emulsion delivered as a single drop is well-tolerated and absorbed with a CONSISTENT increase in circulating 25(Oh)d on the Vitamin D supplementation during a three-month interval that was sustained during the next three-month interval.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 25), ('INCOMPLETE_EVIDENCE', 119)]	4	[('CHEBI_30778', 'gallic acid', 154, '25(OH)'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin D')]
S113-PMC2798111	PMC2798111	12/2010	S113-PMC2798111	['while a group of infants that received placebo would allow for more refined statistical analyses, it is deemed UNETHICAL by the investigators and the irb not to supplement the infants with what is now the standard of care for Vitamin D supplementation of infants and children in both the u.s. and canada (see aap statement 2008 [5] and canadian paediatric society statement 2007 [33]).']	[('DIFFICULT_TASK', 111)]	1	[('CHEBI_27300', 'vitamin D', 226, 'vitamin D')]
S114-PMC2798111	PMC2798111	12/2010	S114-PMC2798111	['the direct effect of the Vitamin D supplementation is SUPPORTED by the following: in this trial, of the mothers who were randomized to receive 2400\u2009iu Vitamin D/day, there was insufficient transfer of Vitamin D in their Milk and 31% of those breastfed infants required open label Vitamin D supplementation at the 4th month visit compared with 6% in the control group and 5% in the 6400\u2009iu Vitamin D supplementation group.']	[('INCOMPLETE_EVIDENCE', 54)]	1	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 151, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 201, 'vitamin D'), ('UBERON_0001913', 'milk', 220, 'milk'), ('CHEBI_27300', 'vitamin D', 280, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 389, 'vitamin D')]
S29-PMC2821652	PMC2821652	2/2010	S29-PMC2821652	['DESPITE an expanding Intravascular volume during Pregnancy, maternal Vitamin D status SHOWS seasonal variation but beyond the typical FACTORS that INFLUENCE Vitamin D status in Adults (such as sunlight exposure and bmi), Vitamin D status does not fluctuate during Pregnancy and once supplemented, maternal Blood levels reach steady-state within 2 months [15].']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 86), ('SUPERFICIAL_RELATIONSHIP', 134), ('SUPERFICIAL_RELATIONSHIP', 147)]	4	[('GO_0005622', 'intracellular anatomical structure', 21, 'intravascular'), ('GO_0007565', 'female pregnancy', 49, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 69, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 157, 'vitamin D'), ('UBERON_0007023', 'adult organism', 177, 'adults'), ('CHEBI_27300', 'vitamin D', 221, 'vitamin D'), ('GO_0007565', 'female pregnancy', 264, 'pregnancy'), ('UBERON_0000178', 'blood', 306, 'blood')]
S31-PMC2821652	PMC2821652	2/2010	S31-PMC2821652	['EXISTING guidelines RECOMMEND that Pregnant women receive 400\u2009iu of Vitamin D per day via an oral supplement [17,18].']	[('INCOMPLETE_EVIDENCE', 0), ('FUTURE_WORK', 20)]	2	[('GO_0007565', 'female pregnancy', 35, 'pregnant'), ('CHEBI_27300', 'vitamin D', 68, 'vitamin D')]
S36-PMC2821652	PMC2821652	2/2010	S36-PMC2821652	['studies are currently UNDERWAY to determine the optimum supplementation dose of Vitamin D among Pregnant women (clinicaltrials.gov: nct00412087 and nct00292591).']	[('INCOMPLETE_EVIDENCE', 22)]	1	[('CHEBI_27300', 'vitamin D', 80, 'vitamin D'), ('GO_0007565', 'female pregnancy', 96, 'pregnant')]
S45-PMC2821652	PMC2821652	2/2010	S45-PMC2821652	"[""the PURPOSES of THIS STUDY were to define parameters for measuring adherence to Vitamin D supplementation by measures of Serum Metabolite, which could then be applied to other medication regimens, and TO EXAMINE the ASSOCIATION between adherence as determined by Serum Metabolites and adherence as determined by patients' pill counts.""]"	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 16), ('QUESTION_ANSWERED_BY_THIS_WORK', 201), ('SUPERFICIAL_RELATIONSHIP', 216)]	4	[('CHEBI_27300', 'vitamin D', 80, 'vitamin D'), ('UBERON_0001977', 'blood serum', 121, 'serum'), ('CHEBI_39382', 'flufenoxuron', 127, 'metabolite'), ('UBERON_0001977', 'blood serum', 263, 'serum'), ('CHEBI_25212', 'metabolite', 269, 'metabolites')]
S74-PMC2821652	PMC2821652	2/2010	S74-PMC2821652	['WHILE there is a MODEL in existence which calculates the predicted change in Serum 25(Oh)D for different doses of Vitamin D supplement, this model was developed using data from men [64], and its applicability to a population of Pregnant females is debatable.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 17)]	2	[('UBERON_0001977', 'blood serum', 77, 'serum'), ('CHEBI_71657', 'versiconol acetate', 83, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 83, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('GO_0007565', 'female pregnancy', 228, 'pregnant')]
S75-PMC2821652	PMC2821652	2/2010	S75-PMC2821652	['THEREFORE, we were faced with the CHALLENGE of establishing novel criteria for Vitamin D supplement adherence by Serum 25(Oh)D levels; HOW we arrived at this definition is described below.']	[('PROBABLE_UNDERSTANDING', 0), ('DIFFICULT_TASK', 34), ('EXPLICIT_QUESTION', 135)]	3	[('CHEBI_27300', 'vitamin D', 79, 'vitamin D'), ('UBERON_0001977', 'blood serum', 113, 'serum'), ('CHEBI_71657', 'versiconol acetate', 119, '25(OH)D'), ('PR_000003010', 'moesin isoform 1', 121, '(OH ... D')]
S119-PMC2821652	PMC2821652	2/2010	S119-PMC2821652	['in THIS TRIAL, we SOUGHT TO DETERMINE WHETHER there was a significant ASSOCIATION between adherence to Vitamin D supplementation as measured by pill count and assessment of a NOVEL measure of adherence BASED UPON Serum levels of Vitamin D Metabolites in a Pregnant population.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('QUESTION_ANSWERED_BY_THIS_WORK', 18), ('QUESTION_ANSWERED_BY_THIS_WORK', 25), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 38), ('SUPERFICIAL_RELATIONSHIP', 70), ('FULL_UNKNOWN', 175), ('QUESTION_ANSWERED_BY_THIS_WORK', 202), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 208)]	8	[('CHEBI_27300', 'vitamin D', 103, 'vitamin D'), ('UBERON_0001977', 'blood serum', 213, 'serum'), ('CHEBI_27300', 'vitamin D', 229, 'vitamin D'), ('CHEBI_25212', 'metabolite', 239, 'metabolites'), ('GO_0007565', 'female pregnancy', 256, 'pregnant')]
S11-PMC2841444	PMC2841444	2/2010	S11-PMC2841444	['the following are SUPPORTED by moderate- to high-quality evidence and STRONGLY RECOMMENDED for lmics:\n• two INTERVENTIONS PREVENT Preterm Births—smoking cessation and Progesterone\n• eight INTERVENTIONS PREVENT stillbirths—balanced protein energy supplementation, screening and treatment of syphilis, intermittant presumptive treatment for malaria during Pregnancy, Insecticide-treated mosquito nets, Birth preparedness, emergency obstetric care, cesarean section for breech presentation, and elective induction for post-term Delivery\n• eleven INTERVENTIONS improve survival of Preterm newborns—prophylactic Steroids in Preterm labor, Antibiotics for prom, Vitamin K supplementation at Delivery, case management of neonatal sepsis and pneumonia, delayed Cord clamping, room air (vs. 100% oxygen) for resuscitation, hospital-based kangaroo mother care, early breastfeeding, thermal care, and Surfactant therapy and application of continued distending pressure to the Lungs for Respiratory Distress syndrome\n\nconclusion\nthe research paradigm for discovery science and intervention development MUST BE BALANCED to address PREVENTION as well as improve morbidity and mortality in all settings.']	[('INCOMPLETE_EVIDENCE', 18), ('PROBABLE_UNDERSTANDING', 70), ('FUTURE_WORK', 79), ('SUPERFICIAL_RELATIONSHIP', 108), ('SUPERFICIAL_RELATIONSHIP', 122), ('SUPERFICIAL_RELATIONSHIP', 188), ('SUPERFICIAL_RELATIONSHIP', 202), ('SUPERFICIAL_RELATIONSHIP', 543), ('IMPORTANT_CONSIDERATION', 1090), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1098), ('SUPERFICIAL_RELATIONSHIP', 1118)]	11	[('GO_0007565', 'female pregnancy', 130, 'preterm births'), ('CHEBI_17026', 'progesterone', 167, 'progesterone'), ('GO_0007565', 'female pregnancy', 354, 'pregnancy'), ('CHEBI_24852', 'insecticide', 365, 'insecticide'), ('GO_0007567', 'parturition', 400, 'birth'), ('GO_0007567', 'parturition', 525, 'delivery'), ('GO_0007565', 'female pregnancy', 577, 'preterm'), ('CHEBI_35341', 'steroid', 607, 'steroids'), ('GO_0007565', 'female pregnancy', 619, 'preterm'), ('CHEBI_33282', 'antibacterial agent', 634, 'antibiotics'), ('CHEBI_27300', 'vitamin D', 656, 'vitamin K'), ('GO_0007567', 'parturition', 685, 'delivery'), ('UBERON_0002240', 'spinal cord', 753, 'cord'), ('CHEBI_35195', 'surfactant', 890, 'surfactant'), ('UBERON_0002048', 'lung', 965, 'lungs'), ('UBERON_0003495', 'respiratory system arteriole', 975, 'respiratory distress')]
S481-PMC2841444	PMC2841444	2/2010	S481-PMC2841444	['preterm infants are deficient in Vitamin A due to INADEQUATE Hepatic stores and the inability to tolerate routine Oral supplementation [243,244].']	[('IMPORTANT_CONSIDERATION', 50)]	1	[('CHEBI_27300', 'vitamin D', 33, 'vitamin A'), ('UBERON_0002107', 'liver', 61, 'hepatic'), ('UBERON_0000165', 'mouth', 114, 'oral')]
S484-PMC2841444	PMC2841444	2/2010	S484-PMC2841444	['the RECENT lancet nutrition series IDENTIFIED neonatal Vitamin A supplementation in south asia were ASSOCIATED with a significant reduction in infant mortality at 6 months [245].']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 35), ('SUPERFICIAL_RELATIONSHIP', 100)]	3	[('CHEBI_27300', 'vitamin D', 55, 'vitamin A')]
S485-PMC2841444	PMC2841444	2/2010	S485-PMC2841444	['from these RECENT trials of neonatal Vitamin A supplementation, it was possible to obtain separate data for preterm infants from three rcts [246-248].']	[('INCOMPLETE_EVIDENCE', 11)]	1	[('CHEBI_27300', 'vitamin D', 37, 'vitamin A')]
S487-PMC2841444	PMC2841444	2/2010	S487-PMC2841444	['neonatal Vitamin A supplementation among preterm infants was ASSOCIATED with a nonsignificant reduction in infant mortality at 6 months of age (rr 0.87; 95% ci 0.65, 1.17).']	[('SUPERFICIAL_RELATIONSHIP', 61)]	1	[('CHEBI_27300', 'vitamin D', 9, 'vitamin A')]
S491-PMC2841444	PMC2841444	2/2010	S491-PMC2841444	['antenatal and Postnatal Vitamin K supplementation in preterm infants\nVitamin K is a fat-soluble Vitamin CRUCIAL to the Production Of many Proteins INVOLVED with the Coagulation Process.']	[('IMPORTANT_CONSIDERATION', 104), ('SUPERFICIAL_RELATIONSHIP', 147)]	2	[('GO_0007567', 'parturition', 14, 'postnatal'), ('CHEBI_27300', 'vitamin D', 24, 'vitamin K'), ('CHEBI_28384', 'vitamin K', 69, 'Vitamin K'), ('CHEBI_33229', 'vitamin (role)', 96, 'vitamin'), ('GO_0006412', 'translation', 119, 'production of ... proteins'), ('GO_0050817', 'coagulation', 165, 'coagulation process')]
S92-PMC2872349	PMC2872349	4/2010	S92-PMC2872349	['estimated exposure to ultraviolet b radiation during late Pregnancy (p < 0.0001) and the maternal use of Vitamin D supplements (p = 0.01) both PREDICTED maternal 25(Oh) Vitamin D concentration, and childhood bone mass (p = 0.03).']	[('SUPERFICIAL_RELATIONSHIP', 143)]	1	[('GO_0007565', 'female pregnancy', 58, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 105, 'vitamin D'), ('CHEBI_30778', 'gallic acid', 162, '25(OH)'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin D')]
S144-PMC2872349	PMC2872349	4/2010	S144-PMC2872349	['the maternal Vitamin D in osteoporosis study (mavidos) is a randomized controlled trial TO INVESTIGATE WHETHER supplementation of Vitamin D during Pregnancy serves to optimize offspring Skeletal Development, and commenced recruitment in 2008.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 88), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 103)]	2	[('CHEBI_28384', 'vitamin K', 13, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D'), ('GO_0007565', 'female pregnancy', 147, 'pregnancy'), ('GO_0001501', 'skeletal system development', 186, 'skeletal development'), ('UBERON_0004288', 'skeleton', 186, 'skeletal')]
S145-PMC2872349	PMC2872349	4/2010	S145-PMC2872349	['the STUDY AIMS TO TEST the HYPOTHESIS that Vitamin D supplementation of Pregnant women who have low levels of Vitamin D will result in improved neonatal bone Mineral content.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 10), ('QUESTION_ANSWERED_BY_THIS_WORK', 15), ('INCOMPLETE_EVIDENCE', 27)]	4	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('GO_0007565', 'female pregnancy', 72, 'pregnant'), ('CHEBI_27300', 'vitamin D', 110, 'vitamin D'), ('CHEBI_46662', 'mineral', 158, 'mineral')]
S111-PMC2874518	PMC2874518	6/2010	S111-PMC2874518	['women in our cohort were receiving adequate amounts of these Micronutrients from their diet alone, as assessed by the 24-hour dietary Recall (table 2), confirming the inverse Supplement HYPOTHESIS, that women who least NEED Supplements are most LIKELY to take them.22\nOTHER STUDIES have SUGGESTED POTENTIAL adverse EFFECTS of SOME Supplements, specifically those containing antioxidant Vitamins such as Vitamins C and E, on Pregnancy outcome when taken by women with adequate dietary Micronutrient intake.']	[('INCOMPLETE_EVIDENCE', 186), ('IMPORTANT_CONSIDERATION', 219), ('PROBABLE_UNDERSTANDING', 245), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 268), ('INCOMPLETE_EVIDENCE', 268), ('INCOMPLETE_EVIDENCE', 287), ('INCOMPLETE_EVIDENCE', 297), ('SUPERFICIAL_RELATIONSHIP', 315), ('INCOMPLETE_EVIDENCE', 326)]	9	[('CHEBI_33839', 'macromolecule', 61, 'micronutrients'), ('GO_0060033', 'anatomical structure regression', 134, 'recall'), ('CHEBI_16158', 'steroid sulfate', 175, 'supplement'), ('CHEBI_33341', 'titanium atom', 224, 'supplements'), ('CHEBI_33341', 'titanium atom', 331, 'supplements'), ('CHEBI_33277', 'gamma-tocotrienol', 386, 'vitamins'), ('CHEBI_27300', 'vitamin D', 403, 'vitamins C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 418, 'E'), ('GO_0007565', 'female pregnancy', 424, 'pregnancy'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 484, 'micronutrient')]
S113-PMC2874518	PMC2874518	6/2010	S113-PMC2874518	[',23in a case–control study of offspring with congenital Heart disease, FOUND that periconceptual use of Vitamin E supplements with high dietary intake of the same Vitamin was ASSOCIATED with up to nine-fold increase in the risk of congenital Heart disease.']	[('INCOMPLETE_EVIDENCE', 71), ('SUPERFICIAL_RELATIONSHIP', 175)]	2	[('UBERON_0000948', 'heart', 56, 'heart'), ('CHEBI_27300', 'vitamin D', 104, 'vitamin E'), ('CHEBI_33229', 'vitamin (role)', 163, 'vitamin'), ('UBERON_0000948', 'heart', 242, 'heart')]
S114-PMC2874518	PMC2874518	6/2010	S114-PMC2874518	['ANOTHER STUDY FOUND that use of supplements for Vitamins C and E was ASSOCIATED with an INCREASED RISK of premature rupture of membranes.24unfortunately, this information was NOT RECORDED in our study.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 14), ('SUPERFICIAL_RELATIONSHIP', 69), ('IMPORTANT_CONSIDERATION', 88), ('FULL_UNKNOWN', 175)]	5	[('CHEBI_27300', 'vitamin D', 48, 'vitamins C'), ('PR_000004900', 'complement C3', 57, 'C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 63, 'E')]
S115-PMC2874518	PMC2874518	6/2010	S115-PMC2874518	['in a randomised controlled trial TO ASSESS the EFFECT of Vitamin E and C supplementation during Pregnancy on the incidence of pre-eclampsia, poston et al.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 33), ('SUPERFICIAL_RELATIONSHIP', 47)]	2	[('CHEBI_27300', 'vitamin D', 57, 'vitamin E'), ('CHEBI_18245', 'carboxylato group', 71, 'C'), ('GO_0007565', 'female pregnancy', 96, 'pregnancy')]
S117-PMC2874518	PMC2874518	6/2010	S117-PMC2874518	['a RECENT-meta-analysis of seven studies CONCLUDED that combined Vitamin C and e supplementation had no potential benefit in the improvement of maternal and neonatal outcome and increased the risk of Gestational Hypertension in women at risk of pre-eclampsia.26\nit is WELL ESTABLISHED that there are significant INTERACTIONS between Micronutrients and their Metabolism.']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 40), ('INCOMPLETE_EVIDENCE', 267), ('PROBABLE_UNDERSTANDING', 267), ('SUPERFICIAL_RELATIONSHIP', 311)]	5	[('CHEBI_27300', 'vitamin D', 64, 'vitamin C'), ('GO_0007549', 'dosage compensation', 199, 'gestational hypertension'), ('CHEBI_33839', 'macromolecule', 332, 'micronutrients'), ('GO_0008152', 'metabolic process', 357, 'metabolism')]
S121-PMC2874518	PMC2874518	6/2010	S121-PMC2874518	['the PATTERN of dietary supplement use in our cohort, with most women taking Supplements (mainly Folic Acid) in the first Trimester, is expected because there is no national RECOMMENDATION in england for routine Supplement-taking during Pregnancy apart from Folic Acid in the first trimester and Vitamin D for Pregnant women in ‘high-RISK’ groups.30there is no national RECOMMENDATION to take multivitamin and Mineral supplements at any stage during Pregnancy.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('FUTURE_WORK', 173), ('IMPORTANT_CONSIDERATION', 333), ('FUTURE_WORK', 369)]	4	[('CHEBI_33341', 'titanium atom', 76, 'supplements'), ('CHEBI_30751', 'formic acid', 96, 'folic acid'), ('GO_0009294', 'DNA mediated transformation', 121, 'trimester'), ('CHEBI_16158', 'steroid sulfate', 211, 'supplement'), ('GO_0007565', 'female pregnancy', 236, 'pregnancy'), ('CHEBI_30751', 'formic acid', 257, 'folic acid'), ('CHEBI_27300', 'vitamin D', 295, 'vitamin D'), ('GO_0007565', 'female pregnancy', 309, 'pregnant'), ('CHEBI_46662', 'mineral', 409, 'mineral'), ('GO_0007565', 'female pregnancy', 449, 'pregnancy')]
S137-PMC2889879	PMC2889879	5/2010	S137-PMC2889879	['results from the northern finland 1966 Birth cohort SHOWED that Vitamin D supplementation during the first year of Life was ASSOCIATED with a reduced risk of schizophrenia in males, BUT NOT in women [32].']	[('INCOMPLETE_EVIDENCE', 52), ('SUPERFICIAL_RELATIONSHIP', 124), ('FULL_UNKNOWN', 182)]	3	[('GO_0007567', 'parturition', 39, 'Birth'), ('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('UBERON_0000104', 'life cycle', 115, 'life')]
S196-PMC2889879	PMC2889879	5/2010	S196-PMC2889879	['UNFORTUNATELY, we DO NOT HAVE information about specific Vitamin D supplementation.']	[('IMPORTANT_CONSIDERATION', 0), ('FULL_UNKNOWN', 18)]	2	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D')]
S197-PMC2889879	PMC2889879	5/2010	S197-PMC2889879	['BUT, adjustment for multivitamin supplement intake, containing Vitamin D, did not change the ESTIMATES.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 93)]	2	[('CHEBI_27300', 'vitamin D', 63, 'vitamin D')]
S49-PMC2913107	PMC2913107	8/2010	S49-PMC2913107	['seventeen Vitamin D EXPERTS RECENTLY STATED, ‘IN OUR OPINION, children with chronic illnesses such as autism, diabetes and/or frequent infections SHOULD BE supplemented with higher doses of sunshine or Vitamin D3, doses ADEQUATE to maintain their 25(Oh)D levels in the mid-normal of the reference range [65 ng/ml (162 nmol/l)] – and SHOULD BE so supplemented year round.’ (22)\nfinally, IF TRUE, a DARKER SIDE of the THEORY EMERGES.']	[('PROBABLE_UNDERSTANDING', 20), ('INCOMPLETE_EVIDENCE', 28), ('INCOMPLETE_EVIDENCE', 37), ('INCOMPLETE_EVIDENCE', 46), ('IMPORTANT_CONSIDERATION', 146), ('IMPORTANT_CONSIDERATION', 220), ('IMPORTANT_CONSIDERATION', 333), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 386), ('PROBABLE_UNDERSTANDING', 389), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 397), ('INCOMPLETE_EVIDENCE', 416), ('INCOMPLETE_EVIDENCE', 423)]	12	[('CHEBI_27300', 'vitamin D', 10, 'vitamin D'), ('CHEBI_33279', 'vitamin D5', 202, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 202, 'vitamin D3'), ('CHEBI_71657', 'versiconol acetate', 247, '25(OH)D')]
S87-PMC2963768	PMC2963768	10/2010	S87-PMC2963768	['to put these FINDINGS in a global context, it is first useful to draw a comparison with WHAT is PERHAPS the ONLY young infant ‘reference’ group studied at the equator where Vitamin D status would be expected to be optimal throughout the year in the absence of dietary supplementation or fortification.']	[('INCOMPLETE_EVIDENCE', 13), ('EXPLICIT_QUESTION', 88), ('INCOMPLETE_EVIDENCE', 96), ('INCOMPLETE_EVIDENCE', 108)]	4	[('CHEBI_27300', 'vitamin D', 173, 'vitamin D')]
S96-PMC2963768	PMC2963768	10/2010	S96-PMC2963768	['so, it is WORTHWHILE NOTING that, among formula-Fed or Vitamin D-supplemented infants (mean Vitamin D intake of ∼370 iu per day) aged 1-6 months (n=37) enrolled in a hospital-based study during the winter in alberta, canada (53°n) (20), the mean 25(Oh)D was 78 nmol/l (roth d et al .']	[('ANOMALY_CURIOUS_FINDING', 10)]	1	[('GO_0007631', 'feeding behavior', 48, 'fed'), ('CHEBI_27300', 'vitamin D', 55, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 92, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 246, '25(OH)D')]
S99-PMC2963768	PMC2963768	10/2010	S99-PMC2963768	['THEREFORE, these data from rural bangladesh, in combination with EARLIER FINDINGS from infants in urban pakistan, india, and uae, have DEMONSTRATED that the Vitamin D status of young infants in south asia and the middle east MAY BE no better than that of unsupplemented infants at much higher northern latitudes in north america, where GUIDELINES SUPPORT the provision of routine Vitamin D supplementation to all breastfed infants (21,22).']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 65), ('INCOMPLETE_EVIDENCE', 73), ('INCOMPLETE_EVIDENCE', 135), ('INCOMPLETE_EVIDENCE', 225), ('PROBABLE_UNDERSTANDING', 336), ('INCOMPLETE_EVIDENCE', 347)]	7	[('CHEBI_27300', 'vitamin D', 157, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 380, 'vitamin D')]
S108-PMC2963768	PMC2963768	10/2010	S108-PMC2963768	['young infants DEPEND ALMOST ENTIRELY on the transplacental transfer of Vitamin D and 25(Oh)D, which EXPLAINS the CONSISTENT ASSOCIATION between maternal and Cord-blood 25(Oh)D (25) and the observation that maternal Antenatal Vitamin D supplementation augments both maternal and Cord-Blood 25(Oh)D (26).']	[('SUPERFICIAL_RELATIONSHIP', 14), ('PROBABLE_UNDERSTANDING', 21), ('PROBABLE_UNDERSTANDING', 100), ('INCOMPLETE_EVIDENCE', 113), ('SUPERFICIAL_RELATIONSHIP', 124)]	5	[('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 85, '25(OH)D'), ('UBERON_0002240', 'spinal cord', 157, 'cord'), ('CHEBI_71657', 'versiconol acetate', 168, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 168, '25(OH ... D'), ('GO_0007567', 'parturition', 215, 'antenatal'), ('CHEBI_27300', 'vitamin D', 225, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 278, 'cord'), ('UBERON_0000178', 'blood', 283, 'blood'), ('CHEBI_71657', 'versiconol acetate', 289, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 289, '25 ... OH ... D')]
S125-PMC2963768	PMC2963768	10/2010	S125-PMC2963768	['Vitamin D Receptor, 24-hydroxylase\nDESPITE the current enthusiasm for Vitamin D supplementation in the usa (22), the EFFECTS of Vitamin D deficits during early infancy are STILL NOT FULLY UNDERSTOOD, and meaningful inflection points in 25(Oh)D-outcome RELATIONSHIPS have NOT BEEN ESTABLISHED.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 35), ('ANOMALY_CURIOUS_FINDING', 35), ('SUPERFICIAL_RELATIONSHIP', 117), ('FULL_UNKNOWN', 172), ('IMPORTANT_CONSIDERATION', 172), ('INCOMPLETE_EVIDENCE', 178), ('SUPERFICIAL_RELATIONSHIP', 252), ('FULL_UNKNOWN', 271), ('ANOMALY_CURIOUS_FINDING', 275)]	9	[('CHEBI_27300', 'vitamin D', 0, 'vitamin D'), ('PR_000001683', 'vasopressin V2 receptor', 0, 'vitamin D receptor'), ('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 128, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 236, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 236, '25'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 239, 'OH ... D')]
S154-PMC2963768	PMC2963768	10/2010	S154-PMC2963768	['THEREFORE, RECOMMENDATIONS for universal Antenatal and/or infant Vitamin D supplementation in bangladesh BASED ON biochemical data ALONE would be premature.']	[('PROBABLE_UNDERSTANDING', 0), ('FUTURE_WORK', 11), ('SUPERFICIAL_RELATIONSHIP', 105), ('ANOMALY_CURIOUS_FINDING', 131)]	4	[('GO_0007567', 'parturition', 41, 'antenatal'), ('CHEBI_27300', 'vitamin D', 65, 'vitamin D')]
S3-PMC3032617	PMC3032617	5/2010	S3-PMC3032617	['the AIM of the study was TO INVESTIGATE, in a ugandan rural Pregnant women cohort, the preventive EFFECTS of Vitamin C supplementation on hospital admission.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 25), ('SUPERFICIAL_RELATIONSHIP', 98)]	3	[('GO_0007565', 'female pregnancy', 60, 'pregnant'), ('CHEBI_27300', 'vitamin D', 109, 'vitamin C')]
S5-PMC3032617	PMC3032617	5/2010	S5-PMC3032617	['the primary outcome measure of this study was TO ASSESS the PREVENTION of hospitalization during Pregnancy in the group of women supplemented with Vitamin C compared to the controls.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 46), ('SUPERFICIAL_RELATIONSHIP', 60)]	2	[('GO_0007565', 'female pregnancy', 97, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 147, 'vitamin C')]
S37-PMC3032617	PMC3032617	5/2010	S37-PMC3032617	['all this considerations led us TO INVESTIGATE, in an open-label cohort randomized study, the preventive EFFECTS of regular Vitamin C supplementation on overall hospitalization rate in the Pregnant women population attending a ugandan rural health centre for Antenatal assessment.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 31), ('SUPERFICIAL_RELATIONSHIP', 104)]	2	[('CHEBI_27300', 'vitamin D', 123, 'vitamin C'), ('GO_0007565', 'female pregnancy', 188, 'pregnant'), ('GO_0007567', 'parturition', 258, 'antenatal')]
S38-PMC3032617	PMC3032617	5/2010	S38-PMC3032617	['the primary outcome measure of this study was TO ASSESS the PREVENTION of hospitalization during Pregnancy in the group of women supplemented with Vitamin C compared to the controls, and the secondary outcome measures were to compare the overall mother-to-child health benefits in the two groups, such as: overall hospitalization rate, weight gain during Pregnancy (normal <16kg), term Pregnancy (≥37 Gestational weeks), Preterm Delivery, Miscarriage (<24 Gestational weeks) and child low Birth weight (<2500g) and Gestational systolic Blood pressure.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 46), ('SUPERFICIAL_RELATIONSHIP', 60)]	2	[('GO_0007565', 'female pregnancy', 97, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 147, 'vitamin C'), ('GO_0007565', 'female pregnancy', 355, 'pregnancy'), ('GO_0007565', 'female pregnancy', 386, 'pregnancy'), ('GO_0007565', 'female pregnancy', 401, 'gestational'), ('GO_0007565', 'female pregnancy', 421, 'preterm'), ('GO_0007567', 'parturition', 429, 'delivery'), ('GO_0046660', 'female sex differentiation', 439, 'miscarriage'), ('GO_0007565', 'female pregnancy', 456, 'gestational'), ('GO_0007567', 'parturition', 489, 'birth'), ('GO_0007565', 'female pregnancy', 515, 'gestational'), ('UBERON_0000178', 'blood', 536, 'blood')]
S60-PMC3032617	PMC3032617	5/2010	S60-PMC3032617	['we HYPOTHESIZED to record at least 30% of women not hospitalized during Pregnancy in the control group in consideration of the fact they were supplemented regularly throughout their Pregnancy with Ferrous, Folic Acid and b-Complex for anemia prevention, also followed-up every month, ON THE OTHER SIDE at least a 50% of women not hospitalized in the group of women supplemented with Vitamin C in a 1:1 randomized ratio.']	[('INCOMPLETE_EVIDENCE', 3), ('DIFFICULT_TASK', 223), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 284)]	3	[('GO_0007565', 'female pregnancy', 72, 'pregnancy'), ('GO_0007565', 'female pregnancy', 182, 'pregnancy'), ('CHEBI_15378', 'hydron', 197, 'ferrous'), ('CHEBI_30751', 'formic acid', 206, 'folic acid'), ('CHEBI_34652', 'compactin diol lactone', 223, 'complex'), ('GO_0032991', 'protein-containing complex', 223, 'complex'), ('CHEBI_27300', 'vitamin D', 383, 'vitamin C')]
S92-PMC3032617	PMC3032617	5/2010	S92-PMC3032617	['chi squared value=9.971 with 4 degrees of freedom\n\ncaption (table-wrap): table 4:\nsystolic Blood pressure (bp) variation from baseline to Delivery in the two groups of womenbaseline (median, range)Delivery*(median, range)average increase (mmhg)p Vitamin C97 (86-134)104 (92-132)8.040.0001controls98 (83-133)103 (79-129)4.50.0001\nin cases of Miscarriage or Preterm Delivery, the last Antenatal bp value was considered in the analysis\n\ncaption (fig): figure 1:\n\nstudy flow diagram\n\ncaption (fig): figure 2:\n\npatients’ distribution in the two treatment groups according to the number of times hospitalized\n\ndiscussion\nin this randomized, open label, cohort study, the daily Vitamin C supplementation provided IMPORTANT clinical signs in the group of women treated.']	[('IMPORTANT_CONSIDERATION', 706)]	1	[('UBERON_0000178', 'blood', 91, 'blood'), ('GO_0007567', 'parturition', 138, 'delivery'), ('GO_0007586', 'digestion', 197, 'Delivery'), ('CHEBI_80326', 'Neuropeptide FF', 246, 'Vitamin C97'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 246, 'Vitamin C97'), ('GO_0046660', 'female sex differentiation', 341, 'miscarriage'), ('GO_0007565', 'female pregnancy', 356, 'preterm'), ('GO_0007567', 'parturition', 364, 'delivery'), ('GO_0007567', 'parturition', 383, 'antenatal'), ('CHEBI_27300', 'vitamin D', 671, 'vitamin C')]
S109-PMC3032617	PMC3032617	5/2010	S109-PMC3032617	['in second place , the higher increase achieved with the Vitamin C supplementation (8mmhg vs. 4.5mmhg), with a TREND towards SIGNIFICANCE, can be INTERPRETED in two ways; as an increased Gastric absorption of iron in the presence of Ascorbic Acid that HAS BEEN DEMONSTRATED in SEVERAL STUDIES [1,3,9,22] and also, the Red Blood Cell protection from oxidation in the presence of high amounts of Ascorbic Acid which HAS BEEN DEMONSTRATED to be an Electron Donor of Glutathione, a vital antioxidant of Red Blood Cells [1,3,24].']	[('INCOMPLETE_EVIDENCE', 110), ('IMPORTANT_CONSIDERATION', 124), ('FULL_UNKNOWN', 145), ('INCOMPLETE_EVIDENCE', 251), ('INCOMPLETE_EVIDENCE', 260), ('INCOMPLETE_EVIDENCE', 276), ('INCOMPLETE_EVIDENCE', 413)]	7	[('CHEBI_27300', 'vitamin D', 56, 'vitamin C'), ('UBERON_0001844', 'cochlea', 186, 'gastric'), ('CHEBI_22652', 'ascorbic acid', 232, 'ascorbic acid'), ('CL_0000232', 'erythrocyte', 317, 'red blood cell'), ('UBERON_0000178', 'blood', 321, 'blood'), ('CHEBI_22652', 'ascorbic acid', 393, 'ascorbic acid'), ('CHEBI_10545', 'electron', 444, 'electron'), ('CHEBI_13193', 'hydrogen acceptor', 453, 'donor'), ('CHEBI_16856', 'glutathione', 462, 'glutathione'), ('CL_0000232', 'erythrocyte', 498, 'red blood cells'), ('UBERON_0000178', 'blood', 502, 'blood')]
S112-PMC3032617	PMC3032617	5/2010	S112-PMC3032617	['the choice of dosing the Vitamin C supplement 400mg daily matured after reviewing the medical literature were it was HIGHLIGHTED that at doses exceeding 1g daily the PROBABILITY of side-effects such as diarrhea and Renal colic increased greatly [1,3,13,14] on the OTHER side doses up to 500 mg daily are advised by the official statement of the linus pauling’s institute to the general population, this led us to choose this dose as the SAFEST.']	[('INCOMPLETE_EVIDENCE', 117), ('PROBABLE_UNDERSTANDING', 166), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 264), ('IMPORTANT_CONSIDERATION', 437)]	4	[('CHEBI_27300', 'vitamin D', 25, 'vitamin C'), ('UBERON_0002113', 'kidney', 215, 'renal')]
S116-PMC3032617	PMC3032617	5/2010	S116-PMC3032617	['moreover, the supplementation of a relatively cheap, clinically SAFE and health-bearing integrator as Vitamin C, PROVED to add overall BENEFITS in terms of hospitalization and several other mother-to-child outcomes RELEVANT during Pregnancy.']	[('IMPORTANT_CONSIDERATION', 64), ('PROBABLE_UNDERSTANDING', 113), ('IMPORTANT_CONSIDERATION', 135), ('IMPORTANT_CONSIDERATION', 215)]	4	[('CHEBI_27300', 'vitamin D', 102, 'vitamin C'), ('GO_0007565', 'female pregnancy', 231, 'pregnancy')]
S128-PMC3032617	PMC3032617	5/2010	S128-PMC3032617	['our results INDICATE the benefit of adding Vitamin C in the guidelines of multivitamin supplementation to Pregnant women.']	[('INCOMPLETE_EVIDENCE', 12)]	1	[('CHEBI_27300', 'vitamin D', 43, 'vitamin C'), ('GO_0007565', 'female pregnancy', 106, 'pregnant')]
S1-PMC3034879	PMC3034879	12/2010	S1-PMC3034879	['Postnatal Vitamin D supplementation improved Vitamin D status BUT ONLY PARTLY eliminated the differences in bone variables induced by maternal Vitamin D status during the fetal period.']	[('ANOMALY_CURIOUS_FINDING', 62), ('ANOMALY_CURIOUS_FINDING', 66), ('INCOMPLETE_EVIDENCE', 66), ('INCOMPLETE_EVIDENCE', 71)]	4	[('GO_0007567', 'parturition', 0, 'Postnatal'), ('CHEBI_27300', 'vitamin D', 10, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 143, 'vitamin D')]
S14-PMC3034879	PMC3034879	12/2010	S14-PMC3034879	['conclusions\nPostnatal Vitamin D supplementation improved Vitamin D status BUT ONLY PARTLY eliminated the differences in bone variables induced by maternal Vitamin D status during the fetal period.']	[('ANOMALY_CURIOUS_FINDING', 74), ('ANOMALY_CURIOUS_FINDING', 78), ('INCOMPLETE_EVIDENCE', 83)]	3	[('GO_0007567', 'parturition', 12, 'Postnatal'), ('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 155, 'vitamin D')]
S104-PMC3034879	PMC3034879	12/2010	S104-PMC3034879	['higher dietary intake of Vitamin D and use of d3supplements were RELATED to improved Vitamin D status.']	[('SUPERFICIAL_RELATIONSHIP', 65)]	1	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 85, 'vitamin D')]
S159-PMC3034879	PMC3034879	12/2010	S159-PMC3034879	['ALTHOUGH all infants received Vitamin D supplementation, the difference between the groups in Tibia csa was maintained until 14\xa0months of age.']	[('ANOMALY_CURIOUS_FINDING', 0)]	1	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('UBERON_0000979', 'tibia', 94, 'tibia')]
S176-PMC3034879	PMC3034879	12/2010	S176-PMC3034879	['all subjects in the present study received supplementation, compared TO a representative study cohort in finland, in which 85% of 1-year-old infants and 70% of 2-year-old infants were reported to receive Vitamin D supplementation [37].']	[('QUESTION_ANSWERED_BY_THIS_WORK', 69)]	1	[('CHEBI_27300', 'vitamin D', 204, 'vitamin D')]
S179-PMC3034879	PMC3034879	12/2010	S179-PMC3034879	['INTERESTINGLY, the use of d3supplements was ASSOCIATED with improved Vitamin D status to a greater extent than use of d2supplements, which is IN LINE WITH FINDINGS of houghton and vieth [38].']	[('ANOMALY_CURIOUS_FINDING', 0), ('SUPERFICIAL_RELATIONSHIP', 44), ('INCOMPLETE_EVIDENCE', 142), ('INCOMPLETE_EVIDENCE', 155)]	4	[('CHEBI_27300', 'vitamin D', 69, 'vitamin D')]
S181-PMC3034879	PMC3034879	12/2010	S181-PMC3034879	['BECAUSE of Vitamin D supplementation, S-25-Ohd concentration increased during the follow-up.']	[('PROBABLE_UNDERSTANDING', 0)]	1	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('CHEBI_86929', 'S b G-5,5-G b S A CH2', 38, 'S-25-OHD')]
S191-PMC3034879	PMC3034879	12/2010	S191-PMC3034879	['given that more than 20% of the infants had S-25-Ohd below 50 nmol/l, DESPITE compliance with supplementation, higher intake of vitamin D is RECOMMENDED in order to obtain all the POTENTIAL health benefits of Vitamin D [43,44].']	[('ANOMALY_CURIOUS_FINDING', 70), ('FUTURE_WORK', 141), ('INCOMPLETE_EVIDENCE', 180)]	3	[('CHEBI_86929', 'S b G-5,5-G b S A CH2', 44, 'S-25-OHD'), ('PR_000001900', 'neuropilin-1', 44, 'S-25-OHD'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 136, 'D'), ('CHEBI_27300', 'vitamin D', 209, 'vitamin D')]
S192-PMC3034879	PMC3034879	12/2010	S192-PMC3034879	['optimally, Vitamin D sufficiency SHOULD BE guaranteed during fetal Life AS the FINDINGS of the PRESENT STUDY SUGGEST that the CONSEQUENCES of POOR Vitamin D status during the fetal period cannot be totally reverted by Postnatal Vitamin D supplementation.']	[('FUTURE_WORK', 33), ('IMPORTANT_CONSIDERATION', 33), ('PROBABLE_UNDERSTANDING', 72), ('INCOMPLETE_EVIDENCE', 79), ('QUESTION_ANSWERED_BY_THIS_WORK', 95), ('INCOMPLETE_EVIDENCE', 109), ('PROBLEM_COMPLICATION', 126), ('IMPORTANT_CONSIDERATION', 142)]	8	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('UBERON_0000104', 'life cycle', 67, 'life'), ('CHEBI_27300', 'vitamin D', 147, 'vitamin D'), ('GO_0007567', 'parturition', 218, 'postnatal'), ('CHEBI_27300', 'vitamin D', 228, 'vitamin D')]
S199-PMC3034879	PMC3034879	12/2010	S199-PMC3034879	['it CAN BE concluded that Postnatal Vitamin D supplementation improved Vitamin D status in infants and PARTLY eliminated the differences in bone variables that had resulted from maternal Vitamin D status during the fetal period.']	[('FUTURE_WORK', 3), ('INCOMPLETE_EVIDENCE', 102)]	2	[('GO_0007567', 'parturition', 25, 'postnatal'), ('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 186, 'vitamin D')]
S2-PMC3061267	PMC3061267	2/2011	S2-PMC3061267	['adequate Vitamin D and Calcium nutrition throughout Life MAY reduce the RISK of osteoporosis, and Calcium supplementation during Pregnancy MAY reduce Preeclampsia and low Birth weight.']	[('INCOMPLETE_EVIDENCE', 57), ('IMPORTANT_CONSIDERATION', 72), ('INCOMPLETE_EVIDENCE', 139)]	3	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 23, 'calcium'), ('UBERON_0000104', 'life cycle', 52, 'life'), ('CHEBI_22313', 'alkaline earth metal atom', 98, 'calcium'), ('GO_0007565', 'female pregnancy', 129, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 150, 'preeclampsia'), ('GO_0007567', 'parturition', 171, 'birth')]
S5-PMC3061267	PMC3061267	2/2011	S5-PMC3061267	['it is UNCLEAR WHETHER maternal Vitamin A supplementation will LEAD TO improved health outcomes for mother OR child.']	[('FULL_UNKNOWN', 6), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 14), ('SUPERFICIAL_RELATIONSHIP', 62)]	3	[('CHEBI_27300', 'vitamin D', 31, 'vitamin A')]
S40-PMC3061267	PMC3061267	2/2011	S40-PMC3061267	['WHILE DEFICIENCIES of several Nutrients besides iron CAN cause anemia, and SOME Nutrients like Vitamin A are OFTEN LINKED to iron status, a RECENT review FOUND no greater IMPACT of a multimicronutrient supplement on iron status THAN supplementing with iron alone [17].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('IMPORTANT_CONSIDERATION', 6), ('INCOMPLETE_EVIDENCE', 53), ('INCOMPLETE_EVIDENCE', 75), ('PROBABLE_UNDERSTANDING', 109), ('SUPERFICIAL_RELATIONSHIP', 115), ('INCOMPLETE_EVIDENCE', 140), ('INCOMPLETE_EVIDENCE', 154), ('SUPERFICIAL_RELATIONSHIP', 171), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 228)]	10	[('CHEBI_33284', 'nutrient', 30, 'nutrients'), ('CHEBI_33284', 'nutrient', 80, 'nutrients'), ('CHEBI_27300', 'vitamin D', 95, 'vitamin A')]
S11-PMC3075531	PMC3075531	7/2010	S11-PMC3075531	['SHOWED that sun exposure in Childhood period PREVENTS from ms.16third, it SEEMS low risk of ms in white population is ASSOCIATED with high Serum level of vitamin d or high oral Intake via supplements or oily fish in SOME STUDIES.217–19fourth, it HAVE BEEN SHOWN that Vitamin D CAN be a PROTECTIVE agent against experimental Autoimmune encephalitis in Mice (like ms in Humans).48finally, some scientists administered 100-1700 iu/day Vitamin D supplements in ms patients and OBSERVED the reduction of relapses.20–22the CANDIDATE for estimating Serum level of Vitamin D is 25-Hydroxy Vitamin D, BECAUSE of its prolonged half-Life.823–25it is used to assess an Individual’s overall Vitamin D nutritional status, BECAUSE its formation, UNLIKE that of 1, 25-Dihydroxy Vitamin D, is not tightly Regulated and it has a relatively long half-life (20-60 days).']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 45), ('ANOMALY_CURIOUS_FINDING', 74), ('SUPERFICIAL_RELATIONSHIP', 118), ('INCOMPLETE_EVIDENCE', 216), ('INCOMPLETE_EVIDENCE', 246), ('INCOMPLETE_EVIDENCE', 277), ('SUPERFICIAL_RELATIONSHIP', 286), ('INCOMPLETE_EVIDENCE', 473), ('INCOMPLETE_EVIDENCE', 517), ('PROBABLE_UNDERSTANDING', 592), ('PROBABLE_UNDERSTANDING', 708), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 731)]	13	[('UBERON_0013628', 'pollical pad', 28, 'childhood'), ('UBERON_0001977', 'blood serum', 139, 'serum'), ('GO_0007631', 'feeding behavior', 177, 'intake'), ('CHEBI_27300', 'vitamin D', 267, 'vitamin D'), ('UBERON_0001442', 'skeleton of manus', 324, 'autoimmune'), ('NCBITaxon_10088', 'Mus <genus>', 351, 'mice'), ('NCBITaxon_9606', 'Homo sapiens', 368, 'humans'), ('CHEBI_27300', 'vitamin D', 432, 'vitamin D'), ('UBERON_0001977', 'blood serum', 542, 'serum'), ('CHEBI_27300', 'vitamin D', 557, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 570, '25-hydroxy vitamin D'), ('UBERON_0000104', 'life cycle', 622, 'life'), ('NCBITaxon_1', 'root', 657, 'individual'), ('CHEBI_27300', 'vitamin D', 678, 'vitamin D'), ('CHEBI_43176', 'hydroxy group', 752, 'dihydroxy'), ('CHEBI_27300', 'vitamin D', 762, 'vitamin D'), ('GO_0065007', 'biological regulation', 788, 'regulated')]
S48-PMC3075531	PMC3075531	7/2010	S48-PMC3075531	['the ONLY study satisfying this condition used a nested case-control design to sample an underlying prospective cohort comprising over 7 million Individuals who served in the us military and had at least two Serum samples stored in the us department of defense Serum repository.18the study CONCLUDED that Serum concentration of 25 Hydroxyvitamin D in healthy young white Adults is an IMPORTANT PREDICTOR of their risk of developing ms, INDEPENDENTLY from their place of Birth and latitude of residence during childhood.18in a prospective investigation comprising approximately 200,000 women in the usa, Vitamin D intake was measured every 4 years by a comprehensive semi-quantitative Food frequency questionnaire.37the incidence of ms during the 30-year follow-up decreased with increasing Vitamin D intake (p=0.03 for trend) and was 33% lower among women in the highest quintile of Vitamin D intake versus those in the lowest quintile.17furthermore, ms incidence was 41% lower among women taking 400 iu per day or more from Supplements compared with non-users.17ATTEMPTS to RELATE Vitamin D intake to ms risk HAVE also BEEN made in casecontrol studies.']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 289), ('IMPORTANT_CONSIDERATION', 383), ('SUPERFICIAL_RELATIONSHIP', 393), ('SUPERFICIAL_RELATIONSHIP', 435), ('INCOMPLETE_EVIDENCE', 1062), ('SUPERFICIAL_RELATIONSHIP', 1074), ('INCOMPLETE_EVIDENCE', 1109)]	8	[('NCBITaxon_1', 'root', 144, 'individuals'), ('UBERON_0001977', 'blood serum', 207, 'serum'), ('UBERON_0001977', 'blood serum', 260, 'Serum'), ('UBERON_0001977', 'blood serum', 304, 'serum'), ('CHEBI_37972', 'phosphorus-32 atom', 327, '25'), ('CHEBI_67825', '17beta,21beta-epoxyhopan-3-one', 330, 'hydroxyvitamin D'), ('UBERON_0007023', 'adult organism', 370, 'adults'), ('GO_0007567', 'parturition', 469, 'birth'), ('CHEBI_27300', 'vitamin D', 602, 'vitamin D'), ('CHEBI_33290', 'food', 683, 'food'), ('CHEBI_27300', 'vitamin D', 789, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 882, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 1024, 'supplements'), ('CHEBI_27300', 'vitamin D', 1081, 'vitamin D')]
S49-PMC3075531	PMC3075531	7/2010	S49-PMC3075531	['in norway, a study comprising 119 ms cases and 251 controls living above the arctic circle, where Fatty Fish is a MAJOR CONTRIBUTOR to Vitamin D intake, REPORTED a lower risk of ms for Individuals who Ate fish three or more times per week at 16–20 years of age compared with those with a lower Consumption (odds ratio=0.57 [95%ci 0.33-0.93]; p=0.024).19supplementation with codliver oil was also ASSOCIATED with lower risk of ms, BUT ONLY among Individuals with low summer outdoor activity.']	[('IMPORTANT_CONSIDERATION', 114), ('SUPERFICIAL_RELATIONSHIP', 120), ('INCOMPLETE_EVIDENCE', 153), ('SUPERFICIAL_RELATIONSHIP', 396), ('ANOMALY_CURIOUS_FINDING', 430)]	5	[('CHEBI_38677', 'famphur', 98, 'fatty fish'), ('CHEBI_27300', 'vitamin D', 135, 'vitamin D'), ('NCBITaxon_1', 'root', 185, 'individuals'), ('GO_0009636', 'response to toxic substance', 201, 'ate'), ('GO_0007631', 'feeding behavior', 294, 'consumption'), ('NCBITaxon_1', 'root', 445, 'individuals')]
S62-PMC3075531	PMC3075531	7/2010	S62-PMC3075531	['WHEREAS FUTURE observational epidemiological studies and Genetic and molecular INVESTIGATIONS WILL be useful to strengthen and refine the HYPOTHESIS, it MIGHT be NECESSARY to do a LARGE randomized TRIAL to establish the SAFETY and efficacy NEEDED to promote large-scale Vitamin D supplementation.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('FUTURE_WORK', 8), ('FUTURE_WORK', 79), ('FUTURE_PREDICTION', 94), ('INCOMPLETE_EVIDENCE', 138), ('INCOMPLETE_EVIDENCE', 153), ('IMPORTANT_CONSIDERATION', 162), ('FUTURE_WORK', 180), ('IMPORTANT_CONSIDERATION', 220), ('FUTURE_WORK', 240)]	10	[('SO_0000704', 'gene', 57, 'genetic'), ('CHEBI_27300', 'vitamin D', 270, 'vitamin D')]
S65-PMC3075531	PMC3075531	7/2010	S65-PMC3075531	['furthermore, screening of Serum 25-Hydroxyvitamin D concentrations is LIKELY to identify a large proportion of patients who are Vitamin D deficient or insufficient, and who MIGHT BENEFIT from Vitamin D supplementation for PREVENTION of osteoporosis and other complications, especially multiple sclerosis.']	[('PROBABLE_UNDERSTANDING', 70), ('INCOMPLETE_EVIDENCE', 173), ('IMPORTANT_CONSIDERATION', 179), ('SUPERFICIAL_RELATIONSHIP', 222)]	4	[('UBERON_0001977', 'blood serum', 26, 'serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 32, '25-hydroxyvitamin D'), ('CHEBI_27300', 'vitamin D', 128, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 192, 'vitamin D')]
S16-PMC3103150	PMC3103150	3/2011	S16-PMC3103150	['this IMPLIES that babies Born to mothers with Vitamin D deficiency are very LIKELY to develop Vitamin D deficiency UNLESS supplemented from outside or adequately exposed to sunlight which is OFTEN NOT PRACTICAL during early Infancy.']	[('PROBABLE_UNDERSTANDING', 5), ('PROBABLE_UNDERSTANDING', 76), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 115), ('PROBABLE_UNDERSTANDING', 191), ('DIFFICULT_TASK', 197)]	5	[('GO_0007567', 'parturition', 25, 'born'), ('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin D'), ('UBERON_0000023', 'wing', 224, 'infancy')]
S107-PMC3103150	PMC3103150	3/2011	S107-PMC3103150	['the intake of Vitamin D is inadequate AS Food items (except infant formula) are not fortified and there is no policy of routine Vitamin D supplementation in pregnant/Lactating women and infants.']	[('PROBABLE_UNDERSTANDING', 38)]	1	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('CHEBI_33290', 'food', 41, 'food'), ('CHEBI_27300', 'vitamin D', 128, 'vitamin D'), ('GO_0007594', 'puparial adhesion', 166, 'lactating')]
S130-PMC3103150	PMC3103150	3/2011	S130-PMC3103150	['maternal Vitamin D status, intake of Vitamin supplement by infant and exposure to sunlight were positively CORRELATED with infants’ 25Ohd concentration.']	[('SUPERFICIAL_RELATIONSHIP', 107)]	1	"[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 37, 'vitamin'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 132, '25OHD')]"
S131-PMC3103150	PMC3103150	3/2011	S131-PMC3103150	['LARGER STUDIES and meta-analysis SHOULD BE conducted to CONFIRM the FINDINGS of the PRESENT study and develop RECOMMENDATIONS for Vitamin D supplementation for Pregnant and Lactating women and young infants.']	[('FUTURE_WORK', 0), ('FUTURE_WORK', 33), ('INCOMPLETE_EVIDENCE', 56), ('INCOMPLETE_EVIDENCE', 68), ('QUESTION_ANSWERED_BY_THIS_WORK', 84), ('FUTURE_WORK', 110)]	6	[('CHEBI_27300', 'vitamin D', 130, 'vitamin D'), ('GO_0007565', 'female pregnancy', 160, 'pregnant'), ('GO_0007594', 'puparial adhesion', 173, 'lactating')]
S37-PMC3107676	PMC3107676	4/2011	S37-PMC3107676	['PREVIOUS STUDIES have NOT REPORTED prevalence of Vitamin C supplementation among women who took Drugs classified as Nitrosatable or INDICATED the EFFECTS of Vitamin C intake on any ASSOCIATIONS between Nitrosatable Drug use and adverse Pregnancy outcomes.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 22), ('INCOMPLETE_EVIDENCE', 132), ('SUPERFICIAL_RELATIONSHIP', 146), ('SUPERFICIAL_RELATIONSHIP', 181)]	5	[('CHEBI_27300', 'vitamin D', 49, 'vitamin C'), ('CHEBI_23888', 'drug', 96, 'drugs'), ('CHEBI_7587', 'nitroalkane', 116, 'nitrosatable'), ('CHEBI_27300', 'vitamin D', 157, 'vitamin C'), ('CHEBI_75872', '(R)-sarin', 202, 'nitrosatable drug'), ('GO_0007565', 'female pregnancy', 236, 'pregnancy')]
S39-PMC3107676	PMC3107676	4/2011	S39-PMC3107676	['the PURPOSE of OUR STUDY was (1) TO describe the prevalence and PATTERNS of Nitrosatable Drug use among u.s. women during the first Trimester of Pregnancy, including type of Drug (secondary or tertiary Amine, amide) and indication of use; (2) TO EXAMINE maternal factors ASSOCIATED with Nitrosatable Drug use; and (3) TO INVESTIGATE the prevalence of supplemental Vitamin C use among women who took Nitrosatable Drugs in early Pregnancy.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 15), ('QUESTION_ANSWERED_BY_THIS_WORK', 33), ('SUPERFICIAL_RELATIONSHIP', 64), ('QUESTION_ANSWERED_BY_THIS_WORK', 243), ('SUPERFICIAL_RELATIONSHIP', 271), ('QUESTION_ANSWERED_BY_THIS_WORK', 318)]	7	[('CHEBI_75872', '(R)-sarin', 76, 'nitrosatable drug'), ('GO_0009294', 'DNA mediated transformation', 132, 'trimester'), ('GO_0007565', 'female pregnancy', 145, 'pregnancy'), ('CHEBI_23888', 'drug', 174, 'drug'), ('CHEBI_32952', 'amine', 202, 'amine'), ('CHEBI_7587', 'nitroalkane', 287, 'nitrosatable'), ('CHEBI_23888', 'drug', 300, 'drug'), ('CHEBI_27300', 'vitamin D', 364, 'vitamin C'), ('CHEBI_7496', 'nelfinavir', 399, 'nitrosatable drugs'), ('GO_0007565', 'female pregnancy', 427, 'pregnancy')]
S71-PMC3107676	PMC3107676	4/2011	S71-PMC3107676	['because Vitamin C supplement use varied CONSIDERABLY by month during the first trimester, we EXAMINED prevalence of supplement use (none, less than daily, daily) separately during the first, second, and third months of Pregnancy by Nitrosatable Drug use during the first trimester.']	[('ANOMALY_CURIOUS_FINDING', 40), ('QUESTION_ANSWERED_BY_THIS_WORK', 93)]	2	[('CHEBI_27300', 'vitamin D', 8, 'vitamin C'), ('GO_0007565', 'female pregnancy', 219, 'pregnancy'), ('CHEBI_75872', '(R)-sarin', 232, 'nitrosatable drug')]
S105-PMC3107676	PMC3107676	4/2011	S105-PMC3107676	['among women who took Nitrosatable Drugs, <40% reported daily use of a supplement with Vitamin C during the first month of Pregnancy (table 3), ALTHOUGH APPROXIMATELY 80% took such a Supplement daily by the third month.']	[('ANOMALY_CURIOUS_FINDING', 143), ('INCOMPLETE_EVIDENCE', 152)]	2	[('CHEBI_7496', 'nelfinavir', 21, 'nitrosatable drugs'), ('CHEBI_27300', 'vitamin D', 86, 'vitamin C'), ('GO_0007565', 'female pregnancy', 122, 'pregnancy'), ('CHEBI_16158', 'steroid sulfate', 182, 'supplement')]
S106-PMC3107676	PMC3107676	4/2011	S106-PMC3107676	['in the first month of Pregnancy, between 40 and 41% (DEPENDING ON the type of Nitrosatable Drug taken) of participants who took Nitrosatable Drugs did not take any Supplements with Vitamin C; the proportion of nonusers dropped to 12.3% by the third month of Pregnancy.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 53)]	1	[('GO_0007565', 'female pregnancy', 22, 'pregnancy'), ('CHEBI_7587', 'nitroalkane', 78, 'nitrosatable'), ('CHEBI_23888', 'drug', 91, 'drug'), ('CHEBI_7587', 'nitroalkane', 128, 'nitrosatable'), ('CHEBI_23888', 'drug', 141, 'drugs'), ('CHEBI_33341', 'titanium atom', 164, 'supplements'), ('CHEBI_27300', 'vitamin D', 181, 'vitamin C'), ('GO_0007565', 'female pregnancy', 258, 'pregnancy')]
S114-PMC3107676	PMC3107676	4/2011	S114-PMC3107676	['during the first and second months of Pregnancy, a sizable proportion of women who took Nitrosatable Drugs denied taking vitamin supplements with Vitamin C (41.6% and 19.3%, respectively), a WELL-DOCUMENTED Inhibitor Of Nitrosation.']	[('PROBABLE_UNDERSTANDING', 191)]	1	[('GO_0007565', 'female pregnancy', 38, 'pregnancy'), ('CHEBI_7496', 'nelfinavir', 88, 'nitrosatable drugs'), ('CHEBI_27300', 'vitamin D', 146, 'vitamin C'), ('CHEBI_50854', 'hydrocortamate hydrochloride', 207, 'inhibitor of'), ('CHEBI_52846', 'cycloalkane ring', 220, 'nitrosation')]
S115-PMC3107676	PMC3107676	4/2011	S115-PMC3107676	['by the third month of Pregnancy, APPROXIMATELY 80% reported taking Supplements that MOST LIKELY contained Vitamin C.\ncompared with prevalence ESTIMATES in PREVIOUSLY PUBLISHED STUDIES, the PRESENT STUDY has the highest REPORTED prevalence of Nitrosatable Drug use during early Pregnancy.']	[('INCOMPLETE_EVIDENCE', 33), ('PROBABLE_UNDERSTANDING', 84), ('PROBABLE_UNDERSTANDING', 89), ('INCOMPLETE_EVIDENCE', 142), ('INCOMPLETE_EVIDENCE', 155), ('QUESTION_ANSWERED_BY_THIS_WORK', 189), ('INCOMPLETE_EVIDENCE', 219)]	7	[('GO_0007565', 'female pregnancy', 22, 'pregnancy'), ('CHEBI_33341', 'titanium atom', 67, 'supplements'), ('CHEBI_27300', 'vitamin D', 106, 'vitamin C'), ('CHEBI_75872', '(R)-sarin', 242, 'nitrosatable drug'), ('GO_0007565', 'female pregnancy', 277, 'pregnancy')]
S129-PMC3169551	PMC3169551	9/2011	S129-PMC3169551	['the cost of coverage with weekly Iron-Folic Acid is COMPARABLE to program ESTIMATES for distribution of other Nutritional Supplements such as twice-yearly Vitamin A, and zinc.']	[('INCOMPLETE_EVIDENCE', 52), ('INCOMPLETE_EVIDENCE', 74)]	2	[('CHEBI_24870', 'ion', 33, 'iron'), ('CHEBI_30751', 'formic acid', 38, 'folic acid'), ('CHEBI_7495', 'nefazodone hydrochloride', 110, 'nutritional'), ('CHEBI_33341', 'titanium atom', 122, 'supplements'), ('CHEBI_27300', 'vitamin D', 155, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 163, 'A')]
S130-PMC3169551	PMC3169551	9/2011	S130-PMC3169551	['a RECENT survey[25]of the cost of Micronutrient supplementation programs (both published and “grey” literature) IDENTIFIED 43 STUDIES, of which 31 were for Vitamin A, and the rest for iron (7), Iodine (4) and zinc (1).']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 112), ('INCOMPLETE_EVIDENCE', 126)]	3	[('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 34, 'micronutrient'), ('CHEBI_27300', 'vitamin D', 156, 'vitamin A'), ('CHEBI_24859', 'iodine atom', 194, 'iodine')]
S141-PMC3171895	PMC3171895	9/2011	S141-PMC3171895	['vitamin c is commonly included in low doses (<200\u2009mg/day) within multivitamin preparations for Pregnancy but HAS also BEEN given in higher doses (up to 1000\u2009mg/day) as a supplement, alone or in combination with Vitamin E [127].']	[('INCOMPLETE_EVIDENCE', 109)]	1	[('GO_0007565', 'female pregnancy', 95, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 211, 'vitamin E')]
S145-PMC3171895	PMC3171895	9/2011	S145-PMC3171895	['a CONSIDERABLE INTEREST exists regarding PREVENTION of Maternal and Perinatal Morbidity with Vitamins C and E. HOWEVER, the most RECENT meta-analysis of ten trials (6533 women) published in 2008 of antioxidant supplementation (including Vitamin C and e but also OTHER supplements such as Lycopene) SHOWED no difference in the relative risk (rr) of Preeclampsia (rr 0.73, 95% ci 0.51 to 1.06), Preterm Birth (before 37 weeks) (rr 1.10, 95% ci 0.99 to 1.22), sga infants (rr 0.83, 95% ci 0.62 to 1.11), or any baby death (rr 1.12, 95% ci 0.81 to 1.53) [7].']	[('ANOMALY_CURIOUS_FINDING', 2), ('ANOMALY_CURIOUS_FINDING', 15), ('IMPORTANT_CONSIDERATION', 15), ('SUPERFICIAL_RELATIONSHIP', 41), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 111), ('INCOMPLETE_EVIDENCE', 129), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 262), ('INCOMPLETE_EVIDENCE', 298)]	8	[('GO_0007618', 'mating', 55, 'maternal ...'), ('GO_0019230', 'proprioception', 68, 'perinatal morbidity'), ('UBERON_0012101', 'perinatal stage', 68, 'perinatal'), ('CHEBI_27300', 'vitamin D', 93, 'vitamins C'), ('PR_000004900', 'complement C3', 102, 'C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 108, 'E'), ('CHEBI_27300', 'vitamin D', 237, 'vitamin C'), ('CHEBI_15948', 'lycopene', 288, 'lycopene'), ('GO_0007128', 'meiotic prophase I', 348, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 393, 'preterm'), ('GO_0007567', 'parturition', 401, 'birth')]
S147-PMC3171895	PMC3171895	9/2011	S147-PMC3171895	['a couple of subsequent RECENT multicentre double-blinded randomised trials of a combination of Vitamin C and E [130,131] also FOUND that supplementation did not reduce the rate of Preeclampsia or Gestational hypertension and, like the Vitamins in Preeclampsia trial in 2006 [132], increased the risk of fetal loss or Perinatal death and preterm prelabour rupture of Membranes.']	[('INCOMPLETE_EVIDENCE', 23), ('INCOMPLETE_EVIDENCE', 126)]	2	[('CHEBI_27300', 'vitamin D', 95, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 109, 'E'), ('GO_0007128', 'meiotic prophase I', 180, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 196, 'gestational'), ('CHEBI_28371', 'vitamin K epoxide', 235, 'Vitamins'), ('GO_0007128', 'meiotic prophase I', 247, 'Preeclampsia'), ('GO_0036268', 'swimming', 317, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 317, 'perinatal'), ('UBERON_0000922', 'embryo', 366, 'membranes')]
S148-PMC3171895	PMC3171895	9/2011	S148-PMC3171895	['ANOTHER RECENT multicentre placebo-controlled TRIAL of Vitamin C and E in women with type-1 diabetes in Pregnancy (Dapit) also REPORTED no differences in the rates of Preeclampsia between supplemented or placebo groups [133].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 8), ('INCOMPLETE_EVIDENCE', 46), ('INCOMPLETE_EVIDENCE', 127)]	4	"[('CHEBI_27300', 'vitamin D', 55, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 69, 'E'), ('GO_0007565', 'female pregnancy', 104, 'pregnancy'), ('CHEBI_73285', ""3-iodo-4-aminobenzyl-5'-N-methylcarboxamidoadenosine"", 115, 'DAPIT'), ('GO_0007128', 'meiotic prophase I', 167, 'preeclampsia')]"
S149-PMC3171895	PMC3171895	9/2011	S149-PMC3171895	['FURTHER INVESTIGATIONS are REQUIRED AS the concentrations of these Vitamins REMAIN significantly reduced in women with Preeclampsia, but in the absence OF FURTHER EVIDENCE, routine supplementation with higher dose Vitamin C and E is not RECOMMENDED AS they CAN be POTENTIALLY dangerous in high concentrations.']	[('FUTURE_WORK', 0), ('FUTURE_WORK', 8), ('IMPORTANT_CONSIDERATION', 27), ('PROBABLE_UNDERSTANDING', 36), ('INCOMPLETE_EVIDENCE', 76), ('ANOMALY_CURIOUS_FINDING', 152), ('INCOMPLETE_EVIDENCE', 155), ('FUTURE_WORK', 237), ('PROBABLE_UNDERSTANDING', 249), ('INCOMPLETE_EVIDENCE', 257), ('INCOMPLETE_EVIDENCE', 264)]	11	[('CHEBI_33277', 'gamma-tocotrienol', 67, 'vitamins'), ('GO_0007128', 'meiotic prophase I', 119, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 214, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 228, 'E')]
S39-PMC3257641	PMC3257641	3/2010	S39-PMC3257641	['the prevalence of low Vitamin D status during Pregnancy\nas noted above, Vitamin D adequacy DEPENDS on both endogenous, uv-induced synthesis, and exogenous sources, i.e., diet and Supplements.']	[('SUPERFICIAL_RELATIONSHIP', 91)]	1	[('CHEBI_28384', 'vitamin K', 22, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 46, 'Pregnancy'), ('CHEBI_27300', 'vitamin D', 72, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 179, 'supplements')]
S45-PMC3257641	PMC3257641	3/2010	S45-PMC3257641	['NEVERTHELESS, low Vitamin D status is also PREVALENT in Pregnant caucasian populations, PARTICULARLY those not receiving supplementation (table 2).nutrients-02-00389-t002_table 2\n\ncaption (table-wrap): table 2\n\nthe prevalence of a low Vitamin D status in Pregnancy.referenceyearcountrypopulationstage Of Pregnancydefinition% n/n[127]1997iraniran women attending largest tehran hospitaldelivery<25 nmol/l80% (40/50)[128]1997-2001usaafrican american–90% receiving Prenatal Vitamins4-21 week Gestation<37.5 nmol/l44.9% (89/194)[128]1997-2001usawhite–90% receiving Prenatal Vitamins4-21 week Gestation<37.5 nmol/l2% (4/199)[128]1997-2001usaafrican–american37-42 weeks<37.5 nmol/l29.2% (54/185)[128]1997-2001usawhite37-42 weeks<37.5 nmol/l5% (10/199)[128]1997-2001usaturkish12 week Gestation<25 nmol/l83.5% (66/79)[128]1997-2001usamoroccan12 week Gestation<25 nmol/l81.2% (56/69)[128]1997-2001usaother non-western12 week Gestation<25 nmol/l59% (62/105)[129]1999irelandcaucasians in ulster–on supplements (54–55on)12 weeks<25 nmol/l4.5% (1/22)[129]1999irelandno supplements12 weeks<25 nmol/l44.2% (34/77)[129]1999irelandsupplements20 weeks<25 nmol/l22.7% (5/22)[129]1999irelandno supplements20 weeks<25 nmol/l50.6% (39/77)[129]1999irelandsupplements35 weeks<25 nmol/l0% (0/22)[129]1999irelandno supplements35 weeks<25 nmol/l20.8% (16/77)[32]1999-2000australiaveiled &/or dark skinned women attending Antenatal clinicduring Antenatal care, when a routine Blood test was ordered<22.5 nmol/l80.5% (66/82)[130]1999-2000united arab emirateskuwaitdelivery<25 nmol/l40% (86/214)[131]2002indiaattendees of queen mary’s hosptal, lucknow (26.8on) northern india – urbandelivery–full term, live<22.5 nmol/l84.3% (118/140)[131]2002indiaattendees of queen mary’s hosptal, lucknow (26.8on) northern india–urbanrural<56.3 nmol/l84%(56/67)[132]2005-2006indiaresidents of barabanki district, 26.8onsecond trimester<50 nmol/l74.1% (103/139)\n\n4.1.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('IMPORTANT_CONSIDERATION', 43), ('ANOMALY_CURIOUS_FINDING', 88), ('IMPORTANT_CONSIDERATION', 88)]	4	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('GO_0007565', 'female pregnancy', 56, 'pregnant'), ('CHEBI_27300', 'vitamin D', 235, 'vitamin D'), ('GO_0007565', 'female pregnancy', 255, 'pregnancy'), ('GO_0007308', 'oocyte construction', 301, 'of PregnancyDefinition'), ('GO_0007565', 'female pregnancy', 462, 'prenatal'), ('CHEBI_38749', 'dihydroxyflavanone', 471, 'vitamins4'), ('GO_0007565', 'female pregnancy', 489, 'gestation'), ('GO_0007565', 'female pregnancy', 561, 'prenatal'), ('CHEBI_38749', 'dihydroxyflavanone', 570, 'vitamins4'), ('GO_0007565', 'female pregnancy', 588, 'gestation'), ('GO_0007565', 'female pregnancy', 777, 'gestation'), ('GO_0007565', 'female pregnancy', 842, 'gestation'), ('GO_0007565', 'female pregnancy', 916, 'gestation'), ('GO_0007567', 'parturition', 1394, 'antenatal'), ('GO_0007567', 'parturition', 1417, 'antenatal'), ('UBERON_0000178', 'blood', 1448, 'blood')]
S51-PMC3257641	PMC3257641	3/2010	S51-PMC3257641	['FEW STUDIES to date have examined Vitamin D supplementation during Pregnancy, and optimal 25(Oh)D levels have not yet been defined [35,36].']	[('INCOMPLETE_EVIDENCE', 0)]	1	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('GO_0007565', 'female pregnancy', 67, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 90, '25(OH)D')]
S56-PMC3257641	PMC3257641	3/2010	S56-PMC3257641	['a RECENT meta-analysis of Vitamin D supplementation in RELATION to bone health in Adults, SHOWED that for every 1 iu increase in oral Vitamin D3, the 25(Oh)D level COULD BE expected to increase by 0.016 nmol/l, with a relatively linear RELATIONSHIP AT LEAST up to 2000 iu/day [45].']	[('INCOMPLETE_EVIDENCE', 2), ('SUPERFICIAL_RELATIONSHIP', 55), ('INCOMPLETE_EVIDENCE', 90), ('INCOMPLETE_EVIDENCE', 164), ('SUPERFICIAL_RELATIONSHIP', 236), ('PROBABLE_UNDERSTANDING', 249)]	6	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('UBERON_0007023', 'adult organism', 82, 'adults'), ('CHEBI_33279', 'vitamin D5', 134, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 134, 'vitamin D3'), ('CHEBI_71657', 'versiconol acetate', 150, '25(OH)D')]
S98-PMC3257641	PMC3257641	3/2010	S98-PMC3257641	['the media REPORTED on a reduction in both Preterm Birth and small-for-dates babies, with Vitamin D supplementation [41], BUT formal publication of the FINDINGS had not occurred at the time of writing this review, THUS these reports cannot BE formally evaluated.']	[('INCOMPLETE_EVIDENCE', 10), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 121), ('INCOMPLETE_EVIDENCE', 151), ('PROBABLE_UNDERSTANDING', 213), ('ANOMALY_CURIOUS_FINDING', 239)]	5	[('GO_0007565', 'female pregnancy', 42, 'preterm'), ('GO_0007567', 'parturition', 50, 'birth'), ('CHEBI_27300', 'vitamin D', 89, 'vitamin D')]
S120-PMC3257641	PMC3257641	3/2010	S120-PMC3257641	['THESE FINDINGS are also CONSISTENT with the FINDING of an inverse ASSOCIATION between Postnatal Vitamin D supplementation in early Life and type 1 diabetes risk [90,91].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 24), ('INCOMPLETE_EVIDENCE', 44), ('SUPERFICIAL_RELATIONSHIP', 66)]	4	[('GO_0007567', 'parturition', 86, 'postnatal'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin D'), ('UBERON_0000104', 'life cycle', 131, 'life')]
S133-PMC3257641	PMC3257641	3/2010	S133-PMC3257641	['in a finnish Birth cohort study, regular Vitamin D supplementation (maternal self-report) during the first year of offspring Life was ASSOCIATED with a reduced risk of schizophrenia in males (but not females) (rr = 0.08, 95% ci 0.01–0.95) [106].']	[('SUPERFICIAL_RELATIONSHIP', 134)]	1	[('GO_0007567', 'parturition', 13, 'birth'), ('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('UBERON_0000104', 'life cycle', 125, 'life')]
S144-PMC3257641	PMC3257641	3/2010	S144-PMC3257641	['one Animal STUDY HAS SHOWN that maternal Antenatal Vitamin D supplementation was ASSOCIATED with greater mean Prostatic weight and a histologically more differentiated Prostatic architecture in offspring in Adulthood [123].']	[('INCOMPLETE_EVIDENCE', 11), ('INCOMPLETE_EVIDENCE', 17), ('SUPERFICIAL_RELATIONSHIP', 81)]	3	[('NCBITaxon_33208', 'Metazoa', 4, 'animal'), ('GO_0007567', 'parturition', 41, 'antenatal'), ('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('UBERON_0000054', 'macula', 110, 'prostatic'), ('UBERON_0000054', 'macula', 168, 'prostatic'), ('UBERON_0000113', 'post-juvenile adult stage', 207, 'adulthood')]
S149-PMC3257641	PMC3257641	3/2010	S149-PMC3257641	['insufficient trials have occurred for Vitamin D supplementation in RELATION to specific clinical outcomes.']	[('SUPERFICIAL_RELATIONSHIP', 67)]	1	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D')]
S150-PMC3257641	PMC3257641	3/2010	S150-PMC3257641	['EVEN with these trials (mostly of high risk women, many years ago) being systematically reviewed, it APPEARS that there is NOT ENOUGH EVIDENCE to evaluate the EFFECTS of Vitamin D supplementation in Pregnancy [124].']	[('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 101), ('INCOMPLETE_EVIDENCE', 123), ('SUPERFICIAL_RELATIONSHIP', 159)]	4	[('CHEBI_27300', 'vitamin D', 170, 'vitamin D'), ('GO_0007565', 'female pregnancy', 199, 'pregnancy')]
S158-PMC3257641	PMC3257641	3/2010	S158-PMC3257641	['CARE IS also NEEDED at the trial design and implementation stages to reduce the POSSIBILITY of POTENTIAL contamination of the placebo or lower dose Vitamin D group by additional subject-initiated Vitamin D supplementation or increased uvr exposure.']	[('FUTURE_WORK', 0), ('FUTURE_WORK', 5), ('FUTURE_WORK', 13), ('INCOMPLETE_EVIDENCE', 80), ('INCOMPLETE_EVIDENCE', 95)]	5	[('CHEBI_27300', 'vitamin D', 148, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 196, 'vitamin D')]
S0-PMC3271033	PMC3271033	1/2012	S0-PMC3271033	['EFFECTS of ethnicity and Vitamin D supplementation on Vitamin D status and changes in bone Mineral content in infants\n\nabstract\n\nabstract\n\nbackground\nTO EVALUATE the EFFECTS on Serum 25(Oh)D and Bone mineralization of supplementation of Breast-Fed hispanic and non-hispanic caucasian infants with Vitamin D in infants in houston, texas.']	[('SUPERFICIAL_RELATIONSHIP', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 150), ('SUPERFICIAL_RELATIONSHIP', 166)]	3	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('CHEBI_46662', 'mineral', 91, 'mineral'), ('UBERON_0001977', 'blood serum', 177, 'serum'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 186, 'OH)D'), ('GO_0007567', 'parturition', 195, 'bone'), ('UBERON_0000310', 'breast', 237, 'breast'), ('GO_0007631', 'feeding behavior', 244, 'fed'), ('CHEBI_27300', 'vitamin D', 297, 'vitamin D')]
S11-PMC3271033	PMC3271033	1/2012	S11-PMC3271033	['formula-Fed infants typically consume 300-500 iu/day from their formula and THEREFORE GENERALLY meet the current recommendations without an additional oral supplement of Vitamin D drops ESPECIALLY after the first 6 to 8 weeks of Life.']	[('PROBABLE_UNDERSTANDING', 76), ('PROBABLE_UNDERSTANDING', 86), ('ANOMALY_CURIOUS_FINDING', 186)]	3	[('GO_0007631', 'feeding behavior', 8, 'fed'), ('CHEBI_27300', 'vitamin D', 170, 'vitamin D'), ('UBERON_0000104', 'life cycle', 229, 'life')]
S13-PMC3271033	PMC3271033	1/2012	S13-PMC3271033	['REMARKABLY, FEW DATA have LOOKED AT modern techniques of assessing bone Mineral status and compared it to Vitamin D levels and supplementation in this population [5].']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 26)]	3	[('CHEBI_46662', 'mineral', 72, 'mineral'), ('CHEBI_27300', 'vitamin D', 106, 'vitamin D')]
S17-PMC3271033	PMC3271033	1/2012	S17-PMC3271033	"['THIS STUDY was CONDUCTED TO EVALUATE early Life bone Mineral content (bmc) and the EFFECTS of three months of Vitamin D supplementation in Breast-Fed hispanic and non-hispanic caucasian (henceforth, ""caucasian"") infants on Vitamin D levels.']"	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 15), ('QUESTION_ANSWERED_BY_THIS_WORK', 25), ('SUPERFICIAL_RELATIONSHIP', 83)]	4	[('UBERON_0000104', 'life cycle', 43, 'life'), ('CHEBI_46662', 'mineral', 53, 'mineral'), ('CHEBI_27300', 'vitamin D', 110, 'vitamin D'), ('UBERON_0000310', 'breast', 139, 'breast'), ('GO_0007631', 'feeding behavior', 146, 'fed'), ('CHEBI_27300', 'vitamin D', 223, 'vitamin D')]
S20-PMC3271033	PMC3271033	1/2012	S20-PMC3271033	['HOWEVER, the RELATIONSHIP between Vitamin D status and bone-related outcomes in supplemented infants provides INFORMATION about the EFFECTS of these Cord levels and Vitamin D supplementation in early Infancy.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('SUPERFICIAL_RELATIONSHIP', 13), ('INCOMPLETE_EVIDENCE', 110), ('SUPERFICIAL_RELATIONSHIP', 132)]	4	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 149, 'cord'), ('CHEBI_27300', 'vitamin D', 165, 'vitamin D'), ('UBERON_0000023', 'wing', 200, 'infancy')]
S79-PMC3271033	PMC3271033	1/2012	S79-PMC3271033	['Prenatal Vitamin Supplement composition VARIED by brand; however, most brands included 200 iu Vitamin D per pill.']	[('DIFFICULT_TASK', 40)]	1	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_63635', 'valganciclovir', 9, 'vitamin supplement'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin D')]
S109-PMC3271033	PMC3271033	1/2012	S109-PMC3271033	['supplementation with 400 iu/day of Vitamin D to these infants LED TO a relatively greater increase in those who were Born with the lowest Vitamin D status and there was no suggestion of any bone Mineral outcome deficits at one week or three months of age in infants with low Cord 25(Oh)D levels.']	[('SUPERFICIAL_RELATIONSHIP', 62)]	1	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('GO_0007567', 'parturition', 117, 'born'), ('CHEBI_27300', 'vitamin D', 138, 'vitamin D'), ('CHEBI_46662', 'mineral', 195, 'mineral'), ('UBERON_0002240', 'spinal cord', 275, 'cord'), ('CHEBI_71657', 'versiconol acetate', 280, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 280, '25(OH)D')]
S137-PMC3271033	PMC3271033	1/2012	S137-PMC3271033	['THEREFORE, in considering early Vitamin D supplementation, the QUESTION becomes WHETHER there is physiological BENEFIT to rapid replenishment with Vitamin D (e.g.']	[('PROBABLE_UNDERSTANDING', 0), ('EXPLICIT_QUESTION', 63), ('EXPLICIT_QUESTION', 80), ('IMPORTANT_CONSIDERATION', 111)]	4	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 147, 'vitamin D')]
S159-PMC3271033	PMC3271033	1/2012	S159-PMC3271033	['OUR FINDINGS SUPPORT current GUIDELINES to begin Vitamin D supplementation of 400 iu/day to all Breast-Fed infants in the first week of Life and to FURTHER ENCOURAGE the provision of adequate Vitamin D to Pregnant women.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 13), ('PROBABLE_UNDERSTANDING', 29), ('FUTURE_WORK', 148), ('FUTURE_WORK', 156)]	5	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('GO_0007567', 'parturition', 96, 'breast'), ('UBERON_0000310', 'breast', 96, 'breast'), ('GO_0007631', 'feeding behavior', 103, 'fed'), ('UBERON_0000104', 'life cycle', 136, 'life'), ('CHEBI_27300', 'vitamin D', 192, 'vitamin D'), ('GO_0007565', 'female pregnancy', 205, 'pregnant')]
S160-PMC3271033	PMC3271033	1/2012	S160-PMC3271033	['LARGER STUDIES ARE NEEDED in diverse populations at various latitudes to FURTHER characterize the RELATIONSHIP between Vitamin D supplementation and bone Mineral content.']	[('FUTURE_WORK', 0), ('FUTURE_WORK', 15), ('FUTURE_WORK', 73), ('SUPERFICIAL_RELATIONSHIP', 98)]	4	[('CHEBI_27300', 'vitamin D', 119, 'vitamin D'), ('CHEBI_46662', 'mineral', 154, 'mineral')]
S39-PMC3274449	PMC3274449	12/2011	S39-PMC3274449	['ACCORDING TO the national policy, children from 6-59 mo SHOULD BE supplemented with Vitamin A every 6 months and mothers SHOULD receive a Vitamin A dose within 2 months after delivary.']	[('INCOMPLETE_EVIDENCE', 0), ('FUTURE_WORK', 56), ('FUTURE_WORK', 121)]	3	[('CHEBI_27300', 'vitamin D', 84, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 138, 'vitamin A')]
S25-PMC3277098	PMC3277098	12/2011	S25-PMC3277098	['WHILE the incidence of rickets has been largely reduced in western countries through the use of dietary supplementation and uv exposure [12], the same societies continue to experience a high prevalence of sub-clinical Vitamin D deficiency or insufficiency [13] that is LIKELY RELATED to indoor lifestyle habits with limited sun exposure.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('PROBABLE_UNDERSTANDING', 269), ('SUPERFICIAL_RELATIONSHIP', 276)]	4	[('CHEBI_27300', 'vitamin D', 218, 'vitamin D')]
S29-PMC3277098	PMC3277098	12/2011	S29-PMC3277098	['such populations are THEREFORE reliant on dietary or supplemental sources of Vitamin D; a FACTOR that MAY BE playing a ROLE in the current allergy epidemic [16,17].']	[('PROBABLE_UNDERSTANDING', 21), ('SUPERFICIAL_RELATIONSHIP', 90), ('INCOMPLETE_EVIDENCE', 102), ('SUPERFICIAL_RELATIONSHIP', 119)]	4	[('CHEBI_27300', 'vitamin D', 77, 'vitamin D')]
S34-PMC3277098	PMC3277098	12/2011	S34-PMC3277098	['in non-supplemented infants serum 25(Oh)D status TENDS to decrease over the first few months of Life until sun exposure is increased and Vitamin D-containing Foods introduced into the diet.']	[('SUPERFICIAL_RELATIONSHIP', 49)]	1	[('CHEBI_71657', 'versiconol acetate', 34, '25(OH)D'), ('UBERON_0000104', 'life cycle', 96, 'life'), ('CHEBI_27300', 'vitamin D', 137, 'vitamin D'), ('CHEBI_33290', 'food', 158, 'foods')]
S59-PMC3277098	PMC3277098	12/2011	S59-PMC3277098	['the “Vitamin D/microbiome HYPOTHESIS” has PROPONENTS on BOTH SIDES, with vassallo and camargo [35] ARGUING that deficiency is causative, WHILE wjst [17] SUGGESTS that the introduction of Vitamin D supplementation COINCIDES with the rise in allergic disease.']	[('INCOMPLETE_EVIDENCE', 26), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 42), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 56), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 99), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 137), ('INCOMPLETE_EVIDENCE', 153), ('SUPERFICIAL_RELATIONSHIP', 213)]	7	[('CHEBI_27300', 'vitamin D', 5, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 187, 'vitamin D')]
S117-PMC3277098	PMC3277098	12/2011	S117-PMC3277098	['basing their “recurrent wheeze” classification on the asthma predictive index, the authors report a significant inverse ASSOCIATION between Antenatal dietary and supplemental Vitamin D intake and the risk of ever having wheeze or having recurrent wheeze symptoms.']	[('SUPERFICIAL_RELATIONSHIP', 120)]	1	[('GO_0007567', 'parturition', 140, 'antenatal'), ('CHEBI_27300', 'vitamin D', 175, 'vitamin D')]
S132-PMC3277098	PMC3277098	12/2011	S132-PMC3277098	['RECORDED Serum 25(Oh)D in addition to dietary and supplemental Vitamin D intake and ESTIMATED uv exposure in 466 Pregnant women in the uk [55].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 84)]	2	[('UBERON_0001977', 'blood serum', 9, 'serum'), ('CHEBI_71657', 'versiconol acetate', 15, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 15, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('GO_0007565', 'female pregnancy', 113, 'pregnant')]
S133-PMC3277098	PMC3277098	12/2011	S133-PMC3277098	['in this cohort 6.5% of women took a Vitamin D-containing Supplement, a FACTOR that was borderline significant for Vitamin D status, and only 3 women met the uk dietary RECOMMENDATION of 10 µg/day.']	[('SUPERFICIAL_RELATIONSHIP', 71), ('FUTURE_WORK', 168)]	2	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('CHEBI_16158', 'steroid sulfate', 57, 'supplement'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D')]
S183-PMC3277098	PMC3277098	12/2011	S183-PMC3277098	['a NUMBER OF longitudinal OBSERVATIONAL studies have specifically examined infant Vitamin D supplementation in the context of allergic disease.']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 25)]	2	[('CHEBI_27300', 'vitamin D', 81, 'vitamin D')]
S184-PMC3277098	PMC3277098	12/2011	S184-PMC3277098	['this data has the advantage of focussing on the Early Life Period and MAY THEREFORE provide INSIGHT into the aetiological ROLE of Vitamin D. DESPITE the OBSERVED PROTECTIVE ASSOCIATION of Serum 25(Oh)D and allergy, it has been NOTED that the widespread practice of supplementation COINCIDED with the rise in allergic disease [35].']	[('INCOMPLETE_EVIDENCE', 70), ('PROBABLE_UNDERSTANDING', 74), ('INCOMPLETE_EVIDENCE', 92), ('SUPERFICIAL_RELATIONSHIP', 122), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 141), ('ANOMALY_CURIOUS_FINDING', 141), ('INCOMPLETE_EVIDENCE', 153), ('SUPERFICIAL_RELATIONSHIP', 162), ('SUPERFICIAL_RELATIONSHIP', 173), ('ANOMALY_CURIOUS_FINDING', 227), ('SUPERFICIAL_RELATIONSHIP', 281)]	11	[('UBERON_0019248', 'early embryo', 48, 'early life period'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D'), ('UBERON_0001977', 'blood serum', 188, 'serum'), ('CHEBI_71657', 'versiconol acetate', 194, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 194, '25(OH)D')]
S185-PMC3277098	PMC3277098	12/2011	S185-PMC3277098	['SUPPORTING this observation are SEVERAL STUDIES which FOUND Vitamin D supplementation to be ASSOCIATED with an INCREASED RISK of atopic dermatitis [73], allergic rhinitis [35,74], asthma, sensitisation [69,74] and Food allergy [70], HOWEVER NONE of these papers are SUPPORTED by biological measures of Vitamin D status.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 32), ('INCOMPLETE_EVIDENCE', 54), ('SUPERFICIAL_RELATIONSHIP', 92), ('IMPORTANT_CONSIDERATION', 111), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 233), ('INCOMPLETE_EVIDENCE', 241), ('INCOMPLETE_EVIDENCE', 266)]	8	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('CHEBI_33290', 'food', 214, 'food'), ('CHEBI_27300', 'vitamin D', 302, 'vitamin D')]
S187-PMC3277098	PMC3277098	12/2011	S187-PMC3277098	['[74] reported that supplementation with 50 µg Vitamin D/day (2000 iu) in the first year of Life was ASSOCIATED with a higher RISK of allergic rhinitis (or 1.66; 95% ci 1.1–1.6, p< 0.001) and atopy (or 1.46; 95% ci 1.4–2.0, p< 0.001).']	[('SUPERFICIAL_RELATIONSHIP', 100), ('IMPORTANT_CONSIDERATION', 125)]	2	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('UBERON_0000104', 'life cycle', 91, 'life')]
S194-PMC3277098	PMC3277098	12/2011	S194-PMC3277098	['there is also SOME EVIDENCE that the EFFECT of supplementation MAY depend ON WHETHER Vitamin D is administered in a fat- OR Water-soluble form.']	[('INCOMPLETE_EVIDENCE', 14), ('SUPERFICIAL_RELATIONSHIP', 37), ('INCOMPLETE_EVIDENCE', 63), ('ANOMALY_CURIOUS_FINDING', 74), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 77), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 121)]	6	[('CHEBI_27300', 'vitamin D', 85, 'vitamin D'), ('CHEBI_15377', 'water', 124, 'water')]
S198-PMC3277098	PMC3277098	12/2011	S198-PMC3277098	['IN SUMMARY, the CONTRARY epidemiological OBSERVATIONS between Serum status (GENERALLY PROTECTIVE) and Oral exposure (supplementation increasing allergy risk in MANY STUDIES) HIGHLIGHT the uncertainty surrounding Vitamin D in Allergy Development and precludes population RECOMMENDATIONS.']	[('INCOMPLETE_EVIDENCE', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 16), ('INCOMPLETE_EVIDENCE', 41), ('PROBABLE_UNDERSTANDING', 76), ('SUPERFICIAL_RELATIONSHIP', 86), ('INCOMPLETE_EVIDENCE', 160), ('INCOMPLETE_EVIDENCE', 174), ('FUTURE_WORK', 270)]	8	[('UBERON_0001977', 'blood serum', 62, 'serum'), ('UBERON_0000165', 'mouth', 102, 'oral'), ('CHEBI_27300', 'vitamin D', 212, 'vitamin D'), ('GO_0060021', 'roof of mouth development', 225, 'allergy development')]
S201-PMC3277098	PMC3277098	12/2011	S201-PMC3277098	['FUTURE RESEARCH MUST accurately account for the DIFFERENT sources of Vitamin D, stage of Immune Development and Genetic FACTORS in order to understand the immunological consequences of changing Vitamin d status through supplementation or lifestyle changes.']	[('FUTURE_WORK', 0), ('IMPORTANT_CONSIDERATION', 16), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 48), ('SUPERFICIAL_RELATIONSHIP', 120)]	4	[('CHEBI_27300', 'vitamin D', 69, 'vitamin D'), ('GO_0001822', 'kidney development', 89, 'immune development'), ('UBERON_0002405', 'immune system', 89, 'immune'), ('SO_0000704', 'gene', 112, 'genetic'), ('CHEBI_33229', 'vitamin (role)', 194, 'vitamin')]
S207-PMC3277098	PMC3277098	12/2011	S207-PMC3277098	['RANDOMIZED control TRIALS are ultimately REQUIRED to determine the EFFECTS of Vitamin D supplementation on the developing Immune System, and any POTENTIAL ROLE in preventing allergic disease.']	[('FUTURE_WORK', 0), ('FUTURE_WORK', 19), ('FUTURE_WORK', 41), ('IMPORTANT_CONSIDERATION', 41), ('SUPERFICIAL_RELATIONSHIP', 67), ('INCOMPLETE_EVIDENCE', 145), ('SUPERFICIAL_RELATIONSHIP', 155)]	7	[('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('UBERON_0002405', 'immune system', 122, 'immune system')]
S137-PMC3278486	PMC3278486	1/2012	S137-PMC3278486	"[""comparison with other studies\nour finding of no benefit, BUT a POSSIBLE adverse EFFECT from Folic Acid supplementation on cancer incidence is IN LINE WITH REPORTED results of studies on other Nutrient supplements, including Vitamin E, Β-Carotene (Vitamin-A precursor) or Selenium; all SHOWING no or an adverse EFFECT of supplementation in controlled clinical trials on cancer development.4243a RECENT meta-analysis of Folic Acid supplements by clarke and coworkers, in the ‘b-Vitamin treatment trialists' collaboration’3with individual patient data, FOUND no increased cancer risk in any subgroups.""]"	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 57), ('INCOMPLETE_EVIDENCE', 63), ('SUPERFICIAL_RELATIONSHIP', 80), ('INCOMPLETE_EVIDENCE', 142), ('INCOMPLETE_EVIDENCE', 155), ('INCOMPLETE_EVIDENCE', 285), ('SUPERFICIAL_RELATIONSHIP', 310), ('INCOMPLETE_EVIDENCE', 394), ('INCOMPLETE_EVIDENCE', 550)]	9	[('CHEBI_30751', 'formic acid', 92, 'folic acid'), ('CHEBI_33284', 'nutrient', 192, 'nutrient'), ('CHEBI_27300', 'vitamin D', 224, 'vitamin E'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 235, 'β-carotene'), ('CHEBI_83326', 'tedizolid phosphate', 247, 'vitamin-A'), ('CHEBI_27568', 'selenium atom', 271, 'selenium'), ('CHEBI_30751', 'formic acid', 418, 'folic acid'), ('CHEBI_33229', 'vitamin (role)', 476, 'Vitamin')]
S3-PMC3347007	PMC3347007	4/2012	S3-PMC3347007	['67.6% of the women reported use of Vitamin D supplements BUT ONLY 36.9% reported use of Vitamin D supplements of at least 10 µg.']	[('ANOMALY_CURIOUS_FINDING', 57)]	1	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 88, 'vitamin D')]
S6-PMC3347007	PMC3347007	4/2012	S6-PMC3347007	['we PROPOSE that clinicians ENCOURAGE Vitamin D supplementation among Pregnant women, with SPECIAL FOCUS on vulnerable groups such as the young, smokers and multiparous women, in order to improve maternal and fetal health both during and after Pregnancy.']	[('INCOMPLETE_EVIDENCE', 3), ('FUTURE_WORK', 27), ('IMPORTANT_CONSIDERATION', 90), ('IMPORTANT_CONSIDERATION', 98)]	4	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('GO_0007565', 'female pregnancy', 69, 'pregnant'), ('GO_0007565', 'female pregnancy', 243, 'pregnancy')]
S11-PMC3347007	PMC3347007	4/2012	S11-PMC3347007	['dietary Vitamin D intake is very LIMITED and THEREFORE supplementation is NEEDED to avoid Vitamin D deficiency during sun-deprived periods.']	[('INCOMPLETE_EVIDENCE', 33), ('PROBABLE_UNDERSTANDING', 45), ('FUTURE_WORK', 74)]	3	[('CHEBI_27300', 'vitamin D', 8, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 90, 'vitamin D')]
S57-PMC3347007	PMC3347007	4/2012	S57-PMC3347007	['the database is NOT VALIDATED but validation of a similar database from the norwegian Birth cohort (moba) SHOWED good agreement between supplementary Vitamin D measured by ffq and 25(Oh)D-levels [24].']	[('FULL_UNKNOWN', 16), ('INCOMPLETE_EVIDENCE', 106)]	2	[('GO_0007567', 'parturition', 86, 'birth'), ('CHEBI_27300', 'vitamin D', 150, 'vitamin D'), ('CHEBI_73376', 'Ala-Met-Ser-Arg', 180, '25(OH)D-')]
S79-PMC3347007	PMC3347007	4/2012	S79-PMC3347007	['67.6% of participants reported use of Vitamin D supplements in any dose (table 1) and 36.9% reported use of Vitamin D supplements of AT LEAST 10 µg, which is the dose now RECOMMENDED during Pregnancy by the danish national board of health .']	[('PROBABLE_UNDERSTANDING', 133), ('FUTURE_WORK', 171)]	2	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin D'), ('GO_0007565', 'female pregnancy', 190, 'pregnancy')]
S82-PMC3347007	PMC3347007	4/2012	S82-PMC3347007	['in Gestational week 20 to 25 (the period also covered by the ffq), the proportion of women reporting use of Vitamin D supplements ≥10 µg per day was APPROXIMATELY 30%.']	[('INCOMPLETE_EVIDENCE', 149)]	1	[('GO_0007565', 'female pregnancy', 3, 'gestational'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin D')]
S85-PMC3347007	PMC3347007	4/2012	S85-PMC3347007	['IN ORDER TO INVESTIGATE the sources of Vitamin D, total Vitamin D intake was divided into quartiles, and mean intake of dietary Vitamin D and Vitamin D from Supplements in each quartile was calculated.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 9)]	2	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 128, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 142, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 157, 'supplements')]
S86-PMC3347007	PMC3347007	4/2012	S86-PMC3347007	['the sources were ranked according to their contribution to total Vitamin D intake (table 2), and we FOUND that supplements were the primary source of Vitamin D for the two higher quartiles and diet was for the two lower quartiles.']	[('INCOMPLETE_EVIDENCE', 100)]	1	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 150, 'vitamin D')]
S87-PMC3347007	PMC3347007	4/2012	S87-PMC3347007	['caption (fig): figure 2\n\nproportion of women (%) reporting intake of Vitamin D supplements ≥10 µg per day per Gestational week in Gestational week 1 to 39 BASED ON information from dnbc interviews 2 and 3 ( n = 68,447).nutrients-04-00259-t002_table 2\n\ncaption (table-wrap): table 2\n\nmean intake of Vitamin D from diet, supplements and total intake, along with ranking of sources according to quartiles of total Vitamin D intake ( n = 68,447) *.quartiles of total Vitamin D intake (µg/day)1234mean Vitamin D intakeµg/day (%)orderµg/day (%)orderµg/day (%)orderµg/day (%)ordertotal2.62 (100)6.82 (100)11.20 (100)16.29 (100)supplements0.03 (1.15)23.31 (48.53)27.88 (70.36)111.46 (70.35)1diet2.59 (98.85)13.51 (51.47)13.33 (29.73)24.83 (29.65)2\n* based on information from the Food frequency questionnaire covering Intake in Gestational weeks 21–25.nutrients-04-00259-t003_table 3\n\ncaption (table-wrap): table 3\n\nmean intake of Vitamin D from Food groups according to quartiles of dietary Vitamin D intake in Gestational weeks 21–25 ( n = 68,447) *.quartiles of dietary Vitamin D intake (µg/day)1234mean Vitamin D intakeµg/day (%)orderµg/day (%)orderµg/day (%)orderµg/day (%)orderall Food groups1.7 (100)2.6 (100)3.7 (100)6.3 (100)Pork0.2 (11.8)30.2 (7.7)40.2 (5.4)40.2 (3.2)3beef/veal0.2 (11.8)30.2 (7.7)40.2 (5.4)40.2 (3.2)3processed meat0.1 (5.9)40.1 (3.8)50.1 (2.7)50.1 (1.6)4fish and seafood0.4 (23.5)10.9 (34.6)11.8 (48.6)14.3 (68.3)1egg0.2 (11.8)30.4 (15.4)30.4 (10.8)30.5 (7.9)2low fat dairy0.3 (17.6)20.5 (19.2)20.5 (13.5)20.5 (7.9)2\n* based on information from the Food frequency questionnaire.']	[('PROBABLE_UNDERSTANDING', 155)]	1	[('CHEBI_27300', 'vitamin D', 69, 'vitamin D'), ('GO_0007565', 'female pregnancy', 110, 'gestational'), ('GO_0007565', 'female pregnancy', 130, 'gestational'), ('CHEBI_27300', 'vitamin D', 298, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 411, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 463, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 497, 'vitamin D'), ('CHEBI_33290', 'food', 772, 'food'), ('GO_0007631', 'feeding behavior', 810, 'intake'), ('GO_0007565', 'female pregnancy', 820, 'gestational'), ('CHEBI_27300', 'vitamin D', 923, 'vitamin D'), ('CHEBI_33290', 'food', 938, 'food'), ('CHEBI_27300', 'vitamin D', 984, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1004, 'gestational'), ('CHEBI_27300', 'vitamin D', 1065, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1099, 'vitamin D'), ('CHEBI_33290', 'food', 1179, 'food'), ('PR_000013039', 'POU domain, class 3, transcription factor 2', 1226, 'Pork0'), ('CHEBI_33290', 'food', 1570, 'food')]
S131-PMC3347007	PMC3347007	4/2012	S131-PMC3347007	['none of the participants reported dietary intakes that match the RECOMMENDED intake level in Pregnancy of 10 µg per day, which underlines the NECESSITY of Vitamin D supplementation.']	[('FUTURE_WORK', 65), ('IMPORTANT_CONSIDERATION', 142)]	2	[('GO_0007565', 'female pregnancy', 93, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 155, 'vitamin D')]
S132-PMC3347007	PMC3347007	4/2012	S132-PMC3347007	['the RECOMMENDATIONS for Pregnant women in most northern countries include a Vitamin D supplement of 10 µg per day.']	[('FUTURE_WORK', 4), ('IMPORTANT_CONSIDERATION', 4)]	2	[('GO_0007565', 'female pregnancy', 24, 'pregnant'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin D')]
S133-PMC3347007	PMC3347007	4/2012	S133-PMC3347007	['in the dnbc, 67.6% of the participants reported use of Vitamin D supplements, BUT ONLY 36.9% used supplements with a Vitamin D dose of 10 µg or more per day.']	[('ANOMALY_CURIOUS_FINDING', 78)]	1	[('CHEBI_27300', 'vitamin D', 55, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin D')]
S134-PMC3347007	PMC3347007	4/2012	S134-PMC3347007	['when the study was conducted there were no formal RECOMMENDATIONS from the danish national board of health on use of Vitamin D supplements during Pregnancy, and both the number of users and the supplement dose MAY THEREFORE be higher today.']	[('FUTURE_WORK', 50), ('INCOMPLETE_EVIDENCE', 210), ('PROBABLE_UNDERSTANDING', 214)]	3	[('CHEBI_27300', 'vitamin D', 117, 'vitamin D'), ('GO_0007565', 'female pregnancy', 146, 'pregnancy')]
S137-PMC3347007	PMC3347007	4/2012	S137-PMC3347007	['the most common doses of Vitamin D in supplements were 10 µg and 5 µg, INDICATING that the available supplements in denmark all have doses of 5 and 10 µg Vitamin D. low dose supplements make it DIFFICULT for the women to obtain the RECOMMENDED dose of Vitamin D. all Vitamin D supplements aimed at Pregnant women SHOULD THEREFORE contain 10 µg.']	[('INCOMPLETE_EVIDENCE', 71), ('DIFFICULT_TASK', 194), ('FUTURE_WORK', 232), ('FUTURE_WORK', 313), ('PROBABLE_UNDERSTANDING', 320)]	5	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 154, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 252, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 267, 'vitamin D'), ('GO_0007565', 'female pregnancy', 298, 'pregnant')]
S138-PMC3347007	PMC3347007	4/2012	S138-PMC3347007	['when looking at the total Vitamin D intake in the dnbc we FOUND that as many as 55.6% had insufficient intakes EVEN THOUGH 67.6% REPORT use of Vitamin D supplements in SOME dose.']	[('INCOMPLETE_EVIDENCE', 58), ('ANOMALY_CURIOUS_FINDING', 111), ('ANOMALY_CURIOUS_FINDING', 116), ('INCOMPLETE_EVIDENCE', 129), ('INCOMPLETE_EVIDENCE', 168)]	5	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 143, 'vitamin D')]
S141-PMC3347007	PMC3347007	4/2012	S141-PMC3347007	['in a finnish Pregnancy study 74% of Vitamin D among Supplement users came from Supplements, BUT ONLY 15% reached the recommended intake level of 10 µg per day [27].']	[('ANOMALY_CURIOUS_FINDING', 92), ('ANOMALY_CURIOUS_FINDING', 96)]	2	[('GO_0007565', 'female pregnancy', 13, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('CHEBI_16158', 'steroid sulfate', 52, 'supplement'), ('CHEBI_33341', 'titanium atom', 79, 'supplements')]
S144-PMC3347007	PMC3347007	4/2012	S144-PMC3347007	['this SUGGESTS that the women who have Vitamin D-containing diets are also the ones who use high dose supplements.']	[('INCOMPLETE_EVIDENCE', 5)]	1	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D')]
S145-PMC3347007	PMC3347007	4/2012	S145-PMC3347007	['we FOUND Supplements to contribute substantially to Vitamin D intake, but a large group of women STILL did not reach the RECOMMENDED level of intake.']	[('INCOMPLETE_EVIDENCE', 3), ('IMPORTANT_CONSIDERATION', 97), ('FUTURE_WORK', 121)]	3	[('CHEBI_33341', 'titanium atom', 9, 'supplements'), ('CHEBI_27300', 'vitamin D', 52, 'vitamin D')]
S146-PMC3347007	PMC3347007	4/2012	S146-PMC3347007	['public ATTENTION MUST BE focused on Vitamin D supplementation in order to improve PUBLIC HEALTH.']	[('IMPORTANT_CONSIDERATION', 7), ('IMPORTANT_CONSIDERATION', 17), ('IMPORTANT_CONSIDERATION', 82)]	3	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D')]
S148-PMC3347007	PMC3347007	4/2012	S148-PMC3347007	['in OTHER studies, maternal age was also FOUND TO BE inversely ASSOCIATED with Vitamin D intake and the use of Supplements, SUGGESTING that younger Individuals MAY BE less conscious about health matters [17,18,27,28,29].']	[('INCOMPLETE_EVIDENCE', 3), ('ANOMALY_CURIOUS_FINDING', 40), ('SUPERFICIAL_RELATIONSHIP', 62), ('INCOMPLETE_EVIDENCE', 123), ('INCOMPLETE_EVIDENCE', 159)]	5	[('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 110, 'supplements'), ('NCBITaxon_1', 'root', 147, 'individuals')]
S155-PMC3347007	PMC3347007	4/2012	S155-PMC3347007	['OTHER STUDIES also FOUND that non-smokers had higher intakes of Vitamin D [19,29] and that non-smokers were more LIKELY to use vitamin D supplements [17,27].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 19), ('PROBABLE_UNDERSTANDING', 113)]	3	[('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 135, 'D')]
S156-PMC3347007	PMC3347007	4/2012	S156-PMC3347007	['smokers MIGHT be overall less health conscious and THEREFORE not aware of the IMPORTANCE of using Vitamin D supplements in Pregnancy.']	[('INCOMPLETE_EVIDENCE', 8), ('PROBABLE_UNDERSTANDING', 51), ('IMPORTANT_CONSIDERATION', 78)]	3	[('CHEBI_27300', 'vitamin D', 98, 'vitamin D'), ('GO_0007565', 'female pregnancy', 123, 'pregnancy')]
S157-PMC3347007	PMC3347007	4/2012	S157-PMC3347007	['in OTHER studies, overweight women HAVE BEEN FOUND to be less LIKELY to have sufficient Vitamin D intake and to use supplements [17,27,29].']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 35), ('PROBABLE_UNDERSTANDING', 62)]	3	[('CHEBI_27300', 'vitamin D', 88, 'vitamin D')]
S159-PMC3347007	PMC3347007	4/2012	S159-PMC3347007	['high socio-economic status and education was found TO BE directly ASSOCIATED with Vitamin D intake and supplement use in OTHER studies [17,18,27,28,29].']	[('ANOMALY_CURIOUS_FINDING', 51), ('SUPERFICIAL_RELATIONSHIP', 66), ('INCOMPLETE_EVIDENCE', 121)]	3	[('CHEBI_27300', 'vitamin D', 82, 'vitamin D')]
S166-PMC3347007	PMC3347007	4/2012	S166-PMC3347007	['it is QUESTIONABLE WHETHER this ASSOCIATION is random OR IF it REFLECTS a seasonal variation in dietary Vitamin D intake OR in the AWARENESS of the IMPORTANCE of Vitamin D supplementation.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 6), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 19), ('SUPERFICIAL_RELATIONSHIP', 32), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 57), ('SUPERFICIAL_RELATIONSHIP', 63), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 121), ('IMPORTANT_CONSIDERATION', 131), ('IMPORTANT_CONSIDERATION', 148)]	8	[('CHEBI_27300', 'vitamin D', 104, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 162, 'vitamin D')]
S169-PMC3347007	PMC3347007	4/2012	S169-PMC3347007	['TOGETHER, these results SUGGEST that women who use Vitamin D supplements or have sufficient total Vitamin D intake MIGHT have a healthier diet than women with insufficient Vitamin D Intake or who do not use supplements.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 24), ('INCOMPLETE_EVIDENCE', 115)]	3	[('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 98, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 172, 'vitamin D'), ('GO_0007631', 'feeding behavior', 182, 'intake')]
S171-PMC3347007	PMC3347007	4/2012	S171-PMC3347007	['a database of all known Supplements in denmark has been developed in order to ESTIMATE Vitamin D intake from Supplements.']	[('INCOMPLETE_EVIDENCE', 78)]	1	[('CHEBI_33341', 'titanium atom', 24, 'supplements'), ('CHEBI_27300', 'vitamin D', 87, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 109, 'supplements')]
S175-PMC3347007	PMC3347007	4/2012	S175-PMC3347007	['also, VALIDATION of a similar database from the norwegian Birth cohort moba SHOWED good agreement between supplementary Vitamin D measured by ffq and 25(Oh)D levels [24].']	[('INCOMPLETE_EVIDENCE', 6), ('INCOMPLETE_EVIDENCE', 76)]	2	[('GO_0007567', 'parturition', 58, 'birth'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 150, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 150, '25(OH ... D')]
S178-PMC3347007	PMC3347007	4/2012	S178-PMC3347007	['IT IS POSSIBLE that null value IMPUTATION has caused an UNDERESTIMATION of Vitamin D supplementation, BUT since the ESTIMATED use of Vitamin D supplements is SIMILAR TO the one SEEN in norway [17], and lower than the one in finland [27], we do not think this ISSUE is RELEVANT.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 31), ('PROBLEM_COMPLICATION', 56), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 102), ('INCOMPLETE_EVIDENCE', 116), ('INCOMPLETE_EVIDENCE', 158), ('INCOMPLETE_EVIDENCE', 177), ('PROBLEM_COMPLICATION', 259), ('IMPORTANT_CONSIDERATION', 268)]	9	[('CHEBI_27300', 'vitamin D', 75, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 133, 'vitamin D')]
S186-PMC3347007	PMC3347007	4/2012	S186-PMC3347007	['conclusions\n55.6% of the dncb participants report insufficient total Vitamin D intake, EVEN THOUGH 67.6% report use of Vitamin D supplements.']	[('ANOMALY_CURIOUS_FINDING', 87)]	1	[('CHEBI_27300', 'vitamin D', 69, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 119, 'vitamin D')]
S187-PMC3347007	PMC3347007	4/2012	S187-PMC3347007	['we FOUND supplements to CONTRIBUTE substantially to Vitamin D intake.']	[('INCOMPLETE_EVIDENCE', 3), ('SUPERFICIAL_RELATIONSHIP', 24)]	2	[('CHEBI_27300', 'vitamin D', 52, 'vitamin D')]
S190-PMC3347007	PMC3347007	4/2012	S190-PMC3347007	['we PROPOSE that clinicians SHOULD ENCOURAGE Vitamin D supplementation among Pregnant women, with a SPECIAL FOCUS on vulnerable groups, such as younger, smoking and multiparous women, IN ORDER to improve maternal and fetal health both during and after Pregnancy.']	[('INCOMPLETE_EVIDENCE', 3), ('FUTURE_WORK', 27), ('FUTURE_WORK', 34), ('IMPORTANT_CONSIDERATION', 99), ('IMPORTANT_CONSIDERATION', 107), ('QUESTION_ANSWERED_BY_THIS_WORK', 183)]	6	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('GO_0007565', 'female pregnancy', 76, 'pregnant'), ('GO_0007565', 'female pregnancy', 251, 'pregnancy')]
S3-PMC3347028	PMC3347028	3/2012	S3-PMC3347028	['until RECENTLY, there HAS BEEN a PAUCITY of data from randomized controlled trials to establish clear cut beneficial EFFECTS of Vitamin D supplementation during Pregnancy.']	[('INCOMPLETE_EVIDENCE', 6), ('INCOMPLETE_EVIDENCE', 22), ('INCOMPLETE_EVIDENCE', 33), ('SUPERFICIAL_RELATIONSHIP', 117)]	4	[('CHEBI_27300', 'vitamin D', 128, 'vitamin D'), ('GO_0007565', 'female pregnancy', 161, 'pregnancy')]
S97-PMC3347028	PMC3347028	3/2012	S97-PMC3347028	['WHILE okonofua, et al, SUGGEST that normalization of maternal calcium and pth would be useful endpoints in determining the success of Vitamin D supplementation during Pregnancy, more RECENT STUDIES SUGGEST that BECAUSE pth threshold ESTIMATES cannot be precisely defined, total circulating 25(Oh)D ALONE is a BETTER measure of maternal Vitamin D status [60,64,65].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 23), ('INCOMPLETE_EVIDENCE', 183), ('INCOMPLETE_EVIDENCE', 198), ('PROBLEM_COMPLICATION', 211), ('INCOMPLETE_EVIDENCE', 233), ('ANOMALY_CURIOUS_FINDING', 298), ('INCOMPLETE_EVIDENCE', 298), ('INCOMPLETE_EVIDENCE', 309)]	9	[('CHEBI_27300', 'vitamin D', 134, 'vitamin D'), ('GO_0007565', 'female pregnancy', 167, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 290, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 336, 'vitamin D')]
S180-PMC3347028	PMC3347028	3/2012	S180-PMC3347028	['SINCE the modern diet supplies less than 10% of one’s total Vitamin D REQUIREMENTS, IF judicious sunlight exposure is not an option, then the only alternative for the Pregnant woman is Vitamin D supplementation.']	[('PROBLEM_COMPLICATION', 0), ('IMPORTANT_CONSIDERATION', 70), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 84)]	3	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('GO_0007565', 'female pregnancy', 167, 'pregnant'), ('CHEBI_27300', 'vitamin D', 185, 'vitamin D')]
S182-PMC3347028	PMC3347028	3/2012	S182-PMC3347028	['effectiveness of Vitamin D supplementation during Pregnancy\nthere HAS BEEN a PAUCITY OF studies evaluating the REQUIREMENTS and EFFECTS of Vitamin D supplementation during Pregnancy.']	[('INCOMPLETE_EVIDENCE', 66), ('INCOMPLETE_EVIDENCE', 77), ('IMPORTANT_CONSIDERATION', 111), ('SUPERFICIAL_RELATIONSHIP', 128)]	4	[('CHEBI_28384', 'vitamin K', 17, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 50, 'Pregnancy'), ('CHEBI_27300', 'vitamin D', 139, 'vitamin D'), ('GO_0007565', 'female pregnancy', 172, 'pregnancy')]
S184-PMC3347028	PMC3347028	3/2012	S184-PMC3347028	['AS PREDICTED by Vitamin D pharmacokinetics, supplements of 1000 iu/day of Vitamin D to Pregnant women result in a 12.5 to 15.0 nmol/l increase in circulating 25(Oh)D concentrations in both maternal and Cord Serum compared with nonsupplemented controls [75,76,77].']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 3)]	2	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('GO_0007565', 'female pregnancy', 87, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 158, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 158, '25(OH)D'), ('UBERON_0002240', 'spinal cord', 202, 'cord'), ('UBERON_0001977', 'blood serum', 207, 'serum')]
S185-PMC3347028	PMC3347028	3/2012	S185-PMC3347028	['this PREMISE is SUPPORTED by our two randomized clinical trials involving Vitamin D supplementation of Pregnant women [6,148].']	[('INCOMPLETE_EVIDENCE', 5), ('INCOMPLETE_EVIDENCE', 16)]	2	[('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('GO_0007565', 'female pregnancy', 103, 'pregnant')]
S187-PMC3347028	PMC3347028	3/2012	S187-PMC3347028	['results of two RECENT randomized controlled trials during Pregnancy\nin our RECENTLY completed nichd Vitamin D supplementation trial involving a diverse group of Pregnant women less than 16 weeks of Gestation, 4000 iu (100 μg) Vitamin D3/day was SUPERIOR to 400 (control)- or 2000 iu/day in achieving circulating 25(Oh)d of at least 40 ng/ml (100 nmol/l), the point at which 1,25(Oh)2D begins to be optimized (seefigure 2) [6].']	[('INCOMPLETE_EVIDENCE', 15), ('INCOMPLETE_EVIDENCE', 75), ('IMPORTANT_CONSIDERATION', 245)]	3	[('GO_0007565', 'female pregnancy', 58, 'Pregnancy'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin D'), ('GO_0007565', 'female pregnancy', 161, 'pregnant'), ('GO_0007565', 'female pregnancy', 198, 'gestation'), ('CHEBI_33279', 'vitamin D5', 226, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 226, 'vitamin D3'), ('CHEBI_63056', 'zinc cation', 312, '25(OH'), ('CHEBI_82784', 'PVP38-Ag NP', 374, '1,25(OH)2D')]
S191-PMC3347028	PMC3347028	3/2012	S191-PMC3347028	['EVEN in the latter trial where women were randomized to either 2000 iu (50 μg) or 4000 iu (100 μg) Vitamin D3/day, there were no safety ISSUES surrounding Vitamin D supplementation and there was a TREND where specific health COMPLICATIONS of Pregnancy such as Preterm Birth, Preterm Labor, hypertensive orders of Pregnancy, Gestational diabetes, and infection were higher in the 400 iu-compared with the 4000 iu-group, but did not reach statistical significance [149].']	[('ANOMALY_CURIOUS_FINDING', 0), ('IMPORTANT_CONSIDERATION', 136), ('PROBLEM_COMPLICATION', 136), ('INCOMPLETE_EVIDENCE', 197), ('IMPORTANT_CONSIDERATION', 225), ('PROBLEM_COMPLICATION', 225)]	6	[('CHEBI_33279', 'vitamin D5', 99, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 99, 'vitamin D3'), ('CHEBI_27300', 'vitamin D', 155, 'vitamin D'), ('GO_0007565', 'female pregnancy', 242, 'pregnancy'), ('GO_0007565', 'female pregnancy', 260, 'preterm birth'), ('GO_0007129', 'homologous chromosome pairing at meiosis', 275, 'preterm labor'), ('GO_0007565', 'female pregnancy', 313, 'pregnancy'), ('GO_0007565', 'female pregnancy', 324, 'gestational')]
S216-PMC3347028	PMC3347028	3/2012	S216-PMC3347028	['having a higher 25(Oh)D concentration was ASSOCIATED with improved health outcomes in both studies, BUT WHETHER improved Vitamin D status is a MARKER of some OTHER parameter or a direct EFFECT of Vitamin D supplementation REMAINS UNCLEAR at this time.']	[('SUPERFICIAL_RELATIONSHIP', 42), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 100), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 104), ('SUPERFICIAL_RELATIONSHIP', 143), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 158), ('SUPERFICIAL_RELATIONSHIP', 186), ('FULL_UNKNOWN', 222)]	7	[('CHEBI_71657', 'versiconol acetate', 16, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 196, 'vitamin D')]
S217-PMC3347028	PMC3347028	3/2012	S217-PMC3347028	['studies specifically designed and powered to answer the QUESTION of WHETHER OR NOT Vitamin D supplementation LEADS TO improved health outcomes—lower RISK of Preterm Birth, preeclampsia, and infection REMAIN to be done.']	[('EXPLICIT_QUESTION', 56), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 68), ('SUPERFICIAL_RELATIONSHIP', 109), ('IMPORTANT_CONSIDERATION', 149), ('INCOMPLETE_EVIDENCE', 200)]	5	[('CHEBI_27300', 'vitamin D', 83, 'vitamin D'), ('GO_0007565', 'female pregnancy', 157, 'preterm birth')]
S226-PMC3347028	PMC3347028	3/2012	S226-PMC3347028	['the health effects data from Vitamin D supplementation trials THUS FAR, WHILE TANTALIZING, are NOT CONCLUSIVE in SHOWING definitive “proof” for Vitamin D AS a POTENTIAL CANDIDATE in the reduction of comorbidities of Pregnancy, YET one CANNOT DISMISS the strong CORRELATION between reduced RISK with increased Serum 25(Oh)D concentrations.']	[('INCOMPLETE_EVIDENCE', 62), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 72), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 78), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 95), ('INCOMPLETE_EVIDENCE', 113), ('PROBABLE_UNDERSTANDING', 154), ('INCOMPLETE_EVIDENCE', 159), ('INCOMPLETE_EVIDENCE', 169), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 227), ('ANOMALY_CURIOUS_FINDING', 227), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 235), ('SUPERFICIAL_RELATIONSHIP', 261), ('IMPORTANT_CONSIDERATION', 289)]	13	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D'), ('GO_0007565', 'female pregnancy', 216, 'pregnancy'), ('UBERON_0001977', 'blood serum', 309, 'serum'), ('CHEBI_71657', 'versiconol acetate', 315, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 315, '25(OH)D')]
S231-PMC3347028	PMC3347028	3/2012	S231-PMC3347028	['IF so, does substrate sufficiency—EITHER through adequate sunlight exposure OR Vitamin D supplementation—saturate such EFFECTS, making them clinically irrelevant?']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 34), ('SUPERFICIAL_RELATIONSHIP', 119), ('EXPLICIT_QUESTION', 161)]	4	[('CHEBI_27300', 'vitamin D', 79, 'vitamin D')]
S0-PMC3348565	PMC3348565	4/2012	S0-PMC3348565	['EFFECT on the incidence of pneumonia of Vitamin D supplementation by quarterly bolus dose to infants in kabul: a randomised controlled superiority trial\n\nabstractsummary\n\nbackground\nVitamin D has a ROLE in Regulating Immune function, and its deficiency is a SUGGESTED risk factor for childhood pneumonia.']	[('SUPERFICIAL_RELATIONSHIP', 0), ('SUPERFICIAL_RELATIONSHIP', 198), ('INCOMPLETE_EVIDENCE', 258)]	3	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 182, 'Vitamin D'), ('GO_0065007', 'biological regulation', 206, 'regulating'), ('UBERON_0002405', 'immune system', 217, 'immune')]
S16-PMC3348565	PMC3348565	4/2012	S16-PMC3348565	['our systematic review identified one randomised placebo controlled trial3RELATING pneumonia or Lower Respiratory infections to Vitamin D deficiency supplementation in young children.']	[('SUPERFICIAL_RELATIONSHIP', 73)]	1	[('UBERON_0009567', 'nail of pedal digit', 95, 'lower'), ('UBERON_0001004', 'respiratory system', 101, 'respiratory'), ('CHEBI_27300', 'vitamin D', 127, 'vitamin D')]
S27-PMC3348565	PMC3348565	4/2012	S27-PMC3348565	['a cross-sectional survey during the high-risk winter months in 2005 SHOWED that greater than 95% of children younger than 5 years in a socioeconomically deprived part of kabul had Serum Calcifediol levels of less than 37·5 nmol/l.12\nON THE BASIS OF findings that Vitamin D is an immunomodulator, that deficiency is a risk factor for pneumonia, and that quarterly supplementation had better compliance than daily or weekly supplementation,13,14we AIMED TO TEST the HYPOTHESIS that quarterly 100\u2008000 iu Vitamin D supplementation WOULD reduce the incidence of radiologically confirmed pneumonia by 35% in our study population.']	[('INCOMPLETE_EVIDENCE', 68), ('INCOMPLETE_EVIDENCE', 233), ('QUESTION_ANSWERED_BY_THIS_WORK', 446), ('QUESTION_ANSWERED_BY_THIS_WORK', 452), ('INCOMPLETE_EVIDENCE', 464), ('FUTURE_PREDICTION', 527)]	6	[('UBERON_0001977', 'blood serum', 180, 'serum'), ('CHEBI_22975', 'cadinane sesquiterpenoid', 186, 'calcifediol'), ('CHEBI_27300', 'vitamin D', 263, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 501, 'vitamin D')]
S47-PMC3348565	PMC3348565	4/2012	S47-PMC3348565	['procedures\nwe chose a quarterly supplementation regimen because in routine programme conditions a quarterly regimen is LIKELY to have better adherence than a daily regimen,13,14and HAS BEEN shown to be effective at maintaining the Serum Vitamin D concentration within normal ranges for 2–3 months in a french high-risk infant population.16the syringes containing Vitamin D or placebo were stored in conditions recommended by the manufacturer—a dry cool environment—between 2 and 24 weeks before administration.']	[('PROBABLE_UNDERSTANDING', 119), ('INCOMPLETE_EVIDENCE', 181)]	2	[('UBERON_0001977', 'blood serum', 231, 'serum'), ('CHEBI_27300', 'vitamin D', 237, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 363, 'vitamin D')]
S110-PMC3348565	PMC3348565	4/2012	S110-PMC3348565	['THUS the LACK OF a PROTECTIVE EFFECT of Vitamin D against pneumonia is PROBABLY not due to MISCLASSIFICATION of outcomes or INADEQUATE supplementation.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 9), ('SUPERFICIAL_RELATIONSHIP', 19), ('SUPERFICIAL_RELATIONSHIP', 30), ('PROBABLE_UNDERSTANDING', 71), ('PROBLEM_COMPLICATION', 91), ('PROBLEM_COMPLICATION', 124)]	7	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D')]
S114-PMC3348565	PMC3348565	4/2012	S114-PMC3348565	['genotyping, which was NOT PRACTICAL in our study setting, MIGHT have aided the INTERPRETATION of our findings, AS SHOWN in a Vitamin D supplementation trial for tuberculosis.20\nwe accounted for nutritional factors through a diet questionnaire, weight at recruitment, and growth comparison at the end of our study—any nutritional deficiencies WOULD HAVE BEEN equally balanced between the two groups.']	[('DIFFICULT_TASK', 22), ('INCOMPLETE_EVIDENCE', 58), ('INCOMPLETE_EVIDENCE', 79), ('INCOMPLETE_EVIDENCE', 111), ('FUTURE_PREDICTION', 342), ('INCOMPLETE_EVIDENCE', 348)]	6	[('CHEBI_27300', 'vitamin D', 125, 'vitamin D')]
S121-PMC3348565	PMC3348565	4/2012	S121-PMC3348565	['ALTHOUGH this is PROBABLY TRUE, a sufficient Serum concentrations for the immunological EFFECTS of Vitamin D is UNKNOWN and COULD BE higher or lower than that of the Skeletal system accepted concentrations.6THE NEED for a steady state is currently highly SPECULATIVE and RELATES to Vitamin D2Supplementation for negative cancer22and bone outcomes.23\nour findings are AT ODDS with SMALLER case-control hospital STUDIES that show an enhanced rate of Vitamin D deficiency or rickets in children with pneumonia and the INCREASING EVIDENCE SUGGESTING that Calcitriol, the biologically active Metabolite of Vitamin D, has an IMPORTANT ROLE in the Human Immune System.4a systematic review of the ROLE of Vitamin D supplementation in infectious diseases had MIXED findings, CONCLUDING that more rigorously designed clinical trials ARE NEEDED (panel).25NO STUDIES report the EFFECT of Vitamin D on radiologically confirmed pneumonias.']	[('ANOMALY_CURIOUS_FINDING', 0), ('PROBABLE_UNDERSTANDING', 17), ('PROBABLE_UNDERSTANDING', 26), ('SUPERFICIAL_RELATIONSHIP', 88), ('FULL_UNKNOWN', 112), ('INCOMPLETE_EVIDENCE', 124), ('INCOMPLETE_EVIDENCE', 207), ('INCOMPLETE_EVIDENCE', 255), ('SUPERFICIAL_RELATIONSHIP', 271), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 367), ('INCOMPLETE_EVIDENCE', 380), ('INCOMPLETE_EVIDENCE', 515), ('INCOMPLETE_EVIDENCE', 535), ('IMPORTANT_CONSIDERATION', 619), ('SUPERFICIAL_RELATIONSHIP', 629), ('SUPERFICIAL_RELATIONSHIP', 689), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 750), ('PROBABLE_UNDERSTANDING', 766), ('FUTURE_WORK', 823), ('INCOMPLETE_EVIDENCE', 844), ('SUPERFICIAL_RELATIONSHIP', 866)]	21	[('UBERON_0001977', 'blood serum', 45, 'serum'), ('CHEBI_27300', 'vitamin D', 99, 'vitamin D'), ('UBERON_0004288', 'skeleton', 166, 'skeletal'), ('CHEBI_52910', 'delta-lactam ring', 282, 'vitamin D2supplementation'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 282, 'vitamin D2supplementation'), ('CHEBI_27300', 'vitamin D', 448, 'vitamin D'), ('CHEBI_17823', 'calcitriol', 551, 'calcitriol'), ('CHEBI_39382', 'flufenoxuron', 587, 'metabolite'), ('CHEBI_27300', 'vitamin D', 601, 'vitamin D'), ('NCBITaxon_9606', 'Homo sapiens', 641, 'human'), ('UBERON_0002405', 'immune system', 647, 'immune system'), ('CHEBI_27300', 'vitamin D', 697, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 876, 'vitamin D')]
S127-PMC3348565	PMC3348565	4/2012	S127-PMC3348565	['AS IN our studies, these INCONSISTENT findings POINT to the existence of COMPLICATED pathways for the function of Vitamin D in disease processes, or simply that the correct effective dose of Vitamin D supplementation NEEDS to be BETTER defined.']	[('INCOMPLETE_EVIDENCE', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 25), ('INCOMPLETE_EVIDENCE', 47), ('DIFFICULT_TASK', 73), ('FUTURE_WORK', 217), ('INCOMPLETE_EVIDENCE', 229)]	6	[('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 191, 'vitamin D')]
S129-PMC3348565	PMC3348565	4/2012	S129-PMC3348565	['an ASSOCIATED ISSUE is that, after the start of our trial, SPECULATIONS arose that high fluctuations of natural or supplemented Vitamin D intake MIGHT be LINKED to negative outcomes.']	[('SUPERFICIAL_RELATIONSHIP', 3), ('PROBLEM_COMPLICATION', 14), ('INCOMPLETE_EVIDENCE', 59), ('INCOMPLETE_EVIDENCE', 145), ('SUPERFICIAL_RELATIONSHIP', 154)]	5	[('CHEBI_27300', 'vitamin D', 128, 'vitamin D')]
S130-PMC3348565	PMC3348565	4/2012	S130-PMC3348565	['these SPECULATIONS RELATE two studies in which supplementation of a single large dose (300\u200800033or 500\u200800023iu) of Vitamin D for reducing fractures in elderly women led to an increase in fractures, plus similar DISCREPANCIES in Prostate cancer research with Vitamin D.22our findings and particularly the slightly higher repeat episodes of pneumonia in the vitamin d group COULD BE DUE TO such fluctuations IF the HYPOTHESIS is TRUE.']	[('INCOMPLETE_EVIDENCE', 6), ('SUPERFICIAL_RELATIONSHIP', 19), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 211), ('INCOMPLETE_EVIDENCE', 372), ('PROBLEM_COMPLICATION', 381), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 406), ('INCOMPLETE_EVIDENCE', 413), ('PROBABLE_UNDERSTANDING', 427)]	8	[('CHEBI_27300', 'vitamin D', 115, 'vitamin D'), ('UBERON_0002367', 'prostate gland', 228, 'prostate'), ('CHEBI_27300', 'vitamin D', 258, 'vitamin D')]
S133-PMC3348565	PMC3348565	4/2012	S133-PMC3348565	['FURTHER QUESTIONS arise with respect to the previous treatment trial in the same region of kabul, which showed that a single high-dose supplementation with 100\u2008000 iu Vitamin D3Given orally to young children, along with Antibiotic treatment at the time of diagnosis, reduced repeat episodes of pneumonia in the subsequent 3 months.3the INCONSISTENT results COULD BE RELATED to the evidence that stimulation of toll-like receptors on Macrophages and Monocytes by Bacterial Antigens is IMPORTANT in up-regulation of Cyp27B1 and the Vitamin D receptor,5which are CRUCIAL in Production Of Cathelicidins in Vitamin-D-depleted Individuals.']	[('FUTURE_WORK', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 336), ('INCOMPLETE_EVIDENCE', 357), ('SUPERFICIAL_RELATIONSHIP', 366), ('IMPORTANT_CONSIDERATION', 484), ('IMPORTANT_CONSIDERATION', 560)]	6	[('CHEBI_67916', '2alpha,3beta,23-trihydroxylup-20(29)-en-28-oic acid', 167, 'vitamin D3given'), ('PR_000001177', 'D(2) dopamine receptor', 175, 'D3given'), ('CHEBI_33282', 'antibacterial agent', 220, 'antibiotic'), ('CL_0000235', 'macrophage', 433, 'macrophages'), ('CL_0000576', 'monocyte', 449, 'monocytes'), ('CHEBI_22695', 'base', 462, 'bacterial'), ('CHEBI_59132', 'antigen', 472, 'antigens'), ('PR_000006101', 'cytochrome P450 1A1', 514, 'CYP27B1'), ('CHEBI_27300', 'vitamin D', 530, 'vitamin D'), ('GO_0030154', 'cell differentiation', 571, 'production of cathelicidins'), ('CHEBI_83326', 'tedizolid phosphate', 602, 'vitamin-D'), ('NCBITaxon_1', 'root', 621, 'individuals')]
S134-PMC3348565	PMC3348565	4/2012	S134-PMC3348565	['in other words, this system MIGHT not be effective unless there is existing infection with pathogens when Vitamin D supplementation is given.']	[('INCOMPLETE_EVIDENCE', 28)]	1	[('CHEBI_27300', 'vitamin D', 106, 'vitamin D')]
S136-PMC3348565	PMC3348565	4/2012	S136-PMC3348565	['AS WITH the trials in the older children, giving higher doses of Vitamin D,25,34we too did not record any adverse effects associated with Vitamin D supplementation.']	[('INCOMPLETE_EVIDENCE', 0)]	1	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 138, 'vitamin D')]
S138-PMC3348565	PMC3348565	4/2012	S138-PMC3348565	['ALTHOUGH Vitamin D overload is a theoretical POSSIBILITY, 100\u2008000 iu of Vitamin D3Has BEEN shown to provide the best protection against Vitamin D deficiency without overload or side-effects in high-risk infants aged 0–9 months with normal baseline ranges of Vitamin D.16furthermore, single intramuscular injection of three times this dose (300\u2008000 iu) was safe in treating nutritional rickets in 6–30-month-old children residing in lower socioeconomic regions of sunny istanbul.35higher than RECOMMENDED doses of daily supplementation of Vitamin D (500–1000 iu per day, adding up to 120\u2008000 iu over 3 months) plus additional milk fortified with Vitamin D, HAS BEEN shown not to induce an overload,13including in infants starting with normal ranges of Vitamin D, EVEN when supplementation continued during the summer (in france) and when mothers had Antenatal Vitamin D supplementation.36it is IMPORTANT to note that in our study, where community supplementation was in a population with known high rates of Vitamin D deficiency, 1% of children tested had a Calcifediol concentration greater than 375 nmol/l—THOUGHT UNDESIRABLY high.6ALTHOUGH these did not produce any clinical signs and symptoms, these measurements raise a NEED for CAUTION with doses for population supplementation.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 45), ('INCOMPLETE_EVIDENCE', 82), ('FUTURE_WORK', 492), ('INCOMPLETE_EVIDENCE', 656), ('ANOMALY_CURIOUS_FINDING', 762), ('IMPORTANT_CONSIDERATION', 893), ('INCOMPLETE_EVIDENCE', 1107), ('PROBLEM_COMPLICATION', 1115), ('ANOMALY_CURIOUS_FINDING', 1133), ('FUTURE_WORK', 1224), ('IMPORTANT_CONSIDERATION', 1233)]	12	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('CHEBI_35646', 'galanthan', 72, 'vitamin D3has'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 72, 'vitamin D3has'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 258, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 538, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 645, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 751, 'vitamin D'), ('GO_0007567', 'parturition', 849, 'antenatal'), ('CHEBI_27300', 'vitamin D', 859, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1007, 'vitamin D'), ('CHEBI_22975', 'cadinane sesquiterpenoid', 1057, 'calcifediol')]
S140-PMC3348565	PMC3348565	4/2012	S140-PMC3348565	['we HAVE SHOWN that a quarterly 100\u2008000 iu supplementation of Vitamin D3Did not reduce the incidence of pneumonias in children living in regions with high Vitamin D deficiency.']	[('INCOMPLETE_EVIDENCE', 3)]	1	"[('CHEBI_75970', ""2'-phospho-cyclic ADP-ribose(3-)"", 61, 'vitamin D3did'), ('PR_000006287', 'deleted in azoospermia protein 4', 69, 'D3did'), ('CHEBI_27300', 'vitamin D', 154, 'vitamin D')]"
S141-PMC3348565	PMC3348565	4/2012	S141-PMC3348565	['in populations with similar characteristics, quarterly population level supplementation of Vitamin D to infants and young children IS NOT a policy OPTION for reducing THE BURDEN of pneumonia in children.']	[('DIFFICULT_TASK', 131), ('IMPORTANT_CONSIDERATION', 167)]	2	[('CHEBI_27300', 'vitamin D', 91, 'vitamin D')]
S85-PMC3355895	PMC3355895	1/2011	S85-PMC3355895	['estimated exposure to ultraviolet b radiation during late Pregnancy ( p \u2009<\u20090.0001) and the maternal use of Vitamin D supplements ( p \u2009=\u20090.01) both PREDICTED maternal 25(oh)-Vitamin D concentration, and childhood bmc ( p \u2009=\u20090.03).']	[('SUPERFICIAL_RELATIONSHIP', 147)]	1	[('GO_0007565', 'female pregnancy', 58, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 173, 'vitamin D')]
S7-PMC3356951	PMC3356951	4/2012	S7-PMC3356951	['AS few Foods contain Vitamin D, guidelines RECOMMENDED supplementation at SUGGESTED daily Intake and tolerable upper limit levels.']	[('PROBABLE_UNDERSTANDING', 0), ('FUTURE_WORK', 43), ('INCOMPLETE_EVIDENCE', 74)]	3	[('CHEBI_33290', 'food', 7, 'foods'), ('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('GO_0007631', 'feeding behavior', 90, 'intake')]
S10-PMC3356951	PMC3356951	4/2012	S10-PMC3356951	['a meta-analysis published in 2007 SHOWED that Vitamin D supplementation was ASSOCIATED with significantly reduced mortality.']	[('INCOMPLETE_EVIDENCE', 34), ('SUPERFICIAL_RELATIONSHIP', 76)]	2	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D')]
S17-PMC3356951	PMC3356951	4/2012	S17-PMC3356951	['many health care providers have increased their RECOMMENDATIONS for Vitamin D supplementation to AT LEAST 1000 iu.']	[('FUTURE_WORK', 48), ('PROBABLE_UNDERSTANDING', 97)]	2	[('CHEBI_27300', 'vitamin D', 68, 'vitamin D')]
S18-PMC3356951	PMC3356951	4/2012	S18-PMC3356951	['[6] a meta-analysis published in 2007 SHOWED that Vitamin D supplementation was ASSOCIATED with significantly reduced mortality.']	[('INCOMPLETE_EVIDENCE', 38), ('SUPERFICIAL_RELATIONSHIP', 80)]	2	[('CHEBI_27300', 'vitamin D', 50, 'vitamin D')]
S36-PMC3356951	PMC3356951	4/2012	S36-PMC3356951	['[12425] Pregnant and Lactating women who take a Prenatal Vitamin and a Calcium supplement with Vitamin D remain at high RISK for vdd.']	[('IMPORTANT_CONSIDERATION', 120)]	1	[('GO_0007565', 'female pregnancy', 8, 'Pregnant'), ('GO_0007594', 'puparial adhesion', 21, 'lactating'), ('GO_0007565', 'female pregnancy', 48, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 57, 'vitamin'), ('CHEBI_22313', 'alkaline earth metal atom', 71, 'calcium'), ('CHEBI_27300', 'vitamin D', 95, 'vitamin D')]
S54-PMC3356951	PMC3356951	4/2012	S54-PMC3356951	['dietary supplements MIGHT be REQUIRED to meet the daily need for Vitamin D in SOME group of People.']	[('INCOMPLETE_EVIDENCE', 20), ('IMPORTANT_CONSIDERATION', 29), ('INCOMPLETE_EVIDENCE', 78)]	3	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 92, 'people')]
S56-PMC3356951	PMC3356951	4/2012	S56-PMC3356951	"[""[52] Vitamin D content of Human Milk is RELATED to the mother's Vitamin D status; THEREFORE mothers who supplement with high doses of Vitamin D MAY have high levels of Vitamin D in their milk.""]"	[('SUPERFICIAL_RELATIONSHIP', 40), ('PROBABLE_UNDERSTANDING', 82), ('INCOMPLETE_EVIDENCE', 144)]	3	[('CHEBI_28384', 'vitamin K', 5, 'Vitamin D'), ('NCBITaxon_9606', 'Homo sapiens', 26, 'human'), ('UBERON_0001913', 'milk', 32, 'milk'), ('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 168, 'vitamin D')]
S57-PMC3356951	PMC3356951	4/2012	S57-PMC3356951	['[52] american association of paediatricians (aap) RECOMMENDS that exclusively and partially Breastfed infants MUST BE supplemented with 400 iu of Vitamin D per day,[5253] the RECOMMENDED daily allowance for this Nutrient during infancy.']	[('FUTURE_WORK', 50), ('IMPORTANT_CONSIDERATION', 110), ('FUTURE_WORK', 175)]	3	[('GO_0007567', 'parturition', 92, 'breastfed'), ('CHEBI_27300', 'vitamin D', 146, 'vitamin D'), ('CHEBI_33284', 'nutrient', 212, 'nutrient')]
S67-PMC3356951	PMC3356951	4/2012	S67-PMC3356951	['individuals with reduced ability to absorb dietary fat MIGHT REQUIRE Vitamin D supplements.']	[('INCOMPLETE_EVIDENCE', 55), ('IMPORTANT_CONSIDERATION', 61)]	2	[('CHEBI_27300', 'vitamin D', 69, 'vitamin D')]
S72-PMC3356951	PMC3356951	4/2012	S72-PMC3356951	['individuals who have undergone Gastric bypass surgery MAY become Vitamin D deficient over time without a sufficient Intake of Vitamin D from Food or supplements; moreover part of the upper Small Intestine where Vitamin D is absorbed is bypassed.']	[('INCOMPLETE_EVIDENCE', 54)]	1	[('UBERON_0001844', 'cochlea', 31, 'gastric'), ('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('GO_0007631', 'feeding behavior', 116, 'intake'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D'), ('CHEBI_33290', 'food', 141, 'food'), ('UBERON_0002108', 'small intestine', 189, 'small intestine'), ('CHEBI_27300', 'vitamin D', 211, 'vitamin D')]
S94-PMC3356951	PMC3356951	4/2012	S94-PMC3356951	['[9]\n\ndosing\nonly a few Foods are a good source of Vitamin D. the BEST way to get additional Vitamin D is through supplementation.']	[('IMPORTANT_CONSIDERATION', 65)]	1	[('CHEBI_33290', 'food', 23, 'foods'), ('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 92, 'vitamin D')]
S129-PMC3356951	PMC3356951	4/2012	S129-PMC3356951	['a combined analysis of 12 fracture-prevention trials FOUND that supplementation with ABOUT 800 iu of Vitamin D per day reduced Hip and Nonspinal fractures by ABOUT 20%, and that supplementation with ABOUT 400 iu per day showed no benefit.']	[('INCOMPLETE_EVIDENCE', 53), ('INCOMPLETE_EVIDENCE', 85), ('INCOMPLETE_EVIDENCE', 158), ('INCOMPLETE_EVIDENCE', 199)]	4	[('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('UBERON_0001464', 'hip', 127, 'hip'), ('UBERON_0001707', 'nasal cavity', 135, 'nonspinal')]
S133-PMC3356951	PMC3356951	4/2012	S133-PMC3356951	['[97] a finnish study that followed children from Birth NOTED that those given Vitamin D supplements during infancy had a nearly 90% lower risk of developing type 1 diabetes compared with children who did not receive Supplements.']	[('ANOMALY_CURIOUS_FINDING', 55)]	1	[('GO_0007567', 'parturition', 49, 'birth'), ('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 216, 'supplements')]
S151-PMC3356951	PMC3356951	4/2012	S151-PMC3356951	['primary hyperparathyroidism and vdd NEED treatment with Vitamin D.[103]\n\ncaption (table-wrap): table 2\n\ntreatment and prevention STRATEGIES[103]\n\nnoncalcemic benefits of Vitamin D\nescp RECOMMENDS prescribing Vitamin D supplementation for fall PREVENTION and do not RECOMMEND supplementation beyond RECOMMENDED daily NEEDS for the purpose of preventing Cardiovascular disease or death or improving quality of life.']	[('IMPORTANT_CONSIDERATION', 36), ('FUTURE_WORK', 129), ('FUTURE_WORK', 185), ('SUPERFICIAL_RELATIONSHIP', 243), ('FUTURE_WORK', 265), ('FUTURE_WORK', 298), ('IMPORTANT_CONSIDERATION', 316)]	7	[('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 170, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 208, 'vitamin D'), ('UBERON_0004535', 'cardiovascular system', 352, 'cardiovascular')]
S174-PMC3356951	PMC3356951	4/2012	S174-PMC3356951	['very few Foods contain Vitamin D THEREFORE GUIDELINES RECOMMENDED supplementation of Vitamin D at tolerable ul levels.']	[('PROBABLE_UNDERSTANDING', 33), ('PROBABLE_UNDERSTANDING', 43), ('FUTURE_WORK', 54)]	3	[('CHEBI_33290', 'food', 9, 'foods'), ('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 85, 'vitamin D')]
S144-PMC3376765	PMC3376765	6/2012	S144-PMC3376765	['BECAUSE the KEY comparisons we make in our rct are between daily supplements with iron versus iron and zinc or between weekly iron supplements with iron versus iron and zinc, Vitamin B-12 is not a factor in INTERPRETING these DIFFERENCES.']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 12), ('PROBABLE_UNDERSTANDING', 207), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 226)]	4	[('CHEBI_27300', 'vitamin D', 175, 'vitamin B')]
S269-PMC3385441	PMC3385441	2/2012	S269-PMC3385441	['caption (table-wrap): table 3\n\nchallenges to developing comprehensive fish Consumption ADVICE.viewpoint and challengesexamplestoxicological hazards: fish contaminants (e.g., mehg, Pcbs, Pesticides)multiple co-occurring contaminantssynergistic adverse EFFECTS on Neurodevelopment with Joint mehg and pcb exposureadvisories for single contaminantfarmed salmon low in mehg but can be high in pcbstoxicant levels vary within and across speciestilefish Mehg: high in gulf of mexico but low in atlanticvariable susceptibility to toxicitiesprenatal exposure: increased susceptibility to Mehg neurotoxicityconfounding by nutritional BENEFITSUNDERESTIMATION of hazard from mehg if CONFOUNDED by n‑3 lcpufasnutritional BENEFITS: fish Nutrients (e.g., n‑3 lcpufas, Vitamin D, Iodine, Selenium)multiple co-occurring nutrientsfor Neurodevelopment, fish intake more CONSISTENTLY beneficial than n‑3 lcpufa supplementsanutrient levels vary within and across specieshealth benefits associated with high n‑3 lcpufa fishaconfounding by contaminant riskunderestimation of benefit from n‑3 lcpufas if CONFOUNDED by Mehgincreased fish intake (for most populations) RECOMMENDED by nutrition GUIDELINESAVAILABLE fish insufficient to meet demand EVEN without greater intakeenvironmental sustainability: overfishing, habitat destruction, aquaculturemodern harvesting can deplete fish stocks, other aquatic wildlife, and habitatsfishing trawls plough the Seafloor, removing most, if not all, aquatic Life and structures in their pathwild fish stocks insufficient to meet projected GLOBAL demandapproximately 90% of large predatory fish stocks (e.g., bluefin Tuna, atlantic salmon) are already depletedaquaculture CAN adversely AFFECT wild fish and ecosystems; CONTAMINANTSFARMED salmon can escape and outcompete wild fish and MAY have higher Pcb levelseconomic INFLUENCES: consumer choice, industry stakeholders, fisheries managementeconomic ASSUMPTION of improved consumer welfare with more information not necessarily TRUE for fish choiceu.s.']	[('FUTURE_WORK', 87), ('SUPERFICIAL_RELATIONSHIP', 251), ('IMPORTANT_CONSIDERATION', 625), ('DIFFICULT_TASK', 672), ('IMPORTANT_CONSIDERATION', 709), ('PROBABLE_UNDERSTANDING', 852), ('DIFFICULT_TASK', 1081), ('FUTURE_WORK', 1144), ('PROBABLE_UNDERSTANDING', 1169), ('ANOMALY_CURIOUS_FINDING', 1222), ('IMPORTANT_CONSIDERATION', 1555), ('INCOMPLETE_EVIDENCE', 1687), ('SUPERFICIAL_RELATIONSHIP', 1701), ('IMPORTANT_CONSIDERATION', 1734), ('INCOMPLETE_EVIDENCE', 1800), ('SUPERFICIAL_RELATIONSHIP', 1835), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1916), ('PROBABLE_UNDERSTANDING', 1994)]	18	[('GO_0007631', 'feeding behavior', 75, 'consumption'), ('CHEBI_26199', 'polyprenol', 180, 'PCBs'), ('CHEBI_35392', 'glucarate(1-)', 186, 'pesticides'), ('GO_0007399', 'nervous system development', 262, 'neurodevelopment'), ('UBERON_0004905', 'articulation', 284, 'joint'), ('CHEBI_82056', 'Mebenil', 448, 'MeHg'), ('CHEBI_82056', 'Mebenil', 580, 'MeHg'), ('CHEBI_33284', 'nutrient', 724, 'nutrients'), ('CHEBI_27300', 'vitamin D', 754, 'vitamin D'), ('CHEBI_24859', 'iodine atom', 765, 'iodine'), ('CHEBI_27568', 'selenium atom', 773, 'selenium'), ('GO_0007399', 'nervous system development', 817, 'neurodevelopment'), ('CHEBI_82492', 'N-Methylolacrylamide', 1095, 'MeHgIncreased'), ('UBERON_0001273', 'ilium', 1429, 'seafloor'), ('UBERON_0000104', 'life cycle', 1474, 'life'), ('NCBITaxon_10088', 'Mus <genus>', 1632, 'tuna'), ('CHEBI_8102', 'phenylmethanesulfonyl fluoride', 1816, 'PCB')]
S1-PMC3407995	PMC3407995	7/2012	S1-PMC3407995	['purpose: to highlight the POTENTIAL BENEFITS of maternal supplementation with Docosahexaenoic Acid (Dha) and other IMPORTANT complimentary Nutrients, including Vitamin D, Folic Acid and Iodine during Pregnancy and/or Breast feeding for Foetal and/or infant Brain Development and/or function.']	[('INCOMPLETE_EVIDENCE', 26), ('IMPORTANT_CONSIDERATION', 36), ('IMPORTANT_CONSIDERATION', 115)]	3	[('CHEBI_36003', 'decenoic acid', 78, 'docosahexaenoic acid'), ('CHEBI_17874', 'dihydrozeatin', 100, 'DHA'), ('CHEBI_33284', 'nutrient', 139, 'nutrients'), ('CHEBI_27300', 'vitamin D', 160, 'vitamin D'), ('CHEBI_30751', 'formic acid', 171, 'folic acid'), ('CHEBI_24859', 'iodine atom', 186, 'iodine'), ('GO_0007565', 'female pregnancy', 200, 'pregnancy'), ('UBERON_0000310', 'breast', 217, 'breast'), ('GO_0000009', 'alpha-1,6-mannosyltransferase activity', 236, 'foetal ...'), ('GO_0007420', 'brain development', 257, 'brain development'), ('UBERON_0000955', 'brain', 257, 'brain')]
S13-PMC3407995	PMC3407995	7/2012	S13-PMC3407995	['a review of current literature was UNDERTAKEN to summarize the POTENTIAL benefits of maternal supplementation with Dha, Vitamin D, Folic Acid and Iodine during Pregnancy and/or Breast feeding for Foetal and/or infant Brain Development and/or function.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 35), ('INCOMPLETE_EVIDENCE', 63)]	2	[('CHEBI_17874', 'dihydrozeatin', 115, 'DHA'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin D'), ('CHEBI_30751', 'formic acid', 131, 'folic acid'), ('CHEBI_24859', 'iodine atom', 146, 'iodine'), ('GO_0007565', 'female pregnancy', 160, 'pregnancy'), ('UBERON_0000310', 'breast', 177, 'breast'), ('GO_0000009', 'alpha-1,6-mannosyltransferase activity', 196, 'foetal ...'), ('GO_0007420', 'brain development', 217, 'brain development'), ('UBERON_0000955', 'brain', 217, 'brain')]
S16-PMC3407995	PMC3407995	7/2012	S16-PMC3407995	['titles and abstracts were reviewed and reports were selected for inclusion in the review if they were systematic reviews, meta-analyses, randomised controlled trials, cohort studies, cross-sectional or case-control studies and IF they reported BENEFITS and/or harms ASSOCIATED with maternal supplementation with Dha, Vitamin D, Folic Acid or Iodine during Pregnancy and/or Lactation.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 227), ('IMPORTANT_CONSIDERATION', 244), ('SUPERFICIAL_RELATIONSHIP', 266)]	3	[('CHEBI_17874', 'dihydrozeatin', 312, 'DHA'), ('CHEBI_27300', 'vitamin D', 317, 'vitamin D'), ('CHEBI_30751', 'formic acid', 328, 'folic acid'), ('CHEBI_24859', 'iodine atom', 342, 'iodine'), ('GO_0007565', 'female pregnancy', 356, 'pregnancy'), ('GO_0007595', 'lactation', 373, 'lactation')]
S18-PMC3407995	PMC3407995	7/2012	S18-PMC3407995	['data was reviewed and summarized to discuss the RELEVANCE of dietary Dha, Vitamin D, Folic Acid and Iodine to Foetal and infant Brain Development and function, to PRESENT EVIDENCE DEMONSTRATING dietary deficiency of these Nutrients in many populations, to highlight the POTENTIAL benefits of maternal supplementation during Pregnancy and/or Lactation on foetal and/or infant outcomes and to include SAFE Intake RECOMMENDATIONS.']	[('IMPORTANT_CONSIDERATION', 48), ('INCOMPLETE_EVIDENCE', 163), ('INCOMPLETE_EVIDENCE', 180), ('INCOMPLETE_EVIDENCE', 270), ('IMPORTANT_CONSIDERATION', 399), ('FUTURE_WORK', 411)]	6	[('CHEBI_17874', 'dihydrozeatin', 69, 'DHA'), ('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('CHEBI_30751', 'formic acid', 85, 'folic acid'), ('CHEBI_24859', 'iodine atom', 100, 'iodine'), ('GO_0000009', 'alpha-1,6-mannosyltransferase activity', 110, 'foetal ...'), ('GO_0007420', 'brain development', 128, 'brain development'), ('UBERON_0000955', 'brain', 128, 'brain'), ('CHEBI_33284', 'nutrient', 222, 'nutrients'), ('GO_0007565', 'female pregnancy', 324, 'pregnancy'), ('GO_0007595', 'lactation', 341, 'lactation'), ('GO_0007631', 'feeding behavior', 404, 'intake')]
S85-PMC3407995	PMC3407995	7/2012	S85-PMC3407995	['HOWEVER, a recent global review of Vitamin D status HAS SHOWN that its Intake is OFTEN TOO low TO sustain healthy circulating 25(Oh)D in countries without mandatory staple Food fortification and is EVEN too low in countries that do fortify due to low Milk Consumption, vegetarianism, non-supplement use and low fish Intake [46].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 52), ('PROBABLE_UNDERSTANDING', 81), ('DIFFICULT_TASK', 87), ('ANOMALY_CURIOUS_FINDING', 198)]	5	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('GO_0007631', 'feeding behavior', 71, 'intake'), ('CHEBI_71657', 'versiconol acetate', 126, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 126, '25(OH ... D'), ('CHEBI_33290', 'food', 172, 'food'), ('UBERON_0001913', 'milk', 251, 'milk'), ('GO_0007631', 'feeding behavior', 256, 'consumption'), ('GO_0007631', 'feeding behavior', 316, 'intake')]
S249-PMC3407995	PMC3407995	7/2012	S249-PMC3407995	['evidence of the POTENTIAL benefits of maternal Vitamin D supplementation for foetal/infant Brain health\npublished placebo-controlled intervention trials studying the IMPACT of Vitamin D supplementation in mothers with low Serum 25(Oh)D are RARE [45] because such trials are deemed UNACCEPTABLE by ethics committees.']	[('INCOMPLETE_EVIDENCE', 16), ('SUPERFICIAL_RELATIONSHIP', 166), ('INCOMPLETE_EVIDENCE', 240), ('IMPORTANT_CONSIDERATION', 281)]	4	[('CHEBI_28384', 'vitamin K', 47, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 47, 'Vitamin D'), ('UBERON_0000955', 'brain', 91, 'Brain'), ('CHEBI_27300', 'vitamin D', 176, 'vitamin D'), ('UBERON_0001977', 'blood serum', 222, 'serum'), ('CHEBI_71657', 'versiconol acetate', 228, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 228, '25(OH)D')]
S264-PMC3407995	PMC3407995	7/2012	S264-PMC3407995	['in addition, one STUDY has SUGGESTED that supplementation during Pregnancy MAY BE NECESSARY to assure adequate concentration of Vitamin D in Breast Milk during Lactation [142].']	[('INCOMPLETE_EVIDENCE', 17), ('INCOMPLETE_EVIDENCE', 27), ('INCOMPLETE_EVIDENCE', 75), ('IMPORTANT_CONSIDERATION', 82)]	4	[('GO_0007565', 'female pregnancy', 65, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 128, 'vitamin D'), ('UBERON_0001348', 'brown adipose tissue', 141, 'breast milk'), ('GO_0007595', 'lactation', 160, 'lactation')]
S289-PMC3407995	PMC3407995	7/2012	S289-PMC3407995	['Pregnancy maintenance\na cohort study of 23,423 nulliparous Pregnant women taking part in the norwegian mother and child cohort study FOUND a 27% reduction in risk of Preeclampsia in women taking Vitamin D supplements relative to those who did not take Supplements [145].']	[('INCOMPLETE_EVIDENCE', 133)]	1	[('GO_0007565', 'female pregnancy', 0, 'Pregnancy'), ('GO_0007565', 'female pregnancy', 59, 'pregnant'), ('GO_0007128', 'meiotic prophase I', 166, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 195, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 252, 'supplements')]
S302-PMC3407995	PMC3407995	7/2012	S302-PMC3407995	['the authors CONCLUDED that Prenatal Vitamin D supplements in women AT RISK of deficiency COULD reduce the risk of schizophrenia in their offspring [149].']	[('INCOMPLETE_EVIDENCE', 12), ('IMPORTANT_CONSIDERATION', 67), ('INCOMPLETE_EVIDENCE', 89)]	3	[('GO_0007565', 'female pregnancy', 27, 'prenatal'), ('CHEBI_27300', 'vitamin D', 36, 'vitamin D')]
S312-PMC3407995	PMC3407995	7/2012	S312-PMC3407995	['these results SUGGEST that Vitamin D supplementation during Pregnancy would be beneficial for mothers, whose intake from diet and skin Synthesis is APPRECIABLY less than 500 iu of vitamin d daily.']	[('INCOMPLETE_EVIDENCE', 14), ('IMPORTANT_CONSIDERATION', 148)]	2	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('GO_0007565', 'female pregnancy', 60, 'pregnancy'), ('GO_0009057', 'macromolecule catabolic process', 135, 'synthesis')]
S436-PMC3407995	PMC3407995	7/2012	S436-PMC3407995	['a RECENT cochrane review ASSESSED the EFFECTS and SAFETY of Vitamin D supplementation in Pregnancy and EXAMINED WHETHER supplementation with Vitamin D alone OR in combination with Calcium and other Vitamins and Minerals given to women during Pregnancy COULD SAFELY improve Pregnancy outcomes [175].']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 25), ('SUPERFICIAL_RELATIONSHIP', 38), ('IMPORTANT_CONSIDERATION', 50), ('QUESTION_ANSWERED_BY_THIS_WORK', 103), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 112), ('INCOMPLETE_EVIDENCE', 252), ('IMPORTANT_CONSIDERATION', 258)]	8	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('GO_0007565', 'female pregnancy', 89, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 141, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 180, 'calcium'), ('CHEBI_33277', 'gamma-tocotrienol', 198, 'vitamins'), ('CHEBI_46751', 'quinolizidine', 211, 'minerals'), ('GO_0007565', 'female pregnancy', 242, 'pregnancy'), ('GO_0007565', 'female pregnancy', 273, 'pregnancy')]
S438-PMC3407995	PMC3407995	7/2012	S438-PMC3407995	['data from four trials involving 414 women CONSISTENTLY SHOWED that women who received Vitamin D supplements during Pregnancy had higher concentrations of Vitamin D in Serum at term than those women who received no intervention or a placebo; HOWEVER the magnitude of the response was highly heterogenous.']	[('PROBABLE_UNDERSTANDING', 42), ('INCOMPLETE_EVIDENCE', 55), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 241)]	3	[('CHEBI_27300', 'vitamin D', 86, 'vitamin D'), ('GO_0007565', 'female pregnancy', 115, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 154, 'vitamin D'), ('UBERON_0001977', 'blood serum', 167, 'serum')]
S439-PMC3407995	PMC3407995	7/2012	S439-PMC3407995	['data from three trials SUGGESTED that Vitamin D supplemented women had babies with Birth weights below 2500 g less frequently than those women receiving no treatment or placebo.']	[('INCOMPLETE_EVIDENCE', 23)]	1	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('GO_0007567', 'parturition', 83, 'birth')]
S440-PMC3407995	PMC3407995	7/2012	S440-PMC3407995	['women with pre-eclampsia who received 1200 iu Vitamin D along with 375 mg of elemental Calcium per day were as LIKELY to develop pre-eclampsia as women who received no supplementation.']	[('PROBABLE_UNDERSTANDING', 111)]	1	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 87, 'calcium')]
S442-PMC3407995	PMC3407995	7/2012	S442-PMC3407995	['the authors CONCLUDED that Vitamin D supplementation in a single or continued dose during Pregnancy increases Serum Vitamin D concentrations.']	[('INCOMPLETE_EVIDENCE', 12)]	1	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('GO_0007565', 'female pregnancy', 90, 'pregnancy'), ('UBERON_0001977', 'blood serum', 110, 'serum'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin D')]
S445-PMC3407995	PMC3407995	7/2012	S445-PMC3407995	['RECENTLY, a randomized, controlled trial, including 350 women with a singleton Pregnancy at 12 to 16 weeks’ Gestation supplemented with 400 (10 μg), 2000 (50 μg), or 4000 iu (100 μg) of Vitamin D per day until Delivery.']	[('INCOMPLETE_EVIDENCE', 0)]	1	[('GO_0007565', 'female pregnancy', 79, 'pregnancy'), ('GO_0007565', 'female pregnancy', 108, 'gestation'), ('CHEBI_27300', 'vitamin D', 186, 'vitamin D'), ('GO_0007567', 'parturition', 210, 'delivery')]
S449-PMC3407995	PMC3407995	7/2012	S449-PMC3407995	['the authors CONCLUDED that Vitamin D supplementation of 4000 iu/day for Pregnant women is SAFE and MOST EFFECTIVE in achieving sufficiency in all women and their neonates regardless of race, WHEREAS the current ESTIMATED average REQUIREMENT is comparatively ineffective at achieving adequate circulating 25(Oh)D concentrations, especially in african americans [179].']	[('INCOMPLETE_EVIDENCE', 12), ('IMPORTANT_CONSIDERATION', 90), ('PROBABLE_UNDERSTANDING', 99), ('SUPERFICIAL_RELATIONSHIP', 104), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 191), ('INCOMPLETE_EVIDENCE', 211), ('IMPORTANT_CONSIDERATION', 229)]	7	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('GO_0007565', 'female pregnancy', 72, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 304, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 304, '25(OH)D')]
S492-PMC3407995	PMC3407995	7/2012	S492-PMC3407995	['maternal supplementation with Dha, Vitamin D, Folic Acid and Iodine within RECOMMENDED SAFE intake quantities in a large segment of the population that is currently DEFICIENT in these Nutrients, COULD significantly prevent many Brain and Central Nervous System malfunctions and EVEN enhance Brain Development and function in future generations.']	[('FUTURE_WORK', 75), ('IMPORTANT_CONSIDERATION', 87), ('IMPORTANT_CONSIDERATION', 165), ('INCOMPLETE_EVIDENCE', 195), ('ANOMALY_CURIOUS_FINDING', 278)]	5	[('CHEBI_17874', 'dihydrozeatin', 30, 'DHA'), ('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('CHEBI_30751', 'formic acid', 46, 'folic acid'), ('CHEBI_24859', 'iodine atom', 61, 'iodine'), ('CHEBI_33284', 'nutrient', 184, 'nutrients'), ('UBERON_0000955', 'brain', 228, 'brain'), ('UBERON_0001017', 'central nervous system', 238, 'central nervous system'), ('GO_0007420', 'brain development', 291, 'brain development'), ('UBERON_0000955', 'brain', 291, 'brain')]
S111-PMC3409554	PMC3409554	7/2012	S111-PMC3409554	['CONSEQUENTLY, Ferrous Iron supplements SHOULD BE taken between meals, preferably with fruit juice containing Vitamin C [38], which enhances absorption, WHEREAS Milk, coffee, and tea inhibit absorption.']	[('PROBABLE_UNDERSTANDING', 0), ('FUTURE_WORK', 39), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 152)]	3	[('CHEBI_5014', 'fenvalerate', 14, 'ferrous iron'), ('CHEBI_27300', 'vitamin D', 109, 'vitamin C'), ('UBERON_0001913', 'milk', 160, 'milk')]
S38-PMC3415261	PMC3415261	7/2012	S38-PMC3415261	['for example, the selection of the Animal model for studying Vitamin A supplementation is CRUCIAL because the Carotenoids are very differently absorbed DEPENDING ON the selected MODEL [7].']	[('IMPORTANT_CONSIDERATION', 89), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 151), ('INCOMPLETE_EVIDENCE', 177)]	3	[('NCBITaxon_33208', 'Metazoa', 34, 'animal'), ('CHEBI_27300', 'vitamin D', 60, 'vitamin A'), ('CHEBI_50815', 'norgestimate', 109, 'carotenoids')]
S26-PMC3427192	PMC3427192	4/2012	S26-PMC3427192	['similarly, in a finnish Birth cohort, infants supplemented with Vitamin D during the first year of Life were not more LIKELY to have asthma in early Adulthood.67rather, in that STUDY67AND another,68the prevalence of allergic sensitization was greater at age 6 and age 31 y in those subjects who received regular Vitamin D supplementation during infancy.']	[('PROBABLE_UNDERSTANDING', 118), ('INCOMPLETE_EVIDENCE', 177)]	2	[('GO_0007567', 'parturition', 24, 'birth'), ('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('UBERON_0000104', 'life cycle', 99, 'life'), ('UBERON_0000113', 'post-juvenile adult stage', 149, 'adulthood'), ('CHEBI_27300', 'vitamin D', 312, 'vitamin D')]
S34-PMC3427192	PMC3427192	4/2012	S34-PMC3427192	['this finding is SIMILAR TO OTHER STUDIES where an INCREASED risk of allergic sensitization was NOTED in infants who received Vitamin D supplementation.67,68likewise, gale et al.63NOTED that maternal 25(Oh)D concentrations greater than 75\u2009nmol/l (30 ng/ml) were ASSOCIATED with 5-fold increased odds of asthma at 9 y of age in the exposed children.']	[('INCOMPLETE_EVIDENCE', 16), ('INCOMPLETE_EVIDENCE', 27), ('IMPORTANT_CONSIDERATION', 50), ('ANOMALY_CURIOUS_FINDING', 95), ('INCOMPLETE_EVIDENCE', 177), ('SUPERFICIAL_RELATIONSHIP', 261)]	6	[('CHEBI_27300', 'vitamin D', 125, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 199, '25(OH)D')]
S35-PMC3427192	PMC3427192	4/2012	S35-PMC3427192	['HOWEVER, it is IMPORTANT TO NOTE that a large percentage of children were lost to follow-up, and THUS the resulting sample of mothers had higher concentrations of 25(Oh)D and were older, less LIKELY to smoke during Pregnancy, and more educated.63therefore WHILE there MAY BE therapeutic window for vitamin D supplementation in early Life, FURTHER STUDIES ARE NEEDED to more clearly understand the RISKS of high Vitamin D intake and bioavailability during the early childhood years.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('IMPORTANT_CONSIDERATION', 15), ('PROBABLE_UNDERSTANDING', 97), ('PROBABLE_UNDERSTANDING', 192), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 256), ('INCOMPLETE_EVIDENCE', 268), ('FUTURE_WORK', 339), ('FUTURE_WORK', 347), ('IMPORTANT_CONSIDERATION', 397)]	9	[('CHEBI_71657', 'versiconol acetate', 163, '25(OH)D'), ('GO_0007565', 'female pregnancy', 215, 'pregnancy'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 306, 'D'), ('UBERON_0000104', 'life cycle', 333, 'life'), ('CHEBI_27300', 'vitamin D', 411, 'vitamin D')]
S42-PMC3427192	PMC3427192	4/2012	S42-PMC3427192	['studies of Vitamin D status in school-age children with asthmaauthoryearn(% male)age (years)study designsampleoutcome measuresfindingsbrehm412009616 (60)8.7cross-sectionalmild-to-severe persistent asthmaasthma exacerbationsincreased 25(Oh)D ASSOCIATED with reduced hospitalization, reduced Anti-Inflammatory Medication use and reduced Airway hyperresponsivenessbrehm6920101024 (60)8.9prospective cohortmild-to-moderate persistent asthmahospitalization or emergency Department visitbaseline 25(Oh)D levels < 30 ng/ml ASSOCIATED with higher odds of hospitalization or emergency department over 4 ychinellato70201175 (60)9.6cross-sectionalwell-controlled and POORLY controlled asthmaspirometry, asthma controlpositive CORRELATIONS NOTED between 25(Oh)d and asthma controlchinellato71201145 (60)10cross-sectionalintermittent asthmalung function and Airway hyperresponsivenesslower Serum 25(Oh)D ASSOCIATED with decreased Lung function and increased Airway hyperresponsiveness with exercisefreishtat72201092 (63)11.1cross-sectionalafrican americans with and without asthmaphysician-diagnosed asthmadecreased 25(Oh)D in asthmatics vs. controlsmajak73201148 (67)11.5randomized, double-blind, parallel arm clinical trialnewly diagnosed asthmaasthma exacerbationsfewer exacerbations in children with Vitamin D3Supplementation added to inhaled Budesonidesearing742010100 (64)7cross-sectionalmoderate to severe persistent asthmacorticosteroid use and Airflow limitationdecreased 25(Oh)D ASSOCIATED with lower Lung function and higher Corticosteroid requirementsurashima752010217 (57)10.0randomized, double-blind clinical trialschoolchildren (allcomers), subgroup with physician-diagnosed asthmaasthma exacerbationsreduced risk of asthma exacerbations in the subgroup with asthma after Vitamin D3Supplementation\nother cross-sectional studies of Vitamin D status have also examined the ASSOCIATIONS between 25(Oh)D concentrations and asthma Control in school-age children.']	[('SUPERFICIAL_RELATIONSHIP', 241), ('SUPERFICIAL_RELATIONSHIP', 516), ('PROBLEM_COMPLICATION', 656), ('SUPERFICIAL_RELATIONSHIP', 715), ('ANOMALY_CURIOUS_FINDING', 728), ('SUPERFICIAL_RELATIONSHIP', 891), ('SUPERFICIAL_RELATIONSHIP', 1476), ('SUPERFICIAL_RELATIONSHIP', 1873)]	8	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 233, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 233, '25(OH)D'), ('CHEBI_60426', 'dioleoyl phosphatidylglycerol', 290, 'anti-inflammatory medication'), ('UBERON_0001005', 'respiratory airway', 335, 'airway'), ('UBERON_0008247', 'tube foot', 465, 'department'), ('CHEBI_71657', 'versiconol acetate', 490, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 490, '25(OH)D'), ('CHEBI_63056', 'zinc cation', 742, '25(OH'), ('UBERON_0001005', 'respiratory airway', 845, 'airway'), ('UBERON_0001977', 'blood serum', 877, 'serum'), ('CHEBI_71657', 'versiconol acetate', 883, '25(OH)D'), ('PR_000003010', 'moesin isoform 1', 885, '(OH ... D'), ('UBERON_0002048', 'lung', 917, 'lung'), ('UBERON_0001005', 'respiratory airway', 945, 'airway'), ('CHEBI_71657', 'versiconol acetate', 1103, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1103, '25(OH)D'), ('CHEBI_52915', 'phosphatediyl group', 1291, 'vitamin D3supplementation'), ('CHEBI_72362', 'phosphatidylethanolamine 44:1-OH', 1334, 'budesonideSearing742010100'), ('UBERON_0001005', 'respiratory airway', 1440, 'airflow'), ('CHEBI_71657', 'versiconol acetate', 1468, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1468, '25(OH)D'), ('UBERON_0002048', 'lung', 1498, 'lung'), ('CHEBI_36916', 'cation', 1523, 'corticosteroid'), ('CHEBI_52915', 'phosphatediyl group', 1774, 'vitamin D3supplementation'), ('CHEBI_27300', 'vitamin D', 1833, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 1894, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 1900, 'D'), ('GO_0065007', 'biological regulation', 1928, 'control')]
S52-PMC3427192	PMC3427192	4/2012	S52-PMC3427192	['in these sub-analyses, Vitamin D3Supplementation was ASSOCIATED with a decreased risk of exacerbations compared with Placebo, with a relative risk of 0.17.75similarly, in a more RECENT randomized, double-blind 6-mo trial where 800 µg of inhaled Budesonide was administered daily to a small group of 48 children with asthma in the presence or absence of 500 iu/day of Vitamin D3, children receiving supplemental Vitamin D did not have a reduction in 25(Oh)D during the winter months and also had a reduced risk of asthma exacerbations triggered by acute Respiratory Viral infections.73these INITIAL FINDINGS SUGGEST that Vitamin D supplementation MAY have therapeutic benefit children with asthma, ALTHOUGH ADDITIONAL randomized, double-blind, placebo-controlled STUDIES ARE NEEDED.']	[('SUPERFICIAL_RELATIONSHIP', 53), ('INCOMPLETE_EVIDENCE', 178), ('INCOMPLETE_EVIDENCE', 590), ('INCOMPLETE_EVIDENCE', 607), ('INCOMPLETE_EVIDENCE', 646), ('ANOMALY_CURIOUS_FINDING', 697), ('FUTURE_WORK', 706), ('FUTURE_WORK', 762)]	8	[('CHEBI_52915', 'phosphatediyl group', 23, 'vitamin D3supplementation'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 23, 'vitamin D3supplementation'), ('CHEBI_26130', 'biological pigment', 117, 'placebo'), ('CHEBI_3219', 'bupropion', 245, 'budesonide'), ('CHEBI_33279', 'vitamin D5', 367, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 367, 'vitamin D3'), ('CHEBI_27300', 'vitamin D', 411, 'vitamin D'), ('CHEBI_63056', 'zinc cation', 449, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 455, 'D'), ('UBERON_0001004', 'respiratory system', 553, 'respiratory'), ('NCBITaxon_1', 'root', 565, 'viral'), ('CHEBI_27300', 'vitamin D', 620, 'vitamin D')]
S53-PMC3427192	PMC3427192	4/2012	S53-PMC3427192	['Vitamin D in Adults with asthma\nin Adults, the RECOMMENDED dietary intake for Vitamin D ranges from 600 to 800 iu daily.47HOWEVER, DESPITE the large variety of Foods supplemented with Vitamin D, a large proportion of the Adult population remains Vitamin D deficient,77,78perhaps DUE IN PART to INADEQUATE sun exposure and the rising PREVALENCE of obesity which CAN LEAD TO decreased Vitamin D bioavailability.79SIMILAR to the studies in school age children, a NUMBER OF cross-sectional studies in Adults have also DEMONSTRATED ASSOCIATIONS between Vitamin D status and asthma Control (table 3).']	[('FUTURE_WORK', 47), ('ANOMALY_CURIOUS_FINDING', 120), ('ANOMALY_CURIOUS_FINDING', 120), ('ANOMALY_CURIOUS_FINDING', 131), ('IMPORTANT_CONSIDERATION', 279), ('INCOMPLETE_EVIDENCE', 283), ('IMPORTANT_CONSIDERATION', 294), ('IMPORTANT_CONSIDERATION', 333), ('INCOMPLETE_EVIDENCE', 361), ('SUPERFICIAL_RELATIONSHIP', 365), ('INCOMPLETE_EVIDENCE', 409), ('INCOMPLETE_EVIDENCE', 460), ('INCOMPLETE_EVIDENCE', 514), ('SUPERFICIAL_RELATIONSHIP', 527)]	14	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('UBERON_0007023', 'adult organism', 13, 'Adults'), ('UBERON_0007023', 'adult organism', 35, 'adults'), ('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('CHEBI_33290', 'food', 160, 'foods'), ('CHEBI_27300', 'vitamin D', 184, 'vitamin D'), ('UBERON_0007023', 'adult organism', 221, 'adult'), ('CHEBI_27300', 'vitamin D', 246, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 383, 'vitamin D'), ('UBERON_0007023', 'adult organism', 497, 'adults'), ('CHEBI_27300', 'vitamin D', 548, 'vitamin D'), ('GO_0065007', 'biological regulation', 576, 'control')]
S57-PMC3427192	PMC3427192	4/2012	S57-PMC3427192	['in the FIRST KNOWN clinical TRIAL focused on the ROLE of Vitamin D in allergic disease, rappaport et al.85found that supplementation with 60,000 to 30,000 iu of Vitamin D2Per day resulted in significant relief of asthma and hay fever symptoms in more than 96% of patients suffering from asthma and seasonal allergies.']	[('INCOMPLETE_EVIDENCE', 7), ('INCOMPLETE_EVIDENCE', 28), ('SUPERFICIAL_RELATIONSHIP', 49)]	3	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('CHEBI_63635', 'valganciclovir', 161, 'vitamin D2per'), ('PR_000001177', 'D(2) dopamine receptor', 169, 'D2per')]
S18-PMC3427250	PMC3427250	8/2012	S18-PMC3427250	['HOWEVER there is so far NO CONCLUSIVE EVIDENCE about the causality of these RELATIONSHIPS, as NO randomised controlled TRIALS of Vitamin D supplementation with an appropriate assessment of a VARIETY of health outcomes have been carried out to date[21].']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 24), ('SUPERFICIAL_RELATIONSHIP', 76), ('FULL_UNKNOWN', 94), ('DIFFICULT_TASK', 191)]	5	[('CHEBI_27300', 'vitamin D', 129, 'vitamin D')]
S118-PMC3427250	PMC3427250	8/2012	S118-PMC3427250	['as those authors recognize that the EVIDENCE to propose such Intakes IS SCARCE and as long as the health benefits of having Serum 25(Oh)D levels higher than 30 ng/ml are NOT clearly ESTABLISHED particularly in Pregnant women, the belgian superior health council STILL RECOMMENDS a Vitamin D supplement of 20 µg/day or 800 iu during Pregnancy[58].']	[('INCOMPLETE_EVIDENCE', 36), ('FULL_UNKNOWN', 170), ('IMPORTANT_CONSIDERATION', 262), ('FUTURE_WORK', 268)]	4	[('GO_0007631', 'feeding behavior', 61, 'intakes'), ('UBERON_0001977', 'blood serum', 124, 'serum'), ('CHEBI_71657', 'versiconol acetate', 130, '25(OH)D'), ('PR_000003010', 'moesin isoform 1', 132, '(OH ... D'), ('GO_0007565', 'female pregnancy', 210, 'pregnant'), ('CHEBI_27300', 'vitamin D', 281, 'vitamin D'), ('GO_0007565', 'female pregnancy', 332, 'pregnancy')]
S126-PMC3427250	PMC3427250	8/2012	S126-PMC3427250	['THEREFORE, there is an URGENT NEED of randomised controlled trials of Vitamin D supplementation to investigate the maternal and neonatal health benefits of correcting Vitamin D deficiency during Pregnancy[24].']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 23), ('FUTURE_WORK', 30)]	3	[('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 167, 'vitamin D'), ('GO_0007565', 'female pregnancy', 195, 'pregnancy')]
S133-PMC3427250	PMC3427250	8/2012	S133-PMC3427250	['WHILE several observational studies POINT to CORRELATIONS between Vitamin D insufficiency and maternal and neonatal ill health, EXPERIMENTAL EVIDENCE from supplementation clinical trials IS NEEDED to inform health policy.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 36), ('SUPERFICIAL_RELATIONSHIP', 45), ('INCOMPLETE_EVIDENCE', 128), ('FUTURE_WORK', 187)]	5	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D')]
S22-PMC3437304	PMC3437304	8/2012	S22-PMC3437304	['Prenatal exposure to Pets, Vitamin D supplement, or antioxidants such as mediterranean diet is shown to be PROTECTIVE from the development of asthma.']	[('SUPERFICIAL_RELATIONSHIP', 107)]	1	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('NCBITaxon_10088', 'Mus <genus>', 21, 'pets'), ('CHEBI_27300', 'vitamin D', 27, 'vitamin D')]
S16-PMC3470091	PMC3470091	9/2012	S16-PMC3470091	['SINCE, fetus and baby are both DEPENDENT upon mother for Blood and milk respectively, mother’s Vitamin D supplementation is highly VITAL.']	[('PROBABLE_UNDERSTANDING', 0), ('SUPERFICIAL_RELATIONSHIP', 31), ('IMPORTANT_CONSIDERATION', 131)]	3	[('UBERON_0000178', 'blood', 57, 'blood'), ('CHEBI_27300', 'vitamin D', 95, 'vitamin D')]
S20-PMC3470091	PMC3470091	9/2012	S20-PMC3470091	['THEREFORE, Vitamin D supplementation in high doses HAS BEEN RECOMMENDED, and oral doses of 20000 or 40000 iu were ASSOCIATED with positive outcomes.6,14moreover, higher oral dose of (6400 iu per day) to Lactating mothers significantly increased Vitamin D status in mothers as well as the Vitamin D content and antirachitic activity of their Milk.14THEREFORE, high doses of Vitamin D, EITHER orally OR through injection, HAS RECENTLY BEEN RECOMMENDED.15-24\na single dose of Vitamin D, administered parenterally, WOULD BE more EFFECTIVE, BECAUSE it is not associated with the NONCOMPLIANCE ASSOCIATED with an oral dose.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 51), ('FUTURE_WORK', 60), ('SUPERFICIAL_RELATIONSHIP', 114), ('PROBABLE_UNDERSTANDING', 348), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 384), ('INCOMPLETE_EVIDENCE', 420), ('FUTURE_WORK', 438), ('FUTURE_PREDICTION', 511), ('SUPERFICIAL_RELATIONSHIP', 525), ('PROBLEM_COMPLICATION', 536), ('PROBLEM_COMPLICATION', 574), ('SUPERFICIAL_RELATIONSHIP', 588)]	13	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('GO_0007594', 'puparial adhesion', 203, 'lactating'), ('CHEBI_27300', 'vitamin D', 245, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 288, 'vitamin D'), ('UBERON_0001913', 'milk', 341, 'milk'), ('CHEBI_27300', 'vitamin D', 373, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 473, 'vitamin D')]
S73-PMC3470091	PMC3470091	9/2012	S73-PMC3470091	['they SHOWED that supplementation with an oral dose of 300,000 iu of Vitamin D and 500-1000 mg daily of Calcium LED TO an increase in the concentration of Serum Vitamin D from 15 to 81.4 nmol/l.']	[('INCOMPLETE_EVIDENCE', 5), ('SUPERFICIAL_RELATIONSHIP', 111)]	2	[('CHEBI_27300', 'vitamin D', 68, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 103, 'calcium'), ('UBERON_0001977', 'blood serum', 154, 'serum'), ('CHEBI_27300', 'vitamin D', 160, 'vitamin D')]
S92-PMC3470091	PMC3470091	9/2012	S92-PMC3470091	['further STUDIES ARE NEEDED to evaluate the EFFECT of Postpartum supplementation of Vitamin D on antirachitic FACTOR of the mother’s Milk, and infant’s health indexes.']	[('FUTURE_WORK', 8), ('SUPERFICIAL_RELATIONSHIP', 43), ('SUPERFICIAL_RELATIONSHIP', 109)]	3	[('GO_0007565', 'female pregnancy', 53, 'postpartum'), ('CHEBI_27300', 'vitamin D', 83, 'vitamin D'), ('UBERON_0001913', 'milk', 132, 'milk')]
S107-PMC3471827	PMC3471827	10/2012	S107-PMC3471827	['in the case of Ttp knockout Mouse MODELS, mothers are infertile unless supplemented with high doses of Vitamin E[4].']	[('INCOMPLETE_EVIDENCE', 34)]	1	[('PR_000016850', 'tyrosine-protein kinase TXK', 15, 'TTP'), ('NCBITaxon_10088', 'Mus <genus>', 28, 'mouse'), ('CHEBI_27300', 'vitamin D', 103, 'vitamin E')]
S54-PMC3472720	PMC3472720	8/2012	S54-PMC3472720	['we PREVIOUSLY DEMONSTRATED that a Postnatal Vitamin D supplementation reduced the severity of eae and delayed the onset of symptoms [15].']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 14)]	2	[('GO_0007567', 'parturition', 34, 'postnatal'), ('CHEBI_27300', 'vitamin D', 44, 'vitamin D')]
S108-PMC3475131	PMC3475131	6/2012	S108-PMC3475131	['use of different Supplements (n\u2009=\u20097 reviews)\n\nlaboratory outcomes\nseven systematic reviews (four of high quality) investigated the EFFECTS of Micronutrients other than iron and Folic Acid [16,18-23] and FOUND NO EVIDENCE TO SUPPORT the use of Vitamin B12, Vitamin C, calcium or zinc to prevent anaemia during Pregnancy.']	[('SUPERFICIAL_RELATIONSHIP', 131), ('INCOMPLETE_EVIDENCE', 203), ('INCOMPLETE_EVIDENCE', 209)]	3	[('CHEBI_33341', 'titanium atom', 17, 'supplements'), ('CHEBI_33839', 'macromolecule', 142, 'micronutrients'), ('CHEBI_30751', 'formic acid', 177, 'folic acid'), ('CHEBI_33279', 'vitamin D5', 243, 'vitamin B12'), ('CHEBI_27300', 'vitamin D', 256, 'vitamin C'), ('GO_0007565', 'female pregnancy', 309, 'pregnancy')]
S145-PMC3476426	PMC3476426	8/2012	S145-PMC3476426	['basic, Genetic, and epidemiological studies INDICATE a POTENTIAL ROLE of Vitamin D in the PREVENTION of Autoimmune diseases, BUT randomized and controlled TRIALS ARE NECESSARY to establish the clinical efficacy of Vitamin D supplementation in ill or at-RISK subjects [48].']	[('INCOMPLETE_EVIDENCE', 44), ('INCOMPLETE_EVIDENCE', 55), ('SUPERFICIAL_RELATIONSHIP', 65), ('SUPERFICIAL_RELATIONSHIP', 90), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 125), ('FUTURE_WORK', 155), ('FUTURE_WORK', 166), ('IMPORTANT_CONSIDERATION', 166), ('IMPORTANT_CONSIDERATION', 253)]	9	[('SO_0000704', 'gene', 7, 'genetic'), ('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('UBERON_0001442', 'skeleton of manus', 104, 'autoimmune'), ('CHEBI_27300', 'vitamin D', 214, 'vitamin D')]
S25-PMC3501517	PMC3501517	11/2012	S25-PMC3501517	['relatively FEW Animal STUDIES to date have evaluated the RELATIONSHIP between Vitamin D and acute Lung injury (ali), and those that HAVE BEEN published examine the EFFECT of Vitamin D supplementation above normal dietary intake[30],[31],[32].']	[('INCOMPLETE_EVIDENCE', 11), ('SUPERFICIAL_RELATIONSHIP', 57), ('INCOMPLETE_EVIDENCE', 132), ('SUPERFICIAL_RELATIONSHIP', 164)]	4	[('NCBITaxon_33208', 'Metazoa', 15, 'animal'), ('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('UBERON_0002048', 'lung', 98, 'lung'), ('CHEBI_27300', 'vitamin D', 174, 'vitamin D')]
S190-PMC3501517	PMC3501517	11/2012	S190-PMC3501517	['these data CONTRAST WITH OTHER published STUDIES that demonstrate a POSSIBLE PROTECTIVE ROLE of Vitamin D supplementation during Lung injury.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 11), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 25), ('INCOMPLETE_EVIDENCE', 41), ('INCOMPLETE_EVIDENCE', 68), ('SUPERFICIAL_RELATIONSHIP', 77), ('SUPERFICIAL_RELATIONSHIP', 88)]	6	[('CHEBI_27300', 'vitamin D', 96, 'vitamin D'), ('UBERON_0002048', 'lung', 129, 'lung')]
S191-PMC3501517	PMC3501517	11/2012	S191-PMC3501517	['using a Rat model of radiation-induced pneumonitis, yazici and co-authors examined the EFFECT of Vitamin D supplementation on Lung injury and remodeling 8 and 12 weeks after Thoracic irradiation[32].']	[('SUPERFICIAL_RELATIONSHIP', 87)]	1	[('NCBITaxon_9986', 'Oryctolagus cuniculus', 8, 'rat'), ('CHEBI_27300', 'vitamin D', 97, 'vitamin D'), ('UBERON_0002048', 'lung', 126, 'lung'), ('UBERON_0000915', 'thoracic segment of trunk', 174, 'thoracic')]
S192-PMC3501517	PMC3501517	11/2012	S192-PMC3501517	['no benefit of Vitamin D supplementation was observed when Lung injury was evaluated by light microscopy; HOWEVER, some statistically significant differences were observed with transmission Electron microscopy (tem).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 105)]	1	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('UBERON_0002048', 'lung', 58, 'lung'), ('CHEBI_10545', 'electron', 189, 'electron')]
S194-PMC3501517	PMC3501517	11/2012	S194-PMC3501517	['these data SUGGEST that SOME PROTECTIVE BENEFIT MAY BE derived from Vitamin D supplementation in the setting of radiation-induced Lung injury; HOWEVER, the POTENTIAL physiological relevance of these differences is DIFFICULT to ascertain given the absence of systematic sampling or the LACK OF DATA on the magnitude of the differences.']	[('INCOMPLETE_EVIDENCE', 11), ('INCOMPLETE_EVIDENCE', 24), ('SUPERFICIAL_RELATIONSHIP', 29), ('IMPORTANT_CONSIDERATION', 40), ('INCOMPLETE_EVIDENCE', 48), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 143), ('INCOMPLETE_EVIDENCE', 156), ('DIFFICULT_TASK', 214), ('INCOMPLETE_EVIDENCE', 285)]	9	[('CHEBI_27300', 'vitamin D', 68, 'vitamin D'), ('UBERON_0002048', 'lung', 130, 'lung')]
S198-PMC3501517	PMC3501517	11/2012	S198-PMC3501517	['shih and co-authors REPORTED that Vitamin D supplementation reduced Lung injury as determined by wet/dry Lung weight ratios and semi-quantitative histological analysis in a Rat model of Hind Limb ischemia and reperfusion[30].']	[('INCOMPLETE_EVIDENCE', 20)]	1	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('UBERON_0002048', 'lung', 68, 'lung'), ('UBERON_0002048', 'lung', 105, 'lung'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 173, 'rat'), ('UBERON_0002103', 'hindlimb', 186, 'hind limb')]
S200-PMC3501517	PMC3501517	11/2012	S200-PMC3501517	['INTERESTINGLY, shih REPORTED that Serum cytokine levels were reduced in this MODEL with Vitamin D supplementation.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 20), ('INCOMPLETE_EVIDENCE', 77)]	3	[('UBERON_0001977', 'blood serum', 34, 'serum'), ('CHEBI_27300', 'vitamin D', 88, 'vitamin D')]
S201-PMC3501517	PMC3501517	11/2012	S201-PMC3501517	['ALTERNATIVELY, DIFFERENCES MAY again reflect the DIFFERENCE of supplementation above a normal level VERSUS chronic Vitamin D deficiency.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 15), ('INCOMPLETE_EVIDENCE', 27), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 49), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 100)]	5	[('CHEBI_27300', 'vitamin D', 115, 'vitamin D')]
S233-PMC3501517	PMC3501517	11/2012	S233-PMC3501517	['the data SUGGEST that Vitamin D supplementation is UNLIKELY to be an effective therapy for acute Lung injury.']	[('INCOMPLETE_EVIDENCE', 9), ('PROBABLE_UNDERSTANDING', 51)]	2	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('UBERON_0002048', 'lung', 97, 'lung')]
S23-PMC3504157	PMC3504157	11/2012	S23-PMC3504157	['MANY health providers NOW RECOMMEND nhps including Prenatal Vitamins, iron supplementation, calcium, and Vitamin D for a range of RECOGNIZED indications including deficiency states such as rickets and anemia, as well as illnesses such as multiple sclerosis.']	[('INCOMPLETE_EVIDENCE', 0), ('IMPORTANT_CONSIDERATION', 22), ('FUTURE_WORK', 26), ('PROBABLE_UNDERSTANDING', 130)]	4	[('GO_0007565', 'female pregnancy', 51, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 60, 'vitamins'), ('CHEBI_27300', 'vitamin D', 105, 'vitamin D')]
S103-PMC3509518	PMC3509518	11/2012	S103-PMC3509518	['discussion\nin this study, there were SOME inverse (“PROTECTIVE”) RELATIONSHIPS between antioxidant intakes in Pregnancy and infant allergic outcomes, but this was ONLY evident for selected antioxidant factors (Vitamin C and copper) and ONLY SEEN in RELATION to dietary Nutrients and not for dietary supplements per se .']	[('INCOMPLETE_EVIDENCE', 37), ('SUPERFICIAL_RELATIONSHIP', 52), ('SUPERFICIAL_RELATIONSHIP', 65), ('INCOMPLETE_EVIDENCE', 163), ('INCOMPLETE_EVIDENCE', 236), ('INCOMPLETE_EVIDENCE', 241), ('SUPERFICIAL_RELATIONSHIP', 249)]	7	[('GO_0007565', 'female pregnancy', 110, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 210, 'vitamin C'), ('CHEBI_33284', 'nutrient', 269, 'nutrients')]
S106-PMC3509518	PMC3509518	11/2012	S106-PMC3509518	['as INDICATED, there were no associations between allergic outcomes and total intakes of copper, Vitamin C or any other antioxidants when we also took maternal Vitamin and mineral supplementation into account.']	[('INCOMPLETE_EVIDENCE', 3)]	1	[('CHEBI_27300', 'vitamin D', 96, 'vitamin C'), ('CHEBI_33229', 'vitamin (role)', 159, 'vitamin')]
S150-PMC3509518	PMC3509518	11/2012	S150-PMC3509518	['the PROTECTIVE EFFECTS of fresh Foods rich in Vitamin C on wheeze is CONSISTENT with PREVIOUS STUDIES, and it is notable that we DID NOT observe any effect of Vitamin supplements on any allergic outcomes.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('SUPERFICIAL_RELATIONSHIP', 15), ('INCOMPLETE_EVIDENCE', 69), ('INCOMPLETE_EVIDENCE', 85), ('INCOMPLETE_EVIDENCE', 129)]	5	[('CHEBI_33290', 'food', 32, 'foods'), ('CHEBI_27300', 'vitamin D', 46, 'vitamin C'), ('CHEBI_33229', 'vitamin (role)', 159, 'vitamin')]
S177-PMC3515553	PMC3515553	12/2012	S177-PMC3515553	['caption (supplementary-material): table s3\n\nASSOCIATION of offspring genotype at Snps RELATED to Vitamin B-12 Metabolism with Vitamin B-12 Cord Blood concentration.']	[('SUPERFICIAL_RELATIONSHIP', 44), ('SUPERFICIAL_RELATIONSHIP', 86)]	2	[('SO_0000694', 'SNP', 81, 'SNPs'), ('CHEBI_70326', 'guttiferone A, (rel-(+))-', 97, 'vitamin B-'), ('GO_0000010', 'trans-hexaprenyltranstransferase activity', 97, 'vitamin B-12'), ('PR_000017269', 'ventral anterior homeobox 2', 97, 'vitamin B-12'), ('GO_0008152', 'metabolic process', 110, 'metabolism'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 126, 'vitamin B-12'), ('UBERON_0002240', 'spinal cord', 139, 'cord'), ('UBERON_0000178', 'blood', 144, 'blood')]
S181-PMC3515553	PMC3515553	12/2012	S181-PMC3515553	['caption (supplementary-material): table s5\n\nASSOCIATION of maternal genotype at Snps RELATED to Vitamin B-12 Metabolism with offspring iq at age 8, stratified by Maternal Pregnancy RECOMMENDED daily amount (rda) of Vitamin B-12.']	[('SUPERFICIAL_RELATIONSHIP', 44), ('SUPERFICIAL_RELATIONSHIP', 85), ('FUTURE_WORK', 181)]	3	[('SO_0000694', 'SNP', 80, 'SNPs'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin B'), ('GO_0009235', 'cobalamin metabolic process', 96, 'vitamin B-12 metabolism'), ('PR_000017269', 'ventral anterior homeobox 2', 96, 'vitamin B-12'), ('GO_0007618', 'mating', 162, 'maternal'), ('GO_0007565', 'female pregnancy', 171, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 215, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 215, 'vitamin B-12')]
S218-PMC3515887	PMC3515887	11/2012	S218-PMC3515887	['Ascorbic Acid\nthe RATIONALE for Ascorbic Acid (Vitamin C) supplementation in large doses is that it blocks binding to da receptors and POSSIBLY corrects redox balance, leading to correction of Metabolic stress that MAY CONTRIBUTE to autism symptoms.']	[('INCOMPLETE_EVIDENCE', 18), ('QUESTION_ANSWERED_BY_THIS_WORK', 18), ('INCOMPLETE_EVIDENCE', 135), ('INCOMPLETE_EVIDENCE', 215), ('SUPERFICIAL_RELATIONSHIP', 219)]	5	[('CHEBI_2878', 'Aspecioside', 0, 'Ascorbic Acid'), ('CHEBI_22652', 'ascorbic acid', 32, 'ascorbic acid'), ('CHEBI_27300', 'vitamin D', 47, 'vitamin C'), ('GO_0008152', 'metabolic process', 193, 'metabolic')]
S27-PMC3521768	PMC3521768	12/2012	S27-PMC3521768	['pertaining Vitamin A, a meta-analysis CONCLUDED that Prenatal Vitamin A supplementation does not significantly reduce RISK of lbw[16].']	[('INCOMPLETE_EVIDENCE', 38), ('IMPORTANT_CONSIDERATION', 118)]	2	[('CHEBI_27300', 'vitamin D', 11, 'vitamin A'), ('GO_0007565', 'female pregnancy', 53, 'prenatal'), ('CHEBI_27300', 'vitamin D', 62, 'vitamin A')]
S169-PMC3534399	PMC3534399	10/2012	S169-PMC3534399	['a single trial (in hiv-infected mothers) has investigated a LIMITED range of T-Cell subsets in Pregnancy, but not in the offspring, and FOUND that limited mmn supplementation (Vitamins B, c and e), BUT NOT Vitamin A alone, increased cd4+ and cd8+ counts [25].']	[('INCOMPLETE_EVIDENCE', 60), ('INCOMPLETE_EVIDENCE', 136), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 198), ('ANOMALY_CURIOUS_FINDING', 202)]	4	[('CL_0000084', 'T cell', 77, 'T-cell'), ('GO_0007565', 'female pregnancy', 95, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 176, 'vitamins B'), ('CHEBI_27300', 'vitamin D', 206, 'vitamin A')]
S76-PMC3544621	PMC3544621	11/2012	S76-PMC3544621	['[21]5 (1999-2006)provision of advice regarding Vitamin A supplementation in hiv infected womenrisk of Mother-To-Child Transmission (mtct) of hiv,Birth weight, stillbirth rate and ptdno evidence of an EFFECT on the risk of Prenatal or Postnatal mtct of hiv (rr 1.06, 95% ci 0.89-1.26).']	[('SUPERFICIAL_RELATIONSHIP', 200)]	1	[('CHEBI_27300', 'vitamin D', 47, 'vitamin A'), ('GO_0060126', 'somatotropin secreting cell differentiation', 102, 'Mother-to-Child Transmission'), ('GO_0007567', 'parturition', 145, 'birth'), ('GO_0007565', 'female pregnancy', 222, 'prenatal'), ('GO_0007567', 'parturition', 234, 'postnatal')]
S14-PMC3552819	PMC3552819	12/2012	S14-PMC3552819	['HOWEVER, VERY FEW STUDIES have rigorously addressed Vitamin D supplementation during Pregnancy, and the single-dose Vitamin D3 Pregnancy trials published to date have provided LITTLE insight into pharmacokinetics or SAFETY [5,6].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('IMPORTANT_CONSIDERATION', 9), ('INCOMPLETE_EVIDENCE', 14), ('INCOMPLETE_EVIDENCE', 176), ('IMPORTANT_CONSIDERATION', 216)]	5	[('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('GO_0007565', 'female pregnancy', 85, 'pregnancy'), ('CHEBI_33279', 'vitamin D5', 116, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 116, 'vitamin D3'), ('GO_0007565', 'female pregnancy', 127, 'pregnancy')]
S18-PMC3552819	PMC3552819	12/2012	S18-PMC3552819	['the AIM was to generate PRELIMINARY pharmacokinetic (pk) and safety data to inform the design of supplementation regimens for use in FUTURE larger-scale TRIALS of Antenatal Vitamin D supplementation in bangladesh.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('INCOMPLETE_EVIDENCE', 24), ('FUTURE_WORK', 133)]	3	[('GO_0007567', 'parturition', 163, 'antenatal'), ('CHEBI_27300', 'vitamin D', 173, 'vitamin D')]
S20-PMC3552819	PMC3552819	12/2012	S20-PMC3552819	['reasons for exclusion were a known medical condition, SELF-REPORTED current use of any dietary supplements containing Vitamin D, use of anti-convulsant or anti-Mycobacterial medications, severe anemia (hemoglobin concentration <70 g/l), or hypertension at enrollment (systolic Blood pressure ≥140 mmhg or diastolic Blood pressure ≥90 mmhg on at least two measurements).']	[('INCOMPLETE_EVIDENCE', 54), ('INCOMPLETE_EVIDENCE', 59)]	2	[('CHEBI_27300', 'vitamin D', 118, 'vitamin D'), ('CHEBI_52217', 'pharmaceutical', 160, 'mycobacterial'), ('UBERON_0000178', 'blood', 277, 'blood'), ('UBERON_0000178', 'blood', 315, 'blood')]
S113-PMC3552819	PMC3552819	12/2012	S113-PMC3552819	['the Stillbirth and newborn deaths were explained by medical problems, and there was NO EVIDENCE that either was RELATED to the Vitamin D supplementation, given their timing (i.e., did not occur at peak [25(Oh)D]) and the absence of biochemical EVIDENCE of Vitamin D toxicity in the mother (table\u20093).']	[('INCOMPLETE_EVIDENCE', 84), ('SUPERFICIAL_RELATIONSHIP', 112), ('INCOMPLETE_EVIDENCE', 244)]	3	[('GO_0001966', 'thigmotaxis', 4, 'stillbirth'), ('CHEBI_27300', 'vitamin D', 127, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 203, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 256, 'vitamin D')]
S202-PMC3552819	PMC3552819	12/2012	S202-PMC3552819	['the single Vitamin D3 dose of 70,000 iu did not provoke hypercalcemia or hypercalciuria in non-Pregnant or Pregnant participants, and available data INDICATED that adverse Perinatal events were neither temporally nor mechanistically linked to Vitamin D supplementation.']	[('INCOMPLETE_EVIDENCE', 149)]	1	[('CHEBI_33279', 'vitamin D5', 11, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 11, 'vitamin D3'), ('GO_0007565', 'female pregnancy', 95, 'pregnant'), ('GO_0007565', 'female pregnancy', 107, 'pregnant'), ('GO_0036268', 'swimming', 172, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 172, 'perinatal'), ('CHEBI_27300', 'vitamin D', 243, 'vitamin D')]
S179-PMC3586494	PMC3586494	2/2013	S179-PMC3586494	['female a/a Mice Fed a methyl-supplemented diet with extra Folate, Vitamin B-12,Choline, and betaine 2 weeks prior to Mating with male Avy/ a agouti Mice and throughout Pregnancy and Lactation passed along the agouti Gene to their offspring intact, YET DEMONSTRATED a shift in distribution towards having more offspring with the pseudoagouti phenotype [76].']	[('ANOMALY_CURIOUS_FINDING', 248), ('INCOMPLETE_EVIDENCE', 252)]	2	[('NCBITaxon_10088', 'Mus <genus>', 11, 'mice'), ('GO_0007631', 'feeding behavior', 16, 'fed'), ('CHEBI_30863', '5-azaorotic acid', 58, 'folate'), ('CHEBI_27300', 'vitamin D', 66, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 66, 'vitamin B-12'), ('CHEBI_15354', 'choline', 79, 'choline'), ('GO_0007618', 'mating', 117, 'mating'), ('PR_000004155', 'apolipoprotein E', 134, 'Avy'), ('NCBITaxon_10088', 'Mus <genus>', 148, 'mice'), ('GO_0007565', 'female pregnancy', 168, 'pregnancy'), ('GO_0007595', 'lactation', 182, 'lactation'), ('SO_0000704', 'gene', 216, 'gene')]
S261-PMC3586494	PMC3586494	2/2013	S261-PMC3586494	['as discussed in the section on epigenetics, experimental studies on the IMPACT of methyl-supplemented diets containing added Folate and Vitamin B-12 REVEALED the POTENTIAL ROLE of these Micronutrients in inducing major changes in offspring phenotype, including the ability to IMPACT the development of chronic diseases.']	[('SUPERFICIAL_RELATIONSHIP', 72), ('INCOMPLETE_EVIDENCE', 149), ('INCOMPLETE_EVIDENCE', 162), ('SUPERFICIAL_RELATIONSHIP', 172), ('SUPERFICIAL_RELATIONSHIP', 276)]	5	[('CHEBI_30863', '5-azaorotic acid', 125, 'folate'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 136, 'vitamin B-12'), ('CHEBI_33839', 'macromolecule', 186, 'micronutrients')]
S199-PMC3599191	PMC3599191	1/2013	S199-PMC3599191	['Intake Of Vitamin D during Pregnancy, EITHER through the diet OR through supplements, has a protective ROLE against asthma and atopic dermatitis.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 38), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 62), ('SUPERFICIAL_RELATIONSHIP', 103)]	3	[('GO_0060384', 'innervation', 0, 'Intake of'), ('CHEBI_27300', 'vitamin D', 10, 'vitamin D'), ('GO_0007565', 'female pregnancy', 27, 'pregnancy')]
S56-PMC3613945	PMC3613945	2/2013	S56-PMC3613945	['OF more immediate clinical INTEREST, PERHAPS, was our OBSERVATION that this Allele was also CORRELATED with the response of Serum 25(Oh)D levels to long-term Vitamin D supplementation.']	[('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 27), ('INCOMPLETE_EVIDENCE', 37), ('ANOMALY_CURIOUS_FINDING', 54), ('SUPERFICIAL_RELATIONSHIP', 92)]	5	[('SO_0001023', 'allele', 76, 'allele'), ('UBERON_0001977', 'blood serum', 124, 'serum'), ('CHEBI_71657', 'versiconol acetate', 130, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 130, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 158, 'vitamin D')]
S57-PMC3613945	PMC3613945	2/2013	S57-PMC3613945	['the subjects with 436kk genotype SHOWED the largest proportional increase in response to a Vitamin D supplement.']	[('INCOMPLETE_EVIDENCE', 33)]	1	[('CHEBI_27300', 'vitamin D', 91, 'vitamin D')]
S187-PMC3613945	PMC3613945	2/2013	S187-PMC3613945	['REPORTED no association between ultraviolet radiation (uvr) or Vitamin D Serum levels; YET, cod Liver oil supplementation earlier in Life was ASSOCIATED with an INCREASED risk of asthma112.']	[('INCOMPLETE_EVIDENCE', 0), ('ANOMALY_CURIOUS_FINDING', 87), ('SUPERFICIAL_RELATIONSHIP', 142), ('IMPORTANT_CONSIDERATION', 161)]	4	[('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('UBERON_0001977', 'blood serum', 73, 'serum'), ('UBERON_0002107', 'liver', 96, 'liver'), ('UBERON_0000104', 'life cycle', 133, 'life')]
S13-PMC3616124	PMC3616124	4/2013	S13-PMC3616124	['hp phenotype does not influence Preeclampsia RISK, or identify a subset of women who MAY BENEFIT from Vitamin C and E supplementation to prevent Preeclampsia.']	[('IMPORTANT_CONSIDERATION', 45), ('INCOMPLETE_EVIDENCE', 85), ('IMPORTANT_CONSIDERATION', 89)]	3	[('GO_0007128', 'meiotic prophase I', 32, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 116, 'E'), ('GO_0007128', 'meiotic prophase I', 145, 'preeclampsia')]
S2-PMC3629265	PMC3629265	4/2013	S2-PMC3629265	['CURRENTLY, Vitamin D supplementation is RECOMMENDED in canada for Breast Fed infants.']	[('INCOMPLETE_EVIDENCE', 0), ('FUTURE_WORK', 40)]	2	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('GO_0007567', 'parturition', 66, 'breast'), ('UBERON_0000310', 'breast', 66, 'breast'), ('GO_0007631', 'feeding behavior', 73, 'fed')]
S8-PMC3629265	PMC3629265	4/2013	S8-PMC3629265	"[""while these infants had several RISK FACTORS for Vitamin D deficiency, they were all receiving Cow's milk based formula supplemented with 400 iu/l of vitamin D.\n\nconclusion\nTHIS report SUGGESTS that CURRENT practice with regards to Vitamin D supplementation MAY BE INADEQUATE, especially for high-risk infants.""]"	[('SUPERFICIAL_RELATIONSHIP', 32), ('QUESTION_ANSWERED_BY_THIS_WORK', 173), ('INCOMPLETE_EVIDENCE', 185), ('INCOMPLETE_EVIDENCE', 199), ('INCOMPLETE_EVIDENCE', 258), ('IMPORTANT_CONSIDERATION', 265), ('PROBLEM_COMPLICATION', 265)]	7	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('NCBITaxon_33208', 'Metazoa', 95, 'cow'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 158, 'D'), ('CHEBI_27300', 'vitamin D', 232, 'vitamin D')]
S64-PMC3629265	PMC3629265	4/2013	S64-PMC3629265	['the current statement put forth by the canadian paediatric society, dieticians of canada, and health canada on nutrition for term infants RECOMMENDS supplementing with 400 iu/day of Vitamin D only for Breast Fed infants (22).']	[('FUTURE_WORK', 138)]	1	[('CHEBI_27300', 'vitamin D', 182, 'vitamin D'), ('GO_0007567', 'parturition', 201, 'breast'), ('UBERON_0000310', 'breast', 201, 'breast'), ('GO_0007631', 'feeding behavior', 208, 'fed')]
S70-PMC3629265	PMC3629265	4/2013	S70-PMC3629265	['the american academy of paediatrics now RECOMMENDS that formula-Fed newborns who do not consume a minimum of 1 litre of formula per day receive supplementation to achieve an intake of 400 iu Vitamin D/day (24).']	[('FUTURE_WORK', 40)]	1	[('GO_0007631', 'feeding behavior', 64, 'fed'), ('CHEBI_27300', 'vitamin D', 191, 'vitamin D')]
S92-PMC3629265	PMC3629265	4/2013	S92-PMC3629265	['conclusion\nwe SUGGEST that the amount of Vitamin D supplementation NEEDED to prevent deficiency in infants residing in communities in the temperate region SHOULD BE REVISITED, PARTICULARLY for those at high risk for Prenatal deficiency.']	[('INCOMPLETE_EVIDENCE', 14), ('FUTURE_WORK', 67), ('IMPORTANT_CONSIDERATION', 67), ('FUTURE_WORK', 155), ('FUTURE_WORK', 165), ('IMPORTANT_CONSIDERATION', 176)]	6	[('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('GO_0007565', 'female pregnancy', 216, 'prenatal')]
S39-PMC3635901	PMC3635901	4/2013	S39-PMC3635901	['THE NEED to provide Vitamin D supplementation for patients with Autoimmune diseases, including ss, is clear.']	[('INCOMPLETE_EVIDENCE', 0)]	1	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('UBERON_0001442', 'skeleton of manus', 64, 'autoimmune')]
S0-PMC3641012	PMC3641012	4/2013	S0-PMC3641012	['randomized placebo-controlled trial of high-dose Prenatal third-Trimester Vitamin D3 supplementation in bangladesh: the avidd trial\n\nabstract\n\nbackground\nantenatal Vitamin D status MAY be ASSOCIATED with the RISK of adverse Pregnancy and neonatal outcomes; HOWEVER, the benefits of Vitamin D supplementation during Pregnancy remain UNKNOWN.']	[('INCOMPLETE_EVIDENCE', 181), ('SUPERFICIAL_RELATIONSHIP', 188), ('IMPORTANT_CONSIDERATION', 208), ('ANOMALY_CURIOUS_FINDING', 257), ('FULL_UNKNOWN', 332)]	5	[('GO_0007565', 'female pregnancy', 49, 'prenatal'), ('GO_0009294', 'DNA mediated transformation', 64, 'trimester'), ('CHEBI_33279', 'vitamin D5', 74, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 74, 'vitamin D3'), ('CHEBI_27300', 'vitamin D', 164, 'vitamin D'), ('GO_0007565', 'female pregnancy', 224, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 282, 'vitamin D'), ('GO_0007565', 'female pregnancy', 315, 'pregnancy')]
S14-PMC3641012	PMC3641012	4/2013	S14-PMC3641012	['CURRENTLY, there is INSUFFICIENT EVIDENCE to EITHER SUPPORT OR REFUTE the benefits of any given supplemental Vitamin D dose during Pregnancy [8,9].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 20), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 45), ('INCOMPLETE_EVIDENCE', 52), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 63)]	5	[('CHEBI_27300', 'vitamin D', 109, 'vitamin D'), ('GO_0007565', 'female pregnancy', 131, 'pregnancy')]
S25-PMC3641012	PMC3641012	4/2013	S25-PMC3641012	['these data MAY serve to design larger rcts to measure the EFFECTS of Antenatal Vitamin D supplementation on functional outcomes of clinical and PUBLIC HEALTH IMPORTANCE.']	[('INCOMPLETE_EVIDENCE', 11), ('SUPERFICIAL_RELATIONSHIP', 58), ('IMPORTANT_CONSIDERATION', 144), ('IMPORTANT_CONSIDERATION', 158)]	4	[('GO_0007567', 'parturition', 69, 'antenatal'), ('CHEBI_27300', 'vitamin D', 79, 'vitamin D')]
S30-PMC3641012	PMC3641012	4/2013	S30-PMC3641012	['individuals were not eligible if they had any of the following exclusion criteria: use of any dietary supplement containing more than 400\xa0iu/day (10 mcg/day) of Vitamin D within the month prior to enrolment, or refusal to stop taking supplemental Vitamin D at any dose after enrollment; current use of anti-convulsant or Anti-Mycobacterial (tuberculosis) Medications; severe anemia (hemoglobin\u2009<\u200970\xa0g/l); systolic Blood pressure\u2009≥140\xa0mm hg or diastolic Blood pressure\u2009≥90\xa0mm hg; positive Urine dipstick for proteinuria or glycosuria; COMPLICATED medical or obstetric history; or, reported prior history of Delivery of an infant with a major congenital anomaly, Birth asphyxia, or Perinatal death.']	[('DIFFICULT_TASK', 534)]	1	[('CHEBI_27300', 'vitamin D', 161, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 247, 'vitamin D'), ('CHEBI_59132', 'antigen', 321, 'anti'), ('CHEBI_52217', 'pharmaceutical', 326, 'mycobacterial'), ('CHEBI_25441', 'mycothiols', 355, 'medications'), ('UBERON_0000178', 'blood', 414, 'blood'), ('UBERON_0000178', 'blood', 453, 'blood'), ('UBERON_0001088', 'urine', 488, 'urine'), ('GO_0007567', 'parturition', 606, 'delivery'), ('GO_0007567', 'parturition', 661, 'birth'), ('GO_0036268', 'swimming', 680, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 680, 'perinatal')]
S94-PMC3641012	PMC3641012	4/2013	S94-PMC3641012	['this approach enabled the estimation of the average difference in 25(Oh)D between the two groups at a PRESUMED ‘steady-state’ (i.e., where group-averaged 25(Oh)D did not continue to appreciably rise DESPITE ongoing Vitamin D supplementation).']	[('PROBABLE_UNDERSTANDING', 102), ('ANOMALY_CURIOUS_FINDING', 199)]	2	[('CHEBI_71657', 'versiconol acetate', 66, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 154, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 215, 'vitamin D')]
S128-PMC3641012	PMC3641012	4/2013	S128-PMC3641012	['Vitamin D supplementation had a substantial, statistically significant EFFECT on maternal and neonatal Vitamin D status at the time of Delivery, as reflected in the overall 25(Oh)D distributions (figure\xa02; table\xa04) as well as the proportion of participants considered to have low 25(Oh)D using cut-offs (table\xa02).']	[('SUPERFICIAL_RELATIONSHIP', 71)]	1	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 103, 'vitamin D'), ('GO_0007567', 'parturition', 135, 'delivery'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 176, 'OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 179, 'D'), ('CHEBI_71657', 'versiconol acetate', 280, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 280, '25(OH)D')]
S132-PMC3641012	PMC3641012	4/2013	S132-PMC3641012	['AS EVIDENCE that this plateau was not an artifact of diminishing supplement adherence over time, a sensitivity analysis in which 25(Oh)D was MODELED as a function of cumulative Vitamin D dose REVEALED the same PATTERN (figure\xa03), and fit the data well (table\xa05).']	[('INCOMPLETE_EVIDENCE', 0), ('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 141), ('INCOMPLETE_EVIDENCE', 192), ('SUPERFICIAL_RELATIONSHIP', 210)]	6	[('CHEBI_71657', 'versiconol acetate', 129, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 177, 'vitamin D')]
S161-PMC3641012	PMC3641012	4/2013	S161-PMC3641012	['given the substantial inter-Individual VARIABILITY in the response to Vitamin D supplementation (figure\xa03), we EXPLORED the ROLE of the following POTENTIAL MODIFIERS of the magnitude of the change in 25(Oh)D (δ25(Oh)D) from baseline to Delivery (selected a priori ): maternal weight at baseline, maternal age, Gestational age, maternal body mass index at baseline (bmi), gravidity, parity, baseline Pth status, season and baseline Vitamin D status.']	[('DIFFICULT_TASK', 39), ('QUESTION_ANSWERED_BY_THIS_WORK', 111), ('SUPERFICIAL_RELATIONSHIP', 124), ('INCOMPLETE_EVIDENCE', 146), ('SUPERFICIAL_RELATIONSHIP', 156)]	5	[('NCBITaxon_1', 'root', 28, 'individual'), ('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 200, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 206, 'D'), ('CHEBI_33010', 'chromide(1-)', 212, '(OH)D'), ('GO_0007567', 'parturition', 236, 'delivery'), ('GO_0007565', 'female pregnancy', 310, 'gestational'), ('CHEBI_8102', 'phenylmethanesulfonyl fluoride', 399, 'PTH'), ('CHEBI_27300', 'vitamin D', 431, 'vitamin D')]
S165-PMC3641012	PMC3641012	4/2013	S165-PMC3641012	['NOTABLY, variation in Cord 25(Oh)D within the Vitamin D group was not associated with duration of supplementation (p\u2009=\u20090.86) or cumulative Vitamin D supplement dose administered (p\u2009=\u20090.93), INDICATING that the maternal-fetal Vitamin D equilibrium was achieved rapidly.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 190)]	2	[('UBERON_0002240', 'spinal cord', 22, 'cord'), ('CHEBI_71657', 'versiconol acetate', 27, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 27, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 139, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 225, 'vitamin D')]
S166-PMC3641012	PMC3641012	4/2013	S166-PMC3641012	['mean maternal adj-ca concentration rose over time within the reference range; the initial rate of rise APPEARED TO BE greater in the Vitamin D group, BUT the difference was attenuated after ~2\xa0months of supplementation (figure\xa04).']	[('ANOMALY_CURIOUS_FINDING', 103), ('ANOMALY_CURIOUS_FINDING', 150)]	2	[('CHEBI_27300', 'vitamin D', 133, 'vitamin D')]
S198-PMC3641012	PMC3641012	4/2013	S198-PMC3641012	['Vitamin D supplementation had a significant suppressive EFFECT on maternal pth concentration, such that the rise in pth observed in the placebo group was completely attenuated in the vitamin D group (figure\xa04), and the average pth concentration was lower in the Vitamin D group at Delivery (figure\xa02; table\xa04).']	[('SUPERFICIAL_RELATIONSHIP', 56)]	1	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 191, 'D'), ('CHEBI_27300', 'vitamin D', 262, 'vitamin D'), ('GO_0007567', 'parturition', 281, 'delivery')]
S236-PMC3641012	PMC3641012	4/2013	S236-PMC3641012	['FURTHER clinical DATA are REQUIRED before conclusive statements can be made regarding the APPROPRIATENESS of high-dose Antenatal Vitamin D supplementation.']	[('FUTURE_WORK', 0), ('IMPORTANT_CONSIDERATION', 26), ('IMPORTANT_CONSIDERATION', 90)]	3	[('GO_0007567', 'parturition', 119, 'antenatal'), ('CHEBI_27300', 'vitamin D', 129, 'vitamin D')]
S0-PMC3651971	PMC3651971	5/2013	S0-PMC3651971	['cognitive and motor skills in school-aged children following maternal Vitamin A supplementation during Pregnancy in rural nepal: a follow-up of a placebo-controlled, randomised cohort\n\nabstract\n\nobjective\nTO DETERMINE the EFFECTS of maternal Vitamin A supplementation from Preconception through Postpartum on Cognitive and Motor Development of children at 10–13\u2005years of age in rural nepal.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 205), ('SUPERFICIAL_RELATIONSHIP', 222)]	2	[('CHEBI_27300', 'vitamin D', 70, 'vitamin A'), ('GO_0007565', 'female pregnancy', 103, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 242, 'vitamin A'), ('GO_0007565', 'female pregnancy', 273, 'preconception'), ('GO_0007565', 'female pregnancy', 295, 'postpartum'), ('GO_0050890', 'cognition', 309, 'cognitive ...'), ('GO_0009653', 'anatomical structure morphogenesis', 323, 'motor development')]
S11-PMC3651971	PMC3651971	5/2013	S11-PMC3651971	['caption (boxed-text)\narticle summary\n\narticle focus\nTHIS ARTICLE EXAMINES the EFFECTS of early Vitamin A supplementation on Cognitive and motor skills in school-aged children.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 52), ('QUESTION_ANSWERED_BY_THIS_WORK', 65), ('SUPERFICIAL_RELATIONSHIP', 78)]	3	[('CHEBI_27300', 'vitamin D', 95, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 103, 'A'), ('GO_0050890', 'cognition', 124, 'cognitive')]
S15-PMC3651971	PMC3651971	5/2013	S15-PMC3651971	['our results provide NO EVIDENCE that early Vitamin A supplementation improves Cognitive or motor skills in 10-year-old to 13-year-old-children in rural nepal.']	[('INCOMPLETE_EVIDENCE', 20)]	1	[('CHEBI_27300', 'vitamin D', 43, 'vitamin A'), ('GO_0050890', 'cognition', 78, 'cognitive')]
S18-PMC3651971	PMC3651971	5/2013	S18-PMC3651971	['THIS STUDY SUGGESTS no benefit of maternal Vitamin A supplementation on Cognitive or motor skills in 10-year-old to 13-year-old offspring.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 11)]	2	[('CHEBI_27300', 'vitamin D', 43, 'vitamin A'), ('GO_0050890', 'cognition', 72, 'cognitive')]
S26-PMC3651971	PMC3651971	5/2013	S26-PMC3651971	['in a study of healthy chinese mothers and newborns, a positive RELATIONSHIP was OBSERVED between Cord Blood Retinol level and motor skill achievements by age 2.17in indonesia, newborn Vitamin A supplementation resulted in modest improvement in Motor Development scores after 3\u2005years,18while Vitamin A supplementation to hiv-positive tanzanian women exerted no detectable changes in infant Psychomotor Development.19there REMAINS, HOWEVER, a NEED FOR ADDITIONAL causal data on early Life Vitamin A exposure and Neurocognitive and motor function.']	[('SUPERFICIAL_RELATIONSHIP', 63), ('INCOMPLETE_EVIDENCE', 80), ('INCOMPLETE_EVIDENCE', 421), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 430), ('FUTURE_WORK', 441)]	5	[('UBERON_0002240', 'spinal cord', 97, 'cord'), ('UBERON_0000178', 'blood', 102, 'blood'), ('CHEBI_26536', 'retinoic acid', 108, 'retinol'), ('CHEBI_27300', 'vitamin D', 184, 'vitamin A'), ('GO_0009653', 'anatomical structure morphogenesis', 244, 'motor development'), ('CHEBI_27300', 'vitamin D', 291, 'vitamin A'), ('GO_0030324', 'lung development', 389, 'psychomotor development'), ('UBERON_0000104', 'life cycle', 482, 'life'), ('CHEBI_27300', 'vitamin D', 487, 'vitamin A'), ('GO_0050905', 'neuromuscular process', 510, 'neurocognitive')]
S27-PMC3651971	PMC3651971	5/2013	S27-PMC3651971	['THIS STUDY is the FIRST TO EXAMINE EFFECTS of routine, maternal Vitamin A supplementation before, during and following Pregnancy, provided via a randomised, placebo-controlled trial, on child Cognitive and motor ability.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 18), ('QUESTION_ANSWERED_BY_THIS_WORK', 24), ('QUESTION_ANSWERED_BY_THIS_WORK', 27), ('SUPERFICIAL_RELATIONSHIP', 35)]	5	[('CHEBI_27300', 'vitamin D', 64, 'vitamin A'), ('GO_0007565', 'female pregnancy', 119, 'pregnancy'), ('GO_0050890', 'cognition', 192, 'cognitive')]
S28-PMC3651971	PMC3651971	5/2013	S28-PMC3651971	['the trial was conducted in a chronically undernourished population where supplementation with Vitamin A or Β-Carotene reduced maternal mortality,20biochemical Vitamin A deficiency,21night blindness22and morbidity,23but had no overall effect on infant mortality.24in the long term, at 9–13\u2005years of age, the intervention HAS BEEN SHOWN to have improved Lung size25and innate aspects of Immunity,26but has not affected biomarker risk factors for Cardiovascular diseases.27\n\nmethods\n\nselection and description of sample\nthis study followed a sample of Children Born to women who participated in a cluster-randomised, placebo-controlled trial of Vitamin A or Β-Carotene supplementation before, during and after Pregnancy.']	[('INCOMPLETE_EVIDENCE', 320)]	1	[('CHEBI_27300', 'vitamin D', 94, 'vitamin A'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 107, 'β-carotene'), ('CHEBI_27300', 'vitamin D', 159, 'vitamin A'), ('UBERON_0002048', 'lung', 352, 'lung'), ('GO_0007566', 'embryo implantation', 385, 'immunity'), ('UBERON_0004535', 'cardiovascular system', 444, 'cardiovascular'), ('GO_0050890', 'cognition', 549, 'children'), ('GO_0007567', 'parturition', 558, 'born'), ('CHEBI_27300', 'vitamin D', 642, 'vitamin A'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 655, 'β-carotene'), ('GO_0007565', 'female pregnancy', 707, 'pregnancy')]
S37-PMC3651971	PMC3651971	5/2013	S37-PMC3651971	['beyond 6\u2005months of age, the national, semiannual Vitamin A supplementation programme, implemented from 1995 onwards, offered children in the sarlahi district Supplements containing 100\u2005000\u2005iu up to 11\u2005months, and 200\u2005000\u2005iu from 12 to ∼60\u2005months of age, with coverage routinely reaching ≥80%.30the study children were THEREFORE LIKELY to have started receiving Vitamin A periodically through the national programme from age 6\u2005months onwards, but there are no individual records of their programme participation.']	[('PROBABLE_UNDERSTANDING', 318), ('PROBABLE_UNDERSTANDING', 328)]	2	[('CHEBI_27300', 'vitamin D', 49, 'vitamin A'), ('CHEBI_33341', 'titanium atom', 158, 'supplements'), ('CHEBI_27300', 'vitamin D', 361, 'vitamin A')]
S38-PMC3651971	PMC3651971	5/2013	S38-PMC3651971	['objective and outcomes\nTHIS STUDY HYPOTHESISED that, by school age, children Born to mothers routinely supplemented with Vitamin A would perform better on tests of Cognitive and motor ability than children Born to Placebo-supplemented women.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 23), ('INCOMPLETE_EVIDENCE', 34), ('QUESTION_ANSWERED_BY_THIS_WORK', 34)]	3	[('GO_0007567', 'parturition', 77, 'born'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin A'), ('GO_0050890', 'cognition', 164, 'cognitive'), ('GO_0007567', 'parturition', 206, 'born'), ('CHEBI_26130', 'biological pigment', 214, 'placebo')]
S54-PMC3651971	PMC3651971	5/2013	S54-PMC3651971	['we HYPOTHESISED that Early Life Vitamin A supplementation COULD yield differences of 40% of an sd based on standardised distributions obtainable from unit and mabc, with 80% power, and arbitrarily assumed a design effect associated with ward randomisation of 2 and a 5% refusal rate.']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 58)]	2	[('UBERON_0001847', 'lobule of pinna', 21, 'early life'), ('CHEBI_27300', 'vitamin D', 32, 'vitamin A')]
S89-PMC3651971	PMC3651971	5/2013	S89-PMC3651971	['comparisons between participants of the randomised Supplement group\nthe Vitamin A and placebo groups of tested children were similar on measures of socioeconomic and nutritional status assessed during the original nnips-2 trial, the one IMPORTANT and expected difference being that a higher proportion of children whose mothers had been night blind during Pregnancy were in the placebo vs Vitamin A group (15.5% vs 8.2%, p=0.02).']	[('IMPORTANT_CONSIDERATION', 237)]	1	[('CHEBI_16158', 'steroid sulfate', 51, 'supplement'), ('CHEBI_27300', 'vitamin D', 72, 'vitamin A'), ('GO_0007565', 'female pregnancy', 356, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 389, 'vitamin A')]
S139-PMC3651971	PMC3651971	5/2013	S139-PMC3651971	['the lack of EFFECT is UNLIKELY to be DUE TO a lack of Vitamin A deficiency among Pregnant women; ∼20% of mothers were NOTED to have a Serum Retinol concentration below 0.70\u2005µmol/l, a prevalence that fell to ∼3% with supplementation.20gestational night blindness of ∼10% also responded to Vitamin A supplementation,37and the risk of Maternal death was reduced by ∼40% through supplementation.20there was no lack of Cognitive or motor effect, which is LIKELY to be OWING TO the POOR response to supplementation among the offspring; infants Born to supplemented women had a higher Serum Retinol than infants Born to Placebo mothers by 3\u2005months of age.24the children Born to supplemented women also had better Lung function (as measured by the forced Expiratory volume at 1\u2005s and forced vital capacity)25and raised natural Antibody levels26in childhood, FURTHER EVIDENCE of a physiological EFFECT.']	[('SUPERFICIAL_RELATIONSHIP', 12), ('PROBABLE_UNDERSTANDING', 22), ('PROBLEM_COMPLICATION', 37), ('ANOMALY_CURIOUS_FINDING', 118), ('PROBABLE_UNDERSTANDING', 450), ('PROBLEM_COMPLICATION', 463), ('PROBLEM_COMPLICATION', 476), ('INCOMPLETE_EVIDENCE', 850), ('SUPERFICIAL_RELATIONSHIP', 886)]	9	[('CHEBI_27300', 'vitamin D', 54, 'vitamin A'), ('GO_0007565', 'female pregnancy', 81, 'pregnant'), ('UBERON_0001977', 'blood serum', 134, 'serum'), ('CHEBI_26536', 'retinoic acid', 140, 'retinol'), ('CHEBI_27300', 'vitamin D', 288, 'vitamin A'), ('GO_0007618', 'mating', 332, 'maternal'), ('GO_0050890', 'cognition', 414, 'cognitive'), ('GO_0007567', 'parturition', 538, 'born'), ('UBERON_0001977', 'blood serum', 578, 'serum'), ('CHEBI_26536', 'retinoic acid', 584, 'retinol'), ('GO_0007567', 'parturition', 605, 'born'), ('CHEBI_26130', 'biological pigment', 613, 'placebo'), ('GO_0007567', 'parturition', 663, 'born'), ('UBERON_0002048', 'lung', 706, 'lung'), ('GO_0010467', 'gene expression', 747, 'expiratory'), ('GO_0042571', 'immunoglobulin complex, circulating', 819, 'antibody')]
S140-PMC3651971	PMC3651971	5/2013	S140-PMC3651971	['the HYPOTHESISED EFFECT of Gestational Vitamin A supplementation on Cognition and Motor Development is BASED ON sound THEORY.']	[('INCOMPLETE_EVIDENCE', 4), ('SUPERFICIAL_RELATIONSHIP', 17), ('PROBABLE_UNDERSTANDING', 103), ('SUPERFICIAL_RELATIONSHIP', 103), ('INCOMPLETE_EVIDENCE', 118)]	5	[('GO_0007565', 'female pregnancy', 27, 'gestational'), ('CHEBI_27300', 'vitamin D', 39, 'vitamin A'), ('GO_0050890', 'cognition', 68, 'cognition'), ('GO_0009653', 'anatomical structure morphogenesis', 82, 'motor development')]
S142-PMC3651971	PMC3651971	5/2013	S142-PMC3651971	['the Human studies that have SUGGESTED a ROLE for Vitamin A in Cognitive and Motor Development are LIMITED to much younger children.1718another POSSIBLE EXPLANATION for our results is that differences between groups were attenuated by routine supplementation from the national Vitamin A programme started in 1995.30given the wide cis for experimental measures of Cognitive and motor development, and the POTENTIAL for Brain plasticity, the supplementation programme MIGHT have attenuated a treatment EFFECT, allowing placebo group children to regain the nutritional losses of their early Life.']	[('INCOMPLETE_EVIDENCE', 28), ('SUPERFICIAL_RELATIONSHIP', 40), ('INCOMPLETE_EVIDENCE', 98), ('INCOMPLETE_EVIDENCE', 143), ('PROBABLE_UNDERSTANDING', 152), ('INCOMPLETE_EVIDENCE', 403), ('INCOMPLETE_EVIDENCE', 465), ('SUPERFICIAL_RELATIONSHIP', 499)]	8	[('NCBITaxon_9606', 'Homo sapiens', 4, 'human'), ('CHEBI_27300', 'vitamin D', 49, 'vitamin A'), ('GO_0050890', 'cognition', 62, 'cognitive ...'), ('GO_0009653', 'anatomical structure morphogenesis', 76, 'motor development'), ('CHEBI_27300', 'vitamin D', 276, 'vitamin A'), ('GO_0050890', 'cognition', 362, 'cognitive'), ('UBERON_0000955', 'brain', 417, 'brain'), ('UBERON_0000104', 'life cycle', 587, 'life')]
S157-PMC3651971	PMC3651971	5/2013	S157-PMC3651971	['the post hoc analyses REPORTED in THIS PAPER HINTED AT differences in motor skills after in utero Vitamin A supplementation, but did so ONLY after excluding children who never attended school and those who repeated a grade.']	[('INCOMPLETE_EVIDENCE', 22), ('QUESTION_ANSWERED_BY_THIS_WORK', 34), ('INCOMPLETE_EVIDENCE', 45), ('ANOMALY_CURIOUS_FINDING', 136), ('INCOMPLETE_EVIDENCE', 136)]	5	[('CHEBI_27300', 'vitamin D', 98, 'vitamin A')]
S161-PMC3651971	PMC3651971	5/2013	S161-PMC3651971	['in conclusion, in this Vitamin A deficient setting, where maternal Vitamin A supplementation reduced maternal night blindness and mortality, no long-term EFFECTS have BEEN observed on the Cognitive and motor skill development of Prepubescent offspring.']	[('SUPERFICIAL_RELATIONSHIP', 154), ('ANOMALY_CURIOUS_FINDING', 167)]	2	[('CHEBI_27300', 'vitamin D', 23, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 67, 'vitamin A'), ('GO_0050890', 'cognition', 188, 'cognitive ...'), ('GO_0048633', 'positive regulation of skeletal muscle tissue growth', 229, 'prepubescent')]
S8-PMC3659910	PMC3659910	1/2013	S8-PMC3659910	['the CURRENTLY RECOMMENDED supplementation amount of Vitamin D is NOT SUFFICIENT to maintain a value of 25 Hydroxy Vitamin D above 30 ng/ml, during Pregnancy.']	[('INCOMPLETE_EVIDENCE', 4), ('FUTURE_WORK', 14), ('IMPORTANT_CONSIDERATION', 65)]	3	[('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('CHEBI_45557', 'sec-butyl group', 103, '25 hydroxy'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 122, 'D'), ('GO_0007565', 'female pregnancy', 147, 'pregnancy')]
S10-PMC3659910	PMC3659910	1/2013	S10-PMC3659910	['clearly, FURTHER INVESTIGATION is REQUIRED into the EFFECTS of Vitamin D, of Vitamin D supplementation, and of Vitamin D analogs for IMPROVEMENT in Human health generally and mothers and children specifically.']	[('FUTURE_WORK', 9), ('IMPORTANT_CONSIDERATION', 34), ('SUPERFICIAL_RELATIONSHIP', 52), ('FUTURE_WORK', 133)]	4	[('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 77, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 111, 'vitamin D'), ('NCBITaxon_9606', 'Homo sapiens', 148, 'human')]
S65-PMC3659910	PMC3659910	1/2013	S65-PMC3659910	['methods are CURRENTLY available to quantify the CONTRIBUTION of Endogenous Vitamin D Synthesis resulting from sun exposure, BUT SERIOUS LIMITATIONS REMAIN in ACCURATELY ESTIMATING dietary Vitamin D intake BECAUSE of the INCOMPLETENESS of Nutrient databases for both Vitamin D-fortified Food and Vitamin D supplements.']	[('INCOMPLETE_EVIDENCE', 12), ('SUPERFICIAL_RELATIONSHIP', 48), ('PROBLEM_COMPLICATION', 124), ('IMPORTANT_CONSIDERATION', 128), ('PROBLEM_COMPLICATION', 136), ('INCOMPLETE_EVIDENCE', 148), ('SUPERFICIAL_RELATIONSHIP', 158), ('INCOMPLETE_EVIDENCE', 169), ('PROBLEM_COMPLICATION', 205), ('INCOMPLETE_EVIDENCE', 220)]	10	[('GO_0009790', 'embryo development', 64, 'endogenous'), ('CHEBI_27300', 'vitamin D', 75, 'vitamin D'), ('GO_0042368', 'vitamin D biosynthetic process', 75, 'vitamin D synthesis'), ('CHEBI_27300', 'vitamin D', 188, 'vitamin D'), ('CHEBI_33284', 'nutrient', 238, 'nutrient'), ('CHEBI_27300', 'vitamin D', 266, 'vitamin D'), ('CHEBI_33290', 'food', 286, 'food'), ('CHEBI_27300', 'vitamin D', 295, 'vitamin D')]
S66-PMC3659910	PMC3659910	1/2013	S66-PMC3659910	"[""THUS, increasing Vitamin D intake from Vitamin D fortified foods, and Vitamin D supplements, in combination with SENSIBLE sun exposure, maximize a Person's vitamin d status to promote good health.""]"	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 113)]	2	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 147, 'person')]
S73-PMC3659910	PMC3659910	1/2013	S73-PMC3659910	"[""women who have Intestinal Malabsorption diseases like celiac disease and crohn's disease or partial removal or bypass of the Stomach or Intestines absorb less of both dietary and supplemental Vitamin D are at INCREASED RISK of deficiency.""]"	[('IMPORTANT_CONSIDERATION', 209)]	1	[('UBERON_0000160', 'intestine', 15, 'intestinal'), ('GO_0046693', 'sperm storage', 26, 'malabsorption'), ('UBERON_0000945', 'stomach', 125, 'stomach'), ('UBERON_0000160', 'intestine', 136, 'intestines'), ('CHEBI_27300', 'vitamin D', 192, 'vitamin D')]
S89-PMC3659910	PMC3659910	1/2013	S89-PMC3659910	['MOST Prenatal Vitamins have around 400 iu of Vitamin D, and MOST health groups RECOMMEND taking no more than 2,000 iu of the Vitamin in supplement form daily.']	[('PROBABLE_UNDERSTANDING', 0), ('PROBABLE_UNDERSTANDING', 60), ('FUTURE_WORK', 79)]	3	[('GO_0007565', 'female pregnancy', 5, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 14, 'vitamins'), ('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 125, 'vitamin')]
S107-PMC3659910	PMC3659910	1/2013	S107-PMC3659910	['two clinical trials SUPPORT a POTENTIAL ROLE of Vitamin D in the PREVENTION of Preeclampsia, ALTHOUGH neither of these treated with Vitamin D supplements alone.']	[('INCOMPLETE_EVIDENCE', 20), ('INCOMPLETE_EVIDENCE', 30), ('SUPERFICIAL_RELATIONSHIP', 40), ('SUPERFICIAL_RELATIONSHIP', 65), ('INCOMPLETE_EVIDENCE', 93)]	5	[('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 79, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 132, 'vitamin D')]
S124-PMC3659910	PMC3659910	1/2013	S124-PMC3659910	['the cochrane review CONCLUDED that there is NOT ENOUGH EVIDENCE TO EVALUATE the REQUIREMENTS and EFFECTS of Vitamin D supplementation during Pregnancy.']	[('INCOMPLETE_EVIDENCE', 20), ('INCOMPLETE_EVIDENCE', 44), ('INCOMPLETE_EVIDENCE', 55), ('FUTURE_WORK', 64), ('IMPORTANT_CONSIDERATION', 80), ('SUPERFICIAL_RELATIONSHIP', 97)]	6	[('CHEBI_27300', 'vitamin D', 108, 'vitamin D'), ('GO_0007565', 'female pregnancy', 141, 'pregnancy')]
S125-PMC3659910	PMC3659910	1/2013	S125-PMC3659910	['data from three trials involving 463 women SHOW a TREND for women who receive Vitamin D supplementation during Pregnancy to more frequently have a baby with a Birth weight below 2500 grams than those women receiving no treatment or placebo, ALTHOUGH the statistical significance was borderline.']	[('INCOMPLETE_EVIDENCE', 43), ('INCOMPLETE_EVIDENCE', 50), ('PROBLEM_COMPLICATION', 241)]	3	[('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('GO_0007565', 'female pregnancy', 111, 'pregnancy'), ('GO_0007567', 'parturition', 159, 'birth')]
S131-PMC3659910	PMC3659910	1/2013	S131-PMC3659910	['RESEARCH has FOUND direct CONNECTIONS between Vitamin D and the Genes KNOWN to be INVOLVED in ms, BUT exact pathology and WHETHER Vitamin D supplements during Pregnancy OR childhood can lessen the likelihood of the child developing ms later in Life is NOT KNOWN.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 13), ('SUPERFICIAL_RELATIONSHIP', 26), ('INCOMPLETE_EVIDENCE', 70), ('SUPERFICIAL_RELATIONSHIP', 82), ('ANOMALY_CURIOUS_FINDING', 98), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 122), ('FULL_UNKNOWN', 252)]	8	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('SO_0000704', 'gene', 64, 'genes'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D'), ('GO_0007565', 'female pregnancy', 159, 'pregnancy'), ('UBERON_0000104', 'life cycle', 244, 'life')]
S132-PMC3659910	PMC3659910	1/2013	S132-PMC3659910	['while there is INTEREST in the ROLE of Vitamin D in the PREVENTION of multiple sclerosis, following epidemiological STUDIES DEMONSTRATING an ASSOCIATION between Vitamin D supplementation and reduced PREVALENCE of the disease, FUTURE RESEARCH, including randomized controlled trials in Pregnant or nonpregnant Individuals, is AWAITED TO CONFIRM OR REFUTE such BENEFIT.']	[('IMPORTANT_CONSIDERATION', 15), ('SUPERFICIAL_RELATIONSHIP', 31), ('SUPERFICIAL_RELATIONSHIP', 56), ('INCOMPLETE_EVIDENCE', 116), ('INCOMPLETE_EVIDENCE', 124), ('SUPERFICIAL_RELATIONSHIP', 141), ('IMPORTANT_CONSIDERATION', 199), ('FUTURE_WORK', 226), ('FUTURE_WORK', 325), ('FUTURE_WORK', 333), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 344), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 347), ('IMPORTANT_CONSIDERATION', 359)]	13	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 161, 'vitamin D'), ('GO_0007565', 'female pregnancy', 285, 'pregnant'), ('NCBITaxon_1', 'root', 309, 'individuals')]
S133-PMC3659910	PMC3659910	1/2013	S133-PMC3659910	['BECAUSE the POOR Vitamin D stores of the mother MAY impair Vitamin D state in the infant, it is IMPORTANT to know WHETHER rickets can be PREVENTED in breast Fed infants by supplementation of the mother.']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 12), ('INCOMPLETE_EVIDENCE', 48), ('IMPORTANT_CONSIDERATION', 96), ('EXPLICIT_QUESTION', 114), ('SUPERFICIAL_RELATIONSHIP', 137)]	6	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('GO_0007631', 'feeding behavior', 157, 'fed')]
S136-PMC3659910	PMC3659910	1/2013	S136-PMC3659910	['a sufficient supply of Vitamin D to the Breast Fed infant is achieved ONLY by increasing the maternal supplementation up to 2000 iu/day.']	[('INCOMPLETE_EVIDENCE', 70)]	1	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('GO_0007567', 'parturition', 40, 'breast fed'), ('UBERON_0000310', 'breast', 40, 'breast')]
S138-PMC3659910	PMC3659910	1/2013	S138-PMC3659910	['OTHER SUGGESTS Vitamin D supplementation of 400 iu/day to Breast Fed infants is the MOST secure way of PREVENTING rickets in infants.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 6), ('PROBABLE_UNDERSTANDING', 84), ('SUPERFICIAL_RELATIONSHIP', 103)]	4	[('CHEBI_27300', 'vitamin D', 15, 'vitamin D'), ('GO_0007567', 'parturition', 58, 'breast fed')]
S142-PMC3659910	PMC3659910	1/2013	S142-PMC3659910	['while Vitamin D supplementation in Pregnancy has PREVIOUSLY been ASSOCIATED with reduced RISK of wheezing and type 1 diabetes.']	[('INCOMPLETE_EVIDENCE', 49), ('SUPERFICIAL_RELATIONSHIP', 65), ('IMPORTANT_CONSIDERATION', 89)]	3	[('CHEBI_27300', 'vitamin D', 6, 'vitamin D'), ('GO_0007565', 'female pregnancy', 35, 'pregnancy')]
S154-PMC3659910	PMC3659910	1/2013	S154-PMC3659910	['AT PRESENT, Vitamin D supplementation is not a part of Antenatal Care programs in india.']	[('INCOMPLETE_EVIDENCE', 0)]	1	[('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('GO_0007608', 'sensory perception of smell', 55, 'antenatal care')]
S155-PMC3659910	PMC3659910	1/2013	S155-PMC3659910	['testing and treatment for Vitamin D deficiency\nwomen of Reproductive age are ASSUMED TO BE able to obtain the RECOMMENDED intake for ALMOST ALL Vitamins without the use of supplements, and no national organization RECOMMENDS routine Vitamin D supplementation during Pregnancy unless a woman is at nutritional RISK.']	[('PROBABLE_UNDERSTANDING', 77), ('FUTURE_PREDICTION', 85), ('FUTURE_WORK', 110), ('PROBABLE_UNDERSTANDING', 133), ('FUTURE_WORK', 214), ('IMPORTANT_CONSIDERATION', 309)]	6	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('GO_0000003', 'reproduction', 56, 'reproductive'), ('CHEBI_33277', 'gamma-tocotrienol', 144, 'vitamins'), ('CHEBI_27300', 'vitamin D', 233, 'vitamin D'), ('GO_0007565', 'female pregnancy', 266, 'pregnancy')]
S175-PMC3659910	PMC3659910	1/2013	S175-PMC3659910	['a RECENT systematic review CONCLUDED that Antenatal Vitamin D supplementation is EFFECTIVE in improving the Vitamin D status of asian and white women, improves growth in the first year of Life in south asian babies and THEREFORE MAY CONTRIBUTE to reducing the incidence of rickets in this latter group, without evidence of harm.']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 27), ('SUPERFICIAL_RELATIONSHIP', 81), ('PROBABLE_UNDERSTANDING', 219), ('FUTURE_PREDICTION', 229), ('SUPERFICIAL_RELATIONSHIP', 233)]	6	[('GO_0007567', 'parturition', 42, 'antenatal'), ('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin D'), ('UBERON_0000104', 'life cycle', 188, 'life')]
S185-PMC3659910	PMC3659910	1/2013	S185-PMC3659910	['HOWEVER, getting 25(Oh) D levels consistently above 75 nmol/l (30 ng/ml) MAY REQUIRE AT LEAST 1500-2000 iu/day of Vitamin D. if a mother is Vitamin D deficient, Breast Milk is not a good source of Vitamin D, so infants need to be given Vitamin D supplementation until they are weaned.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 73), ('FUTURE_WORK', 77), ('PROBABLE_UNDERSTANDING', 85)]	4	[('CHEBI_71657', 'versiconol acetate', 17, '25(OH) D'), ('PR_000006444', 'diacylglycerol kinase delta', 24, 'D'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 140, 'vitamin D'), ('UBERON_0000310', 'breast', 161, 'breast'), ('UBERON_0001913', 'milk', 168, 'milk'), ('CHEBI_27300', 'vitamin D', 197, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 236, 'vitamin D')]
S186-PMC3659910	PMC3659910	1/2013	S186-PMC3659910	['also women are ENCOURAGED to continue to take Vitamin D supplements after Pregnancy to HELP PROTECT against health PROBLEMS such as osteoporosis.']	[('IMPORTANT_CONSIDERATION', 15), ('FUTURE_WORK', 87), ('SUPERFICIAL_RELATIONSHIP', 92), ('IMPORTANT_CONSIDERATION', 115)]	4	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('GO_0007565', 'female pregnancy', 74, 'pregnancy')]
S187-PMC3659910	PMC3659910	1/2013	S187-PMC3659910	['it was RECENTLY SHOWN that a maternal supplementation of 2100 iu Vitamin D/day was NEEDED, when administered during the period of Lactation, in order to observe an increase in Serum levels of 25(Oh) D in the Breast-Fed infants comparable to that observed in children given 400 iu/day.']	[('INCOMPLETE_EVIDENCE', 7), ('INCOMPLETE_EVIDENCE', 16), ('IMPORTANT_CONSIDERATION', 83)]	3	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('GO_0007595', 'lactation', 130, 'lactation'), ('UBERON_0001977', 'blood serum', 176, 'serum'), ('CHEBI_71657', 'versiconol acetate', 192, '25(OH) D'), ('PR_000010220', 'mannose-binding protein C', 194, '('), ('PR_000006444', 'diacylglycerol kinase delta', 199, 'D'), ('GO_0007567', 'parturition', 208, 'breast'), ('UBERON_0000310', 'breast', 208, 'breast'), ('GO_0007631', 'feeding behavior', 215, 'fed')]
S189-PMC3659910	PMC3659910	1/2013	S189-PMC3659910	['the current LACK OF EVIDENCE of benefit for women at lower RISK of Vitamin D deficiency points to the NEED FOR FURTHER RESEARCH into Vitamin D supplementation in Pregnant women with clinical neonatal and infant end-points under SCRUTINY.']	[('INCOMPLETE_EVIDENCE', 12), ('IMPORTANT_CONSIDERATION', 59), ('FUTURE_WORK', 102), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 228)]	4	[('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 133, 'vitamin D'), ('GO_0007565', 'female pregnancy', 162, 'pregnant')]
S191-PMC3659910	PMC3659910	1/2013	S191-PMC3659910	['FURTHER RESEARCH is REQUIRED, PARTICULARLY to establish the dose NEEDED to supplement Pregnant women with pre-existing deficiency and the OPTIMAL Gestation at which Vitamin D supplementation SHOULD BE started.']	[('FUTURE_WORK', 0), ('IMPORTANT_CONSIDERATION', 20), ('IMPORTANT_CONSIDERATION', 30), ('IMPORTANT_CONSIDERATION', 65), ('IMPORTANT_CONSIDERATION', 138), ('IMPORTANT_CONSIDERATION', 191)]	6	[('GO_0007565', 'female pregnancy', 86, 'pregnant'), ('GO_0007565', 'female pregnancy', 146, 'gestation'), ('CHEBI_27300', 'vitamin D', 165, 'vitamin D')]
S198-PMC3660294	PMC3660294	5/2013	S198-PMC3660294	['WHILE more than 20% of breastfeeding mothers in this study did not provide Vitamin D supplements to their infants, ABOUT half of exclusively breastfeeding mothers in another national survey gave their infants Vitamin D supplements [24].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 115)]	2	[('CHEBI_27300', 'vitamin D', 75, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 209, 'vitamin D')]
S199-PMC3660294	PMC3660294	5/2013	S199-PMC3660294	['exclusively breastfed infants living in canada who do not take Vitamin D supplements are at greater RISK of Vitamin D deficiency and insufficiency as well as rickets [21,65,66].']	[('IMPORTANT_CONSIDERATION', 100)]	1	[('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin D')]
S200-PMC3660294	PMC3660294	5/2013	S200-PMC3660294	['in canada, a daily supplement of Vitamin D (400\xa0iu) is RECOMMENDED for all breastfed full-term infants as a way to compensate for minimal exposure to sunlight [21,64,65], to promote health and to prevent deficiency.']	[('FUTURE_WORK', 55)]	1	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D')]
S0-PMC3668200	PMC3668200	5/2013	S0-PMC3668200	['comparison of the Serum Vitamin D level between breastfed and formula-Fed infants: several FACTORS which CAN AFFECT Serum Vitamin D concentration\nit is COMMON KNOWLEDGE among pediatricians that exclusively breastfed infants SHOULD BE supplemented with Vitamin D (400 iu/day) BECAUSE Human Breast Milk contains an INADEQUATE amount of Vitamin D. accordingly, choi et al.1)REPORTED a vitamin deficiency in early infants in a comparative study between Breastfed and formula-Fed infants in this issue.']	[('SUPERFICIAL_RELATIONSHIP', 91), ('INCOMPLETE_EVIDENCE', 105), ('SUPERFICIAL_RELATIONSHIP', 109), ('INCOMPLETE_EVIDENCE', 152), ('FUTURE_WORK', 159), ('FUTURE_WORK', 224), ('PROBABLE_UNDERSTANDING', 275), ('IMPORTANT_CONSIDERATION', 313), ('INCOMPLETE_EVIDENCE', 371)]	9	[('UBERON_0001977', 'blood serum', 18, 'serum'), ('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('GO_0007631', 'feeding behavior', 70, 'fed'), ('UBERON_0001977', 'blood serum', 116, 'serum'), ('CHEBI_27300', 'vitamin D', 122, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 252, 'vitamin D'), ('NCBITaxon_9606', 'Homo sapiens', 283, 'human'), ('UBERON_0001348', 'brown adipose tissue', 289, 'breast milk'), ('CHEBI_27300', 'vitamin D', 334, 'vitamin D'), ('GO_0007567', 'parturition', 449, 'breastfed'), ('GO_0007631', 'feeding behavior', 471, 'fed')]
S11-PMC3668200	PMC3668200	5/2013	S11-PMC3668200	['in exclusively breastfed infants, 25(Oh)D Serum levels were low during the winter DESPITE supplementation3), whereas Serum levels of 1,25-Oh2-D and Vitamin D-Binding Protein were higher in the winter than in the summer4).']	[('ANOMALY_CURIOUS_FINDING', 82)]	1	[('CHEBI_71657', 'versiconol acetate', 34, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 34, '25'), ('PR_000006444', 'diacylglycerol kinase delta', 40, 'D'), ('UBERON_0001977', 'blood serum', 42, 'serum'), ('UBERON_0001977', 'blood serum', 117, 'serum'), ('CHEBI_17996', 'chloride', 134, ','), ('CHEBI_34309', '21-Fluoroprogesterone', 135, '25-OH2'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 142, 'D'), ('CHEBI_27300', 'vitamin D', 148, 'vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 148, 'vitamin D-binding protein')]
S29-PMC3668200	PMC3668200	5/2013	S29-PMC3668200	['ON the CONTRARY, Vitamin D content of the Breast Milk does not meet the REQUIRED daily amount for the infants DESPITE adequate dietary supplementation of Vitamin D12), because this supplementing does not substantially increase the Vitamin D concentration in Human milk13).']	[('ANOMALY_CURIOUS_FINDING', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 7), ('IMPORTANT_CONSIDERATION', 72), ('ANOMALY_CURIOUS_FINDING', 110)]	4	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('UBERON_0001348', 'brown adipose tissue', 42, 'breast milk'), ('CHEBI_33279', 'vitamin D5', 154, 'vitamin D12'), ('CHEBI_27300', 'vitamin D', 231, 'vitamin D'), ('NCBITaxon_9606', 'Homo sapiens', 258, 'human')]
S30-PMC3668200	PMC3668200	5/2013	S30-PMC3668200	['ALTHOUGH nursing mothers were supplemented with 1,000 to 2,000 iu of Vitamin D daily, the supplementation had little effect on the Vitamin D concentration status of breastfed infants14).']	[('ANOMALY_CURIOUS_FINDING', 0)]	1	[('CHEBI_27300', 'vitamin D', 69, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D')]
S33-PMC3668200	PMC3668200	5/2013	S33-PMC3668200	['RECENTLY, aap RECOMMENDATION of 400 iu/day for Vitamin D supplementation was DOCUMENTED to maintain a 25(Oh)D Serum concentration higher than 50 nmol/l in exclusively Breast-Fed infants15).']	[('INCOMPLETE_EVIDENCE', 0), ('FUTURE_WORK', 14), ('INCOMPLETE_EVIDENCE', 77)]	3	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 102, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 102, '25(OH)D'), ('UBERON_0001977', 'blood serum', 110, 'serum'), ('GO_0007567', 'parturition', 167, 'breast'), ('UBERON_0000310', 'breast', 167, 'breast'), ('GO_0007631', 'feeding behavior', 174, 'fed')]
S37-PMC3668200	PMC3668200	5/2013	S37-PMC3668200	['in addition, women with increased skin pigmentation or those with little sunlight exposure are AT RISK of Vitamin D deficiency and MAY NEED additional Vitamin D supplementation, especially during Pregnancy and Lactation.']	[('IMPORTANT_CONSIDERATION', 95), ('INCOMPLETE_EVIDENCE', 131), ('IMPORTANT_CONSIDERATION', 135)]	3	[('CHEBI_27300', 'vitamin D', 106, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 151, 'vitamin D'), ('GO_0007565', 'female pregnancy', 196, 'pregnancy'), ('GO_0007595', 'lactation', 210, 'lactation')]
S41-PMC3668200	PMC3668200	5/2013	S41-PMC3668200	['THEREFORE, daily supplementation with 400 iu of Vitamin D during the last Trimester of Pregnancy HAS BEEN practiced, ALBEIT with MINIMAL EFFECT on circulating 25(Oh)D concentrations in the mother and infant at term.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 97), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 117), ('ANOMALY_CURIOUS_FINDING', 117), ('INCOMPLETE_EVIDENCE', 129), ('SUPERFICIAL_RELATIONSHIP', 137)]	6	[('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 74, 'trimester'), ('GO_0007565', 'female pregnancy', 87, 'pregnancy'), ('CHEBI_30778', 'gallic acid', 159, '25(OH)'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 165, 'D')]
S42-PMC3668200	PMC3668200	5/2013	S42-PMC3668200	['NEVERTHELESS, it is NOTEWORTHY that infants Born to unsupplemented Vitamin D-deficient mothers were LIKELY to have early Vitamin D deficiency compared with those whose mothers were supplemented with Vitamin D during Pregnancy.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 20), ('PROBABLE_UNDERSTANDING', 100)]	3	[('GO_0007567', 'parturition', 44, 'born'), ('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 199, 'vitamin D'), ('GO_0007565', 'female pregnancy', 216, 'pregnancy')]
S50-PMC3668200	PMC3668200	5/2013	S50-PMC3668200	['with respect to Prenatal supplementation, the GENERALLY prescribed daily intake of 400 iu of Vitamin D is NOT sufficient to achieve the OPTIMAL Vitamin D status in newborns18).']	[('PROBABLE_UNDERSTANDING', 46), ('ANOMALY_CURIOUS_FINDING', 106), ('IMPORTANT_CONSIDERATION', 136)]	3	[('GO_0007565', 'female pregnancy', 16, 'prenatal'), ('CHEBI_27300', 'vitamin D', 93, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D')]
S7-PMC3672018	PMC3672018	5/2013	S7-PMC3672018	['discussion\nthe results of the study will contribute to our CURRENT understanding of the SIGNIFICANCE of supplementation with Vitamin D. more specifically, they will enable new RESEARCH in related fields, including interventional research designed to assess supplementation NEEDS for different subgroups of Pregnant women.']	[('INCOMPLETE_EVIDENCE', 59), ('IMPORTANT_CONSIDERATION', 88), ('FUTURE_WORK', 176), ('IMPORTANT_CONSIDERATION', 273)]	4	[('CHEBI_27300', 'vitamin D', 125, 'vitamin D'), ('GO_0007565', 'female pregnancy', 306, 'pregnant')]
S8-PMC3672018	PMC3672018	5/2013	S8-PMC3672018	['also, OTHER health outcomes can subsequently be studied to generate multiple health research OPPORTUNITIES involving Vitamin D. finally, the results of the study will justify the DEBATE of danish health authorities whether to resume Vitamin D supplementation policies.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 6), ('FUTURE_WORK', 93), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 179)]	3	[('CHEBI_27300', 'vitamin D', 117, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 233, 'vitamin D')]
S24-PMC3672018	PMC3672018	5/2013	S24-PMC3672018	['ALTHOUGH adequate exposure to uvb sunlight is PARAMOUNT to an ample supply of Vitamin D, Oral Intake, augmented by both fortification and supplementation, is NECESSARY to maintain baseline stores in populations at high latitudes were the sun can only drive dermal Synthesis Of Vitamin D from april to october [8].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('IMPORTANT_CONSIDERATION', 46), ('IMPORTANT_CONSIDERATION', 158)]	4	[('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('UBERON_0000165', 'mouth', 89, 'oral'), ('GO_0007631', 'feeding behavior', 94, 'intake'), ('GO_0030474', 'spindle pole body duplication', 264, 'synthesis of vitamin D'), ('CHEBI_27300', 'vitamin D', 277, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 285, 'D')]
S166-PMC3672018	PMC3672018	5/2013	S166-PMC3672018	['adequate exposure to uvb sunlight is PARAMOUNT IMPORTANCE for supply of Vitamin D, BUT Oral Intake, augmented by fortification and supplementation, is NECESSARY to maintain baseline stores, particularly in winter when sunlight is limited [8,33,34].']	[('IMPORTANT_CONSIDERATION', 37), ('IMPORTANT_CONSIDERATION', 47), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 83), ('IMPORTANT_CONSIDERATION', 151)]	4	[('CHEBI_27300', 'vitamin D', 72, 'vitamin D'), ('UBERON_0000165', 'mouth', 87, 'oral'), ('GO_0007631', 'feeding behavior', 92, 'intake')]
S173-PMC3672018	PMC3672018	5/2013	S173-PMC3672018	['Human intervention studies to determine the level of Vitamin D supplementation NECESSARY to reduce susceptibility to diseases later in Life and concomitant basic research exploring the biological mechanisms that may be INVOLVED.']	[('IMPORTANT_CONSIDERATION', 79), ('SUPERFICIAL_RELATIONSHIP', 219)]	2	[('NCBITaxon_9606', 'Homo sapiens', 0, 'human'), ('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('UBERON_0000104', 'life cycle', 135, 'life')]
S7-PMC3679329	PMC3679329	6/2013	S7-PMC3679329	['among Pregnant women, the proportion of women with an Intake of Vitamin C (from diet alone) below the ESTIMATED average REQUIREMENTS (ear) was lower among supplement users [users (44%) vs. non-users (68%)], and the proportion of Lactating women with intakes of iron (from diet alone) below the ear was lower among Supplement users [usesr (17%) vs. non-users (38%)].']	[('INCOMPLETE_EVIDENCE', 102), ('IMPORTANT_CONSIDERATION', 120)]	2	[('GO_0007565', 'female pregnancy', 6, 'pregnant'), ('GO_0007631', 'feeding behavior', 54, 'intake'), ('CHEBI_27300', 'vitamin D', 64, 'vitamin C'), ('GO_0007594', 'puparial adhesion', 229, 'lactating'), ('CHEBI_16158', 'steroid sulfate', 314, 'supplement')]
S8-PMC3679329	PMC3679329	6/2013	S8-PMC3679329	['these results SUGGEST that among Pregnant and Lactating women, those who do not use dietary supplements TEND to have a lower intake of healthy Foods, such as beans and vegetables, as well as a lower intake of dietary fiber and Β-Carotene, which are abundant in these Foods, and non-users are more LIKELY than users to have INADEQUATE Intake of micro-Nutrient such as Vitamin C and iron.']	[('INCOMPLETE_EVIDENCE', 14), ('SUPERFICIAL_RELATIONSHIP', 104), ('PROBABLE_UNDERSTANDING', 297), ('IMPORTANT_CONSIDERATION', 323), ('PROBLEM_COMPLICATION', 323)]	5	[('GO_0007565', 'female pregnancy', 33, 'pregnant'), ('GO_0007594', 'puparial adhesion', 46, 'lactating'), ('CHEBI_33290', 'food', 143, 'foods'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 227, 'β-carotene'), ('CHEBI_33290', 'food', 267, 'foods'), ('GO_0007631', 'feeding behavior', 334, 'intake'), ('CHEBI_33284', 'nutrient', 350, 'nutrient'), ('CHEBI_27300', 'vitamin D', 367, 'vitamin C')]
S79-PMC3679329	PMC3679329	6/2013	S79-PMC3679329	['a population based cohort study of Adults in the us DEMONSTRATED that supplement users, COMPARED TO non-users, GENERALLY had higher average Intakes of Foods which are IMPORTANT sources of Vitamin C and Carotenoids (i.e., fruits and certain vegetables) [12].']	[('INCOMPLETE_EVIDENCE', 52), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 88), ('PROBABLE_UNDERSTANDING', 111), ('IMPORTANT_CONSIDERATION', 167)]	4	[('UBERON_0007023', 'adult organism', 35, 'adults'), ('GO_0007631', 'feeding behavior', 140, 'intakes'), ('CHEBI_33290', 'food', 151, 'foods'), ('CHEBI_27300', 'vitamin D', 188, 'vitamin C'), ('CHEBI_50815', 'norgestimate', 202, 'carotenoids')]
S81-PMC3679329	PMC3679329	6/2013	S81-PMC3679329	['also SHOWED that non-Pregnant, non-Lactating Adults who were regular users of any type of Supplement consumed more vegetables and fruits, especially those high in Vitamin C [20].']	[('INCOMPLETE_EVIDENCE', 5)]	1	[('GO_0007565', 'female pregnancy', 21, 'pregnant'), ('GO_0007594', 'puparial adhesion', 35, 'lactating'), ('UBERON_0007023', 'adult organism', 45, 'adults'), ('CHEBI_16158', 'steroid sulfate', 90, 'supplement'), ('CHEBI_27300', 'vitamin D', 163, 'vitamin C')]
S82-PMC3679329	PMC3679329	6/2013	S82-PMC3679329	['in the PRESENT STUDY, among Pregnant women, the proportion of women with an Intake of Vitamin C (from diet alone) below the ear was significantly higher among Supplement non-users (68%) than among users (44%).']	[('QUESTION_ANSWERED_BY_THIS_WORK', 7)]	1	[('GO_0007565', 'female pregnancy', 28, 'pregnant'), ('GO_0007631', 'feeding behavior', 76, 'intake'), ('CHEBI_27300', 'vitamin D', 86, 'vitamin C'), ('CHEBI_16158', 'steroid sulfate', 159, 'supplement')]
S7-PMC3685533	PMC3685533	6/2013	S7-PMC3685533	['25Ohd values were higher in Cord Blood (p\u2009<\u20090.01) and neonatal Serum (p\u2009<\u20090.001) in subjects supplemented with Vitamin D. newborn fs SHOWED higher Vitamin D levels in Cord Blood when compared to lob and mbb (p\u2009<\u20090.01), and higher levels in neonatal Serum when compared to lob (p\u2009<\u20090.01).']	[('INCOMPLETE_EVIDENCE', 133)]	1	"[('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 0, '25OHD'), ('UBERON_0002240', 'spinal cord', 28, 'cord'), ('UBERON_0000178', 'blood', 33, 'blood'), ('UBERON_0001977', 'blood serum', 63, 'serum'), ('CHEBI_28384', 'vitamin K', 111, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 147, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 167, 'cord'), ('UBERON_0000178', 'blood', 172, 'blood'), ('UBERON_0001977', 'blood serum', 249, 'serum')]"
S10-PMC3685533	PMC3685533	6/2013	S10-PMC3685533	['conclusions\nthe PRESENT STUDY SHOWS a high prevalence of Vitamin D insufficiency and deficiency in newborns with significant differences observed to be DUE TO ethnicity, skin colour and maternal supplementation during the Pregnancy.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 16), ('INCOMPLETE_EVIDENCE', 30), ('PROBLEM_COMPLICATION', 152)]	3	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('GO_0007565', 'female pregnancy', 222, 'pregnancy')]
S17-PMC3685533	PMC3685533	6/2013	S17-PMC3685533	['moreover, Vitamin D is a modulator of the Innate and Adaptive Immune System and prospective observational studies SUGGEST that Vitamin D supplements in infancy and early childhood MAY decrease the incidence of chronic diseases such as type 1 diabetes mellitus [1,2].']	[('INCOMPLETE_EVIDENCE', 114), ('INCOMPLETE_EVIDENCE', 180)]	2	[('CHEBI_27300', 'vitamin D', 10, 'vitamin D'), ('GO_0007631', 'feeding behavior', 42, 'innate ...'), ('GO_0051866', 'general adaptation syndrome', 53, 'adaptive immune system'), ('UBERON_0002405', 'immune system', 62, 'immune system'), ('CHEBI_27300', 'vitamin D', 127, 'vitamin D')]
S19-PMC3685533	PMC3685533	6/2013	S19-PMC3685533	['RISK FACTORS for Vitamin D deficiency and rickets in early Life include Breast-Feeding without Vitamin D supplementation, dark skin pigmentation, season, latitude and maternal Vitamin d deficiency [1].']	[('SUPERFICIAL_RELATIONSHIP', 0)]	1	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('UBERON_0000104', 'life cycle', 59, 'life'), ('GO_0007567', 'parturition', 72, 'breast'), ('GO_0007631', 'feeding behavior', 79, 'feeding'), ('CHEBI_27300', 'vitamin D', 95, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 176, 'vitamin')]
S32-PMC3685533	PMC3685533	6/2013	S32-PMC3685533	['DISCORDANT data are present with respect to the ROLE of Vitamin D supplementation during Pregnancy.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('SUPERFICIAL_RELATIONSHIP', 48)]	2	[('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('GO_0007565', 'female pregnancy', 89, 'pregnancy')]
S78-PMC3685533	PMC3685533	6/2013	S78-PMC3685533	['when CONSIDERING the maternal multivitamin Intake during Pregnancy, all mothers supplemented with Vitamin D DEMONSTRATED higher 25Ohd values in both Cord Blood (24.5\u2009±\u200911.9 vs 17.2\u2009±\u20099.2 ng/ml; p\u2009<\u20090.01) and in neonatal Serum (17.7\u2009±\u20099.3 vs 11.1\u2009±\u20096 ng/ml; p\u2009<\u20090.001).']	[('IMPORTANT_CONSIDERATION', 5), ('INCOMPLETE_EVIDENCE', 108)]	2	"[('GO_0007631', 'feeding behavior', 43, 'intake'), ('GO_0007565', 'female pregnancy', 57, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 98, 'vitamin D'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 128, '25OHD'), ('UBERON_0002240', 'spinal cord', 149, 'cord'), ('UBERON_0000178', 'blood', 154, 'blood'), ('UBERON_0001977', 'blood serum', 220, 'serum')]"
S84-PMC3685533	PMC3685533	6/2013	S84-PMC3685533	['differences according to maternal supplementation, were shown ONLY in the mbb group (p\u2009<\u20090.01) with higher Vitamin D levels in Cord Blood and neonatal Serum with supplementation.']	[('INCOMPLETE_EVIDENCE', 62)]	1	[('CHEBI_27300', 'vitamin D', 107, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 127, 'cord'), ('UBERON_0000178', 'blood', 132, 'blood'), ('UBERON_0001977', 'blood serum', 151, 'serum')]
S87-PMC3685533	PMC3685533	6/2013	S87-PMC3685533	['neonates fs with no supplementation during Pregnancy, SHOWED Vitamin D levels higher than unsupplemented lob and mbb neonates (p\u2009<\u20090.05).']	[('INCOMPLETE_EVIDENCE', 54)]	1	[('GO_0007565', 'female pregnancy', 43, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 61, 'vitamin D')]
S98-PMC3685533	PMC3685533	6/2013	S98-PMC3685533	['multiple regression analysis REVEALED that Vitamin D levels in Cord Blood were PREDICTED (r2: 0.670; p\u2009<\u20090.0001) by neonatal Vitamin D values (standardized β: 0.818), when corrected for Vitamin D supplementation and Gestational age.']	[('INCOMPLETE_EVIDENCE', 29), ('SUPERFICIAL_RELATIONSHIP', 79)]	2	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 63, 'cord'), ('UBERON_0000178', 'blood', 68, 'blood'), ('CHEBI_28384', 'vitamin K', 125, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 186, 'vitamin D'), ('GO_0007565', 'female pregnancy', 216, 'gestational')]
S99-PMC3685533	PMC3685533	6/2013	S99-PMC3685533	['likewise neonatal Vitamin D levels were PREDICTED (r2: 0.670; p\u2009<\u20090.0001) by Vitamin D values on Cord Blood (standardized β: 0.818), when corrected for Vitamin D supplementation and Gestational age.']	[('SUPERFICIAL_RELATIONSHIP', 40)]	1	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 77, 'Vitamin D'), ('UBERON_0002240', 'spinal cord', 97, 'cord'), ('UBERON_0000178', 'blood', 102, 'blood'), ('CHEBI_27300', 'vitamin D', 152, 'vitamin D'), ('GO_0007565', 'female pregnancy', 182, 'gestational')]
S119-PMC3685533	PMC3685533	6/2013	S119-PMC3685533	['we have also INVESTIGATED the ROLE of supplementation in Pregnancy on Vitamin D Cord Blood and Serum levels.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 13), ('SUPERFICIAL_RELATIONSHIP', 30)]	2	[('GO_0007565', 'female pregnancy', 57, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 80, 'cord'), ('UBERON_0000178', 'blood', 85, 'blood'), ('UBERON_0001977', 'blood serum', 95, 'serum')]
S120-PMC3685533	PMC3685533	6/2013	S120-PMC3685533	['analyzing all subjects together, mothers supplemented with Vitamin D SHOWED 25Ohd values higher than mothers not supplemented both on Cord Blood and neonatal Serum.']	[('INCOMPLETE_EVIDENCE', 69)]	1	"[('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 76, '25OHD'), ('UBERON_0009472', 'axilla', 134, 'cord blood'), ('UBERON_0001977', 'blood serum', 158, 'serum')]"
S123-PMC3685533	PMC3685533	6/2013	S123-PMC3685533	['Cord Blood Vitamin D levels were higher in fs than lob or mbb REGARDLESS of supplementation.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 62)]	1	[('UBERON_0000948', 'heart', 0, 'Cord'), ('UBERON_0000178', 'blood', 5, 'blood'), ('CHEBI_27300', 'vitamin D', 11, 'vitamin D')]
S124-PMC3685533	PMC3685533	6/2013	S124-PMC3685533	['after Birth ONLY fs newborns unsupplemented SHOWED Vitamin D levels higher than lob and mbb; no differences were found in case of maternal supplementation in Pregnancy, MOST LIKELY DUE TO a specific ROLE of supplementation in neonates.']	[('ANOMALY_CURIOUS_FINDING', 12), ('INCOMPLETE_EVIDENCE', 44), ('PROBABLE_UNDERSTANDING', 169), ('PROBABLE_UNDERSTANDING', 181), ('PROBLEM_COMPLICATION', 181), ('SUPERFICIAL_RELATIONSHIP', 199)]	6	[('GO_0007567', 'parturition', 6, 'birth'), ('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('GO_0007565', 'female pregnancy', 158, 'pregnancy')]
S126-PMC3685533	PMC3685533	6/2013	S126-PMC3685533	['ALTHOUGH SEVERAL STUDIES are AVAILABLE on Vitamin D supplementation during Pregnancy, its APPROPRIATE dose is NOT CLEAR [19-21].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 9), ('INCOMPLETE_EVIDENCE', 29), ('IMPORTANT_CONSIDERATION', 90), ('FULL_UNKNOWN', 110)]	5	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('GO_0007565', 'female pregnancy', 75, 'pregnancy')]
S128-PMC3685533	PMC3685533	6/2013	S128-PMC3685533	['a RECENT cochrane on Vitamin D supplementation during Pregnancy SHOWED that with supplementation, there is an increase Serum 25Ohd levels in neonates [22].']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 64)]	2	"[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('GO_0007565', 'female pregnancy', 54, 'pregnancy'), ('UBERON_0001977', 'blood serum', 119, 'serum'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 125, '25OHD')]"
S136-PMC3685533	PMC3685533	6/2013	S136-PMC3685533	['conclusions\nthe PRESENT STUDY DEMONSTRATES a high prevalence of Vitamin D deficiency and insufficiency both in Cord Blood and in neonatal Serum with significant differences DUE TO ethnicity, skin colour and presence or absence of supplementation.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 16), ('INCOMPLETE_EVIDENCE', 30), ('PROBLEM_COMPLICATION', 173)]	3	[('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('UBERON_0009472', 'axilla', 111, 'cord blood'), ('UBERON_0001977', 'blood serum', 138, 'serum')]
S137-PMC3685533	PMC3685533	6/2013	S137-PMC3685533	['identifying Vitamin D deficiency at Birth is ESSENTIAL for the development of public policy for PREVENTION and supplementation.']	[('IMPORTANT_CONSIDERATION', 45), ('SUPERFICIAL_RELATIONSHIP', 96)]	2	[('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('GO_0007567', 'parturition', 36, 'birth')]
S0-PMC3691177	PMC3691177	6/2013	S0-PMC3691177	['Prenatal Vitamin D supplementation and child Respiratory health: a randomised controlled trial\n\nabstract\n\nbackground\nOBSERVATIONAL studies SUGGEST high Prenatal Vitamin D intake MAY BE ASSOCIATED with reduced childhood wheezing.']	[('INCOMPLETE_EVIDENCE', 117), ('INCOMPLETE_EVIDENCE', 139), ('INCOMPLETE_EVIDENCE', 178), ('SUPERFICIAL_RELATIONSHIP', 185)]	4	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_28384', 'vitamin K', 9, 'Vitamin D'), ('UBERON_0001004', 'respiratory system', 45, 'Respiratory'), ('GO_0007565', 'female pregnancy', 152, 'prenatal'), ('CHEBI_27300', 'vitamin D', 161, 'vitamin D')]
S12-PMC3691177	PMC3691177	6/2013	S12-PMC3691177	['conclusion\nPrenatal Vitamin D supplementation in late Pregnancy that had a modest EFFECT on Cord Blood Vitamin D level, was not associated with decreased wheezing in offspring at age three years.']	[('SUPERFICIAL_RELATIONSHIP', 82)]	1	[('GO_0007565', 'female pregnancy', 11, 'Prenatal'), ('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('GO_0007565', 'female pregnancy', 54, 'pregnancy'), ('UBERON_0002240', 'spinal cord', 92, 'cord'), ('UBERON_0000178', 'blood', 97, 'blood'), ('CHEBI_27300', 'vitamin D', 103, 'vitamin D')]
S21-PMC3691177	PMC3691177	6/2013	S21-PMC3691177	['Vitamin D insufficiency is NEVERTHELESS very common during Pregnancy[15]–[17], and it HAS BEEN PROPOSED that Prenatal Vitamin D supplementation MAY PREVENT childhood wheezing and asthma[18].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 27), ('INCOMPLETE_EVIDENCE', 86), ('INCOMPLETE_EVIDENCE', 95), ('INCOMPLETE_EVIDENCE', 144), ('SUPERFICIAL_RELATIONSHIP', 148)]	5	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 59, 'pregnancy'), ('GO_0007565', 'female pregnancy', 109, 'prenatal'), ('CHEBI_27300', 'vitamin D', 118, 'vitamin D')]
S22-PMC3691177	PMC3691177	6/2013	S22-PMC3691177	['we assessed children whose mothers had taken part in a randomised controlled trial of Prenatal Vitamin D supplementation, TO DETERMINE WHETHER supplementation PREVENTED wheezing or allergic disease in the first 3 years of Life[19].']	[('QUESTION_ANSWERED_BY_THIS_WORK', 122), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 135), ('SUPERFICIAL_RELATIONSHIP', 159)]	3	[('GO_0007565', 'female pregnancy', 86, 'prenatal'), ('CHEBI_27300', 'vitamin D', 95, 'vitamin D'), ('UBERON_0000104', 'life cycle', 222, 'life')]
S35-PMC3691177	PMC3691177	6/2013	S35-PMC3691177	['women were given instructions to swallow the tablets whole and to avoid other multivitamin supplements containing Vitamin D. this trial was CONDUCTED before national guidance on routinely providing advice on Vitamin D intake during Pregnancy was introduced in march 2008[14].']	[('QUESTION_ANSWERED_BY_THIS_WORK', 140)]	1	[('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 208, 'vitamin D'), ('GO_0007565', 'female pregnancy', 232, 'pregnancy')]
S74-PMC3691177	PMC3691177	6/2013	S74-PMC3691177	['as PREVIOUSLY reported[19], median Cord 25(Oh)D levels at Delivery were significantly higher in supplemented children COMPARED TO the control group [control 17 nmol/l (interquartile range (iqr) 14–22); daily dose 26 nmol/l (iqr 17–45); p<0.001; bolus dose 25 nmol/l (iqr 18–34); p<0.001)].10.1371/journal.pone.0066627.g001\n\ncaption (fig): figure 1\nrecruitment and follow up of study participants.10.1371/journal.pone.0066627.t001\n\ncaption (table-wrap): table 1\ncharacteristics of study participants followed up at age three years.controldaily Vitamin dbolus vitamin dcombined Vitamin D(n\u200a=\u200a50)(n\u200a=\u200a56)(n\u200a=\u200a52)(n\u200a=\u200a108)baseline maternal 25(Oh)D <25 nmol/l, n/n (%)24/50 (48)25/56 (45)22/52 (42)47/108 (44)male sex, n/n (%)27/50 (54)32/56 (57)26/52 (50)58/108 (55)Birth weight (g), mean (sd)3268 (585)3321 (525)3290 (467)3307 (497)ethnicity, n (%)asian12 (24)15 (27)13 (25)28 (26)middle eastern13 (26)14 (25)14 (26)28 (26)black12 (24)14 (25)13 (25)27 (25)white13 (26)13 (23)12 (24)25 (23)ga at Delivery (weeks), mean (sd)40 (1)39 (2)40 (1)39 (2)nulliparous mother, n/n (%)23/50 (46)20/56 (36)21/52 (40)41/108 (38)Vaginal Delivery, n/n (%)29/50 (58)35/56 (63)28/52 (54)63/108 (58)maternal smoking during Pregnancy, n/n (%)2/48 (4)3/55 (5)0/46 (0)3/101 (3)presence of household smokers, n/n (%)16/48 (33)15/55 (27)17/46 (37)32/101 (32)number of children in household, mean (sd)2 (1)2 (1)2 (1)2 (1)age mother left full time education, mean (sd)20 (3)20 (4)21 (4)21 (4)child in nursery, n/n (%)27/48 (56)36/55 (65)20/45 (44)57/101 (56)Cat or Dog in household, n/n (%)4/48 (8)5/54 (9)4/46 (9)9/100 (9)maternal fitzpatrick skin score grade 3–6, n/n (%)28/44 (64)33/49 (67)28/43 (65)61/92 (66)maternal regular vitamin intake at three years, n/n (%)9/46 (20)16/53 (30)16/45 (36)32/98 (33)at least one parent with allergic disease, n/n (%)23/45 (51)35/53 (66)21/45 (47)56/98 (57)exclusively Breast-Fed for 4 months, n/n (%)22/48 (46)20/54 (37)23/44 (52)43/98 (44)any child vitamin supplementation, n/n (%)30/48 (63)34/55 (62)30/46 (65)64/101 (63)completed immunizations to date, n/n (%)48/49 (98)54/55 (98)43/47 (91)97/102 (95)age at time of assessment (months), median (iqr)37.9 (36.9, 39.9)37.1 (36.5, 38.8)37.4 (36.5, 39.5)37.3 (36.5, 39.0)child fitzpatrick skin score grade 3–6, n (%)29/42 (69)34/48 (71)29/43 (67)63/91 (69)child bmi z score age 3, mean (sd)0.51 (1.48)0.35 (1.15)0.62 (1.15)0.47 (1.15)child outdoors >1 hour/day, n/n (%)32/48 (67)34/53 (64)33/45 (73)67/98 (68)child tv/computer >2 hours/day, n/n (%)24/48 (50)18/53 (34)17/45 (38)35/98 (36)child 25(Oh)D (nmol/l) age 3, median (iqr)42 (27, 68)35 (21, 66)42 (30, 93)41 (26, 72)\ndata shown are for all participants analysed.']	[('INCOMPLETE_EVIDENCE', 3), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 118)]	2	[('UBERON_0002240', 'spinal cord', 35, 'cord'), ('CHEBI_71657', 'versiconol acetate', 40, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 40, '25(OH ... D'), ('GO_0007567', 'parturition', 58, 'delivery'), ('CHEBI_33229', 'vitamin (role)', 543, 'vitamin'), ('CHEBI_27300', 'vitamin D', 576, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 636, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 636, '25(OH ... D'), ('GO_0007567', 'parturition', 762, 'Birth'), ('GO_0007567', 'parturition', 992, 'delivery'), ('GO_0007567', 'parturition', 1111, 'Vaginal'), ('UBERON_0000970', 'eye', 1111, 'Vaginal'), ('GO_0007567', 'parturition', 1119, 'delivery'), ('GO_0007565', 'female pregnancy', 1201, 'pregnancy'), ('NCBITaxon_10088', 'Mus <genus>', 1529, 'Cat'), ('NCBITaxon_33208', 'Metazoa', 1536, 'dog'), ('GO_0007567', 'parturition', 1880, 'breast'), ('UBERON_0000310', 'breast', 1880, 'breast'), ('GO_0007631', 'feeding behavior', 1887, 'fed'), ('CHEBI_71657', 'versiconol acetate', 2555, '25(OH)D'), ('PR_000011614', 'opioid growth factor receptor', 2558, 'OH)D')]
S107-PMC3691177	PMC3691177	6/2013	S107-PMC3691177	['discussion\nin THIS randomised CONTROLLED TRIAL of Vitamin D supplementation in late Pregnancy in a relatively deficient mixed race population, daily supplementation with 800 iu Ergocalciferol or a single bolus dose of 200,000 iu Cholecalciferol from 27 weeks Gestation did not prevent wheezing, allergic disease or influence measures of Lung function or allergic inflammation in offspring in the first three years of Life.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 14), ('QUESTION_ANSWERED_BY_THIS_WORK', 30)]	2	[('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('GO_0007565', 'female pregnancy', 84, 'pregnancy'), ('CHEBI_4910', 'etomidate', 177, 'ergocalciferol'), ('CHEBI_52550', 'theopalauamide', 229, 'cholecalciferol'), ('GO_0007565', 'female pregnancy', 259, 'gestation'), ('UBERON_0002048', 'lung', 337, 'lung'), ('UBERON_0000104', 'life cycle', 417, 'life')]
S117-PMC3691177	PMC3691177	6/2013	S117-PMC3691177	['the 95% confidence interval for our primary outcome measure was 0.49 to 1.50, so we are UNABLE TO confidently exclude EFFECTS of Prenatal vitamin D supplementation on RISK of wheezing, or on the development of atopy especially in mothers treated with daily Vitamin D. third, we DID NOT assess Vitamin D receptor polymorphisms or OTHER POTENTIALLY IMPORTANT genotypic variations.']	[('DIFFICULT_TASK', 88), ('SUPERFICIAL_RELATIONSHIP', 118), ('IMPORTANT_CONSIDERATION', 167), ('INCOMPLETE_EVIDENCE', 278), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 329), ('INCOMPLETE_EVIDENCE', 335), ('IMPORTANT_CONSIDERATION', 347)]	7	[('GO_0007565', 'female pregnancy', 129, 'prenatal'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 146, 'D'), ('CHEBI_27300', 'vitamin D', 257, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 293, 'vitamin D')]
S118-PMC3691177	PMC3691177	6/2013	S118-PMC3691177	['IT IS POSSIBLE that Vitamin D supplementation is effective for preventing wheezing or atopy in the presence of specific maternal or infant genotypes, as SUGGESTED by others[27].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 153)]	2	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D')]
S125-PMC3691177	PMC3691177	6/2013	S125-PMC3691177	['finally, we are also unable to exclude the POSSIBILITY that Vitamin D supplementation at a higher dose, MIGHT PROTECT against early childhood wheezing.']	[('INCOMPLETE_EVIDENCE', 43), ('INCOMPLETE_EVIDENCE', 104), ('SUPERFICIAL_RELATIONSHIP', 110)]	3	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D')]
S128-PMC3691177	PMC3691177	6/2013	S128-PMC3691177	['two on-going trials, the Vitamin D Prenatal asthma reduction trial (nct00920621), and abcvitamind (nct00856947) are specifically exploring the EFFECTS of earlier and higher dose Prenatal Vitamin D supplementation on child health.']	[('SUPERFICIAL_RELATIONSHIP', 143)]	1	[('CHEBI_28384', 'vitamin K', 25, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 35, 'Prenatal'), ('GO_0007565', 'female pregnancy', 178, 'prenatal'), ('CHEBI_27300', 'vitamin D', 187, 'vitamin D')]
S134-PMC3691177	PMC3691177	6/2013	S134-PMC3691177	['the FINDINGS of OUR STUDY are specific to a population of Vitamin D deficient women (half had baseline 25(Oh)D levels below 25 nmol/l) and two specific forms of Prenatal Vitamin D supplementation.']	[('INCOMPLETE_EVIDENCE', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 16)]	2	[('CHEBI_27300', 'vitamin D', 58, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 103, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 103, '25(OH)D'), ('GO_0007565', 'female pregnancy', 161, 'prenatal'), ('CHEBI_27300', 'vitamin D', 170, 'vitamin D')]
S137-PMC3691177	PMC3691177	6/2013	S137-PMC3691177	['ALTHOUGH THESE FINDINGS cannot automatically be generalised to OTHER populations of Pregnant women, one MIGHT expect Prenatal Vitamin D supplementation to SHOW its clearest clinical EFFECTS in a deficient population such as this.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 9), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 63), ('INCOMPLETE_EVIDENCE', 104), ('INCOMPLETE_EVIDENCE', 155), ('SUPERFICIAL_RELATIONSHIP', 182)]	7	[('GO_0007565', 'female pregnancy', 84, 'pregnant'), ('GO_0007565', 'female pregnancy', 117, 'prenatal'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D')]
S138-PMC3691177	PMC3691177	6/2013	S138-PMC3691177	['IN SUMMARY we FOUND NO EVIDENCE for a protective effect of Prenatal Vitamin D supplementation from 27 weeks Gestation on childhood wheezing, allergic disease, Lung function or markers of Airway inflammation in the first 3 years of Life.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 14), ('INCOMPLETE_EVIDENCE', 20)]	3	[('GO_0007565', 'female pregnancy', 59, 'prenatal'), ('CHEBI_27300', 'vitamin D', 68, 'vitamin D'), ('GO_0007565', 'female pregnancy', 108, 'gestation'), ('UBERON_0002048', 'lung', 159, 'lung'), ('UBERON_0001005', 'respiratory airway', 187, 'airway'), ('UBERON_0000104', 'life cycle', 231, 'life')]
S139-PMC3691177	PMC3691177	6/2013	S139-PMC3691177	['given the modest EFFECTS on Cord Blood Vitamin D achieved by these INTERVENTIONS, the SAFETY and efficacy of higher dose Prenatal Vitamin D supplementation STRATEGIES NEED TO BE explored.']	[('SUPERFICIAL_RELATIONSHIP', 17), ('SUPERFICIAL_RELATIONSHIP', 67), ('IMPORTANT_CONSIDERATION', 86), ('FUTURE_WORK', 156), ('FUTURE_WORK', 167)]	5	[('UBERON_0002240', 'spinal cord', 28, 'cord'), ('UBERON_0000178', 'blood', 33, 'blood'), ('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('GO_0007565', 'female pregnancy', 121, 'prenatal'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D')]
S59-PMC3695234	PMC3695234	7/2013	S59-PMC3695234	['BASED ON the RELATIONSHIP between Vitamin D deficiency and ad, trials of Vitamin D supplementation in atopic populations or high-risk groups HAVE BEEN conducted.']	[('PROBABLE_UNDERSTANDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('SUPERFICIAL_RELATIONSHIP', 13), ('INCOMPLETE_EVIDENCE', 141)]	4	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 73, 'vitamin D')]
S60-PMC3695234	PMC3695234	7/2013	S60-PMC3695234	['supplementation with oral Vitamin D in 14 atopic subjects with moderate-to-severe atopic dermatitis for 21 days resulted in a significant increase in Cathelicidin Expression in ad-lesional skin.11ANOTHER pilot STUDY of winter-time onset or exacerbation of ad also SHOWED a favorable IMPACT of Vitamin D supplementation.12HOWEVER, there are CONFLICTING data surrounding the EFFECT of Vitamin D on the development of allergic Skin disease.']	[('INCOMPLETE_EVIDENCE', 194), ('INCOMPLETE_EVIDENCE', 264), ('SUPERFICIAL_RELATIONSHIP', 283), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 319), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 340), ('SUPERFICIAL_RELATIONSHIP', 373)]	6	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('PR_000006009', 'alpha-catulin', 150, 'cathelicidin'), ('GO_0010467', 'gene expression', 163, 'expression'), ('CHEBI_27300', 'vitamin D', 293, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 383, 'vitamin D'), ('GO_0036331', 'avascular cornea development in camera-type eye', 424, 'skin')]
S61-PMC3695234	PMC3695234	7/2013	S61-PMC3695234	['camargo et al.13found no decreased risk of ad in the children of mothers with higher intakes of Vitamin D. a northern finland Birth cohort INDICATED the ASSOCIATION between Vitamin D supplementation in the first year of Life and an increased risk of atopy at age 31 years.14a FURTHER prospective study REPORTED that an increased concentration of 25(Oh)D3In maternal Serum predisposed infants to ad at 9 months of age.15these variable results MAY BE secondary to the differences in the absolute amount of Vitamin D exposure, the baseline Vitamin D status, and the timing of exposure.']	[('INCOMPLETE_EVIDENCE', 139), ('SUPERFICIAL_RELATIONSHIP', 153), ('INCOMPLETE_EVIDENCE', 276), ('INCOMPLETE_EVIDENCE', 302), ('INCOMPLETE_EVIDENCE', 442)]	5	[('CHEBI_27300', 'vitamin D', 96, 'vitamin D'), ('GO_0007567', 'parturition', 126, 'birth'), ('CHEBI_27300', 'vitamin D', 173, 'vitamin D'), ('UBERON_0000104', 'life cycle', 220, 'life'), ('PR_000001883', 'lysosome-associated membrane protein', 346, '25(OH)D3in'), ('UBERON_0001977', 'blood serum', 366, 'serum'), ('CHEBI_27300', 'vitamin D', 504, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 537, 'vitamin D')]
S9-PMC3702245	PMC3702245	6/2013	S9-PMC3702245	['SEVERAL REPORTS in the literature HAVE SHOWN that INADEQUATE or lack of sunlight exposure without appropriate corrective Vitamin D intake or supplements accounts FOR the high prevalence of Vitamin D deficiency in women.11–18\nafter synthesis in the skin, Vitamin D attaches to Vitamin D-binding protein and is transported to the Liver, where it undergoes a process of hydroxylation to form 25-Hydroxyvitamin D [25(Oh)D].9the Serum concentration of 25(Oh)D is the MOST reliable MARKER of Vitamin D nutritional status.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 8), ('INCOMPLETE_EVIDENCE', 34), ('IMPORTANT_CONSIDERATION', 50), ('QUESTION_ANSWERED_BY_THIS_WORK', 162), ('PROBABLE_UNDERSTANDING', 462), ('SUPERFICIAL_RELATIONSHIP', 476)]	7	[('CHEBI_27300', 'vitamin D', 121, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 189, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 254, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 276, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 284, 'D'), ('UBERON_0002107', 'liver', 328, 'liver'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 389, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 410, '25(OH)D'), ('UBERON_0001977', 'blood serum', 424, 'serum'), ('CHEBI_71657', 'versiconol acetate', 447, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 486, 'vitamin D')]
S31-PMC3702245	PMC3702245	6/2013	S31-PMC3702245	['RANDOMIZED controlled TRIALS with large sample sizes ARE NEEDED to assess the EFFECT of maternal Vitamin D supplementation on fetal Bone Development.']	[('FUTURE_WORK', 0), ('FUTURE_WORK', 22), ('FUTURE_WORK', 53), ('SUPERFICIAL_RELATIONSHIP', 78)]	4	[('CHEBI_27300', 'vitamin D', 97, 'vitamin D'), ('GO_0048539', 'bone marrow development', 132, 'bone development')]
S34-PMC3702245	PMC3702245	6/2013	S34-PMC3702245	['Fetal growth\nthe ASSOCIATION between Birth weight and maternal Vitamin D status or intake REMAINS INCONCLUSIVE.5while SOME OBSERVATIONAL68–71and interventional53,72,73studies FOUND improvement in Birth weight with maternal Vitamin D supplementation or improved Vitamin D status, several other observational studies31,74–76and SOME interventional studies18,33,77,78showed no improvement with higher Vitamin D status or supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 17), ('INCOMPLETE_EVIDENCE', 90), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 98), ('INCOMPLETE_EVIDENCE', 118), ('INCOMPLETE_EVIDENCE', 123), ('INCOMPLETE_EVIDENCE', 175), ('INCOMPLETE_EVIDENCE', 326)]	7	[('GO_0008618', '7-methylguanosine metabolic process', 0, 'Fetal'), ('GO_0007567', 'parturition', 37, 'birth'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('GO_0007567', 'parturition', 196, 'birth'), ('CHEBI_27300', 'vitamin D', 223, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 261, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 398, 'vitamin D')]
S35-PMC3702245	PMC3702245	6/2013	S35-PMC3702245	['a RECENT cochrane review79of five SMALL-sized intervention trials of Vitamin D supplementation CONCLUDED that mothers who were supplemented TENDED to have fewer babies weighing <2500 g (relative risk 0.48; 95% confidence interval [ci] 0.23–1.01).']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 34), ('INCOMPLETE_EVIDENCE', 95), ('SUPERFICIAL_RELATIONSHIP', 140)]	4	[('CHEBI_27300', 'vitamin D', 69, 'vitamin D')]
S40-PMC3702245	PMC3702245	6/2013	S40-PMC3702245	['randomized controlled STUDIES including larger sample sizes and repeated Vitamin D measurements during Pregnancy WILL BE NEEDED to CONFIRM the RELATIONSHIP between Vitamin D supplementation and fetal growth.82\n\nmaternal COMPLICATIONS\nOBSERVATIONAL studies REPORTED an ASSOCIATION between maternal Vitamin D status during Pregnancy and development of pre-eclampsia, which has both a Genetic and an immunologic pathogenesis.']	[('FUTURE_WORK', 22), ('FUTURE_WORK', 113), ('INCOMPLETE_EVIDENCE', 131), ('SUPERFICIAL_RELATIONSHIP', 143), ('PROBLEM_COMPLICATION', 220), ('INCOMPLETE_EVIDENCE', 234), ('INCOMPLETE_EVIDENCE', 256), ('SUPERFICIAL_RELATIONSHIP', 268)]	8	[('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('GO_0007565', 'female pregnancy', 103, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 164, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 297, 'vitamin D'), ('GO_0007565', 'female pregnancy', 321, 'pregnancy'), ('SO_0000704', 'gene', 382, 'genetic')]
S51-PMC3702245	PMC3702245	6/2013	S51-PMC3702245	['further, there is a SUGGESTION of an ASSOCIATION between Vitamin D and Periodontal disease,90and maternal Serum 25(Oh)D < 75 nmol/l during Early Pregnancy HAS BEEN ASSOCIATED with a two-fold INCREASED risk of Periodontal disease.91in a RECENT randomized controlled TRIAL of Vitamin D supplementation from south carolina, Vitamin D supplementation of 4000 iu/day during Pregnancy was ASSOCIATED with a reduction in the risk of combined morbidities, such as Maternal infection, Preterm labor, and Preterm Birth.92\nIN VIEW of the POSSIBLE ASSOCIATION between maternal Vitamin D status and the pattern of fetal growth, pre-eclampsia, Gestational diabetes mellitus, and maternal infection, and the significant POTENTIAL for Perinatal morbidities ASSOCIATED with these conditions, evaluation of Vitamin D nutrition in early Pregnancy and the EFFECT of appropriate supplementation SEEMS WARRANTED.']	[('INCOMPLETE_EVIDENCE', 20), ('SUPERFICIAL_RELATIONSHIP', 37), ('INCOMPLETE_EVIDENCE', 155), ('SUPERFICIAL_RELATIONSHIP', 164), ('IMPORTANT_CONSIDERATION', 191), ('INCOMPLETE_EVIDENCE', 236), ('SUPERFICIAL_RELATIONSHIP', 383), ('QUESTION_ANSWERED_BY_THIS_WORK', 512), ('INCOMPLETE_EVIDENCE', 515), ('INCOMPLETE_EVIDENCE', 527), ('SUPERFICIAL_RELATIONSHIP', 536), ('INCOMPLETE_EVIDENCE', 705), ('SUPERFICIAL_RELATIONSHIP', 741), ('SUPERFICIAL_RELATIONSHIP', 836), ('ANOMALY_CURIOUS_FINDING', 874), ('FUTURE_WORK', 874)]	16	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('UBERON_0001758', 'periodontium', 71, 'periodontal'), ('UBERON_0001977', 'blood serum', 106, 'serum'), ('CHEBI_71657', 'versiconol acetate', 112, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 112, '25(OH ... D'), ('GO_0051318', 'G1 phase', 139, 'early'), ('GO_0007565', 'female pregnancy', 145, 'pregnancy'), ('UBERON_0001758', 'periodontium', 209, 'periodontal'), ('CHEBI_27300', 'vitamin D', 274, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 321, 'vitamin D'), ('GO_0007565', 'female pregnancy', 369, 'pregnancy'), ('GO_0007618', 'mating', 456, 'maternal'), ('GO_0007565', 'female pregnancy', 476, 'preterm'), ('GO_0007565', 'female pregnancy', 495, 'preterm'), ('GO_0007567', 'parturition', 503, 'birth'), ('CHEBI_27300', 'vitamin D', 565, 'vitamin D'), ('GO_0007565', 'female pregnancy', 630, 'gestational'), ('GO_0036268', 'swimming', 719, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 719, 'perinatal'), ('CHEBI_27300', 'vitamin D', 789, 'vitamin D'), ('GO_0007565', 'female pregnancy', 818, 'pregnancy')]
S57-PMC3702245	PMC3702245	6/2013	S57-PMC3702245	['regarding Neurocognitive Development, WHILE ONE STUDY FOUND no association between maternal Vitamin D status during Pregnancy and Neurocognitive function,76a RECENT larger-sized STUDY LINKED maternal Serum 25(Oh)D levels during Pregnancy with Language Development in the offspring.98the results of the above studies SUGGEST that childhood infections, atopy, and Neurocognitive development NEED TO BE included as outcomes of interest following Vitamin D supplementation in Pregnancy, and that clinical trials SHOULD include a RELEVANT group of subjects CONSIDERED to be replete for Vitamin D.\ntaken TOGETHER, the high prevalence of Vitamin D deficiency in Pregnancy and the POSSIBLE multiple POTENTIAL adverse EFFECTS on mother and offspring IDENTIFIED in SEVERAL epidemiologic STUDIES UNDERSCORE the URGENT NEED FOR large randomized controlled TRIALS to identify the amount of Vitamin D supplementation that optimizes Vitamin D status during Pregnancy, and to DETERMINE the EFFECT of supplementation on POTENTIAL adverse conditions ASSOCIATED with Vitamin D deficiency and any POSSIBLE Vitamin D excess.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 38), ('INCOMPLETE_EVIDENCE', 44), ('INCOMPLETE_EVIDENCE', 54), ('INCOMPLETE_EVIDENCE', 158), ('SUPERFICIAL_RELATIONSHIP', 184), ('INCOMPLETE_EVIDENCE', 316), ('FUTURE_WORK', 389), ('FUTURE_WORK', 508), ('IMPORTANT_CONSIDERATION', 525), ('IMPORTANT_CONSIDERATION', 552), ('INCOMPLETE_EVIDENCE', 598), ('INCOMPLETE_EVIDENCE', 673), ('INCOMPLETE_EVIDENCE', 691), ('SUPERFICIAL_RELATIONSHIP', 709), ('INCOMPLETE_EVIDENCE', 741), ('INCOMPLETE_EVIDENCE', 755), ('IMPORTANT_CONSIDERATION', 785), ('IMPORTANT_CONSIDERATION', 800), ('FUTURE_WORK', 807), ('INCOMPLETE_EVIDENCE', 807), ('FUTURE_WORK', 844), ('QUESTION_ANSWERED_BY_THIS_WORK', 960), ('SUPERFICIAL_RELATIONSHIP', 974), ('INCOMPLETE_EVIDENCE', 1003), ('SUPERFICIAL_RELATIONSHIP', 1032), ('INCOMPLETE_EVIDENCE', 1077)]	26	[('GO_0007399', 'nervous system development', 10, 'neurocognitive development'), ('CHEBI_27300', 'vitamin D', 92, 'vitamin D'), ('GO_0007565', 'female pregnancy', 116, 'pregnancy'), ('GO_0050905', 'neuromuscular process', 130, 'neurocognitive'), ('UBERON_0001977', 'blood serum', 200, 'serum'), ('CHEBI_71657', 'versiconol acetate', 206, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 206, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 228, 'pregnancy'), ('GO_0060132', 'prolactin secreting cell development', 243, 'language development'), ('GO_0050905', 'neuromuscular process', 362, 'neurocognitive'), ('CHEBI_27300', 'vitamin D', 443, 'vitamin D'), ('GO_0007565', 'female pregnancy', 472, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 581, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 631, 'vitamin D'), ('GO_0007565', 'female pregnancy', 655, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 877, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 918, 'vitamin D'), ('GO_0007565', 'female pregnancy', 942, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 1048, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1086, 'vitamin D')]
S63-PMC3702245	PMC3702245	6/2013	S63-PMC3702245	['a review of the FEW previous randomized controlled TRIALS of Vitamin D supplementation during Pregnancy INDICATES that doses of 400–1600 iu/day were INSUFFICIENT in achieving a mean Serum 25(Oh)D concentration ≥50 nmol/l in most of the studies.41in a RECENT Vitamin D supplementation TRIAL from the uk, a multiethnic group of 180 Pregnant women were randomized at 27 weeks’ Gestation to receive a single Oral dose of 200,000 iu of Vitamin D, daily supplementation of 800 iu, or no treatment.33the median Serum 25(Oh)D concentration in the 800 iu/day group at study entry was 26 nmol/l (interquartile range 22–37), and the median 25(Oh)D concentration at delivery following supplementation was 42 nmol/l (interquartile range 31–76).']	[('INCOMPLETE_EVIDENCE', 16), ('FUTURE_WORK', 51), ('INCOMPLETE_EVIDENCE', 104), ('IMPORTANT_CONSIDERATION', 149), ('PROBLEM_COMPLICATION', 149), ('INCOMPLETE_EVIDENCE', 251), ('INCOMPLETE_EVIDENCE', 284)]	7	[('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('GO_0007565', 'female pregnancy', 94, 'pregnancy'), ('UBERON_0001977', 'blood serum', 182, 'serum'), ('CHEBI_71657', 'versiconol acetate', 188, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 188, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 258, 'vitamin D'), ('GO_0007565', 'female pregnancy', 330, 'pregnant'), ('GO_0007565', 'female pregnancy', 374, 'gestation'), ('UBERON_0000165', 'mouth', 404, 'oral'), ('CHEBI_27300', 'vitamin D', 431, 'vitamin D'), ('UBERON_0001977', 'blood serum', 504, 'serum'), ('CHEBI_71657', 'versiconol acetate', 510, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 510, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 629, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 629, '25(OH)D')]
S68-PMC3702245	PMC3702245	6/2013	S68-PMC3702245	['these two studies and older RESEARCH41INDICATE that, in populations with a high prevalence of SEVERE Vitamin D sufficiency, supplementation up to 1600 iu/day MAY BE inadequate to achieve the RECOMMENDED target Serum 25(Oh)D concentration of 50 nmol/l.7in two RECENT STUDIES from india, which used large single-dose supplementation of 120,000 iu at the fifth and seventh month of Gestation15Or at the second and third trimester,69only 25% and 62%, respectively, achieved a Serum 25(Oh)D concentration >50 nmol/l.']	[('INCOMPLETE_EVIDENCE', 28), ('IMPORTANT_CONSIDERATION', 94), ('INCOMPLETE_EVIDENCE', 158), ('FUTURE_WORK', 191), ('INCOMPLETE_EVIDENCE', 259)]	5	[('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('UBERON_0001977', 'blood serum', 210, 'serum'), ('CHEBI_71657', 'versiconol acetate', 216, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 216, '25(OH)D'), ('GO_0007565', 'female pregnancy', 379, 'gestation15or'), ('UBERON_0001977', 'blood serum', 472, 'serum'), ('CHEBI_71657', 'versiconol acetate', 478, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 478, '25(OH)D')]
S69-PMC3702245	PMC3702245	6/2013	S69-PMC3702245	['the RECENT cochrane review of Vitamin D supplementation alone during Pregnancy79Considered five trials that compared the EFFECTS of supplementation with placebo or no supplementation.33,73,77,78,102the review CONCLUDED that Vitamin D supplementation increases Serum 25(Oh)D concentrations during Pregnancy.']	[('INCOMPLETE_EVIDENCE', 4), ('SUPERFICIAL_RELATIONSHIP', 121), ('INCOMPLETE_EVIDENCE', 209)]	3	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0016441', 'posttranscriptional gene silencing', 69, 'pregnancy79considered'), ('CHEBI_27300', 'vitamin D', 224, 'vitamin D'), ('UBERON_0001977', 'blood serum', 260, 'serum'), ('CHEBI_71657', 'versiconol acetate', 266, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 266, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 296, 'pregnancy')]
S70-PMC3702245	PMC3702245	6/2013	S70-PMC3702245	['OF NOTE, in two of the five studies, the mean concentration of 25(Oh)D after supplementation was <50 nmol/l,33,78and Serum 25(Oh)D WAS NOT MEASURED in ONE STUDY.73all these STUDIES underscore the uncertainty about the amount of Vitamin D supplementation REQUIRED to optimize Vitamin D status in Pregnancy and which would be generalizable worldwide.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 131), ('INCOMPLETE_EVIDENCE', 151), ('INCOMPLETE_EVIDENCE', 173), ('IMPORTANT_CONSIDERATION', 254)]	5	[('CHEBI_71657', 'versiconol acetate', 63, '25(OH)D'), ('UBERON_0001977', 'blood serum', 117, 'serum'), ('CHEBI_71657', 'versiconol acetate', 123, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 123, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 228, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 275, 'vitamin D'), ('GO_0007565', 'female pregnancy', 295, 'pregnancy')]
S75-PMC3702245	PMC3702245	6/2013	S75-PMC3702245	['because of CONTROVERSY surrounding Vitamin D REQUIREMENTS during Pregnancy, investigators from south carolina performed a comprehensive, large, randomized controlled study of Vitamin D supplementation in Pregnancy to achieve optimal Vitamin D status, DEFINED as a Serum 25(Oh)D concentration ≥80 nmol/l at Delivery.18BASED on the pharmacokinetics of Vitamin d, the authors INVESTIGATED the SAFETY and EFFECTIVENESS of high-dose Vitamin D supplementation.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 11), ('IMPORTANT_CONSIDERATION', 45), ('PROBABLE_UNDERSTANDING', 251), ('PROBABLE_UNDERSTANDING', 315), ('QUESTION_ANSWERED_BY_THIS_WORK', 373), ('IMPORTANT_CONSIDERATION', 390), ('SUPERFICIAL_RELATIONSHIP', 401)]	7	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('GO_0007565', 'female pregnancy', 65, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 175, 'vitamin D'), ('GO_0007565', 'female pregnancy', 204, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 233, 'vitamin D'), ('UBERON_0001977', 'blood serum', 264, 'serum'), ('CHEBI_71657', 'versiconol acetate', 270, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 270, '25(OH)D'), ('GO_0007567', 'parturition', 306, 'delivery'), ('CHEBI_33229', 'vitamin (role)', 350, 'vitamin'), ('CHEBI_27300', 'vitamin D', 428, 'vitamin D')]
S76-PMC3702245	PMC3702245	6/2013	S76-PMC3702245	['they HYPOTHESIZED that daily Vitamin D3Supplementation of 4000 iu/day would be more effective than 2000 iu and a standard dosing regimen of 400 iu in achieving a Serum 25(Oh)D concentration of >80 nmol/l without any safety ISSUES referable to Vitamin D supplementation.']	[('INCOMPLETE_EVIDENCE', 5), ('IMPORTANT_CONSIDERATION', 223), ('PROBLEM_COMPLICATION', 223)]	3	[('CHEBI_52915', 'phosphatediyl group', 29, 'vitamin D3supplementation'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 29, 'vitamin D3supplementation'), ('UBERON_0001977', 'blood serum', 162, 'serum'), ('CHEBI_71657', 'versiconol acetate', 168, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 168, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 243, 'vitamin D')]
S91-PMC3702245	PMC3702245	6/2013	S91-PMC3702245	['based on this protocol, the authors CONCLUDED that 4000 iu/day of Vitamin D3Supplementation is SAFE and MOST EFFECTIVE in achieving Vitamin D sufficiency in mothers and adequate Vitamin D status in their offspring, irrespective of ethnicity.']	[('INCOMPLETE_EVIDENCE', 36), ('IMPORTANT_CONSIDERATION', 95), ('PROBABLE_UNDERSTANDING', 104), ('SUPERFICIAL_RELATIONSHIP', 109)]	4	[('CHEBI_52915', 'phosphatediyl group', 66, 'vitamin D3supplementation'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 66, 'vitamin D3supplementation'), ('CHEBI_27300', 'vitamin D', 132, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 178, 'vitamin D')]
S92-PMC3702245	PMC3702245	6/2013	S92-PMC3702245	['the authors also FOUND that maternal Vitamin D supplementation with 4000 iu/day decreased the risk of combined comorbidities, including infection, Preterm Birth, Gestational diabetes, and pre-eclampsia,82and SUGGESTED that ADDITIONAL STUDIES with adequate power for assessment of OTHER endpoints WERE NEEDED.']	[('INCOMPLETE_EVIDENCE', 17), ('INCOMPLETE_EVIDENCE', 208), ('FUTURE_WORK', 223), ('FUTURE_WORK', 234), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 280), ('FUTURE_WORK', 296)]	6	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('GO_0007565', 'female pregnancy', 147, 'preterm birth'), ('GO_0007565', 'female pregnancy', 162, 'gestational')]
S93-PMC3702245	PMC3702245	6/2013	S93-PMC3702245	['another RECENT STUDY from the united arab emirates among Pregnant arab women with a high prevalence of Vitamin D deficiency also CONFIRMED that 4000 iu/day of Vitamin D supplementation was SAFE and more EFFECTIVE than 2000 iu/day and 400 iu/day in optimizing Vitamin D status during Pregnancy and in achieving Vitamin D sufficiency at Birth in mothers and offspring.106in the united arab emirates study, the increment from baseline to Delivery was about four-fold higher than expected BASED ON previous pharmacokinetic STUDIES, POSSIBLY RELATED to low baseline Vitamin D status.100this INDICATES that baseline Vitamin D status SHOULD BE taken INTO CONSIDERATION when evaluating Vitamin D supplementation.100,107\nthe FINDINGS of these RECENT intervention STUDIES INDICATE an URGENT NEED for more randomized controlled trials in diverse geographic locations with large sample sizes to identify the Vitamin D intake REQUIRED to optimize Vitamin D status, and TO ASSESS the EFFECT on Pregnancy-related and infant-related COMPLICATIONS.']	[('INCOMPLETE_EVIDENCE', 8), ('INCOMPLETE_EVIDENCE', 129), ('IMPORTANT_CONSIDERATION', 189), ('SUPERFICIAL_RELATIONSHIP', 203), ('PROBABLE_UNDERSTANDING', 485), ('INCOMPLETE_EVIDENCE', 519), ('INCOMPLETE_EVIDENCE', 528), ('SUPERFICIAL_RELATIONSHIP', 537), ('INCOMPLETE_EVIDENCE', 586), ('FUTURE_WORK', 627), ('IMPORTANT_CONSIDERATION', 643), ('FUTURE_WORK', 648), ('INCOMPLETE_EVIDENCE', 716), ('INCOMPLETE_EVIDENCE', 734), ('INCOMPLETE_EVIDENCE', 762), ('IMPORTANT_CONSIDERATION', 774), ('FUTURE_WORK', 781), ('IMPORTANT_CONSIDERATION', 913), ('QUESTION_ANSWERED_BY_THIS_WORK', 956), ('SUPERFICIAL_RELATIONSHIP', 970), ('PROBLEM_COMPLICATION', 1017)]	21	[('GO_0007565', 'female pregnancy', 57, 'pregnant'), ('CHEBI_27300', 'vitamin D', 103, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 159, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 259, 'vitamin D'), ('GO_0007565', 'female pregnancy', 283, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 310, 'vitamin D'), ('GO_0007567', 'parturition', 335, 'birth'), ('GO_0007567', 'parturition', 435, 'delivery'), ('CHEBI_27300', 'vitamin D', 561, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 610, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 678, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 896, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 934, 'vitamin D'), ('GO_0007565', 'female pregnancy', 980, 'pregnancy')]
S94-PMC3702245	PMC3702245	6/2013	S94-PMC3702245	['BASED ON BIOMARKERS AFFECTED by Vitamin D status, and FINDINGS from observational studies and recent randomized trials, FUTURE STUDIES SHOULD include trial arms to achieve Serum 25(Oh)D concentrations that HAVE BEEN ASSOCIATED with POTENTIAL Extraskeletal benefits8,82,84,94–96of Vitamin D to understand BETTER both the benefits and risks of Vitamin D supplementation to mother and offspring.']	[('PROBABLE_UNDERSTANDING', 0), ('SUPERFICIAL_RELATIONSHIP', 0), ('SUPERFICIAL_RELATIONSHIP', 9), ('SUPERFICIAL_RELATIONSHIP', 20), ('INCOMPLETE_EVIDENCE', 54), ('FUTURE_WORK', 120), ('FUTURE_WORK', 135), ('INCOMPLETE_EVIDENCE', 206), ('SUPERFICIAL_RELATIONSHIP', 216), ('INCOMPLETE_EVIDENCE', 232), ('INCOMPLETE_EVIDENCE', 304)]	11	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('UBERON_0001977', 'blood serum', 172, 'serum'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 181, 'OH)D'), ('UBERON_0001431', 'distal carpal bone 2', 242, 'extraskeletal'), ('CHEBI_27300', 'vitamin D', 280, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 342, 'vitamin D')]
S199-PMC3702339	PMC3702339	6/2013	S199-PMC3702339	['Zinc supplementation trial in Pregnant nepalese women also SUGGESTED that Zinc potentiates the EFFECT of Vitamin A in restoring night-Vision among night-blind Pregnant women with low initial Serum zinc concentrations (44).']	[('INCOMPLETE_EVIDENCE', 59), ('SUPERFICIAL_RELATIONSHIP', 95)]	2	"[('CHEBI_27377', ""Unsym-bis(4'-chlorophenyl)ethylene"", 0, 'Zinc'), ('GO_0007565', 'female pregnancy', 30, 'pregnant'), ('CHEBI_33340', 'zinc group element atom', 74, 'zinc'), ('CHEBI_27300', 'vitamin D', 105, 'vitamin A'), ('GO_0007601', 'visual perception', 134, 'vision'), ('GO_0007565', 'female pregnancy', 159, 'pregnant'), ('UBERON_0001977', 'blood serum', 191, 'serum')]"
S13-PMC3705320	PMC3705320	3/2013	S13-PMC3705320	['introduction\nthe maternal-infant health benefits of Vitamin D supplementation during Pregnancy remain UNCERTAIN [1,2].']	[('FULL_UNKNOWN', 102)]	1	[('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('GO_0007565', 'female pregnancy', 85, 'pregnancy')]
S18-PMC3705320	PMC3705320	3/2013	S18-PMC3705320	['THEREFORE, to guide the design of clinical trials of Antenatal Vitamin D supplementation in bangladesh, we CONDUCTED a randomized open-label pilot trial of two Antenatal Vitamin d3 supplementation doses that were several fold higher than those in typical Prenatal supplements.']	[('PROBABLE_UNDERSTANDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 107)]	2	[('GO_0007567', 'parturition', 53, 'antenatal'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('GO_0007567', 'parturition', 160, 'antenatal'), ('CHEBI_33229', 'vitamin (role)', 170, 'vitamin'), ('GO_0007565', 'female pregnancy', 255, 'prenatal')]
S25-PMC3705320	PMC3705320	3/2013	S25-PMC3705320	['reasons for exclusion were: preexisting medical condition; current Vitamin D supplement use; Anti-convulsant or anti-Mycobacterial medications; severe anemia (hemoglobin concentration <70 g/l); hypertension at enrollment (systolic Blood pressure ≥140 mmhg or diastolic Blood pressure ≥90 mmhg on at least two measurements); major risk FACTORS for Preterm Delivery or Pregnancy complications; or previous delivery of an infant with a congenital anomaly or Perinatal death.']	[('SUPERFICIAL_RELATIONSHIP', 335)]	1	[('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('CHEBI_59132', 'antigen', 93, 'anti'), ('CHEBI_52217', 'pharmaceutical', 117, 'mycobacterial'), ('UBERON_0000178', 'blood', 231, 'blood'), ('UBERON_0000178', 'blood', 269, 'blood'), ('GO_0007565', 'female pregnancy', 347, 'preterm'), ('GO_0007567', 'parturition', 355, 'delivery'), ('GO_0007565', 'female pregnancy', 367, 'pregnancy'), ('GO_0036268', 'swimming', 455, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 455, 'perinatal')]
S114-PMC3705320	PMC3705320	3/2013	S114-PMC3705320	['there was substantial inter-subject variability in the response to Vitamin D supplementation, with one pl participant demonstrating ONLY a 7 nmol/l final increase in [25(Oh)D] above her baseline.']	[('INCOMPLETE_EVIDENCE', 132)]	1	[('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 167, '25(OH)D'), ('PR_000011614', 'opioid growth factor receptor', 170, 'OH'), ('PR_000006444', 'diacylglycerol kinase delta', 173, 'D')]
S193-PMC3705320	PMC3705320	3/2013	S193-PMC3705320	['first, precision of ESTIMATES of Pharmacokinetic parameters and between-group comparisons, as well as the generalizability of inferences regarding maternal-fetal SAFETY of high-dose Vitamin D supplementation, were LIMITED by the SMALL number of participants, stringent inclusion/exclusion criteria, and enrolment of Pregnant and non-Pregnant participants at one clinic site.']	[('INCOMPLETE_EVIDENCE', 20), ('IMPORTANT_CONSIDERATION', 162), ('INCOMPLETE_EVIDENCE', 214), ('INCOMPLETE_EVIDENCE', 229)]	4	[('CHEBI_87163', 'dihydroisopentenyldehydrorhodopin', 33, 'pharmacokinetic'), ('GO_0006909', 'phagocytosis', 33, 'pharmacokinetic'), ('CHEBI_27300', 'vitamin D', 182, 'vitamin D'), ('GO_0007565', 'female pregnancy', 316, 'pregnant'), ('GO_0007565', 'female pregnancy', 333, 'pregnant')]
S201-PMC3705320	PMC3705320	3/2013	S201-PMC3705320	['NONETHELESS, increases in the mean calcium concentration (within the normal range) and suppression of pth secretion among Pregnant women receiving the higher-dose regimen (70,000 iu initial dose followed by weekly doses of 35,000 iu) HIGHLIGHTED the physiological IMPACT of the intervention and the NEED to cautiously address POTENTIAL Pregnancy-specific sensitivities to Vitamin D supplementation.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 234), ('SUPERFICIAL_RELATIONSHIP', 264), ('FUTURE_WORK', 299), ('INCOMPLETE_EVIDENCE', 299), ('INCOMPLETE_EVIDENCE', 326)]	7	[('GO_0007565', 'female pregnancy', 122, 'pregnant'), ('GO_0007565', 'female pregnancy', 336, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 372, 'vitamin D')]
S204-PMC3705320	PMC3705320	3/2013	S204-PMC3705320	['the most direct application of the present OBSERVATIONS is to guide the design of FUTURE TRIALS of Vitamin D3 (at doses up to 35,000 iu per week) AIMED at CONFIRMING SAFETY and establishing the health benefits of Antenatal Vitamin D supplementation in south asia, where many POTENTIALLY Vitamin D-responsive outcomes (e.g., infant growth and infectious disease morbidity) are MAJOR PUBLIC HEALTH PRIORITIES.']	[('INCOMPLETE_EVIDENCE', 43), ('FUTURE_WORK', 82), ('QUESTION_ANSWERED_BY_THIS_WORK', 146), ('PROBABLE_UNDERSTANDING', 155), ('IMPORTANT_CONSIDERATION', 166), ('INCOMPLETE_EVIDENCE', 275), ('IMPORTANT_CONSIDERATION', 376), ('IMPORTANT_CONSIDERATION', 382), ('IMPORTANT_CONSIDERATION', 396)]	9	[('CHEBI_33279', 'vitamin D5', 99, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 99, 'vitamin D3'), ('GO_0007567', 'parturition', 213, 'antenatal'), ('CHEBI_27300', 'vitamin D', 223, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 287, 'vitamin D')]
S206-PMC3705320	PMC3705320	3/2013	S206-PMC3705320	['FUTURE TRIALS in dhaka will address the dose-dependency of the EFFECTS of Prenatal Vitamin D supplementation on infant growth and morbidity.']	[('FUTURE_WORK', 0), ('SUPERFICIAL_RELATIONSHIP', 63)]	2	[('GO_0007565', 'female pregnancy', 74, 'prenatal'), ('CHEBI_27300', 'vitamin D', 83, 'vitamin D')]
S378-PMC3710934	PMC3710934	7/2013	S378-PMC3710934	['ON THE OTHER HAND, dietary Heme Iron Intake was positively ASSOCIATED with Lung cancer when subjects were stratified by Vitamin C supplements Intake.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('SUPERFICIAL_RELATIONSHIP', 59)]	3	[('CHEBI_36084', 'dihydroxybenzoate', 27, 'heme iron'), ('GO_0007631', 'feeding behavior', 37, 'intake'), ('UBERON_0002048', 'lung', 75, 'lung'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin C'), ('GO_0007631', 'feeding behavior', 142, 'intake')]
S380-PMC3710934	PMC3710934	7/2013	S380-PMC3710934	['among current or ex-smokers, the ASSOCIATION was EVEN stronger (rr=20.38; 95% ci: 22.50–185.8) and reached statistical significance EVEN in the group having Vitamin C supplement Intake of >100 mg/day (rr=3.52; 95% ci: 1.24–8.97).']	[('SUPERFICIAL_RELATIONSHIP', 33), ('ANOMALY_CURIOUS_FINDING', 49), ('ANOMALY_CURIOUS_FINDING', 132)]	3	[('CHEBI_27300', 'vitamin D', 157, 'vitamin C'), ('GO_0007631', 'feeding behavior', 178, 'intake')]
S381-PMC3710934	PMC3710934	7/2013	S381-PMC3710934	['the authors SUGGEST that high dietary Heme Iron intake in combination with high intake of Vitamin C supplements MAY increase the risk of Lung cancer in Postmenopausal women.']	[('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 112)]	2	[('CHEBI_36084', 'dihydroxybenzoate', 38, 'heme iron'), ('CHEBI_27300', 'vitamin D', 90, 'vitamin C'), ('UBERON_0002048', 'lung', 137, 'lung'), ('GO_0007595', 'lactation', 152, 'postmenopausal')]
S48-PMC3713405	PMC3713405	7/2013	S48-PMC3713405	['schizophrenia HAS BEEN SHOWN to be ameliorated by Vitamin D supplementation in the 1 year of Life (mcgrath et al., 2004).']	[('INCOMPLETE_EVIDENCE', 14)]	1	[('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('UBERON_0000104', 'life cycle', 93, 'life')]
S45-PMC3717170	PMC3717170	5/2013	S45-PMC3717170	['the extent to which Vitamin D deficiency is a cause of Immune disease has yet to be demonstrated and will REQUIRE new prospective clinical trials of Vitamin D supplementation.']	[('FUTURE_WORK', 106), ('IMPORTANT_CONSIDERATION', 106)]	2	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('UBERON_0002405', 'immune system', 55, 'immune'), ('CHEBI_27300', 'vitamin D', 149, 'vitamin D')]
S69-PMC3717170	PMC3717170	5/2013	S69-PMC3717170	"[""in addition, FEW randomized controlled trials HAVE BEEN conducted in Pregnant women to determine optimal Vitamin D status.13–15\ncarol l. wagner (medical university of south carolina) DISCUSSED two RECENT STUDIES performed by her group in collaboration with bruce hollis's group—the national institute of child health and Human development (nichd) Vitamin D Pregnancy trial12and the thrasher research fund Vitamin D community-based supplementation trial16—that INDICATE that 400 iu Vitamin D, the amount found in MOST Prenatal Vitamins, is INADEQUATE and that 4000 iu/day is NECESSARY to optimize 1,25(Oh)2D3Production, achieved when total circulating 25(Oh)d3is at least 40 ng/ml (fig.""]"	[('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 46), ('INCOMPLETE_EVIDENCE', 183), ('INCOMPLETE_EVIDENCE', 197), ('INCOMPLETE_EVIDENCE', 460), ('PROBABLE_UNDERSTANDING', 512), ('IMPORTANT_CONSIDERATION', 539), ('PROBLEM_COMPLICATION', 539), ('IMPORTANT_CONSIDERATION', 574)]	9	[('GO_0007565', 'female pregnancy', 69, 'pregnant'), ('CHEBI_27300', 'vitamin D', 105, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 321, 'Human'), ('CHEBI_28384', 'vitamin K', 347, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 357, 'Pregnancy'), ('CHEBI_28384', 'vitamin K', 405, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 405, 'Vitamin'), ('CHEBI_27300', 'vitamin D', 481, 'vitamin D'), ('GO_0007565', 'female pregnancy', 517, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 526, 'vitamins'), ('CHEBI_37983', 'sulfur-35 atom', 596, '1'), ('CHEBI_74151', 'S-palmitoyl-L-cysteine residue', 597, ',25(OH)2D3production'), ('PR_000029121', 'leucine-rich repeat and guanylate kinase domain-containing protein', 604, '2D3production'), ('CHEBI_33310', 'neon atom', 653, '(OH)')]
S76-PMC3717170	PMC3717170	5/2013	S76-PMC3717170	['it WAS THOUGHT for decades that Human Milk was minimally sufficient in Vitamin D;17yet, PRELIMINARY results of the RECENTLY COMPLETED nichd Vitamin D supplementation trial during Lactation SHOW that when a mother is Vitamin D replete, with an Intake of 6400 iu Vitamin D3/day, Breast Milk is replete and a breastfeeding infant has excellent Vitamin D status without infant supplementation that is COMPARABLE to combined maternal and infant supplementation of 400 iu Vitamin D3/day.18the IMPLICATIONS of SAFELY achieving vitamin d SUFFICIENCY for both mother and breastfeeding infant solely through maternal supplementation is just BEGINNING TO BE UNDERSTOOD and will LIKELY CHALLENGE researchers for decades to come.']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 7), ('INCOMPLETE_EVIDENCE', 88), ('INCOMPLETE_EVIDENCE', 115), ('INCOMPLETE_EVIDENCE', 189), ('INCOMPLETE_EVIDENCE', 397), ('IMPORTANT_CONSIDERATION', 487), ('IMPORTANT_CONSIDERATION', 503), ('IMPORTANT_CONSIDERATION', 530), ('INCOMPLETE_EVIDENCE', 631), ('PROBABLE_UNDERSTANDING', 667), ('DIFFICULT_TASK', 674)]	12	[('NCBITaxon_9606', 'Homo sapiens', 32, 'human'), ('UBERON_0001913', 'milk', 38, 'milk'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 140, 'vitamin D'), ('GO_0007595', 'lactation', 179, 'lactation'), ('CHEBI_27300', 'vitamin D', 216, 'vitamin D'), ('GO_0007631', 'feeding behavior', 243, 'intake'), ('CHEBI_33279', 'vitamin D5', 261, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 261, 'vitamin D3'), ('UBERON_0000310', 'breast', 277, 'breast'), ('UBERON_0001913', 'milk', 284, 'milk'), ('CHEBI_27300', 'vitamin D', 341, 'vitamin D'), ('CHEBI_33279', 'vitamin D5', 466, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 466, 'vitamin D3')]
S77-PMC3717170	PMC3717170	5/2013	S77-PMC3717170	['Vitamin D and obesity\nigor n. sergeev (south dakota state university) DISCUSSED the POSSIBILITY of integrating Vitamin D supplementation with current STRATEGIES in the PREVENTION and treatment of obesity.']	[('INCOMPLETE_EVIDENCE', 70), ('INCOMPLETE_EVIDENCE', 84), ('FUTURE_WORK', 150), ('SUPERFICIAL_RELATIONSHIP', 168)]	4	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'Vitamin'), ('CHEBI_27300', 'vitamin D', 111, 'vitamin D')]
S91-PMC3717170	PMC3717170	5/2013	S91-PMC3717170	['targeting Ca2+Signaling and the Vitamin D/Ca2+–dependent calpains and caspases in Adipocytes with Vitamin D supplementation MAY THEREFORE be an effective and affordable approach for chemoprevention and treatment of obesity.']	[('INCOMPLETE_EVIDENCE', 124), ('PROBABLE_UNDERSTANDING', 128)]	2	[('CHEBI_29108', 'calcium(2+)', 10, 'Ca2+'), ('GO_0016215', 'acyl-CoA desaturase activity', 10, 'Ca2'), ('GO_0023051', 'regulation of signaling', 14, 'signaling'), ('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('CHEBI_51231', 'DAPI', 42, 'Ca2+–'), ('CL_0000136', 'fat cell', 82, 'adipocytes'), ('CHEBI_27300', 'vitamin D', 98, 'vitamin D')]
S141-PMC3717170	PMC3717170	5/2013	S141-PMC3717170	['the results from SMALL clinical trials and post hoc analyses of larger trials on the EFFECT of Vitamin D supplementation on diabetes-related parameters HAVE BEEN INCONCLUSIVE, although Vitamin D APPEARS to have beneficial EFFECTS in Persons AT RISK for diabetes.36–39HOWEVER, no firm conclusions can be drawn from the available intervention studies BECAUSE of several LIMITATIONS: (1) NEARLY ALL studies were UNDERPOWERED; (2) the MINORITY of studies were designed specifically for Glycemic outcomes; (3) MOST STUDIES DID NOT REPORT use of diabetes medications at baseline or during the study; (4) SOME TRIALS used large infrequent doses of Vitamin D, which MAY BE Metabolized DIFFERENTLY compared to daily doses and MAY provide EITHER no benefit OR result in an UNFAVORABLE benefit/risk ratio.']	[('INCOMPLETE_EVIDENCE', 17), ('SUPERFICIAL_RELATIONSHIP', 85), ('INCOMPLETE_EVIDENCE', 152), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 162), ('ANOMALY_CURIOUS_FINDING', 195), ('SUPERFICIAL_RELATIONSHIP', 222), ('IMPORTANT_CONSIDERATION', 241), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 265), ('PROBLEM_COMPLICATION', 349), ('INCOMPLETE_EVIDENCE', 368), ('PROBLEM_COMPLICATION', 368), ('PROBABLE_UNDERSTANDING', 385), ('PROBLEM_COMPLICATION', 409), ('INCOMPLETE_EVIDENCE', 431), ('INCOMPLETE_EVIDENCE', 505), ('INCOMPLETE_EVIDENCE', 518), ('INCOMPLETE_EVIDENCE', 598), ('INCOMPLETE_EVIDENCE', 658), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 677), ('INCOMPLETE_EVIDENCE', 717), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 729), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 747), ('IMPORTANT_CONSIDERATION', 763)]	23	[('CHEBI_27300', 'vitamin D', 95, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 185, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 233, 'persons'), ('GO_0006096', 'glycolytic process', 482, 'glycemic'), ('CHEBI_27300', 'vitamin D', 641, 'vitamin D'), ('GO_0008152', 'metabolic process', 665, 'metabolized')]
S177-PMC3717170	PMC3717170	5/2013	S177-PMC3717170	['a RECENT STUDY DEMONSTRATED that Vitamin D level CORRELATES with maximal oxygen consumption, and that supplementation of Vitamin D increases fitness in athletes.']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 15), ('SUPERFICIAL_RELATIONSHIP', 49)]	3	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin D')]
S184-PMC3717170	PMC3717170	5/2013	S184-PMC3717170	['WHETHER Vitamin D supplementation MAY positively IMPACT the Aging process REMAINS UNKNOWN and will REQUIRE FURTHER long-term intervention STUDIES.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 34), ('SUPERFICIAL_RELATIONSHIP', 49), ('FULL_UNKNOWN', 74), ('FUTURE_WORK', 99), ('FUTURE_WORK', 107)]	6	[('CHEBI_27300', 'vitamin D', 8, 'vitamin D'), ('GO_0007568', 'aging', 60, 'aging')]
S191-PMC3717170	PMC3717170	5/2013	S191-PMC3717170	['the iom EXPERT panel CONCLUDED that MOST americans (97.5%) had adequate levels of Vitamin D, BASED ON their CONCLUSION that a 25(Oh)d3of 20 ng/ml or greater was sufficient, RAISING the QUESTION of WHETHER supplementation was EVEN NEEDED.']	[('PROBABLE_UNDERSTANDING', 8), ('INCOMPLETE_EVIDENCE', 21), ('PROBABLE_UNDERSTANDING', 36), ('INCOMPLETE_EVIDENCE', 93), ('PROBABLE_UNDERSTANDING', 93), ('INCOMPLETE_EVIDENCE', 108), ('IMPORTANT_CONSIDERATION', 173), ('EXPLICIT_QUESTION', 185), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 197), ('EXPLICIT_QUESTION', 197), ('ANOMALY_CURIOUS_FINDING', 225), ('IMPORTANT_CONSIDERATION', 230)]	12	[('CHEBI_27300', 'vitamin D', 82, 'vitamin D'), ('CHEBI_30778', 'gallic acid', 126, '25(OH)')]
S0-PMC3717763	PMC3717763	8/2013	S0-PMC3717763	['a qualitative study of uptake of free Vitamins in england\n\nabstract\n\nobjective\nTO IDENTIFY reasons WHY eligible families are not accessing free ‘healthy start’ Vitamin supplementation (providing Vitamins A, C and d) in england.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 79), ('EXPLICIT_QUESTION', 99)]	2	[('CHEBI_33277', 'gamma-tocotrienol', 38, 'vitamins'), ('CHEBI_33229', 'vitamin (role)', 160, 'vitamin'), ('CHEBI_27300', 'vitamin D', 195, 'vitamins A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 204, 'A'), ('PR_000004900', 'complement C3', 207, 'C')]
S9-PMC3717763	PMC3717763	8/2013	S9-PMC3717763	['this scheme provides low-income families in the uk with fixed-value Food vouchers and vitamin coupons for eligible women and young children.1vitamin coupons can be exchanged for branded hs vitamin tablets for women (70\u2005mg Vitamin C, 10\u2005µg Vitamin D and 400\u2005µg Folic Acid daily during Pregnancy, and one year Postpartum) and drops for children (233\u2005µg Vitamin A, 20\u2005µg Vitamin C, and 7.5\u2005µg Vitamin D3 daily between\n\ncaption (boxed-text)\nwhat is already known on THIS topic\ncurrent uk GUIDANCE is that vulnerable groups of Pregnant and breastfeeding women and young children SHOULD take Vitamin Supplements (including Vitamins A, c and d) to protect against the greater RISK of Birth defects and poor health outcomes in later Life.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 462), ('FUTURE_WORK', 484), ('FUTURE_WORK', 574), ('IMPORTANT_CONSIDERATION', 669)]	4	[('CHEBI_33290', 'food', 68, 'food'), ('CHEBI_27300', 'vitamin D', 222, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 239, 'vitamin D'), ('CHEBI_30751', 'formic acid', 260, 'folic acid'), ('GO_0007565', 'female pregnancy', 284, 'pregnancy'), ('GO_0007565', 'female pregnancy', 308, 'postpartum'), ('CHEBI_27300', 'vitamin D', 351, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 368, 'vitamin C'), ('CHEBI_33279', 'vitamin D5', 390, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 390, 'vitamin D3'), ('GO_0007565', 'female pregnancy', 522, 'pregnant'), ('CHEBI_33229', 'vitamin (role)', 586, 'vitamin'), ('CHEBI_33341', 'titanium atom', 594, 'supplements'), ('CHEBI_27300', 'vitamin D', 617, 'vitamins A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 626, 'A'), ('GO_0007567', 'parturition', 677, 'birth'), ('UBERON_0000104', 'life cycle', 725, 'life')]
S109-PMC3717763	PMC3717763	8/2013	S109-PMC3717763	['reports SUGGEST that less than half the midwives and health visitors are aware of the current uk Vitamin D GUIDELINES for ages under 5 years, and RECOMMEND supplementation to parents.29–31additionally, THIS STUDY INDICATES that workload pressures and infrequent contact with mothers CAN also discourage them from promoting hs Vitamins.']	[('INCOMPLETE_EVIDENCE', 8), ('IMPORTANT_CONSIDERATION', 107), ('FUTURE_WORK', 146), ('QUESTION_ANSWERED_BY_THIS_WORK', 202), ('INCOMPLETE_EVIDENCE', 213), ('INCOMPLETE_EVIDENCE', 283)]	6	[('CHEBI_27300', 'vitamin D', 97, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 105, 'D'), ('CHEBI_33277', 'gamma-tocotrienol', 326, 'vitamins')]
S312-PMC3728489	PMC3728489	7/2013	S312-PMC3728489	['it HAS BEEN PROPOSED, THOUGH NOT PROVEN, that low levels of Vitamin D during Pregnancy and infancy COULD increase the RISK of Neurodevelopmental disorders, and that supplementation COULD play a ROLE in prevention.']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 12), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 22), ('INCOMPLETE_EVIDENCE', 29), ('INCOMPLETE_EVIDENCE', 99), ('IMPORTANT_CONSIDERATION', 118), ('INCOMPLETE_EVIDENCE', 181), ('SUPERFICIAL_RELATIONSHIP', 194)]	8	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('GO_0007565', 'female pregnancy', 77, 'pregnancy'), ('GO_0007399', 'nervous system development', 126, 'neurodevelopmental')]
S319-PMC3728489	PMC3728489	7/2013	S319-PMC3728489	['fish oil (that commonly contains Vitamin D) and OTHER omega 3 Fatty Acid supplements taken in infancy HAVE BEEN ASSOCIATED with improved Cognitive development, THOUGH this evidence is also far from definitive (auestad et al.,2003; karr et al.,2011; meldrum et al.,2012; luchtman and song,2013).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 48), ('INCOMPLETE_EVIDENCE', 102), ('SUPERFICIAL_RELATIONSHIP', 112), ('ANOMALY_CURIOUS_FINDING', 160)]	4	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('CHEBI_35366', 'fatty acid', 62, 'fatty acid'), ('GO_0050890', 'cognition', 137, 'cognitive')]
S320-PMC3728489	PMC3728489	7/2013	S320-PMC3728489	['the american academy of pediatrics RECOMMENDS that all breastfed infants receive a daily Vitamin D supplement of 400 iu, beginning in the first few days of Life (wagner et al.,2008).']	[('FUTURE_WORK', 35)]	1	[('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('UBERON_0000104', 'life cycle', 156, 'life')]
S169-PMC3739737	PMC3739737	8/2013	S169-PMC3739737	['evidence from a RECENTLY published randomized controlled trial of Vitamin D supplementation for the treatment of parkinson’s disease (pd) SUPPORT THIS HYPOTHESIS[40].']	[('INCOMPLETE_EVIDENCE', 16), ('INCOMPLETE_EVIDENCE', 138), ('QUESTION_ANSWERED_BY_THIS_WORK', 146), ('INCOMPLETE_EVIDENCE', 151)]	4	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D')]
S171-PMC3739737	PMC3739737	8/2013	S171-PMC3739737	['IN CONTRAST, those on Vitamin D supplements had no change in pd outcomes over the year.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0)]	1	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D')]
S27-PMC3742894	PMC3742894	7/2013	S27-PMC3742894	['to improve the nutritional status (the MAJOR cause of anemia in Pregnancy) of ethiopian women, there HAVE BEEN several interventions by the ministry of health through its essential nutrition action plan (ena), consisting of supplementation of three major Nutrients (Vitamin A, Iron, and Iodine) and other promotive activities to improve maternal and child nutrition (18).']	[('IMPORTANT_CONSIDERATION', 39), ('INCOMPLETE_EVIDENCE', 101)]	2	[('GO_0007565', 'female pregnancy', 64, 'pregnancy'), ('CHEBI_33284', 'nutrient', 255, 'nutrients'), ('CHEBI_27300', 'vitamin D', 266, 'vitamin A'), ('CHEBI_24870', 'ion', 277, 'iron'), ('CHEBI_24859', 'iodine atom', 287, 'iodine')]
S159-PMC3760821	PMC3760821	9/2013	S159-PMC3760821	['THESE FINDINGS SUPPORT the CONTENTION that measurement of Vitamin D levels prior to, and during Pregnancy, SHOULD BE RECOMMENDED, and that Vitamin D supplementation be initiated when deficiency is CONFIRMED.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 15), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 27), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 27), ('FUTURE_WORK', 107), ('FUTURE_WORK', 117), ('INCOMPLETE_EVIDENCE', 197)]	7	[('CHEBI_27300', 'vitamin D', 58, 'vitamin D'), ('GO_0007565', 'female pregnancy', 96, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 139, 'vitamin D')]
S160-PMC3760821	PMC3760821	9/2013	S160-PMC3760821	['EVEN given the LACK OF EVIDENCE SUPPORTING a causal LINK between low Vitamin D and a range of non-bone health outcomes, assessment and supplementation are ESSENTIAL with respect to the optimal bone health of both mother and off-spring.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 15), ('INCOMPLETE_EVIDENCE', 32), ('SUPERFICIAL_RELATIONSHIP', 52), ('IMPORTANT_CONSIDERATION', 155)]	5	[('CHEBI_27300', 'vitamin D', 69, 'vitamin D')]
S163-PMC3760821	PMC3760821	9/2013	S163-PMC3760821	['department of health GUIDELINES in the uk CURRENTLY RECOMMEND Pregnant women to supplement with 10 µg/day to protect against Vitamin D deficiency[29], but this is DISPUTED by SOME[30].']	[('PROBABLE_UNDERSTANDING', 21), ('INCOMPLETE_EVIDENCE', 42), ('FUTURE_WORK', 52), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 163), ('INCOMPLETE_EVIDENCE', 175)]	5	[('GO_0007565', 'female pregnancy', 62, 'pregnant'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin D')]
S164-PMC3760821	PMC3760821	9/2013	S164-PMC3760821	['hollis et al .,[30]ARGUE that supplementation of up to 100 µg/day is more effective at maintaining Vitamin D sufficiency throughout Pregnancy, when compared with 10 and 50 µg/day.']	[('INCOMPLETE_EVIDENCE', 19)]	1	[('CHEBI_27300', 'vitamin D', 99, 'vitamin D'), ('GO_0007565', 'female pregnancy', 132, 'pregnancy')]
S177-PMC3760821	PMC3760821	9/2013	S177-PMC3760821	['with respect to a causal LINK between Vitamin D repletion and improved Glucose Homeostasis, LIMITED STUDIES HAVE REPORTED substantial improvements in Glycaemic Control (hba1clevels) in t1dm patients who achieved higher circulating 25Ohd levels via supplementation[36],[37].']	[('SUPERFICIAL_RELATIONSHIP', 25), ('INCOMPLETE_EVIDENCE', 92), ('INCOMPLETE_EVIDENCE', 108)]	3	"[('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('CHEBI_17234', 'glucose', 71, 'glucose'), ('GO_0042593', 'glucose homeostasis', 71, 'glucose homeostasis'), ('GO_0051162', 'L-arabitol metabolic process', 150, 'glycaemic control'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 231, '25OHD')]"
S178-PMC3760821	PMC3760821	9/2013	S178-PMC3760821	['the results of a recent systematic review SUGGEST a weak EFFECT of Vitamin D supplementation in reducing fasting Glucose and improving Insulin resistance in patients with t2dm or impaired glucose tolerance[38].']	[('INCOMPLETE_EVIDENCE', 42), ('SUPERFICIAL_RELATIONSHIP', 57)]	2	[('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('CHEBI_17234', 'glucose', 113, 'glucose'), ('PR_000045358', 'insulin family protein', 135, 'insulin')]
S181-PMC3760821	PMC3760821	9/2013	S181-PMC3760821	['clearly, prospective clinical randomised controlled trials of Vitamin D supplementation ARE REQUIRED TO evaluate and CLARIFY the ASSOCIATION between Vitamin D status and Glycaemic Control in t1dm Pregnancy.']	[('FUTURE_WORK', 88), ('IMPORTANT_CONSIDERATION', 92), ('QUESTION_ANSWERED_BY_THIS_WORK', 101), ('FUTURE_WORK', 117), ('SUPERFICIAL_RELATIONSHIP', 129)]	5	[('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 149, 'vitamin D'), ('GO_0051162', 'L-arabitol metabolic process', 170, 'glycaemic control'), ('GO_0007565', 'female pregnancy', 196, 'pregnancy')]
S182-PMC3760821	PMC3760821	9/2013	S182-PMC3760821	['a further LIMITATION is that information is NOT AVAILABLE on dietary or supplemental Vitamin D intake, in these women.']	[('INCOMPLETE_EVIDENCE', 10), ('INCOMPLETE_EVIDENCE', 44)]	2	[('CHEBI_27300', 'vitamin D', 85, 'vitamin D')]
S185-PMC3760821	PMC3760821	9/2013	S185-PMC3760821	['GIVEN the SAFETY of Vitamin D, the low cost of supplementation and its REQUIREMENT for OPTIMAL bone health (and POTENTIALLY other health outcomes) in both the mother and off-spring, the FINDINGS of THE CURRENT STUDY SUPPORT the case for determining Vitamin D status and, IF NECESSARY, administering Vitamin D in t1dm pregnancy.']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 10), ('IMPORTANT_CONSIDERATION', 71), ('IMPORTANT_CONSIDERATION', 87), ('INCOMPLETE_EVIDENCE', 112), ('INCOMPLETE_EVIDENCE', 186), ('QUESTION_ANSWERED_BY_THIS_WORK', 198), ('INCOMPLETE_EVIDENCE', 216), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 271), ('IMPORTANT_CONSIDERATION', 274)]	10	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 249, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 299, 'vitamin D')]
S64-PMC3773018	PMC3773018	4/2013	S64-PMC3773018	['the MAJORITY of the Vitamin D REQUIREMENT for MOST People in the u.s. is achieved through both sun exposure and fortified Food or Vitamin D nutritional supplements.']	[('PROBABLE_UNDERSTANDING', 4), ('IMPORTANT_CONSIDERATION', 30), ('PROBABLE_UNDERSTANDING', 46)]	3	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 51, 'people'), ('CHEBI_33290', 'food', 122, 'food'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D')]
S65-PMC3773018	PMC3773018	4/2013	S65-PMC3773018	['toddlers’ patterns of physical activity (i.e., sun exposure) and dietary habits (i.e., supplementation) are more like their mothers’, WHILE infants obtain their Vitamin D mainly through fortified formula.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 134)]	1	[('CHEBI_27300', 'vitamin D', 161, 'vitamin D')]
S69-PMC3773018	PMC3773018	4/2013	S69-PMC3773018	['AS SUCH, IT IS POSSIBLE that SOME of the children in this study did not consume 1,000 ml Vitamin D-fortified formula per day, and were not Fed additional Vitamin D supplements to meet the RECOMMENDED intake of 400 iu/day for infants, children, and adolescents (30).']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 9), ('INCOMPLETE_EVIDENCE', 29), ('FUTURE_WORK', 188)]	4	[('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('GO_0007631', 'feeding behavior', 139, 'fed'), ('CHEBI_27300', 'vitamin D', 154, 'vitamin D')]
S0-PMC3798907	PMC3798907	8/2013	S0-PMC3798907	['COMPLEX EFFECTS of Vitamin E and vitamin c supplementation on in vitro neonatal Mononuclear Cell responses to allergens\n\nabstract\nlow maternal dietary Vitamin E (but not Vitamin C) Intake during Pregnancy HAS BEEN ASSOCIATED with increased in vitro Cord Blood Mononuclear Cell (Cbmc) proliferative responses, childhood wheezing and asthma.']	[('DIFFICULT_TASK', 0), ('SUPERFICIAL_RELATIONSHIP', 8), ('INCOMPLETE_EVIDENCE', 205), ('SUPERFICIAL_RELATIONSHIP', 214)]	4	[('CHEBI_28384', 'vitamin K', 19, 'Vitamin E'), ('CL_0000842', 'mononuclear cell', 80, 'Mononuclear Cell'), ('GO_0030061', 'mitochondrial crista', 80, 'Mononuclear'), ('CHEBI_27300', 'vitamin D', 151, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 170, 'vitamin C'), ('GO_0007631', 'feeding behavior', 181, 'intake'), ('GO_0007565', 'female pregnancy', 195, 'pregnancy'), ('CL_0002153', 'corneocyte', 249, 'cord'), ('UBERON_0002240', 'spinal cord', 249, 'cord'), ('CL_0000081', 'blood cell', 254, 'blood'), ('UBERON_0000178', 'blood', 254, 'blood'), ('CL_0000842', 'mononuclear cell', 260, 'mononuclear cell'), ('GO_0031097', 'medial cortex', 260, 'mononuclear'), ('CL_0002062', 'type I pneumocyte', 278, 'CBMC')]
S1-PMC3798907	PMC3798907	8/2013	S1-PMC3798907	['we INVESTIGATED WHETHER these ASSOCIATIONS REFLECT direct EFFECTS of Vitamin E by INVESTIGATING the EFFECTS of supplementing cbmc cultures with physiological concentrations of Vitamin E. cbmc from seventy neonates were cultured supplemented with either nothing, Α-Tocopherol or Ascorbic Acid.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 16), ('SUPERFICIAL_RELATIONSHIP', 30), ('SUPERFICIAL_RELATIONSHIP', 43), ('SUPERFICIAL_RELATIONSHIP', 58), ('QUESTION_ANSWERED_BY_THIS_WORK', 82), ('SUPERFICIAL_RELATIONSHIP', 100)]	7	[('CHEBI_27300', 'vitamin D', 69, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 176, 'vitamin E'), ('CHEBI_27725', 'butin', 262, 'α-tocopherol'), ('CHEBI_22652', 'ascorbic acid', 278, 'ascorbic acid')]
S3-PMC3798907	PMC3798907	8/2013	S3-PMC3798907	['IN GENERAL, Vitamin E supplementation was ASSOCIATED with a TREND for reduced proliferative responses after stimulation with Antigens and house dust mite, and with increased Proliferation after stimulation with timothy grass allergen.']	[('PROBABLE_UNDERSTANDING', 0), ('SUPERFICIAL_RELATIONSHIP', 42), ('INCOMPLETE_EVIDENCE', 60)]	3	[('CHEBI_27300', 'vitamin D', 12, 'vitamin E'), ('CHEBI_59132', 'antigen', 125, 'antigens'), ('GO_0008283', 'cell proliferation', 174, 'proliferation')]
S5-PMC3798907	PMC3798907	8/2013	S5-PMC3798907	['supplementation with Vitamin C had no effect on Cbmc Proliferation, BUT increased Ifn-Γ and Il-4 production, and decreased Il-10 production.']	[('ANOMALY_CURIOUS_FINDING', 68)]	1	[('CHEBI_27300', 'vitamin D', 21, 'vitamin C'), ('CL_0002062', 'type I pneumocyte', 48, 'CBMC'), ('GO_0008283', 'cell proliferation', 53, 'proliferation'), ('PR_000008920', 'interferon alpha-7', 82, 'IFN-γ'), ('GO_0015114', 'phosphate ion transmembrane transporter activity', 85, '- ... - ...'), ('PR_000001470', 'interleukin-28B', 92, 'IL-4'), ('PR_000001470', 'interleukin-28B', 123, 'IL-10')]
S17-PMC3798907	PMC3798907	8/2013	S17-PMC3798907	['ALTHOUGH keen to conduct such an intervention trial we considered it IMPORTANT to conduct PRELIMINARY work to justify/REFUTE the use of Vitamin E supplements for several reasons.']	[('ANOMALY_CURIOUS_FINDING', 0), ('IMPORTANT_CONSIDERATION', 69), ('INCOMPLETE_EVIDENCE', 90), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 118)]	4	[('CHEBI_27300', 'vitamin D', 136, 'vitamin E')]
S38-PMC3798907	PMC3798907	8/2013	S38-PMC3798907	['antioxidant supplementation was at final concentrations of 6.5 μmol/l for Α-Tocopherol and 44.11 μmol/l for Ascorbic Acid, corresponding to the Cord Blood 95th centile concentrations measured in the original general population study that REPORTED an ASSOCIATION between maternal Vitamin E intake and cbmc responses [18].']	[('INCOMPLETE_EVIDENCE', 238), ('SUPERFICIAL_RELATIONSHIP', 250)]	2	[('CHEBI_27725', 'butin', 74, 'α-tocopherol'), ('CHEBI_22652', 'ascorbic acid', 108, 'ascorbic acid'), ('UBERON_0009472', 'axilla', 144, 'cord blood'), ('CHEBI_27300', 'vitamin D', 279, 'vitamin E')]
S59-PMC3798907	PMC3798907	8/2013	S59-PMC3798907	['Vitamin E supplementation of cbmc\nthe addition of Vitamin E to 70 cbmc cultures REVEALED COMPLEX EFFECTS.']	[('INCOMPLETE_EVIDENCE', 80), ('DIFFICULT_TASK', 89), ('SUPERFICIAL_RELATIONSHIP', 97)]	3	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin E'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'Vitamin'), ('CHEBI_27300', 'vitamin D', 50, 'vitamin E')]
S65-PMC3798907	PMC3798907	8/2013	S65-PMC3798907	['significant p values for differences in responses between paired samples in cultures with or without Vitamin E supplementation are shown on the RELEVANT panels.nutrients-05-03337-t001_table 1\n\ncaption (table-wrap): table 1\n\nsummary table representing the mean responses of cbmc and Peripheral Blood Mononuclear Cell (Pbmc) samples to control stimuli and Allergens, after supplementation with Vitamin E or Vitamin C. the mean change in response is shown for 70 cbmc samples and 18 pbmc samples, after supplementation with Vitamin E, and for 51 cbmc and 18 pbmc samples, after supplementation with Vitamin C. significant p values for differences in responses between paired samples in cultures with or without Vitamin E/Vitamin C supplementation are shown on the RELEVANT panels.Vitamin eprolififn-γil-4il-10Tgf-βvitamin cprolififn-γil-4il-10tgf-β cordcord tg↑ p< 0.05↓ p< 0.05↓↓↑tg↑↑↑ p< 0.05↓↓hdm↓↓↓↓↑hdm↓↑↑↓ p< 0.05↓con a↓↑↓↓↑con a↓ p< 0.05↑↑↓↓ppd↓ p< 0.001↓↑↓↑ppd↓↑ p< 0.05↑ p< 0.05↓ p< 0.05↓klh↓ p< 0.001↓↓↓↑klh↓↑↑ p< 0.05↓↓ adultadult tg↓↑↑↑↑tg↑ p< 0.05↑↑↓↑hdm↓↑↑↑↑ p< 0.05hdm↓↑↑↓↑con a↓↓↑↓↑ p< 0.05con a↑↓ p< 0.05↑↓ p< 0.05↑ppd↑↓↑↓↑ppd↓↑↑↓↑klh↓↓↑↑↑klh↓↑↑ p< 0.05↓↑\noverall, there was a TREND for Antigen or allergen cbmc cultures supplemented with Vitamin E to exhibit decreased secretion of the cytokines Ifn-Γ, il-10 and Il-4 (figure 1andtable 1), ALTHOUGH Production Of Tgf-Β did NOT fit this pattern and was GENERALLY increased.']	[('IMPORTANT_CONSIDERATION', 144), ('IMPORTANT_CONSIDERATION', 761), ('INCOMPLETE_EVIDENCE', 1191), ('ANOMALY_CURIOUS_FINDING', 1355), ('ANOMALY_CURIOUS_FINDING', 1388), ('PROBABLE_UNDERSTANDING', 1417)]	6	[('CHEBI_27300', 'vitamin D', 101, 'vitamin E'), ('CL_0000111', 'peripheral neuron', 282, 'peripheral blood mononuclear cell'), ('UBERON_0012101', 'perinatal stage', 282, 'peripheral blood'), ('GO_0031097', 'medial cortex', 299, 'mononuclear'), ('CL_0002246', 'peripheral blood stem cell', 317, 'PBMC'), ('CHEBI_33663', 'cyclic hydrocarbon', 354, 'allergens'), ('CHEBI_27300', 'vitamin D', 392, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 405, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 521, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 596, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 708, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 718, 'vitamin C'), ('CHEBI_33229', 'vitamin (role)', 777, 'Vitamin'), ('PR_000000037', 'BMP receptor type-2', 803, '-10TGF'), ('CHEBI_59132', 'antigen', 1201, 'antigen'), ('CHEBI_27300', 'vitamin D', 1253, 'vitamin E'), ('PR_000008920', 'interferon alpha-7', 1311, 'IFN-γ'), ('PR_000001470', 'interleukin-28B', 1328, 'IL-4'), ('GO_0036309', 'protein localization to M-band', 1364, 'production of TGF-β'), ('PR_000000046', 'TGF-beta', 1378, 'TGF-β')]
S68-PMC3798907	PMC3798907	8/2013	S68-PMC3798907	['Vitamin E supplementation of Adult pbmc\nwhen the EFFECTS of Vitamin E supplementation were tested on pbmc responses, UNLIKE the results for cbmc, there were no consistent trends or significant differences in Proliferation induced by the set of T-Cell stimuli (figure 2andtable 1).']	[('SUPERFICIAL_RELATIONSHIP', 49), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 117)]	2	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin E'), ('UBERON_0007023', 'adult organism', 29, 'Adult'), ('CHEBI_27300', 'vitamin D', 60, 'vitamin E'), ('GO_0008283', 'cell proliferation', 208, 'proliferation'), ('CL_0000084', 'T cell', 244, 'T-cell')]
S69-PMC3798907	PMC3798907	8/2013	S69-PMC3798907	['LIKEWISE, there were no consistent trends in the EFFECTS of Vitamin E supplementation on cytokine responses by pbmc.']	[('SUPERFICIAL_RELATIONSHIP', 0), ('SUPERFICIAL_RELATIONSHIP', 49)]	2	[('CHEBI_27300', 'vitamin D', 60, 'vitamin E')]
S70-PMC3798907	PMC3798907	8/2013	S70-PMC3798907	['HOWEVER, just as for cbmc, there was a TREND for GENERALLY enhanced secretion of the Regulatory cytokine Tgf-Β when pbmc were supplemented with Vitamin E, and these increases were significant in the cultures responding to con a (13 of 17 cultures exhibiting an increase) or hdm, (13 of 17 cultures exhibiting an increase) (figure 2andtable 1).']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 39), ('PROBABLE_UNDERSTANDING', 49)]	3	[('GO_0065007', 'biological regulation', 85, 'regulatory'), ('PR_000000046', 'TGF-beta', 105, 'TGF-β'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin E')]
S72-PMC3798907	PMC3798907	8/2013	S72-PMC3798907	['vitamin c supplementation of cbmc\nfor comparison with the effects of Vitamin E, 51 cbmc cultures responding to the set of T-Cell stimuli were supplemented with Vitamin c. there was no general effect of Vitamin C on Proliferation, ALTHOUGH it did significantly reduce the proliferative response to con a (30 of 48 cultures demonstrating a decrease) (figure 3andtable 1).']	[('ANOMALY_CURIOUS_FINDING', 230)]	1	[('CHEBI_27300', 'vitamin D', 69, 'vitamin E'), ('CL_0000084', 'T cell', 122, 'T-cell'), ('CHEBI_33229', 'vitamin (role)', 160, 'vitamin'), ('CHEBI_27300', 'vitamin D', 202, 'vitamin C'), ('GO_0008283', 'cell proliferation', 215, 'proliferation')]
S73-PMC3798907	PMC3798907	8/2013	S73-PMC3798907	['UNLIKE Vitamin E supplementation, addition of Vitamin C was ASSOCIATED with a general TREND for increases in the Effector cytokines Ifn-Γ and Il-4, which was significant for both cytokines after ppd stimulation (Ifn-Γ: 26 of 43 cultures DEMONSTRATING an increase in Ifn-Γ, Il-4: 20 of 42 cultures), and for Il-4 in cultures responding to klh (21 of 41 cultures) or tg (20 of 46 cultures).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('SUPERFICIAL_RELATIONSHIP', 60), ('INCOMPLETE_EVIDENCE', 86), ('INCOMPLETE_EVIDENCE', 237)]	4	[('CHEBI_27300', 'vitamin D', 7, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 46, 'vitamin C'), ('CHEBI_35224', 'effector', 113, 'effector'), ('PR_000008920', 'interferon alpha-7', 132, 'IFN-γ'), ('PR_000001470', 'interleukin-28B', 142, 'IL-4'), ('PR_000008920', 'interferon alpha-7', 212, 'IFN-γ'), ('PR_000008920', 'interferon alpha-7', 266, 'IFN-γ'), ('PR_000001470', 'interleukin-28B', 273, 'IL-4'), ('PR_000001470', 'interleukin-28B', 307, 'IL-4')]
S75-PMC3798907	PMC3798907	8/2013	S75-PMC3798907	['the TREND for enhanced Tgf-Β Responses after Vitamin E supplementation was NOT REPLICATED for Vitamin C, which GENERALLY reduced Production Of this Regulatory Cytokine, (figure 3andtable 1).']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 75), ('PROBABLE_UNDERSTANDING', 111)]	3	[('GO_0033077', 'T cell differentiation in thymus', 23, 'TGF-β responses'), ('PR_000000046', 'TGF-beta', 23, 'TGF-β'), ('CHEBI_27300', 'vitamin D', 45, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin C'), ('GO_0008283', 'cell proliferation', 129, 'production of ...'), ('GO_0043654', 'recognition of apoptotic cell', 148, 'regulatory cytokine')]
S78-PMC3798907	PMC3798907	8/2013	S78-PMC3798907	['significant p values for differences in responses between paired samples in cultures with or without Vitamin E supplementation are shown on the RELEVANT panels.']	[('IMPORTANT_CONSIDERATION', 144)]	1	[('CHEBI_27300', 'vitamin D', 101, 'vitamin E')]
S81-PMC3798907	PMC3798907	8/2013	S81-PMC3798907	['significant p values for differences in responses between paired samples in cultures with or without Vitamin C supplementation are shown on the RELEVANT panels.']	[('IMPORTANT_CONSIDERATION', 144)]	1	[('CHEBI_27300', 'vitamin D', 101, 'vitamin C')]
S85-PMC3798907	PMC3798907	8/2013	S85-PMC3798907	['HOWEVER, as was the case for cbmc, in general, Vitamin C supplementation was ASSOCIATED with a TREND for an increase in cytokines characteristic of Th Effector Cells; Ifn-Γ and Il-4, which was significant for the Il-4 response to klh, (10 of 16 cultures) ALTHOUGH this trend was not universal and there was decreased Ifn-Γ after stimulation with con a (figure 4andtable 1).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('SUPERFICIAL_RELATIONSHIP', 77), ('INCOMPLETE_EVIDENCE', 95), ('ANOMALY_CURIOUS_FINDING', 255)]	5	"[('CHEBI_27300', 'vitamin D', 47, 'vitamin C'), ('CL_0000635', ""Deiter's cell"", 148, 'Th effector cells'), ('CHEBI_35224', 'effector', 151, 'effector'), ('PR_000008920', 'interferon alpha-7', 167, 'IFN-γ'), ('PR_000001470', 'interleukin-28B', 177, 'IL-4'), ('PR_000001470', 'interleukin-28B', 213, 'IL-4'), ('PR_000008920', 'interferon alpha-7', 317, 'IFN-γ')]"
S86-PMC3798907	PMC3798907	8/2013	S86-PMC3798907	['Production Of the Regulatory Cytokine Il-10 TENDED to be lower after Vitamin C supplementation of pbmc, significantly so for con a, WHEREAS, UNLIKE cbmc, there was a TREND for Tgf-Β secretion to be increased.']	[('SUPERFICIAL_RELATIONSHIP', 44), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 132), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 141), ('INCOMPLETE_EVIDENCE', 166)]	4	[('GO_0008283', 'cell proliferation', 0, 'Production of ...'), ('GO_0090106', 'pancreatic E cell fate commitment', 18, 'regulatory cytokine IL-'), ('PR_000001470', 'interleukin-28B', 38, 'IL-10'), ('CHEBI_27300', 'vitamin D', 69, 'vitamin C'), ('PR_000000046', 'TGF-beta', 176, 'TGF-β')]
S89-PMC3798907	PMC3798907	8/2013	S89-PMC3798907	['significant p values for differences in responses between paired samples in cultures with or without Vitamin C supplementation are shown on the RELEVANT panels.']	[('IMPORTANT_CONSIDERATION', 144)]	1	[('CHEBI_27300', 'vitamin D', 101, 'vitamin C')]
S91-PMC3798907	PMC3798907	8/2013	S91-PMC3798907	['summary of supplementation results\nthe COMPLEX results of supplementation of cbmc and pbmc cultures with Vitamins E and c are summarised for responses to the two Allergens hdm and tg infigure 5and intable 1.']	[('DIFFICULT_TASK', 39)]	1	[('CHEBI_27300', 'vitamin D', 105, 'vitamins E'), ('CHEBI_33663', 'cyclic hydrocarbon', 162, 'allergens')]
S93-PMC3798907	PMC3798907	8/2013	S93-PMC3798907	['it can be seen that the EFFECTS of Vitamin E supplementation on cbmc responses to these Allergens were GENERALLY inhibitory, with the NOTABLE EXCEPTIONS of stronger Proliferation to tg and increased secretion of the Regulatory cytokine Tgf-Β in cultures stimulated with either hdm or tg.']	[('SUPERFICIAL_RELATIONSHIP', 24), ('PROBABLE_UNDERSTANDING', 103), ('ANOMALY_CURIOUS_FINDING', 134), ('ANOMALY_CURIOUS_FINDING', 142)]	4	[('CHEBI_27300', 'vitamin D', 35, 'vitamin E'), ('CHEBI_33663', 'cyclic hydrocarbon', 88, 'allergens'), ('GO_0008283', 'cell proliferation', 165, 'proliferation'), ('GO_0065007', 'biological regulation', 216, 'regulatory'), ('PR_000000046', 'TGF-beta', 236, 'TGF-β')]
S94-PMC3798907	PMC3798907	8/2013	S94-PMC3798907	['IN CONTRAST, the pattern of EFFECTS of Vitamin E supplementation on pbmc responses was typified by increases in both th Effector and Regulatory cytokine responses.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('SUPERFICIAL_RELATIONSHIP', 28)]	2	[('CHEBI_27300', 'vitamin D', 39, 'vitamin E'), ('CHEBI_35224', 'effector', 120, 'effector'), ('GO_0065007', 'biological regulation', 133, 'regulatory')]
S96-PMC3798907	PMC3798907	8/2013	S96-PMC3798907	['caption (fig): figure 5\n\nsummary of differential EFFECTS of Vitamin E or C supplementation on cbmc or pbmc responses to Allergen.']	[('SUPERFICIAL_RELATIONSHIP', 49)]	1	[('CHEBI_27300', 'vitamin D', 60, 'vitamin E'), ('CHEBI_18245', 'carboxylato group', 73, 'C'), ('CHEBI_50904', 'allergen', 120, 'allergen')]
S102-PMC3798907	PMC3798907	8/2013	S102-PMC3798907	['before embarking on a Vitamin E intervention study during Pregnancy we wanted TO TEST WHETHER in vitro Vitamin E supplementation COULD Modulate Neonatal Immune Responses, REASONING that the demonstration of a direct EFFECT would justify Vitamin E supplementation, WHEREAS FAILURE to demonstrate a direct EFFECT would justify ALTERNATIVE dietary STRATEGIES to increase Vitamin E intake.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 78), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 86), ('INCOMPLETE_EVIDENCE', 129), ('PROBABLE_UNDERSTANDING', 171), ('PROBABLE_UNDERSTANDING', 171), ('SUPERFICIAL_RELATIONSHIP', 216), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 264), ('PROBLEM_COMPLICATION', 272), ('SUPERFICIAL_RELATIONSHIP', 304), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 325), ('FUTURE_WORK', 345)]	11	[('CHEBI_27300', 'vitamin D', 22, 'vitamin E'), ('GO_0007565', 'female pregnancy', 58, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 103, 'vitamin E'), ('GO_0065007', 'biological regulation', 135, 'modulate'), ('GO_0007567', 'parturition', 144, 'neonatal'), ('GO_0006955', 'immune response', 153, 'immune responses'), ('UBERON_0002405', 'immune system', 153, 'immune'), ('CHEBI_27300', 'vitamin D', 237, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 368, 'vitamin E')]
S105-PMC3798907	PMC3798907	8/2013	S105-PMC3798907	['this EXPLANATION PREDICTS that that Vitamin E supplementation of cbmc cultures would reduce proliferative responses.']	[('PROBABLE_UNDERSTANDING', 5), ('INCOMPLETE_EVIDENCE', 17)]	2	[('CHEBI_27300', 'vitamin D', 36, 'vitamin E')]
S106-PMC3798907	PMC3798907	8/2013	S106-PMC3798907	['HOWEVER, ALTHOUGH direct supplementation of cbmc with Vitamin E was ASSOCIATED with decreased proliferative responses to ppd, klh and hdm, there was an OPPOSITE EFFECT on Proliferation to the allergen tg.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 9), ('SUPERFICIAL_RELATIONSHIP', 68), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 152), ('SUPERFICIAL_RELATIONSHIP', 161)]	6	[('CHEBI_27300', 'vitamin D', 54, 'vitamin E'), ('GO_0008283', 'cell proliferation', 171, 'proliferation')]
S109-PMC3798907	PMC3798907	8/2013	S109-PMC3798907	['a further POSSIBILITY raised by THE CURRENT STUDY is that isolated maternal Vitamin E supplementation during Pregnancy MAY have MIXED or EVEN adverse CONSEQUENCES for atopic sensitisation to different Allergens.']	[('INCOMPLETE_EVIDENCE', 10), ('QUESTION_ANSWERED_BY_THIS_WORK', 32), ('INCOMPLETE_EVIDENCE', 119), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 128), ('ANOMALY_CURIOUS_FINDING', 137), ('PROBLEM_COMPLICATION', 150)]	6	[('CHEBI_27300', 'vitamin D', 76, 'vitamin E'), ('GO_0007565', 'female pregnancy', 109, 'pregnancy'), ('CHEBI_33663', 'cyclic hydrocarbon', 201, 'allergens')]
S110-PMC3798907	PMC3798907	8/2013	S110-PMC3798907	['this CONCERN is SUPPORTED by the RECENT report that high-dose Antenatal Vitamin C and E supplementation is ASSOCIATED with increased infant healthcare utilisation and cost of care [23].']	[('IMPORTANT_CONSIDERATION', 5), ('PROBLEM_COMPLICATION', 5), ('INCOMPLETE_EVIDENCE', 16), ('INCOMPLETE_EVIDENCE', 33), ('SUPERFICIAL_RELATIONSHIP', 107)]	5	[('GO_0007567', 'parturition', 62, 'antenatal'), ('CHEBI_27300', 'vitamin D', 72, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 86, 'E')]
S111-PMC3798907	PMC3798907	8/2013	S111-PMC3798907	['the DIFFERENTIAL EFFECTS of supplementation on hdm and tg responses EXCLUDES the POSSIBILITY that any suppressive EFFECTS of Vitamin E supplementation REPRESENT toxicity, which was also avoided by adding physiological concentrations representative of those measured in Cord Blood at Birth in the epidemiological study DEMONSTRATING an ASSOCIATION between Vitamin E and cbmc responses [18].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 4), ('SUPERFICIAL_RELATIONSHIP', 17), ('PROBABLE_UNDERSTANDING', 68), ('PROBABLE_UNDERSTANDING', 68), ('INCOMPLETE_EVIDENCE', 81), ('SUPERFICIAL_RELATIONSHIP', 114), ('PROBABLE_UNDERSTANDING', 151), ('INCOMPLETE_EVIDENCE', 318), ('SUPERFICIAL_RELATIONSHIP', 335)]	9	[('CHEBI_27300', 'vitamin D', 125, 'vitamin E'), ('UBERON_0002240', 'spinal cord', 269, 'cord'), ('UBERON_0000178', 'blood', 274, 'blood'), ('GO_0007567', 'parturition', 283, 'birth'), ('CHEBI_27300', 'vitamin D', 355, 'vitamin E')]
S114-PMC3798907	PMC3798907	8/2013	S114-PMC3798907	['this SEEMS an UNLIKELY EXPLANATION for the DIFFERENTIAL EFFECTS of Vitamin E supplementation on tg and hdm responses SEEN in the current work because, as in our original observational study, cbmc samples were collected throughout the year [12].']	[('ANOMALY_CURIOUS_FINDING', 5), ('PROBABLE_UNDERSTANDING', 14), ('PROBABLE_UNDERSTANDING', 23), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 43), ('SUPERFICIAL_RELATIONSHIP', 56), ('INCOMPLETE_EVIDENCE', 117)]	6	[('CHEBI_27300', 'vitamin D', 67, 'vitamin E')]
S115-PMC3798907	PMC3798907	8/2013	S115-PMC3798907	['the EFFECTS of Vitamin E supplementation of cbmc cultures on cytokine responses were also not straightforward.']	[('SUPERFICIAL_RELATIONSHIP', 4)]	1	[('CHEBI_27300', 'vitamin D', 15, 'vitamin E')]
S116-PMC3798907	PMC3798907	8/2013	S116-PMC3798907	['on the one hand, the POSSIBLE therapeutic use of Vitamin E to help produce a “balanced” Th-Cell profile in early Life is SUPPORTED by the FINDING that supplementation of cbmc with this Nutrient GENERALLY inhibited cytokines characteristic of Th Effector Responses, including both th1 (Ifn-Γ) and th2 (il-4) cytokines.']	[('INCOMPLETE_EVIDENCE', 21), ('INCOMPLETE_EVIDENCE', 121), ('INCOMPLETE_EVIDENCE', 138), ('PROBABLE_UNDERSTANDING', 194)]	4	[('CHEBI_27300', 'vitamin D', 49, 'vitamin E'), ('CL_0000545', 'T-helper 1 cell', 88, 'Th-cell'), ('UBERON_0000104', 'life cycle', 113, 'life'), ('CHEBI_33284', 'nutrient', 185, 'nutrient'), ('GO_0007596', 'blood coagulation', 242, 'Th ... responses'), ('CHEBI_35224', 'effector', 245, 'effector'), ('PR_000008920', 'interferon alpha-7', 285, 'IFN-γ')]
S122-PMC3798907	PMC3798907	8/2013	S122-PMC3798907	['ALTHOUGH the main FOCUS of our work was the supplementation of cbmc, we included a parallel study of Adult pbmc TO EXAMINE the EFFECT of the same in vitro Vitamin E supplementation on Adult Pbmc IN LIGHT OF the REPORTS of age RELATED differential responsiveness.']	[('ANOMALY_CURIOUS_FINDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 18), ('QUESTION_ANSWERED_BY_THIS_WORK', 112), ('SUPERFICIAL_RELATIONSHIP', 127), ('PROBABLE_UNDERSTANDING', 195), ('INCOMPLETE_EVIDENCE', 211), ('SUPERFICIAL_RELATIONSHIP', 226)]	7	[('UBERON_0007023', 'adult organism', 101, 'adult'), ('CHEBI_27300', 'vitamin D', 155, 'vitamin E'), ('UBERON_0007023', 'adult organism', 184, 'adult'), ('UBERON_2005026', 'primary head sinus', 190, 'PBMC')]
S123-PMC3798907	PMC3798907	8/2013	S123-PMC3798907	['Vitamin E supplementation STUDIES in Colorectal cancer HAVE REPORTED a more pronounced stimulatory EFFECT by Vitamin E on naïve (Cd45Ra(+)) Th-Cells as compared with T Cells with a Memory/activated phenotype (Cd45Ro(+)) [4].']	[('INCOMPLETE_EVIDENCE', 26), ('INCOMPLETE_EVIDENCE', 55), ('SUPERFICIAL_RELATIONSHIP', 99)]	3	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin E'), ('UBERON_0012652', 'colorectum', 37, 'colorectal'), ('CHEBI_27300', 'vitamin D', 109, 'vitamin E'), ('PR_000005164', 'CD2 cytoplasmic tail-binding protein 2', 129, 'CD45RA'), ('CL_0000545', 'T-helper 1 cell', 140, 'Th-cells'), ('CL_0000084', 'T cell', 166, 'T cells'), ('GO_0007613', 'memory', 181, 'memory'), ('PR_000005170', 'CD37 molecule', 209, 'CD45RO')]
S125-PMC3798907	PMC3798907	8/2013	S125-PMC3798907	['we FOUND NO CONVINCING evidence of differential responsiveness of cbmc and Adult Pbmc to Vitamin E supplementation; HOWEVER the dose of Vitamin E used in THE current study was CONSIDERABLY LESS than that REPORTED in PREVIOUS work [4].']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 9), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 116), ('QUESTION_ANSWERED_BY_THIS_WORK', 154), ('ANOMALY_CURIOUS_FINDING', 176), ('INCOMPLETE_EVIDENCE', 189), ('INCOMPLETE_EVIDENCE', 204), ('INCOMPLETE_EVIDENCE', 216)]	8	[('UBERON_0007023', 'adult organism', 75, 'adult'), ('UBERON_2005026', 'primary head sinus', 81, 'PBMC'), ('CHEBI_27300', 'vitamin D', 89, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin E')]
S129-PMC3798907	PMC3798907	8/2013	S129-PMC3798907	['the single supplemental Vitamin E dose was chosen because it would be representative, in a general population, of a clinically RELEVANT Vitamin E intervention resulting in a minimal twofold increase in Cord Blood Α-Tocopherol.']	[('IMPORTANT_CONSIDERATION', 127)]	1	[('CHEBI_27300', 'vitamin D', 24, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin E'), ('UBERON_0002240', 'spinal cord', 202, 'cord'), ('UBERON_0000178', 'blood', 207, 'blood'), ('CHEBI_27725', 'butin', 213, 'α-tocopherol')]
S136-PMC3798907	PMC3798907	8/2013	S136-PMC3798907	['the original ASSOCIATION between maternal Vitamin E and cbmc responses was INDEPENDENT of many POTENTIALLY CONFOUNDING FACTORS (Birth order, maternal atopy, maternal smoking, sex [12], and maternal bmi [27], MAKING IT UNLIKELY that any EFFECT of in vitro Vitamin E supplementation was being negated by extraneous factors, moreover the EFFECT of supplementation was compared with an unsupplemented control for each subject.']	[('SUPERFICIAL_RELATIONSHIP', 13), ('SUPERFICIAL_RELATIONSHIP', 75), ('INCOMPLETE_EVIDENCE', 95), ('PROBLEM_COMPLICATION', 107), ('PROBABLE_UNDERSTANDING', 208), ('PROBABLE_UNDERSTANDING', 218), ('SUPERFICIAL_RELATIONSHIP', 236), ('SUPERFICIAL_RELATIONSHIP', 335)]	8	[('CHEBI_27300', 'vitamin D', 42, 'vitamin E'), ('GO_0007567', 'parturition', 128, 'birth'), ('CHEBI_27300', 'vitamin D', 255, 'vitamin E')]
S139-PMC3798907	PMC3798907	8/2013	S139-PMC3798907	['a SMALL number ( n = 40) of Adult Pbmc samples were obtained to investigate a POSSIBLE age RELATED differential responsiveness to Vitamin E. consequently the concentrations of Ascorbate and Α-Tocopherol used to supplement these pbmc cultures, was the same as that used to supplement cbmc cultures, HOWEVER these levels are lower than those FOUND in the Plasma of healthy Adults, which COULD EXPLAIN the LACK OF EFFECTS SEEN in pbmc cultures.']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 78), ('SUPERFICIAL_RELATIONSHIP', 91), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 298), ('ANOMALY_CURIOUS_FINDING', 298), ('INCOMPLETE_EVIDENCE', 340), ('INCOMPLETE_EVIDENCE', 385), ('PROBABLE_UNDERSTANDING', 391), ('INCOMPLETE_EVIDENCE', 403), ('SUPERFICIAL_RELATIONSHIP', 411), ('INCOMPLETE_EVIDENCE', 419)]	11	[('UBERON_0007023', 'adult organism', 28, 'adult'), ('UBERON_2005026', 'primary head sinus', 34, 'PBMC'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin E'), ('CHEBI_22651', 'ascorbate', 176, 'ascorbate'), ('CHEBI_27725', 'butin', 190, 'α-tocopherol'), ('UBERON_0001969', 'blood plasma', 353, 'plasma'), ('UBERON_0007023', 'adult organism', 371, 'adults')]
S148-PMC3798907	PMC3798907	8/2013	S148-PMC3798907	['in THE CURRENT STUDY, the EFFECTS of in vitro Vitamin E supplementation on cbmc and pbmc Effector cytokine responses did DIFFER, BUT the EFFECTS of in vitro Vitamin C supplementation were broadly SIMILAR in neonates and Adults.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('SUPERFICIAL_RELATIONSHIP', 26), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 121), ('ANOMALY_CURIOUS_FINDING', 129), ('SUPERFICIAL_RELATIONSHIP', 137), ('SUPERFICIAL_RELATIONSHIP', 196)]	6	[('CHEBI_27300', 'vitamin D', 46, 'vitamin E'), ('CHEBI_35224', 'effector', 89, 'effector'), ('CHEBI_33229', 'vitamin (role)', 157, 'vitamin'), ('CHEBI_18245', 'carboxylato group', 165, 'C'), ('UBERON_0007023', 'adult organism', 220, 'adults')]
S151-PMC3798907	PMC3798907	8/2013	S151-PMC3798907	['conclusions\noverall, THIS WORK DEMONSTRATES that in vitro supplementation of cbmc with Vitamins E or C CAN INFLUENCE their Immune function but NOT in the simple and consistent manner predicted by models arising from observational epidemiological studies.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 21), ('INCOMPLETE_EVIDENCE', 31), ('QUESTION_ANSWERED_BY_THIS_WORK', 31), ('INCOMPLETE_EVIDENCE', 103), ('SUPERFICIAL_RELATIONSHIP', 107), ('ANOMALY_CURIOUS_FINDING', 143)]	6	[('CHEBI_27300', 'vitamin D', 87, 'vitamins E'), ('CHEBI_18245', 'carboxylato group', 101, 'C'), ('UBERON_0002405', 'immune system', 123, 'immune')]
S154-PMC3798907	PMC3798907	8/2013	S154-PMC3798907	['the FINDINGS of THE CURRENT STUDY have changed the direction of our Vitamin E based intervention away from supplementation, towards dietary intervention, with Vitamin E in its natural Food based form [33].']	[('INCOMPLETE_EVIDENCE', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 16)]	2	[('CHEBI_27300', 'vitamin D', 68, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 159, 'vitamin E'), ('CHEBI_33290', 'food', 184, 'food')]
S18-PMC3809191	PMC3809191	1/2013	S18-PMC3809191	['Pregnant women with history of Pregestational diabetes, multiple Pregnancies, fetal abnormality, chronic Renal or Liver failure and history of Consumption of Calcium supplements or Vitamin D were EXCLUDED from the study.']	[('INCOMPLETE_EVIDENCE', 196)]	1	[('GO_0007565', 'female pregnancy', 0, 'Pregnant'), ('GO_0007565', 'female pregnancy', 31, 'pregestational'), ('GO_0007565', 'female pregnancy', 65, 'pregnancies'), ('UBERON_0002113', 'kidney', 105, 'renal'), ('UBERON_0002107', 'liver', 114, 'liver'), ('GO_0007631', 'feeding behavior', 143, 'consumption'), ('CHEBI_22313', 'alkaline earth metal atom', 158, 'calcium'), ('CHEBI_27300', 'vitamin D', 181, 'vitamin D')]
S55-PMC3809191	PMC3809191	1/2013	S55-PMC3809191	['in ONE cross-sectional STUDY, Serum 25(Oh) D levels during 24-28 weeks of Gestation were lower in gdm women than in nondiabetic Pregnant women.9in ANOTHER STUDY, maternal Serum 25 (Oh) D concentrations measured at the time of gdm screening test were significantly and inversely ASSOCIATED with fasting glucose, ALTHOUGH the ASSOCIATION of Vitamin D with gdm risk was not statistically significant.8our FINDINGS are also CONSISTENT with a study in an indian population, SHOWING no significant ASSOCIATION between 25 (Oh) D concentrations (at 30 weeks of Gestation) and gdm risk.6\ndeficiency of Vitamin D was shown to be ASSOCIATED with fetal and Brain growth deficiency and type 1 diabetes in children.13significantly reduced risk of type 1 Diabetes Mellitus Development was FOUND when high doses of Vitamin D supplementation (up to 2000 iu/d) were given during infancy in a Birth-cohort study.14\nVitamin D deficiency was also ASSOCIATED with INCREASED risk for Pregnancy complications and SERIOUS health PROBLEMS in the offspring.5,15-17higher risks of Preeclampsia and cesarean section ratios were shown in Pregnants with low levels of Vitamin D.16,17moreover supplementation of Vitamin D HAS BEEN DEMONSTRATED to decrease the RISK of Preeclampsia by 27% in a STUDY.18\n\ncaption (fig): fig.1\n\nthe correlation between Serum Vitamin D and pth levels\n\ncaption (fig): fig.2\n\nSerum Vitamin D levels in veiled and nonveiled Pregnant\n\ncaption (fig): fig.3\n\nVitamin D levels and the frequency of muscle cramps (x²=3.57, p=0.05).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 3), ('INCOMPLETE_EVIDENCE', 23), ('INCOMPLETE_EVIDENCE', 147), ('SUPERFICIAL_RELATIONSHIP', 278), ('ANOMALY_CURIOUS_FINDING', 311), ('SUPERFICIAL_RELATIONSHIP', 324), ('INCOMPLETE_EVIDENCE', 402), ('INCOMPLETE_EVIDENCE', 420), ('INCOMPLETE_EVIDENCE', 469), ('SUPERFICIAL_RELATIONSHIP', 492), ('SUPERFICIAL_RELATIONSHIP', 619), ('INCOMPLETE_EVIDENCE', 774), ('SUPERFICIAL_RELATIONSHIP', 926), ('IMPORTANT_CONSIDERATION', 942), ('IMPORTANT_CONSIDERATION', 989), ('IMPORTANT_CONSIDERATION', 1004), ('INCOMPLETE_EVIDENCE', 1190), ('IMPORTANT_CONSIDERATION', 1228), ('INCOMPLETE_EVIDENCE', 1261)]	19	[('UBERON_0001977', 'blood serum', 30, 'serum'), ('CHEBI_71657', 'versiconol acetate', 36, '25(OH) D'), ('PR_000008838', 'serine protease HTRA1', 36, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 74, 'gestation'), ('GO_0007565', 'female pregnancy', 128, 'pregnant'), ('UBERON_0001977', 'blood serum', 171, 'serum'), ('CHEBI_71657', 'versiconol acetate', 177, '25 (OH) D'), ('PR_000009880', 'Lon protease, mitochondrial', 177, '25 ... OH ... D'), ('CHEBI_28384', 'vitamin K', 339, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 339, 'Vitamin'), ('CHEBI_71657', 'versiconol acetate', 512, '25 (OH) D'), ('GO_0007565', 'female pregnancy', 553, 'gestation'), ('CHEBI_27300', 'vitamin D', 593, 'vitamin D'), ('UBERON_0000955', 'brain', 645, 'brain'), ('GO_1903709', 'uterine gland development', 740, 'diabetes mellitus development'), ('CHEBI_27300', 'vitamin D', 799, 'vitamin D'), ('GO_0007567', 'parturition', 874, 'birth'), ('CHEBI_28384', 'vitamin K', 896, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 961, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 1053, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 1108, 'pregnants'), ('CHEBI_28384', 'vitamin K', 1137, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 1180, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 1236, 'preeclampsia'), ('UBERON_0001977', 'blood serum', 1317, 'serum'), ('CHEBI_28384', 'vitamin K', 1323, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 1323, 'Vitamin D'), ('UBERON_0001977', 'blood serum', 1371, 'Serum'), ('CHEBI_28384', 'vitamin K', 1377, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 1377, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 1418, 'pregnant'), ('CHEBI_28384', 'vitamin K', 1450, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 1450, 'Vitamin D')]
S124-PMC3814422	PMC3814422	10/2013	S124-PMC3814422	['for instance, it HAS BEEN SUGGESTED that there is a NEED to DISTINGUISH between Serum 25(Oh)D and EFFECTS of Vitamin D supplementation, the former being a prohormone representing a physiological state that is only relevant at extremely high or low levels, and the latter representing the non-physiological action of interest4.']	[('INCOMPLETE_EVIDENCE', 17), ('FUTURE_WORK', 52), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 60), ('SUPERFICIAL_RELATIONSHIP', 98)]	4	[('UBERON_0001977', 'blood serum', 80, 'serum'), ('CHEBI_71657', 'versiconol acetate', 86, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 86, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 109, 'vitamin D')]
S140-PMC3814422	PMC3814422	10/2013	S140-PMC3814422	['WHILST definitive evidence will ONLY come from randomized trials of Vitamin D supplementation during Pregnancy, which are currently underway (e.g.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 32)]	2	[('CHEBI_27300', 'vitamin D', 68, 'vitamin D'), ('GO_0007565', 'female pregnancy', 101, 'pregnancy')]
S6-PMC3827489	PMC3827489	10/2013	S6-PMC3827489	['in conclusion, given the IMPORTANT ROLE of Vitamin D in childhood health, more time spent in outdoor activity (for sunlight exposure) and Vitamin D supplementation MAY be NECESSARY for optimal health in infants, children, and adolescents.']	[('IMPORTANT_CONSIDERATION', 25), ('SUPERFICIAL_RELATIONSHIP', 35), ('INCOMPLETE_EVIDENCE', 164), ('IMPORTANT_CONSIDERATION', 171)]	4	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 138, 'vitamin D')]
S40-PMC3827489	PMC3827489	10/2013	S40-PMC3827489	['a RECENT STUDY based on the knhanes iv 2008-2009 examining a total of 1,510 healthy adolescents aged 12-18 years (806 male subjects and 704 female subjects; mean age, 14.7 years) ASSESSED that the prevalence of Vitamin D deficiency (25[Oh]D<20.0 ng/ml) was 89.1% in spring, 53.7% in summer, 63.9% in autumn, and 90.5% in winter, and that independent PREDICTORS for low Vitamin D status were season (winter), higher education level, and a lack of Vitamin D supplementation22).']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 179), ('SUPERFICIAL_RELATIONSHIP', 350)]	3	[('CHEBI_27300', 'vitamin D', 211, 'vitamin D'), ('CHEBI_15643', '(6R)-6-(L-erythro-1,2-dihydroxypropyl)-7,8-dihydro-6H-pterin', 233, '25[OH]D'), ('CHEBI_27300', 'vitamin D', 369, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 446, 'vitamin D')]
S70-PMC3827489	PMC3827489	10/2013	S70-PMC3827489	['IN CONTRAST, a cochrane review REPORTED that Vitamin D supplementation in patients diagnosed with tuberculosis did not alter the rates of Sputum smear Conversion in Adults or body weight in children47).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 31)]	2	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('UBERON_0007311', 'sputum', 138, 'sputum'), ('GO_0006936', 'muscle contraction', 151, 'conversion'), ('UBERON_0007023', 'adult organism', 165, 'adults')]
S74-PMC3827489	PMC3827489	10/2013	S74-PMC3827489	['a randomized placebo-controlled prospective study by majak et al.50)SHOWED that Vitamin D supplementation (500 iu of Cholecalciferol) daily for 6 months reduced the risk of bronchial asthma exacerbation triggered by acute Respiratory Tract infection.']	[('INCOMPLETE_EVIDENCE', 68)]	1	[('CHEBI_27300', 'vitamin D', 80, 'vitamin D'), ('CHEBI_52550', 'theopalauamide', 117, 'cholecalciferol'), ('UBERON_0000065', 'respiratory tract', 222, 'respiratory tract')]
S75-PMC3827489	PMC3827489	10/2013	S75-PMC3827489	['these observational and clinical studies INDICATE a beneficial EFFECT of Vitamin D supplementation in Vitamin D deficient children with asthma or acute or chronic Respiratory infections.']	[('INCOMPLETE_EVIDENCE', 41), ('SUPERFICIAL_RELATIONSHIP', 63)]	2	[('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 163, 'respiratory')]
S79-PMC3827489	PMC3827489	10/2013	S79-PMC3827489	['SOME obesity-related health consequences HAVE BEEN CORRELATED with Vitamin D deficiency or insufficiency5,52-54), and RECENT reports have SUGGESTED that Vitamin D supplementation MAY reduce these RISKS, ALTHOUGH the data are INCONSISTENT55,56).']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 41), ('SUPERFICIAL_RELATIONSHIP', 51), ('INCOMPLETE_EVIDENCE', 118), ('INCOMPLETE_EVIDENCE', 138), ('INCOMPLETE_EVIDENCE', 179), ('IMPORTANT_CONSIDERATION', 196), ('ANOMALY_CURIOUS_FINDING', 203), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 225)]	9	[('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 153, 'vitamin D')]
S86-PMC3827489	PMC3827489	10/2013	S86-PMC3827489	['moreover, a randomized clinical trial determining the efficacy of Vitamin D supplementation in obese adolescents SHOWED that supplementation of 4,000 iu Vitamin D3/day for 6 months significantly improved Insulin sensitivity60).']	[('INCOMPLETE_EVIDENCE', 113)]	1	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('CHEBI_33279', 'vitamin D5', 153, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 153, 'vitamin D3'), ('PR_000045358', 'insulin family protein', 204, 'insulin')]
S87-PMC3827489	PMC3827489	10/2013	S87-PMC3827489	['taken TOGETHER, THESE FINDINGS SUGGEST that PUBLIC HEALTH INTERVENTIONS such as outdoor activity and Vitamin D supplementation, which enhance Vitamin D status, MAY improve the health of adolescents with Metabolic PROBLEMS.']	[('INCOMPLETE_EVIDENCE', 6), ('INCOMPLETE_EVIDENCE', 16), ('INCOMPLETE_EVIDENCE', 31), ('IMPORTANT_CONSIDERATION', 44), ('FUTURE_WORK', 58), ('INCOMPLETE_EVIDENCE', 160), ('IMPORTANT_CONSIDERATION', 213)]	7	[('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 142, 'vitamin D'), ('GO_0008152', 'metabolic process', 203, 'metabolic')]
S97-PMC3827489	PMC3827489	10/2013	S97-PMC3827489	['RECOMMENDATION of Vitamin D supplementation for infants, children, and adolescents\nRECENTLY, the american academy of pediatrics (aap) RECOMMENDED that all infants (beginning soon after Birth), children, and adolescents have a minimum daily intake of 400 iu (10 µg) of Vitamin D74), which is two times the previous recommended dose of Vitamin D supplementation SUGGESTED in a 2003 clinical report from the aap.']	[('FUTURE_WORK', 0), ('INCOMPLETE_EVIDENCE', 83), ('FUTURE_WORK', 134), ('INCOMPLETE_EVIDENCE', 360)]	4	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('GO_0007567', 'parturition', 185, 'birth'), ('CHEBI_33279', 'vitamin D5', 268, 'vitamin D74'), ('CHEBI_27300', 'vitamin D', 334, 'vitamin D')]
S100-PMC3827489	PMC3827489	10/2013	S100-PMC3827489	['it is NOT KNOWN, however, HOW much amount of Vitamin D supplementation is NEEDED for korean children and Pregnant women in order to maintain adequate concentrations of vitamin D. CONSIDERING the high prevalence of Vitamin D insufficiency or deficiency in koreans, ESPECIALLY children and adolscents6,22-24), this ISSUE NEEDS TO BE addressed URGENTLY by FUTURE STUDIES.']	[('FULL_UNKNOWN', 6), ('EXPLICIT_QUESTION', 26), ('IMPORTANT_CONSIDERATION', 74), ('INCOMPLETE_EVIDENCE', 179), ('IMPORTANT_CONSIDERATION', 264), ('PROBLEM_COMPLICATION', 313), ('IMPORTANT_CONSIDERATION', 319), ('IMPORTANT_CONSIDERATION', 341), ('FUTURE_WORK', 353)]	9	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('GO_0007565', 'female pregnancy', 105, 'pregnant'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 176, 'D'), ('CHEBI_27300', 'vitamin D', 214, 'vitamin D')]
S103-PMC3827489	PMC3827489	10/2013	S103-PMC3827489	['from a perspective of integrative childhood care, it MAY BE advantageous to RECOMMEND more time spent in outdoor activity for sunlight exposure and increased Vitamin D supplementation to achieve OPTIMAL health in children and adolescents.']	[('INCOMPLETE_EVIDENCE', 53), ('FUTURE_WORK', 76), ('IMPORTANT_CONSIDERATION', 195)]	3	[('CHEBI_27300', 'vitamin D', 158, 'vitamin D')]
S146-PMC3829207	PMC3829207	11/2013	S146-PMC3829207	['again, strict monitoring IS NEEDED to prevent Vitamin A and D toxicity in case of excessive Supplements [39].']	[('FUTURE_WORK', 25)]	1	[('CHEBI_27300', 'vitamin D', 46, 'vitamin A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 60, 'D'), ('CHEBI_33341', 'titanium atom', 92, 'supplements')]
S30-PMC3829803	PMC3829803	11/2013	S30-PMC3829803	['in the last 2 decades, MANY STUDIES have DOCUMENTED the beneficial EFFECTS of Vitamin A supplements on general mortality and/or morbidity in young children in a wide range of developing countries.']	[('INCOMPLETE_EVIDENCE', 23), ('INCOMPLETE_EVIDENCE', 41), ('SUPERFICIAL_RELATIONSHIP', 67)]	3	[('CHEBI_27300', 'vitamin D', 78, 'vitamin A')]
S31-PMC3829803	PMC3829803	11/2013	S31-PMC3829803	['in 2000, a meta-analysis of eight studies DEMONSTRATED an overall 30% reduction in infant mortality attributable to Vitamin A supplements [13]–[15].']	[('INCOMPLETE_EVIDENCE', 42)]	1	[('CHEBI_27300', 'vitamin D', 116, 'vitamin A')]
S32-PMC3829803	PMC3829803	11/2013	S32-PMC3829803	['a SURPRISING spin-OFF from these Vitamin A supplementation STUDIES was the re-discovery that Vitamin A ‘treatment’ CAN significantly decrease the morbidity and mortality ASSOCIATED with acute Mev infection [16]–[19].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 2), ('ANOMALY_CURIOUS_FINDING', 2), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 18), ('INCOMPLETE_EVIDENCE', 59), ('INCOMPLETE_EVIDENCE', 115), ('SUPERFICIAL_RELATIONSHIP', 170)]	6	[('CHEBI_27300', 'vitamin D', 33, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 93, 'vitamin A'), ('NCBITaxon_10088', 'Mus <genus>', 192, 'MeV')]
S33-PMC3829803	PMC3829803	11/2013	S33-PMC3829803	['the mechanism UNDERLYING the positive EFFECTS of Vitamin A supplements and treatment in measles are not well understood [13].']	[('SUPERFICIAL_RELATIONSHIP', 14), ('SUPERFICIAL_RELATIONSHIP', 38)]	2	[('CHEBI_27300', 'vitamin D', 49, 'vitamin A')]
S163-PMC3829803	PMC3829803	11/2013	S163-PMC3829803	['IN FACT, both Vitamin A supplementation and therapy APPEAR TO have SIGNIFICANT clinical BENEFIT in natural Mev infection [16]–[19,21].']	[('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 52), ('IMPORTANT_CONSIDERATION', 67), ('IMPORTANT_CONSIDERATION', 88)]	4	[('CHEBI_27300', 'vitamin D', 14, 'vitamin A'), ('NCBITaxon_10088', 'Mus <genus>', 107, 'MeV')]
S165-PMC3829803	PMC3829803	11/2013	S165-PMC3829803	['ALTHOUGH reduced mortality from diarrheal disease is ASSOCIATED with Vitamin A supplements in children of the developing world this BENEFIT APPEARS TO BE due largely to milder bacterial infections [14,62,63].']	[('ANOMALY_CURIOUS_FINDING', 0), ('SUPERFICIAL_RELATIONSHIP', 53), ('IMPORTANT_CONSIDERATION', 132), ('ANOMALY_CURIOUS_FINDING', 140)]	4	[('CHEBI_27300', 'vitamin D', 69, 'vitamin A')]
S168-PMC3829803	PMC3829803	11/2013	S168-PMC3829803	['Perinatal Vitamin A Supplements in hiv-positive women CAN improve the survival of the seronegative children but CAN increase Mother-To-Child Hiv Transmission [65], POSSIBLY through increased Viral loads in Breast Milk [66].']	[('INCOMPLETE_EVIDENCE', 54), ('INCOMPLETE_EVIDENCE', 112), ('INCOMPLETE_EVIDENCE', 164)]	3	[('GO_0036268', 'swimming', 0, 'Perinatal'), ('UBERON_0012101', 'perinatal stage', 0, 'Perinatal'), ('CHEBI_27300', 'vitamin D', 10, 'vitamin A'), ('CHEBI_33341', 'titanium atom', 20, 'supplements'), ('GO_0007063', 'regulation of sister chromatid cohesion', 125, 'mother-to-child HIV transmission'), ('NCBITaxon_1', 'root', 191, 'viral'), ('UBERON_0001348', 'brown adipose tissue', 206, 'breast milk')]
S172-PMC3829803	PMC3829803	11/2013	S172-PMC3829803	['both Vitamin A supplementation and treatment have either no or negative EFFECTS on Respiratory Tract infections including the Common paramyxovirus, Respiratory syncytial virus (Rsv) [72]–[74].']	[('SUPERFICIAL_RELATIONSHIP', 72)]	1	[('CHEBI_27300', 'vitamin D', 5, 'vitamin A'), ('UBERON_0000065', 'respiratory tract', 83, 'respiratory tract'), ('NCBITaxon_33208', 'Metazoa', 126, 'common'), ('UBERON_0001004', 'respiratory system', 148, 'respiratory'), ('NCBITaxon_10088', 'Mus <genus>', 177, 'RSV')]
S115-PMC3855580	PMC3855580	10/2013	S115-PMC3855580	['in the ONLY data from a randomised controlled trial, children of women in nepal who were supplemented with Vitamin A plus Folic Acid from early Gestation had less microalbuminuria and a lower prevalence of Metabolic syndrome at 6–8\xa0years than children of mothers supplemented with Vitamin A alone [29].']	[('INCOMPLETE_EVIDENCE', 7)]	1	[('CHEBI_27300', 'vitamin D', 107, 'vitamin A'), ('CHEBI_30751', 'formic acid', 122, 'folic acid'), ('GO_0007565', 'female pregnancy', 144, 'gestation'), ('GO_0008152', 'metabolic process', 206, 'metabolic'), ('CHEBI_27300', 'vitamin D', 281, 'vitamin A')]
S13-PMC3873449	PMC3873449	12/2013	S13-PMC3873449	['HOWEVER, neither prolonging the time of sunlight exposure nor Multivitamin supplements CAN effectively prevent Pregnant women from Vitamin D deficiency.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 87)]	2	[('CHEBI_7025', 'mupirocin', 62, 'multivitamin'), ('GO_0007565', 'female pregnancy', 111, 'pregnant'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D')]
S169-PMC3873449	PMC3873449	12/2013	S169-PMC3873449	['it HAS BEEN REPORTED that Vitamin D supplementation CAN EFFECTIVELY improve Vitamin D status [36].']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 52), ('IMPORTANT_CONSIDERATION', 56)]	4	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin D')]
S170-PMC3873449	PMC3873449	12/2013	S170-PMC3873449	['a RECENT randomized clinical TRIAL in non-western immigrants in the netherlands (none asian) FOUND Vitamin D supplementation to be more EFFECTIVE than advised sunlight exposure for treating Vitamin D deficiency [37].']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 93), ('SUPERFICIAL_RELATIONSHIP', 136)]	3	[('CHEBI_27300', 'vitamin D', 99, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 190, 'vitamin D')]
S172-PMC3873449	PMC3873449	12/2013	S172-PMC3873449	['the Supplements in our study used were most commonly Pregnancy-specific multivitamins, containing relatively low doses of Vitamin D (between 5 and 12·5 μg/d), OBVIOUSLY, which does not effectively alter the outcome of high prevalence of Vitamin D deficiency.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 159)]	1	[('CHEBI_33341', 'titanium atom', 4, 'supplements'), ('GO_0007565', 'female pregnancy', 53, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 122, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 237, 'vitamin D')]
S173-PMC3873449	PMC3873449	12/2013	S173-PMC3873449	['appropriate dose of Vitamin D supplementation for women MAY BE REQUIRED.']	[('INCOMPLETE_EVIDENCE', 56), ('IMPORTANT_CONSIDERATION', 63)]	2	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D')]
S180-PMC3873449	PMC3873449	12/2013	S180-PMC3873449	['HOWEVER, EVEN with supplementation, ONLY a SMALL percentage of women and babies were Vitamin D sufficient.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 9), ('ANOMALY_CURIOUS_FINDING', 36), ('INCOMPLETE_EVIDENCE', 36), ('INCOMPLETE_EVIDENCE', 43)]	6	[('CHEBI_27300', 'vitamin D', 85, 'vitamin D')]
S182-PMC3873449	PMC3873449	12/2013	S182-PMC3873449	['HOWEVER, in Pregnant women, a study evaluating Plasma Vitamin D status HAS SHOWN that Vitamin D supplementation of <2000 iu/day is not EFFECTIVE in achieving sufficiency [42].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 71), ('SUPERFICIAL_RELATIONSHIP', 135)]	3	[('GO_0007565', 'female pregnancy', 12, 'pregnant'), ('UBERON_0001969', 'blood plasma', 47, 'plasma'), ('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 86, 'vitamin D')]
S183-PMC3873449	PMC3873449	12/2013	S183-PMC3873449	['ANOTHER STUDY SHOWED that Vitamin D supplementation of 4000 iu/day for Pregnant women is MOST EFFECTIVE in achieving sufficiency in all women REGARDLESS OF race [43].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 14), ('PROBABLE_UNDERSTANDING', 89), ('SUPERFICIAL_RELATIONSHIP', 94), ('INCOMPLETE_EVIDENCE', 142)]	5	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('GO_0007565', 'female pregnancy', 71, 'pregnant')]
S184-PMC3873449	PMC3873449	12/2013	S184-PMC3873449	['in 2011, the us endocrine society endorsed the need for at LEAST 600 iu(15 ug)/ day of Vitamin D supplementation for women during Pregnancy and up to 1500–2000 iu/day to maintain 25(Oh)D Blood levels above 30 ng/ml [16].']	[('PROBABLE_UNDERSTANDING', 59)]	1	[('CHEBI_27300', 'vitamin D', 87, 'vitamin D'), ('GO_0007565', 'female pregnancy', 130, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 179, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 179, '25(OH)D'), ('UBERON_0000178', 'blood', 187, 'blood')]
S187-PMC3873449	PMC3873449	12/2013	S187-PMC3873449	['ON THE BASIS of THESE FINDINGS, it SEEMS logical that Pregnant women SHOULD routinely be supplemented with Vitamin D in china.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 16), ('ANOMALY_CURIOUS_FINDING', 35), ('FUTURE_WORK', 69)]	4	[('GO_0007565', 'female pregnancy', 54, 'pregnant'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin D')]
S188-PMC3873449	PMC3873449	12/2013	S188-PMC3873449	['HOWEVER, SINCE there is INSUFFICIENT DATA to evaluate the EFFECTIVENESS of Vitamin D supplementation during Pregnancy Vitamin D supplementation as routine Antenatal care is YET TO BE DETERMINED.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('PROBLEM_COMPLICATION', 9), ('INCOMPLETE_EVIDENCE', 24), ('SUPERFICIAL_RELATIONSHIP', 58), ('FULL_UNKNOWN', 173)]	5	[('CHEBI_27300', 'vitamin D', 75, 'vitamin D'), ('GO_0007565', 'female pregnancy', 108, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 118, 'vitamin D'), ('GO_0007567', 'parturition', 155, 'antenatal')]
S189-PMC3873449	PMC3873449	12/2013	S189-PMC3873449	['FURTHER high quality randomized TRIALS ARE REQUIRED to evaluate the SAFETY and effectiveness of Vitamin D supplementation in Pregnancy.']	[('FUTURE_WORK', 0), ('IMPORTANT_CONSIDERATION', 68)]	2	[('CHEBI_27300', 'vitamin D', 96, 'vitamin D'), ('GO_0007565', 'female pregnancy', 125, 'pregnancy')]
S213-PMC3873449	PMC3873449	12/2013	S213-PMC3873449	['IMPORTANTLY, we did have the INFORMATION on multivitamin supplement usage, which allowed us to SHOW that WHILE Pregnancy-specific multivitamin supplements improve the status in women at low risk of severe Vitamin D deficiency, it does not prevent women from Vitamin D deficiency in winter.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 29), ('INCOMPLETE_EVIDENCE', 95), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 105)]	4	[('GO_0007565', 'female pregnancy', 111, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 205, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 258, 'vitamin D')]
S2-PMC3882256	PMC3882256	1/2014	S2-PMC3882256	['objective\nTO EXAMINE the RELATIONSHIP between Maternal Pregnancy dietary and supplement iron Intake and hemoglobin, with offspring’s Arterial stiffness (measured by Carotid-radial pulse wave velocity), Endothelial function (measured by Brachial Artery flow mediated dilatation), Blood pressure, and adiposity (measured by body mass index), test for mediation by cord ferritin, Birth weight, Gestational age, and child dietary iron intake, and for EFFECT modification by maternal Vitamin C intake and offspring sex.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 10), ('SUPERFICIAL_RELATIONSHIP', 25), ('SUPERFICIAL_RELATIONSHIP', 447)]	3	[('GO_0007618', 'mating', 46, 'maternal'), ('GO_0007565', 'female pregnancy', 55, 'pregnancy'), ('GO_0007631', 'feeding behavior', 93, 'intake'), ('UBERON_0001637', 'artery', 133, 'arterial'), ('UBERON_0005396', 'carotid artery segment', 165, 'carotid'), ('UBERON_0001986', 'endothelium', 202, 'endothelial'), ('UBERON_0001398', 'brachial artery', 236, 'brachial artery'), ('UBERON_0000178', 'blood', 279, 'blood'), ('GO_0007567', 'parturition', 377, 'birth'), ('GO_0007565', 'female pregnancy', 391, 'gestational'), ('CHEBI_27300', 'vitamin D', 479, 'vitamin C')]
S86-PMC3882256	PMC3882256	1/2014	S86-PMC3882256	['women with dietary iron intake equal to or more than the uk reference Nutrient intake for iron were more LIKELY to be older, vegetarian, with higher educational qualification, report higher total energy and Vitamin C intake, have lower pre-Pregnancy body mass index, and were less LIKELY to smoke during Pregnancy.10.1371/journal.pone.0084684.t001\n\ncaption (table-wrap): table 1\nstudy sample characteristics (complete cases for exposures, outcomes, confounders and Mediators n\u200a=\u200a2958) and alspac sample characteristics (with dietary iron intake data n\u200a=\u200a12116).complete case samplealspac sample (with dietary data) dietary iron Intake # (mg/day) (m, sd * ) 10.7 (3.2)10.4 (3.4) dietary iron intake <uk rni ## (%, 95% ci ** ) 89.2 (88.0, 90.3)90.3 (89.7, 90.8) dietary iron intake <uk lrni ### (%, 95% ci) 18.0 (16.7, 19.5)25.0 (24.2, 25.8) dietary Vitamin C intake ## (mg/day) (m, sd) 85.9 (34.5)80.1 (35.3) age of mother (yrs) (m, sd) 29.5 (4.2)28.5 (4.8) pre-Pregnancy bmi (kg/m2) (m, sd) 22.8 (3.5)22.9 (3.6) total energy Intake (kj) (m, sd) 7,483 (1,908)7,415 (2,081) smoking in Pregnancy (%, 95% ci ** ) 15.4 (14.1, 16.7)25.2 (24.4, 26.0) caucasian (%, 95% ci) 98.8 (98.4, 99.2)97.5 (97.2, 97.8) university degree (%, 95% ci) 18.6 (17.2, 20.0)13.8 (13.1, 14.4) vegetarian (%, 95% ci) 6.1 (5.3, 7.0)5.2 (4.8, 5.6) primigravida (%, 95% ci) 48.8 (47.0, 50.6)44.8 (43.9, 45.7) early Pregnancy maternal anemia (<11 g/dl) (%, 95% ci) 4.4 (3.7, 5.1)5.1 (4.6, 5.5) report taking Iron supplements before 32 wks Gestation (%, 95% ci) 44.9 (43.1, 46.7)47.5 (46.6, 48.4) child gender (male) (%, 95% ci) 50.8 (49.0, 52.6)51.5 (50.6, 52.4) Birthweight (g) (m, sd) 3,448 (499)3,411 (544) Gestational age (wks) (m, sd) 39.6 (1.6)39.5 (1.8)\n#Food frequency questionnaire at 32 weeks Gestation.']	[('PROBABLE_UNDERSTANDING', 105), ('PROBABLE_UNDERSTANDING', 281)]	2	[('CHEBI_33284', 'nutrient', 70, 'Nutrient'), ('CHEBI_27300', 'vitamin D', 207, 'vitamin C'), ('GO_0007565', 'female pregnancy', 240, 'pregnancy'), ('GO_0007565', 'female pregnancy', 304, 'pregnancy'), ('CHEBI_35222', 'inhibitor', 465, 'mediators'), ('GO_0007631', 'feeding behavior', 628, 'intake'), ('CHEBI_27300', 'vitamin D', 848, 'vitamin C'), ('GO_0007565', 'female pregnancy', 961, 'pregnancy'), ('GO_0007631', 'feeding behavior', 1025, 'intake'), ('GO_0007565', 'female pregnancy', 1083, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1384, 'pregnancy'), ('CHEBI_24870', 'ion', 1476, 'iron'), ('GO_0007565', 'female pregnancy', 1507, 'gestation'), ('GO_0007608', 'sensory perception of smell', 1631, 'Birthweight'), ('GO_0007565', 'female pregnancy', 1678, 'Gestational'), ('CHEBI_33290', 'food', 1730, 'Food'), ('GO_0007565', 'female pregnancy', 1771, 'gestation')]
S108-PMC3882256	PMC3882256	1/2014	S108-PMC3882256	['there was also no association between cord ferritin and either maternal dietary iron intake or hemoglobin.10.1371/journal.pone.0084684.t005\n\ncaption (table-wrap): table 5\nmultivariable linear regression estimates from stratified analyses for associations between Maternal Iron intake and hemoglobin in Pregnancy with offspring vascular indicators and body mass index with testing for EFFECT modification by maternal Vitamin C intake during Pregnancy and child sex (n\u200a=\u200a2958).offspring pulse wavevelocity (m/s)offspring Flow mediateddilatation (%)offspring systolic bloodpressure (mmhg)offspring diastolic bloodpressure (mmhg)offspring body massindex (kg/m2)b#99% ci®p*b#99% ci®p*b#99% ci®p*b#99% ci®p*b#99% ci®p* Maternal Pregnancy dietary iron intake (continuous) (per 10 mg/d) in participants with Vitamin Cintake >50 mg/day0−0.3, 0.30.50.6−0.2, 1.50.5−0.3−2.4, 1.90.70.8−1.1, 2.70.80−.0.7, 0.60.3in participants with Vitamin Cintake ≤50 mg/day0.2−0.7, 1.1−0.3−2.7, 2.1−1.8−7.3, 3.71.2−4.0, 6.41.2−1.1, 3.5males0.2−0.2, 0.60.40.6−0.4, 1.60.20.4−2.3, 3.10.90.9−1.5, 3.20.70.2−0.7, 1.00.4females0−0.4, 0.40.5−0.7, 1.6−0.9−3.8, 2.00.7−1.9, 3.30.1−0.9, 1.0 maternal Pregnancy Iron supplement use in participants with Vitamin cintake >50 mg/day0−0.1, 0.20.20.30, 0.70.1−0.8−1.7, 0.10.9−0.4−1.2, 0.50.90.1−0.2, 0.30.9in participants with Vitamin Cintake ≤50 mg/day0.2−0.1, 0.5−0.3−1.1, 0.6−0.8−2.7, 1.2−0.1−2.0, 1.80−0.8, 0.8males0.1−0.1, 0.20.80.2−0.2, 0.60.9−0.9−2.1, 0.30.7−0.9−1.9, 0.10.06−0.1−0.4, 0.30.5females0.1−0.1, 0.20.3−0.3, 0.7−0.7−1.9, 0.50.2−0.8, 1.30.1−0.3, 0.5 maternal early Pregnancy anemia (<11 g/dl) males0−0.4, 0.40.90.2−0.9, 1.20.3−1.3−4.1, 1.40.80.3−2.1, 2.60.40.4−0.5, 1.20.2females−0.1−0.5, 0.4−0.5−1.7, 0.7−1.0−4.1, 2.1−0.9−3.7, 1.8−0.2−1.2, 0.8\n#adjusting for potential CONFOUNDING characteristics: maternal age, pre-Pregnancy bmi, smoking in Pregnancy, educational qualification (AS a PROXY for socioeconomic status), parity, and maternal total energy intake in the models with dietary iron intake as exposure).']	[('SUPERFICIAL_RELATIONSHIP', 384), ('PROBLEM_COMPLICATION', 1794), ('PROBABLE_UNDERSTANDING', 1905), ('SUPERFICIAL_RELATIONSHIP', 1910)]	4	[('GO_0007618', 'mating', 263, 'maternal'), ('CHEBI_24870', 'ion', 272, 'iron'), ('GO_0007565', 'female pregnancy', 302, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 416, 'vitamin C'), ('GO_0007565', 'female pregnancy', 440, 'pregnancy'), ('GO_0007601', 'visual perception', 519, 'flow'), ('GO_0007618', 'mating', 713, 'Maternal'), ('GO_0007565', 'female pregnancy', 722, 'pregnancy'), ('CHEBI_64167', 'alpha-D-Manp-(1->3)-alpha-D-Manp-(1->2)-alpha-D-Manp', 800, 'vitamin Cintake'), ('CHEBI_64167', 'alpha-D-Manp-(1->3)-alpha-D-Manp-(1->2)-alpha-D-Manp', 920, 'vitamin Cintake'), ('GO_0007565', 'female pregnancy', 1164, 'pregnancy'), ('CHEBI_24870', 'ion', 1174, 'iron'), ('CHEBI_33229', 'vitamin (role)', 1215, 'vitamin'), ('CHEBI_64167', 'alpha-D-Manp-(1->3)-alpha-D-Manp-(1->2)-alpha-D-Manp', 1334, 'vitamin Cintake'), ('GO_0007565', 'female pregnancy', 1589, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1841, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1867, 'pregnancy')]
S12-PMC3888066	PMC3888066	12/2012	S12-PMC3888066	['this NOTION is BASED ON the KNOWN Teratogenic EFFECTS of Retinoic Acids on the Central Nervous System,1–3the CALCULATED dose of Retinol and Beta Carotene Ingested by the mother during early Pregnancy, and STRONG EVIDENCE that the fetus Metabolizes Beta Carotene to Retinoids and has LIMITED ability to store Beta Carotene in Fat Cells.4–7\nin 1995, rothman et al DEMONSTRATED that high maternal dietary intake of Vitamin A in the form of Retinol, ie, >10,000 iu/day, particularly in the first Trimester, MAY BE ASSOCIATED with Cranial-Neural-Crest Birth defects.8using a smooth regression curve, THIS study of 22,748 Pregnant women and their offspring IDENTIFIED 1 infant in 57 with malformations that COULD BE ATTRIBUTED to the intake of supplements of Preformed Vitamin A at a dose >10,000 iu/day.']	[('INCOMPLETE_EVIDENCE', 5), ('SUPERFICIAL_RELATIONSHIP', 15), ('ANOMALY_CURIOUS_FINDING', 21), ('ANOMALY_CURIOUS_FINDING', 21), ('INCOMPLETE_EVIDENCE', 28), ('SUPERFICIAL_RELATIONSHIP', 46), ('INCOMPLETE_EVIDENCE', 109), ('INCOMPLETE_EVIDENCE', 205), ('INCOMPLETE_EVIDENCE', 283), ('INCOMPLETE_EVIDENCE', 362), ('INCOMPLETE_EVIDENCE', 503), ('SUPERFICIAL_RELATIONSHIP', 510), ('QUESTION_ANSWERED_BY_THIS_WORK', 595), ('INCOMPLETE_EVIDENCE', 651), ('INCOMPLETE_EVIDENCE', 701), ('SUPERFICIAL_RELATIONSHIP', 710)]	16	[('CHEBI_50905', 'teratogenic agent', 34, 'teratogenic'), ('CHEBI_26536', 'retinoic acid', 57, 'retinoic acids'), ('UBERON_0001017', 'central nervous system', 79, 'central nervous system'), ('CHEBI_26536', 'retinoic acid', 128, 'retinol'), ('CHEBI_51438', 'D-isoascorbic acid', 140, 'beta carotene'), ('GO_0007631', 'feeding behavior', 154, 'ingested'), ('GO_0007565', 'female pregnancy', 190, 'pregnancy'), ('GO_0008152', 'metabolic process', 236, 'metabolizes'), ('CHEBI_51438', 'D-isoascorbic acid', 248, 'beta carotene'), ('CHEBI_26537', 'retinoid', 265, 'retinoids'), ('CHEBI_51438', 'D-isoascorbic acid', 308, 'beta carotene'), ('CL_0000136', 'fat cell', 325, 'fat cells'), ('CHEBI_27300', 'vitamin D', 412, 'vitamin A'), ('CHEBI_26536', 'retinoic acid', 437, 'retinol'), ('GO_0009294', 'DNA mediated transformation', 492, 'trimester'), ('UBERON_0001456', 'face', 526, 'cranial'), ('UBERON_0002342', 'neural crest', 534, 'neural-crest'), ('GO_0007567', 'parturition', 547, 'birth'), ('GO_0007565', 'female pregnancy', 616, 'pregnant'), ('GO_0007565', 'female pregnancy', 753, 'preformed'), ('CHEBI_27300', 'vitamin D', 763, 'vitamin A')]
S14-PMC3888066	PMC3888066	12/2012	S14-PMC3888066	['methodologies used in this study HAVE BEEN CRITICIZED, including aggregating Heart defects as Neural Crest defects, ESTIMATING missing information on Retinol supplementation and DEMONSTRATING the Vitamin A threshold of >10,000 iu/day.9SUBSEQUENT STUDIES have DISPUTED the 10,000 iu/day THRESHOLD BASED ON Non-Human Primate STUDIES and SMALL clinical trials in Humans.10\n\nEVIDENCE to SUPPORT the NOTION that a Toxin is responsible for SOME Neurodevelopmental disorders\na Toxin that MAY cause Neurodevelopmental disorders MUST BE able to cross NOT ONLY the Placenta, BUT ALSO the Blood Brain Barrier (bbb).']	[('INCOMPLETE_EVIDENCE', 33), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 43), ('INCOMPLETE_EVIDENCE', 116), ('INCOMPLETE_EVIDENCE', 178), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 234), ('INCOMPLETE_EVIDENCE', 234), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 259), ('PROBABLE_UNDERSTANDING', 286), ('INCOMPLETE_EVIDENCE', 296), ('PROBABLE_UNDERSTANDING', 296), ('INCOMPLETE_EVIDENCE', 323), ('INCOMPLETE_EVIDENCE', 335), ('INCOMPLETE_EVIDENCE', 371), ('INCOMPLETE_EVIDENCE', 383), ('INCOMPLETE_EVIDENCE', 395), ('INCOMPLETE_EVIDENCE', 434), ('INCOMPLETE_EVIDENCE', 481), ('IMPORTANT_CONSIDERATION', 520), ('ANOMALY_CURIOUS_FINDING', 542)]	19	[('UBERON_0000948', 'heart', 77, 'heart'), ('UBERON_0002342', 'neural crest', 94, 'neural crest'), ('CHEBI_26536', 'retinoic acid', 150, 'retinol'), ('CHEBI_27300', 'vitamin D', 196, 'vitamin A'), ('NCBITaxon_10088', 'Mus <genus>', 305, 'non'), ('NCBITaxon_9606', 'Homo sapiens', 309, 'human'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 315, 'primate'), ('NCBITaxon_9606', 'Homo sapiens', 360, 'humans'), ('CHEBI_27026', 'toxin', 409, 'toxin'), ('GO_0007399', 'nervous system development', 439, 'neurodevelopmental'), ('CHEBI_27026', 'toxin', 470, 'toxin'), ('GO_0007399', 'nervous system development', 491, 'neurodevelopmental'), ('UBERON_0001987', 'placenta', 555, 'placenta'), ('UBERON_0000120', 'blood brain barrier', 578, 'blood brain barrier')]
S45-PMC3888066	PMC3888066	12/2012	S45-PMC3888066	['examples of non-fortified Foods that are high in Vitamin A or beta Carotene are listed intable 5.37\n\ncalculation of Vitamin A and beta Carotene intake during Pregnancy\nthe absorption, Metabolism, storage, and Excretion Of Beta Carotene and Retinol in the mother are NOT COMPLETELY UNDERSTOOD; HOWEVER, most investigators agree that consumption of these forms of Vitamin A is RELATED to maternal Serum levels.38–40in ONE STUDY, maternal diet INFLUENCED Cord levels of Beta Carotene, but not Vitamin A.41absorption Of Beta Carotene from raw carrots and a low fat diet is very low compared to carrot juice.42according to current literature, 6 μg of Ingested Beta Carotene convert to 1 Retinol equivalent, or 1 μg Retinol, but ratios have ranged from 3.3:1 to 26:1.43,44\nbased on the discussion above, it MAY BE apparent that Maternal Ingestion of non-Beta Carotene sources of Vitamin A in foods + fortified foods + nutritional supplements would not LIKELY elevate Retinoic Acid levels in the fetus to Teratogenic levels.']	[('INCOMPLETE_EVIDENCE', 266), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 293), ('SUPERFICIAL_RELATIONSHIP', 375), ('INCOMPLETE_EVIDENCE', 416), ('SUPERFICIAL_RELATIONSHIP', 441), ('INCOMPLETE_EVIDENCE', 801), ('PROBABLE_UNDERSTANDING', 946)]	7	[('CHEBI_33290', 'food', 26, 'foods'), ('CHEBI_27300', 'vitamin D', 49, 'vitamin A'), ('CHEBI_23042', 'carotene', 67, 'carotene'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin A'), ('CHEBI_23042', 'carotene', 135, 'carotene'), ('GO_0007565', 'female pregnancy', 158, 'pregnancy'), ('GO_0008152', 'metabolic process', 184, 'metabolism'), ('GO_0007530', 'sex determination', 209, 'excretion of ... carotene'), ('CHEBI_51438', 'D-isoascorbic acid', 222, 'beta carotene'), ('CHEBI_26536', 'retinoic acid', 240, 'retinol'), ('GO_0060033', 'anatomical structure regression', 240, 'retinol'), ('CHEBI_27300', 'vitamin D', 362, 'vitamin A'), ('UBERON_0001977', 'blood serum', 395, 'serum'), ('UBERON_0002240', 'spinal cord', 452, 'cord'), ('CHEBI_51438', 'D-isoascorbic acid', 467, 'beta carotene'), ('CHEBI_27300', 'vitamin D', 490, 'vitamin A'), ('GO_0046311', 'prenylcysteine biosynthetic process', 513, 'of ... carotene'), ('CHEBI_51438', 'D-isoascorbic acid', 516, 'beta carotene'), ('GO_0007631', 'feeding behavior', 646, 'ingested'), ('CHEBI_51438', 'D-isoascorbic acid', 655, 'beta carotene'), ('CHEBI_26536', 'retinoic acid', 682, 'retinol'), ('CHEBI_26536', 'retinoic acid', 710, 'retinol'), ('GO_0007618', 'mating', 822, 'maternal'), ('GO_0007631', 'feeding behavior', 831, 'ingestion'), ('CHEBI_51438', 'D-isoascorbic acid', 848, 'beta carotene'), ('CHEBI_27300', 'vitamin D', 873, 'vitamin A'), ('CHEBI_26536', 'retinoic acid', 961, 'retinoic acid'), ('CHEBI_50905', 'teratogenic agent', 998, 'teratogenic'), ('GO_0031649', 'heat generation', 998, 'teratogenic')]
S58-PMC3888066	PMC3888066	12/2012	S58-PMC3888066	['this author BELIEVES that AWARENESS and simple monitoring of all POTENTIAL sources of Retinoic Acid during the first Trimester of Pregnancy, including nutritional supplements, dietary Vitamin A from Animal sources, and Beta Carotene, MAY decrease the incidence of Neurodevelopmental disorders.']	[('INCOMPLETE_EVIDENCE', 12), ('IMPORTANT_CONSIDERATION', 26), ('INCOMPLETE_EVIDENCE', 65), ('INCOMPLETE_EVIDENCE', 234)]	4	[('CHEBI_26536', 'retinoic acid', 86, 'retinoic acid'), ('GO_0009294', 'DNA mediated transformation', 117, 'trimester'), ('GO_0007565', 'female pregnancy', 130, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 184, 'vitamin A'), ('NCBITaxon_33208', 'Metazoa', 199, 'animal'), ('CHEBI_86157', 'cadmium sulfate hydrate', 219, 'beta'), ('CHEBI_23042', 'carotene', 224, 'carotene'), ('GO_0007399', 'nervous system development', 264, 'neurodevelopmental')]
S109-PMC3901983	PMC3901983	1/2013	S109-PMC3901983	['HOWEVER, there are no RECOMMENDATIONS about supplementation of the Vitamin K [22].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('FUTURE_WORK', 22)]	2	[('CHEBI_27300', 'vitamin D', 67, 'vitamin K')]
S162-PMC3901983	PMC3901983	1/2013	S162-PMC3901983	['it is ESSENTIAL to maintain Micronutrients supplementation also after Delivery and during breastfeeding, to ensure appropriate Vitamins and Minerals intake to neonate and to prevent Vitamin B deficiency, which CAN INDICATE SEVERE COMPLICATIONS including failure in thriving, megaloblastic anemia, and development delays [3,14].']	[('IMPORTANT_CONSIDERATION', 6), ('INCOMPLETE_EVIDENCE', 210), ('INCOMPLETE_EVIDENCE', 214), ('IMPORTANT_CONSIDERATION', 223), ('PROBLEM_COMPLICATION', 230)]	5	[('CHEBI_33839', 'macromolecule', 28, 'micronutrients'), ('GO_0007567', 'parturition', 70, 'delivery'), ('CHEBI_33277', 'gamma-tocotrienol', 127, 'vitamins'), ('CHEBI_46751', 'quinolizidine', 140, 'minerals'), ('CHEBI_27300', 'vitamin D', 182, 'vitamin B')]
S163-PMC3901983	PMC3901983	1/2013	S163-PMC3901983	['it was REPORTED that after adequate Vitamin B supplementation improvements in growth, development and reversal of anemia are OBSERVED [7].']	[('INCOMPLETE_EVIDENCE', 7), ('INCOMPLETE_EVIDENCE', 125)]	2	[('CHEBI_27300', 'vitamin D', 36, 'vitamin B')]
S28-PMC3930526	PMC3930526	2/2014	S28-PMC3930526	['in another STUDY carried out in indonesia, Vitamin A supplementation among Pregnant women improves child growth at certain periods in the first two years compared with the combined supplementation of zinc and Vitamin A[11].']	[('INCOMPLETE_EVIDENCE', 11)]	1	[('CHEBI_27300', 'vitamin D', 43, 'vitamin A'), ('GO_0007565', 'female pregnancy', 75, 'pregnant'), ('CHEBI_27300', 'vitamin D', 209, 'vitamin A')]
S23-PMC3970319	PMC3970319	5/2013	S23-PMC3970319	['multiple-Micronutrient supplements (mmss) provided in Pregnancy compared with Iron and Folate supplements were marginally ASSOCIATED with lower offspring systolic, BUT NOT diastolic, Blood pressure at 2 y of age in one nepalese study (10) but were unrelated to offspring Blood pressure at 6–8 y in a separate nepalese trial where mmss were compared with Vitamin A supplementation (11).']	[('SUPERFICIAL_RELATIONSHIP', 122), ('ANOMALY_CURIOUS_FINDING', 164)]	2	[('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 9, 'micronutrient'), ('GO_0007565', 'female pregnancy', 54, 'pregnancy'), ('CHEBI_24870', 'ion', 78, 'iron'), ('CHEBI_30863', '5-azaorotic acid', 87, 'folate'), ('UBERON_0000178', 'blood', 183, 'blood'), ('UBERON_0000178', 'blood', 271, 'blood'), ('CHEBI_27300', 'vitamin D', 354, 'vitamin A')]
S164-PMC3970319	PMC3970319	5/2013	S164-PMC3970319	['in the second nepalese trial REPORTED above, the control group (Vitamin A supplements only) had a higher risk of Urinary microalbuminuria (microalbumin:creatinine ratio ≥3.4 mg/mmol) compared with Individuals whose mothers received Folic Acid or Folic Acid, iron, and zinc in addition to Vitamin A (11).']	[('INCOMPLETE_EVIDENCE', 29)]	1	[('CHEBI_27300', 'vitamin D', 64, 'vitamin A'), ('UBERON_0001088', 'urine', 113, 'urinary'), ('NCBITaxon_1', 'root', 197, 'individuals'), ('CHEBI_30751', 'formic acid', 232, 'folic acid'), ('CHEBI_30751', 'formic acid', 246, 'folic acid'), ('CHEBI_27300', 'vitamin D', 288, 'vitamin A')]
S3-PMC3991049	PMC3991049	11/2013	S3-PMC3991049	['we CONDUCTED THIS STUDY TO DETERMINE the prevalence of Vitamin D deficiency among Pregnant women and TO EVALUATE the EFFECTIVENESS and level of weekly Oral 50,000 iu of Vitamin D supplementation for the mother and the newborn.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('QUESTION_ANSWERED_BY_THIS_WORK', 13), ('QUESTION_ANSWERED_BY_THIS_WORK', 24), ('QUESTION_ANSWERED_BY_THIS_WORK', 101), ('SUPERFICIAL_RELATIONSHIP', 117)]	5	[('CHEBI_27300', 'vitamin D', 55, 'vitamin D'), ('GO_0007565', 'female pregnancy', 82, 'pregnant'), ('UBERON_0000165', 'mouth', 151, 'oral'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin D')]
S22-PMC3991049	PMC3991049	11/2013	S22-PMC3991049	['Vitamin D supplementation during Pregnancy REMAINS CONTROVERSIAL and the current RECOMMENDED REQUIREMENT for Vitamin D during Pregnancy (200–400 iu/d) has LITTLE scientific SUPPORT.']	[('INCOMPLETE_EVIDENCE', 43), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 51), ('FUTURE_WORK', 81), ('IMPORTANT_CONSIDERATION', 93), ('INCOMPLETE_EVIDENCE', 155), ('INCOMPLETE_EVIDENCE', 173)]	6	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 33, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 109, 'vitamin D'), ('GO_0007565', 'female pregnancy', 126, 'pregnancy')]
S24-PMC3991049	PMC3991049	11/2013	S24-PMC3991049	"[""a RECENT STUDY SHOWED that a daily supplement of 4000 iu of Vitamin D was REQUIRED to sustain normal Metabolism in Pregnancy and this dose was EFFECTIVE and SAFE.9\nin THIS STUDY we EVALUATED the prevalence of Vitamin D deficiency in Pregnant women and EVALUATED the EFFECT of weekly Oral 50,000 iu of Vitamin D on mothers' and newborn's level of Vitamin D.\n\nmethods\nTHIS is a prospective observational study conducted at a single center at hamad medical corporation in doha, qatar.""]"	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 15), ('IMPORTANT_CONSIDERATION', 74), ('SUPERFICIAL_RELATIONSHIP', 143), ('IMPORTANT_CONSIDERATION', 157), ('QUESTION_ANSWERED_BY_THIS_WORK', 167), ('QUESTION_ANSWERED_BY_THIS_WORK', 181), ('QUESTION_ANSWERED_BY_THIS_WORK', 252), ('SUPERFICIAL_RELATIONSHIP', 266), ('QUESTION_ANSWERED_BY_THIS_WORK', 366)]	10	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('GO_0008152', 'metabolic process', 101, 'metabolism'), ('GO_0007565', 'female pregnancy', 115, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 209, 'vitamin D'), ('GO_0007565', 'female pregnancy', 233, 'pregnant'), ('UBERON_0000165', 'mouth', 283, 'oral'), ('CHEBI_27300', 'vitamin D', 301, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 346, 'vitamin D')]
S58-PMC3991049	PMC3991049	11/2013	S58-PMC3991049	"[""the level of Vitamin D in newborns CORRELATED with the mothers' 3rdtrimester level with significant p value (tables 1 and 2).table 3shows the level of vitamin d level in subjects who were on multivitamin supplement and those who were not on it before being recruited for the study.""]"	[('SUPERFICIAL_RELATIONSHIP', 35)]	1	[('CHEBI_27300', 'vitamin D', 13, 'vitamin D')]
S69-PMC3991049	PMC3991049	11/2013	S69-PMC3991049	['the RECOMMENDED daily intake of Vitamin D is 200 iu/day in the united states, australia, new zealand and canada.18–20in the uk, the daily recommended dose is 400 iu/day.21HISTORICALLY, Vitamin D supplementation during Pregnancy WAS THOUGHT TO be a risk factor for Supravalvular stenosis in infants, which was BASED ON a 1964 case report.22\nDIFFERENT STUDIES SUGGESTED that the daily use 1000 iu,23–272000 iu,284000 iu,29and 6400 iu30would HELP to eliminate Vitamin D insufficiency without apparent toxicity in Pregnant women and their infants.']	[('FUTURE_WORK', 4), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 169), ('INCOMPLETE_EVIDENCE', 228), ('INCOMPLETE_EVIDENCE', 232), ('INCOMPLETE_EVIDENCE', 309), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 340), ('INCOMPLETE_EVIDENCE', 350), ('INCOMPLETE_EVIDENCE', 358), ('FUTURE_WORK', 439)]	9	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 185, 'vitamin D'), ('GO_0007565', 'female pregnancy', 218, 'pregnancy'), ('UBERON_2000442', 'supraneural bone', 264, 'supravalvular'), ('CHEBI_27300', 'vitamin D', 457, 'vitamin D'), ('GO_0007565', 'female pregnancy', 510, 'pregnant')]
S70-PMC3991049	PMC3991049	11/2013	S70-PMC3991049	['all of this SUPPORTS that 400 iu of Vitamin D MAY BE INADEQUATE to raise the maternal Vitamin D level to optimum level PARTICULARLY for women living in northern latitude, women with darker skin or covered women, as well as for women who are not exposed to sunlight, not on dietary supplements or have absorption and metabolic PROBLEMS.']	[('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 46), ('IMPORTANT_CONSIDERATION', 53), ('PROBLEM_COMPLICATION', 53), ('ANOMALY_CURIOUS_FINDING', 119), ('PROBLEM_COMPLICATION', 326)]	6	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 86, 'vitamin D')]
S71-PMC3991049	PMC3991049	11/2013	S71-PMC3991049	['we used a 50,000 iu dose, AS per our PREVIOUS STUDIES, which DEMONSTRATED no toxicity when Vitamin D deficient rheumatology outpatient and health care professional were supplemented this dose.31–32\nthe CONCERN of using higher doses of Vitamin D MIGHT cause hypercalcemia, hypercalciuria, Renal calculi and soft Tissue and vascular calcification toxicity is LIKELY to worsen with Calcium supplementation.']	[('PROBABLE_UNDERSTANDING', 26), ('INCOMPLETE_EVIDENCE', 37), ('INCOMPLETE_EVIDENCE', 61), ('IMPORTANT_CONSIDERATION', 202), ('PROBLEM_COMPLICATION', 202), ('INCOMPLETE_EVIDENCE', 245), ('PROBABLE_UNDERSTANDING', 357)]	7	[('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 235, 'vitamin D'), ('UBERON_0002113', 'kidney', 288, 'renal'), ('UBERON_0000479', 'tissue', 311, 'tissue'), ('CHEBI_22313', 'alkaline earth metal atom', 379, 'calcium')]
S72-PMC3991049	PMC3991049	11/2013	S72-PMC3991049	['hypercalcemia, which is the most WORRYING toxicity, occurs with Vitamin D levels of more than 80 or 100\xa0ng/ml; and in OUR STUDY no one reached this level through out Pregnancy and in newborns with normal levels of calcium IN SPITE of supplementation.']	[('IMPORTANT_CONSIDERATION', 33), ('QUESTION_ANSWERED_BY_THIS_WORK', 118), ('ANOMALY_CURIOUS_FINDING', 222)]	3	[('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('GO_0007565', 'female pregnancy', 166, 'pregnancy')]
S80-PMC3991049	PMC3991049	11/2013	S80-PMC3991049	['we NEED rct of Vitamin D supplementation with measurement of 25-Hydroxyvitamin D to determine the baseline status, the level achieved on supplementation with appropriate design to avoid any CONFOUNDER, and TO ASSESS WHAT is the appropriate level of Vitamin D during Pregnancy and in newborns with no complications or toxicity through out.']	[('FUTURE_WORK', 3), ('PROBLEM_COMPLICATION', 190), ('QUESTION_ANSWERED_BY_THIS_WORK', 206), ('EXPLICIT_QUESTION', 216)]	4	[('CHEBI_27300', 'vitamin D', 15, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 61, '25-hydroxyvitamin D'), ('CHEBI_27300', 'vitamin D', 249, 'vitamin D'), ('GO_0007565', 'female pregnancy', 266, 'pregnancy')]
S128-PMC3994635	PMC3994635	8/2010	S128-PMC3994635	['the EFFECTS of the Pregnancy Supplement were superimposed on the changes in biochemistry from 20 wk of Pregnancy to 13 wk Postpartum as experienced by both groups of women (ie, significant reductions in Urinary Calcium Excretion and Plasma concentrations of Vitamin D Metabolites plus increases in Plasma concentrations of pth and bone turnover markers) (table 5).']	[('SUPERFICIAL_RELATIONSHIP', 4)]	1	[('GO_0007565', 'female pregnancy', 19, 'pregnancy'), ('CHEBI_16158', 'steroid sulfate', 29, 'supplement'), ('GO_0007565', 'female pregnancy', 103, 'pregnancy'), ('GO_0007565', 'female pregnancy', 122, 'postpartum'), ('GO_0060073', 'micturition', 203, 'urinary'), ('UBERON_0001088', 'urine', 203, 'urinary'), ('GO_0036161', 'calcitonin secretion', 211, 'calcium excretion'), ('UBERON_0001969', 'blood plasma', 233, 'plasma'), ('CHEBI_27300', 'vitamin D', 258, 'vitamin D'), ('CHEBI_25212', 'metabolite', 268, 'metabolites'), ('UBERON_0001969', 'blood plasma', 298, 'plasma')]
S22-PMC4018592	PMC4018592	4/2014	S22-PMC4018592	['[17] in a study in nepal, multiple Micronutrient supplementations during Pregnancy did NOT reduce early infant mortality;[18] HOWEVER, it led TO improved folate status and reduced the prevalence of riboflavin, Vitamin B6, Vitamin B12, Folate and Vitamin D deficiencies.']	[('ANOMALY_CURIOUS_FINDING', 87), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 126), ('QUESTION_ANSWERED_BY_THIS_WORK', 142)]	3	[('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 35, 'micronutrient'), ('GO_0007565', 'female pregnancy', 73, 'pregnancy'), ('CHEBI_33237', 'vitamin D4', 210, 'vitamin B6'), ('CHEBI_33279', 'vitamin D5', 222, 'vitamin B12'), ('CHEBI_30863', '5-azaorotic acid', 235, 'folate'), ('CHEBI_27300', 'vitamin D', 246, 'vitamin D')]
S114-PMC4018592	PMC4018592	4/2014	S114-PMC4018592	['[43] in tanzania, when Micronutrient supplements providing amounts twice the RECOMMENDED dietary allowance (rda) for Vitamin E and 6-10 times for Vitamin C and several b Vitamins were administered, mean Birth weight increased by 67 g.[36] finally, the provision of multivitamin and multivitamin-Mineral supplements from two different Pharmaceutical companies MIGHT be INFLUENCED infants’ size.']	[('FUTURE_WORK', 77), ('INCOMPLETE_EVIDENCE', 359), ('SUPERFICIAL_RELATIONSHIP', 368)]	3	[('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 23, 'micronutrient'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 146, 'vitamin C'), ('CHEBI_33277', 'gamma-tocotrienol', 170, 'vitamins'), ('GO_0007567', 'parturition', 203, 'birth'), ('CHEBI_46662', 'mineral', 295, 'mineral'), ('CHEBI_52217', 'pharmaceutical', 334, 'pharmaceutical')]
S227-PMC4045304	PMC4045304	2/2014	S227-PMC4045304	['the ROLE or ROLES Vitamin D MAY play in development of asd MAY BE resolved by randomized clinical trials of Prenatal Vitamin D supplementation or Vitamin D supplementation of newborns or in early childhood.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('SUPERFICIAL_RELATIONSHIP', 12), ('INCOMPLETE_EVIDENCE', 28), ('INCOMPLETE_EVIDENCE', 59)]	4	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('GO_0007565', 'female pregnancy', 108, 'prenatal'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 146, 'vitamin D')]
S243-PMC4045304	PMC4045304	2/2014	S243-PMC4045304	['these studies INDICATE that maternal mcs, particularly diabetes, MAY BE ASSOCIATED with Neurodevelopmental PROBLEMS in children and Vitamin D supplementation early in childhood SHOULD BE given further CONSIDERATION in treatment of asd [103–105].']	[('INCOMPLETE_EVIDENCE', 14), ('INCOMPLETE_EVIDENCE', 65), ('SUPERFICIAL_RELATIONSHIP', 72), ('IMPORTANT_CONSIDERATION', 107), ('FUTURE_WORK', 177), ('FUTURE_WORK', 201)]	6	[('GO_0007399', 'nervous system development', 88, 'neurodevelopmental'), ('CHEBI_27300', 'vitamin D', 132, 'vitamin D')]
S64-PMC4071151	PMC4071151	6/2014	S64-PMC4071151	['RISK factors MAY include preoperative malnutrition (e.g., Vitamin D, iron), decreased Food Intake (dumping syndrome, reduced hunger and increased satiety, Food intolerances), inadequate Nutrient supplementation (POOR compliance with multivitamin/multimineral regimen, insufficient amounts of Vitamins and/or Minerals in supplements) and/or nutritional support (lack of follow-up, INSUFFICIENT monitoring, DIFFICULTY in recognizing symptoms of deficiency), Nutrient malabsorption (reduced absorptive Gastro-Intestinal area) [18,19].']	[('SUPERFICIAL_RELATIONSHIP', 0), ('INCOMPLETE_EVIDENCE', 13), ('IMPORTANT_CONSIDERATION', 212), ('PROBLEM_COMPLICATION', 380), ('DIFFICULT_TASK', 405)]	5	[('CHEBI_27300', 'vitamin D', 58, 'vitamin D'), ('CHEBI_33290', 'food', 86, 'food'), ('GO_0007631', 'feeding behavior', 86, 'food intake'), ('CHEBI_33290', 'food', 155, 'food'), ('CHEBI_33284', 'nutrient', 186, 'nutrient'), ('CHEBI_33277', 'gamma-tocotrienol', 292, 'vitamins'), ('CHEBI_46751', 'quinolizidine', 308, 'minerals'), ('CHEBI_33284', 'nutrient', 456, 'nutrient'), ('UBERON_0005409', 'alimentary part of gastrointestinal system', 499, 'gastro-intestinal')]
S10-PMC4072587	PMC4072587	6/2014	S10-PMC4072587	['OUR FINDINGS STRENGTHEN the EVIDENCE for giving Vitamin D supplementation during Pregnancy.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 28)]	3	[('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('GO_0007565', 'female pregnancy', 81, 'pregnancy')]
S128-PMC4072587	PMC4072587	6/2014	S128-PMC4072587	['PREVIOUS authors have SUGGESTED that accelerated growth in length MAY occur during an infant’s first year of Life in infants Born to mothers with Vitamin D <30 nmol/l, as infant Vitamin D levels increase Postnatally, through post-Natal Vitamin D supplementation[5].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 22), ('INCOMPLETE_EVIDENCE', 66)]	3	[('UBERON_0000104', 'life cycle', 109, 'life'), ('GO_0007567', 'parturition', 125, 'born'), ('CHEBI_27300', 'vitamin D', 146, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 178, 'vitamin D'), ('GO_0007565', 'female pregnancy', 204, 'postnatally'), ('GO_0007567', 'parturition', 230, 'natal'), ('CHEBI_27300', 'vitamin D', 236, 'vitamin D')]
S133-PMC4072587	PMC4072587	6/2014	S133-PMC4072587	['a pooled analyses of two PREVIOUS STUDIES[17]SHOWED no significant link between Vitamin D supplementation and Preterm Delivery, however the two studies had SMALL sample sizes (350 and 180 participants)[4],[44], with relatively large loss to follow up (30%).']	[('INCOMPLETE_EVIDENCE', 25), ('INCOMPLETE_EVIDENCE', 45), ('INCOMPLETE_EVIDENCE', 156)]	3	[('CHEBI_27300', 'vitamin D', 80, 'vitamin D'), ('GO_0007565', 'female pregnancy', 110, 'preterm'), ('GO_0007567', 'parturition', 118, 'delivery')]
S137-PMC4072587	PMC4072587	6/2014	S137-PMC4072587	['this is IN KEEPING WITH a cochrane review of data from three trials SHOWING that Vitamin D supplementation during Pregnancy did not affect Birth weight or Birth length[13].']	[('INCOMPLETE_EVIDENCE', 8), ('INCOMPLETE_EVIDENCE', 68)]	2	[('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('GO_0007565', 'female pregnancy', 114, 'pregnancy'), ('GO_0007567', 'parturition', 139, 'birth'), ('GO_0007567', 'parturition', 155, 'birth')]
S156-PMC4072587	PMC4072587	6/2014	S156-PMC4072587	['our results STRENGTHEN the EVIDENCE for giving Vitamin D supplementation during Pregnancy and HIGHLIGHT the NEED FOR FURTHER RESEARCH to explore the IMPACT of supplementation on longer term child growth and developmental outcomes, PARTICULARLY with regard to language.']	[('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 27), ('INCOMPLETE_EVIDENCE', 94), ('FUTURE_WORK', 108), ('INCOMPLETE_EVIDENCE', 108), ('SUPERFICIAL_RELATIONSHIP', 149), ('IMPORTANT_CONSIDERATION', 231)]	7	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('GO_0007565', 'female pregnancy', 80, 'pregnancy')]
S57-PMC4074693	PMC4074693	3/2014	S57-PMC4074693	['the types of dietary supplement commonly used by these students were Vitamin C, multivitamins, Vitamin A, Vitamin B12 and Vitamin B Complex.']	[('DIFFICULT_TASK', 132)]	1	[('CHEBI_27300', 'vitamin D', 69, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 95, 'vitamin A'), ('CHEBI_33279', 'vitamin D5', 106, 'vitamin B12'), ('CHEBI_27300', 'vitamin D', 122, 'vitamin B'), ('CHEBI_34652', 'compactin diol lactone', 132, 'complex')]
S79-PMC4074693	PMC4074693	3/2014	S79-PMC4074693	['the types of dietary supplement commonly used by these students were Vitamin C, multivitamins, Vitamin A, Vitamin B12 and Vitamin B Complex.']	[('DIFFICULT_TASK', 132)]	1	[('CHEBI_27300', 'vitamin D', 69, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 95, 'vitamin A'), ('CHEBI_33279', 'vitamin D5', 106, 'vitamin B12'), ('CHEBI_27300', 'vitamin D', 122, 'vitamin B'), ('CHEBI_34652', 'compactin diol lactone', 132, 'complex')]
S36-PMC4106226	PMC4106226	7/2014	S36-PMC4106226	['OF INTEREST, asthmatic children had less exposure to sunlight and ate a diet less rich in Vitamin D. this MAY INDICATE that asthma Control MAY benefit from a healthier Life-style and a Vitamin D supplementation.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 106), ('INCOMPLETE_EVIDENCE', 110), ('INCOMPLETE_EVIDENCE', 139)]	4	[('CHEBI_27300', 'vitamin D', 90, 'vitamin D'), ('GO_0065007', 'biological regulation', 131, 'control'), ('UBERON_0000104', 'life cycle', 168, 'life'), ('CHEBI_27300', 'vitamin D', 185, 'vitamin D')]
S4-PMC4113768	PMC4113768	7/2014	S4-PMC4113768	['commencing with a session of talks providing overviews of randomised trials of supplementation and global Vitamin D status, the meeting proceeded with a session on pre-Birth related Vitamin D RESEARCH—evolution, genetics & fertility—which led into several talks in the area of child health.']	[('INCOMPLETE_EVIDENCE', 192)]	1	[('CHEBI_27300', 'vitamin D', 106, 'vitamin D'), ('GO_0007567', 'parturition', 168, 'birth'), ('CHEBI_27300', 'vitamin D', 182, 'vitamin D')]
S9-PMC4113768	PMC4113768	7/2014	S9-PMC4113768	['mega-trials have the POTENTIAL to detect small effect sizes of Vitamin D supplementation on end-points such as incidence and mortality from Cardiovascular disease and cancer.']	[('INCOMPLETE_EVIDENCE', 21)]	1	[('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('UBERON_0004535', 'cardiovascular system', 140, 'cardiovascular')]
S13-PMC4113768	PMC4113768	7/2014	S13-PMC4113768	['finally, the meeting also addressed STRATEGIES to tackle Vitamin D deficiency at the population level, by alteration of sun-seeking behaviour, use of Nutritional Supplements and Food Fortification.']	[('FUTURE_WORK', 36)]	1	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('CHEBI_7495', 'nefazodone hydrochloride', 150, 'nutritional'), ('CHEBI_33341', 'titanium atom', 162, 'supplements'), ('CHEBI_33290', 'food', 178, 'food'), ('GO_0031318', 'detection of folic acid', 178, 'food fortification')]
S179-PMC4113768	PMC4113768	7/2014	S179-PMC4113768	['FURTHER STUDIES assessing the EFFECT of Vitamin D supplementation, and RELATED molecular and Genetic FACTORS, on Colorectal cancer survival ARE WARRANTED.']	[('FUTURE_WORK', 0), ('SUPERFICIAL_RELATIONSHIP', 30), ('SUPERFICIAL_RELATIONSHIP', 71), ('SUPERFICIAL_RELATIONSHIP', 101), ('FUTURE_WORK', 140)]	5	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('SO_0000704', 'gene', 93, 'genetic'), ('UBERON_0012652', 'colorectum', 113, 'colorectal')]
S214-PMC4113768	PMC4113768	7/2014	S214-PMC4113768	['we THEREFORE AIMED TO DETERMINE WHETHER seasonal Vitamin D deficiency occurs in two healthy young Adult populations with moderate or dark skin pigmentation in cape town, WHETHER this had an EFFECT on the number and function of Circulating Blood Cells, their ability to Control to hiv-1 infection and WHETHER Vitamin D supplementation modifies the investigated responses.']	[('PROBABLE_UNDERSTANDING', 3), ('QUESTION_ANSWERED_BY_THIS_WORK', 13), ('QUESTION_ANSWERED_BY_THIS_WORK', 19), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 32), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 170), ('SUPERFICIAL_RELATIONSHIP', 190), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 300)]	7	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('UBERON_0007023', 'adult organism', 98, 'adult'), ('CL_0000080', 'circulating cell', 227, 'circulating'), ('CL_0000081', 'blood cell', 239, 'blood cells'), ('UBERON_0000178', 'blood', 239, 'blood'), ('GO_0065007', 'biological regulation', 269, 'control'), ('CHEBI_27300', 'vitamin D', 308, 'vitamin D')]
S321-PMC4113768	PMC4113768	7/2014	S321-PMC4113768	['AT PRESENT, THERE ARE NO DATA about Vitamin D (vd) supplementation, osteopenia and bone Mineral density (bmd) in Adult burn patients.']	[('INCOMPLETE_EVIDENCE', 0), ('FULL_UNKNOWN', 12)]	2	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('CHEBI_46662', 'mineral', 88, 'mineral'), ('UBERON_0007023', 'adult organism', 113, 'adult')]
S367-PMC4113768	PMC4113768	7/2014	S367-PMC4113768	['ALTHOUGH no children were taking vitamin supplements at the time of the study, the average Vitamin D level in african children who had ever been prescribed Vitadol-c was 34 nmol/l WHILST those who had never been prescribed Vitadol-c was 16 nmol/l.']	[('ANOMALY_CURIOUS_FINDING', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 180)]	2	[('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('CHEBI_27355', 'xylulose phosphate', 156, 'vitadol'), ('CHEBI_27355', 'xylulose phosphate', 223, 'vitadol')]
S368-PMC4113768	PMC4113768	7/2014	S368-PMC4113768	['conclusion: we have decreased the incidence of rickets in our community and RAISED AWARENESS of the need for Vitamin D supplementation in AT RISK communities in nz.']	[('IMPORTANT_CONSIDERATION', 76), ('IMPORTANT_CONSIDERATION', 138)]	2	[('CHEBI_27300', 'vitamin D', 109, 'vitamin D')]
S371-PMC4113768	PMC4113768	7/2014	S371-PMC4113768	['HOW HARD should we fight for improved affordable access to daily Vitamin D supplementation?']	[('EXPLICIT_QUESTION', 0), ('IMPORTANT_CONSIDERATION', 4), ('EXPLICIT_QUESTION', 90)]	3	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 73, 'D')]
S428-PMC4113768	PMC4113768	7/2014	S428-PMC4113768	['ONLY 8% of patients took multivitamin or Vitamin D supplements daily.']	[('INCOMPLETE_EVIDENCE', 0)]	1	[('CHEBI_27300', 'vitamin D', 41, 'vitamin D')]
S435-PMC4113768	PMC4113768	7/2014	S435-PMC4113768	['upcoming work with this group of patients will include 25Ohd testing, and a randomized, double-blind, placebo-controlled trial that will test the EFFECT of weekly Vitamin D supplementation on ad severity in children.']	[('SUPERFICIAL_RELATIONSHIP', 146)]	1	"[('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 55, '25OHD'), ('CHEBI_27300', 'vitamin D', 163, 'vitamin D')]"
S463-PMC4113768	PMC4113768	7/2014	S463-PMC4113768	['populations in developing countries are OFTEN deficient in Vitamin A. u or j shaped curves for benefits of increases in Vitamin D supplementation in are a GROWING CONCERN, as REPORTED in the western world.']	[('PROBABLE_UNDERSTANDING', 40), ('IMPORTANT_CONSIDERATION', 155), ('INCOMPLETE_EVIDENCE', 155), ('IMPORTANT_CONSIDERATION', 163), ('INCOMPLETE_EVIDENCE', 175)]	5	[('CHEBI_27300', 'vitamin D', 59, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin D')]
S476-PMC4113768	PMC4113768	7/2014	S476-PMC4113768	['overall reductions in Lung cancer RISKS in never-smokers in the women’s health initiative (1771 cases in 128,779 women) were seen with vitamin D intakes >400 iu/day (or = 0.37, 95% ci: 0.18–0.77); HOWEVER, rct data for the 12% of women given Vitamin D supplements SHOWED lower Lung cancer risk ONLY in those with low intakes of Retinol (or = 0.69, 95% ci, 0.5–0.96).']	[('IMPORTANT_CONSIDERATION', 34), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 197), ('ANOMALY_CURIOUS_FINDING', 197), ('INCOMPLETE_EVIDENCE', 264), ('ANOMALY_CURIOUS_FINDING', 294), ('INCOMPLETE_EVIDENCE', 294)]	6	[('UBERON_0002048', 'lung', 22, 'lung'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 143, 'D'), ('CHEBI_27300', 'vitamin D', 242, 'vitamin D'), ('UBERON_0002048', 'lung', 277, 'lung'), ('CHEBI_26536', 'retinoic acid', 328, 'retinol')]
S479-PMC4113768	PMC4113768	7/2014	S479-PMC4113768	['conclusions: (1) SINCE the use of supplements containing Vitamin A as well as Vitamin D is common, WHETHER in Cod Liver oil OR multi-vitamins, especially in developed countries, Vitamin A status is LIKELY to CONFOUND rcts of Vitamin D in westernized populations; (2) in particular, high Vitamin A Intakes COULD ACCOUNT for j or inverse u shaped curves for outcomes in rcts, AS COULD Gene polymorphisms increasing circulating Retinol/Retinoids; (3) CONVERSELY, poor Vitamin D status MAY BE expected to CONFOUND rcts of Vitamin A in developing countries; (4) as well as Vitamin A intakes, other lifestyle factors that are POTENTIAL CONFOUNDERS of the EFFECTS of Vitamin D SHOULD BE CONSIDERED in the PLANNING of FUTURE rcts of supplemental Vitamin D, including intakes of other Nutrients, tobacco usage, and also betel-chewing which MAY increase Catabolism Of Vitamin D and is a habit used by 10% of the world population.']	[('PROBABLE_UNDERSTANDING', 17), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 99), ('PROBABLE_UNDERSTANDING', 198), ('PROBLEM_COMPLICATION', 208), ('INCOMPLETE_EVIDENCE', 305), ('IMPORTANT_CONSIDERATION', 311), ('PROBABLE_UNDERSTANDING', 374), ('INCOMPLETE_EVIDENCE', 377), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 448), ('INCOMPLETE_EVIDENCE', 482), ('PROBLEM_COMPLICATION', 501), ('INCOMPLETE_EVIDENCE', 620), ('PROBLEM_COMPLICATION', 630), ('SUPERFICIAL_RELATIONSHIP', 649), ('FUTURE_WORK', 670), ('FUTURE_WORK', 680), ('FUTURE_WORK', 698), ('FUTURE_WORK', 710), ('INCOMPLETE_EVIDENCE', 831)]	19	[('CHEBI_27300', 'vitamin D', 57, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 110, 'cod'), ('UBERON_0002107', 'liver', 114, 'liver'), ('CHEBI_27300', 'vitamin D', 178, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 225, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 287, 'vitamin A'), ('GO_0007631', 'feeding behavior', 297, 'intakes'), ('SO_0000704', 'gene', 383, 'gene'), ('CHEBI_26536', 'retinoic acid', 425, 'retinol'), ('CHEBI_26537', 'retinoid', 433, 'retinoids'), ('CHEBI_27300', 'vitamin D', 465, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 518, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 568, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 660, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 738, 'vitamin D'), ('CHEBI_33284', 'nutrient', 776, 'nutrients'), ('GO_0044851', 'hair cycle phase', 844, 'catabolism of vitamin D'), ('CHEBI_27300', 'vitamin D', 858, 'vitamin D')]
S512-PMC4113768	PMC4113768	7/2014	S512-PMC4113768	['randomised controlled trials of Vitamin D supplementation in children with asthma for PREVENTION of exacerbation and uri HAVE REPORTED positive results; such trials have not previously been conducted in Adults.']	[('SUPERFICIAL_RELATIONSHIP', 86), ('INCOMPLETE_EVIDENCE', 121)]	2	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('UBERON_0007023', 'adult organism', 203, 'adults')]
S683-PMC4113768	PMC4113768	7/2014	S683-PMC4113768	['poorer Vitamin D status in māori MAY REFLECT darker skin tone or inequitable supply of oral Vitamin D. primary care practitioners SHOULD BE aware of the availability and common use of high-dose Vitamin D preparations, and SHOULD ask about over-the-counter Supplement use before prescribing Pharmaceutical Vitamin D in those of advanced aged.']	[('INCOMPLETE_EVIDENCE', 33), ('SUPERFICIAL_RELATIONSHIP', 37), ('FUTURE_WORK', 130), ('FUTURE_WORK', 222)]	4	[('CHEBI_27300', 'vitamin D', 7, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 92, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 194, 'vitamin D'), ('CHEBI_16158', 'steroid sulfate', 256, 'supplement'), ('CHEBI_52217', 'pharmaceutical', 290, 'pharmaceutical'), ('CHEBI_27300', 'vitamin D', 305, 'vitamin D')]
S747-PMC4113768	PMC4113768	7/2014	S747-PMC4113768	['25(Oh)D assay standardization is, THEREFORE, ESSENTIAL to the development of EVIDENCED-BASED clinical and PUBLIC HEALTH guidelines for Vitamin D.\nmethods: Vitamin D standardization program (vdsp) is an international program designed to promote the standardized laboratory measurement of 25(Oh)D. it was established in 2010 by the us nih office of dietary supplements in collaboration with us national institute of standards and technology (nist), cdc, and ghent university.']	[('PROBABLE_UNDERSTANDING', 34), ('IMPORTANT_CONSIDERATION', 45), ('INCOMPLETE_EVIDENCE', 77), ('IMPORTANT_CONSIDERATION', 106)]	4	[('CHEBI_71657', 'versiconol acetate', 0, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 6, 'D'), ('CHEBI_27300', 'vitamin D', 135, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 155, 'Vitamin D'), ('CHEBI_71657', 'versiconol acetate', 287, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 287, '25(OH)D')]
S782-PMC4113768	PMC4113768	7/2014	S782-PMC4113768	['RANDOMIZED controlled trials of Vitamin D supplementation MAY BE WARRANTED for infants with low 25(Oh)D during the initial months of Life, BUT careful selection of the regimen with close monitoring of safety for those who reach high 25(Oh)D levels will be NECESSARY.']	[('FUTURE_WORK', 0), ('INCOMPLETE_EVIDENCE', 58), ('FUTURE_WORK', 62), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 139), ('IMPORTANT_CONSIDERATION', 256)]	5	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 96, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 102, 'D'), ('UBERON_0000104', 'life cycle', 133, 'life'), ('CHEBI_71657', 'versiconol acetate', 233, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 233, '25(OH ... D')]
S825-PMC4113768	PMC4113768	7/2014	S825-PMC4113768	['there is wide VARIATION in the content and availability of Vitamin D supplements, and DESPITE nice guidelines on Vitamin D supplementation implementation REMAINS UNCERTAIN.']	[('DIFFICULT_TASK', 14), ('ANOMALY_CURIOUS_FINDING', 86), ('INCOMPLETE_EVIDENCE', 154), ('FULL_UNKNOWN', 162)]	4	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D')]
S827-PMC4113768	PMC4113768	7/2014	S827-PMC4113768	['the audit was based on two standards: (1) antenatal standard nice 62- at booking women SHOULD BE given information and advice on the IMPORTANCE of taking a 10 microgram Vitamin D supplement per day during Pregnancy and whilst breastfeeding.']	[('FUTURE_WORK', 87), ('IMPORTANT_CONSIDERATION', 133)]	2	[('CHEBI_27300', 'vitamin D', 169, 'vitamin D'), ('GO_0007565', 'female pregnancy', 205, 'pregnancy')]
S828-PMC4113768	PMC4113768	7/2014	S828-PMC4113768	['health professionals SHOULD ensure that women at greatest RISK of Vitamin D deficiency are asked about Vitamin D supplementation; (2) nice public health GUIDELINE 11- all infants and young children aged 6 months to 5 years SHOULD take a daily supplement containing Vitamin D.\nwe surveyed 20 mothers and 15 health professionals on the Postnatal wards.']	[('FUTURE_WORK', 21), ('IMPORTANT_CONSIDERATION', 21), ('IMPORTANT_CONSIDERATION', 58), ('PROBABLE_UNDERSTANDING', 153), ('FUTURE_WORK', 223)]	5	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 103, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 265, 'vitamin D'), ('GO_0007567', 'parturition', 334, 'postnatal')]
S829-PMC4113768	PMC4113768	7/2014	S829-PMC4113768	['the staff were asked WHETHER they knew WHY Vitamin D is IMPORTANT, WHO should BE offered Vitamin D supplementation and at WHAT dose.']	[('EXPLICIT_QUESTION', 21), ('EXPLICIT_QUESTION', 39), ('IMPORTANT_CONSIDERATION', 56), ('EXPLICIT_QUESTION', 67), ('ANOMALY_CURIOUS_FINDING', 78), ('EXPLICIT_QUESTION', 122)]	6	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 89, 'vitamin D')]
S830-PMC4113768	PMC4113768	7/2014	S830-PMC4113768	['the patients were asked similar questions to ascertain their knowledge of Vitamin D and the level of information they had been given, whether they were taking or plan to take Supplements, whether any other young children in their family take Supplements and their AT-RISK status.']	[('IMPORTANT_CONSIDERATION', 264), ('IMPORTANT_CONSIDERATION', 267)]	2	[('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 175, 'supplements'), ('CHEBI_33341', 'titanium atom', 242, 'supplements')]
S835-PMC4113768	PMC4113768	7/2014	S835-PMC4113768	['only 40% women could give a REASON WHY Vitamin D supplements were IMPORTANT- all of them had taken Supplements.']	[('PROBABLE_UNDERSTANDING', 28), ('EXPLICIT_QUESTION', 35), ('IMPORTANT_CONSIDERATION', 66)]	3	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 99, 'supplements')]
S841-PMC4113768	PMC4113768	7/2014	S841-PMC4113768	['ONLY one-third of staff IDENTIFIED (from options given) the correct dose of Vitamin D supplement for high-risk women.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 24)]	2	[('CHEBI_27300', 'vitamin D', 76, 'vitamin D')]
S843-PMC4113768	PMC4113768	7/2014	S843-PMC4113768	['knowledge levels APPEAR TO CORRELATE with use of Vitamin D supplementation, SUGGESTING that APPROPRIATE information provision is VITAL.']	[('ANOMALY_CURIOUS_FINDING', 17), ('SUPERFICIAL_RELATIONSHIP', 27), ('INCOMPLETE_EVIDENCE', 76), ('IMPORTANT_CONSIDERATION', 92), ('IMPORTANT_CONSIDERATION', 129)]	5	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D')]
S874-PMC4113768	PMC4113768	7/2014	S874-PMC4113768	['they ATTRIBUTED this improvement to an increase in both jumping velocity and height, SUGGESTING greater flexibility and muscular co-ordination after Vitamin D supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 5), ('INCOMPLETE_EVIDENCE', 85)]	2	[('CHEBI_27300', 'vitamin D', 149, 'vitamin D')]
S966-PMC4113768	PMC4113768	7/2014	S966-PMC4113768	['the following lifestyle factors were FOUND to INDEPENDENTLY ASSOCIATE with reduced risk of Vitamin D deficiency: Consumption of a Vitamin D supplement, 100–400 iu/day (or 0.42, p< 0.01); a sunny holiday abroad defined as: a trip to any location within a latitude 51 degrees north or south of the equator, during the local sunny season, 2 months prior to Blood draw, for a duration of ≥1 week (or 0.27, p = 0.02).']	[('INCOMPLETE_EVIDENCE', 37), ('SUPERFICIAL_RELATIONSHIP', 46), ('SUPERFICIAL_RELATIONSHIP', 60)]	3	[('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('GO_0007631', 'feeding behavior', 113, 'consumption'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D'), ('UBERON_0000178', 'blood', 354, 'blood')]
S970-PMC4113768	PMC4113768	7/2014	S970-PMC4113768	['recent travel to a sunny country and Consumption of Vitamin D supplements were PROTECTIVE.']	[('SUPERFICIAL_RELATIONSHIP', 79)]	1	[('GO_0007631', 'feeding behavior', 37, 'consumption'), ('CHEBI_27300', 'vitamin D', 52, 'vitamin D')]
S995-PMC4113768	PMC4113768	7/2014	S995-PMC4113768	['our AIM was to EXPLORE ASSOCIATIONS between maternal and Cord 25(Oh)D concentrations and Vitamin D supplementation during Pregnancy and infancy and Gross Motor Development in infants.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 15), ('SUPERFICIAL_RELATIONSHIP', 23)]	3	[('UBERON_0002240', 'spinal cord', 57, 'cord'), ('CHEBI_71657', 'versiconol acetate', 62, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 65, 'OH ... D'), ('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('GO_0007565', 'female pregnancy', 122, 'pregnancy'), ('GO_0008406', 'gonad development', 148, 'gross motor development')]
S1026-PMC4113768	PMC4113768	7/2014	S1026-PMC4113768	['maternal Vitamin D supplementation reduces the risk of infection and pre-term Birth: a population study on 36,181 Pregnancies\n\nhyppönen, e.; cavadino, a.; williams, d.; czeizel, e.\nbackground: adequate Vitamin D nutrition HAS BEEN SUGGESTED to be ESSENTIAL for the successful maintenance of Pregnancy, with increasing interest on its EFFECTS on Placental function, infection risk and inflammatory responses.']	[('INCOMPLETE_EVIDENCE', 222), ('IMPORTANT_CONSIDERATION', 247), ('SUPERFICIAL_RELATIONSHIP', 334)]	3	[('CHEBI_28384', 'vitamin K', 9, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 9, 'Vitamin D'), ('GO_0007567', 'parturition', 78, 'Birth'), ('GO_0007565', 'female pregnancy', 114, 'Pregnancies'), ('CHEBI_27300', 'vitamin D', 202, 'vitamin D'), ('GO_0007565', 'female pregnancy', 291, 'pregnancy'), ('UBERON_0001987', 'placenta', 345, 'placental')]
S1027-PMC4113768	PMC4113768	7/2014	S1027-PMC4113768	['THIS STUDY was done TO EVALUATE the ASSOCIATION between maternal Vitamin D supplementation during Pregnancy, the risk of bacterial and Viral infections, and their POSSIBLE CONTRIBUTION to the risk of pre-term Birth.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 20), ('SUPERFICIAL_RELATIONSHIP', 36), ('INCOMPLETE_EVIDENCE', 163), ('SUPERFICIAL_RELATIONSHIP', 172)]	5	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('GO_0007565', 'female pregnancy', 98, 'pregnancy'), ('NCBITaxon_1', 'root', 135, 'viral'), ('GO_0007567', 'parturition', 209, 'birth')]
S1033-PMC4113768	PMC4113768	7/2014	S1033-PMC4113768	['compared TO mothers who did not take Vitamin D supplements, risk of any infection was lower for mothers taking Vitamin D as a single Nutrient preparation (or 0.28, 95% ci 0.27–0.30, p< 1.0e−250) and for those using multivitamin only (0.53, 0.52–0.55, p = 1.1e−18).']	[('QUESTION_ANSWERED_BY_THIS_WORK', 9)]	1	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 111, 'vitamin D'), ('CHEBI_33284', 'nutrient', 133, 'nutrient')]
S1035-PMC4113768	PMC4113768	7/2014	S1035-PMC4113768	['risk of premature Birth was NOTABLY lower for mothers who took Vitamin D supplementation during Pregnancy (0.53, 0.43–0.66 for multivitamin; 0.44, 0.40–0.49 for single preparation), with the ASSOCIATION remaining unaffected by adjustment for infections.']	[('ANOMALY_CURIOUS_FINDING', 28), ('SUPERFICIAL_RELATIONSHIP', 191)]	2	[('GO_0007567', 'parturition', 18, 'birth'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('GO_0007565', 'female pregnancy', 96, 'pregnancy')]
S1037-PMC4113768	PMC4113768	7/2014	S1037-PMC4113768	['conclusions: maternal Vitamin D supplementation during Pregnancy was ASSOCIATED with NOTABLE reductions in the risk of infections and pre-term Birth.']	[('SUPERFICIAL_RELATIONSHIP', 69), ('ANOMALY_CURIOUS_FINDING', 85), ('IMPORTANT_CONSIDERATION', 85)]	3	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('GO_0007565', 'female pregnancy', 55, 'pregnancy'), ('GO_0007567', 'parturition', 143, 'birth')]
S1045-PMC4113768	PMC4113768	7/2014	S1045-PMC4113768	['HOWEVER randomized controlled trials in children and adolescents did not show significant EFFECTS on total body bone Mineral density after Vitamin D supplementation.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('SUPERFICIAL_RELATIONSHIP', 90)]	2	[('CHEBI_46662', 'mineral', 117, 'mineral'), ('CHEBI_27300', 'vitamin D', 139, 'vitamin D')]
S1118-PMC4113768	PMC4113768	7/2014	S1118-PMC4113768	['background: approximately one billion People worldwide have low Serum levels of Vitamin D. the AIM of THIS STUDY was TO EVALUATE the dose-response EFFECT in order TO DETERMINE the level of supplementation of Vitamin D REQUIRED in patients with deficiency in Vitamin D concentration (≤20 ng/ml).']	[('QUESTION_ANSWERED_BY_THIS_WORK', 95), ('QUESTION_ANSWERED_BY_THIS_WORK', 102), ('QUESTION_ANSWERED_BY_THIS_WORK', 117), ('SUPERFICIAL_RELATIONSHIP', 147), ('QUESTION_ANSWERED_BY_THIS_WORK', 163), ('IMPORTANT_CONSIDERATION', 218)]	6	[('NCBITaxon_10088', 'Mus <genus>', 38, 'people'), ('UBERON_0001977', 'blood serum', 64, 'serum'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 208, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 258, 'vitamin D')]
S1132-PMC4113768	PMC4113768	7/2014	S1132-PMC4113768	['overall, 98% of the subjects supplemented with 400,000 iu of Vitamin D had their level of 25(Oh)D above 20 ng/ml at week 8, WHILE 84% and 52% of patients receiving 200,000 iu or 100,000 iu reached that level after 12 weeks of treatment.']	[('ANOMALY_CURIOUS_FINDING', 124)]	1	[('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 90, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 90, '25(OH)D')]
S1283-PMC4113768	PMC4113768	7/2014	S1283-PMC4113768	['; filteau, s.; trilok, kumar, g.\nbackground: Vitamin D status or parent-selected Vitamin D supplementation in infancy HAVE BEEN ASSOCIATED with better bone growth and mineralization in later childhood.']	[('INCOMPLETE_EVIDENCE', 118), ('SUPERFICIAL_RELATIONSHIP', 128)]	2	[('CHEBI_28384', 'vitamin K', 45, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 81, 'vitamin D')]
S1285-PMC4113768	PMC4113768	7/2014	S1285-PMC4113768	['a RECENT meta-analysis SHOWED INCONSISTENT EFFECTS of Vitamin D supplementation on bone Mineral density of healthy children.']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 23), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 30), ('SUPERFICIAL_RELATIONSHIP', 43)]	4	[('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('CHEBI_46662', 'mineral', 88, 'mineral')]
S1288-PMC4113768	PMC4113768	7/2014	S1288-PMC4113768	['for the present divids-2 study we followed up the children, now aged 3–6 years, to measure bone structure and strength by quantitative ultrasound (qus).the PURPOSE of THE STUDY was (1) TO DETERMINE the EFFECT of Vitamin D supplementation in infancy on bone structure and strength of children aged 3–6 years; (2) TO EVALUATE the ASSOCIATION of current Vitamin D status with bone structure and strength.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 156), ('QUESTION_ANSWERED_BY_THIS_WORK', 167), ('QUESTION_ANSWERED_BY_THIS_WORK', 185), ('SUPERFICIAL_RELATIONSHIP', 202), ('QUESTION_ANSWERED_BY_THIS_WORK', 312), ('SUPERFICIAL_RELATIONSHIP', 328)]	6	[('CHEBI_27300', 'vitamin D', 212, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 351, 'vitamin D')]
S1331-PMC4113768	PMC4113768	7/2014	S1331-PMC4113768	"[""Vitamin D supplementation in an edinburgh general practice population and ANECDOTAL evidence\n\nrhein, h.m.; johnson, g.\nbackground: after we became aware of the widespread Vitamin D deficiency in our scottish general practice population in edinburgh at a latitude of 56', our patients have received for the past few years the offer of prescriptions for Vitamin D supplements: 20,000 iu weekly for MOST Adults, 2000 iu daily for Pregnant women, 1000 iu daily for children aged 5–12, 400 iu daily for babies and children aged 0–5.""]"	[('INCOMPLETE_EVIDENCE', 74), ('PROBABLE_UNDERSTANDING', 396)]	2	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'Vitamin'), ('CHEBI_27300', 'vitamin D', 171, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 352, 'vitamin D'), ('UBERON_0007023', 'adult organism', 401, 'adults'), ('GO_0007565', 'female pregnancy', 427, 'pregnant')]
S1345-PMC4113768	PMC4113768	7/2014	S1345-PMC4113768	['it is our IMPRESSION that quality of Life in MOST cancer patients was good after Vitamin D supplementation, and in those who died this was right up until their final stage.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 10), ('PROBABLE_UNDERSTANDING', 45)]	2	[('UBERON_0000104', 'life cycle', 37, 'life'), ('CHEBI_27300', 'vitamin D', 81, 'vitamin D')]
S1347-PMC4113768	PMC4113768	7/2014	S1347-PMC4113768	['cancer patients APPEAR to have an improved quality of Life after Vitamin D supplementation.']	[('ANOMALY_CURIOUS_FINDING', 16)]	1	[('UBERON_0000104', 'life cycle', 54, 'life'), ('CHEBI_27300', 'vitamin D', 65, 'vitamin D')]
S1348-PMC4113768	PMC4113768	7/2014	S1348-PMC4113768	['in the absence of any known negative EFFECTS of Vitamin D supplementation and WHILE waiting for conclusive trials it COULD BE beneficial for many cancer patients to be tested and treated for Vitamin D deficiency.']	[('SUPERFICIAL_RELATIONSHIP', 37), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 78), ('INCOMPLETE_EVIDENCE', 117)]	3	[('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 191, 'vitamin D')]
S1524-PMC4113768	PMC4113768	7/2014	S1524-PMC4113768	['we ESTIMATED total Vitamin D intake as the sum of dietary Vitamin D, usage of multivitamin and Vitamin D supplementation and intake of Vitamin D3-fortified bread and Milk for the fortification group.']	[('INCOMPLETE_EVIDENCE', 3)]	1	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 58, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 95, 'vitamin D'), ('CHEBI_33279', 'vitamin D5', 135, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 135, 'vitamin D3'), ('UBERON_0001913', 'milk', 166, 'milk')]
S1534-PMC4113768	PMC4113768	7/2014	S1534-PMC4113768	['carriers of a high grs MAY NEED a higher amount of Vitamin D supplementation to achieve adequate s-25(Oh)D concentrations.']	[('INCOMPLETE_EVIDENCE', 23), ('IMPORTANT_CONSIDERATION', 27)]	2	[('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('PR_000000036', 'BMP receptor type-1B', 98, '-25'), ('CHEBI_71657', 'versiconol acetate', 99, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 105, 'D')]
S1536-PMC4113768	PMC4113768	7/2014	S1536-PMC4113768	['in the FUTURE, Genetic FACTORS MIGHT be taken into ACCOUNT when RECOMMENDING Vitamin D supplementation or Food fortification.']	[('FUTURE_WORK', 7), ('SUPERFICIAL_RELATIONSHIP', 23), ('INCOMPLETE_EVIDENCE', 31), ('IMPORTANT_CONSIDERATION', 51), ('FUTURE_WORK', 64)]	5	[('SO_0000704', 'gene', 15, 'genetic'), ('CHEBI_27300', 'vitamin D', 77, 'vitamin D'), ('CHEBI_33290', 'food', 106, 'food')]
S1542-PMC4113768	PMC4113768	7/2014	S1542-PMC4113768	['further, Vitamin D supplementation MAY specifically lower anti-Ebna-1 titres.']	[('INCOMPLETE_EVIDENCE', 35)]	1	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('PR_000006877', 'Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial', 63, 'EBNA-1')]
S1641-PMC4113768	PMC4113768	7/2014	S1641-PMC4113768	['background: meta-analysis of clinical trials of Vitamin D supplementation for the PREVENTION of acute Respiratory infection (ari) SHOWS a PROTECTIVE EFFECT in the general population, BUT there is CONTROVERSY regarding the OPTIMAL dosing regimen.']	[('SUPERFICIAL_RELATIONSHIP', 82), ('INCOMPLETE_EVIDENCE', 130), ('SUPERFICIAL_RELATIONSHIP', 138), ('SUPERFICIAL_RELATIONSHIP', 149), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 183), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 196), ('IMPORTANT_CONSIDERATION', 222)]	7	[('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 102, 'respiratory')]
S1642-PMC4113768	PMC4113768	7/2014	S1642-PMC4113768	['low-dose Vitamin D supplementation is already RECOMMENDED in older Adults for PREVENTION of fractures and falls, but clinical trials investigating WHETHER higher doses COULD provide additional protection against ari are LACKING.']	[('FUTURE_WORK', 46), ('SUPERFICIAL_RELATIONSHIP', 78), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 147), ('INCOMPLETE_EVIDENCE', 168), ('FULL_UNKNOWN', 220)]	5	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('UBERON_0007023', 'adult organism', 67, 'adults')]
S1643-PMC4113768	PMC4113768	7/2014	S1643-PMC4113768	['methods: we CONDUCTED a double-blind cluster-randomised placebo-controlled trial of high- vs. low-dose Vitamin D supplementation in residents and staff of sheltered accommodation schemes in london, uk.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 12)]	1	[('CHEBI_27300', 'vitamin D', 103, 'vitamin D')]
S1651-PMC4113768	PMC4113768	7/2014	S1651-PMC4113768	['conclusions: addition of intermittent bolus-dose Vitamin D supplementation to a daily low-dose regimen improved Vitamin D status in older Adults and their carers, BUT it did not influence risk of ari, and was less effective at preventing uri.']	[('ANOMALY_CURIOUS_FINDING', 163)]	1	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 112, 'vitamin D'), ('UBERON_0007023', 'adult organism', 138, 'adults')]
S1670-PMC4113768	PMC4113768	7/2014	S1670-PMC4113768	['the difference in mean Serum 25(Oh)D concentration at follow-up vs. baseline REMAINED statistically significant after exclusion of 14 participants who were taking supplemental Vitamin D at follow-up and/or who had increased their sun exposure since time of diagnosis ( p = 0.005), and after exclusion of 17 participants whose baseline sample was taken from march to july inclusive ( p = 0.0003).']	[('INCOMPLETE_EVIDENCE', 77)]	1	[('UBERON_0001977', 'blood serum', 23, 'serum'), ('CHEBI_71657', 'versiconol acetate', 29, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 29, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 176, 'vitamin D')]
S1673-PMC4113768	PMC4113768	7/2014	S1673-PMC4113768	['differences in mean Serum 25(Oh)D concentration between the two time points were not EXPLAINED by differences in use of Vitamin D supplements, self-reported sun exposure or season of sampling at follow-up vs. baseline.']	[('PROBABLE_UNDERSTANDING', 85)]	1	[('UBERON_0001977', 'blood serum', 20, 'serum'), ('CHEBI_71657', 'versiconol acetate', 26, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 26, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin D')]
S1718-PMC4113768	PMC4113768	7/2014	S1718-PMC4113768	['the MAJOR DETERMINANTS of Vitamin D status were season of sampling, sun-seeking behaviour, use of Vitamin D supplements and bmi.']	[('IMPORTANT_CONSIDERATION', 4), ('SUPERFICIAL_RELATIONSHIP', 10)]	2	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 98, 'vitamin D')]
S1748-PMC4113768	PMC4113768	7/2014	S1748-PMC4113768	['MANY STUDIES HAVE SHOWN an inverse ASSOCIATION between 25Ohd levels and a wide range of disorders, THUS Vitamin D supplementation HAS BEEN promoted to support good health.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 13), ('SUPERFICIAL_RELATIONSHIP', 35), ('PROBABLE_UNDERSTANDING', 99), ('INCOMPLETE_EVIDENCE', 130)]	5	"[('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 55, '25OHD'), ('CHEBI_27300', 'vitamin D', 104, 'vitamin D')]"
S1801-PMC4113768	PMC4113768	7/2014	S1801-PMC4113768	['HOWEVER, 25(Oh)D3Levels at year one SHOWED an INDEPENDENT TREND: due to the general rickets prophylaxis within the first year (87% of the children were supplemented with Vitamin D at least during the first 3 months), absolute 25(Oh)D3Was generally higher with almost no variations due to seasonal sunlight exposure.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 36), ('SUPERFICIAL_RELATIONSHIP', 46), ('INCOMPLETE_EVIDENCE', 58)]	5	[('CHEBI_51924', 'ethyl 2-cyanoacetoacetate', 9, '25(OH)D3levels'), ('PR_000006775', 'cytoplasmic dynein 2 heavy chain 1', 15, 'D3levels'), ('CHEBI_27300', 'vitamin D', 170, 'vitamin D'), ('CHEBI_73386', 'Ala-Val-Asp-Ser', 226, '25(OH)D3was'), ('PR_000012979', 'DNA-directed DNA/RNA polymerase mu', 232, 'D3was')]
S1828-PMC4113768	PMC4113768	7/2014	S1828-PMC4113768	['in SOME of the elderly subjects lower Plasma 25(Oh)D levels coexisting with high alkaline phosphatase activity MAY INDICATE developing osteomalacia.taking INTO ACCOUNT lower Plasma 25(Oh)D, 1,25(Oh)D and calcium levels among the MAJORITY of centenarians, the sufficient Vitamin D and calcium supplementation SHOULD be systematically APPLIED also in the oldest old.']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 111), ('INCOMPLETE_EVIDENCE', 115), ('INCOMPLETE_EVIDENCE', 155), ('PROBABLE_UNDERSTANDING', 229), ('FUTURE_WORK', 308), ('SUPERFICIAL_RELATIONSHIP', 333)]	7	[('UBERON_0001969', 'blood plasma', 38, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 45, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 45, '25(OH)D'), ('UBERON_0001969', 'blood plasma', 174, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 181, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 192, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 270, 'vitamin D')]
S1881-PMC4113768	PMC4113768	7/2014	S1881-PMC4113768	['by proving the effectiveness of Food fortification in this manner, the OPPORTUNITY now exists to increase the diversity and range of Foods available to the population that could provide adequate Vitamin D. population groups TYPICALLY resistant to traditional methods of supplementation ( i.e.']	[('FUTURE_WORK', 71), ('PROBABLE_UNDERSTANDING', 224)]	2	[('CHEBI_33290', 'food', 32, 'food'), ('CHEBI_33290', 'food', 133, 'foods'), ('CHEBI_27300', 'vitamin D', 195, 'vitamin D')]
S1890-PMC4113768	PMC4113768	7/2014	S1890-PMC4113768	['a universal approach to Vitamin D supplementation HAS RECENTLY BEEN SUGGESTED by the chief medical officer (davies, d.c.']	[('INCOMPLETE_EVIDENCE', 50)]	1	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D')]
S1970-PMC4113768	PMC4113768	7/2014	S1970-PMC4113768	['SINCE Vitamin D is also obtained from dietary sources and Vitamin D supplements; THIS STUDY INVESTIGATED the INFLUENCE of Food and Vitamin D supplements on the Serum 25-Hydroxy Vitamin D (25(Oh)D) concentration in children in the netherlands between october and april.']	[('PROBABLE_UNDERSTANDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 81), ('QUESTION_ANSWERED_BY_THIS_WORK', 92), ('SUPERFICIAL_RELATIONSHIP', 109)]	4	[('CHEBI_27300', 'vitamin D', 6, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 58, 'vitamin D'), ('CHEBI_33290', 'food', 122, 'food'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D'), ('UBERON_0001977', 'blood serum', 160, 'serum'), ('CHEBI_43176', 'hydroxy group', 169, 'hydroxy'), ('CHEBI_27300', 'vitamin D', 177, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 188, '25(OH)D')]
S2040-PMC4113768	PMC4113768	7/2014	S2040-PMC4113768	['one of our early OBSERVATIONS was to note the primacy of Oral Intake over sunlight exposure in both the prevention and correction of hypovitaminosis d. we have DEMONSTRATED immense improvement in Vitamin D status since that time, DUE TO ready availability of low dose Vitamin D supplements and DUE TO the increasing fortification of foodstuffs with Vitamin D, starting with the fortification of milk in the mid-1980s.']	[('INCOMPLETE_EVIDENCE', 17), ('INCOMPLETE_EVIDENCE', 160), ('PROBABLE_UNDERSTANDING', 230), ('PROBABLE_UNDERSTANDING', 294)]	4	[('UBERON_0000165', 'mouth', 57, 'oral'), ('GO_0007631', 'feeding behavior', 62, 'intake'), ('CHEBI_27300', 'vitamin D', 196, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 268, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 349, 'vitamin D')]
S2049-PMC4113768	PMC4113768	7/2014	S2049-PMC4113768	['conclusions: Vitamin D status in ireland has improved immensely in ireland over the past 40 years, but TARGETED PUBLIC HEALTH policies of low-dose supplementation ARE NEEDED TO address AT-RISK groups, and mandated fortification to SAFE levels SHOULD maintain Vitamin D adequacy in the population.']	[('FUTURE_WORK', 103), ('IMPORTANT_CONSIDERATION', 112), ('FUTURE_WORK', 163), ('QUESTION_ANSWERED_BY_THIS_WORK', 174), ('IMPORTANT_CONSIDERATION', 185), ('IMPORTANT_CONSIDERATION', 231), ('FUTURE_WORK', 243)]	7	[('CHEBI_28384', 'vitamin K', 13, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 259, 'vitamin D')]
S2086-PMC4113768	PMC4113768	7/2014	S2086-PMC4113768	['conclusions: groups AT RISK of hypovitaminosis D NEED to consume Vitamin D-rich or fortified Foods and would BENEFIT from taking a daily low dose Vitamin D supplement of 5–10 µg (200–400 iu) IN KEEPING WITH the iom specifications for total daily Vitamin D intake.']	[('IMPORTANT_CONSIDERATION', 20), ('IMPORTANT_CONSIDERATION', 49), ('IMPORTANT_CONSIDERATION', 109), ('INCOMPLETE_EVIDENCE', 191)]	4	[('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 47, 'D'), ('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('CHEBI_33290', 'food', 93, 'foods'), ('CHEBI_27300', 'vitamin D', 146, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 246, 'vitamin D')]
S2088-PMC4113768	PMC4113768	7/2014	S2088-PMC4113768	['the ESTIMATED average Vitamin D REQUIREMENT from all dietary sources is STRONGLY EVIDENCE-BASED and SHOULD represent the target total daily amount for everyone including Supplement users.']	[('INCOMPLETE_EVIDENCE', 4), ('IMPORTANT_CONSIDERATION', 32), ('PROBABLE_UNDERSTANDING', 72), ('INCOMPLETE_EVIDENCE', 81), ('FUTURE_WORK', 100), ('IMPORTANT_CONSIDERATION', 100)]	6	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('CHEBI_16158', 'steroid sulfate', 170, 'supplement')]
S2132-PMC4113768	PMC4113768	7/2014	S2132-PMC4113768	['in multivariate analyses, sunnier season, lower latitude, higher Vitamin D intake index, Vitamin D supplement use, higher physical activity, lower bmi, and marital status were significantly ASSOCIATED with higher Serum 25(Oh)D levels in both sexes.']	[('SUPERFICIAL_RELATIONSHIP', 190)]	1	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('UBERON_0001977', 'blood serum', 213, 'serum'), ('CHEBI_71657', 'versiconol acetate', 219, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 219, '25 ... OH ... D')]
S2147-PMC4113768	PMC4113768	7/2014	S2147-PMC4113768	['Vitamin D deficient Rats were further subdivided into three groups: one group continued on deficient diet, second group was rescued with control diet to see for reversal of EFFECTS observed in d-deficiency, and the third group of Rats was supplemented with high calcium diet alone to delineate the ROLE of calcium per se on the muscle atrophy SEEN in Vitamin D deficiency.']	[('SUPERFICIAL_RELATIONSHIP', 173), ('SUPERFICIAL_RELATIONSHIP', 298), ('INCOMPLETE_EVIDENCE', 343)]	3	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 20, 'rats'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 230, 'rats'), ('CHEBI_27300', 'vitamin D', 351, 'vitamin D')]
S2159-PMC4113768	PMC4113768	7/2014	S2159-PMC4113768	['IN CONTRAST, a GROWING NUMBER OF SMALL randomised trials testing the EFFECT of Vitamin D supplementation on Blood pressure have REPORTED MIXED results.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 15), ('INCOMPLETE_EVIDENCE', 23), ('INCOMPLETE_EVIDENCE', 33), ('SUPERFICIAL_RELATIONSHIP', 69), ('INCOMPLETE_EVIDENCE', 128), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 137)]	7	[('CHEBI_27300', 'vitamin D', 79, 'vitamin D'), ('UBERON_0000178', 'blood', 108, 'blood')]
S2172-PMC4113768	PMC4113768	7/2014	S2172-PMC4113768	['conclusion: this meta-analysis SUGGESTS Vitamin D supplementation does not significantly reduce Blood pressure at the doses tested to date.']	[('INCOMPLETE_EVIDENCE', 31)]	1	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('UBERON_0000178', 'blood', 96, 'blood')]
S2210-PMC4113768	PMC4113768	7/2014	S2210-PMC4113768	['increased Food allergy with Vitamin D: a randomized, double-blind, placebo-controlled trial\n\nurashima, m.; norizoe, c.; akiyama, n.; segawa, t.; tachimoto, h.; mezawa, h.; ida, h.\nbackground: to elucidate WHETHER maternal Vitamin D supplementation during Lactation improves infantile eczema and other subsequent allergic disorders, a randomized, double-blind, placebo-controlled trial was performed.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 205)]	1	[('CHEBI_33290', 'food', 10, 'Food'), ('CHEBI_28384', 'vitamin K', 28, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 222, 'vitamin D'), ('GO_0007595', 'lactation', 255, 'lactation')]
S2216-PMC4113768	PMC4113768	7/2014	S2216-PMC4113768	['conclusions: these results SUGGEST that Vitamin D supplementation MAY not decrease the severity of infantile eczema at three months of age, but MAY RATHER increase the risk of later Food allergy up to two years of age.']	[('INCOMPLETE_EVIDENCE', 27), ('INCOMPLETE_EVIDENCE', 66), ('INCOMPLETE_EVIDENCE', 144), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 148)]	4	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('CHEBI_33290', 'food', 182, 'food')]
S2219-PMC4113768	PMC4113768	7/2014	S2219-PMC4113768	['randomized, double-blind, placebo-controlled trial of Vitamin D supplement in parkinson’s disease\n\nurashima, m.; suzuki, m.; yoshioka, m.; hashimoto, m.; murakami, m.; noya, m.; takahashi, d.\nbackground: in our PREVIOUS STUDY, higher Serum 25-Hydroxy Vitamin D (25Ohd) levels and the Vitamin D receptor (vdr) fokicc genotype were ASSOCIATED with milder parkinson’s disease (pd).']	[('INCOMPLETE_EVIDENCE', 211), ('SUPERFICIAL_RELATIONSHIP', 330)]	2	"[('CHEBI_28384', 'vitamin K', 54, 'Vitamin D'), ('UBERON_0001977', 'blood serum', 234, 'serum'), ('CHEBI_67376', 'dihydrooroxylin A', 240, '25-hydroxy vitamin'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 259, 'D'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 262, '25OHD'), ('CHEBI_27300', 'vitamin D', 284, 'vitamin D')]"
S2334-PMC4113768	PMC4113768	7/2014	S2334-PMC4113768	['in THIS PROSPECTIVE INTERVENTIONAL STUDY we INVESTIGATED the EFFECTS of Vitamin D3Supplementation on the Metabolic profiles of saudi t2dm subjects pre- and post-Vitamin D supplementation over an 18-month period.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('QUESTION_ANSWERED_BY_THIS_WORK', 20), ('QUESTION_ANSWERED_BY_THIS_WORK', 44), ('SUPERFICIAL_RELATIONSHIP', 61)]	4	[('CHEBI_52915', 'phosphatediyl group', 72, 'vitamin D3supplementation'), ('PR_000006649', 'zinc finger protein neuro-d4', 80, 'D3supplementation'), ('GO_0008152', 'metabolic process', 105, 'metabolic'), ('CHEBI_27300', 'vitamin D', 161, 'vitamin D')]
S2357-PMC4113768	PMC4113768	7/2014	S2357-PMC4113768	['background: seasonal variations in circulating Vitamin D levels provide VITAL INFORMATION as to the most APPROPRIATE time to either start or increase Vitamin D supplementation in order to maintain OPTIMAL Vitamin D levels.']	[('IMPORTANT_CONSIDERATION', 72), ('INCOMPLETE_EVIDENCE', 78), ('IMPORTANT_CONSIDERATION', 105), ('IMPORTANT_CONSIDERATION', 197)]	4	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 150, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 205, 'vitamin D')]
S2367-PMC4113768	PMC4113768	7/2014	S2367-PMC4113768	['increased Vitamin D supplementation is THUS RECOMMENDED to maintain OPTIMAL Serum 25(Oh) Vitamin D levels during the summer season.']	[('PROBABLE_UNDERSTANDING', 39), ('FUTURE_WORK', 44), ('IMPORTANT_CONSIDERATION', 68)]	3	[('CHEBI_27300', 'vitamin D', 10, 'vitamin D'), ('UBERON_0001977', 'blood serum', 76, 'serum'), ('CHEBI_30778', 'gallic acid', 82, '25(OH)'), ('CHEBI_27300', 'vitamin D', 89, 'vitamin D')]
S2385-PMC4113768	PMC4113768	7/2014	S2385-PMC4113768	['OUR FINDINGS implicate that Vitamin D supplementation becomes more IMPORTANT in older age groups and during wintertime.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('IMPORTANT_CONSIDERATION', 67)]	2	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D')]
S2393-PMC4113768	PMC4113768	7/2014	S2393-PMC4113768	['background: we performed a systematic review TO EXPLORE WHETHER (1) low maternal circulating 25(Oh)-Vitamin D (25(Oh)D) during Pregnancy is ASSOCIATED with impairment of offspring health; and (2) maternal supplementation with Vitamin D in Pregnancy MIGHT ameliorate these EFFECTS.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 45), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 56), ('SUPERFICIAL_RELATIONSHIP', 140), ('INCOMPLETE_EVIDENCE', 249), ('SUPERFICIAL_RELATIONSHIP', 272)]	5	[('CHEBI_63056', 'zinc cation', 93, '25(OH'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 111, '25(OH)D'), ('GO_0007565', 'female pregnancy', 127, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 226, 'vitamin D'), ('GO_0007565', 'female pregnancy', 239, 'pregnancy')]
S2398-PMC4113768	PMC4113768	7/2014	S2398-PMC4113768	['eligible studies included Pregnant women and their offspring, and one or more RELEVANT exposures (either assessment of Vitamin D status (dietary intake, sunlight exposure, circulating 25(Oh)D) or supplementation of participants with Vitamin D or Vitamin D containing Food e.g., oily fish) and outcomes (offspring birth weight, Birth length, Head circumference, bone mass, anthropometry and body composition, risk of asthma and atopy, small for Gestational dates, Preterm Birth, type 1 diabetes, low Birth weight, Serum calcium concentration, Blood pressure and rickets).']	[('IMPORTANT_CONSIDERATION', 78)]	1	[('GO_0007565', 'female pregnancy', 26, 'pregnant'), ('CHEBI_27300', 'vitamin D', 119, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 184, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 184, '25(OH'), ('PR_000006444', 'diacylglycerol kinase delta', 190, 'D'), ('CHEBI_27300', 'vitamin D', 233, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 246, 'vitamin D'), ('CHEBI_33290', 'food', 267, 'food'), ('GO_0007567', 'parturition', 327, 'birth'), ('UBERON_0000033', 'head', 341, 'head'), ('GO_0007565', 'female pregnancy', 444, 'gestational'), ('GO_0007565', 'female pregnancy', 463, 'preterm birth'), ('GO_0007567', 'parturition', 499, 'birth'), ('UBERON_0001977', 'blood serum', 513, 'serum'), ('UBERON_0000178', 'blood', 542, 'blood')]
S2465-PMC4113768	PMC4113768	7/2014	S2465-PMC4113768	['of the participants who did not take Supplements, none achieved the current uk RECOMMENDED dietary intake of 400 iu Vitamin D per day for those AT RISK of deficiency; and for the supplement users the RECOMMENDATION was ONLY achieved by one Person in spring and 2 People in summer and autumn.']	[('FUTURE_WORK', 79), ('IMPORTANT_CONSIDERATION', 144), ('FUTURE_WORK', 200), ('INCOMPLETE_EVIDENCE', 219)]	4	[('CHEBI_33341', 'titanium atom', 37, 'supplements'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 240, 'person'), ('NCBITaxon_10088', 'Mus <genus>', 263, 'people')]
S2467-PMC4113768	PMC4113768	7/2014	S2467-PMC4113768	['use of Vitamin D supplements is RECOMMENDED and NEEDS to be consistent to avoid risk of Vitamin D deficiency in this population.']	[('FUTURE_WORK', 32), ('FUTURE_WORK', 48)]	2	[('CHEBI_27300', 'vitamin D', 7, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 88, 'vitamin D')]
S2500-PMC4113768	PMC4113768	7/2014	S2500-PMC4113768	['the AIM of THIS STUDY was TO INVESTIGATE the EFFECT of supplemental Vitamin D on bone Mineral accretion in adolescent female athletes.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 11), ('QUESTION_ANSWERED_BY_THIS_WORK', 26), ('SUPERFICIAL_RELATIONSHIP', 45)]	4	[('CHEBI_27300', 'vitamin D', 68, 'vitamin D'), ('CHEBI_46662', 'mineral', 86, 'mineral')]
S2517-PMC4113768	PMC4113768	7/2014	S2517-PMC4113768	['THESE FINDINGS SUGGEST that; (1) there is no additional BENEFIT to calcium absorption or bone mineralisation from a Blood level for 25(Oh)D above ~75 nmol/l; (2)DESPITE adequate Vitamin D and regular physical activity lower dietary Calcium intake is STILL a PREDICTOR of lower total body bmd and bmc; and (3) in certain population groups with baseline 25(Oh)D > 75 nmol/l, Vitamin D supplementation of 50,000 iu/month does not significantly increase 25(Oh)D concentrations over a 12 month period, but POSSIBLY PREVENTS seasonal decline.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 15), ('IMPORTANT_CONSIDERATION', 56), ('ANOMALY_CURIOUS_FINDING', 161), ('IMPORTANT_CONSIDERATION', 250), ('SUPERFICIAL_RELATIONSHIP', 258), ('INCOMPLETE_EVIDENCE', 501), ('SUPERFICIAL_RELATIONSHIP', 510)]	8	[('UBERON_0000178', 'blood', 116, 'blood'), ('CHEBI_71657', 'versiconol acetate', 132, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 132, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 178, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 232, 'calcium'), ('CHEBI_71657', 'versiconol acetate', 352, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 352, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 373, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 450, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 450, '25(OH)D')]
S2521-PMC4113768	PMC4113768	7/2014	S2521-PMC4113768	['background: understanding of the EFFECT of Vitamin D supplementation on Plasma 25(Oh)D levels is ESSENTIAL to optimizing nutritional status and health.']	[('SUPERFICIAL_RELATIONSHIP', 33), ('IMPORTANT_CONSIDERATION', 97)]	2	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 72, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 79, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 79, '25 ... OH ... D')]
S2523-PMC4113768	PMC4113768	7/2014	S2523-PMC4113768	['the dose response RELATIONSHIP between Vitamin D supplementation and Plasma 25(Oh)D levels IS THOUGHT TO be biphasic (exponential at low intakes and linear at high), HOWEVER this is NOT WELL DOCUMENTED for supplementation levels that exceed 2000 iu per day for large populations of healthy Individuals.']	[('SUPERFICIAL_RELATIONSHIP', 18), ('INCOMPLETE_EVIDENCE', 91), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 166), ('INCOMPLETE_EVIDENCE', 182)]	4	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 69, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 76, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 76, '25(OH ... D'), ('NCBITaxon_1', 'root', 290, 'individuals')]
S2544-PMC4113768	PMC4113768	7/2014	S2544-PMC4113768	['our OBJECTIVE is TO EXAMINE the INFLUENCE of Vitamin D supplementation on Serum calcium levels and the RISK for hypercalcimia in healthy volunteers in the pure north health program.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 17), ('SUPERFICIAL_RELATIONSHIP', 32), ('IMPORTANT_CONSIDERATION', 103)]	4	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('UBERON_0001977', 'blood serum', 74, 'serum')]
S2546-PMC4113768	PMC4113768	7/2014	S2546-PMC4113768	['methods: the examination of the INFLUENCE of Vitamin D supplementation and 25(Oh)D on Serum calcium levels was based on 8906 baseline and follow-up assessments of Vitamin D supplementation, Serum 25(Oh)D and calcium of healthy participants of the pure north wellness program.']	[('SUPERFICIAL_RELATIONSHIP', 32)]	1	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 75, '25(OH)D'), ('UBERON_0001977', 'blood serum', 86, 'serum'), ('CHEBI_27300', 'vitamin D', 163, 'vitamin D'), ('UBERON_0001977', 'blood serum', 190, 'serum'), ('CHEBI_71657', 'versiconol acetate', 196, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 196, '25 ... OH ... D')]
S2547-PMC4113768	PMC4113768	7/2014	S2547-PMC4113768	['we applied gee regression methods to quantify the ASSOCIATIONS of Vitamin D supplementation and 25(Oh)D with Serum Calcium, while considering the CONFOUNDING POTENTIAL of age, gender, and body weight status.']	[('SUPERFICIAL_RELATIONSHIP', 50), ('PROBLEM_COMPLICATION', 146), ('INCOMPLETE_EVIDENCE', 158)]	3	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 96, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 102, 'D'), ('UBERON_0001977', 'blood serum', 109, 'serum'), ('CHEBI_22313', 'alkaline earth metal atom', 115, 'calcium')]
S2549-PMC4113768	PMC4113768	7/2014	S2549-PMC4113768	['the risk for hypercalcemia in this sample of healthy volunteers was low and did not increase AS a result of higher levels of Vitamin D supplementation.']	[('PROBABLE_UNDERSTANDING', 93)]	1	[('CHEBI_27300', 'vitamin D', 125, 'vitamin D')]
S2552-PMC4113768	PMC4113768	7/2014	S2552-PMC4113768	['conclusion: these FINDING CONFIRM that healthy subjects supplementing with Vitamin D at modest levels are not at INCREASED RISK for hypercalcemia and SUGGEST that the same applies for supplementation levels as high as 20,000 iu per day.']	[('INCOMPLETE_EVIDENCE', 18), ('INCOMPLETE_EVIDENCE', 26), ('IMPORTANT_CONSIDERATION', 113), ('INCOMPLETE_EVIDENCE', 150)]	4	[('CHEBI_27300', 'vitamin D', 75, 'vitamin D')]
S2554-PMC4113768	PMC4113768	7/2014	S2554-PMC4113768	['we RECOMMEND that 25(Oh)D and Serum calcium be monitored when supplementing higher doses of Vitamin D.\n\n2.123.']	[('FUTURE_WORK', 3)]	1	[('CHEBI_71657', 'versiconol acetate', 18, '25(OH)D'), ('UBERON_0001977', 'blood serum', 30, 'serum'), ('CHEBI_27300', 'vitamin D', 92, 'vitamin D')]
S2561-PMC4113768	PMC4113768	7/2014	S2561-PMC4113768	['it CAN be simply and effectively treated through Vitamin D supplementation.']	[('INCOMPLETE_EVIDENCE', 3)]	1	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D')]
S2574-PMC4113768	PMC4113768	7/2014	S2574-PMC4113768	['conclusion: THIS work SHOWS that Genetic FACTORS are ASSOCIATED with change in 25(Oh)D after Vitamin D supplementation.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 12), ('INCOMPLETE_EVIDENCE', 22), ('SUPERFICIAL_RELATIONSHIP', 41), ('SUPERFICIAL_RELATIONSHIP', 53)]	4	[('SO_0000704', 'gene', 33, 'genetic'), ('CHEBI_71657', 'versiconol acetate', 79, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 93, 'vitamin D')]
S2616-PMC4113768	PMC4113768	7/2014	S2616-PMC4113768	['we INVESTIGATED the EFFECT of Vitamin D supplementation on the Metabolic status of Individuals at increased risk of developing t2d.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('SUPERFICIAL_RELATIONSHIP', 20)]	2	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0008152', 'metabolic process', 63, 'metabolic'), ('NCBITaxon_1', 'root', 83, 'individuals')]
S2631-PMC4113768	PMC4113768	7/2014	S2631-PMC4113768	['placebo is SUGGESTIVE of a beneficial EFFECT of Vitamin D supplementation on Arterial stiffness.']	[('INCOMPLETE_EVIDENCE', 11), ('SUPERFICIAL_RELATIONSHIP', 38)]	2	[('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('UBERON_0001637', 'artery', 77, 'arterial')]
S2646-PMC4113768	PMC4113768	7/2014	S2646-PMC4113768	['median maternal 25(Oh)D was 61 nmol/l (iqr 43–88 nmol/l), and ONLY 9.2% of mothers were using Vitamin D supplementation (at LEAST 400 iu/day) in late Pregnancy.']	[('ANOMALY_CURIOUS_FINDING', 62), ('PROBABLE_UNDERSTANDING', 124)]	2	[('CHEBI_71657', 'versiconol acetate', 16, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 16, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin D'), ('GO_0007565', 'female pregnancy', 150, 'pregnancy')]
S2664-PMC4113768	PMC4113768	7/2014	S2664-PMC4113768	['this uncertainty can ONLY be resolved by well-designed randomized controlled trials (rcts) to determine the EFFECT of Vitamin D supplementation on bp.']	[('INCOMPLETE_EVIDENCE', 21), ('SUPERFICIAL_RELATIONSHIP', 108)]	2	[('CHEBI_27300', 'vitamin D', 118, 'vitamin D')]
S2674-PMC4113768	PMC4113768	7/2014	S2674-PMC4113768	['conclusions: long-term monthly Vitamin D supplementation, which increased mean 25(Oh)D concentration above 100 nmol/l for 18 months, had no EFFECT on systolic or diastolic bp in predominantly white, healthy Adults without severe Vitamin D deficiency.']	[('SUPERFICIAL_RELATIONSHIP', 140)]	1	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 79, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 79, '25(OH ... D'), ('UBERON_0007023', 'adult organism', 207, 'adults'), ('CHEBI_27300', 'vitamin D', 229, 'vitamin D')]
S2722-PMC4113768	PMC4113768	7/2014	S2722-PMC4113768	['conclusions: our results SHOW the WIDE RANGE of Vitamin D supplement regimes used by members of the public that have resulted in them having high to toxic levels of 25Ohd.']	[('INCOMPLETE_EVIDENCE', 25), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 34)]	2	"[('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 165, '25OHD')]"
S2727-PMC4113768	PMC4113768	7/2014	S2727-PMC4113768	['many of the websites that patients bought their Supplements from did not APPEAR to clearly highlight the risk of toxicity from Vitamin D, ALTHOUGH they all described the potential health benefits of taking Vitamin D supplements.']	[('ANOMALY_CURIOUS_FINDING', 73), ('ANOMALY_CURIOUS_FINDING', 138)]	2	[('CHEBI_33341', 'titanium atom', 48, 'supplements'), ('CHEBI_27300', 'vitamin D', 127, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 206, 'vitamin D')]
S2753-PMC4113768	PMC4113768	7/2014	S2753-PMC4113768	['this MAY LINK in with the increased availability or awareness of Vitamin D supplementation through the healthy start scheme, launched in 2006, and other initiatives.']	[('INCOMPLETE_EVIDENCE', 5), ('SUPERFICIAL_RELATIONSHIP', 9)]	2	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D')]
S2772-PMC4113768	PMC4113768	7/2014	S2772-PMC4113768	['these RELATIONS were almost exclusively SEEN in subjects not using Vitamin D and/or Calcium supplements.']	[('SUPERFICIAL_RELATIONSHIP', 6), ('INCOMPLETE_EVIDENCE', 40)]	2	[('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 84, 'calcium')]
S3047-PMC4113768	PMC4113768	7/2014	S3047-PMC4113768	['the main DETERMINANTS of Cord 25(Oh)D [adjusted mean difference in nmol/l (95% ci)] were summer season of sampling [19.2 (17.4, 20.9), p < 0.0001], maternal 25(Oh)D concentrations at 15 weeks [0.3 (0.26, 0.34), p < 0.0001] and the maternal use of a Vitamin D containing supplement at 15 weeks [2.5 (0.6, 4.42), p = 0.011].']	[('SUPERFICIAL_RELATIONSHIP', 9)]	1	[('UBERON_0002240', 'spinal cord', 25, 'cord'), ('CHEBI_71657', 'versiconol acetate', 30, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 30, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 157, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 157, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 249, 'vitamin D')]
S3066-PMC4113768	PMC4113768	7/2014	S3066-PMC4113768	['RISK FACTORS for Cardiovascular disease HAVE also BEEN ASSOCIATED with low Serum (25(Oh)D. we AIMED TO INVESTIGATE WHETHER high-dose Vitamin D supplementation CAN improve Glucose Metabolism in a population with impaired fasting Glucose and/or impaired Glucose tolerance.']	[('SUPERFICIAL_RELATIONSHIP', 0), ('INCOMPLETE_EVIDENCE', 40), ('SUPERFICIAL_RELATIONSHIP', 55), ('QUESTION_ANSWERED_BY_THIS_WORK', 94), ('QUESTION_ANSWERED_BY_THIS_WORK', 100), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 115), ('INCOMPLETE_EVIDENCE', 159)]	7	[('UBERON_0004535', 'cardiovascular system', 17, 'cardiovascular'), ('UBERON_0001977', 'blood serum', 75, 'serum'), ('CHEBI_71657', 'versiconol acetate', 82, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 133, 'vitamin D'), ('CHEBI_17234', 'glucose', 171, 'glucose'), ('GO_0006006', 'glucose metabolic process', 171, 'glucose metabolism'), ('CHEBI_17234', 'glucose', 228, 'glucose'), ('CHEBI_17234', 'glucose', 252, 'glucose')]
S3091-PMC4113768	PMC4113768	7/2014	S3091-PMC4113768	['conclusion: Prenatal Vitamin D supplementation in late Pregnancy that had a modest EFFECT on Cord Blood Vitamin D level, was not associated with decreased wheezing in offspring at age three years.']	[('SUPERFICIAL_RELATIONSHIP', 83)]	1	[('GO_0007565', 'female pregnancy', 12, 'Prenatal'), ('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('GO_0007565', 'female pregnancy', 55, 'pregnancy'), ('UBERON_0002240', 'spinal cord', 93, 'cord'), ('UBERON_0000178', 'blood', 98, 'blood'), ('CHEBI_27300', 'vitamin D', 104, 'vitamin D')]
S3136-PMC4113768	PMC4113768	7/2014	S3136-PMC4113768	['DEPENDING ON the cutoff chosen, dietary intakes of Vitamin D MAY OR MAY NOT provide sufficient IMPACT upon Vitamin D status, in improving levels of 25(Oh)d. purpose: we SOUGHT TO EXAMINE WHETHER a supplemental dose of 10 mcg (400 iu) as found in fortified foods OR as a supplement, has a measurable IMPACT on Vitamin D status, as defined by improving status from below to above 50 nmol/l, or from less than 30 nmol/l to above 30 nmol/l.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 61), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 65), ('INCOMPLETE_EVIDENCE', 68), ('SUPERFICIAL_RELATIONSHIP', 95), ('QUESTION_ANSWERED_BY_THIS_WORK', 169), ('QUESTION_ANSWERED_BY_THIS_WORK', 176), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 187), ('SUPERFICIAL_RELATIONSHIP', 299)]	9	[('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin D'), ('CHEBI_63056', 'zinc cation', 148, '25(OH'), ('CHEBI_27300', 'vitamin D', 309, 'vitamin D')]
S3200-PMC4113768	PMC4113768	7/2014	S3200-PMC4113768	['use of Vitamin D supplements, living in an institution and season of Blood sampling were significant independent predictors of 25(Oh)D concentrations using linear regression models, while non-use of Vitamin D containing supplements, season and low physical activity PREDICTED Vitamin D deficiency using logistic regression models.']	[('SUPERFICIAL_RELATIONSHIP', 266)]	1	[('CHEBI_27300', 'vitamin D', 7, 'vitamin D'), ('UBERON_0000178', 'blood', 69, 'blood'), ('CHEBI_71657', 'versiconol acetate', 127, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 127, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 199, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 276, 'vitamin D')]
S3267-PMC4113768	PMC4113768	7/2014	S3267-PMC4113768	['Vitamin D Metabolites SUPPORT anti-Viral activity in vitro , and a single-centre TRIAL in patients with predominantly SEVERE copd has REPORTED that Vitamin D supplementation reduced exacerbation RISK in patients with baseline Vitamin D deficiency.']	[('INCOMPLETE_EVIDENCE', 22), ('INCOMPLETE_EVIDENCE', 81), ('IMPORTANT_CONSIDERATION', 118), ('INCOMPLETE_EVIDENCE', 134), ('IMPORTANT_CONSIDERATION', 195)]	5	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_25212', 'metabolite', 10, 'metabolites'), ('NCBITaxon_1', 'root', 35, 'viral'), ('CHEBI_27300', 'vitamin D', 148, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 226, 'vitamin D')]
S3268-PMC4113768	PMC4113768	7/2014	S3268-PMC4113768	['multi-centre trials of Vitamin D supplementation for PREVENTION of exacerbation and uri in patients with less SEVERE copd are LACKING.']	[('SUPERFICIAL_RELATIONSHIP', 53), ('IMPORTANT_CONSIDERATION', 110), ('FULL_UNKNOWN', 126)]	3	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D')]
S3279-PMC4113768	PMC4113768	7/2014	S3279-PMC4113768	['sub-group analysis REVEALED that Vitamin D supplementation was PROTECTIVE against moderate/severe exacerbation among the 148 participants who were Vitamin D deficient at baseline (ahr 0.57, 95% ci 0.35 to 0.92, p = 0.02), but not among the 92 participants with baseline Serum 25(Oh)D ≥ 50 nmol/l (ahr 1.45, 95% ci 0.81 to 2.62, p = 0.21; p for interaction = 0.02).']	[('INCOMPLETE_EVIDENCE', 19), ('SUPERFICIAL_RELATIONSHIP', 63)]	2	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 147, 'vitamin D'), ('UBERON_0001977', 'blood serum', 270, 'serum'), ('CHEBI_33010', 'chromide(1-)', 278, '(OH)D')]
S3280-PMC4113768	PMC4113768	7/2014	S3280-PMC4113768	['conclusions: in the study population as a whole, intermittent bolus-dose Vitamin D supplementation did not influence time to exacerbation or time to uri, but it was ASSOCIATED with a modest reduction in severity of exacerbation symptoms.']	[('SUPERFICIAL_RELATIONSHIP', 165)]	1	[('CHEBI_27300', 'vitamin D', 73, 'vitamin D')]
S3281-PMC4113768	PMC4113768	7/2014	S3281-PMC4113768	['pre-specified sub-group analysis REVEALED a PROTECTIVE EFFECT of Vitamin D supplementation against moderate/severe exacerbations among participants who were Vitamin D deficient at baseline.']	[('INCOMPLETE_EVIDENCE', 33), ('SUPERFICIAL_RELATIONSHIP', 44), ('SUPERFICIAL_RELATIONSHIP', 55)]	3	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 157, 'vitamin D')]
S3303-PMC4113768	PMC4113768	7/2014	S3303-PMC4113768	['HOWEVER, rcts in iran, where the mean Serum 25(Oh)D levels TEND to be low, IN PART DUE TO sun avoidance during the hot summers, have FOUND beneficial EFFECTS of Vitamin D supplementation on cvd RISK FACTORS.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('SUPERFICIAL_RELATIONSHIP', 59), ('INCOMPLETE_EVIDENCE', 75), ('PROBLEM_COMPLICATION', 83), ('INCOMPLETE_EVIDENCE', 133), ('SUPERFICIAL_RELATIONSHIP', 150), ('SUPERFICIAL_RELATIONSHIP', 194)]	7	[('UBERON_0001977', 'blood serum', 38, 'serum'), ('CHEBI_71657', 'versiconol acetate', 44, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 44, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 161, 'vitamin D')]
S3367-PMC4113768	PMC4113768	7/2014	S3367-PMC4113768	['our OBJECTIVES are (1) to conduct unbiased Genome-wide methylation profiling of Vitamin D in Human Peripheral Leukocytes; (2) to comprehensively search differential functional Methylation Sites UNDERLYING Vitamin D deficiency; (3) TO TEST the HYPOTHESIS that Vitamin D supplementation increases global Dna Methylation level by performing a randomized clinical trial (rct) in overweight/obese african americans with Vitamin D deficiency.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('SUPERFICIAL_RELATIONSHIP', 194), ('QUESTION_ANSWERED_BY_THIS_WORK', 231), ('INCOMPLETE_EVIDENCE', 243)]	4	[('SO_0001026', 'genome', 43, 'genome'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin D'), ('NCBITaxon_9606', 'Homo sapiens', 93, 'human'), ('CL_0000118', 'basket cell', 99, 'peripheral leukocytes'), ('SO_0000134', 'genomically_imprinted', 176, 'methylation sites'), ('CHEBI_27300', 'vitamin D', 205, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 259, 'vitamin D'), ('GO_0006306', 'DNA methylation', 302, 'DNA methylation'), ('CHEBI_27300', 'vitamin D', 415, 'vitamin D')]
S218-PMC4161853	PMC4161853	8/2014	S218-PMC4161853	['AS SEVERE malnutrition is one of the risk FACTORS to develop malaria-ibi co-infection, it is IMPORTANT TO evaluate the IMPACT of Vitamin A administration in the clinical management of children with malaria and ibi-co-infection in africa, EITHER as a therapeutic and/OR prophylactic measure, ESPECIALLY due to recent EVIDENCE of the positive IMPACT of Vitamin A and zinc supplementation on malaria morbidity in a study conducted in ghana [121,122].']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 3), ('SUPERFICIAL_RELATIONSHIP', 42), ('IMPORTANT_CONSIDERATION', 93), ('QUESTION_ANSWERED_BY_THIS_WORK', 103), ('SUPERFICIAL_RELATIONSHIP', 119), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 238), ('IMPORTANT_CONSIDERATION', 291), ('INCOMPLETE_EVIDENCE', 316), ('SUPERFICIAL_RELATIONSHIP', 341)]	10	[('CHEBI_27300', 'vitamin D', 129, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 351, 'vitamin A')]
S2-PMC4169453	PMC4169453	9/2014	S2-PMC4169453	['THIS STUDY EVALUATED WHETHER Vitamin D supplementation during Lactation enhances the maternal and infant’s Vitamin D status, bone mass and body composition.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 11), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 21)]	3	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('GO_0007595', 'lactation', 62, 'lactation'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin D')]
S11-PMC4169453	PMC4169453	9/2014	S11-PMC4169453	['conclusions\nVitamin D supplementation at a dose of 400 iu/d was not sufficient to maintain 25(Oh)D >20 ng/ml in nursing women, WHILE 1200 iu/d APPEARED more EFFECTIVE, but had no effect on Breastfed offspring Vitamin D status, or changes in the bone mass and the body composition OBSERVED in both during breastfeeding.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 127), ('ANOMALY_CURIOUS_FINDING', 127), ('ANOMALY_CURIOUS_FINDING', 143), ('SUPERFICIAL_RELATIONSHIP', 157), ('INCOMPLETE_EVIDENCE', 280)]	5	[('CHEBI_28384', 'vitamin K', 12, 'Vitamin D'), ('CHEBI_71657', 'versiconol acetate', 91, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 91, '25(OH)D'), ('GO_0007567', 'parturition', 189, 'breastfed'), ('CHEBI_27300', 'vitamin D', 209, 'vitamin D')]
S16-PMC4169453	PMC4169453	9/2014	S16-PMC4169453	['Vitamin D supplementation in Lactating women MAY ensure APPROPRIATE maternal Vitamin D status in cases of low Vitamin D dietary consumption and restricted synthesis in the skin[7].']	[('INCOMPLETE_EVIDENCE', 45), ('IMPORTANT_CONSIDERATION', 56)]	2	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007594', 'puparial adhesion', 29, 'lactating'), ('CHEBI_27300', 'vitamin D', 77, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 110, 'vitamin D')]
S17-PMC4169453	PMC4169453	9/2014	S17-PMC4169453	['most of the RECENTLY PUBLISHED rct in Lactating women HAVE BEEN focused on maternal supplementation as a method of achieving APPROPRIATE Vitamin D status in both, mothers and their Breastfed offspring[8]–[11].']	[('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 54), ('IMPORTANT_CONSIDERATION', 125)]	3	[('GO_0007594', 'puparial adhesion', 38, 'lactating'), ('CHEBI_27300', 'vitamin D', 137, 'vitamin D'), ('GO_0007567', 'parturition', 181, 'breastfed')]
S20-PMC4169453	PMC4169453	9/2014	S20-PMC4169453	['the RECOMMENDED Vitamin D intake VARIES from 400 iu/d to 2000 iu/d[7],[12]–[16], BUT supplementation using less than 1000 iu/d MAY BE INADEQUATE for maintaining an “optimal” 25(Oh)D level[17].']	[('FUTURE_WORK', 4), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 33), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 81), ('INCOMPLETE_EVIDENCE', 127), ('IMPORTANT_CONSIDERATION', 134), ('PROBLEM_COMPLICATION', 134)]	6	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 174, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 180, 'D')]
S26-PMC4169453	PMC4169453	9/2014	S26-PMC4169453	['a RECENTLY published rct of Vitamin D supplementation in breastfed infants SHOWED no effect of different oral dosages of Vitamin D (from 400 iu/d up to 1600 iu/d) on infants’ bone Mineral content[26].']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 75)]	2	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin D'), ('CHEBI_46662', 'mineral', 180, 'mineral')]
S28-PMC4169453	PMC4169453	9/2014	S28-PMC4169453	['we HYPOTHESIZED that maternal Vitamin D supplementation during Lactation at a dose of 1200 iu/d, BUT NOT 400 iu/d, is more beneficial for both breastfeeding mothers and Breastfed infants, when Vitamin D status, bone mass and body composition are controlled for.']	[('INCOMPLETE_EVIDENCE', 3), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 97)]	2	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0007595', 'lactation', 63, 'lactation'), ('GO_0007567', 'parturition', 169, 'breastfed'), ('CHEBI_27300', 'vitamin D', 193, 'vitamin D')]
S88-PMC4169453	PMC4169453	9/2014	S88-PMC4169453	['sample size calculation\nto detect a statistically significant difference in Serum 25(Oh)D level (primary outcome) by 4 ng/ml between the intervention groups after Vitamin D supplementation at least 64 mother-infant pairs per group were REQUIRED at 80% power using a two-sided t-test at α\u200a=\u200a0.05.']	[('IMPORTANT_CONSIDERATION', 236)]	1	[('UBERON_0001977', 'blood serum', 76, 'serum'), ('CHEBI_71657', 'versiconol acetate', 82, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 82, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 163, 'vitamin D')]
S103-PMC4169453	PMC4169453	9/2014	S103-PMC4169453	['the itt approach ASSESSES the EFFECTIVENESS of improving Vitamin D status via different oral Vitamin D supplementation, regardless of whether the subject adhered to the dosing regimen.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 17), ('SUPERFICIAL_RELATIONSHIP', 30)]	2	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 93, 'vitamin D')]
S124-PMC4169453	PMC4169453	9/2014	S124-PMC4169453	['Vitamin D status\nmaternal 25(Oh)D level was SIMILAR in both groups at baseline and after 3 months of Vitamin D supplementation, HOWEVER, at v6 significantly higher 25(Oh)D levels were NOTED in the 1200 iu/d group (fig.']	[('SUPERFICIAL_RELATIONSHIP', 44), ('ANOMALY_CURIOUS_FINDING', 128), ('ANOMALY_CURIOUS_FINDING', 184)]	3	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_71657', 'versiconol acetate', 26, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 164, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 170, 'D')]
S131-PMC4169453	PMC4169453	9/2014	S131-PMC4169453	['ON THE OTHER HAND, the prevalence of Vitamin D sufficiency (≥30 ng/ml) was comparable across the intervention groups (400 iu/d vs. 1200 iu/d) during Vitamin D supplementation, at v3 (22.4% vs. 22.8%; p \u200a=\u200a0.95) and v6 (13.4% vs.24.9%; p \u200a=\u200a0.1) (fig.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0)]	1	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 149, 'vitamin D')]
S133-PMC4169453	PMC4169453	9/2014	S133-PMC4169453	['AS EXPECTED, a significant increase in 25(Oh)D occurred in breastfed infants supplemented with 400 iu/d of Vitamin D, and no differences were FOUND between the study groups (fig.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 142)]	2	[('CHEBI_71657', 'versiconol acetate', 39, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin D')]
S142-PMC4169453	PMC4169453	9/2014	S142-PMC4169453	['a CORRELATION between maternal and breastfed infants’ 25(Oh)D levels was STILL significant after 3 and 6 months of Vitamin D supplementation BUT APPEARED weaker than the Postpartum CORRELATION: in the 400 iu/d group at v3 r\u200a=\u200a0.35 ( p \u200a=\u200a0.003) and at v6 r\u200a=\u200a0.4 ( p \u200a=\u200a0.0009), and in the 1200 iu/d group at v3 r\u200a=\u200a0.3 ( p \u200a=\u200a0.01) and at v6 r\u200a=\u200a0.39 ( p \u200a=\u200a0.0007), respectively.']	[('SUPERFICIAL_RELATIONSHIP', 2), ('ANOMALY_CURIOUS_FINDING', 73), ('IMPORTANT_CONSIDERATION', 73), ('ANOMALY_CURIOUS_FINDING', 141), ('ANOMALY_CURIOUS_FINDING', 145), ('SUPERFICIAL_RELATIONSHIP', 181)]	6	[('CHEBI_71657', 'versiconol acetate', 54, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 60, 'D'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin D'), ('GO_0007565', 'female pregnancy', 170, 'postpartum')]
S150-PMC4169453	PMC4169453	9/2014	S150-PMC4169453	['HOWEVER, when Cord Blood was controlled for, the CORRELATION was not significant (r\u200a=\u200a0.001, p\u200a=\u200a0.99 ).10.1371/journal.pone.0107708.t004\n\ncaption (table-wrap): table 4\nSerum ipth and calcium concentrations, and Urinary Ca/cr ratio during 6 months of Vitamin D supplementation.parametertime400 iu/d group1200 iu/d group p -value between groups mothers n\u200a=\u200a67n\u200a=\u200a70ipth, pg/mlbaseline30.4 (20.2–43.5)28.6 (20–42)0.54δipth, pg/mlbaseline to 3 months−8.7±18.2−9.0±15.90.703 to 6 months4.1±10.43.5±10.30.75serum Ca, mmol/l3 months2.43 (2.36–2.49)2.44 (2.38–2.52)0.546 months2.37 (2.33–2.43)2.40 (2.36–2.47)0.13Uca/cr ratio, mmol/mmol3 months0.22 (0.12–0.38)0.3 (0.16–0.43)0.176 months0.19 (0.08–0.34)0.23 (0.11–0.41)0.27 infants n\u200a=\u200a67n\u200a=\u200a70ipth, pg/mlbaseline4.8 (3.7–7.1) (n\u200a=\u200a61)4.5 (3.8–5.8) (n\u200a=\u200a60)0.69δipth, pg/mlbaseline to 3 months10.7±10.011.5±6.30.803 to 6 months5.1±8.43.0±6.40.08serum ca, mmol/l3 months2.66 (2.61–2.73)2.67 (2.62–2.74)0.766 months2.62 (2.57–2.68)2.65 (2.62–2.7)0.009uca/cr ratio, mmol/mmol3 month1.58 (1.02–2.40)1.51 (0.89–2.47)0.556 months1.26 (0.87–1.81)1.47 (0.86–2.27)0.17\ndata presented as median (interquartile range: q1–q3) or mean ± sd.']	[('ANOMALY_CURIOUS_FINDING', 0), ('SUPERFICIAL_RELATIONSHIP', 49)]	2	[('UBERON_0002240', 'spinal cord', 14, 'cord'), ('UBERON_0000178', 'blood', 19, 'blood'), ('UBERON_0001977', 'blood serum', 169, 'Serum'), ('UBERON_0001088', 'urine', 212, 'urinary'), ('CHEBI_32588', 'potassium chloride', 220, 'Ca'), ('CHEBI_27300', 'vitamin D', 251, 'vitamin D'), ('CHEBI_32588', 'potassium chloride', 508, 'Ca'), ('CHEBI_73165', 'elf18', 604, '13UCa')]
S162-PMC4169453	PMC4169453	9/2014	S162-PMC4169453	['HOWEVER, maternal total body fat mass was comparable between groups, significant negative CORRELATIONS were noted between maternal 25(Oh)D level and maternal fat mass (r\u200a=\u200a−0.49, p \u200a=\u200a0.00001), Android fat mass (r\u200a=\u200a−0.53, p \u200a=\u200a0.00001), and gynoid fat mass (r\u200a=\u200a−0.43, p \u200a=\u200a0.00001) after 6 months of Vitamin D supplementation.']	[('ANOMALY_CURIOUS_FINDING', 0), ('SUPERFICIAL_RELATIONSHIP', 90)]	2	[('CHEBI_71657', 'versiconol acetate', 131, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 131, '25(OH)D'), ('UBERON_0001428', 'intermedium', 194, 'android'), ('CHEBI_27300', 'vitamin D', 302, 'vitamin D')]
S178-PMC4169453	PMC4169453	9/2014	S178-PMC4169453	['hollis and wagner[31]REPORTED a much larger decline (by ∼10 ng/ml) of maternal 25(Oh)D3 level during the first 3 months of Vitamin D supplementation at a dose of 400 iu/d.']	[('INCOMPLETE_EVIDENCE', 21)]	1	[('CHEBI_62946', 'ammonium sulfate', 79, '25(OH)D3'), ('PR_000029655', '28S rRNA (cytosine-C(5))-methyltransferase', 79, '25(OH)D3'), ('CHEBI_27300', 'vitamin D', 123, 'vitamin D')]
S186-PMC4169453	PMC4169453	9/2014	S186-PMC4169453	['the studies performed in healthy Individuals INDICATE that Vitamin D supplementation at a dose of 3000–7000 iu/d MIGHT be NECESSARY to achieve a Serum 25(Oh)D level of at least 30 ng/ml in 97.5% of that population[17],[35]–[37].']	[('INCOMPLETE_EVIDENCE', 45), ('INCOMPLETE_EVIDENCE', 113), ('IMPORTANT_CONSIDERATION', 122)]	3	[('NCBITaxon_1', 'root', 33, 'individuals'), ('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('UBERON_0001977', 'blood serum', 145, 'serum'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 154, 'OH)D')]
S187-PMC4169453	PMC4169453	9/2014	S187-PMC4169453	['our study was designed at the beginning of 2009, when RECOMMENDED supplemental doses of Vitamin D were around 400–600 iu/d.']	[('FUTURE_WORK', 54)]	1	[('CHEBI_27300', 'vitamin D', 88, 'vitamin D')]
S200-PMC4169453	PMC4169453	9/2014	S200-PMC4169453	['though supplementation at a dose of 2000 iu/d was PREVIOUSLY REPORTED to increase maternal 25(Oh)D to 30–39 ng/ml[35],[38],[39], it STILL MIGHT be insufficient for Vitamin D-deficient women[40],[41].']	[('INCOMPLETE_EVIDENCE', 50), ('INCOMPLETE_EVIDENCE', 61), ('IMPORTANT_CONSIDERATION', 132), ('INCOMPLETE_EVIDENCE', 138)]	4	[('CHEBI_71657', 'versiconol acetate', 91, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 91, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 164, 'vitamin D')]
S201-PMC4169453	PMC4169453	9/2014	S201-PMC4169453	['EVEN higher doses of Vitamin D (4000–6400 iu/d) were tested in breastfeeding women as the combined maternal and Breastfed infant supplementation[8]–[10],[31],[42].']	[('ANOMALY_CURIOUS_FINDING', 0)]	1	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('GO_0007567', 'parturition', 112, 'breastfed')]
S203-PMC4169453	PMC4169453	9/2014	S203-PMC4169453	['it is JUSTIFIED to RECOMMEND Vitamin D supplementation in breastfeeding women BASED ON their NEEDS and separately in Breastfed infants.']	[('IMPORTANT_CONSIDERATION', 6), ('FUTURE_WORK', 19), ('SUPERFICIAL_RELATIONSHIP', 78), ('IMPORTANT_CONSIDERATION', 93)]	4	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('GO_0007567', 'parturition', 117, 'breastfed')]
S204-PMC4169453	PMC4169453	9/2014	S204-PMC4169453	['our results REVEALED that maternal Vitamin D supplementation at a dose up to 1200 iu/d had no influence on the breastfed offspring’s Vitamin D status.']	[('INCOMPLETE_EVIDENCE', 12)]	1	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 133, 'vitamin D')]
S205-PMC4169453	PMC4169453	9/2014	S205-PMC4169453	['THEREFORE, breastfeeding infants NEED additional Vitamin D supplementation when maternal intake is 1200 iu/d.']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 33)]	2	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D')]
S211-PMC4169453	PMC4169453	9/2014	S211-PMC4169453	['in the light of the aforementioned studies, Vitamin D supplements SEEMS to be more effective as a source of Vitamin D in many contemporary industrialized populations SUFFERING from changing lifestyles (restricted sun exposure, obesity, unhealthy diet).']	[('ANOMALY_CURIOUS_FINDING', 66), ('IMPORTANT_CONSIDERATION', 166)]	2	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin D')]
S215-PMC4169453	PMC4169453	9/2014	S215-PMC4169453	['during Vitamin D supplementation in our infants, an increasing infants’ 25(Oh)D level COINCIDED with an increase in ipth.']	[('SUPERFICIAL_RELATIONSHIP', 86)]	1	[('CHEBI_27300', 'vitamin D', 7, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 72, '25(OH)D')]
S217-PMC4169453	PMC4169453	9/2014	S217-PMC4169453	['ON THE OTHER HAND, stable and comparable pth concentrations were REPORTED by greer in infants supplemented with Vitamin D or receiving a placebo, DESPITE significantly lower 25(Oh)D levels in the placebo group[45].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 65), ('ANOMALY_CURIOUS_FINDING', 146)]	3	[('CHEBI_27300', 'vitamin D', 112, 'vitamin D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 177, 'OH)D')]
S232-PMC4169453	PMC4169453	9/2014	S232-PMC4169453	['additionally, the dose of maternal Vitamin D supplementation had no impact on their infants’ measured dxa variables DESPITE the fact that infants received Vitamin D at a dose of 400 iu/d.']	[('ANOMALY_CURIOUS_FINDING', 116)]	1	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 155, 'vitamin D')]
S233-PMC4169453	PMC4169453	9/2014	S233-PMC4169453	['gallo et al, also FOUND no differences in bmc between infants supplemented with diverse doses of Vitamin D (400–1600 iu/d)[26].']	[('INCOMPLETE_EVIDENCE', 18)]	1	[('CHEBI_27300', 'vitamin D', 97, 'vitamin D')]
S241-PMC4169453	PMC4169453	9/2014	S241-PMC4169453	['Vitamin D3 supplementation at a dose of 1200 iu/d is more EFFECTIVE at improving Vitamin D status of nursing women, but STILL SEEMS TOO low TO fully replenish Vitamin D deficiency/insufficiency.']	[('SUPERFICIAL_RELATIONSHIP', 58), ('ANOMALY_CURIOUS_FINDING', 120), ('IMPORTANT_CONSIDERATION', 120), ('ANOMALY_CURIOUS_FINDING', 126), ('DIFFICULT_TASK', 132)]	5	[('CHEBI_33237', 'vitamin D4', 0, 'Vitamin D3'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'Vitamin D3'), ('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 159, 'vitamin D')]
S243-PMC4169453	PMC4169453	9/2014	S243-PMC4169453	['FURTHER STUDIES of Vitamin D supplementation during Lactation are NECESSARY to determine the OPTIMAL dosing for nursing women when taking into account maternal NEEDS.']	[('FUTURE_WORK', 0), ('IMPORTANT_CONSIDERATION', 66), ('IMPORTANT_CONSIDERATION', 93), ('IMPORTANT_CONSIDERATION', 160)]	4	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('GO_0007595', 'lactation', 52, 'lactation')]
S84-PMC4171568	PMC4171568	9/2014	S84-PMC4171568	['these levels increased significantly at 4-month follow-up after Omega-3 Epufa supplementation combined with Vitamin C and E and were ASSOCIATED with improvements in psychopathology and quality Of Life.']	[('SUPERFICIAL_RELATIONSHIP', 133)]	1	[('CHEBI_82678', '3beta-hydroxy-7-oxo-5beta-cholan-24-oic acid', 64, 'omega-3 EPUFA'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 122, 'E'), ('GO_0007608', 'sensory perception of smell', 193, 'of life')]
S138-PMC4171568	PMC4171568	9/2014	S138-PMC4171568	['in a large-scale Birth cohort study of 9,114 people in finland, the use of Vitamin D supplements in the first year of Life was ASSOCIATED with a reduced risk of developing schizophrenia at 31\xa0years of age, with higher doses SEEN as more beneficial than lower amounts [110].']	[('SUPERFICIAL_RELATIONSHIP', 127), ('INCOMPLETE_EVIDENCE', 224)]	2	[('GO_0007567', 'parturition', 17, 'birth'), ('CHEBI_27300', 'vitamin D', 75, 'vitamin D'), ('UBERON_0000104', 'life cycle', 118, 'life')]
S142-PMC4171568	PMC4171568	9/2014	S142-PMC4171568	['THEREFORE, the RELATIONSHIP between Vitamin D and schizophrenia NEEDS FURTHER INVESTIGATION, EVEN THOUGH a RECENT review of the EVIDENCE CONCLUDED that adequate levels of Vitamin D are needed for normal Brain Development and function and furthermore that at-risk groups SHOULD BE offered supplementation [112].']	[('PROBABLE_UNDERSTANDING', 0), ('SUPERFICIAL_RELATIONSHIP', 15), ('FUTURE_WORK', 64), ('FUTURE_WORK', 70), ('ANOMALY_CURIOUS_FINDING', 93), ('INCOMPLETE_EVIDENCE', 107), ('INCOMPLETE_EVIDENCE', 128), ('INCOMPLETE_EVIDENCE', 137), ('FUTURE_WORK', 270)]	9	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 171, 'vitamin D'), ('GO_0007420', 'brain development', 203, 'brain development'), ('UBERON_0000955', 'brain', 203, 'brain')]
S39-PMC4188019	PMC4188019	1/2010	S39-PMC4188019	['linear regression was used to analyse wether Vitamin D level is INFLUENCED by Gestational age, maternal age, parity, gravidity, sun exposure, intake of Supplements and/or date of Blood sample .']	[('SUPERFICIAL_RELATIONSHIP', 64)]	1	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('GO_0007565', 'female pregnancy', 78, 'gestational'), ('CHEBI_33341', 'titanium atom', 152, 'supplements'), ('UBERON_0000178', 'blood', 179, 'blood')]
S69-PMC4188019	PMC4188019	1/2010	S69-PMC4188019	['NO CONSENSUS exists on the RECOMMENDED intake and supplementation of 25-Oh Vitamin D during Pregnancy.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('FUTURE_WORK', 27)]	2	[('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 69, '25-OH'), ('CHEBI_27300', 'vitamin D', 75, 'vitamin D'), ('GO_0007565', 'female pregnancy', 92, 'pregnancy')]
S72-PMC4188019	PMC4188019	1/2010	S72-PMC4188019	['this fact is CONFIRMED in our pilot study: no significant difference in Vitamin D levels between women taking Supplements and those who did not.']	[('INCOMPLETE_EVIDENCE', 13)]	1	[('CHEBI_27300', 'vitamin D', 72, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 110, 'supplements')]
S217-PMC4192458	PMC4192458	9/2014	S217-PMC4192458	['CONSISTENT with results from randomized controlled trials on Nutrient supplementation, our results did not show associations between pre-eclampsia and reported intakes of Vitamin D, c, and e, and N-3 polyunsaturated Fatty Acids [11-13].']	[('INCOMPLETE_EVIDENCE', 0)]	1	[('CHEBI_33284', 'nutrient', 61, 'nutrient'), ('CHEBI_27300', 'vitamin D', 171, 'vitamin D'), ('CHEBI_30256', 'thiocarbonyl group', 196, 'n-3'), ('CHEBI_35366', 'fatty acid', 216, 'fatty acids')]
S188-PMC4193194	PMC4193194	10/2014	S188-PMC4193194	['results from this STUDY SHOWED that the supplementation with Vitamin C and E in a low-risk cohort of women DEMONSTRATED no significant differences in maternal or newborn complications RELATED to hypertension during Pregnancy (roberts et al.,2010; weissgerber et al.,2013).']	[('QUESTION_ANSWERED_BY_THIS_WORK', 18), ('INCOMPLETE_EVIDENCE', 24), ('INCOMPLETE_EVIDENCE', 107), ('SUPERFICIAL_RELATIONSHIP', 184)]	4	[('CHEBI_27300', 'vitamin D', 61, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 75, 'E'), ('GO_0007565', 'female pregnancy', 215, 'pregnancy')]
S212-PMC4193194	PMC4193194	10/2014	S212-PMC4193194	['oral supplementation with Antioxidants like Vitamin C and E and EVEN N-Acetylcysteine HAVE BEEN PROVEN to be a failure on the prevention of the disease.']	[('ANOMALY_CURIOUS_FINDING', 64), ('INCOMPLETE_EVIDENCE', 86)]	2	[('CHEBI_60641', 'methyl 5-aminolevulinate hydrochloride', 26, 'antioxidants'), ('CHEBI_27300', 'vitamin D', 44, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 58, 'E'), ('CHEBI_44482', 'N-oxalylglycine', 69, 'n-acetylcysteine')]
S14-PMC4210927	PMC4210927	10/2014	S14-PMC4210927	['in Preconception nutrition care, besides Folic Acid supplementation [3], it is IMPORTANT to have an adequate intake of Iron, Iodine, Calcium, Vitamins A and d, essential Fatty-Acids and dietary supplements, when NECESSARY [4,5].']	[('IMPORTANT_CONSIDERATION', 79), ('IMPORTANT_CONSIDERATION', 212)]	2	[('GO_0007565', 'female pregnancy', 3, 'preconception'), ('CHEBI_30751', 'formic acid', 41, 'folic acid'), ('CHEBI_24870', 'ion', 119, 'iron'), ('CHEBI_24859', 'iodine atom', 125, 'iodine'), ('CHEBI_22313', 'alkaline earth metal atom', 133, 'calcium'), ('CHEBI_27300', 'vitamin D', 142, 'vitamins A'), ('CHEBI_35366', 'fatty acid', 170, 'fatty-acids')]
S72-PMC4216020	PMC4216020	10/2014	S72-PMC4216020	['a larger prospective study, HOWEVER, DID NOT demonstrate an ASSOCIATED RISK between maternal smoking and jia.92\nOTHER Perinatal exposures and Pregnancy-related FACTORS HAVE BEEN investigated.47,92an australian study that reviewed 262 cases and matched controls IDENTIFIED a TREND towards a PROTECTIVE EFFECT with Prenatal Nutritional Supplements.47the mothers of children that eventually developed jia were less LIKELY to receive supplementation with Prenatal multivitamins (24.9% versus 30.8%), Vitamin D (3.3% versus 7.8%), Fish Oil (2.9% versus 6.4%), Calcium (10.2% versus 14.9%), Iron (35.4% versus 40.3%), and Folate (61.4% versus 64.8%) while Pregnant compared to controls.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 28), ('INCOMPLETE_EVIDENCE', 37), ('SUPERFICIAL_RELATIONSHIP', 60), ('IMPORTANT_CONSIDERATION', 71), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 112), ('SUPERFICIAL_RELATIONSHIP', 160), ('INCOMPLETE_EVIDENCE', 168), ('INCOMPLETE_EVIDENCE', 261), ('INCOMPLETE_EVIDENCE', 274), ('SUPERFICIAL_RELATIONSHIP', 290), ('SUPERFICIAL_RELATIONSHIP', 301), ('PROBABLE_UNDERSTANDING', 412)]	12	[('GO_0036268', 'swimming', 118, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 118, 'perinatal'), ('GO_0007565', 'female pregnancy', 142, 'pregnancy'), ('GO_0007565', 'female pregnancy', 313, 'prenatal'), ('CHEBI_7495', 'nefazodone hydrochloride', 322, 'nutritional'), ('CHEBI_33341', 'titanium atom', 334, 'supplements'), ('GO_0007565', 'female pregnancy', 451, 'prenatal'), ('CHEBI_27300', 'vitamin D', 496, 'vitamin D'), ('CHEBI_34766', 'Furamizole', 526, 'fish oil'), ('CHEBI_22313', 'alkaline earth metal atom', 555, 'calcium'), ('CHEBI_24870', 'ion', 585, 'iron'), ('CHEBI_30863', '5-azaorotic acid', 616, 'folate'), ('GO_0007565', 'female pregnancy', 650, 'pregnant')]
S7-PMC4221707	PMC4221707	11/2014	S7-PMC4221707	['intake of Folate and Vitamin D supplements was GENERALLY high in the Pregnant group and LED TO significantly higher total estimated Intake of Vitamin D and Folate in the pregnant group.']	[('PROBABLE_UNDERSTANDING', 47), ('SUPERFICIAL_RELATIONSHIP', 88)]	2	[('CHEBI_30863', '5-azaorotic acid', 10, 'folate'), ('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('GO_0007565', 'female pregnancy', 69, 'pregnant'), ('GO_0007631', 'feeding behavior', 132, 'intake'), ('CHEBI_27300', 'vitamin D', 142, 'vitamin D'), ('CHEBI_30863', '5-azaorotic acid', 156, 'folate')]
S137-PMC4221707	PMC4221707	11/2014	S137-PMC4221707	['addition from Supplements LED TO significantly higher estimated intake of Vitamin D and Folate and borderline significantly higher intake of Calcium and Vitamin B12 in the Pregnant than referent women, WHEREAS ESTIMATED Intake of iron supplement EVENED out the difference in Intakes from Foods only (table\xa02).']	[('SUPERFICIAL_RELATIONSHIP', 26), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 202), ('INCOMPLETE_EVIDENCE', 210), ('ANOMALY_CURIOUS_FINDING', 246)]	4	[('CHEBI_33341', 'titanium atom', 14, 'supplements'), ('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('CHEBI_30863', '5-azaorotic acid', 88, 'folate'), ('CHEBI_22313', 'alkaline earth metal atom', 141, 'calcium'), ('CHEBI_33279', 'vitamin D5', 153, 'vitamin B12'), ('PR_000004481', 'V-type proton ATPase subunit B, kidney isoform', 153, 'vitamin B12'), ('GO_0007565', 'female pregnancy', 172, 'pregnant'), ('GO_0007631', 'feeding behavior', 220, 'intake'), ('GO_0007631', 'feeding behavior', 275, 'intakes'), ('CHEBI_33290', 'food', 288, 'foods')]
S178-PMC4221707	PMC4221707	11/2014	S178-PMC4221707	['IN GENERAL, this 2009 report FOUND that the intake of Folate and Vitamin D from foods was not sufficient to cover the nutritional demands during Pregnancy, and supplements were USUALLY REQUIRED before and during Pregnancy [37,38].']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 29), ('INCOMPLETE_EVIDENCE', 177), ('IMPORTANT_CONSIDERATION', 185)]	4	[('CHEBI_30863', '5-azaorotic acid', 54, 'folate'), ('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('GO_0007565', 'female pregnancy', 145, 'pregnancy'), ('GO_0007565', 'female pregnancy', 212, 'pregnancy')]
S113-PMC4231606	PMC4231606	10/2013	S113-PMC4231606	['WHILE HISTORICAL EVIDENCE SUGGESTS that Vitamin D supplementation CAN PREVENT caries onset and progression, much of this RESEARCH has been OVERLOOKED [18,29,30].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 6), ('INCOMPLETE_EVIDENCE', 17), ('INCOMPLETE_EVIDENCE', 26), ('INCOMPLETE_EVIDENCE', 66), ('SUPERFICIAL_RELATIONSHIP', 70), ('INCOMPLETE_EVIDENCE', 121), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 139)]	8	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D')]
S116-PMC4231606	PMC4231606	10/2013	S116-PMC4231606	['much of the EARLY RESEARCH in this field was conducted by may mellanby, who IDENTIFIED an ASSOCIATION between Vitamin D supplementation and reduced caries-risk [18,31].']	[('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 76), ('SUPERFICIAL_RELATIONSHIP', 90)]	3	[('CHEBI_27300', 'vitamin D', 110, 'vitamin D')]
S117-PMC4231606	PMC4231606	10/2013	S117-PMC4231606	['RECENTLY, a meta-analysis REPORTED that Vitamin D supplementation in childhood CAN help PREVENT caries [30], and it HAS also BEEN SUGGESTED that concentrations of 25(Oh)D between 75–100\xa0nmol/l MAY reduce the RISK for Caries [22].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 26), ('INCOMPLETE_EVIDENCE', 79), ('SUPERFICIAL_RELATIONSHIP', 88), ('INCOMPLETE_EVIDENCE', 116), ('INCOMPLETE_EVIDENCE', 130), ('INCOMPLETE_EVIDENCE', 193), ('IMPORTANT_CONSIDERATION', 208)]	8	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('CHEBI_33010', 'chromide(1-)', 165, '(OH)D'), ('CHEBI_23042', 'carotene', 217, 'caries')]
S157-PMC4231606	PMC4231606	10/2013	S157-PMC4231606	['specifically, RECOMMENDING Vitamin D supplementation for children AT RISK of Dental caries MAY result in a decrease in the overall PREVALENCE of s-ecc and, ULTIMATELY, reduce THE BURDEN on pediatric day surgery centres.']	[('FUTURE_WORK', 14), ('IMPORTANT_CONSIDERATION', 66), ('FUTURE_PREDICTION', 91), ('IMPORTANT_CONSIDERATION', 131), ('FUTURE_PREDICTION', 156), ('IMPORTANT_CONSIDERATION', 175)]	6	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('UBERON_0001091', 'calcareous tooth', 77, 'dental')]
S27-PMC4251419	PMC4251419	12/2014	S27-PMC4251419	['DESPITE these relatively COHERENT FINDINGS from ecologic and OBSERVATIONAL studies, and PLAUSIBLE biological mechanisms, trials of Vitamin D supplementation for the PREVENTION of Immune-related diseases have LARGELY returned null results [17].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('SUPERFICIAL_RELATIONSHIP', 25), ('INCOMPLETE_EVIDENCE', 34), ('INCOMPLETE_EVIDENCE', 61), ('INCOMPLETE_EVIDENCE', 88), ('SUPERFICIAL_RELATIONSHIP', 165), ('INCOMPLETE_EVIDENCE', 208)]	8	[('CHEBI_27300', 'vitamin D', 131, 'vitamin D'), ('UBERON_0002405', 'immune system', 179, 'immune')]
S30-PMC4251419	PMC4251419	12/2014	S30-PMC4251419	['NEVERTHELESS, there is not yet COMPELLING EVIDENCE from these studies that Vitamin D supplementation ameliorates any Immune-related disease.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 31)]	2	[('CHEBI_27300', 'vitamin D', 75, 'vitamin D'), ('UBERON_0002405', 'immune system', 117, 'immune')]
S71-PMC4251419	PMC4251419	12/2014	S71-PMC4251419	['YET, DESPITE PLAUSIBLE immunological pathways whereby Vitamin D (through stimulation of tregsand dampening of T Helper Type 1 over-reactivity) COULD diminish the risk of multiple sclerosis or disease activity, Vitamin D supplementation trials HAVE SHOWN immunological [42] and radiological [43], BUT NOT CLINICAL, benefit for People with multiple sclerosis.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 5), ('ANOMALY_CURIOUS_FINDING', 5), ('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 143), ('INCOMPLETE_EVIDENCE', 243), ('FULL_UNKNOWN', 296), ('ANOMALY_CURIOUS_FINDING', 300)]	9	[('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('CL_0002061', 'T-helper 9 cell', 110, 'T helper'), ('PR_000016293', 'protein-glutamine gamma-glutamyltransferase 2', 110, 'T helper type 1'), ('CHEBI_27300', 'vitamin D', 210, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 326, 'people')]
S73-PMC4251419	PMC4251419	12/2014	S73-PMC4251419	['LIMITED SUCCESS in Vitamin D supplementation trials SUGGESTS that Vitamin D-INDEPENDENT EFFECTS MAY CONTRIBUTE more strongly to disease RISK.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 52), ('SUPERFICIAL_RELATIONSHIP', 76), ('SUPERFICIAL_RELATIONSHIP', 88), ('INCOMPLETE_EVIDENCE', 96), ('SUPERFICIAL_RELATIONSHIP', 100), ('IMPORTANT_CONSIDERATION', 136)]	7	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 66, 'vitamin D')]
S79-PMC4251419	PMC4251419	12/2014	S79-PMC4251419	['additionally, WHILE increased sun exposure during childhood was inversely ASSOCIATED with risk of multiple sclerosis, there was no decreased risk associated with intake of Vitamin D supplements during childhood [40].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 14), ('ANOMALY_CURIOUS_FINDING', 14), ('SUPERFICIAL_RELATIONSHIP', 74)]	3	[('CHEBI_27300', 'vitamin D', 172, 'vitamin D')]
S85-PMC4251419	PMC4251419	12/2014	S85-PMC4251419	['in the experimental Autoimmune encephalomyelitis Animal MODEL, Vitamin D supplementation in the Postnatal period delays the onset of the disease [52] but there is NO EVIDENCE that Antenatal Vitamin D supplementation has any EFFECT.']	[('INCOMPLETE_EVIDENCE', 56), ('INCOMPLETE_EVIDENCE', 163), ('SUPERFICIAL_RELATIONSHIP', 224)]	3	[('UBERON_0001442', 'skeleton of manus', 20, 'autoimmune'), ('NCBITaxon_33208', 'Metazoa', 49, 'animal'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('GO_0007567', 'parturition', 96, 'postnatal'), ('GO_0007567', 'parturition', 180, 'antenatal'), ('CHEBI_27300', 'vitamin D', 190, 'vitamin D')]
S104-PMC4251419	PMC4251419	12/2014	S104-PMC4251419	['Vitamin D deficiency increased the severity of colitis and bacterial numbers in the Colons of Mice [66] and, in male Mice with allergic Airway disease (modelling allergic asthma), Vitamin D deficiency increased Lung inflammation and bacterial numbers [65]; these EFFECTS were reversed by Vitamin D supplementation [65].']	[('SUPERFICIAL_RELATIONSHIP', 263)]	1	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('UBERON_0001155', 'colon', 84, 'colons'), ('NCBITaxon_10088', 'Mus <genus>', 94, 'mice'), ('NCBITaxon_10088', 'Mus <genus>', 117, 'mice'), ('UBERON_0001005', 'respiratory airway', 136, 'airway'), ('CHEBI_27300', 'vitamin D', 180, 'vitamin D'), ('UBERON_0002048', 'lung', 211, 'lung'), ('CHEBI_27300', 'vitamin D', 288, 'vitamin D')]
S116-PMC4251419	PMC4251419	12/2014	S116-PMC4251419	['we ANTICIPATE that a deeper understanding of HOW Vitamin D Modulates the microbiomes of the skin and other Tissues will come through ONGOING Vitamin D supplementation trials [74].']	[('IMPORTANT_CONSIDERATION', 3), ('IMPORTANT_CONSIDERATION', 3), ('EXPLICIT_QUESTION', 45), ('IMPORTANT_CONSIDERATION', 133)]	4	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('GO_0065007', 'biological regulation', 59, 'modulates'), ('UBERON_0000479', 'tissue', 107, 'tissues'), ('CHEBI_27300', 'vitamin D', 141, 'vitamin D')]
S118-PMC4251419	PMC4251419	12/2014	S118-PMC4251419	['furthermore, Vitamin D supplementation MAY suppress the development of Intestinal Tumours in susceptible Mice [76].']	[('INCOMPLETE_EVIDENCE', 39)]	1	[('CHEBI_27300', 'vitamin D', 13, 'vitamin D'), ('GO_0048262', 'determination of dorsal/ventral asymmetry', 71, 'intestinal tumours'), ('UBERON_0000160', 'intestine', 71, 'intestinal'), ('NCBITaxon_10088', 'Mus <genus>', 105, 'mice')]
S122-PMC4251419	PMC4251419	12/2014	S122-PMC4251419	"[""WHY doesn't Vitamin D supplementation decrease disease RISKS?""]"	[('EXPLICIT_QUESTION', 0), ('IMPORTANT_CONSIDERATION', 55), ('EXPLICIT_QUESTION', 60)]	3	[('CHEBI_27300', 'vitamin D', 12, 'vitamin D')]
S123-PMC4251419	PMC4251419	12/2014	S123-PMC4251419	"[""in the face of SUPPORTIVE OBSERVATIONAL and mechanistic EVIDENCE, WHY doesn't Vitamin D supplementation decrease disease RISKS?""]"	[('INCOMPLETE_EVIDENCE', 15), ('INCOMPLETE_EVIDENCE', 26), ('INCOMPLETE_EVIDENCE', 56), ('EXPLICIT_QUESTION', 66), ('IMPORTANT_CONSIDERATION', 121), ('EXPLICIT_QUESTION', 126)]	6	[('CHEBI_27300', 'vitamin D', 78, 'vitamin D')]
S130-PMC4251419	PMC4251419	12/2014	S130-PMC4251419	['in addition, with respect to an ability of supplemental Vitamin D to alter the course of Autoimmune diseases, there is DEBATE about the VALIDITY of biochemical OR cellular markers from Blood AS TRULY representative of disease status.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 119), ('IMPORTANT_CONSIDERATION', 136), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 160), ('PROBABLE_UNDERSTANDING', 191), ('PROBABLE_UNDERSTANDING', 194)]	5	[('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('UBERON_0001442', 'skeleton of manus', 89, 'autoimmune'), ('UBERON_0000178', 'blood', 185, 'blood')]
S134-PMC4251419	PMC4251419	12/2014	S134-PMC4251419	['Vitamin D supplementation STUDIES take ACCOUNT ONLY of Vitamin D, without the POSSIBLY NECESSARY additional benefits of sun exposure.']	[('INCOMPLETE_EVIDENCE', 26), ('IMPORTANT_CONSIDERATION', 39), ('INCOMPLETE_EVIDENCE', 47), ('INCOMPLETE_EVIDENCE', 78), ('IMPORTANT_CONSIDERATION', 87)]	5	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 55, 'vitamin D')]
S138-PMC4251419	PMC4251419	12/2014	S138-PMC4251419	['the LACK OF any PROTECTIVE EFFECT of Vitamin D supplementation in Adulthood MAY BE BECAUSE the processes necessary for disease have already been put in place much earlier in life.']	[('INCOMPLETE_EVIDENCE', 4), ('SUPERFICIAL_RELATIONSHIP', 16), ('SUPERFICIAL_RELATIONSHIP', 27), ('INCOMPLETE_EVIDENCE', 76), ('PROBABLE_UNDERSTANDING', 83), ('PROBLEM_COMPLICATION', 83)]	6	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('UBERON_0000113', 'post-juvenile adult stage', 66, 'adulthood')]
S139-PMC4251419	PMC4251419	12/2014	S139-PMC4251419	['Genetic variation in the physiological response to Vitamin D supplementation\na high degree of Individual VARIABILITY in the 25(Oh)D response to Vitamin D supplementation has been DESCRIBED that is the result of demographic, environmental and Genetic FACTORS [79].']	[('DIFFICULT_TASK', 105), ('INCOMPLETE_EVIDENCE', 179), ('SUPERFICIAL_RELATIONSHIP', 250)]	3	[('SO_0000704', 'gene', 0, 'Genetic'), ('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('NCBITaxon_1', 'root', 94, 'individual'), ('CHEBI_71657', 'versiconol acetate', 124, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D'), ('SO_0000704', 'gene', 242, 'genetic')]
S140-PMC4251419	PMC4251419	12/2014	S140-PMC4251419	['the EFFECT of these factors on the physiological, or disease-relevant, response to Vitamin D supplementation has not been explored.']	[('SUPERFICIAL_RELATIONSHIP', 4)]	1	[('CHEBI_27300', 'vitamin D', 83, 'vitamin D')]
S149-PMC4251419	PMC4251419	12/2014	S149-PMC4251419	['most RECENT Vitamin D supplementation TRIALS use Vitamin D3, SUGGESTING that any DIFFERENCES between d2and d3do NOT ACCOUNT for the DIFFERENT findings from OBSERVATIONAL and Vitamin D supplementation trials.']	[('INCOMPLETE_EVIDENCE', 5), ('FUTURE_WORK', 38), ('INCOMPLETE_EVIDENCE', 61), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 81), ('ANOMALY_CURIOUS_FINDING', 112), ('IMPORTANT_CONSIDERATION', 116), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 132), ('INCOMPLETE_EVIDENCE', 156)]	8	[('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('CHEBI_33279', 'vitamin D5', 49, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 49, 'vitamin D3'), ('CHEBI_27300', 'vitamin D', 174, 'vitamin D')]
S155-PMC4251419	PMC4251419	12/2014	S155-PMC4251419	['SIMILARLY, in ONE rct of high-dose Vitamin D supplementation there was an INCREASED RISK of falls and fractures [93].']	[('INCOMPLETE_EVIDENCE', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 14), ('IMPORTANT_CONSIDERATION', 74)]	3	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D')]
S156-PMC4251419	PMC4251419	12/2014	S156-PMC4251419	['it is LIKELY that there is a loss of study power and a risk of harm IF participants in Vitamin D supplementation trials already have adequate 25(Oh)d levels at baseline [91].']	[('PROBABLE_UNDERSTANDING', 6), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 68)]	2	[('CHEBI_27300', 'vitamin D', 87, 'vitamin D'), ('CHEBI_30778', 'gallic acid', 142, '25(OH)')]
S158-PMC4251419	PMC4251419	12/2014	S158-PMC4251419	['YET Vitamin D supplementation trials are GENERALLY relatively short-term, with supplementation for ONLY 1-2 years.']	[('ANOMALY_CURIOUS_FINDING', 0), ('PROBABLE_UNDERSTANDING', 41), ('INCOMPLETE_EVIDENCE', 99)]	3	[('CHEBI_27300', 'vitamin D', 4, 'vitamin D')]
S159-PMC4251419	PMC4251419	12/2014	S159-PMC4251419	['this DISCREPANCY in timing MAY CONTRIBUTE to the failure of Vitamin D supplementation trials to decrease the RISK of disease onset.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 5), ('INCOMPLETE_EVIDENCE', 27), ('SUPERFICIAL_RELATIONSHIP', 31), ('IMPORTANT_CONSIDERATION', 109)]	4	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D')]
S138-PMC4256222	PMC4256222	12/2014	S138-PMC4256222	['THUS, we cannot preclude that early Vitamin D supplementation IMPACTED offspring bone fracture RISK in our data and has blurred an ASSOCIATION with maternal Vitamin D status.']	[('PROBABLE_UNDERSTANDING', 0), ('SUPERFICIAL_RELATIONSHIP', 62), ('IMPORTANT_CONSIDERATION', 95), ('SUPERFICIAL_RELATIONSHIP', 131)]	4	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 157, 'vitamin D')]
S296-PMC4258799	PMC4258799	11/2014	S296-PMC4258799	['rcts and prospective studies CONCUR that oral supplementation of Vitamin E reduces Lipid Peroxidation damage [102,150], improves Sperm Motility [102,103] and function [101] as well as improve Fertilization [150] and Pregnancy rates [102,103].']	[('INCOMPLETE_EVIDENCE', 29)]	1	[('CHEBI_27300', 'vitamin D', 65, 'vitamin E'), ('CHEBI_18059', 'lipid', 83, 'lipid'), ('GO_0007129', 'homologous chromosome pairing at meiosis', 89, 'peroxidation'), ('CL_0000019', 'sperm', 129, 'sperm'), ('GO_0065007', 'biological regulation', 135, 'motility'), ('GO_0009566', 'fertilization', 192, 'fertilization'), ('GO_0007565', 'female pregnancy', 216, 'pregnancy')]
S309-PMC4258799	PMC4258799	11/2014	S309-PMC4258799	['an initial rct REPORTED that Sperm parameters did not change after co-supplementation with Vitamins E and C [106].']	[('INCOMPLETE_EVIDENCE', 15)]	1	[('CL_0000019', 'sperm', 29, 'sperm'), ('CHEBI_27300', 'vitamin D', 91, 'vitamins E'), ('CHEBI_18245', 'carboxylato group', 106, 'C'), ('PR_000004900', 'complement C3', 106, 'C')]
S310-PMC4258799	PMC4258799	11/2014	S310-PMC4258799	['HOWEVER, subsequent observational studies in men with POOR Sperm dna integrity showed that supplementation with both Vitamins E and C resulted in fewer Spermatozoa with fragmented dna [107,108], as well as higher Implantation and clinical Pregnancy rates [108].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('IMPORTANT_CONSIDERATION', 54)]	2	[('CL_0000019', 'sperm', 59, 'sperm'), ('CHEBI_27300', 'vitamin D', 117, 'vitamins E'), ('CHEBI_18245', 'carboxylato group', 132, 'C'), ('CL_0000019', 'sperm', 152, 'spermatozoa'), ('GO_0007566', 'embryo implantation', 213, 'implantation'), ('GO_0007565', 'female pregnancy', 239, 'pregnancy')]
S315-PMC4258799	PMC4258799	11/2014	S315-PMC4258799	['HOWEVER, smaller prospective studies SHOWED that oral Vitamin C supplementation in women, EITHER undergoing ivf-et treatment [123] or with Luteal phase defects [124], LEAD TO increased Pregnancy rates.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 37), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 90), ('SUPERFICIAL_RELATIONSHIP', 167)]	4	[('CHEBI_27300', 'vitamin D', 54, 'vitamin C'), ('GO_0007565', 'female pregnancy', 139, 'luteal'), ('GO_0007565', 'female pregnancy', 185, 'pregnancy')]
S2-PMC4263713	PMC4263713	12/2014	S2-PMC4263713	['the PRESENT STUDY AIMS TO TEST WHETHER Vitamin A supplementation CAN restore Lymphocyte pools in Vitamin A-deficient Rats and thereby improve the function of their Intestinal Mucosa; furthermore, the study AIMED TO IDENTIFY the BEST time frame for Vitamin A supplementation.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 18), ('QUESTION_ANSWERED_BY_THIS_WORK', 23), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 31), ('INCOMPLETE_EVIDENCE', 65), ('QUESTION_ANSWERED_BY_THIS_WORK', 206), ('QUESTION_ANSWERED_BY_THIS_WORK', 212), ('IMPORTANT_CONSIDERATION', 228)]	8	[('CHEBI_27300', 'vitamin D', 39, 'vitamin A'), ('CL_0000542', 'lymphocyte', 77, 'lymphocyte'), ('CHEBI_27300', 'vitamin D', 97, 'vitamin A'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 117, 'rats'), ('UBERON_0001242', 'intestinal mucosa', 164, 'intestinal mucosa'), ('CHEBI_27300', 'vitamin D', 248, 'vitamin A')]
S6-PMC4263713	PMC4263713	12/2014	S6-PMC4263713	"[""the Rats in this group had higher numbers of Cd8+Intestinal Intraepithelial Lymphocytes, Cd11C+Dendritic Cells in the Peyer'S Patches and Cd4+Cd25+T Cells in the Spleen compared with the Vitamin A-deficient Rats; flow cytometric analysis also DEMONSTRATED that Vitamin A supplementation decreased the number of B Cells in the Mesenteric Lymph Nodes.""]"	[('INCOMPLETE_EVIDENCE', 243)]	1	"[('NCBITaxon_9986', 'Oryctolagus cuniculus', 4, 'rats'), ('PR_000005170', 'CD37 molecule', 45, 'CD8'), ('CL_0002063', 'type II pneumocyte', 49, 'intestinal intraepithelial lymphocytes'), ('UBERON_0000160', 'intestine', 49, 'intestinal'), ('UBERON_0004821', 'pulmonary alveolus epithelium', 60, 'intraepithelial'), ('PR_000001309', 'CD70 molecule', 89, 'CD11C'), ('CL_0000451', 'dendritic cell', 95, 'dendritic cells'), ('UBERON_0001330', 'pampiniform plexus', 118, ""Peyer's patches""), ('PR_000001204', 'C-C chemokine receptor type 8', 138, 'CD4'), ('PR_000002030', 'alpha-type platelet-derived growth factor receptor', 142, 'CD25'), ('CL_0000084', 'T cell', 147, 'T cells'), ('UBERON_0002106', 'spleen', 162, 'spleen'), ('CHEBI_27300', 'vitamin D', 187, 'vitamin A'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 207, 'rats'), ('CHEBI_27300', 'vitamin D', 261, 'vitamin A'), ('CL_0000236', 'B cell', 311, 'B cells'), ('UBERON_0002509', 'mesenteric lymph node', 326, 'mesenteric lymph nodes')]"
S8-PMC4263713	PMC4263713	12/2014	S8-PMC4263713	['HOWEVER, no significant differences in Lymphocyte levels were found between the Rats in the other two Vitamin A supplement groups and the Vitamin A-deficient group.']	[('ANOMALY_CURIOUS_FINDING', 0)]	1	[('CL_0000542', 'lymphocyte', 39, 'lymphocyte'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 80, 'rats'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 138, 'vitamin A')]
S9-PMC4263713	PMC4263713	12/2014	S9-PMC4263713	['in conclusion, the BEST recovery of a subset of Lymphocytes in the offspring of Gestational Vitamin A-deficient Rats and the greatest improvement in the Intestinal Mucosal immune response are achieved when Vitamin A supplementation occurs during the early Postnatal period.']	[('IMPORTANT_CONSIDERATION', 19)]	1	[('CL_0000542', 'lymphocyte', 48, 'lymphocytes'), ('GO_0007565', 'female pregnancy', 80, 'gestational'), ('CHEBI_27300', 'vitamin D', 92, 'vitamin A'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 112, 'rats'), ('UBERON_0001262', 'wall of intestine', 153, 'intestinal mucosal'), ('CHEBI_27300', 'vitamin D', 206, 'vitamin A'), ('GO_0007567', 'parturition', 256, 'postnatal')]
S29-PMC4268639	PMC4268639	11/2014	S29-PMC4268639	['caption (table-wrap): table 1\n\nEMPHASIS of nutrition education classesnutrientspreconception1st trimester2nd trimester3rd trimesterpostnatal protein adequatecomplete, Carnitine, methionine, cysteine, 0.8 g/kgcomplete, adequate 1.1 g/kgcomplete, adequate 1.1 g/kgcomplete, adequate fat essential Fatty Acidsomega 3omega 3omega 3omega 3 Carbohydrate complexcomplexcomplex,fiber complexcomplex Minerals Iodine, iron, magnesium, zinc, calcium, Seleniumiodine, Seleniumiron, magnesium, calciumiron, zinc, magnesiumiron, calcium Vitamins methylation factorsvitamins d, b6, b12, folatevitamins e, D, cvitamins C, ab Vitamins, Vitamin D Phytonutrients full range of colors of fruits and vegetablescolors: oxidative reservecolors: Organ growthcolors: newborn preferencecolors: oxidant balance Probiotics immune balanceimmune balanceimmune balance\n\ncaption (table-wrap): table 2\n\nPrenatal supplements adjusted to levels of Hemoglobin, hematocrit, mean corpuscular volume, Vitamin D, Zinc, Carnitine, and mthfr statusvitamin a Mixed Carotenoids5000 iumethylcobalamin800 µgchromium (Chromium Niacinate)200 µgvitamin c250 mgbiotin100 µgmolybdenum (Molybdenum Glycinate)25 µgvitamin d32000 iupantothenic Acid (D-Calcium Pantothenate)25 mgomega-3 Fatty Acids620 mgvitamin E (Mixed)110 iuiron (iron Bisglycinate)25 mgepa400 mgthiamine (Mononitrate)5 mgiodine (Potassium Iodide)150 µgdha200 mgriboflavin (5 phosphate)5 mgzinc (Zinc Citrate)25 mgother omega-320 mgniacinamide25 mgselenium (l Selenomethionine)100 µgl-Carnitine as 1492 mg l-Carnitine tartrate1000 mgb6(Pyridoxal 5 Phosphate)15 mgcopper (Copper Gluconate)1.5 mgprobiotic blend: lactobacillus acidophilus 60 b cful-5-Methylfolate1000 µgmanganese (manganese gluconate)5 mg bifidobacterium lectis, lactobacillus plantarum, lactobacillus salivarius, streptococcus thermophilus\nabbreviations: cfu, colony-forming unit; Dha, Docosahexaenoic Acid; Epa, Eicosapentaenoic Acid; mthfr, Methylenetetrahydrofolate reductase.']	[('IMPORTANT_CONSIDERATION', 31)]	1	"[('CHEBI_17126', 'carnitine', 167, 'carnitine'), ('CHEBI_39327', '(1S)-cis-(alphaR)-cyhalothrin', 295, 'fatty acidsOmega'), ('CHEBI_16646', 'carbohydrate', 335, 'Carbohydrate'), ('CHEBI_25468', 'naphthaldehydes', 391, 'Minerals'), ('CHEBI_31719', 'ipriflavone', 400, 'Iodine'), ('CHEBI_9107', 'senecionine', 440, 'seleniumIodine'), ('CHEBI_30483', 'trihydridotellurate(1-)', 456, 'seleniumIron'), ('CHEBI_28371', 'vitamin K epoxide', 523, 'Vitamins'), ('PR_000006444', 'diacylglycerol kinase delta', 590, 'D'), ('PR_000004900', 'complement C3', 603, 'C'), ('CHEBI_33277', 'gamma-tocotrienol', 609, 'vitamins'), ('CHEBI_27300', 'vitamin D', 619, 'vitamin D'), ('CHEBI_36961', 'chalcocarbonic acid', 629, 'Phytonutrients'), ('UBERON_0000062', 'organ', 722, 'organ'), ('CHEBI_8474', 'propane-2-thiol', 784, 'Probiotics'), ('GO_0007565', 'female pregnancy', 870, 'Prenatal'), ('CHEBI_5679', 'herniarin', 913, 'Hemoglobin'), ('CHEBI_28384', 'vitamin K', 962, 'Vitamin D'), ('CHEBI_27377', ""Unsym-bis(4'-chlorophenyl)ethylene"", 973, 'Zinc'), ('CHEBI_17126', 'carnitine', 979, 'Carnitine'), ('CHEBI_60004', 'mixture', 1016, 'mixed'), ('CHEBI_77957', 'm-fluoro-L-phenylalanine', 1022, 'carotenoids5000'), ('CHEBI_53471', 'chromium(III) sulfate', 1071, 'chromium niacinate'), ('UBERON_0002365', 'exocrine gland', 1135, 'molybdenum'), ('CHEBI_32508', 'glycinate', 1146, 'glycinate'), ('CHEBI_37527', 'acid', 1190, 'acid'), ('CHEBI_38294', 'dicarba-nido-undecaborane(11)', 1196, 'd-calcium pantothenate'), ('CHEBI_78128', 'fatty acid anion 24:0', 1232, 'fatty acids620'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 1257, 'E'), ('CHEBI_60004', 'mixture', 1260, 'mixed'), ('CHEBI_32499', 'amineptine', 1283, 'bisglycinate'), ('CHEBI_29440', 'methanuidyl', 1320, 'mononitrate'), ('CHEBI_8346', 'potassium iodide', 1344, 'potassium iodide'), ('CHEBI_46916', 'vinyl acetate', 1410, 'zinc citrate'), ('CHEBI_26630', 'selenocystathionine', 1474, 'selenomethionine'), ('CHEBI_17126', 'carnitine', 1499, 'carnitine'), ('CHEBI_17126', 'carnitine', 1522, 'carnitine'), ('CHEBI_16462', 'glycylpeptide', 1550, 'Pyridoxal 5 phosphate'), ('CHEBI_23401', 'coumaric acid', 1585, 'copper gluconate'), ('CHEBI_82350', '5-Nitroacenaphthene', 1661, '5-Methylfolate1000'), ('CHEBI_17874', 'dihydrozeatin', 1861, 'DHA'), ('CHEBI_36003', 'decenoic acid', 1866, 'docosahexaenoic acid'), ('CHEBI_34733', 'EPN', 1888, 'EPA'), ('CHEBI_36003', 'decenoic acid', 1893, 'eicosapentaenoic acid'), ('CHEBI_38725', 'mevinphos', 1923, 'methylenetetrahydrofolate')]"
S45-PMC4275593	PMC4275593	9/2014	S45-PMC4275593	['the supply of free or cheap Vitamin A and D tablets, milk, orange juice and cod Liver oil to expectant mothers and children through the wartime vitamin welfare scheme, with their perceived ROLE in the decline of maternal mortality, consolidated the IMPORTANCE of dietary supplements in Pregnancy.']	[('SUPERFICIAL_RELATIONSHIP', 189), ('IMPORTANT_CONSIDERATION', 249)]	2	[('CHEBI_27300', 'vitamin D', 28, 'vitamin A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 42, 'D'), ('PR_000006444', 'diacylglycerol kinase delta', 42, 'D'), ('UBERON_0002107', 'liver', 80, 'liver'), ('GO_0007565', 'female pregnancy', 286, 'pregnancy')]
S26-PMC4289064	PMC4289064	1/2015	S26-PMC4289064	['we FOCUSED our analyses on children and women in developing countries, where high rates of malnutrition and limited access to Nutrient Supplements MAY make Individuals more susceptible to the EFFECTS of pollinator declines, and analyzed five of the most IMPORTANT Nutrients to global nutrition: Vitamin A, zinc, iron, Folate, and Calcium[14],[15](data on Iodine, another globally IMPORTANT Nutrient, were not available in the datasets we analyzed).']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('INCOMPLETE_EVIDENCE', 147), ('SUPERFICIAL_RELATIONSHIP', 192), ('IMPORTANT_CONSIDERATION', 254), ('IMPORTANT_CONSIDERATION', 380)]	5	[('CHEBI_33284', 'nutrient', 126, 'nutrient'), ('CHEBI_33341', 'titanium atom', 135, 'supplements'), ('NCBITaxon_1', 'root', 156, 'individuals'), ('CHEBI_33284', 'nutrient', 264, 'nutrients'), ('CHEBI_27300', 'vitamin D', 295, 'vitamin A'), ('CHEBI_30863', '5-azaorotic acid', 318, 'folate'), ('CHEBI_22313', 'alkaline earth metal atom', 330, 'calcium'), ('CHEBI_24859', 'iodine atom', 355, 'iodine'), ('CHEBI_33284', 'nutrient', 390, 'nutrient')]
S34-PMC4302429	PMC4302429	1/2015	S34-PMC4302429	['the AIMS of THIS STUDY were (i) TO INVESTIGATE the immunomodulatory capacity of Vitamin D and (ii) TO EXAMINE the IMPACT of Vitamin D3 supplementation as a preventive or adjuvant therapeutic intervention on the course and mortality of experimental E. Coli meningoencephalitis.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 12), ('QUESTION_ANSWERED_BY_THIS_WORK', 32), ('QUESTION_ANSWERED_BY_THIS_WORK', 99), ('SUPERFICIAL_RELATIONSHIP', 114)]	5	[('CHEBI_27300', 'vitamin D', 80, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 88, 'D'), ('CHEBI_33279', 'vitamin D5', 124, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 124, 'vitamin D3'), ('NCBITaxon_10088', 'Mus <genus>', 248, 'E. coli')]
S172-PMC4302429	PMC4302429	1/2015	S172-PMC4302429	['a randomized double-blind intervention study SHOWED that supplementation with Vitamin D MAY reduce disease BURDEN in patients with frequent Respiratory Tract infections [33].']	[('INCOMPLETE_EVIDENCE', 45), ('INCOMPLETE_EVIDENCE', 88), ('IMPORTANT_CONSIDERATION', 107)]	3	[('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('UBERON_0000065', 'respiratory tract', 140, 'respiratory tract')]
S190-PMC4302429	PMC4302429	1/2015	S190-PMC4302429	['a study on the Immune Response to an allergic stimulus in Mice in vivo SUGGESTED that Vitamin D supplementation (100\xa0ng 1,25(Oh)2D injection) given after the initial period of sensitization prevented high levels of Eosinophils ASSOCIATED with a reduced local inflammatory response in Bronchoalveolar Lavage Fluid and Lung Tissue.']	[('INCOMPLETE_EVIDENCE', 71), ('SUPERFICIAL_RELATIONSHIP', 227)]	2	[('GO_0006955', 'immune response', 15, 'immune response'), ('UBERON_0002405', 'immune system', 15, 'immune'), ('NCBITaxon_10088', 'Mus <genus>', 58, 'mice'), ('CHEBI_27300', 'vitamin D', 86, 'vitamin D'), ('CHEBI_82784', 'PVP38-Ag NP', 120, '1,25(OH)2D'), ('CL_0000771', 'eosinophil', 215, 'eosinophils'), ('UBERON_0004212', 'glomerular capillary', 284, 'bronchoalveolar lavage fluid'), ('UBERON_0002048', 'lung', 317, 'lung tissue')]
S191-PMC4302429	PMC4302429	1/2015	S191-PMC4302429	['constant Vitamin D supplementation (100\xa0ng 1,25(Oh)2D injection every other day during the whole study period), HOWEVER, did not reduce the Entry Of Eosinophils Into the Respiratory Epithelia [45]; this is IN ACCORDANCE WITH our observation.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 112), ('INCOMPLETE_EVIDENCE', 206)]	2	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('CHEBI_82784', 'PVP38-Ag NP', 43, '1,25(OH)2D'), ('GO_0051639', 'actin filament network formation', 140, 'entry of eosinophils into ...'), ('CL_0000771', 'eosinophil', 149, 'eosinophils'), ('GO_0006314', 'intron homing', 170, 'respiratory epithelia'), ('UBERON_0004802', 'respiratory tract epithelium', 170, 'respiratory epithelia')]
S10-PMC4329404	PMC4329404	10/2014	S10-PMC4329404	['IMPORTANTLY, supplementation with Vitamin D improves both of these pathological abnormalities.']	[('ANOMALY_CURIOUS_FINDING', 0)]	1	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D')]
S17-PMC4329404	PMC4329404	10/2014	S17-PMC4329404	['CONVERSELY, increased asthma was REPORTED in Adulthood after a period of Vitamin D supplementation during the first year of Life (10).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 33)]	2	[('UBERON_0000113', 'post-juvenile adult stage', 45, 'adulthood'), ('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('UBERON_0000104', 'life cycle', 124, 'life')]
S102-PMC4329404	PMC4329404	10/2014	S102-PMC4329404	['supplementation with Vitamin D after in utero and early-Life insufficiency reduces Serum Ige in pups at 6\xa0weeks of age, BUT NOT th2 cytokines\nwe measured Serum total and hdm-specific Ige TO ASSESS whether early-Life Vitamin D insufficiency AFFECTED sensitization to Allergen (fig.4a).']	[('ANOMALY_CURIOUS_FINDING', 120), ('QUESTION_ANSWERED_BY_THIS_WORK', 187), ('SUPERFICIAL_RELATIONSHIP', 240)]	3	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('UBERON_0000104', 'life cycle', 56, 'life'), ('UBERON_0001977', 'blood serum', 83, 'serum'), ('GO_0071743', 'IgE immunoglobulin complex, circulating', 89, 'IgE'), ('UBERON_0001977', 'blood serum', 154, 'serum'), ('GO_0071743', 'IgE immunoglobulin complex, circulating', 183, 'IgE'), ('UBERON_0000104', 'life cycle', 211, 'life'), ('CHEBI_27300', 'vitamin D', 216, 'vitamin D'), ('CHEBI_50904', 'allergen', 266, 'allergen')]
S119-PMC4329404	PMC4329404	10/2014	S119-PMC4329404	['Vitamin D supplementation reduces Airway collagen in hdm-exposed pups\nGoblet Cell hyperplasia was evident in hdm-exposed pups; HOWEVER, Vitamin D status did not alter this (fig.5a).']	[('ANOMALY_CURIOUS_FINDING', 127)]	1	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('UBERON_0001005', 'respiratory airway', 34, 'airway'), ('CL_0000160', 'goblet cell', 70, 'Goblet cell'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin D')]
S122-PMC4329404	PMC4329404	10/2014	S122-PMC4329404	['the same reduction was still evident when Peri-Bronchiolar collagen was quantified (fig.5c,d), SUGGESTING Vitamin D supplementation MAY PROTECT from the development of Airway Remodelling.']	[('INCOMPLETE_EVIDENCE', 95), ('INCOMPLETE_EVIDENCE', 132), ('SUPERFICIAL_RELATIONSHIP', 136)]	3	[('UBERON_0001789', 'outer nuclear layer of retina', 42, 'peri'), ('UBERON_0002186', 'bronchiole', 47, 'bronchiolar'), ('CHEBI_27300', 'vitamin D', 106, 'vitamin D'), ('GO_0003313', 'heart rudiment development', 168, 'airway remodelling'), ('UBERON_0001005', 'respiratory airway', 168, 'airway')]
S157-PMC4329404	PMC4329404	10/2014	S157-PMC4329404	['our data SUGGEST Vitamin D is playing a widespread ROLE in Immunomodulation, and further SUGGESTS that supplementation MAY BE beneficial and MAY reduce disease severity.']	[('INCOMPLETE_EVIDENCE', 9), ('SUPERFICIAL_RELATIONSHIP', 51), ('INCOMPLETE_EVIDENCE', 89), ('INCOMPLETE_EVIDENCE', 119), ('INCOMPLETE_EVIDENCE', 141)]	5	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('GO_0050900', 'leukocyte migration', 59, 'immunomodulation')]
S159-PMC4329404	PMC4329404	10/2014	S159-PMC4329404	['SIMILARLY, Serum Ige levels were lowest in Mice that were supplemented with Vitamin D at weaning, EVEN lower than those that were always Vitamin D sufficient (fig.4a).']	[('SUPERFICIAL_RELATIONSHIP', 0), ('ANOMALY_CURIOUS_FINDING', 98)]	2	[('UBERON_0001977', 'blood serum', 11, 'serum'), ('GO_0071743', 'IgE immunoglobulin complex, circulating', 17, 'IgE'), ('NCBITaxon_10088', 'Mus <genus>', 43, 'mice'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 137, 'vitamin D')]
S160-PMC4329404	PMC4329404	10/2014	S160-PMC4329404	['the same EFFECT was seen in a PREVIOUS STUDY that has investigated the EFFECTS of Vitamin D supplementation on allergic Airways disease in an ovalbumin MODEL using Adult Mice.']	[('SUPERFICIAL_RELATIONSHIP', 9), ('INCOMPLETE_EVIDENCE', 30), ('SUPERFICIAL_RELATIONSHIP', 71), ('INCOMPLETE_EVIDENCE', 152)]	4	[('CHEBI_27300', 'vitamin D', 82, 'vitamin D'), ('UBERON_0001005', 'respiratory airway', 120, 'airways'), ('UBERON_0007023', 'adult organism', 164, 'adult'), ('NCBITaxon_10088', 'Mus <genus>', 170, 'mice')]
S161-PMC4329404	PMC4329404	10/2014	S161-PMC4329404	['that study by agrawal and colleagues HAS SHOWN that the improvement in inflammation is significantly better in Mice that are supplemented with Vitamin D compared TO controls that were vitamin d sufficient (31).']	[('INCOMPLETE_EVIDENCE', 37), ('QUESTION_ANSWERED_BY_THIS_WORK', 162)]	2	[('NCBITaxon_10088', 'Mus <genus>', 111, 'mice'), ('CHEBI_27300', 'vitamin D', 143, 'vitamin D')]
S162-PMC4329404	PMC4329404	10/2014	S162-PMC4329404	['a mechanism for this FINDING was NOT REPORTED, but IN AGREEMENT with OUR FINDINGS, Vitamin D supplementation in that MODEL also ONLY SHOWED an improvement in allergic inflammation, BUT NOT a complete resolution down to levels in nonallergic Mice, and THUS, the authors conclude Vitamin D supplementation is LIKELY an IMPORTANT adjunct in the treatment of asthma, RATHER than a candidate that will achieve a cure.']	[('INCOMPLETE_EVIDENCE', 21), ('INCOMPLETE_EVIDENCE', 33), ('INCOMPLETE_EVIDENCE', 51), ('QUESTION_ANSWERED_BY_THIS_WORK', 69), ('INCOMPLETE_EVIDENCE', 117), ('INCOMPLETE_EVIDENCE', 128), ('INCOMPLETE_EVIDENCE', 133), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 181), ('PROBABLE_UNDERSTANDING', 251), ('PROBABLE_UNDERSTANDING', 307), ('IMPORTANT_CONSIDERATION', 317), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 363)]	12	[('CHEBI_27300', 'vitamin D', 83, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 241, 'mice'), ('CHEBI_27300', 'vitamin D', 278, 'vitamin D')]
S163-PMC4329404	PMC4329404	10/2014	S163-PMC4329404	['SIMILAR FINDINGS HAVE not been REPORTED from trials of Vitamin D supplementation in Humans as they ONLY include patients that have deficient or insufficient levels prior to an intervention with Vitamin D or placebo.']	[('INCOMPLETE_EVIDENCE', 0), ('IMPORTANT_CONSIDERATION', 17), ('INCOMPLETE_EVIDENCE', 31), ('INCOMPLETE_EVIDENCE', 99)]	4	[('CHEBI_27300', 'vitamin D', 55, 'vitamin D'), ('NCBITaxon_9606', 'Homo sapiens', 84, 'humans'), ('CHEBI_27300', 'vitamin D', 194, 'vitamin D')]
S165-PMC4329404	PMC4329404	10/2014	S165-PMC4329404	['MODELS of Autoimmune disease have either supplemented Vitamin D-sufficient Animals and shown benefit or only compared responses in Vitamin D-deficient Animals, without a sufficient positive control group.']	[('INCOMPLETE_EVIDENCE', 0)]	1	[('UBERON_0001442', 'skeleton of manus', 10, 'autoimmune'), ('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('NCBITaxon_33208', 'Metazoa', 75, 'animals'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D'), ('NCBITaxon_33208', 'Metazoa', 151, 'animals')]
S167-PMC4329404	PMC4329404	10/2014	S167-PMC4329404	['we HAVE SHOWN a reduction in both total Lung collagen and Peri-Bronchiolar collagen in Mice that were exposed to hdm and had Vitamin D supplementation after weaning.']	[('INCOMPLETE_EVIDENCE', 3)]	1	[('UBERON_0002048', 'lung', 40, 'lung'), ('UBERON_0001789', 'outer nuclear layer of retina', 58, 'peri'), ('UBERON_0002186', 'bronchiole', 63, 'bronchiolar'), ('NCBITaxon_10088', 'Mus <genus>', 87, 'mice'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin D')]
S171-PMC4329404	PMC4329404	10/2014	S171-PMC4329404	['HOWEVER, numbers of Cd4+Il-10+cells were not significantly higher in the supplemented Mice compared to those that remained Vitamin D deficient.']	[('ANOMALY_CURIOUS_FINDING', 0)]	1	[('PR_000001204', 'C-C chemokine receptor type 8', 20, 'CD4'), ('PR_000001470', 'interleukin-28B', 24, 'IL-10'), ('NCBITaxon_10088', 'Mus <genus>', 86, 'mice'), ('CHEBI_27300', 'vitamin D', 123, 'vitamin D')]
S173-PMC4329404	PMC4329404	10/2014	S173-PMC4329404	['a pilot STUDY of high-dose Vitamin D supplementation in Adults ( n \xa0=\xa04) HAS SHOWN an increase in circulating Il-10-producing Peripheral Blood Mononuclear Cells (Pbmcs) (37); HOWEVER, these were otherwise healthy subjects and only Circulating Cells were assessed.']	[('INCOMPLETE_EVIDENCE', 8), ('INCOMPLETE_EVIDENCE', 73), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 175)]	3	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('UBERON_0007023', 'adult organism', 56, 'adults'), ('PR_000001470', 'interleukin-28B', 110, 'IL-10'), ('UBERON_0012101', 'perinatal stage', 126, 'peripheral blood'), ('CL_0000226', 'single nucleate cell', 143, 'mononuclear cells'), ('GO_0031097', 'medial cortex', 143, 'mononuclear'), ('CL_0002246', 'peripheral blood stem cell', 162, 'PBMCs'), ('CL_0000080', 'circulating cell', 231, 'circulating cells')]
S178-PMC4329404	PMC4329404	10/2014	S178-PMC4329404	['in addition, an Adult Murine MODEL of Vitamin D supplementation in ovalbumin-induced allergic Airways disease DEMONSTRATED an increase in Circulating T Regulatory Cells after Vitamin D supplementation, but levels of Pulmonary Tregs were NOT REPORTED (31).']	[('INCOMPLETE_EVIDENCE', 29), ('INCOMPLETE_EVIDENCE', 110), ('INCOMPLETE_EVIDENCE', 237)]	3	[('UBERON_0007023', 'adult organism', 16, 'adult'), ('NCBITaxon_39107', 'Murinae', 22, 'murine'), ('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('UBERON_0001005', 'respiratory airway', 94, 'airways'), ('CL_0000080', 'circulating cell', 138, 'circulating'), ('CL_0000902', 'induced T-regulatory cell', 150, 'T regulatory cells'), ('GO_0065007', 'biological regulation', 152, 'regulatory'), ('CHEBI_27300', 'vitamin D', 175, 'vitamin D'), ('UBERON_0002048', 'lung', 216, 'pulmonary'), ('CL_0000909', 'CD8-positive, alpha-beta memory T cell', 226, 'Tregs')]
S180-PMC4329404	PMC4329404	10/2014	S180-PMC4329404	['it MAY BE that ONLY alterations in circulating T Regulatory Cells are apparent following supplementation with Vitamin D.\nwe have PREVIOUSLY SHOWN that transfer of T Regulatory Cells prevented Development Of Airway Remodelling in an Adult Mouse MODEL of aad (40).']	[('INCOMPLETE_EVIDENCE', 3), ('ANOMALY_CURIOUS_FINDING', 15), ('INCOMPLETE_EVIDENCE', 15), ('INCOMPLETE_EVIDENCE', 129), ('INCOMPLETE_EVIDENCE', 244)]	5	[('CL_0000902', 'induced T-regulatory cell', 47, 'T regulatory cells'), ('GO_0065007', 'biological regulation', 49, 'regulatory'), ('CHEBI_27300', 'vitamin D', 110, 'vitamin D'), ('CL_0000902', 'induced T-regulatory cell', 163, 'T regulatory cells'), ('GO_0065007', 'biological regulation', 165, 'regulatory'), ('GO_0032498', 'detection of muramyl dipeptide', 192, 'development of airway remodelling'), ('UBERON_0001005', 'respiratory airway', 207, 'airway'), ('UBERON_0007023', 'adult organism', 232, 'adult'), ('NCBITaxon_10088', 'Mus <genus>', 238, 'mouse')]
S181-PMC4329404	PMC4329404	10/2014	S181-PMC4329404	['a PROMISING ROLE of Vitamin D supplementation in children with asthma is the POTENTIAL of minimizing the development of a very early feature of Airway Remodelling, increased thickness of the reticular basement membrane (41,42), which would incorporate a NOVEL therapeutic target in asthma.']	[('PROBABLE_UNDERSTANDING', 2), ('SUPERFICIAL_RELATIONSHIP', 12), ('INCOMPLETE_EVIDENCE', 77), ('FULL_UNKNOWN', 254)]	4	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('GO_0003313', 'heart rudiment development', 144, 'airway remodelling'), ('UBERON_0001005', 'respiratory airway', 144, 'airway')]
S184-PMC4329404	PMC4329404	10/2014	S184-PMC4329404	['our data SUGGEST Vitamin D deficiency in utero and early Life CONTRIBUTES to worse Eosinophilic inflammation and that Vitamin D supplementation after weaning reduces the development of both Pulmonary Eosinophilia and remodelling.']	[('INCOMPLETE_EVIDENCE', 9), ('SUPERFICIAL_RELATIONSHIP', 62)]	2	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('UBERON_0000104', 'life cycle', 57, 'life'), ('CL_0000771', 'eosinophil', 83, 'eosinophilic'), ('CHEBI_27300', 'vitamin D', 118, 'vitamin D'), ('UBERON_0002048', 'lung', 190, 'pulmonary'), ('CL_0000771', 'eosinophil', 200, 'eosinophilia')]
S185-PMC4329404	PMC4329404	10/2014	S185-PMC4329404	['THEREFORE, ALTHOUGH it does not SEEM LIKELY that Vitamin D deficiency per se causes asthma in early Life, it is LIKELY that Vitamin D deficiency CONTRIBUTES to increased disease severity in children with asthma and that supplementation MAY reduce severity.']	[('PROBABLE_UNDERSTANDING', 0), ('ANOMALY_CURIOUS_FINDING', 11), ('ANOMALY_CURIOUS_FINDING', 32), ('PROBABLE_UNDERSTANDING', 37), ('PROBABLE_UNDERSTANDING', 112), ('SUPERFICIAL_RELATIONSHIP', 145), ('INCOMPLETE_EVIDENCE', 236)]	7	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('UBERON_0000104', 'life cycle', 100, 'life'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D')]
S21-PMC4329745	PMC4329745	10/2014	S21-PMC4329745	['those who consumed multivitamin supplements containing less than 100 units Vitamin D per daily servings were NOT excluded.']	[('ANOMALY_CURIOUS_FINDING', 109)]	1	[('CHEBI_27300', 'vitamin D', 75, 'vitamin D')]
S94-PMC4329745	PMC4329745	10/2014	S94-PMC4329745	['OTHER POSSIBLE causes of reduced Vitamin D Synthesis in the skin in our area COULD BE dark skin color, indoor lifestyle and air pollution (2); lack of dietary fortification with Vitamin D multivitamin supplements MIGHT as well AGGRAVATE the situation in iranian women (18).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 6), ('INCOMPLETE_EVIDENCE', 77), ('INCOMPLETE_EVIDENCE', 213), ('SUPERFICIAL_RELATIONSHIP', 227)]	5	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('GO_0042368', 'vitamin D biosynthetic process', 33, 'vitamin D synthesis'), ('CHEBI_27300', 'vitamin D', 178, 'vitamin D')]
S21-PMC4352710	PMC4352710	2/2015	S21-PMC4352710	['investigated the ROLE of supplemental Folate, zinc and antioxidants (Vitamins C, e, and Β-Carotene) on Spermatocyte aneuploidy.']	[('SUPERFICIAL_RELATIONSHIP', 17)]	1	[('CHEBI_30863', '5-azaorotic acid', 38, 'folate'), ('CHEBI_27300', 'vitamin D', 69, 'vitamins C'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 88, 'β-carotene'), ('CL_0000017', 'spermatocyte', 103, 'spermatocyte')]
S80-PMC4377870	PMC4377870	3/2015	S80-PMC4377870	['anti-inflammatory and anti-asthmatic EFFECTS of Vitamin C supplementation in vivo , HAVE BEEN SHOWN through allergic Mouse MODELS of asthma.']	[('SUPERFICIAL_RELATIONSHIP', 37), ('INCOMPLETE_EVIDENCE', 84), ('INCOMPLETE_EVIDENCE', 123)]	3	[('CHEBI_27300', 'vitamin D', 48, 'vitamin C'), ('NCBITaxon_10088', 'Mus <genus>', 117, 'mouse')]
S82-PMC4377870	PMC4377870	3/2015	S82-PMC4377870	['[60] reported decreased ahr to Methacholine and Inflammatory Cell infiltration of Perivascular and Peribronchiolar spaces when Vitamin C was supplemented during Allergen CHALLENGE.']	[('DIFFICULT_TASK', 170)]	1	[('CHEBI_6805', 'methacycline', 31, 'methacholine'), ('CL_0009002', 'inflammatory cell', 48, 'inflammatory cell'), ('GO_0043204', 'perikaryon', 82, 'perivascular'), ('UBERON_0014930', 'perivascular space', 82, 'perivascular'), ('GO_0043204', 'perikaryon', 99, 'peribronchiolar'), ('UBERON_0001297', 'serosa of uterus', 99, 'peribronchiolar'), ('CHEBI_27300', 'vitamin D', 127, 'vitamin C'), ('CHEBI_50904', 'allergen', 161, 'allergen')]
S88-PMC4377870	PMC4377870	3/2015	S88-PMC4377870	['DESPITE the OBSERVATIONAL data LINKING Vitamin C to Lung health, supplementation with Vitamin C has not been shown to reduce the RISK of asthma [66] which MAY be RELATED to the interdependence of Nutrients found in Foods, resulting in lack OF efficacy when supplementing with isolated Nutrients.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 12), ('SUPERFICIAL_RELATIONSHIP', 31), ('IMPORTANT_CONSIDERATION', 129), ('INCOMPLETE_EVIDENCE', 155), ('SUPERFICIAL_RELATIONSHIP', 162), ('ANOMALY_CURIOUS_FINDING', 240)]	7	[('CHEBI_27300', 'vitamin D', 39, 'vitamin C'), ('UBERON_0002048', 'lung', 52, 'lung'), ('CHEBI_27300', 'vitamin D', 86, 'vitamin C'), ('CHEBI_33284', 'nutrient', 196, 'nutrients'), ('CHEBI_33290', 'food', 215, 'foods'), ('CHEBI_33284', 'nutrient', 285, 'nutrients')]
S94-PMC4377870	PMC4377870	3/2015	S94-PMC4377870	['THUS, in SUMMARY, WHILE OBSERVATIONAL data has SUGGESTED that Vitamin C is IMPORTANT for Lung health, intervention trials SHOWING efficacy are lacking and it APPEARS that supplementation with Vitamin C-rich whole foods, such as fruit and vegetables MAY BE more EFFECTIVE.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 9), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 18), ('INCOMPLETE_EVIDENCE', 24), ('INCOMPLETE_EVIDENCE', 47), ('IMPORTANT_CONSIDERATION', 75), ('INCOMPLETE_EVIDENCE', 122), ('ANOMALY_CURIOUS_FINDING', 158), ('INCOMPLETE_EVIDENCE', 249), ('SUPERFICIAL_RELATIONSHIP', 261)]	10	[('CHEBI_27300', 'vitamin D', 62, 'vitamin C'), ('UBERON_0002048', 'lung', 89, 'lung'), ('CHEBI_27300', 'vitamin D', 192, 'vitamin C')]
S103-PMC4377870	PMC4377870	3/2015	S103-PMC4377870	['the CONFLICTING results from these supplementation studies are LIKELY to be INFLUENCED by baseline Tissue levels of Vitamin E [72], with Α-Tocopherol supplementation leading to improved Lung function and wheeze in europe, where Γ-Tocopherol levels are low [78,79,80], BUT NOT in the us, where γ-Tocopherol Intake is high due to Soybean oil Consumption [81,82,83].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 4), ('PROBABLE_UNDERSTANDING', 63), ('SUPERFICIAL_RELATIONSHIP', 76), ('FULL_UNKNOWN', 268), ('ANOMALY_CURIOUS_FINDING', 272)]	5	[('UBERON_0000479', 'tissue', 99, 'tissue'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin E'), ('CHEBI_27725', 'butin', 137, 'α-tocopherol'), ('UBERON_0002048', 'lung', 186, 'lung'), ('CHEBI_27725', 'butin', 228, 'γ-tocopherol'), ('CHEBI_27013', 'tocopherol', 295, 'tocopherol'), ('GO_0007631', 'feeding behavior', 306, 'intake'), ('CHEBI_36933', 'oxygen-19 atom', 328, 'soybean'), ('GO_0007631', 'feeding behavior', 340, 'consumption')]
S104-PMC4377870	PMC4377870	3/2015	S104-PMC4377870	['as a result, meta-analysis of Vitamin E EFFECTS on asthma outcomes is EQUIVOCAL; it is LIKELY that supplementation with physiological concentrations of Α-Tocopherol in the context of a background diet low in Γ-Tocopherol, MAY BE MOST beneficial in asthma and FURTHER RESEARCH testing this HYPOTHESIS IS REQUIRED.']	[('SUPERFICIAL_RELATIONSHIP', 40), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 70), ('PROBABLE_UNDERSTANDING', 87), ('INCOMPLETE_EVIDENCE', 222), ('PROBABLE_UNDERSTANDING', 229), ('FUTURE_WORK', 259), ('INCOMPLETE_EVIDENCE', 289), ('FUTURE_WORK', 300), ('IMPORTANT_CONSIDERATION', 303)]	9	[('CHEBI_27300', 'vitamin D', 30, 'vitamin E'), ('CHEBI_27725', 'butin', 152, 'α-tocopherol'), ('CHEBI_27725', 'butin', 208, 'γ-tocopherol')]
S118-PMC4377870	PMC4377870	3/2015	S118-PMC4377870	['in asthma the experimental data for Vitamin E are COMPELLING, YET supplementation benefits are NOT WELL DESCRIBED.']	[('INCOMPLETE_EVIDENCE', 50), ('ANOMALY_CURIOUS_FINDING', 62), ('INCOMPLETE_EVIDENCE', 95)]	3	[('CHEBI_27300', 'vitamin D', 36, 'vitamin E')]
S119-PMC4377870	PMC4377870	3/2015	S119-PMC4377870	['in copd there is currently NOT ENOUGH EVIDENCE to make CONCLUSIONS about Vitamin E supplementation.']	[('INCOMPLETE_EVIDENCE', 27), ('PROBABLE_UNDERSTANDING', 55)]	2	[('CHEBI_27300', 'vitamin D', 73, 'vitamin E')]
S138-PMC4377870	PMC4377870	3/2015	S138-PMC4377870	['Vitamin D CAN be obtained from dietary sources or supplementation; HOWEVER sun exposure is the main CONTRIBUTOR to Vitamin D levels [108].']	[('INCOMPLETE_EVIDENCE', 10), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 67), ('SUPERFICIAL_RELATIONSHIP', 100)]	3	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin D')]
S154-PMC4377870	PMC4377870	3/2015	S154-PMC4377870	['ONLY ONE intervention TRIAL HAS BEEN conducted using Vitamin D in Adults with asthma, which FOUND that rate of first exacerbation was reduced in subjects who demonstrated an increase in circulating Vitamin D3 following supplementation [122].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 28), ('INCOMPLETE_EVIDENCE', 92)]	3	[('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('UBERON_0007023', 'adult organism', 66, 'adults'), ('CHEBI_33279', 'vitamin D5', 198, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 198, 'vitamin D3')]
S249-PMC4377870	PMC4377870	3/2015	S249-PMC4377870	['a whole Foods approach to Nutrient supplementation—for example, increasing intake of fruit and vegetables, has the benefit of increasing intake of multiple Nutrients, including vitamin C, Vitamin E, Carotenoids and Flavonoids and SHOWS more promise in Respiratory diseases in terms of reducing risk of copd [3] and incidence of asthma exacerbations [25].']	[('INCOMPLETE_EVIDENCE', 230)]	1	[('CHEBI_33290', 'food', 8, 'foods'), ('CHEBI_33284', 'nutrient', 26, 'nutrient'), ('CHEBI_33284', 'nutrient', 156, 'nutrients'), ('CHEBI_18245', 'carboxylato group', 185, 'C'), ('CHEBI_27300', 'vitamin D', 188, 'vitamin E'), ('CHEBI_50815', 'norgestimate', 199, 'carotenoids'), ('CHEBI_72544', 'flavonoids', 215, 'flavonoids'), ('UBERON_0001004', 'respiratory system', 252, 'respiratory')]
S251-PMC4377870	PMC4377870	3/2015	S251-PMC4377870	['it APPEARS that Vitamin D is IMPORTANT in Respiratory diseases and infections, HOWEVER the temporal ROLE of Vitamin D deficiency in disease onset, pathogenesis and exacerbations and WHETHER supplementation is indicated is yet to be clarified.']	[('ANOMALY_CURIOUS_FINDING', 3), ('IMPORTANT_CONSIDERATION', 29), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 79), ('ANOMALY_CURIOUS_FINDING', 79), ('SUPERFICIAL_RELATIONSHIP', 100), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 182)]	6	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 42, 'respiratory'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin D')]
S139-PMC4377879	PMC4377879	3/2015	S139-PMC4377879	['high-dose supplementation with Vitamin C and Vitamin E HAS BEEN FOUND to not prevent Preeclampsia but to increase the rate of babies Born with low birthweight [59].']	[('INCOMPLETE_EVIDENCE', 55)]	1	[('CHEBI_27300', 'vitamin D', 31, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 45, 'vitamin E'), ('GO_0007128', 'meiotic prophase I', 85, 'preeclampsia'), ('GO_0007567', 'parturition', 133, 'born')]
S141-PMC4377879	PMC4377879	3/2015	S141-PMC4377879	['there DOES NOT APPEAR TO BE EVIDENCE to RECOMMEND supplementation with Vitamins C and E.\n\n7.']	[('INCOMPLETE_EVIDENCE', 6), ('ANOMALY_CURIOUS_FINDING', 11), ('ANOMALY_CURIOUS_FINDING', 15), ('INCOMPLETE_EVIDENCE', 15), ('INCOMPLETE_EVIDENCE', 25), ('FUTURE_WORK', 40)]	6	[('CHEBI_27300', 'vitamin D', 71, 'vitamins C'), ('PR_000004900', 'complement C3', 80, 'C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 86, 'E')]
S181-PMC4377879	PMC4377879	3/2015	S181-PMC4377879	['oral supplementation of urban indian women with Vitamin B-12 throughout Pregnancy and early Lactation significantly increased Vitamin B-12 status of both mothers and infants [9] and so WORTH CONSIDERING where Vitamin B12 intakes are marginal.']	[('IMPORTANT_CONSIDERATION', 185), ('FUTURE_WORK', 191)]	2	[('CHEBI_27300', 'vitamin D', 48, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 48, 'vitamin B-12'), ('GO_0007565', 'female pregnancy', 72, 'pregnancy'), ('GO_0007595', 'lactation', 92, 'lactation'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 126, 'vitamin B-12'), ('CHEBI_33279', 'vitamin D5', 209, 'vitamin B12'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 217, 'B12')]
S262-PMC4377879	PMC4377879	3/2015	S262-PMC4377879	['the provision of balanced energy protein supplementary Foods to underweight Pregnant women was also considered to have enough EVIDENCE of reduction in sga and stillbirths and improved Birthweights for widespread implementation, WHEREAS maternal Vitamin D and zinc supplementation, WHILE promising, were CONSIDERED to have INSUFFICIENT evidence [18].']	[('INCOMPLETE_EVIDENCE', 126), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 228), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 281), ('ANOMALY_CURIOUS_FINDING', 281), ('INCOMPLETE_EVIDENCE', 303), ('INCOMPLETE_EVIDENCE', 322)]	6	[('CHEBI_33290', 'food', 55, 'foods'), ('GO_0007565', 'female pregnancy', 76, 'pregnant'), ('GO_0007596', 'blood coagulation', 184, 'birthweights'), ('CHEBI_27300', 'vitamin D', 245, 'vitamin D')]
S18-PMC4379001	PMC4379001	3/2015	S18-PMC4379001	['waterland[8] et al SHOWED that dietary methyl supplementation with extra Folic Acid, Vitamin B (12), Choline, and betaine altered the phenotype of their offspring via increased Cpg Methylation.']	[('INCOMPLETE_EVIDENCE', 19)]	1	[('CHEBI_30751', 'formic acid', 73, 'folic acid'), ('CHEBI_27300', 'vitamin D', 85, 'vitamin B'), ('CHEBI_15354', 'choline', 101, 'choline'), ('GO_0010424', 'DNA methylation on cytosine within a CG sequence', 177, 'CpG methylation')]
S6-PMC4380518	PMC4380518	9/2014	S6-PMC4380518	['conclusions\nongoing trials of Vitamin D supplementation during Pregnancy SHOULD CONSIDER POTENTIAL EFFECT MODIFICATION by race/ethnicity.']	[('FUTURE_WORK', 73), ('FUTURE_WORK', 80), ('INCOMPLETE_EVIDENCE', 89), ('PROBLEM_COMPLICATION', 99)]	4	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0007565', 'female pregnancy', 63, 'pregnancy')]
S59-PMC4380518	PMC4380518	9/2014	S59-PMC4380518	['we DID NOT HAVE DATA on WHETHER women were taking separate Calcium or Vitamin D supplements beyond what is contained in pnvs.']	[('FULL_UNKNOWN', 3), ('EXPLICIT_QUESTION', 24)]	2	[('CHEBI_22313', 'alkaline earth metal atom', 59, 'calcium'), ('CHEBI_27300', 'vitamin D', 70, 'vitamin D')]
S69-PMC4380518	PMC4380518	9/2014	S69-PMC4380518	['ONGOING TRIALS of Vitamin D supplementation during Pregnancy SHOULD CONSIDER EFFECT MODIFICATION by race/ethnicity.']	[('INCOMPLETE_EVIDENCE', 0), ('FUTURE_WORK', 61), ('FUTURE_WORK', 68), ('PROBLEM_COMPLICATION', 77)]	4	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('GO_0007565', 'female pregnancy', 51, 'pregnancy')]
S0-PMC4383226	PMC4383226	2/2015	S0-PMC4383226	['vitamin a Supplements, routine immunization, and the subsequent risk of plasmodium infection among children under 5 years in sub-saharan africa\n\nabstract\nRECENT STUDIES, PARTLY based on Murine MODELS, SUGGEST childhood immunization and Vitamin A Supplements MAY confer protection against malaria infection, ALTHOUGH STRONG EVIDENCE TO SUPPORT these THEORIES in Humans has so far BEEN LACKING.']	[('INCOMPLETE_EVIDENCE', 154), ('INCOMPLETE_EVIDENCE', 170), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 193), ('INCOMPLETE_EVIDENCE', 193), ('INCOMPLETE_EVIDENCE', 201), ('INCOMPLETE_EVIDENCE', 258), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 307), ('ANOMALY_CURIOUS_FINDING', 307), ('INCOMPLETE_EVIDENCE', 316), ('INCOMPLETE_EVIDENCE', 349), ('INCOMPLETE_EVIDENCE', 379)]	11	[('CHEBI_33341', 'titanium atom', 10, 'supplements'), ('NCBITaxon_39107', 'Murinae', 186, 'murine'), ('CHEBI_27300', 'vitamin D', 236, 'vitamin A'), ('CHEBI_33341', 'titanium atom', 246, 'supplements'), ('NCBITaxon_9606', 'Homo sapiens', 361, 'humans')]
S2-PMC4383226	PMC4383226	2/2015	S2-PMC4383226	['parasitemia (n=8390) and plasmodium falciparum Hrp-2 ( pf Hrp-2)-RELATED antigenemia (n=6121) following Vitamin A supplementation and standard vaccination.']	[('SUPERFICIAL_RELATIONSHIP', 65)]	1	[('PR_000008820', 'heat shock protein beta-8', 47, 'HRP-2'), ('PR_000008820', 'heat shock protein beta-8', 58, 'HRP-2'), ('CHEBI_27300', 'vitamin D', 104, 'vitamin A')]
S11-PMC4383226	PMC4383226	2/2015	S11-PMC4383226	"[""many also receive Vitamin A supplements, which HAVE BEEN LINKED not ONLY to the protection of a child's Vision, but also to a lower RISK of death and an improved ability to Fight off infections.""]"	[('INCOMPLETE_EVIDENCE', 47), ('SUPERFICIAL_RELATIONSHIP', 57), ('ANOMALY_CURIOUS_FINDING', 68), ('IMPORTANT_CONSIDERATION', 132)]	4	[('CHEBI_27300', 'vitamin D', 18, 'vitamin A'), ('GO_0007601', 'visual perception', 104, 'vision'), ('GO_0007631', 'feeding behavior', 173, 'fight')]
S12-PMC4383226	PMC4383226	2/2015	S12-PMC4383226	['SOME researchers have SUGGESTED that Vitamin A supplements and routine childhood vaccinations for other diseases MAY also provide SOME protection against malaria.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 22), ('INCOMPLETE_EVIDENCE', 113), ('INCOMPLETE_EVIDENCE', 130)]	4	[('CHEBI_27300', 'vitamin D', 37, 'vitamin A')]
S25-PMC4383226	PMC4383226	2/2015	S25-PMC4383226	['FOUND that children who received Vitamin A supplements were less LIKELY to become infected with malaria.']	[('INCOMPLETE_EVIDENCE', 0), ('PROBABLE_UNDERSTANDING', 65)]	2	[('CHEBI_27300', 'vitamin D', 33, 'vitamin A')]
S31-PMC4383226	PMC4383226	2/2015	S31-PMC4383226	['SEVERAL STUDIES have SUGGESTED that childhood immunization MAY confer non-specific health EFFECTS beyond targeted diseases, BUT the IMPACT of standard vaccination and Vitamin A supplementation on malaria Infection is UNCLEAR.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 21), ('INCOMPLETE_EVIDENCE', 59), ('SUPERFICIAL_RELATIONSHIP', 90), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 124), ('SUPERFICIAL_RELATIONSHIP', 132), ('FULL_UNKNOWN', 217)]	7	[('CHEBI_27300', 'vitamin D', 167, 'vitamin A'), ('GO_0007586', 'digestion', 204, 'infection')]
S36-PMC4383226	PMC4383226	2/2015	S36-PMC4383226	['multiple clinical TRIALS in infants and young children have also IDENTIFIED PROTECTIVE EFFECTS from Vitamin A supplementation against illness (number and time to first clinical episode, risk of febrile illness, Spleen enlargement, and mean parasite density) (shankar et al., 1999;zeba et al., 2008) and death caused by malaria (fawzi et al., 1999;varandas et al., 2001;mwanga-amumpaire et al., 2012).']	[('FUTURE_WORK', 18), ('INCOMPLETE_EVIDENCE', 65), ('SUPERFICIAL_RELATIONSHIP', 76), ('SUPERFICIAL_RELATIONSHIP', 87)]	4	[('CHEBI_27300', 'vitamin D', 100, 'vitamin A'), ('UBERON_0002106', 'spleen', 211, 'spleen')]
S42-PMC4383226	PMC4383226	2/2015	S42-PMC4383226	['ON THE OTHER HAND, CONCERN HAS BEEN RAISED by an APPARENT increase in levels of parasitemia within Mouse MODELS, when combining Vitamin A supplements with dtp vaccination; an EFFECT THOUGHT TO be stronger among female Mice (jorgensen et al., 2011).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('PROBLEM_COMPLICATION', 19), ('INCOMPLETE_EVIDENCE', 27), ('EXPLICIT_QUESTION', 36), ('ANOMALY_CURIOUS_FINDING', 49), ('INCOMPLETE_EVIDENCE', 105), ('SUPERFICIAL_RELATIONSHIP', 175), ('INCOMPLETE_EVIDENCE', 182)]	8	[('NCBITaxon_10088', 'Mus <genus>', 99, 'mouse'), ('CHEBI_27300', 'vitamin D', 128, 'vitamin A'), ('NCBITaxon_10088', 'Mus <genus>', 218, 'mice')]
S44-PMC4383226	PMC4383226	2/2015	S44-PMC4383226	['BASED ON this evidence, the PURPOSE of THIS STUDY was TO DETERMINE the risk of plasmodium parasitemia and p. falciparum -specific antigenemia following Vitamin A supplementation and standard vaccination in children under 5 years of age in sub-saharan africa.']	[('SUPERFICIAL_RELATIONSHIP', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 28), ('QUESTION_ANSWERED_BY_THIS_WORK', 39), ('QUESTION_ANSWERED_BY_THIS_WORK', 54)]	4	[('CHEBI_27300', 'vitamin D', 152, 'vitamin A')]
S78-PMC4383226	PMC4383226	2/2015	S78-PMC4383226	['doi: http://dx.doi.org/10.7554/elife.03925.006\n\nIMPACT of Vitamin A supplementation on malaria infection\nvitamin a supplementation APPEARED PROTECTIVE against plasmodium parasitemia and p ƒhrp-2 antigenemia (table 2).']	[('SUPERFICIAL_RELATIONSHIP', 48), ('ANOMALY_CURIOUS_FINDING', 131), ('SUPERFICIAL_RELATIONSHIP', 140)]	3	[('CHEBI_27300', 'vitamin D', 58, 'vitamin A'), ('PR_000000164', 'BMP2', 192, '-2')]
S79-PMC4383226	PMC4383226	2/2015	S79-PMC4383226	['these EFFECTS REMAINED after weighting.figure 2illustrates that the association between Vitamin A and plasmodium parasitemia was not impacted by season, age or time since supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 6), ('INCOMPLETE_EVIDENCE', 14)]	2	[('CHEBI_27300', 'vitamin D', 88, 'vitamin A')]
S80-PMC4383226	PMC4383226	2/2015	S80-PMC4383226	['HOWEVER, for antigenemia, Vitamin A was moderately more PROTECTIVE in older children (ptrend<0.001), the more time passed since supplementation (ptrend<0.001) or if supplementation was given during the wet season (ptrend=0.04).table 3reveals that ASSOCIATIONS between Vitamin A and parasitemia were stronger among children 36–59 months of age or if their mother took an Antimalarial during Pregnancy.']	[('ANOMALY_CURIOUS_FINDING', 0), ('SUPERFICIAL_RELATIONSHIP', 56), ('SUPERFICIAL_RELATIONSHIP', 247)]	3	[('CHEBI_27300', 'vitamin D', 26, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 268, 'vitamin A'), ('CHEBI_67261', '(Z)-2,3-dehydroadipyl-CoA(5-)', 370, 'antimalarial'), ('GO_0007565', 'female pregnancy', 390, 'pregnancy')]
S85-PMC4383226	PMC4383226	2/2015	S85-PMC4383226	['we had INSUFFICIENT data to identify cross-INTERACTIONS between vaccines and Vitamin A using an adjusted model, BUT in unadjusted models we found no significant interactions between vaccination and Vitamin A supplementation.10.7554/elife.03925.007\n\ncaption (table-wrap): table 3.']	[('INCOMPLETE_EVIDENCE', 7), ('SUPERFICIAL_RELATIONSHIP', 43), ('ANOMALY_CURIOUS_FINDING', 112)]	3	[('CHEBI_27300', 'vitamin D', 77, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 198, 'vitamin A')]
S86-PMC4383226	PMC4383226	2/2015	S86-PMC4383226	['modifiers of the ASSOCIATION between Vitamin A supplementation and malaria infection among children 6–59 months of age\ndoi: http://dx.doi.org/10.7554/elife.03925.007characteristics at Blood testinglevel in the model plasmodium species (parasitemia)* plasmodium falciparum (antigenemia)†no.']	[('SUPERFICIAL_RELATIONSHIP', 17)]	1	[('CHEBI_27300', 'vitamin D', 37, 'vitamin A'), ('UBERON_0000178', 'blood', 184, 'blood')]
S94-PMC4383226	PMC4383226	2/2015	S94-PMC4383226	['discussion\nin THIS large, population-BASED STUDY within sub-saharan africa, Vitamin A supplementation was ASSOCIATED with a negative risk of plasmodium parasitemia and p ƒhrp-2 antigenemia among children aged 6–59 months.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 14), ('QUESTION_ANSWERED_BY_THIS_WORK', 37), ('SUPERFICIAL_RELATIONSHIP', 106)]	3	[('CHEBI_27300', 'vitamin D', 76, 'vitamin A')]
S112-PMC4383226	PMC4383226	2/2015	S112-PMC4383226	['ADDITIONAL RESEARCH MAY BE WARRANTED on the IMPACT of Vitamin A supplementation in young children with known Prenatal exposure to malaria.']	[('FUTURE_WORK', 0), ('FUTURE_WORK', 11), ('FUTURE_WORK', 20), ('SUPERFICIAL_RELATIONSHIP', 44)]	4	[('CHEBI_27300', 'vitamin D', 54, 'vitamin A'), ('GO_0007565', 'female pregnancy', 109, 'prenatal')]
S133-PMC4383226	PMC4383226	2/2015	S133-PMC4383226	"[""in particular, our study ONLY CONSIDERED information regarding the last recorded dose of Vitamin A supplement RATHER than a child's history of supplementation.""]"	[('INCOMPLETE_EVIDENCE', 25), ('INCOMPLETE_EVIDENCE', 30), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 110)]	3	[('CHEBI_27300', 'vitamin D', 89, 'vitamin A')]
S134-PMC4383226	PMC4383226	2/2015	S134-PMC4383226	['given that Vitamin A is fat soluble and CAN be stored in the Liver for long periods of time (blomhoff, 1994;tanumihardjo, 2011), ADDITIONAL RESEARCH IS NEEDED to examine WHETHER regular supplementation has an IMPACT on increased protection.']	[('INCOMPLETE_EVIDENCE', 40), ('FUTURE_WORK', 129), ('FUTURE_WORK', 149), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 170), ('SUPERFICIAL_RELATIONSHIP', 209)]	5	[('CHEBI_27300', 'vitamin D', 11, 'vitamin A'), ('UBERON_0002107', 'liver', 61, 'liver')]
S150-PMC4383226	PMC4383226	2/2015	S150-PMC4383226	"[""we FOCUSED on standard dhs surveys carried out since january 2010, which tested children for malaria using Blood films (gold standard malaria test) and documented children's use of standard vaccines and Vitamin A supplements.""]"	[('QUESTION_ANSWERED_BY_THIS_WORK', 3)]	1	[('UBERON_0000178', 'blood', 107, 'blood'), ('CHEBI_27300', 'vitamin D', 203, 'vitamin A')]
S8-PMC4396835	PMC4396835	1/2015	S8-PMC4396835	['FUTURE RESEARCH SHOULD study WHETHER OR NOT adequate supplementation of Vitamin D to Pregnant women MIGHT lower the RISK for asd in the offspring.']	[('FUTURE_WORK', 0), ('FUTURE_WORK', 16), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 29), ('INCOMPLETE_EVIDENCE', 100), ('IMPORTANT_CONSIDERATION', 116)]	5	[('CHEBI_27300', 'vitamin D', 72, 'vitamin D'), ('GO_0007565', 'female pregnancy', 85, 'pregnant')]
S171-PMC4396835	PMC4396835	1/2015	S171-PMC4396835	['FUTURE RESEARCH SHOULD include a larger cohort followed prospectively and also study WHETHER OR NOT adequate supplementation of Vitamin D to Pregnant women MIGHT lower the RISK for asd in the offspring.']	[('FUTURE_WORK', 0), ('FUTURE_WORK', 16), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 85), ('INCOMPLETE_EVIDENCE', 156), ('IMPORTANT_CONSIDERATION', 172)]	5	[('CHEBI_27300', 'vitamin D', 128, 'vitamin D'), ('GO_0007565', 'female pregnancy', 141, 'pregnant')]
S121-PMC4405493	PMC4405493	4/2015	S121-PMC4405493	['UNFORTUNATELY, the increasing use of multivitamins and Mineral dietary supplements in younger to older Adults DOES NOT APPEAR TO BE ASSOCIATED with a corresponding increase in Serum 25-oh Vitamin D concentrations [3,19,41].']	[('IMPORTANT_CONSIDERATION', 0), ('ANOMALY_CURIOUS_FINDING', 110), ('ANOMALY_CURIOUS_FINDING', 119), ('SUPERFICIAL_RELATIONSHIP', 132)]	4	[('CHEBI_46662', 'mineral', 55, 'mineral'), ('UBERON_0007023', 'adult organism', 103, 'adults'), ('UBERON_0001977', 'blood serum', 176, 'serum'), ('CHEBI_27300', 'vitamin D', 188, 'vitamin D')]
S157-PMC4405493	PMC4405493	4/2015	S157-PMC4405493	['HOWEVER, WHETHER Vitamin D deficiency is a RISK FACTOR for Gestational diabetes in itself OR IF Vitamin D supplementation CAN PREVENT gdm is YET UNKNOWN [72].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 9), ('SUPERFICIAL_RELATIONSHIP', 43), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 93), ('INCOMPLETE_EVIDENCE', 122), ('SUPERFICIAL_RELATIONSHIP', 126), ('FULL_UNKNOWN', 141)]	7	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('GO_0007565', 'female pregnancy', 59, 'gestational'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin D')]
S4-PMC4417995	PMC4417995	4/2015	S4-PMC4417995	['as of today, the ROLE of Vitamin D in ad is FAR FROM CLEAR; ADDITIONAL STUDIES ARE PARTICULARLY NEEDED in order to confirm the PROMISING therapeutic ROLE of Vitamin D supplementation in childhood ad.']	[('SUPERFICIAL_RELATIONSHIP', 17), ('FULL_UNKNOWN', 44), ('FUTURE_WORK', 60), ('FUTURE_WORK', 71), ('IMPORTANT_CONSIDERATION', 83), ('INCOMPLETE_EVIDENCE', 127), ('PROBABLE_UNDERSTANDING', 127), ('SUPERFICIAL_RELATIONSHIP', 149)]	8	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 157, 'vitamin D')]
S111-PMC4417995	PMC4417995	4/2015	S111-PMC4417995	['TRYING to elucidate WHETHER maternal Vitamin D supplementation during Lactation improves infantile eczema and other subsequent allergic disorders, a randomized double-blind, placebo-controlled trial [52] was conducted on 164 breastfeeding mothers of infants with Facial eczema.']	[('INCOMPLETE_EVIDENCE', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 20)]	2	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('GO_0007595', 'lactation', 70, 'lactation'), ('UBERON_0001456', 'face', 263, 'facial')]
S112-PMC4417995	PMC4417995	4/2015	S112-PMC4417995	['the analysis SHOWED that Vitamin D supplementation MAY not decrease the severity of infantile eczema at 3 months of age but MAY RATHER increase the risk of later Food allergy up to 2 years of age.']	[('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 51), ('INCOMPLETE_EVIDENCE', 124), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 128)]	4	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('CHEBI_33290', 'food', 162, 'food')]
S134-PMC4417995	PMC4417995	4/2015	S134-PMC4417995	['Vitamin D supplementation\na nutritional survey [59] comparing ad patients ( n = 132) with healthy controls ( n = 132) DEMONSTRATED that patients with ad had a lower Vitamin D dietary intake than the control group.']	[('INCOMPLETE_EVIDENCE', 118)]	1	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 165, 'vitamin D')]
S136-PMC4417995	PMC4417995	4/2015	S136-PMC4417995	['based on this RATIONALE and comforted by the data obtained from observational studies, the following clinical trials INVESTIGATED the therapeutic ROLE of Vitamin D supplementation in the treatment of ad.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 14), ('QUESTION_ANSWERED_BY_THIS_WORK', 117), ('SUPERFICIAL_RELATIONSHIP', 146)]	3	[('CHEBI_27300', 'vitamin D', 154, 'vitamin D')]
S145-PMC4417995	PMC4417995	4/2015	S145-PMC4417995	['a larger trial [62] also SHOWED a significant reduction in scorad after Vitamin D supplementation.']	[('INCOMPLETE_EVIDENCE', 25)]	1	[('CHEBI_27300', 'vitamin D', 72, 'vitamin D')]
S150-PMC4417995	PMC4417995	4/2015	S150-PMC4417995	['[63] tested a 3-week supplementation with 1000\u2009iu/day Vitamin D in 14 atopic subjects with moderate to severe ad, SHOWING a significant increase in Cathelicidins Expression in lesional skin.']	[('INCOMPLETE_EVIDENCE', 114)]	1	[('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('PR_000005190', 'cell division cycle protein 23', 148, 'cathelicidins'), ('GO_0010467', 'gene expression', 162, 'expression')]
S154-PMC4417995	PMC4417995	4/2015	S154-PMC4417995	['HOWEVER, DESPITE all of the above EVIDENCES, no significant difference in ad severity after Vitamin D supplementation compared with Placebo was FOUND in a 2012 systematic literature review [65].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 9), ('INCOMPLETE_EVIDENCE', 34), ('INCOMPLETE_EVIDENCE', 144)]	5	[('CHEBI_27300', 'vitamin D', 92, 'vitamin D'), ('CHEBI_26130', 'biological pigment', 132, 'placebo')]
S187-PMC4417995	PMC4417995	4/2015	S187-PMC4417995	['THEREFORE systematic supplementation of Vitamin D in childhood ad currently cannot be RECOMMENDED EXCEPT for UNCOMMON cases which MAY prove refractory to traditional therapeutic options.']	[('PROBABLE_UNDERSTANDING', 0), ('FUTURE_WORK', 86), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 98), ('INCOMPLETE_EVIDENCE', 109), ('INCOMPLETE_EVIDENCE', 130)]	5	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D')]
S47-PMC4427001	PMC4427001	4/2015	S47-PMC4427001	['study participants were not reporting Vitamin D or multivitamin supplementation on top of routinely RECOMMENDED Folic Acid supplementation.']	[('FUTURE_WORK', 100)]	1	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('CHEBI_30751', 'formic acid', 112, 'folic acid')]
S137-PMC4427001	PMC4427001	4/2015	S137-PMC4427001	['SEVERAL STUDIES investigated Vitamin D supplementation in women with gdm [23,31].']	[('INCOMPLETE_EVIDENCE', 0)]	1	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D')]
S139-PMC4427001	PMC4427001	4/2015	S139-PMC4427001	['[31] studied WHETHER Vitamin D supplementation MAY improve Glycaemic Control in women with gdm.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 13), ('INCOMPLETE_EVIDENCE', 47)]	2	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('GO_0051162', 'L-arabitol metabolic process', 59, 'glycaemic control')]
S142-PMC4427001	PMC4427001	4/2015	S142-PMC4427001	['[44] assessed the EFFECT of Calcium and Vitamin D cosupplementation on gdm in a randomised placebo-controlled study (56 iranian women with gdm) and they OBSERVED a significant reduction in fpg, serum Insulin levels, and homa-ir and increase in quicki compared with placebo, and also an increase in Glutathione and a reduction in Serum ldl-Cholesterol and total Cholesterol and a significant elevation in hdl-Cholesterol were common.']	[('SUPERFICIAL_RELATIONSHIP', 18), ('INCOMPLETE_EVIDENCE', 153)]	2	[('CHEBI_22313', 'alkaline earth metal atom', 28, 'calcium'), ('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('PR_000045358', 'insulin family protein', 200, 'insulin'), ('CHEBI_16856', 'glutathione', 298, 'glutathione'), ('UBERON_0001977', 'blood serum', 329, 'serum'), ('CHEBI_16113', 'cholesterol', 339, 'cholesterol'), ('CHEBI_16113', 'cholesterol', 361, 'cholesterol'), ('CHEBI_16113', 'cholesterol', 408, 'cholesterol')]
S143-PMC4427001	PMC4427001	4/2015	S143-PMC4427001	['rudnicki and mølsted-pedersen [45] reported that supplementation with an active form of Vitamin D (1,25(Oh)2D) was ASSOCIATED with significant decrease of plasma Glucose level and POSSIBLE EFFECT on Insulin sensitivity.']	[('SUPERFICIAL_RELATIONSHIP', 115), ('INCOMPLETE_EVIDENCE', 180), ('SUPERFICIAL_RELATIONSHIP', 189)]	3	"[('CHEBI_27300', 'vitamin D', 88, 'vitamin D'), ('CHEBI_37958', 'dye', 99, '1,'), ('CHEBI_66212', ""5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone"", 101, '25(OH)2D'), ('CHEBI_17234', 'glucose', 162, 'glucose'), ('PR_000045358', 'insulin family protein', 199, 'insulin')]"
S153-PMC4427001	PMC4427001	4/2015	S153-PMC4427001	['POTENTIALLY beneficial EFFECT of Vitamin D supplementation and the PLAUSIBLE pathogenic ROLE of 25(Oh)D deficiency in the subsequent development of diabetes mellitus type 2 in women with gdm history HAS to be FURTHER explored considering the ROLE of Vitamin D in Modulating Insulin sensitivity and Glucose Metabolism.']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 23), ('INCOMPLETE_EVIDENCE', 67), ('SUPERFICIAL_RELATIONSHIP', 88), ('IMPORTANT_CONSIDERATION', 199), ('FUTURE_WORK', 209), ('SUPERFICIAL_RELATIONSHIP', 242)]	7	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 96, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 250, 'vitamin D'), ('GO_0065007', 'biological regulation', 263, 'modulating'), ('PR_000045358', 'insulin family protein', 274, 'insulin'), ('CHEBI_17234', 'glucose', 298, 'glucose'), ('GO_0006006', 'glucose metabolic process', 298, 'glucose metabolism')]
S25-PMC4438573	PMC4438573	5/2015	S25-PMC4438573	['the ONLY STUDY to date that has assessed the EFFECTS of maternal Nutrient supplementation on malaria Antibody levels REPORTED that Vitamin A Prenatal supplements were ASSOCIATED with a reduction in Antibody responses to a Placental-binding isolate ej-24, but no significant changes in Antibody responses to non-Pregnancy related parasite Isolates were observed [22].']	[('INCOMPLETE_EVIDENCE', 4), ('SUPERFICIAL_RELATIONSHIP', 45), ('INCOMPLETE_EVIDENCE', 117), ('SUPERFICIAL_RELATIONSHIP', 167)]	4	[('CHEBI_33284', 'nutrient', 65, 'nutrient'), ('GO_0042571', 'immunoglobulin complex, circulating', 101, 'antibody'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin A'), ('GO_0007565', 'female pregnancy', 141, 'prenatal'), ('GO_0042571', 'immunoglobulin complex, circulating', 198, 'antibody'), ('UBERON_0001987', 'placenta', 222, 'placental'), ('GO_0042571', 'immunoglobulin complex, circulating', 285, 'antibody'), ('GO_0007565', 'female pregnancy', 311, 'pregnancy'), ('SO_0001040', 'integrated_plasmid', 338, 'isolates')]
S412-PMC4448820	PMC4448820	5/2015	S412-PMC4448820	['by using Pbmcs from healthy men who were treated with Lps, ANOTHER STUDY SHOWED that anti-inflammatory EFFECTS of Vitamin E supplementation (e.g., decreased Il-6 secretion) DEPENDS on having the gg genotype at position 313 of the Gstp1 Gene (236).']	[('INCOMPLETE_EVIDENCE', 59), ('INCOMPLETE_EVIDENCE', 73), ('SUPERFICIAL_RELATIONSHIP', 103), ('SUPERFICIAL_RELATIONSHIP', 173)]	4	[('CL_0002246', 'peripheral blood stem cell', 9, 'PBMCs'), ('CHEBI_16412', 'lipopolysaccharide', 54, 'LPS'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin E'), ('PR_000001470', 'interleukin-28B', 157, 'IL-6'), ('PR_000008294', 'glutathione S-transferase A1', 230, 'GSTP1'), ('SO_0000704', 'gene', 236, 'gene')]
S527-PMC4448820	PMC4448820	5/2015	S527-PMC4448820	['● supplementation CAN have BENEFITS (e.g., reducing mortality and some types of morbidity in the case of Vitamin A and zinc) but MAY also increase risk of adverse outcomes in selected populations as HAS BEEN seen for both Vitamin A and iron.']	[('INCOMPLETE_EVIDENCE', 18), ('IMPORTANT_CONSIDERATION', 27), ('INCOMPLETE_EVIDENCE', 129), ('INCOMPLETE_EVIDENCE', 199)]	4	[('CHEBI_27300', 'vitamin D', 105, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 222, 'vitamin A')]
S537-PMC4448820	PMC4448820	5/2015	S537-PMC4448820	['caption (table-wrap): table 6\n\neffects of Micronutrient supplementation on Immune function and vaccine responses (Human studies)1type of malnutrition and type of Immune functioneffects of supplementation on Immune System (reference)vitamin a\u2003Epithelial barrier function● high-dose vas above 6 mo of age decreases risk of death from infections such as measles and diarrheal diseases (290)● vas in the context of hiv infection or Lower Respiratory Tract infections HAS BEEN ASSOCIATED with adverse outcomes (105,263,290–292)● improved barrier function (105)● abnormal dual-Sugar (Lactulose, Mannitol) Intestinal permeability inversely CORRELATED with Serum Retinol (293) and PARTIALLY normalized by supplementation in va-deficient Individuals in SOME STUDIES (294) BUT NOT OTHERS (295,296)● increased symptomatology after high-dose vas during acute Lower Respiratory Tract infections REPORTED in SOME STUDIES (105) MAY INDICATE restored Mucus Production\u2003innate physiologic barriers● vas did not affect crp, saa, and/or agp concentrations among children with subclinical or clinical vad (297–299)● crp and agp did not change in men with low va stores given va (300)\u2003Macrophage function● increased Monocyte numbers (301)● decreased Tnf-Α concentrations in children (301) BUT the OPPOSITE in men (106)● decreased Ifn-Γ concentrations in children (302) but not in Pregnant women (303)● increased Il-10 concentrations in children (105,301) BUT no or an opposite effect in Adults (106,303,304)\u2003Neutrophil function● Neutrophil Phagocytosis of latex beads increased in va-deficient children given a single dose of Va (305)● Neutrophil Phagocytosis of E. Coli did not change in men with low Va stores given Va (300)\u2003Nk Cell function● an increase in Nk Cells in hiv-infected children supplemented with Va (105)● Nk Cell numbers did not change in men with low Va given supplemental Va; HOWEVER, there was a positive CORRELATION between Va stores and Peripheral Blood Nk Cells (300)\u2003T Cell function● increased Lymphocyte counts, particularly cd4 counts (105)● Cd4:Cd8 ratios were increased or unchanged by supplementation (306)● increase in Naive cd4 T Cells after supplementation; higher Memory Cd8, Cd45Ro (307)● higher Mitogen-induced Il-2, Il-4, and Tnf in response to supplementation (106)\u2003B Cell function● supplementation had no overall effect on Measles vaccine response (308) and a negative response in Individuals with baseline high titers (103)● no overall effect on oral polio vaccination● supplemented children increased Igg1 responses to dtp, minor igg3 response, no change in igg2 and igg4 (309)● no overall effect on bcg vaccine in Va-supplemented children, lower response in va-supplemented boys at 2 mo (310)● increased Antibody responses to some vaccines (Measles vaccine by 9 mo of age, oral polio vaccine, type 1, hepatitis b vaccine, rabies vaccine) (103)● short-term diminished cellular response to ppd in boys (103) and hospitalized children (105)Zinc\u2003Epithelial barrier function● zn supplementation in children LED TO an improvement in the lactulose:Mannitol Excretion ratio in SOME (311) BUT NOT OTHER (312,313) STUDIES; ratio MAY improve in infected children without zn deficiency given supplemental zn (314)\u2003innate physiologic barriers ● zn-supplemented children had higher Serum Complement C3 (315)\u2003Nk Cell function● children with diarrhea supplemented with zn supplementation do not exhibit an increase in Nk Cells (316)● increased Nk Cell activity in the elderly (317)\u2003T Cell function● increased cd4+ cell count in aids patients (318)● increased Thymocyte count in Thymus (319)● increased thymulin activity (320)● no CONSISTENT effect of zn supplementation on dth to tb Antigen [reviewed in (103)]\u2003B Cell function● no effect of zn supplementation of mothers on Bcg response in children (321)\nagp, α1-acid Glycoprotein; bcg, bacille calmette-guérin; cd, cluster of differentiation; Cd45Ro , Cluster Of Differentiation Antigen 45 Ro; Crp, c-reactive protein; dth, delayed-type hypersensitivity; dtp, diphtheria tetanus-pertussis; ppd, purified protein derivative; saa, Serum Amyloid a; tb, tuberculosis; va, Vitamin A; vad, Vitamin A deficiency; vas, Vitamin A supplementation.']	[('INCOMPLETE_EVIDENCE', 463), ('SUPERFICIAL_RELATIONSHIP', 472), ('SUPERFICIAL_RELATIONSHIP', 633), ('INCOMPLETE_EVIDENCE', 673), ('INCOMPLETE_EVIDENCE', 744), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 763), ('INCOMPLETE_EVIDENCE', 882), ('INCOMPLETE_EVIDENCE', 894), ('INCOMPLETE_EVIDENCE', 913), ('INCOMPLETE_EVIDENCE', 917), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1267), ('ANOMALY_CURIOUS_FINDING', 1267), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1275), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1433), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1873), ('SUPERFICIAL_RELATIONSHIP', 1903), ('SUPERFICIAL_RELATIONSHIP', 3021), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 3088), ('INCOMPLETE_EVIDENCE', 3088), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 3099), ('INCOMPLETE_EVIDENCE', 3123), ('INCOMPLETE_EVIDENCE', 3138), ('INCOMPLETE_EVIDENCE', 3633)]	23	"[('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 42, 'micronutrient'), ('UBERON_0002405', 'immune system', 75, 'immune'), ('NCBITaxon_9606', 'Homo sapiens', 114, 'human'), ('UBERON_0002405', 'immune system', 162, 'immune'), ('UBERON_0002405', 'immune system', 207, 'immune system'), ('UBERON_0000483', 'epithelium', 242, 'Epithelial'), ('UBERON_0004905', 'articulation', 428, 'lower respiratory tract'), ('CHEBI_24870', 'ion', 571, 'sugar'), ('CHEBI_25098', 'lyxoside', 578, 'lactulose'), ('CHEBI_25169', 'mannoside', 589, 'mannitol'), ('UBERON_0000160', 'intestine', 599, 'intestinal'), ('UBERON_0001977', 'blood serum', 649, 'serum'), ('CHEBI_26536', 'retinoic acid', 655, 'retinol'), ('NCBITaxon_1', 'root', 729, 'individuals'), ('UBERON_0004905', 'articulation', 847, 'lower respiratory tract'), ('GO_0007498', 'mesoderm development', 935, 'mucus production'), ('UBERON_0000912', 'mucus', 935, 'mucus'), ('CL_0000235', 'macrophage', 1163, 'Macrophage'), ('CL_0000576', 'monocyte', 1194, 'monocyte'), ('PR_000000134', 'tumor necrosis factor alpha', 1228, 'TNF-α'), ('PR_000008920', 'interferon alpha-7', 1308, 'IFN-γ'), ('GO_0007565', 'female pregnancy', 1358, 'pregnant'), ('PR_000001470', 'interleukin-28B', 1390, 'IL-10'), ('UBERON_0007023', 'adult organism', 1465, 'adults'), ('CL_0000775', 'neutrophil', 1486, 'Neutrophil'), ('CL_0000775', 'neutrophil', 1507, 'Neutrophil'), ('GO_0007608', 'sensory perception of smell', 1507, 'Neutrophil'), ('GO_0006909', 'phagocytosis', 1518, 'phagocytosis'), ('CHEBI_37958', 'dye', 1604, 'VA'), ('CL_0000775', 'neutrophil', 1614, 'Neutrophil'), ('GO_0070231', 'T cell apoptotic process', 1614, 'Neutrophil phagocytosis'), ('NCBITaxon_10088', 'Mus <genus>', 1641, 'E. coli'), ('CHEBI_37958', 'dye', 1680, 'VA'), ('CHEBI_37958', 'dye', 1696, 'VA'), ('CL_0000623', 'natural killer cell', 1705, 'NK cell'), ('GO_0005634', 'nucleus', 1705, 'NK'), ('CL_0000623', 'natural killer cell', 1738, 'NK cells'), ('GO_0005634', 'nucleus', 1738, 'NK'), ('CHEBI_37958', 'dye', 1790, 'VA'), ('CL_0000623', 'natural killer cell', 1800, 'NK cell'), ('GO_0005634', 'nucleus', 1800, 'NK'), ('CHEBI_37958', 'dye', 1847, 'VA'), ('CHEBI_37958', 'dye', 1869, 'VA'), ('CHEBI_37958', 'dye', 1923, 'VA'), ('UBERON_0012101', 'perinatal stage', 1937, 'peripheral blood'), ('CL_0000623', 'natural killer cell', 1954, 'NK cells'), ('GO_0005634', 'nucleus', 1954, 'NK'), ('CL_0000084', 'T cell', 1969, 'T cell'), ('CL_0000542', 'lymphocyte', 1996, 'lymphocyte'), ('PR_000001204', 'C-C chemokine receptor type 8', 2046, 'CD4'), ('PR_000005170', 'CD37 molecule', 2050, 'CD8'), ('CL_0000898', 'naive T cell', 2127, 'naive ... T cells'), ('GO_0007613', 'memory', 2175, 'memory'), ('PR_000005170', 'CD37 molecule', 2182, 'CD8'), ('PR_000005170', 'CD37 molecule', 2187, 'CD45RO'), ('CHEBI_52290', 'mitogen', 2208, 'mitogen'), ('PR_000001470', 'interleukin-28B', 2224, 'IL-2'), ('PR_000001470', 'interleukin-28B', 2230, 'IL-4'), ('PR_000016482', 'tumor necrosis factor receptor superfamily member 18', 2240, 'TNF'), ('CL_0000236', 'B cell', 2281, 'B cell'), ('NCBITaxon_33208', 'Metazoa', 2339, 'measles'), ('NCBITaxon_1', 'root', 2397, 'individuals'), ('GO_0071735', 'IgG immunoglobulin complex', 2519, 'IgG1'), ('CHEBI_37958', 'dye', 2633, 'VA'), ('GO_0042571', 'immunoglobulin complex, circulating', 2723, 'antibody'), ('NCBITaxon_33208', 'Metazoa', 2760, 'measles'), ('CHEBI_27377', ""Unsym-bis(4'-chlorophenyl)ethylene"", 2956, 'Zinc'), ('UBERON_0000483', 'epithelium', 2961, 'Epithelial'), ('CHEBI_25169', 'mannoside', 3060, 'mannitol'), ('GO_0007588', 'excretion', 3069, 'excretion'), ('UBERON_0001977', 'blood serum', 3287, 'serum'), ('PR_000004908', 'complement component C8 alpha chain', 3293, 'complement C3'), ('CL_0000623', 'natural killer cell', 3313, 'NK cell'), ('GO_0005634', 'nucleus', 3313, 'NK'), ('CL_0000623', 'natural killer cell', 3421, 'NK cells'), ('CL_0000623', 'natural killer cell', 3447, 'NK cell'), ('CL_0000084', 'T cell', 3485, 'T cell'), ('CL_0000893', 'thymocyte', 3562, 'thymocyte'), ('UBERON_0002370', 'thymus', 3581, 'thymus'), ('CHEBI_59132', 'antigen', 3686, 'antigen'), ('CL_0000236', 'B cell', 3714, 'B cell'), ('CHEBI_33250', 'atom', 3777, 'BCG'), ('CHEBI_17089', 'glycoprotein', 3821, 'glycoprotein'), ('PR_000005170', 'CD37 molecule', 3897, 'CD45RO'), ('PR_000011040', 'nuclear receptor coactivator 1', 3906, 'cluster of differentiation antigen 45 RO'), ('CHEBI_59132', 'antigen', 3933, 'antigen'), ('PR_000005890', 'crooked neck-like protein 1', 3948, 'CRP'), ('UBERON_0001977', 'blood serum', 4083, 'serum'), ('CHEBI_60425', 'amyloid fibril', 4089, 'amyloid'), ('CHEBI_27300', 'vitamin D', 4122, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 4138, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 4165, 'vitamin A')]"
S568-PMC4448820	PMC4448820	5/2015	S568-PMC4448820	['EFFECTS of vad/Vitamin A supplementation on Immune function and disease risk.']	[('SUPERFICIAL_RELATIONSHIP', 0)]	1	[('CHEBI_27300', 'vitamin D', 15, 'vitamin A'), ('UBERON_0002405', 'immune system', 44, 'immune')]
S569-PMC4448820	PMC4448820	5/2015	S569-PMC4448820	['as discussed by wg 1, Vad and Vitamin A supplementation AFFECT a range of innate and Adaptive Immune functions.']	[('SUPERFICIAL_RELATIONSHIP', 56)]	1	"[('CHEBI_16695', ""uridine 5'-monophosphate"", 22, 'VAD'), ('CHEBI_27300', 'vitamin D', 30, 'vitamin A'), ('GO_0019825', 'oxygen binding', 85, 'adaptive immune'), ('UBERON_0002405', 'immune system', 94, 'immune')]"
S571-PMC4448820	PMC4448820	5/2015	S571-PMC4448820	['SEVERAL Human STUDIES DOCUMENTED that vad is ASSOCIATED with increased Th1-Driven Delayed-type Hypersensitivity (dth) Responses and reduced th2-driven Antibody responses to vaccines; Vitamin A supplementation reverses these responses (104,105,326).']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 22), ('SUPERFICIAL_RELATIONSHIP', 45)]	3	[('NCBITaxon_9606', 'Homo sapiens', 8, 'human'), ('GO_0044808', 'oncostatin M production', 71, 'Th1-driven'), ('GO_0001866', 'NK T cell proliferation', 82, 'delayed- ... hypersensitivity'), ('GO_0060033', 'anatomical structure regression', 118, 'responses'), ('GO_0042571', 'immunoglobulin complex, circulating', 151, 'antibody'), ('CHEBI_27300', 'vitamin D', 183, 'vitamin A')]
S575-PMC4448820	PMC4448820	5/2015	S575-PMC4448820	['large randomized trials led to meta-analyses CONCLUDING that prophylactic Vitamin A supplementation of children between 6 mo and 5 y of age reduces overall mortality by 23–30% (290, 327–328) ( table 7 ).']	[('PROBABLE_UNDERSTANDING', 45)]	1	[('CHEBI_27300', 'vitamin D', 74, 'vitamin A')]
S578-PMC4448820	PMC4448820	5/2015	S578-PMC4448820	['one POSSIBLE EXPLANATION for the APPARENT lack of benefit of Vitamin A supplementation below 6 mo of age is that infants in SUCH studies are PROTECTED from infection by maternally derived Immune factors (e.g., Serum Igg, factors in Breast Milk) to a greater degree than are older infants.']	[('INCOMPLETE_EVIDENCE', 4), ('PROBABLE_UNDERSTANDING', 13), ('ANOMALY_CURIOUS_FINDING', 33), ('PROBABLE_UNDERSTANDING', 124), ('SUPERFICIAL_RELATIONSHIP', 141)]	5	[('CHEBI_27300', 'vitamin D', 61, 'vitamin A'), ('UBERON_0002405', 'immune system', 188, 'immune'), ('UBERON_0001977', 'blood serum', 210, 'serum'), ('GO_0071735', 'IgG immunoglobulin complex', 216, 'IgG'), ('UBERON_0001348', 'brown adipose tissue', 232, 'breast milk')]
S584-PMC4448820	PMC4448820	5/2015	S584-PMC4448820	['for instance, neonatal Vitamin A supplementation had a DIFFERENT EFFECT on in vitro whole-Blood cytokine responses DEPENDING ON the sex and the vaccination status of the children (301).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 55), ('SUPERFICIAL_RELATIONSHIP', 65), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 115)]	3	[('CHEBI_27300', 'vitamin D', 23, 'vitamin A'), ('UBERON_0000178', 'blood', 90, 'blood')]
S586-PMC4448820	PMC4448820	5/2015	S586-PMC4448820	['also, ALTHOUGH it IS CLEAR that inflammation is ASSOCIATED with decreased Serum Retinol and rbp concentrations, the ROLE of Vitamin A supplementation on inflammation and its MARKERS is LESS CLEAR.']	[('ANOMALY_CURIOUS_FINDING', 6), ('PROBABLE_UNDERSTANDING', 18), ('SUPERFICIAL_RELATIONSHIP', 48), ('SUPERFICIAL_RELATIONSHIP', 116), ('SUPERFICIAL_RELATIONSHIP', 174), ('FULL_UNKNOWN', 185), ('INCOMPLETE_EVIDENCE', 185)]	7	[('UBERON_0001977', 'blood serum', 74, 'serum'), ('CHEBI_26536', 'retinoic acid', 80, 'retinol'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin A')]
S593-PMC4448820	PMC4448820	5/2015	S593-PMC4448820	['HOWEVER, the EFFECTS of Vitamin A supplementation on the Immune System MAY lead TO variable clinical outcomes, DEPENDING ON the nature of the Immune Response NEEDED to combat the infecting pathogens.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('SUPERFICIAL_RELATIONSHIP', 13), ('INCOMPLETE_EVIDENCE', 71), ('QUESTION_ANSWERED_BY_THIS_WORK', 80), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 111), ('IMPORTANT_CONSIDERATION', 158)]	6	[('CHEBI_27300', 'vitamin D', 24, 'vitamin A'), ('UBERON_0002405', 'immune system', 57, 'immune system'), ('GO_0006955', 'immune response', 142, 'immune response'), ('UBERON_0002405', 'immune system', 142, 'immune')]
S594-PMC4448820	PMC4448820	5/2015	S594-PMC4448820	['FOR THIS REASON, Vitamin A supplementation MAY BE a double-edged sword.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 43)]	2	[('CHEBI_27300', 'vitamin D', 17, 'vitamin A')]
S595-PMC4448820	PMC4448820	5/2015	S595-PMC4448820	['for SOME—and on THE BASIS of the clinical trials, PRESUMABLY most—infectious diseases, Vitamin A supplementation MAY BE beneficial; in OTHER situations it MAY be harmful (369,370).']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 16), ('PROBABLE_UNDERSTANDING', 50), ('INCOMPLETE_EVIDENCE', 113), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 135), ('INCOMPLETE_EVIDENCE', 155)]	6	[('CHEBI_27300', 'vitamin D', 87, 'vitamin A')]
S774-PMC4448820	PMC4448820	5/2015	S774-PMC4448820	['as discussed above, adverse outcomes were SEEN during Vitamin A and Iron supplementation programs, and the mechanisms underlying these adverse EFFECTS MAY involve altered host resistance.']	[('INCOMPLETE_EVIDENCE', 42), ('SUPERFICIAL_RELATIONSHIP', 143), ('INCOMPLETE_EVIDENCE', 151)]	3	[('CHEBI_27300', 'vitamin D', 54, 'vitamin A'), ('CHEBI_24870', 'ion', 68, 'iron')]
S782-PMC4448820	PMC4448820	5/2015	S782-PMC4448820	['caption (boxed-text): text box 27\u2003\nresearch priorities\n\n● accurate and stable biomarkers of vad\n● EFFECT of Vitamin A supplementation on inflammation and inflammatory markers\n● mechanisms behind the variable clinical outcomes SEEN as a result of the IMPACT of Vitamin A on the different Immune Responses\n● EFFECT of Vitamin A supplementation on neonates and infants <6 mo\n● INFLUENCE of zinc status on vaccine response\n● other CONFOUNDERS in the zinc–vaccine response ASSOCIATION (age, sex, degree of zinc deficiency, etc.)']	[('SUPERFICIAL_RELATIONSHIP', 98), ('INCOMPLETE_EVIDENCE', 226), ('SUPERFICIAL_RELATIONSHIP', 250), ('SUPERFICIAL_RELATIONSHIP', 306), ('SUPERFICIAL_RELATIONSHIP', 374), ('PROBLEM_COMPLICATION', 427), ('SUPERFICIAL_RELATIONSHIP', 468)]	7	[('CHEBI_27300', 'vitamin D', 108, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 260, 'vitamin A'), ('GO_0006955', 'immune response', 287, 'immune responses'), ('UBERON_0002405', 'immune system', 287, 'immune'), ('CHEBI_27300', 'vitamin D', 316, 'vitamin A')]
S867-PMC4448820	PMC4448820	5/2015	S867-PMC4448820	['ANOTHER example is the observation that Vitamin A supplementation, which GENERALLY lowers mortality in children, increased the RISK of Mother-To-Child Hiv Transmission in pregnant and Postpartum hiv-infected women in tanzania (469), ALTHOUGH not in south africa (470) or malawi (471).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('PROBABLE_UNDERSTANDING', 73), ('IMPORTANT_CONSIDERATION', 127), ('ANOMALY_CURIOUS_FINDING', 233)]	4	[('CHEBI_27300', 'vitamin D', 40, 'vitamin A'), ('GO_0007063', 'regulation of sister chromatid cohesion', 135, 'mother-to-child HIV transmission'), ('GO_0007565', 'female pregnancy', 184, 'postpartum')]
S868-PMC4448820	PMC4448820	5/2015	S868-PMC4448820	['in infants of hiv-positive mothers, Postpartum maternal and neonatal Vitamin A supplementation MAY hasten progression to death in breastfed children who are pcr negative at 6 wk (291).']	[('INCOMPLETE_EVIDENCE', 95)]	1	[('GO_0007565', 'female pregnancy', 36, 'postpartum'), ('CHEBI_27300', 'vitamin D', 69, 'vitamin A')]
S1045-PMC4448820	PMC4448820	5/2015	S1045-PMC4448820	['● no randomized trials HAVE BEEN published on the EFFECTS of Vitamin D supplementation to prevent asthma or to reduce morbidity.']	[('INCOMPLETE_EVIDENCE', 23), ('SUPERFICIAL_RELATIONSHIP', 50)]	2	[('CHEBI_27300', 'vitamin D', 61, 'vitamin D')]
S1135-PMC4448820	PMC4448820	5/2015	S1135-PMC4448820	['in SOME conditions, supplementation with Vitamins A, d, and e and copper and Selenium was PROTECTIVE against mastitis (652), BUT others REPORTED in hiv-infected women that antioxidant Micronutrient supplementation did not lower (660), and MIGHT EVEN increase the risk of scm (661).']	[('INCOMPLETE_EVIDENCE', 3), ('SUPERFICIAL_RELATIONSHIP', 90), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 125), ('INCOMPLETE_EVIDENCE', 136), ('INCOMPLETE_EVIDENCE', 239), ('ANOMALY_CURIOUS_FINDING', 245)]	6	[('CHEBI_27300', 'vitamin D', 41, 'vitamins A'), ('CHEBI_27568', 'selenium atom', 77, 'selenium'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 184, 'micronutrient')]
S1194-PMC4448820	PMC4448820	5/2015	S1194-PMC4448820	['this phenomenon SHOULD BE evaluated closely, particularly in light of the EXPANDING INTEREST in Vitamin D supplementation to boost Immune function and for use in numerous conditions including hiv and other infections.']	[('FUTURE_WORK', 16), ('INCOMPLETE_EVIDENCE', 74)]	2	[('CHEBI_27300', 'vitamin D', 96, 'vitamin D'), ('UBERON_0002405', 'immune system', 131, 'immune')]
S13-PMC4452099	PMC4452099	6/2015	S13-PMC4452099	['a variety of environmental t1d risk and PROTECTIVE FACTORS, including Vitamin D supplementation during Gestation and in early infancy, HAVE BEEN investigated [5–9].']	[('SUPERFICIAL_RELATIONSHIP', 40), ('INCOMPLETE_EVIDENCE', 135)]	2	[('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('GO_0007565', 'female pregnancy', 103, 'gestation')]
S14-PMC4452099	PMC4452099	6/2015	S14-PMC4452099	['there are several REASONS to SUGGEST that Vitamin D supplementation early in Life MAY CONTRIBUTE to PREVENTING t1d.']	[('PROBABLE_UNDERSTANDING', 18), ('INCOMPLETE_EVIDENCE', 29), ('INCOMPLETE_EVIDENCE', 82), ('SUPERFICIAL_RELATIONSHIP', 86), ('SUPERFICIAL_RELATIONSHIP', 100)]	5	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('UBERON_0000104', 'life cycle', 77, 'life')]
S17-PMC4452099	PMC4452099	6/2015	S17-PMC4452099	['Animal studies DEMONSTRATED that in Mice, Prenatal Vitamin D supplementation PREVENTED the development of t1d [13,14].']	[('INCOMPLETE_EVIDENCE', 15), ('SUPERFICIAL_RELATIONSHIP', 77)]	2	[('NCBITaxon_33208', 'Metazoa', 0, 'Animal'), ('NCBITaxon_10088', 'Mus <genus>', 36, 'mice'), ('GO_0007565', 'female pregnancy', 42, 'prenatal'), ('CHEBI_27300', 'vitamin D', 51, 'vitamin D')]
S18-PMC4452099	PMC4452099	6/2015	S18-PMC4452099	['SEVERAL epidemiological STUDIES also FOUND that the risk of t1d was decreased in Individuals supplemented with Vitamin D during Gestation or infancy, and that the PROTECTIVE EFFECT was directly DEPENDENT ON the supplementation dose: the larger the dose, the smaller t1d risk [15].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 24), ('INCOMPLETE_EVIDENCE', 37), ('SUPERFICIAL_RELATIONSHIP', 163), ('SUPERFICIAL_RELATIONSHIP', 174), ('SUPERFICIAL_RELATIONSHIP', 194)]	6	[('NCBITaxon_1', 'root', 81, 'individuals'), ('CHEBI_27300', 'vitamin D', 111, 'vitamin D'), ('GO_0007565', 'female pregnancy', 128, 'gestation')]
S22-PMC4452099	PMC4452099	6/2015	S22-PMC4452099	['oral Intake MIGHT be further augmented by fortification and supplementation, which is especially IMPORTANT in order to maintain baseline Vitamin stores during winter in populations at northern latitudes, where the sun can initiate dermal Synthesis Of Vitamin D only from april to october [17,18].']	[('INCOMPLETE_EVIDENCE', 12), ('IMPORTANT_CONSIDERATION', 97)]	2	[('GO_0007631', 'feeding behavior', 5, 'intake'), ('CHEBI_33229', 'vitamin (role)', 137, 'vitamin'), ('GO_0030474', 'spindle pole body duplication', 238, 'synthesis of vitamin D'), ('CHEBI_27300', 'vitamin D', 251, 'vitamin D')]
S95-PMC4452099	PMC4452099	6/2015	S95-PMC4452099	['in comparison, in the PREVIOUSLY CONDUCTED finnish cohort STUDY, which SHOWED a decrease in t1d of around 20%, the Vitamin D supplementation doses given to infants were 50 μg per day [31].']	[('INCOMPLETE_EVIDENCE', 22), ('INCOMPLETE_EVIDENCE', 58), ('INCOMPLETE_EVIDENCE', 71)]	3	[('CHEBI_27300', 'vitamin D', 115, 'vitamin D')]
S35-PMC4466139	PMC4466139	6/2015	S35-PMC4466139	['we considered, and analyzed AS adequately supplemented all mothers with an intake of 400 iu Vitamin D per day as recommended by the institute of medicine [14].']	[('PROBABLE_UNDERSTANDING', 28)]	1	[('CHEBI_27300', 'vitamin D', 92, 'vitamin D')]
S82-PMC4466139	PMC4466139	6/2015	S82-PMC4466139	['s: subjects supplemented with Vitamin D; not s: subjects not supplemented with Vitamin D\nanalyzing epic italy semiquantitative questionnaires we FOUND an average daily Vitamin D intake of 136±68 ui (3.4 ± 1.7 μg) with a higher Intake in migrant mothers than italian (p = 0.0003) (table 3).']	[('INCOMPLETE_EVIDENCE', 145)]	1	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 79, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 168, 'vitamin D'), ('GO_0007631', 'feeding behavior', 227, 'intake')]
S83-PMC4466139	PMC4466139	6/2015	S83-PMC4466139	['a daily supplementation of 400 iu of Vitamin D LED TO 105 (37%) mothers (93 italian and 12 migrants) and 56 (20%) newborns (53 italian and 3 migrants) to have Blood 25Ohd values above the cut-off of sufficiency (fixed at 50 nmol/l) (table 5).10.1371/journal.pone.0129586.t005\n\ncaption (table-wrap): table 5\nnumber and percentage of subjects under Vitamin D supplementation (400 iu per day) SHOWING sufficient levels of Vitamin D (25Ohd≥50 nmol/l).subjectsall (283)italian (213)migrant (70)p value newborns 56 (20%)53 (24.9%)3 (4.3%)<0.001 mothers 105 (37%)93 (43.7%)12 (17.1%)<0.001\nno significant associations between maternal and neonatal 25Ohd levels and maternal weight gain in Pregnancy or Birth weight were FOUND.']	[('SUPERFICIAL_RELATIONSHIP', 47), ('INCOMPLETE_EVIDENCE', 390), ('INCOMPLETE_EVIDENCE', 713)]	3	"[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('UBERON_0000178', 'blood', 159, 'blood'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 165, '25OHD'), ('CHEBI_27300', 'vitamin D', 347, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 419, 'vitamin D'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 430, '25OHD'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 641, '25OHD'), ('GO_0007565', 'female pregnancy', 682, 'pregnancy'), ('GO_0007567', 'parturition', 695, 'birth')]"
S84-PMC4466139	PMC4466139	6/2015	S84-PMC4466139	['multivariate adjusted regression model analysis (r-square: 0.302), adjusted for maternal age and education SHOWED a LINK between maternal 25Ohd level and season (p<0.0001), country of origin (north africa, p<0.0001; africa, p = 0.0052; asia, p = 0.0003; south america, p = 0.0002) and Vitamin D supplementation in Pregnancy (p<0.0001), while Vitamin D Intake from diet was non-significant (p = 0.944).']	[('INCOMPLETE_EVIDENCE', 107), ('SUPERFICIAL_RELATIONSHIP', 116)]	2	"[('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 138, '25OHD'), ('CHEBI_27300', 'vitamin D', 285, 'vitamin D'), ('GO_0007565', 'female pregnancy', 314, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 342, 'vitamin D'), ('GO_0007631', 'feeding behavior', 352, 'intake')]"
S102-PMC4466139	PMC4466139	6/2015	S102-PMC4466139	['our results SHOW that few migrant mothers are supplemented with Vitamin D during Pregnancy, especially in the last month, SUGGESTING that more extensive PREVENTION and education programs SHOULD be adopted.']	[('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 122), ('SUPERFICIAL_RELATIONSHIP', 153), ('FUTURE_WORK', 187)]	4	[('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('GO_0007565', 'female pregnancy', 81, 'pregnancy')]
S103-PMC4466139	PMC4466139	6/2015	S103-PMC4466139	['furthermore, when we analyzed the ROLE of diet and supplementation in Pregnancy and their EFFECTS on mothers and newborns, Vitamin D intake through diet was (136 iu on average) under 400 iu (recommended minimum), with an Intake slightly higher in migrants than italian mothers.']	[('SUPERFICIAL_RELATIONSHIP', 34), ('SUPERFICIAL_RELATIONSHIP', 90)]	2	[('GO_0007565', 'female pregnancy', 70, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 123, 'vitamin D'), ('GO_0007631', 'feeding behavior', 221, 'intake')]
S104-PMC4466139	PMC4466139	6/2015	S104-PMC4466139	['in italy Foods are not supplemented with Vitamin D and the Consumption of foods with high content of Vitamin D is UNUSUAL.']	[('ANOMALY_CURIOUS_FINDING', 114)]	1	[('CHEBI_33290', 'food', 9, 'foods'), ('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('GO_0007631', 'feeding behavior', 59, 'consumption'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin D')]
S105-PMC4466139	PMC4466139	6/2015	S105-PMC4466139	['all mothers supplemented with Vitamin D had higher values of 25Ohd and the same was TRUE for their babies.']	[('PROBABLE_UNDERSTANDING', 84)]	1	"[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 61, '25OHD')]"
S106-PMC4466139	PMC4466139	6/2015	S106-PMC4466139	['these results SHOW a strong ROLE for supplementation in increasing 25Ohd levels and also that supplementation at 400 iu/die is INSUFFICIENT to provide an appropriate Vitamin D status in Pregnant women and their offsprings.']	[('INCOMPLETE_EVIDENCE', 14), ('SUPERFICIAL_RELATIONSHIP', 28), ('PROBLEM_COMPLICATION', 127)]	3	"[('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 67, '25OHD'), ('CHEBI_27300', 'vitamin D', 166, 'vitamin D'), ('GO_0007565', 'female pregnancy', 186, 'pregnant')]"
S108-PMC4466139	PMC4466139	6/2015	S108-PMC4466139	['Vitamin D deficiency in Pregnancy in spite of taking supplementation MAY BE AS a result of an INSUFFICIENT dose of Vitamin D contained in multivitamins in Prenatal supplements many of which contain only 400 iu or 500 iu, as PREVIOUSLY SHOWN in OTHER studies [33,34].']	[('INCOMPLETE_EVIDENCE', 69), ('PROBABLE_UNDERSTANDING', 76), ('IMPORTANT_CONSIDERATION', 94), ('INCOMPLETE_EVIDENCE', 224), ('INCOMPLETE_EVIDENCE', 244)]	5	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 24, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin D'), ('GO_0007565', 'female pregnancy', 155, 'prenatal')]
S111-PMC4466139	PMC4466139	6/2015	S111-PMC4466139	['PREVIOUS STUDIES HAVE SHOWN that Vitamin D supplementation of 600 ui/die leads to Vitamin D insufficiency in >50% of cases [33].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 17)]	2	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 82, 'vitamin D')]
S112-PMC4466139	PMC4466139	6/2015	S112-PMC4466139	['RECENTLY, an increasing NUMBER OF STUDIES HAVE SHOWN that higher doses of Vitamin D supplementation are SAFE and EFFECTIVE in Pregnant women.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 24), ('INCOMPLETE_EVIDENCE', 42), ('IMPORTANT_CONSIDERATION', 104), ('SUPERFICIAL_RELATIONSHIP', 113)]	5	[('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('GO_0007565', 'female pregnancy', 126, 'pregnant')]
S115-PMC4466139	PMC4466139	6/2015	S115-PMC4466139	['moreover, SOME STUDIES HAVE SHOWN a large inter-Individual difference in response to treatment with identical doses of Vitamin D SUGGESTING that common Genetic variants IMPLICATED in Vitamin d Homeostasis MAY AFFECT the response to sun exposure or to Vitamin D supplementation [39].']	[('INCOMPLETE_EVIDENCE', 10), ('INCOMPLETE_EVIDENCE', 23), ('INCOMPLETE_EVIDENCE', 129), ('SUPERFICIAL_RELATIONSHIP', 169), ('INCOMPLETE_EVIDENCE', 205), ('SUPERFICIAL_RELATIONSHIP', 209)]	6	[('NCBITaxon_1', 'root', 48, 'individual'), ('CHEBI_27300', 'vitamin D', 119, 'vitamin D'), ('SO_0000704', 'gene', 152, 'genetic'), ('CHEBI_33229', 'vitamin (role)', 183, 'vitamin'), ('GO_0042592', 'homeostatic process', 193, 'homeostasis'), ('CHEBI_27300', 'vitamin D', 251, 'vitamin D')]
S116-PMC4466139	PMC4466139	6/2015	S116-PMC4466139	['the RELATIONSHIP between 25Ohd levels, ethnicity and supplementation in Pregnancy SUGGESTS a ROLE for Genetic DETERMINANTS for Vitamin D status and STRESSES the IMPORTANCE of Vitamin D integration in preventative STRATEGIES.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('INCOMPLETE_EVIDENCE', 82), ('SUPERFICIAL_RELATIONSHIP', 93), ('SUPERFICIAL_RELATIONSHIP', 110), ('IMPORTANT_CONSIDERATION', 148), ('IMPORTANT_CONSIDERATION', 161), ('FUTURE_WORK', 213)]	7	"[('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 25, '25OHD'), ('GO_0007565', 'female pregnancy', 72, 'pregnancy'), ('SO_0000704', 'gene', 102, 'genetic'), ('CHEBI_27300', 'vitamin D', 127, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 175, 'vitamin D')]"
S117-PMC4466139	PMC4466139	6/2015	S117-PMC4466139	['OUR FINDINGS also underline the IMPORTANCE of certain RISK FACTORS in causing Vitamin D deficiency such as immigration, dark skin, and lack of Vitamin D supplementation during the Third Trimester of Pregnancy.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('IMPORTANT_CONSIDERATION', 32), ('SUPERFICIAL_RELATIONSHIP', 54)]	3	[('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 143, 'vitamin D'), ('GO_0042793', 'plastid transcription', 180, 'third trimester'), ('GO_0007565', 'female pregnancy', 199, 'pregnancy')]
S8-PMC4488777	PMC4488777	5/2015	S8-PMC4488777	['MOST experts agree that Vitamin D supplementation is a necessity, PARTICULARLY in women suffering from obesity, Insulin resistance or small Ovarian reserve, as well as in men with oligo- and asthenozoospermia if Serum concentration should fall below 50 nmol/l (normal range up to 125 nmol/l).']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 66)]	2	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('PR_000045358', 'insulin family protein', 112, 'insulin'), ('UBERON_0000992', 'ovary', 140, 'ovarian'), ('UBERON_0001977', 'blood serum', 212, 'serum')]
S179-PMC4488777	PMC4488777	5/2015	S179-PMC4488777	['this is why even during the most physiological Pregnancy Vitamin D supplementation in the amount of 800–1000 iu daily is HIGHLY RECOMMENDED [65].']	[('IMPORTANT_CONSIDERATION', 121)]	1	[('GO_0007565', 'female pregnancy', 47, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 57, 'vitamin D')]
S182-PMC4488777	PMC4488777	5/2015	S182-PMC4488777	['during the preparation for Pregnancy in vd-deficient females (with Serum vd 50–125nmol/l), it is ADVISED to supplement Vitamin D prior to the first visit in a Fertility clinic.']	[('FUTURE_WORK', 97)]	1	[('GO_0007565', 'female pregnancy', 27, 'pregnancy'), ('UBERON_0001977', 'blood serum', 67, 'serum'), ('CHEBI_27300', 'vitamin D', 119, 'vitamin D'), ('GO_0009566', 'fertilization', 159, 'fertility')]
S189-PMC4488777	PMC4488777	5/2015	S189-PMC4488777	['couples with Serum concentration exceeding 50 nmol/l have a higher CHANCE of Conception, but this DOES NOT REGARD all patients, where ESPECIALLY males SHOULD BE supplemented with Vitamin D from the beginning of the therapy.']	[('PROBABLE_UNDERSTANDING', 67), ('INCOMPLETE_EVIDENCE', 98), ('ANOMALY_CURIOUS_FINDING', 134), ('FUTURE_WORK', 151)]	4	[('UBERON_0001977', 'blood serum', 13, 'serum'), ('GO_0007620', 'copulation', 77, 'conception'), ('CHEBI_27300', 'vitamin D', 179, 'vitamin D')]
S308-PMC4490503	PMC4490503	6/2015	S308-PMC4490503	['FURTHER rcts are CRUCIAL to determining WHETHER Vitamin D has a ROLE in pathophysiology of gdm and WHETHER supplementation has a ROLE in preventing gdm [129].']	[('FUTURE_WORK', 0), ('IMPORTANT_CONSIDERATION', 17), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 40), ('SUPERFICIAL_RELATIONSHIP', 64), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 99), ('SUPERFICIAL_RELATIONSHIP', 129)]	6	[('CHEBI_27300', 'vitamin D', 48, 'vitamin D')]
S1-PMC4499946	PMC4499946	7/2015	S1-PMC4499946	['SOME observational STUDIES have SUGGESTED that Prenatal Vitamin D deficiency increases the RISK of adverse Pregnancy and/or Birth outcomes; HOWEVER, there is SCANT EVIDENCE from controlled trials, leading the world health organization to advise against routine Vitamin D supplementation in Pregnancy.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 32), ('IMPORTANT_CONSIDERATION', 91), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 140), ('INCOMPLETE_EVIDENCE', 158)]	5	[('GO_0007565', 'female pregnancy', 47, 'prenatal'), ('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('GO_0007608', 'sensory perception of smell', 107, 'pregnancy ...'), ('GO_0007567', 'parturition', 124, 'birth'), ('CHEBI_27300', 'vitamin D', 261, 'vitamin D'), ('GO_0007565', 'female pregnancy', 290, 'pregnancy')]
S22-PMC4499946	PMC4499946	7/2015	S22-PMC4499946	['EFFECTS of improvements in Vitamin D status on linear growth in infants and children without rickets have not been widely studied; HOWEVER, in one TRIAL in india, weekly Vitamin D supplementation of low Birth weight infants reduced the risk of stunting in adjusted analyses [14].']	[('SUPERFICIAL_RELATIONSHIP', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 131), ('INCOMPLETE_EVIDENCE', 147)]	3	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 170, 'vitamin D'), ('GO_0007567', 'parturition', 203, 'birth')]
S27-PMC4499946	PMC4499946	7/2015	S27-PMC4499946	['because maternal Vitamin D status is the PREDOMINANT DETERMINANT of fetal and neonatal Vitamin D stores [18], Prenatal Vitamin D supplementation represents the OPTIMAL approach to testing the EFFECT of improving maternal-infant Vitamin D status on fetal-infant growth and other health outcomes.']	[('PROBABLE_UNDERSTANDING', 41), ('SUPERFICIAL_RELATIONSHIP', 53), ('IMPORTANT_CONSIDERATION', 160), ('SUPERFICIAL_RELATIONSHIP', 192)]	4	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 87, 'vitamin D'), ('GO_0007565', 'female pregnancy', 110, 'prenatal'), ('CHEBI_27300', 'vitamin D', 119, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 228, 'vitamin D')]
S29-PMC4499946	PMC4499946	7/2015	S29-PMC4499946	['the EFFECTS of Prenatal Vitamin D supplementation on infant length have not been widely studied in controlled trials.']	[('SUPERFICIAL_RELATIONSHIP', 4)]	1	[('GO_0007565', 'female pregnancy', 15, 'prenatal'), ('CHEBI_27300', 'vitamin D', 24, 'vitamin D')]
S30-PMC4499946	PMC4499946	7/2015	S30-PMC4499946	['in a study conducted in the 1970s in london, england, Prenatal Vitamin D supplementation reduced the RISK of small for Gestational age (sga) versus control, BUT there was no significant effect on Birth length [24]; however, the infants in the Vitamin D group had significantly greater mean length at 1 year of age [25].']	[('IMPORTANT_CONSIDERATION', 101), ('ANOMALY_CURIOUS_FINDING', 157)]	2	[('GO_0007565', 'female pregnancy', 54, 'prenatal'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('GO_0007565', 'female pregnancy', 119, 'gestational'), ('GO_0007567', 'parturition', 196, 'birth'), ('CHEBI_27300', 'vitamin D', 243, 'vitamin D')]
S34-PMC4499946	PMC4499946	7/2015	S34-PMC4499946	['analyses of the EFFECT of Prenatal Vitamin D supplementation on infant length among 134 infants followed up to 1 year of age REVEALED that infants Born to women in the Vitamin D group had mean length for age z-scores (lazs) at 1 year that were significantly greater than infants in the placebo group (mean = 0.44 z-score units higher; 95% confidence interval [ci], 0.06–0.82) [26].']	[('SUPERFICIAL_RELATIONSHIP', 16), ('INCOMPLETE_EVIDENCE', 125)]	2	[('GO_0007565', 'female pregnancy', 26, 'prenatal'), ('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('GO_0007567', 'parturition', 147, 'born'), ('CHEBI_27300', 'vitamin D', 168, 'vitamin D')]
S40-PMC4499946	PMC4499946	7/2015	S40-PMC4499946	['HOWEVER, there is SCANT EVIDENCE from controlled clinical trials [31,32], and the world health organization (who) RECENTLY advised against routine Vitamin D supplementation in Pregnancy until further data become available [33].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 18), ('INCOMPLETE_EVIDENCE', 114)]	3	[('CHEBI_27300', 'vitamin D', 147, 'vitamin D'), ('GO_0007565', 'female pregnancy', 176, 'pregnancy')]
S41-PMC4499946	PMC4499946	7/2015	S41-PMC4499946	['BUILDING ON our EARLIER FINDINGS of a beneficial EFFECT of Prenatal Vitamin D supplementation on infant length in a PRELIMINARY TRIAL [26], we are conducting a larger dose-ranging trial of maternal Vitamin D3Supplementation in dhaka, bangladesh.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 16), ('INCOMPLETE_EVIDENCE', 24), ('SUPERFICIAL_RELATIONSHIP', 49), ('INCOMPLETE_EVIDENCE', 116)]	5	[('GO_0007565', 'female pregnancy', 59, 'prenatal'), ('CHEBI_27300', 'vitamin D', 68, 'vitamin D'), ('CHEBI_52915', 'phosphatediyl group', 198, 'vitamin D3supplementation'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 198, 'vitamin D3supplementation')]
S42-PMC4499946	PMC4499946	7/2015	S42-PMC4499946	['the primary AIM is TO INVESTIGATE the EFFECT of maternal Vitamin D supplementation on infant length at 1 year of age, but the trial also provides an OPPORTUNITY to study a range of OTHER POTENTIAL Vitamin D–responsive outcomes.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 12), ('QUESTION_ANSWERED_BY_THIS_WORK', 19), ('SUPERFICIAL_RELATIONSHIP', 38), ('FUTURE_WORK', 149), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 181), ('INCOMPLETE_EVIDENCE', 187)]	6	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 197, 'vitamin D')]
S46-PMC4499946	PMC4499946	7/2015	S46-PMC4499946	['objectives\nthe primary AIMS of the trial are to estimate (1) the effect of maternal Prenatal oral Vitamind3Supplementation (4200 iu/wk, 16,800 iu/wk, or 28,000 iu/wk administered as weekly doses) versus placebo on infant length at 1 year of age in dhaka, bangladesh; and (2) the EFFECT of maternal Postpartum oral Vitamin D3Supplementation (28,000 iu/wk) versus placebo on length at 1 year of age among infants Born to women who received Vitamin D 28,000 iu/wk during Pregnancy.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 23), ('SUPERFICIAL_RELATIONSHIP', 279)]	2	[('GO_0007565', 'female pregnancy', 84, 'prenatal'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 98, 'vitaminD3supplementation'), ('GO_0007565', 'female pregnancy', 298, 'postpartum'), ('CHEBI_52915', 'phosphatediyl group', 314, 'vitamin D3supplementation'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 314, 'vitamin D3supplementation'), ('GO_0007567', 'parturition', 411, 'born'), ('CHEBI_27300', 'vitamin D', 438, 'vitamin D'), ('GO_0007565', 'female pregnancy', 468, 'pregnancy')]
S48-PMC4499946	PMC4499946	7/2015	S48-PMC4499946	['clinical, biochemical, and microbiological Surveillance of enrolled mother-infant pairs will enable a range of secondary objectives to be addressed, including (1) estimation of the EFFECT of maternal Vitamin D supplementation on the incidence of acute Respiratory infections (aris) during early infancy; (2) exploration of the ROLES of specific hormones, Nutrients, environmental Contaminants, and inflammatory markers in the mediation or modification of the EFFECT of Vitamin D on fetal and infant growth, with particular emphasis on the ROLE of the Parathyroid hormone (pth) system; and (3) investigation of the ROLE of epigenetic modification of Genes involved in Perinatal Vitamin D Metabolism in infant stunting.']	[('SUPERFICIAL_RELATIONSHIP', 181), ('SUPERFICIAL_RELATIONSHIP', 327), ('SUPERFICIAL_RELATIONSHIP', 459), ('SUPERFICIAL_RELATIONSHIP', 539), ('SUPERFICIAL_RELATIONSHIP', 614)]	5	[('GO_0065007', 'biological regulation', 43, 'surveillance'), ('CHEBI_27300', 'vitamin D', 200, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 252, 'respiratory'), ('CHEBI_33284', 'nutrient', 355, 'nutrients'), ('CHEBI_60688', 'EC 4.2.1.20 (tryptophan synthase) inhibitor', 380, 'contaminants'), ('CHEBI_27300', 'vitamin D', 469, 'vitamin D'), ('UBERON_0001132', 'parathyroid gland', 551, 'parathyroid'), ('SO_0000704', 'gene', 649, 'genes'), ('GO_0036268', 'swimming', 667, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 667, 'perinatal'), ('CHEBI_27300', 'vitamin D', 677, 'vitamin D'), ('GO_0008152', 'metabolic process', 687, 'metabolism')]
S65-PMC4499946	PMC4499946	7/2015	S65-PMC4499946	['Pregnant women are not enrolled if any of the following exclusion criteria apply: self-reported history of any medical condition or Medications that MAY predispose to Vitamin D sensitivity, altered Vitamin D Metabolism, and/or hypercalcemia (e.g., active tuberculosis or current therapy for tuberculosis, sarcoidosis, history of Renal and/or Ureteral stones, Parathyroid disease, Renal or Liver failure, or current use of antiseizure Medications); high-risk Pregnancy based on point-of-care (poc) testing (hemoglobin [hb]<70 g/l; proteinuria, defined as ≥300 mg/dl based on Urine dipstick; hypertension, defined as systolic Blood pressure ≥140 mmhg and/or diastolic Blood pressure ≥90 mmhg); high-risk Pregnancy based on maternal report and/or past ultrasound findings (multiple Gestation, major congenital anomaly, severe oligohydramnios); unwillingness to stop taking non-study Vitamin D or Calcium supplements or a multivitamins containing Calcium and/or Vitamin D; currently prescribed Vitamin D supplements as part of a physician’s treatment plan for Vitamin D deficiency; and/or previous enrollment in the mdig trial during a prior Pregnancy.']	[('INCOMPLETE_EVIDENCE', 149)]	1	[('GO_0007565', 'female pregnancy', 0, 'Pregnant'), ('CHEBI_25441', 'mycothiols', 132, 'medications'), ('CHEBI_27300', 'vitamin D', 167, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 198, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 198, 'vitamin D metabolism'), ('UBERON_0002113', 'kidney', 329, 'renal'), ('UBERON_0000056', 'ureter', 342, 'ureteral'), ('UBERON_0001132', 'parathyroid gland', 359, 'parathyroid'), ('UBERON_0002113', 'kidney', 380, 'renal'), ('UBERON_0002107', 'liver', 389, 'liver'), ('CHEBI_25441', 'mycothiols', 434, 'medications'), ('GO_0007565', 'female pregnancy', 458, 'pregnancy'), ('UBERON_0001088', 'urine', 574, 'urine'), ('UBERON_0000178', 'blood', 624, 'blood'), ('UBERON_0000178', 'blood', 666, 'blood'), ('GO_0007565', 'female pregnancy', 702, 'pregnancy'), ('GO_0007565', 'female pregnancy', 779, 'gestation'), ('CHEBI_27300', 'vitamin D', 880, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 893, 'calcium'), ('CHEBI_22313', 'alkaline earth metal atom', 943, 'calcium'), ('CHEBI_27300', 'vitamin D', 958, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 990, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1056, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1138, 'pregnancy')]
S80-PMC4499946	PMC4499946	7/2015	S80-PMC4499946	['in our PRELIMINARY trial, we OBSERVED an increase in Laz of 0.44 at 1 year attributable to Prenatal Vitamin D supplementation, which CORRESPONDED to an increase of 1.1 cm (95 % ci, 0.06–2.0), adjusted for sex [26].']	[('INCOMPLETE_EVIDENCE', 7), ('INCOMPLETE_EVIDENCE', 29), ('SUPERFICIAL_RELATIONSHIP', 133)]	3	[('PR_000009655', 'laminin subunit beta-2', 53, 'LAZ'), ('GO_0007565', 'female pregnancy', 91, 'prenatal'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin D')]
S93-PMC4499946	PMC4499946	7/2015	S93-PMC4499946	['the allocation scheme will be made available to the data and safety monitoring board (dsmb) in cases in which individual participants need to be unmasked because of suspected Supplement-related adverse events (i.e., hypercalcemia or clinical features SUGGESTIVE of Vitamin D toxicity).']	[('INCOMPLETE_EVIDENCE', 251)]	1	[('CHEBI_16158', 'steroid sulfate', 175, 'supplement'), ('CHEBI_27300', 'vitamin D', 265, 'vitamin D')]
S121-PMC4499946	PMC4499946	7/2015	S121-PMC4499946	['from a practical standpoint, the INVESTIGATION of Vitamin D supplementation in the context of routine Calcium supplementation will facilitate the translation of trial findings into anticipated FUTURE contexts in which supplemental Calcium is more routinely provided.']	[('FUTURE_WORK', 33), ('FUTURE_WORK', 193)]	2	[('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 102, 'calcium'), ('CHEBI_22313', 'alkaline earth metal atom', 231, 'calcium')]
S218-PMC4499946	PMC4499946	7/2015	S218-PMC4499946	['our PRELIMINARY trial data REVEALED a discernible EFFECT of Prenatal Vitamin D supplementation on infant Laz at 1 year [26].']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 27), ('SUPERFICIAL_RELATIONSHIP', 50)]	3	[('GO_0007565', 'female pregnancy', 60, 'prenatal'), ('CHEBI_27300', 'vitamin D', 69, 'vitamin D'), ('PR_000009655', 'laminin subunit beta-2', 105, 'LAZ')]
S284-PMC4499946	PMC4499946	7/2015	S284-PMC4499946	['the only clinical events that will routinely lead to discontinuation of study supplementation are those adverse events that are ascertained to be Supplement-related or the diagnosis of a medical condition that POTENTIALLY or THEORETICALLY increases sensitivity to Vitamin D supplementation following clinical review by the trial steering committee (tsc): confirmed hypercalcemia (see definition above), symptomatic Vitamin D deficiency diagnosed by a study physician or consultant physician (e.g., osteomalacia), fetal or infant death, or onset of a medical condition or initiation of a Medication following enrollment that MAY REASONABLY predispose to Vitamin D sensitivity, altered Vitamin D Metabolism, and/or hypercalcemia (e.g., tuberculosis or therapy for tuberculosis, sarcoidosis, Renal and/or Ureteral stones, Parathyroid disease, Renal or Liver failure, or use of Anticonvulsants).']	[('INCOMPLETE_EVIDENCE', 210), ('INCOMPLETE_EVIDENCE', 225), ('INCOMPLETE_EVIDENCE', 624), ('PROBABLE_UNDERSTANDING', 628)]	4	[('CHEBI_16158', 'steroid sulfate', 146, 'supplement'), ('CHEBI_27300', 'vitamin D', 264, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 415, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 423, 'D'), ('CHEBI_60211', 'compound Z', 587, 'medication'), ('CHEBI_27300', 'vitamin D', 653, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 684, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 684, 'vitamin D metabolism'), ('UBERON_0002113', 'kidney', 789, 'renal'), ('UBERON_0000056', 'ureter', 802, 'ureteral'), ('UBERON_0001132', 'parathyroid gland', 819, 'parathyroid'), ('UBERON_0002113', 'kidney', 840, 'renal'), ('UBERON_0002107', 'liver', 849, 'liver'), ('CHEBI_37540', 'arabinarate(2-)', 874, 'anticonvulsants')]
S290-PMC4499946	PMC4499946	7/2015	S290-PMC4499946	['discussion\nsince the publication of the 2010 iom report on Vitamin D and the design of the mdig trial and dosing regimens in 2012, there have been several new REPORTS of biochemical and clinical findings of Prenatal Vitamin D supplementation trials conducted in iran [67–69], the united arab emirates [70], pakistan [71], new zealand [72], and australia [73].']	[('INCOMPLETE_EVIDENCE', 159)]	1	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('GO_0007565', 'female pregnancy', 207, 'prenatal'), ('CHEBI_27300', 'vitamin D', 216, 'vitamin D')]
S87-PMC4514967	PMC4514967	12/2014	S87-PMC4514967	['low Cord Blood Vitamin D levels are a PREDICTOR of subsequent infant Respiratory infections.70,71HOWEVER, data from clinical trials are too LIMITED to draw conclusions about the efficacy and SAFETY of Vitamin D supplementation in Pregnancy.72meta-analyses have HIGHLIGHTED THE NEED to extend endpoints in intervention trials of multiple Micronutrients in Pregnancy.30the timing of Nutrient interventions during Pregnancy or before Conception is an IMPORTANT clinical study parameter to CONSIDER in any meta-analysis designed to evaluate the EFFECTS of an intervention or interventions and the OBSERVED effect size.']	[('SUPERFICIAL_RELATIONSHIP', 38), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 95), ('INCOMPLETE_EVIDENCE', 140), ('IMPORTANT_CONSIDERATION', 191), ('INCOMPLETE_EVIDENCE', 261), ('INCOMPLETE_EVIDENCE', 273), ('FUTURE_WORK', 277), ('IMPORTANT_CONSIDERATION', 448), ('FUTURE_WORK', 486), ('SUPERFICIAL_RELATIONSHIP', 541), ('INCOMPLETE_EVIDENCE', 593)]	11	[('UBERON_0002240', 'spinal cord', 4, 'cord'), ('UBERON_0000178', 'blood', 9, 'blood'), ('CHEBI_27300', 'vitamin D', 15, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 69, 'respiratory'), ('CHEBI_27300', 'vitamin D', 201, 'vitamin D'), ('GO_0007565', 'female pregnancy', 230, 'pregnancy'), ('CHEBI_33839', 'macromolecule', 337, 'micronutrients'), ('GO_0007565', 'female pregnancy', 355, 'pregnancy'), ('CHEBI_33284', 'nutrient', 381, 'nutrient'), ('GO_0007565', 'female pregnancy', 411, 'pregnancy'), ('GO_0007620', 'copulation', 431, 'conception')]
S251-PMC4586450	PMC4586450	10/2015	S251-PMC4586450	['in ndns 2008–2012, young children obtained only a quarter of the Vitamin D intake RECOMMENDED to be obtained from diet and only 12% took dietary supplements102; thus, there is a continuing PROBLEM in the united kingdom.']	[('FUTURE_WORK', 82), ('IMPORTANT_CONSIDERATION', 189)]	2	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D')]
S252-PMC4586450	PMC4586450	10/2015	S252-PMC4586450	['WHETHER fortification of Foods COULD BE the answer to THIS problem was EXAMINED; the THEORETICAL intakes from DIFFERENT fortification regimens tested SUGGESTED that milk fortified at 2 µg vitamin d/100 g would provide MOST preschool children with adequate but not excessive intakes.24later work in the alspac looking at Plasma concentrations in mid-childhood of Vitamin D (25-Hydroxyvitamin-D2And 25-Hydroxyvitamin-D3) in RELATION to Cortical bone measures FOUND positive ASSOCIATIONS with D3Only, SUGGESTING that in supplementation OR fortification, d3should be used in PREFERENCE to d2.25these 2 PAPERS give valuable INSIGHTS into HOW the lack of Vitamin D in the diets of the majority of uk residents COULD BE TACKLED.iron\niron is a Nutrient that is ESSENTIAL to a child’s growth and development.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 31), ('QUESTION_ANSWERED_BY_THIS_WORK', 54), ('QUESTION_ANSWERED_BY_THIS_WORK', 71), ('INCOMPLETE_EVIDENCE', 85), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 110), ('INCOMPLETE_EVIDENCE', 150), ('PROBABLE_UNDERSTANDING', 218), ('SUPERFICIAL_RELATIONSHIP', 422), ('INCOMPLETE_EVIDENCE', 457), ('SUPERFICIAL_RELATIONSHIP', 472), ('INCOMPLETE_EVIDENCE', 498), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 533), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 571), ('INCOMPLETE_EVIDENCE', 598), ('INCOMPLETE_EVIDENCE', 619), ('EXPLICIT_QUESTION', 633), ('INCOMPLETE_EVIDENCE', 704), ('FUTURE_WORK', 713), ('IMPORTANT_CONSIDERATION', 753)]	20	[('CHEBI_33290', 'food', 25, 'foods'), ('UBERON_0001969', 'blood plasma', 320, 'plasma'), ('CHEBI_27300', 'vitamin D', 362, 'vitamin D'), ('CHEBI_66469', 'senegin III', 373, '25-hydroxyvitamin-D2and'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 373, '25'), ('PR_000000045', 'S-phase kinase-associated protein 1A', 390, '-D2and'), ('CHEBI_65129', '2-hydroxy-AMP', 397, '25-hydroxyvitamin-D3'), ('PR_000000037', 'BMP receptor type-2', 414, '-D3'), ('UBERON_0001851', 'cortex', 434, 'cortical'), ('PR_000002325', 'dynein light chain 1, cytoplasmic', 490, 'D3only'), ('CHEBI_27300', 'vitamin D', 649, 'vitamin D'), ('CHEBI_33284', 'nutrient', 736, 'nutrient')]
S528-PMC4586450	PMC4586450	10/2015	S528-PMC4586450	['uptake of Vitamin D supplements was low, IN LINE WITH national surveys and DESPITE RECOMMENDATIONS that all children aged 1–5 years SHOULD receive them.']	[('INCOMPLETE_EVIDENCE', 41), ('ANOMALY_CURIOUS_FINDING', 75), ('FUTURE_WORK', 83), ('FUTURE_WORK', 132)]	4	[('CHEBI_27300', 'vitamin D', 10, 'vitamin D')]
S544-PMC4586450	PMC4586450	10/2015	S544-PMC4586450	['overall, the diets of children in the alspac were adequate for most Nutrients, with the NOTABLE EXCEPTION of Vitamin D. at age 1.5 years and age 3.5 years, all of the alspac children were found to be below the united kingdom dietary recommendations for Vitamin D intake, and children who had low intakes at age 1.5 years were twice as LIKELY to have low intakes at age 3.5 years.24ALTHOUGH it HAS BEEN RECOMMENDED for 25 years or more that children aged <5 years SHOULD BE given Vitamin D supplements,93only a minority in either the alspac24or the national surveys actually were supplemented.101it IS POSSIBLE that a fortification program COULD be a good option to improve this situation.']	[('ANOMALY_CURIOUS_FINDING', 88), ('ANOMALY_CURIOUS_FINDING', 96), ('PROBABLE_UNDERSTANDING', 335), ('ANOMALY_CURIOUS_FINDING', 379), ('INCOMPLETE_EVIDENCE', 393), ('FUTURE_WORK', 402), ('FUTURE_WORK', 463), ('INCOMPLETE_EVIDENCE', 598), ('INCOMPLETE_EVIDENCE', 639)]	9	[('CHEBI_33284', 'nutrient', 68, 'nutrients'), ('CHEBI_27300', 'vitamin D', 109, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 253, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 479, 'vitamin D')]
S18-PMC4586451	PMC4586451	10/2015	S18-PMC4586451	['this has LED to dietary RECOMMENDATIONS for Pregnancy that limit concentrated sources of Vitamin A and stress the IMPORTANCE of periconceptional Folic Acid supplementation, which HAS BEEN SHOWN to be PROTECTIVE against Neural Tube defects.4\nTHERE IS EVIDENCE that optimal fetal Neurodevelopment is DEPENDENT on specific Nutrients supplied by the mother mainly from dietary sources; these MAY include Long-Chain polyunsaturated Fatty Acids (lc-pufas) such as Docosahexaenoic Acid (Dha), an N-3 Fatty Acid, and arachidonic acid, an N-6 Fatty Acid.']	[('SUPERFICIAL_RELATIONSHIP', 9), ('FUTURE_WORK', 24), ('IMPORTANT_CONSIDERATION', 114), ('INCOMPLETE_EVIDENCE', 179), ('SUPERFICIAL_RELATIONSHIP', 200), ('INCOMPLETE_EVIDENCE', 241), ('SUPERFICIAL_RELATIONSHIP', 298), ('INCOMPLETE_EVIDENCE', 388)]	8	[('GO_0007565', 'female pregnancy', 44, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 89, 'vitamin A'), ('CHEBI_30751', 'formic acid', 145, 'folic acid'), ('UBERON_0001049', 'neural tube', 219, 'neural tube'), ('GO_0007399', 'nervous system development', 278, 'neurodevelopment'), ('CHEBI_33284', 'nutrient', 320, 'nutrients'), ('CHEBI_28911', 'cob(III)alamin', 400, 'long-chain'), ('CHEBI_35366', 'fatty acid', 427, 'fatty acids'), ('CHEBI_36003', 'decenoic acid', 458, 'docosahexaenoic acid'), ('CHEBI_17874', 'dihydrozeatin', 480, 'DHA'), ('CHEBI_35245', 'GDP-galactose', 489, 'n-3 fatty acid'), ('CHEBI_18320', '1,4-dithiothreitol', 530, 'n-6'), ('CHEBI_35366', 'fatty acid', 534, 'fatty acid')]
S190-PMC4586451	PMC4586451	10/2015	S190-PMC4586451	['a weak ASSOCIATION was FOUND between maternal dietary iron and magnesium Intake and height, particularly sitting height; it was greatly attenuated on full adjustment.19\n\ncaption (table-wrap): table 3\n\nassociations of maternal dietary intakes, iron supplement use, anemia, and Vitamin D status during Pregnancy with measures of offspring growth, Blood pressure, and Bone developmentmeasure in childdietary factoradjustments appliedminimally adjusted resultsfully adjusted resultscommentsheight at 7.5 y, n = 6663 singletons19\niron\nmagnesium\nvitamin c\nminimal: child sex, age at measurement, Pregnancy energy Intake\nfull: plus maternal age, bmi, height, smoking, seb, parity, breastfeeding\nβ = 0.08 (95% ci, 0.05–0.12), p< 0.001\nβ = 0.10 (95% ci, 0.07–0.14), p< 0.001\nβ = 0.05 (95% ci, 0.03–0.08), p< 0.001\nβ = 0.04 (95% ci, 0.01–0.08), p = 0.02\nβ = 0.05 (95% ci, 0.01–0.08), p = 0.04\nβ = 0.02 (95% ci, −0.01 to 0.04), p = 0.2\nregression analysis using standard deviation scores.']	[('SUPERFICIAL_RELATIONSHIP', 7), ('INCOMPLETE_EVIDENCE', 23)]	2	[('GO_0007631', 'feeding behavior', 73, 'intake'), ('CHEBI_27300', 'vitamin D', 276, 'vitamin D'), ('GO_0007565', 'female pregnancy', 300, 'pregnancy'), ('UBERON_0000178', 'blood', 345, 'blood'), ('GO_0007567', 'parturition', 365, 'bone'), ('GO_0007565', 'female pregnancy', 590, 'pregnancy'), ('GO_0007631', 'feeding behavior', 607, 'intake')]
S47-PMC4592566	PMC4592566	10/2015	S47-PMC4592566	['the topic guide contained a list of LIKELY pre-Pregnancy actions which interviewers could use as a prompt if needed (the list included: supplements – Folic Acid, multivitamins for Pregnancy, ordinary multivitamins, Vitamin D, iron, omega 3, Vitamin C, zinc; lifestyle actions – Eating a healthy diet, weight, Caffeine, Alcohol, smoking, Drugs, including street Drugs, prescription Drugs, over-the-counter Drugs; and health care advice – seeing a health professional for advice about getting Pregnant, immunizations, Dental checks, Sexually Transmitted infections, and stopping contraception).']	[('PROBABLE_UNDERSTANDING', 36)]	1	[('GO_0007565', 'female pregnancy', 47, 'pregnancy'), ('CHEBI_30751', 'formic acid', 150, 'folic acid'), ('GO_0007565', 'female pregnancy', 180, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 215, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 241, 'vitamin C'), ('GO_0051318', 'G1 phase', 278, 'eating'), ('CHEBI_27732', 'caffeine', 309, 'caffeine'), ('CHEBI_30879', 'alcohol', 319, 'alcohol'), ('CHEBI_23888', 'drug', 337, 'drugs'), ('CHEBI_23888', 'drug', 361, 'drugs'), ('CHEBI_23888', 'drug', 381, 'drugs'), ('CHEBI_23888', 'drug', 405, 'drugs'), ('GO_0007565', 'female pregnancy', 491, 'pregnant'), ('UBERON_0001091', 'calcareous tooth', 516, 'dental'), ('GO_0019095', 'pole plasm mitochondrial rRNA localization', 531, 'sexually transmitted')]
S3-PMC4595656	PMC4595656	10/2015	S3-PMC4595656	['there are FEW STUDIES to date of Vitamin D deprivation or supplementation on early hippocampal development in vivo .']	[('INCOMPLETE_EVIDENCE', 10)]	1	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D')]
S5-PMC4595656	PMC4595656	10/2015	S5-PMC4595656	['there is also LIMITED EVIDENCE that supplementation with Vitamin D following a period of deprivation is capable of restoring cellular activity and later function.']	[('INCOMPLETE_EVIDENCE', 14)]	1	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D')]
S95-PMC4595656	PMC4595656	10/2015	S95-PMC4595656	['in vitro studies\nSEVERAL groups have investigated Vitamin D supplementation of up to 100 nm on developing cultured Hippocampal Neurons (brann et al.,1999; brown et al.,2003; marini et al.,2010).']	[('INCOMPLETE_EVIDENCE', 17)]	1	[('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('CL_0002608', 'hippocampal neuron', 115, 'hippocampal neurons')]
S107-PMC4595656	PMC4595656	10/2015	S107-PMC4595656	['ALTHOUGH the concentration of hormone used to supplement in vitro is higher than that DETECTED in standard Rat Chow, Vitamin D levels in Humans HAVE BEEN FOUND in more than ONE STUDY to be elevated in Pregnancy (seki et al.,1991; ardawi et al.,1997).']	[('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 86), ('INCOMPLETE_EVIDENCE', 144), ('INCOMPLETE_EVIDENCE', 154), ('INCOMPLETE_EVIDENCE', 173)]	5	[('NCBITaxon_9986', 'Oryctolagus cuniculus', 107, 'rat'), ('CHEBI_33290', 'food', 111, 'chow'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin D'), ('NCBITaxon_9606', 'Homo sapiens', 137, 'humans'), ('GO_0007565', 'female pregnancy', 201, 'pregnancy')]
S110-PMC4595656	PMC4595656	10/2015	S110-PMC4595656	['they FOUND an increase in the number of Neurospheres formed in culture from the Subventricular Zone (Svz), which was unaffected by subsequent supplementation with Vitamin D. the authors CONCLUDED that Vitamin D CAN Regulate Cellular Proliferation in the developing Brain.']	[('INCOMPLETE_EVIDENCE', 5), ('INCOMPLETE_EVIDENCE', 186), ('INCOMPLETE_EVIDENCE', 211)]	3	[('CL_0000855', 'sensory hair cell', 40, 'neurospheres'), ('UBERON_0004922', 'postnatal subventricular zone', 80, 'subventricular zone'), ('UBERON_0004922', 'postnatal subventricular zone', 101, 'SVZ'), ('CHEBI_27300', 'vitamin D', 163, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 201, 'vitamin D'), ('GO_0065007', 'biological regulation', 215, 'regulate'), ('GO_0008283', 'cell proliferation', 224, 'cellular proliferation'), ('UBERON_0000955', 'brain', 265, 'brain')]
S111-PMC4595656	PMC4595656	10/2015	S111-PMC4595656	['it is NOTEWORTHY that exogenous Vitamin D supplementation of an initially deprived medium failed to elicit any cellular response.']	[('ANOMALY_CURIOUS_FINDING', 6)]	1	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D')]
S11-PMC4598849	PMC4598849	10/2015	S11-PMC4598849	['the LINK between maternal Vitamin D status and fetal growth, AS measured most frequently by infant Birth weight and small for Gestational age (sga), HAS BEEN explored by a NUMBER OF observational STUDIES9101112131415AND randomized supplementation trials1617181920worldwide with MIXED results.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('PROBABLE_UNDERSTANDING', 61), ('INCOMPLETE_EVIDENCE', 149), ('INCOMPLETE_EVIDENCE', 172), ('INCOMPLETE_EVIDENCE', 196), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 278)]	6	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('GO_0007567', 'parturition', 99, 'birth'), ('GO_0007565', 'female pregnancy', 126, 'gestational')]
S80-PMC4598849	PMC4598849	10/2015	S80-PMC4598849	['the FINDINGS SUGGESTED that Vitamin D supplements during Pregnancy SHOULD BE ENCOURAGED, BUT with CAUTION.']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 13), ('FUTURE_WORK', 67), ('FUTURE_WORK', 77), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 89), ('INCOMPLETE_EVIDENCE', 98)]	6	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('GO_0007565', 'female pregnancy', 57, 'pregnancy')]
S3-PMC4600246	PMC4600246	10/2015	S3-PMC4600246	['additionally, Vitamin K antagonists such as warfarin MAY cause DETRIMENTAL side EFFECTS, which MAY PARTLY be blunted through Vitamin K supplementation.']	[('INCOMPLETE_EVIDENCE', 53), ('IMPORTANT_CONSIDERATION', 63), ('SUPERFICIAL_RELATIONSHIP', 80), ('INCOMPLETE_EVIDENCE', 95)]	4	[('CHEBI_27300', 'vitamin D', 14, 'vitamin K'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin K')]
S5-PMC4600246	PMC4600246	10/2015	S5-PMC4600246	['Plasma Phylloquinone concentrations fluctuate BASED on recent dietary intakes.213DESPITE the fact that a high percentage of undercarboxylated osteocalcin INDICATES poor Vitamin K status, this value can also vary based on recent Vitamin K intake and supplementation214and MAY not INDICATE chronic Vitamin K status.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 46), ('ANOMALY_CURIOUS_FINDING', 78), ('INCOMPLETE_EVIDENCE', 154), ('INCOMPLETE_EVIDENCE', 271), ('INCOMPLETE_EVIDENCE', 279)]	5	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('CHEBI_26124', 'phytosteroid', 7, 'phylloquinone'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin K'), ('CHEBI_27300', 'vitamin D', 228, 'vitamin K'), ('CHEBI_27300', 'vitamin D', 296, 'vitamin K')]
S9-PMC4600246	PMC4600246	10/2015	S9-PMC4600246	['HOWEVER, the RECENTLY updated usa preventive services task force (uspstf) has RECENTLY STATED that there is INSUFFICIENT EVIDENCE that Calcium and Vitamin D PREVENT a fracture in Premenopausal women or in men who have not experienced a fracture and now RECOMMENDS against daily supplementation with 400\u2005iu or less of Vitamin D3 and 1000\u2005mg or less of calcium for the primary prevention of fractures in non-institutionalised Postmenopausal women.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 78), ('INCOMPLETE_EVIDENCE', 87), ('INCOMPLETE_EVIDENCE', 108), ('SUPERFICIAL_RELATIONSHIP', 157), ('FUTURE_WORK', 253)]	7	[('CHEBI_22313', 'alkaline earth metal atom', 135, 'calcium'), ('CHEBI_27300', 'vitamin D', 147, 'vitamin D'), ('GO_0043277', 'apoptotic cell clearance', 179, 'premenopausal'), ('CHEBI_33279', 'vitamin D5', 317, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 317, 'vitamin D3'), ('GO_0007595', 'lactation', 424, 'postmenopausal')]
S12-PMC4600246	PMC4600246	10/2015	S12-PMC4600246	['a broad amount of DATA SEEMS to INDICATE substantial POTENTIAL for supplementary Vitamin K. HOWEVER, currently FEW GUIDELINES RECOMMEND Vitamin K therapy for PREVENTION or treatment of osteoporosis.']	[('FUTURE_WORK', 18), ('ANOMALY_CURIOUS_FINDING', 23), ('INCOMPLETE_EVIDENCE', 32), ('INCOMPLETE_EVIDENCE', 53), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 92), ('INCOMPLETE_EVIDENCE', 111), ('PROBABLE_UNDERSTANDING', 115), ('FUTURE_WORK', 126), ('SUPERFICIAL_RELATIONSHIP', 158)]	9	[('CHEBI_27300', 'vitamin D', 81, 'vitamin K'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin K')]
S24-PMC4600246	PMC4600246	10/2015	S24-PMC4600246	['Coronary Heart disease (chd)\nMAY reduce the RISK of chd, chd mortality and all-cause mortality52676\nInsulin sensitivity\nMAY help improve Insulin sensitivity40\nwarfarin international normalised ratio (inr)\nMAY help to stabilise inr in patients on warfarin41\nlow Vitamin K status (indicated by undercarboxylated mgp) is ASSOCIATED with increased vascular calcifications, and these levels CAN be improved by effective Vitamin K supplementation28–32it was long BELIEVED that Vitamin K was ONLY INVOLVED in forming Coagulation factors (ie, maintaining Haemostasis).']	[('INCOMPLETE_EVIDENCE', 29), ('IMPORTANT_CONSIDERATION', 44), ('INCOMPLETE_EVIDENCE', 120), ('INCOMPLETE_EVIDENCE', 205), ('SUPERFICIAL_RELATIONSHIP', 318), ('INCOMPLETE_EVIDENCE', 386), ('INCOMPLETE_EVIDENCE', 457), ('INCOMPLETE_EVIDENCE', 485), ('SUPERFICIAL_RELATIONSHIP', 490)]	9	[('UBERON_0002949', 'tectospinal tract', 0, 'Coronary heart'), ('PR_000045358', 'insulin family protein', 100, 'Insulin'), ('PR_000045358', 'insulin family protein', 137, 'insulin'), ('CHEBI_27300', 'vitamin D', 261, 'vitamin K'), ('CHEBI_27300', 'vitamin D', 415, 'vitamin K'), ('CHEBI_27300', 'vitamin D', 471, 'vitamin K'), ('GO_0050817', 'coagulation', 510, 'coagulation'), ('GO_0007599', 'hemostasis', 547, 'haemostasis')]
S77-PMC4600246	PMC4600246	10/2015	S77-PMC4600246	['finally, in the RECENT vitamin k italian (viki) dialysis STUDY, 23.5% of patients were FOUND to be Vitamin K deficient, and this deficiency was FOUND TO BE the strongest PREDICTOR of vertebral fractures (or: 2.94; 95% ci 1.38 to 6.26).72other data HAVE SHOWN that vitamin K2May improve Bone Remodelling in patients with haemodialysis with low Serum Parathyroid hormone levels.73supplementing with at LEAST 200\u2005µg Menaquinone-7 (a form of Vitamin K2) daily MAY help to achieve near maximal protection from vascular calcification, osteoporosis and cancer (measured by maximal gamma carboxylation of Vitamin K dependent proteins).35\n\nconclusion\nVitamin K has a plethora of POTENTIAL IMPLICATIONS, including prevention and treatment of Arterial calcifications, Coronary Heart disease and cancer, improvements in bone strength and reduced risks of fractures as well as improvements in Insulin sensitivity.']	[('INCOMPLETE_EVIDENCE', 16), ('INCOMPLETE_EVIDENCE', 57), ('INCOMPLETE_EVIDENCE', 87), ('ANOMALY_CURIOUS_FINDING', 144), ('SUPERFICIAL_RELATIONSHIP', 170), ('INCOMPLETE_EVIDENCE', 248), ('PROBABLE_UNDERSTANDING', 400), ('INCOMPLETE_EVIDENCE', 456), ('INCOMPLETE_EVIDENCE', 670), ('IMPORTANT_CONSIDERATION', 680)]	10	[('CHEBI_27300', 'vitamin D', 99, 'vitamin K'), ('PR_000009481', 'keratin, type II cytoskeletal 5', 272, 'K2may'), ('GO_0046849', 'bone remodeling', 286, 'bone remodelling'), ('UBERON_0001977', 'blood serum', 343, 'serum'), ('UBERON_0001132', 'parathyroid gland', 349, 'parathyroid'), ('CHEBI_18154', 'polysaccharide', 413, 'menaquinone'), ('CHEBI_28934', 'vitamin D2', 438, 'vitamin K2'), ('PR_000017299', 'VIP peptides', 438, 'vitamin K2'), ('CHEBI_27300', 'vitamin D', 597, 'vitamin K'), ('CHEBI_28384', 'vitamin K', 642, 'Vitamin K'), ('UBERON_0001637', 'artery', 732, 'arterial'), ('UBERON_0004151', 'cardiac chamber', 757, 'coronary heart'), ('PR_000045358', 'insulin family protein', 880, 'insulin')]
S79-PMC4600246	PMC4600246	10/2015	S79-PMC4600246	['on THE BASIS of PREVIOUSLY PRESENTED data, Warfarin MAY increase Arterial calcifications and osteoporosis through the inhibition of Vitamin K. LARGER TRIALS SHOULD BE performed to FURTHER ELUCIDATE the negative long-term health CONSEQUENCES of warfarin and IF these CAN PERHAPS be PREVENTED through the institution of supplemental Vitamin K.\n\npubmed central:']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 16), ('INCOMPLETE_EVIDENCE', 52), ('FUTURE_WORK', 143), ('FUTURE_WORK', 157), ('FUTURE_WORK', 180), ('INCOMPLETE_EVIDENCE', 188), ('PROBLEM_COMPLICATION', 228), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 257), ('INCOMPLETE_EVIDENCE', 266), ('INCOMPLETE_EVIDENCE', 270), ('SUPERFICIAL_RELATIONSHIP', 281)]	12	[('CHEBI_10033', 'warfarin', 43, 'warfarin'), ('UBERON_0001637', 'artery', 65, 'arterial'), ('CHEBI_27300', 'vitamin D', 132, 'vitamin K'), ('CHEBI_27300', 'vitamin D', 331, 'vitamin K')]
S2-PMC4605923	PMC4605923	11/2015	S2-PMC4605923	['Food intake is a WELL-known environmental FACTOR that INFLUENCES Allergy Development and three specific Nutrients-Vitamin D, Omega 3 polyunsaturated Fatty Acids and Folate-have RECENTLY attracted ATTENTION.1\nthe methyl donor Folate is a WELL-KNOWN Nutrient supplement given during early Pregnancy to prevent neutral Tube defects in the developing fetus.']	[('PROBABLE_UNDERSTANDING', 17), ('SUPERFICIAL_RELATIONSHIP', 42), ('SUPERFICIAL_RELATIONSHIP', 54), ('INCOMPLETE_EVIDENCE', 177), ('INCOMPLETE_EVIDENCE', 196), ('PROBABLE_UNDERSTANDING', 237)]	6	"[('CHEBI_33290', 'food', 0, 'Food'), ('GO_0060021', 'roof of mouth development', 65, 'allergy development'), ('CHEBI_33284', 'nutrient', 104, 'nutrients'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('CHEBI_82673', ""2-amino-6,7-dimethyl-4-oxo-8-(1'-D-ribityl)-4,8-dihydropteridine"", 125, 'omega 3'), ('CHEBI_35366', 'fatty acid', 149, 'fatty acids'), ('CHEBI_30863', '5-azaorotic acid', 165, 'folate'), ('CHEBI_30863', '5-azaorotic acid', 225, 'folate'), ('CHEBI_33284', 'nutrient', 248, 'nutrient'), ('GO_0007565', 'female pregnancy', 287, 'pregnancy'), ('UBERON_0000025', 'tube', 316, 'tube')]"
S85-PMC4613350	PMC4613350	9/2015	S85-PMC4613350	['matched for body mass index (bmi);6exclusion: Vitamin C and/or Vitamin E supplements, history of major medical complications, major fetal defects, repeated spontaneous abortion, use of an Illicit Drug or Warfarin treatment during the current Pregnancy;7inclusion: nulliparous women with singleton Pregnancies without major fetal chromosomal or structural anomaly;8exclusion: women who had a previous fetus with a chromosomal abnormality and women with Insulin-dependent diabetes mellitus;9exclusion: aids or hepatitis, cases of major fetal anomaly, fetal death and women with Placenta previa, Placenta accrete, or Placental abruption;10general population, singleton Pregnancies;11a priori high risk Pregnancies;12general population;13inclusion: singleton Pregnancy, exclusion: diabetes and chromosomal abnormalities;14exclusion: chronic Hepatic or Renal diseases, Pregnancies with major fetal abnormalities and those ending in termination, Miscarriage or fetal death <24 weeks;15exclusion : known aneuploidy and major congenital malformations;16exclusion: Miscarriages;17exclusion: congenital abnormalities or Medication use;18randomly selected controls;19exclusion: multifetal Gestation, diabetes, chromosomal or structural abnormalities;20exclusion: increased risk factors of pe, sga or ptb, known major fetal anomaly or abnormal karyotype, intervention that MAY modify Pregnancy outcome such as treatment with Aspirin or Progesterone;21inclusion: history of pe in a previous Pregnancy, chronic hypertension, chronic Renal disease, Antiphospholipid syndrome, systemic lupus erythematosus, Pregestational diabetes mellitus, obesity (bmi ≥ 30 kg/m2).']	[('INCOMPLETE_EVIDENCE', 1361)]	1	[('CHEBI_27300', 'vitamin D', 46, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin E'), ('CHEBI_35704', 'N(2)-acetyl-L-lysine', 188, 'illicit drug'), ('CHEBI_10033', 'warfarin', 204, 'warfarin'), ('GO_0007565', 'female pregnancy', 242, 'pregnancy'), ('GO_0007565', 'female pregnancy', 297, 'pregnancies'), ('PR_000045358', 'insulin family protein', 452, 'insulin'), ('UBERON_0001987', 'placenta', 576, 'placenta'), ('UBERON_0001987', 'placenta', 593, 'placenta'), ('UBERON_0001987', 'placenta', 614, 'placental'), ('GO_0007565', 'female pregnancy', 666, 'pregnancies'), ('GO_0007565', 'female pregnancy', 699, 'pregnancies'), ('GO_0007565', 'female pregnancy', 755, 'pregnancy'), ('UBERON_0002107', 'liver', 837, 'hepatic'), ('UBERON_0002113', 'kidney', 848, 'renal'), ('GO_0007565', 'female pregnancy', 864, 'pregnancies'), ('GO_0046660', 'female sex differentiation', 940, 'miscarriage'), ('GO_0042706', 'eye photoreceptor cell fate commitment', 1056, 'miscarriages'), ('CHEBI_60211', 'compound Z', 1110, 'medication'), ('GO_0007565', 'female pregnancy', 1178, 'gestation'), ('GO_0007565', 'female pregnancy', 1372, 'pregnancy'), ('CHEBI_2904', 'atenolol', 1413, 'aspirin'), ('CHEBI_17026', 'progesterone', 1424, 'progesterone'), ('GO_0007565', 'female pregnancy', 1478, 'pregnancy'), ('UBERON_0002113', 'kidney', 1519, 'renal'), ('CHEBI_16240', 'hydrogen peroxide', 1534, 'antiphospholipid'), ('GO_0007565', 'female pregnancy', 1591, 'pregestational')]
S93-PMC4627942	PMC4627942	10/2015	S93-PMC4627942	['(31) FOUND that providing Pregnant women who are hiv-positive with Vitamin A supplementation MAY improve the Gut function of their hiv-infected infants.']	[('INCOMPLETE_EVIDENCE', 5), ('INCOMPLETE_EVIDENCE', 93)]	2	[('GO_0007565', 'female pregnancy', 26, 'pregnant'), ('CHEBI_27300', 'vitamin D', 67, 'vitamin A'), ('UBERON_0001555', 'digestive tract', 109, 'gut')]
S94-PMC4627942	PMC4627942	10/2015	S94-PMC4627942	['they also FOUND that Vitamin A supplementation for hiv-infected infants MAY decrease Gastrointestinal morbidity.']	[('INCOMPLETE_EVIDENCE', 10), ('INCOMPLETE_EVIDENCE', 72)]	2	[('CHEBI_27300', 'vitamin D', 21, 'vitamin A'), ('UBERON_0005409', 'alimentary part of gastrointestinal system', 85, 'gastrointestinal')]
S103-PMC4627942	PMC4627942	10/2015	S103-PMC4627942	['caption (table-wrap): table 2\n\nbiological causes of malnutrition: findings from indepth studieshdss siteyearauthorsmain findingsagincourt hdss, south africa2011kimani-murage et al.children infected with hiv had significantly worse nutritional outcomes than their uninfected peers.west kiang hdss, gambia2008nwenekahiv-positive children had significantly worse scores in terms of weight-for-age, height-for-age, and bmi than hiv-negative children.africa centre, south africa2007papathakis et al.breastfeeding mothers in south africa who were hiv-positive had poorer protein and Micronutrient status than hiv-negative women.africa centre, south africa2001filteau et al.providing Pregnant women who are hiv-positive with Vitamin A supplementation MAY improve Gut function of their hiv-infected infants.']	[('INCOMPLETE_EVIDENCE', 744)]	1	[('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 577, 'micronutrient'), ('GO_0007565', 'female pregnancy', 677, 'pregnant'), ('CHEBI_27300', 'vitamin D', 718, 'vitamin A'), ('UBERON_0001555', 'digestive tract', 756, 'gut')]
S179-PMC4627942	PMC4627942	10/2015	S179-PMC4627942	"[""studies by the bandim hdss in guinea-bissau of malnutrition campaigns during that country's 1998 civil war FOUND that Vitamin A supplementation for children (64) and a supplementary Feeding programme for children (65) helped to reduce mortality during the conflict.""]"	[('INCOMPLETE_EVIDENCE', 107)]	1	[('CHEBI_27300', 'vitamin D', 118, 'vitamin A'), ('GO_0007631', 'feeding behavior', 182, 'feeding')]
S184-PMC4627942	PMC4627942	10/2015	S184-PMC4627942	['the effectiveness of Vitamin A supplementation HAS also BEEN QUESTIONED.']	[('INCOMPLETE_EVIDENCE', 47), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 61)]	2	[('CHEBI_27300', 'vitamin D', 21, 'vitamin A')]
S185-PMC4627942	PMC4627942	10/2015	S185-PMC4627942	['ALTHOUGH it APPEARED TO BE beneficial in the above-mentioned trial in guinea-bissau, researchers at kintampo hdss in ghana FOUND no positive effect of Vitamin A supplements in combination with vaccines during the first few months of Life (68).']	[('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 12), ('INCOMPLETE_EVIDENCE', 123)]	3	[('CHEBI_27300', 'vitamin D', 151, 'vitamin A'), ('UBERON_0000104', 'life cycle', 233, 'life')]
S197-PMC4627942	PMC4627942	10/2015	S197-PMC4627942	['in ghana, Vitamin A supplementation was found to increase Liver reserves of mothers during the Postpartum period, with the EFFECTS persisting for at least five months (72).']	[('SUPERFICIAL_RELATIONSHIP', 123)]	1	[('CHEBI_27300', 'vitamin D', 10, 'vitamin A'), ('UBERON_0002107', 'liver', 58, 'liver'), ('GO_0007565', 'female pregnancy', 95, 'postpartum')]
S221-PMC4627942	PMC4627942	10/2015	S221-PMC4627942	"[""caption (table-wrap): table 5\n\ntackling malnutrition – prevention EFFORTS: findings from indepth studieshdss siteyearauthorsmain findingsbandim hdss, guinea-bissau2004nielsen et al.during civil war, Vitamin A supplementation for children helped reduce mortality.bandim hdss, guinea-bissau2005nielsen et al.during civil war, supplementary Feeding programme helped reduce mortality in children.filabavi hdss, vietnam2009nga et al.fortification with multiple Micronutrients of biscuits provided in schools reduced risk of anaemia and of iron and zinc deficiencies by 40%.nouna hdss, burkina faso2003müller et al.no significant impact of Zinc supplementation for children on height-for-age, weight-for-age, and weight-for-height scores.kintampo hdss, ghana2007newton et al.no positive EFFECT of Vitamin A supplements in combination with vaccines during the first few months of Life.farafenni hdss, gambia2013van der merwe et al.fish oil supplementation had no effect on growth, Intestinal integrity, morbidity, or cognitive development.kilifi hdss, kenya2010akech et al.use of low-dose hypotonic Fluid resuscitation for children who develop shock AS a result of SEVERE malnutrition has poor outcomes in terms of persistent shock, oliguria, and high case fatality.agincourt hdss, south africa2003deen et al.introduction of who guidelines in two hospitals strengthened the management of malnutrition.kintampo hdss, ghana2006tchum et al.vitamin a supplementation increased Liver reserves of mothers during the Postpartum period, with EFFECTS persisting for at least five months.niakhar hdss, senegal2006ly et al.provision of high energy, Nutrient-dense Food supplements to infants aged between four and seven months contributed to decreased Postpartum weight loss in their mothers.west kiang hdss, gambia2011hawkesworth et al.Nutrient supplementation during Pregnancy had little effect on infants’ risk of cardiovascular disease.west kiang hdss, gambia2009hawkesworth et al.protein-energy supplementation of mothers during Pregnancy had no effect on the Blood pressure of their children in adolescence.west kiang hdss, gambia2009prentice et al.Calcium supplementation for Pregnant mothers had no effect on foetal and infant growth.west kiang hdss, gambia2010jarjou et al.women given Calcium Supplements while Pregnant had lower bone Mineral content, bone area and bone Mineral density at the Hip during the 12-month Lactation period than other women.dikgale hdss, south africa2002nthangeni et al.the majority of People with type 2 diabetes had poor Glycaemic Control and were obese or had high blood pressure and were given poor advice by health educators.africa centre hdss, south africa2002o'donnell et al.agencies working to tackle a flood disaster in bangladesh in 1998 achieved MIXED results in terms of meeting international disaster response standards.""]"	[('FUTURE_WORK', 66), ('SUPERFICIAL_RELATIONSHIP', 781), ('PROBABLE_UNDERSTANDING', 1143), ('IMPORTANT_CONSIDERATION', 1158), ('SUPERFICIAL_RELATIONSHIP', 1527), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 2776)]	6	[('CHEBI_27300', 'vitamin D', 199, 'vitamin A'), ('GO_0007631', 'feeding behavior', 338, 'feeding'), ('CHEBI_33839', 'macromolecule', 456, 'micronutrients'), ('CHEBI_33340', 'zinc group element atom', 634, 'zinc'), ('CHEBI_27300', 'vitamin D', 791, 'vitamin A'), ('UBERON_0000104', 'life cycle', 873, 'life'), ('UBERON_0000160', 'intestine', 974, 'intestinal'), ('UBERON_0006314', 'bodily fluid', 1092, 'fluid'), ('UBERON_0002107', 'liver', 1466, 'liver'), ('GO_0007565', 'female pregnancy', 1503, 'postpartum'), ('CHEBI_33284', 'nutrient', 1631, 'nutrient'), ('CHEBI_33290', 'food', 1646, 'food'), ('GO_0007565', 'female pregnancy', 1734, 'postpartum'), ('CHEBI_33284', 'nutrient', 1819, 'Nutrient'), ('GO_0007565', 'female pregnancy', 1851, 'pregnancy'), ('GO_0007565', 'female pregnancy', 2016, 'pregnancy'), ('UBERON_0000178', 'blood', 2047, 'blood'), ('CHEBI_31341', 'calcium dihydroxide', 2137, 'Calcium'), ('GO_0007565', 'female pregnancy', 2165, 'pregnant'), ('CHEBI_22313', 'alkaline earth metal atom', 2276, 'calcium'), ('CHEBI_33341', 'titanium atom', 2284, 'supplements'), ('GO_0007565', 'female pregnancy', 2302, 'pregnant'), ('CHEBI_46662', 'mineral', 2326, 'mineral'), ('CHEBI_46662', 'mineral', 2362, 'mineral'), ('UBERON_0001464', 'hip', 2385, 'hip'), ('GO_0007595', 'lactation', 2409, 'lactation'), ('NCBITaxon_10088', 'Mus <genus>', 2505, 'people'), ('GO_0051162', 'L-arabitol metabolic process', 2542, 'glycaemic control')]
S8-PMC4632418	PMC4632418	10/2015	S8-PMC4632418	['HOWEVER, well-designed randomized controlled TRIALS ARE NEEDED to elicit the clear EFFECT of Vitamin D supplementation on PREVENTION of gdm.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('FUTURE_WORK', 45), ('SUPERFICIAL_RELATIONSHIP', 83), ('SUPERFICIAL_RELATIONSHIP', 122)]	4	[('CHEBI_27300', 'vitamin D', 93, 'vitamin D')]
S19-PMC4632418	PMC4632418	10/2015	S19-PMC4632418	['furthermore, Pregnant and Lactating women who take a Prenatal Vitamin and a Calcium supplement with Vitamin D remain at HIGH RISK for Vitamin D deficiency.']	[('IMPORTANT_CONSIDERATION', 120)]	1	[('GO_0007565', 'female pregnancy', 13, 'pregnant'), ('GO_0007594', 'puparial adhesion', 26, 'lactating'), ('GO_0007565', 'female pregnancy', 53, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 62, 'vitamin'), ('CHEBI_22313', 'alkaline earth metal atom', 76, 'calcium'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin D')]
S34-PMC4632418	PMC4632418	10/2015	S34-PMC4632418	['study selection\noriginal research evaluating the ASSOCIATIONS between Vitamin D status and Pregnancy outcomes were scrutinized and subsequently selected if they fulfilled the following inclusion criteria: a. study population was Pregnant women without pre-existing chronic disease; b. gdm as outcome and the control were women with normal Glucose tolerance (ngt); c. contained RELEVANT data to calculate the effect size and corresponding 95% confidence intervals (ci); d. met the predefined methodological quality assessment criteria for observational studies (supplementary data box 1) [18]; e. only studies published in english were considered.']	[('SUPERFICIAL_RELATIONSHIP', 49), ('IMPORTANT_CONSIDERATION', 377)]	2	[('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('GO_0007565', 'female pregnancy', 91, 'pregnancy'), ('GO_0007565', 'female pregnancy', 229, 'pregnant'), ('CHEBI_17234', 'glucose', 339, 'glucose')]
S77-PMC4632418	PMC4632418	10/2015	S77-PMC4632418	['it is WORTH NOTING that two pooled ors for Vitamin D severe deficiency and insufficiency were calculated with the outcomes of 1.59 (95% ci, 1.11, 2.27) and 1.39 (95% ci, 1.07, 1.82), respectively (supplementary table s2).']	[('ANOMALY_CURIOUS_FINDING', 6), ('ANOMALY_CURIOUS_FINDING', 6)]	2	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D')]
S107-PMC4632418	PMC4632418	10/2015	S107-PMC4632418	['for ONE STUDY, the majority of study participants were reported Consuming Prenatal multivitamins or taking Nutritional supplements, as well as living in a geographical location which MAY AFFECT the Vitamin D status [15].']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 183), ('SUPERFICIAL_RELATIONSHIP', 187)]	3	[('GO_0007631', 'feeding behavior', 64, 'consuming'), ('GO_0007565', 'female pregnancy', 74, 'prenatal'), ('CHEBI_7495', 'nefazodone hydrochloride', 107, 'nutritional'), ('CHEBI_27300', 'vitamin D', 198, 'vitamin D')]
S116-PMC4632418	PMC4632418	10/2015	S116-PMC4632418	['there are MAJOR causes behind Vitamin D deficiency during Pregnancy, such as INADEQUATE exposure to sunlight, low Vitamin D intake and more REQUIREMENTS for Vitamin D. Vitamin D supplementation during Pregnancy has beneficial EFFECTS on glycaemia, Insulin sensitivity [45], Insulin resistance [46] and Metabolic profiles [47].']	[('IMPORTANT_CONSIDERATION', 10), ('IMPORTANT_CONSIDERATION', 77), ('IMPORTANT_CONSIDERATION', 140), ('SUPERFICIAL_RELATIONSHIP', 226)]	4	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0007565', 'female pregnancy', 58, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 157, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 168, 'Vitamin'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 176, 'D'), ('GO_0007565', 'female pregnancy', 201, 'pregnancy'), ('PR_000045358', 'insulin family protein', 248, 'insulin'), ('PR_000045358', 'insulin family protein', 274, 'insulin'), ('GO_0008152', 'metabolic process', 302, 'metabolic')]
S118-PMC4632418	PMC4632418	10/2015	S118-PMC4632418	['apart from diet and Supplements, ANOTHER way of keeping OPTIMAL level of body Vitamin D is from skin exposure to sunlight, which is REMARKABLY INFLUENCED by geographical location, season, dark skin tone, sunscreen use and EVEN the air pollution [48].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 33), ('IMPORTANT_CONSIDERATION', 56), ('ANOMALY_CURIOUS_FINDING', 132), ('SUPERFICIAL_RELATIONSHIP', 143), ('ANOMALY_CURIOUS_FINDING', 222)]	5	[('CHEBI_33341', 'titanium atom', 20, 'supplements'), ('CHEBI_27300', 'vitamin D', 78, 'vitamin D')]
S129-PMC4632418	PMC4632418	10/2015	S129-PMC4632418	['HOWEVER, the ASSOCIATION between Vitamin D deficiency and gdm STILL REMAINS (or = 1.67; 95% ci, 1.31, 2.13; i2= 25.6%, p = 0.251) EVEN after adjusting for maternal age, bmi and ethnicity (supplementary figure s4).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('SUPERFICIAL_RELATIONSHIP', 13), ('ANOMALY_CURIOUS_FINDING', 62), ('IMPORTANT_CONSIDERATION', 62), ('INCOMPLETE_EVIDENCE', 68), ('ANOMALY_CURIOUS_FINDING', 130)]	7	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D')]
S134-PMC4632418	PMC4632418	10/2015	S134-PMC4632418	['HOWEVER, well-designed randomized controlled TRIALS ARE NEEDED to determine the explicit EFFECT of Vitamin D supplementation on PREVENTION of gdm.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('FUTURE_WORK', 45), ('SUPERFICIAL_RELATIONSHIP', 89), ('SUPERFICIAL_RELATIONSHIP', 128)]	4	[('CHEBI_27300', 'vitamin D', 99, 'vitamin D')]
S135-PMC4632418	PMC4632418	10/2015	S135-PMC4632418	['UNTIL then, screening women who are AT RISK of Vitamin D deficiency and supplementation with Vitamin D COULD BE CONSIDERED.']	[('FUTURE_WORK', 0), ('IMPORTANT_CONSIDERATION', 36), ('FUTURE_WORK', 103), ('INCOMPLETE_EVIDENCE', 103), ('FUTURE_WORK', 112)]	5	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 93, 'vitamin D')]
S2-PMC4645901	PMC4645901	8/2014	S2-PMC4645901	['prior to our newly designed INTERVENTION, those babies with low Vitamin D levels would be given a letter to ENCOURAGE collection of supplementation from their gp.']	[('SUPERFICIAL_RELATIONSHIP', 28), ('FUTURE_WORK', 108)]	2	[('CHEBI_27300', 'vitamin D', 64, 'vitamin D')]
S14-PMC4645901	PMC4645901	8/2014	S14-PMC4645901	['WHILE an increase in government advertising would have CONTRIBUTED to the rise in uptake of Vitamin D supplementation, a leaflet proved to be a simple YET EFFECTIVE INTERVENTION in improving Vitamin uptake in babies.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('SUPERFICIAL_RELATIONSHIP', 55), ('ANOMALY_CURIOUS_FINDING', 151), ('SUPERFICIAL_RELATIONSHIP', 155), ('SUPERFICIAL_RELATIONSHIP', 165)]	5	[('CHEBI_27300', 'vitamin D', 92, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 191, 'vitamin')]
S19-PMC4645901	PMC4645901	8/2014	S19-PMC4645901	['[2]\nHOWEVER, it is ESSENTIAL to APPRECIATE that RECOMMENDED doses of Vitamin D supplementation are arbitary, and the THRESHOLD for toxicity is far higher.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 4), ('IMPORTANT_CONSIDERATION', 19), ('IMPORTANT_CONSIDERATION', 32), ('FUTURE_WORK', 48), ('IMPORTANT_CONSIDERATION', 117)]	5	[('CHEBI_27300', 'vitamin D', 69, 'vitamin D')]
S52-PMC4645901	PMC4645901	8/2014	S52-PMC4645901	['see supplementary file: ds2663.doc - “tables and figures”\n\ndesign\nfollowing discussions with the parents and the clinical team, we RECOGNISED that there was a LACK OF AWARENESS of the IMPORTANCE of Vitamin D for the health and Development Of Babies.']	[('PROBABLE_UNDERSTANDING', 131), ('PROBLEM_COMPLICATION', 159), ('IMPORTANT_CONSIDERATION', 167), ('IMPORTANT_CONSIDERATION', 184)]	4	[('CHEBI_27300', 'vitamin D', 198, 'vitamin D'), ('GO_0048513', 'animal organ development', 227, 'development of babies')]
S73-PMC4645901	PMC4645901	8/2014	S73-PMC4645901	['this MAY BE due to the increased AWARENESS of Vitamin D deficiency by the general public, and THEREFORE an increased uptake of Vitamin supplements during Pregnancy.']	[('INCOMPLETE_EVIDENCE', 5), ('IMPORTANT_CONSIDERATION', 33), ('PROBABLE_UNDERSTANDING', 94)]	3	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 127, 'vitamin'), ('GO_0007565', 'female pregnancy', 154, 'pregnancy')]
S83-PMC4645901	PMC4645901	8/2014	S83-PMC4645901	['a relatively SMALL data set MEANT it was NOT POSSIBLE to draw convincing CONCLUSIONS between dose of vitamin supplementation during Pregnancy and Vitamin D levels in babies.']	[('INCOMPLETE_EVIDENCE', 13), ('PROBABLE_UNDERSTANDING', 28), ('DIFFICULT_TASK', 41), ('PROBABLE_UNDERSTANDING', 73)]	4	[('GO_0007565', 'female pregnancy', 132, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 146, 'vitamin D')]
S88-PMC4645901	PMC4645901	8/2014	S88-PMC4645901	['conclusion\ndesigning a leaflet to ENCOURAGE patients and clinicians to increase uptake of Vitamin D had a positive IMPACT on the number of babies having correct supplementation.']	[('FUTURE_WORK', 34), ('SUPERFICIAL_RELATIONSHIP', 115)]	2	[('CHEBI_27300', 'vitamin D', 90, 'vitamin D')]
S175-PMC4663595	PMC4663595	11/2015	S175-PMC4663595	['our group also REPORTED that Dha supplementation with 400 mg/day during Pregnancy induced Dna Methylation changes in inflammatory Genes and Line-1 , especially in infants born to mothers who smoked during Pregnancy [99].nutrients-07-05467-t002_table 2\n\ncaption (table-wrap): table 2\n\nintervention studies for maternal nutritional status and epigenetic profile in offspring.Nutrientsmechanismoutcomesamplemethodref.Folate and Multivitamins(1)Dna Methylation↓ methylation of Igf2 2r in girls, ↓ methylation of Gtl2-2 in boyscord Blood27K illumina[93]folatedna methylation↓ methylation of Line1 Cord Bloodpyrosequencing[94]Dna Methylation↑ methylation of Igf2 dmrcord Bloodepi-typer[95]Dna Methylation↓ methylation of h19 dmr (4 cpgs)Cord Bloodpyrosequencing[96]Dna Methylation↓ methylation of peg3 and Line1 ; ↑ methylation of Igf2 Cord Bloodpyrosequencing[97]cholinedna methylationhistone modification↑ methylation of crh , Nr3C1 in Placenta; ↓ methylation of crh , Nr3C1 in Cord Blood Leukocyte; ↑ H3K9Me2Placenta, Cord Bloodlc-ms/ms[98]Dhadna Methylation↑ Line1 methylation ↑ Infγ/Il13 methylation ratiocord Bloodpyrosequencing[99]\n(1)Zinc and Vitamins A, b, c and d; Peg3, Paternally-Expressed Gene 3; Crh, Corticotropin-Releasing Hormone; Nr3C1, Nuclear receptor subfamily 3, Group C, Member 1.']	[('INCOMPLETE_EVIDENCE', 15)]	1	"[('CHEBI_17874', 'dihydrozeatin', 29, 'DHA'), ('GO_0007565', 'female pregnancy', 72, 'pregnancy'), ('GO_0006306', 'DNA methylation', 90, 'DNA methylation'), ('SO_0000704', 'gene', 130, 'genes'), ('PR_000009877', 'loss of heterozygosity 11 chromosomal region 2 gene A protein', 140, 'LINE-1'), ('GO_0007565', 'female pregnancy', 205, 'pregnancy'), ('CHEBI_8329', 'Pomiferin', 373, 'NutrientsMechanismOutcomeSampleMethodRef'), ('CHEBI_81245', 'Vulpecholate', 414, 'Folate'), ('CHEBI_7036', 'Musennin', 425, 'Multivitamins'), ('GO_0006323', 'DNA packaging', 441, 'DNA methylation↓'), ('PR_000008989', 'interleukin-1 family member 7', 473, 'IGF2'), ('PR_000008305', 'glutathione S-transferase theta-1', 508, 'GTL2'), ('UBERON_0001977', 'blood serum', 527, 'blood27k'), ('PR_000009877', 'loss of heterozygosity 11 chromosomal region 2 gene A protein', 586, 'LINE1'), ('UBERON_0000948', 'heart', 592, 'Cord'), ('UBERON_0011919', 'yolk sac blood island', 597, 'bloodPyrosequencing'), ('GO_0006306', 'DNA methylation', 620, 'DNA methylation'), ('PR_000008989', 'interleukin-1 family member 7', 652, 'IGF2'), ('UBERON_0001970', 'bile', 665, 'bloodEpi'), ('GO_0006323', 'DNA packaging', 683, 'DNA methylation↓'), ('UBERON_0000948', 'heart', 731, 'Cord'), ('UBERON_0011919', 'yolk sac blood island', 736, 'bloodPyrosequencing'), ('GO_0006323', 'DNA packaging', 759, 'DNA methylation↓'), ('PR_000009877', 'loss of heterozygosity 11 chromosomal region 2 gene A protein', 800, 'LINE1'), ('PR_000008989', 'interleukin-1 family member 7', 825, 'IGF2'), ('UBERON_0000948', 'heart', 830, 'Cord'), ('UBERON_0011919', 'yolk sac blood island', 835, 'bloodPyrosequencing'), ('PR_000011403', 'photoreceptor-specific nuclear receptor', 923, 'NR3C1'), ('UBERON_0001987', 'placenta', 932, 'placenta'), ('PR_000011403', 'photoreceptor-specific nuclear receptor', 965, 'NR3C1'), ('CL_0000107', 'autonomic neuron', 974, 'cord blood'), ('UBERON_0002240', 'spinal cord', 974, 'cord'), ('UBERON_0000178', 'blood', 979, 'blood'), ('CL_0000738', 'leukocyte', 985, 'leukocyte'), ('SO_0001736', 'H3K9_methylation_site', 998, 'H3K9me2Placenta'), ('UBERON_0002240', 'spinal cord', 1015, 'cord'), ('UBERON_0000178', 'blood', 1020, 'bloodLC'), ('GO_0010424', 'DNA methylation on cytosine within a CG sequence', 1037, 'DHADNA methylation'), ('PR_000009877', 'loss of heterozygosity 11 chromosomal region 2 gene A protein', 1057, 'LINE1'), ('PR_000009020', ""Golgi-resident adenosine 3',5'-bisphosphate 3'-phosphatase"", 1077, 'INFγ'), ('PR_000001470', 'interleukin-28B', 1082, 'IL13'), ('UBERON_0011919', 'yolk sac blood island', 1109, 'bloodPyrosequencing'), ('CHEBI_27377', ""Unsym-bis(4'-chlorophenyl)ethylene"", 1136, 'Zinc'), ('CHEBI_27300', 'vitamin D', 1145, 'vitamins A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 1154, 'A'), ('PR_000012529', 'PDZK1-interacting protein 1', 1169, 'PEG3'), ('PR_000012270', 'pappalysin-1', 1175, 'paternally-expressed gene 3'), ('GO_0010467', 'gene expression', 1186, 'expressed'), ('SO_0000704', 'gene', 1196, 'gene'), ('PR_000005864', 'protein CREG2', 1204, 'CRH'), ('CHEBI_3918', 'crocetin', 1209, 'corticotropin'), ('PR_000005968', 'cystatin-M', 1209, 'corticotropin-releasing hormone'), ('CHEBI_33280', 'molecular messenger', 1233, 'hormone'), ('PR_000011403', 'photoreceptor-specific nuclear receptor', 1242, 'NR3C1'), ('GO_0005634', 'nucleus', 1249, 'nuclear'), ('PR_000008294', 'glutathione S-transferase A1', 1279, 'group C, member 1')]"
S131-PMC4673623	PMC4673623	11/2015	S131-PMC4673623	['Vitamin B-12 supplementation) MAY BE WARRANTED.']	[('FUTURE_WORK', 30), ('INCOMPLETE_EVIDENCE', 30)]	2	[('CHEBI_27300', 'vitamin D', 0, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 0, 'vitamin B-12')]
S111-PMC4676908	PMC4676908	12/2015	S111-PMC4676908	['the content of each anc visit is also IMPORTANT, AS SOME anc INTERVENTIONS MAY not be beneficial, such as high does concomitant supplementation with Vitamin C and Vitamin e to PREVENT pre-eclampsia in high-risk women (poston2006).']	[('IMPORTANT_CONSIDERATION', 38), ('PROBABLE_UNDERSTANDING', 49), ('INCOMPLETE_EVIDENCE', 52), ('SUPERFICIAL_RELATIONSHIP', 61), ('INCOMPLETE_EVIDENCE', 75), ('SUPERFICIAL_RELATIONSHIP', 176)]	6	[('CHEBI_27300', 'vitamin D', 149, 'vitamin C'), ('CHEBI_33229', 'vitamin (role)', 163, 'vitamin')]
S55-PMC4684854	PMC4684854	12/2015	S55-PMC4684854	['ACCORDINGLY, exploration of consensus FINDINGS on the clinical BENEFITS of Vitamin D supplementation is in order in all medical disciplines including Reproductive healthcare.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 38), ('IMPORTANT_CONSIDERATION', 63)]	3	[('CHEBI_27300', 'vitamin D', 75, 'vitamin D'), ('GO_0000003', 'reproduction', 150, 'reproductive')]
S58-PMC4684854	PMC4684854	12/2015	S58-PMC4684854	['specifically, supplementation of Vitamin D in Pregnancy in SOME studies APPEARS TO SUGGEST marked BENEFIT WHILE research in OTHER publications does NOT APPEAR TO confer significant improvement in maternal-fetal outcomes [44].']	[('INCOMPLETE_EVIDENCE', 59), ('ANOMALY_CURIOUS_FINDING', 72), ('INCOMPLETE_EVIDENCE', 83), ('IMPORTANT_CONSIDERATION', 98), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 106), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 124), ('ANOMALY_CURIOUS_FINDING', 148), ('ANOMALY_CURIOUS_FINDING', 152)]	8	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('GO_0007565', 'female pregnancy', 46, 'pregnancy')]
S60-PMC4684854	PMC4684854	12/2015	S60-PMC4684854	['FOUND that Gestational Vitamin D supplementation was ASSOCIATED with increased Birth weight and Birth length BUT, UNLIKE SOME OTHER RESEARCH, was not associated with other beneficial maternal and neonatal outcomes such as reductions in preeclampsia, Gestational diabetes, small for Gestational age infants, Preterm Birth, or rates of cesarean Delivery [44].']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 53), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 109), ('ANOMALY_CURIOUS_FINDING', 109), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 114), ('INCOMPLETE_EVIDENCE', 121), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 126)]	7	[('GO_0007565', 'female pregnancy', 11, 'gestational'), ('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('GO_0007567', 'parturition', 79, 'birth'), ('GO_0007567', 'parturition', 96, 'birth'), ('GO_0007565', 'female pregnancy', 250, 'gestational'), ('GO_0007565', 'female pregnancy', 282, 'gestational'), ('GO_0007565', 'female pregnancy', 307, 'preterm birth'), ('GO_0007567', 'parturition', 343, 'delivery')]
S62-PMC4684854	PMC4684854	12/2015	S62-PMC4684854	['studies on Reproductive outcomes RELATED to Vitamin D supplementation, HOWEVER, are inherently PLAGUED by a NUMBER OF common CONFOUNDERS which CLOUD the picture.']	[('SUPERFICIAL_RELATIONSHIP', 33), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 71), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 95), ('INCOMPLETE_EVIDENCE', 108), ('PROBLEM_COMPLICATION', 125), ('INCOMPLETE_EVIDENCE', 143)]	6	[('GO_0000003', 'reproduction', 11, 'reproductive'), ('CHEBI_27300', 'vitamin D', 44, 'vitamin D')]
S63-PMC4684854	PMC4684854	12/2015	S63-PMC4684854	['it is IMPORTANT TO REALIZE that Vitamin D status is very different from WHETHER OR not someone is consuming Vitamin D supplementation.']	[('IMPORTANT_CONSIDERATION', 6), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 72)]	2	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin D')]
S64-PMC4684854	PMC4684854	12/2015	S64-PMC4684854	['many FACTORS MAY AFFECT the resultant status of Vitamin D in the body (AS reflected by measurement of 25(Oh)D levels) after Ingested supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 5), ('INCOMPLETE_EVIDENCE', 13), ('SUPERFICIAL_RELATIONSHIP', 17), ('PROBABLE_UNDERSTANDING', 71)]	4	[('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 102, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 108, 'D'), ('GO_0007631', 'feeding behavior', 124, 'ingested')]
S65-PMC4684854	PMC4684854	12/2015	S65-PMC4684854	['dosing of Supplements, body weight, levels of various Toxicants, and individual Metabolism can all be FACTORS in consequent Vitamin D indices after supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 102)]	1	[('CHEBI_33341', 'titanium atom', 10, 'supplements'), ('CHEBI_35704', 'N(2)-acetyl-L-lysine', 54, 'toxicants'), ('GO_0008152', 'metabolic process', 80, 'metabolism'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D')]
S66-PMC4684854	PMC4684854	12/2015	S66-PMC4684854	['many of the RECENT publications CHALLENGING the efficacy of Gestational Vitamin D sufficiency HAVE BEEN meta-analyses which ATTEMPT to synthesize diverse data from numerous observational and supplementation studies which do NOT NECESSARILY incorporate individual differences in these central DETERMINANTS.']	[('INCOMPLETE_EVIDENCE', 12), ('DIFFICULT_TASK', 32), ('INCOMPLETE_EVIDENCE', 94), ('DIFFICULT_TASK', 124), ('INCOMPLETE_EVIDENCE', 224), ('SUPERFICIAL_RELATIONSHIP', 292)]	6	[('GO_0007565', 'female pregnancy', 60, 'gestational'), ('CHEBI_27300', 'vitamin D', 72, 'vitamin D')]
S68-PMC4684854	PMC4684854	12/2015	S68-PMC4684854	['(i) there is wide HETEROGENEITY of studied populations with VARIATIONS in Vitamin D supplement dosing, geophysical location, social and dietary conditions, and OTHER FACTORS in studied groups [45].']	[('DIFFICULT_TASK', 18), ('DIFFICULT_TASK', 60), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 160), ('SUPERFICIAL_RELATIONSHIP', 166)]	4	[('CHEBI_27300', 'vitamin D', 74, 'vitamin D')]
S70-PMC4684854	PMC4684854	12/2015	S70-PMC4684854	['(ii) commencement of supplementation at differing times during the Gestation MAY miss CRITICAL periods when Vitamin D MAY play a PIVOTAL ROLE.']	[('INCOMPLETE_EVIDENCE', 77), ('IMPORTANT_CONSIDERATION', 86), ('INCOMPLETE_EVIDENCE', 118), ('IMPORTANT_CONSIDERATION', 129), ('SUPERFICIAL_RELATIONSHIP', 137)]	5	[('GO_0007565', 'female pregnancy', 67, 'gestation'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin D')]
S74-PMC4684854	PMC4684854	12/2015	S74-PMC4684854	['accordingly, a CRITICAL appraisal of such meta-analyses is in order to achieve an accurate perspective on the efficacy of Gestational Vitamin D supplementation.']	[('IMPORTANT_CONSIDERATION', 15)]	1	[('GO_0007565', 'female pregnancy', 122, 'gestational'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin D')]
S127-PMC4684854	PMC4684854	12/2015	S127-PMC4684854	['with regard to economic challenges ASSOCIATED with Vitamin D insufficiency, SUFFICE it to say that there are CONSIDERABLE costs POTENTIALLY ASSOCIATED with Gestational Vitamin D insufficiency [99] as well as corresponding BENEFITS and cost savings resulting from inexpensive supplementation with this ESSENTIAL Nutrient [99].']	[('SUPERFICIAL_RELATIONSHIP', 35), ('IMPORTANT_CONSIDERATION', 76), ('IMPORTANT_CONSIDERATION', 109), ('INCOMPLETE_EVIDENCE', 128), ('SUPERFICIAL_RELATIONSHIP', 140), ('IMPORTANT_CONSIDERATION', 222), ('IMPORTANT_CONSIDERATION', 301)]	7	[('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('GO_0007565', 'female pregnancy', 156, 'gestational'), ('CHEBI_27300', 'vitamin D', 168, 'vitamin D'), ('CHEBI_33284', 'nutrient', 311, 'nutrient')]
S136-PMC4684854	PMC4684854	12/2015	S136-PMC4684854	['one researcher has SUGGESTED that the dietary REQUIREMENT during Pregnancy and Lactation MAY actually be as high as 6000\u2009iu/day [108], BUT most researchers have concluded, with OUR CURRENT KNOWLEDGE, that a supplemental Vitamin D intake of 4000\u2009iu/day is OPTIMAL [30].']	[('INCOMPLETE_EVIDENCE', 19), ('IMPORTANT_CONSIDERATION', 46), ('INCOMPLETE_EVIDENCE', 89), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 135), ('QUESTION_ANSWERED_BY_THIS_WORK', 177), ('INCOMPLETE_EVIDENCE', 181), ('FUTURE_WORK', 189), ('IMPORTANT_CONSIDERATION', 255)]	8	[('GO_0007565', 'female pregnancy', 65, 'pregnancy'), ('GO_0007595', 'lactation', 79, 'lactation'), ('CHEBI_27300', 'vitamin D', 220, 'vitamin D')]
S137-PMC4684854	PMC4684854	12/2015	S137-PMC4684854	"[""as discussed, individual Vitamin D indices CAN be INFLUENCED by various DETERMINANTS DESPITE specific levels of supplementation; it is THUS the author's RECOMMENDATION that a personalized medical approach be taken via individual screening for 25(Oh)D as a routine part of Preconception and Prenatal care.""]"	[('INCOMPLETE_EVIDENCE', 43), ('SUPERFICIAL_RELATIONSHIP', 50), ('SUPERFICIAL_RELATIONSHIP', 72), ('ANOMALY_CURIOUS_FINDING', 85), ('PROBABLE_UNDERSTANDING', 135), ('FUTURE_WORK', 153)]	6	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 243, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 243, '25(OH)D'), ('GO_0007565', 'female pregnancy', 272, 'preconception'), ('GO_0007565', 'female pregnancy', 290, 'prenatal')]
S5-PMC4689556	PMC4689556	12/2015	S5-PMC4689556	['supplementation increased maternal and Cord Blood 25(Oh) Vitamin D concentrations, BUT levels remained lower than current recommendations.']	[('ANOMALY_CURIOUS_FINDING', 83)]	1	[('UBERON_0002240', 'spinal cord', 39, 'cord'), ('UBERON_0000178', 'blood', 44, 'blood'), ('CHEBI_30778', 'gallic acid', 50, '25(OH)'), ('CHEBI_27300', 'vitamin D', 57, 'vitamin D')]
S13-PMC4689556	PMC4689556	12/2015	S13-PMC4689556	['conclusions\nwe FOUND NO EVIDENCE that Prenatal Vitamin D supplementation from 27 weeks Gestation to Delivery, at doses which FAILED to completely correct maternal Vitamin D deficiency, INFLUENCE overall healthcare utilisation in children in the first 3 years.']	[('INCOMPLETE_EVIDENCE', 15), ('INCOMPLETE_EVIDENCE', 21), ('DIFFICULT_TASK', 125), ('SUPERFICIAL_RELATIONSHIP', 185)]	4	[('GO_0007565', 'female pregnancy', 38, 'prenatal'), ('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('GO_0007565', 'female pregnancy', 87, 'gestation'), ('GO_0007567', 'parturition', 100, 'delivery'), ('CHEBI_27300', 'vitamin D', 163, 'vitamin D')]
S26-PMC4689556	PMC4689556	12/2015	S26-PMC4689556	['we HYPOTHESIZED that Prenatal Vitamin D supplementation during Pregnancy would reduce a child’s healthcare utilisation during the first three years of Life through improved health status, by using the e-hr to quantify our outcome total healthcare utilisation.']	[('INCOMPLETE_EVIDENCE', 3)]	1	[('GO_0007565', 'female pregnancy', 21, 'prenatal'), ('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0007565', 'female pregnancy', 63, 'pregnancy'), ('UBERON_0000104', 'life cycle', 151, 'life')]
S39-PMC4689556	PMC4689556	12/2015	S39-PMC4689556	['women were given instructions to swallow the tablets whole and to avoid other multivitamin supplements containing Vitamin D. this trial was CONDUCTED before national guidance on routinely providing advice on Vitamin D intake during Pregnancy was introduced in march 2008 [26].']	[('QUESTION_ANSWERED_BY_THIS_WORK', 140)]	1	[('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 208, 'vitamin D'), ('GO_0007565', 'female pregnancy', 232, 'pregnancy')]
S141-PMC4689556	PMC4689556	12/2015	S141-PMC4689556	['discussion\nwe EVALUATED WHETHER two specific dosing regimens of Prenatal Vitamin D supplementation COULD reduce health care utilisation in the first three years of Life.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 14), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 24), ('INCOMPLETE_EVIDENCE', 99)]	3	[('GO_0007565', 'female pregnancy', 64, 'prenatal'), ('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('UBERON_0000104', 'life cycle', 164, 'life')]
S165-PMC4689556	PMC4689556	12/2015	S165-PMC4689556	['), there REMAINS an IMPORTANT QUESTION WHETHER Prenatal Vitamin D supplementation at doses which reliably achieve sufficiency in the target population, CAN improve healthcare outcomes for young children.']	[('INCOMPLETE_EVIDENCE', 9), ('IMPORTANT_CONSIDERATION', 20), ('EXPLICIT_QUESTION', 30), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 39), ('EXPLICIT_QUESTION', 39), ('INCOMPLETE_EVIDENCE', 152)]	6	[('GO_0007565', 'female pregnancy', 47, 'prenatal'), ('CHEBI_27300', 'vitamin D', 56, 'vitamin D')]
S167-PMC4689556	PMC4689556	12/2015	S167-PMC4689556	['given that SOME observational studies SUGGEST adverse child Respiratory health outcomes are ASSOCIATED with very high maternal Vitamin D level during Pregnancy, empiric data ARE NEEDED before high dose Prenatal Vitamin D supplementation CAN be routinely RECOMMENDED [44].']	[('INCOMPLETE_EVIDENCE', 11), ('INCOMPLETE_EVIDENCE', 38), ('SUPERFICIAL_RELATIONSHIP', 92), ('FUTURE_WORK', 174), ('INCOMPLETE_EVIDENCE', 237), ('FUTURE_WORK', 254)]	6	[('UBERON_0001004', 'respiratory system', 60, 'respiratory'), ('CHEBI_27300', 'vitamin D', 127, 'vitamin D'), ('GO_0007565', 'female pregnancy', 150, 'pregnancy'), ('GO_0007565', 'female pregnancy', 202, 'prenatal'), ('CHEBI_27300', 'vitamin D', 211, 'vitamin D')]
S173-PMC4689556	PMC4689556	12/2015	S173-PMC4689556	['overall the data SUGGEST that a clinically meaningful RELATIONSHIP between this regime of Vitamin D supplementation in Pregnancy in a deficient population, or these levels of Vitamin D in Cord-Blood or at three years of age, and healthcare utilization is UNLIKELY.']	[('INCOMPLETE_EVIDENCE', 17), ('SUPERFICIAL_RELATIONSHIP', 54), ('PROBABLE_UNDERSTANDING', 255)]	3	[('CHEBI_27300', 'vitamin D', 90, 'vitamin D'), ('GO_0007565', 'female pregnancy', 119, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 175, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 188, 'cord'), ('UBERON_0000178', 'blood', 193, 'blood')]
S181-PMC4689556	PMC4689556	12/2015	S181-PMC4689556	['in conclusion we have FOUND NO EVIDENCE that supplementation of a Vitamin D deficient, urban mixed race population with either a single Oral bolus dose of 200,000 iu Cholecalciferol at 27 weeks or 800 iu Ergocalciferol daily from 27 weeks until Delivery had any EFFECT on child healthcare utilization in the first 3 years of Life.']	[('INCOMPLETE_EVIDENCE', 22), ('INCOMPLETE_EVIDENCE', 28), ('SUPERFICIAL_RELATIONSHIP', 262)]	3	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('UBERON_0000165', 'mouth', 136, 'oral'), ('CHEBI_52550', 'theopalauamide', 166, 'cholecalciferol'), ('CHEBI_4910', 'etomidate', 204, 'ergocalciferol'), ('GO_0007567', 'parturition', 245, 'delivery'), ('UBERON_0000104', 'life cycle', 325, 'life')]
S184-PMC4689556	PMC4689556	12/2015	S184-PMC4689556	['a RECENT systematic REVIEW of Prenatal Vitamin D supplementation FOUND HETEROGENEOUS study designs and INCONSISTENT findings [52].']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 20), ('INCOMPLETE_EVIDENCE', 65), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 71), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 103)]	5	[('GO_0007565', 'female pregnancy', 30, 'prenatal'), ('CHEBI_27300', 'vitamin D', 39, 'vitamin D')]
S185-PMC4689556	PMC4689556	12/2015	S185-PMC4689556	['outcomes of a subsequent intervention trial SUGGEST that higher dose Vitamin D, and POSSIBLY combined mother/infant supplementation MAY BE NEEDED for positive health EFFECTS on the child [38].']	[('INCOMPLETE_EVIDENCE', 44), ('INCOMPLETE_EVIDENCE', 84), ('INCOMPLETE_EVIDENCE', 132), ('FUTURE_WORK', 139), ('SUPERFICIAL_RELATIONSHIP', 166)]	5	[('CHEBI_27300', 'vitamin D', 69, 'vitamin D')]
S186-PMC4689556	PMC4689556	12/2015	S186-PMC4689556	['in that context FURTHER DATA are AWAITED from two larger randomised controlled trials, vdarrt [53] and abcvitamind [54], to establish WHETHER higher dose daily Prenatal Vitamin D supplementation will IMPACT on child health outcomes.']	[('FUTURE_WORK', 16), ('FUTURE_WORK', 33), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 134), ('SUPERFICIAL_RELATIONSHIP', 200)]	4	[('GO_0007565', 'female pregnancy', 160, 'prenatal'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin D')]
S74-PMC4690051	PMC4690051	12/2015	S74-PMC4690051	['BASED ON supplemental studies of Vitamin D during Pregnancy, a 10 ng/ml increase in 25(Oh)D has resulted in a PROTECTIVE odds ratio for healthy Pregnancy outcomes [37]; THUS, we ASSESSED such EFFECTS on Cognitive and language scaled scores.']	[('PROBABLE_UNDERSTANDING', 0), ('SUPERFICIAL_RELATIONSHIP', 110), ('PROBABLE_UNDERSTANDING', 169), ('QUESTION_ANSWERED_BY_THIS_WORK', 178), ('SUPERFICIAL_RELATIONSHIP', 192)]	5	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('GO_0007565', 'female pregnancy', 50, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 84, '25(OH)D'), ('GO_0007565', 'female pregnancy', 144, 'pregnancy'), ('GO_0050890', 'cognition', 203, 'cognitive')]
S0-PMC4691762	PMC4691762	12/2015	S0-PMC4691762	['vitality trial: protocol for a randomised controlled trial to establish the ROLE of Postnatal Vitamin D supplementation in infant Immune health\n\nabstract\n\nintroduction\nPostnatal Vitamin D supplementation MAY be ASSOCIATED with a reduction in Ige-mediated Food allergy, Lower Respiratory Tract infections and improved bone health.']	[('SUPERFICIAL_RELATIONSHIP', 76), ('INCOMPLETE_EVIDENCE', 204), ('SUPERFICIAL_RELATIONSHIP', 211)]	3	[('GO_0007567', 'parturition', 84, 'postnatal'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin D'), ('UBERON_0002405', 'immune system', 130, 'immune'), ('GO_0007567', 'parturition', 168, 'Postnatal'), ('CHEBI_27300', 'vitamin D', 178, 'vitamin D'), ('GO_0007630', 'jump response', 242, 'IgE'), ('GO_0071743', 'IgE immunoglobulin complex, circulating', 242, 'IgE'), ('CHEBI_33290', 'food', 255, 'food'), ('GO_0007631', 'feeding behavior', 255, 'food'), ('UBERON_0004905', 'articulation', 269, 'lower respiratory tract')]
S1-PMC4691762	PMC4691762	12/2015	S1-PMC4691762	['countries in the northern hemisphere RECOMMEND universal infant Vitamin D supplementation to optimise early Vitamin D levels, DESPITE the absence of large TRIALS proving SAFETY or efficacy for any disease outcome.']	[('FUTURE_WORK', 37), ('ANOMALY_CURIOUS_FINDING', 126), ('FUTURE_WORK', 155), ('IMPORTANT_CONSIDERATION', 170)]	4	[('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin D')]
S2-PMC4691762	PMC4691762	12/2015	S2-PMC4691762	['with the AIM of determining the clinical and cost-effectiveness of daily Vitamin D supplementation in breastfed infants from age 6–8\u2005weeks to 12\u2005months of age, we have started a double-blind, randomised, placebo-controlled trial of daily 400\u2005iu Vitamin D supplementation during the first year of Life, vitality.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 9)]	1	[('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 245, 'vitamin D'), ('UBERON_0000104', 'life cycle', 296, 'life')]
S17-PMC4691762	PMC4691762	12/2015	S17-PMC4691762	['RECENT EVIDENCE SUGGESTS that low Vitamin D at Birth or during Infancy is ASSOCIATED with an increased RISK of Food allergy6and eczema.7in addition Food allergy and eczema prevalence is higher the further from the equator a Person resides, LENDING SUPPORT to the HYPOTHESES that low Vitamin D (through low ultraviolet (uv) exposure) MAY play a ROLE in aberrant Immune Development in early Life and increase the risk of developing Food allergy and eczema.3food allergy is one of the earliest manifestations of the Immune deviation,8but also STRONGLY COASSOCIATES with eczema in infancy and asthma later in Life.9\nVitamin D supplementation in the first year of Life has also BEEN ASSOCIATED with a reduced risk of lris10and reduced recovery time in infants with acute bronchiolitis.11since early Life wheezy lris are also strongly ASSOCIATED with longer term respiratory outcomes including asthma12understanding the ROLE of Vitamin D in the RISK of early Life Respiratory diseases is also IMPORTANT.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 16), ('SUPERFICIAL_RELATIONSHIP', 74), ('IMPORTANT_CONSIDERATION', 103), ('INCOMPLETE_EVIDENCE', 240), ('INCOMPLETE_EVIDENCE', 248), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 263), ('INCOMPLETE_EVIDENCE', 263), ('INCOMPLETE_EVIDENCE', 333), ('SUPERFICIAL_RELATIONSHIP', 344), ('PROBABLE_UNDERSTANDING', 540), ('SUPERFICIAL_RELATIONSHIP', 549), ('ANOMALY_CURIOUS_FINDING', 673), ('SUPERFICIAL_RELATIONSHIP', 678), ('SUPERFICIAL_RELATIONSHIP', 829), ('SUPERFICIAL_RELATIONSHIP', 914), ('IMPORTANT_CONSIDERATION', 939), ('IMPORTANT_CONSIDERATION', 987)]	18	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('GO_0007567', 'parturition', 47, 'birth'), ('GO_0007631', 'feeding behavior', 63, 'infancy'), ('CHEBI_33290', 'food', 111, 'food'), ('CHEBI_33290', 'food', 148, 'food'), ('NCBITaxon_10088', 'Mus <genus>', 224, 'person'), ('CHEBI_27300', 'vitamin D', 283, 'vitamin D'), ('GO_0001822', 'kidney development', 361, 'immune development'), ('UBERON_0002405', 'immune system', 361, 'immune'), ('UBERON_0000104', 'life cycle', 389, 'life'), ('CHEBI_33290', 'food', 430, 'food'), ('UBERON_0002405', 'immune system', 513, 'immune'), ('UBERON_0000104', 'life cycle', 605, 'life'), ('CHEBI_28384', 'vitamin K', 612, 'Vitamin D'), ('UBERON_0000104', 'life cycle', 659, 'life'), ('UBERON_0000104', 'life cycle', 794, 'life'), ('CHEBI_27300', 'vitamin D', 922, 'vitamin D'), ('UBERON_0000104', 'life cycle', 953, 'life'), ('UBERON_0001004', 'respiratory system', 958, 'respiratory')]
S18-PMC4691762	PMC4691762	12/2015	S18-PMC4691762	['Vitamin D deficiency (currently defined as 25Ohd3<50\u2005nmol/l) has become MORE COMMON in modern communities over time, PRESUMABLY DUE TO INADEQUATE sun exposure resulting from indoor activities and skin cancer CONCERNS.13vitamin d deficiency is common in victoria, australia and also APPEARS TO BE increasing among Pregnant women14and infants.6in addition, the prevalence of infant Vitamin D deficiency was fourfold higher among fully Breastfed infants than fully formula Fed (p<0.001) EVEN at 12\u2005months after solid Food had been introduced.15\nUNLIKE OTHER countries in the northern hemisphere, australia does not RECOMMEND universal Vitamin D supplementation.']	[('PROBABLE_UNDERSTANDING', 72), ('PROBABLE_UNDERSTANDING', 117), ('PROBABLE_UNDERSTANDING', 128), ('IMPORTANT_CONSIDERATION', 135), ('IMPORTANT_CONSIDERATION', 208), ('ANOMALY_CURIOUS_FINDING', 282), ('ANOMALY_CURIOUS_FINDING', 484), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 542), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 549), ('FUTURE_WORK', 612)]	10	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_63058', '(2R,3S)-EHNA', 43, '25OHD3'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 43, '25OHD3'), ('GO_0007565', 'female pregnancy', 313, 'pregnant'), ('CHEBI_27300', 'vitamin D', 380, 'vitamin D'), ('GO_0007567', 'parturition', 433, 'breastfed'), ('GO_0007631', 'feeding behavior', 470, 'fed'), ('CHEBI_33290', 'food', 514, 'food'), ('CHEBI_27300', 'vitamin D', 632, 'vitamin D')]
S20-PMC4691762	PMC4691762	12/2015	S20-PMC4691762	['objectives\nwith the ultimate GOAL of developing improved PUBLIC HEALTH GUIDELINES for Vitamin D supplementation of infants, we AIM TO DETERMINE IF Vitamin D supplementation in infants from 6 to 8\u2005weeks of age LEADS to a reduction in the following during the first year of Life:\nchallenge-proven Food allergy\nlower Respiratory infections\nFood sensitisation\ndoctor diagnosed eczema\nvitamin D deficiency\n\nmethods and analysis\n\ndesign\nvitality is a double-blind, randomised, placebo-controlled trial of Vitamin D supplementation during the first year of Life.']	[('IMPORTANT_CONSIDERATION', 29), ('IMPORTANT_CONSIDERATION', 57), ('IMPORTANT_CONSIDERATION', 71), ('FUTURE_WORK', 127), ('QUESTION_ANSWERED_BY_THIS_WORK', 127), ('QUESTION_ANSWERED_BY_THIS_WORK', 131), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 144), ('SUPERFICIAL_RELATIONSHIP', 209)]	8	[('CHEBI_27300', 'vitamin D', 86, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 147, 'vitamin D'), ('UBERON_0000104', 'life cycle', 272, 'life'), ('CHEBI_33290', 'food', 295, 'food'), ('UBERON_0001004', 'respiratory system', 314, 'respiratory'), ('CHEBI_33290', 'food', 337, 'Food'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 388, 'D'), ('CHEBI_27300', 'vitamin D', 499, 'vitamin D'), ('UBERON_0000104', 'life cycle', 550, 'life')]
S25-PMC4691762	PMC4691762	12/2015	S25-PMC4691762	['the study is restricted to Breast Fed infants because formula Feeding from Birth can be equivalent to Vitamin D supplementation as formula contains APPROXIMATELY 400\u2005iu of Vitamin D/l.']	[('INCOMPLETE_EVIDENCE', 148)]	1	[('GO_0007567', 'parturition', 27, 'breast'), ('GO_0007631', 'feeding behavior', 34, 'fed'), ('GO_0007631', 'feeding behavior', 62, 'feeding'), ('GO_0007567', 'parturition', 75, 'birth'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 172, 'vitamin D')]
S29-PMC4691762	PMC4691762	12/2015	S29-PMC4691762	['infants of mothers who intend to continue predominantly breastfeeding until 6\u2005months will be recruited since Formula Feeding is a SURROGATE form of partial Vitamin D supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 130)]	1	[('GO_0009057', 'macromolecule catabolic process', 109, 'formula'), ('GO_0007631', 'feeding behavior', 117, 'feeding'), ('CHEBI_27300', 'vitamin D', 156, 'vitamin D')]
S31-PMC4691762	PMC4691762	12/2015	S31-PMC4691762	['mothers who receive Antenatal Vitamin D supplementation will not be excluded BECAUSE in our setting, this has not been shown to be PROTECTIVE against Postnatal infant Vitamin D deficiency.15\n\nrandomisation\nrandomisation will be undertaken using a web-based randomisation system set up within the trial database (redcap).']	[('PROBLEM_COMPLICATION', 77), ('SUPERFICIAL_RELATIONSHIP', 131)]	2	[('GO_0007567', 'parturition', 20, 'antenatal'), ('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0007567', 'parturition', 150, 'postnatal'), ('CHEBI_27300', 'vitamin D', 167, 'vitamin D')]
S69-PMC4691762	PMC4691762	12/2015	S69-PMC4691762	"[""participant's Vitamin D status will be defined by their Blood 25Ohd3 level, AS: severely deficient <12.5\u2005nmol/l; moderately deficient 12.5–25\u2005nmol/l; mild deficiency 26–49\u2005nmol/l; sufficient ≥50\u2005nmol/l; and elevated >220\u2005nmol/l.23\nparent baseline questionnaire : to check that potential environmental and OTHER CONFOUNDING factors are balanced between the two randomisation groups, baseline parent questionnaires will collect data on: parental smoking, medication use, parental ancestry, ethnicity, education, employment, occupation, family history of allergy, use of supplements including Vitamin A, d and cod Liver oil, number of siblings; and pet ownership.""]"	[('PROBABLE_UNDERSTANDING', 76), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 305), ('PROBLEM_COMPLICATION', 311)]	3	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('UBERON_0000178', 'blood', 56, 'blood'), ('CHEBI_63058', '(2R,3S)-EHNA', 62, '25OHD3'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 62, '25OHD3'), ('CHEBI_27300', 'vitamin D', 590, 'vitamin A'), ('UBERON_0002107', 'liver', 611, 'liver')]
S70-PMC4691762	PMC4691762	12/2015	S70-PMC4691762	['parent questionnaire (3 monthly) : to capture dietary Vitamin D intake and environmental uv radiation (uvr) exposure, we will ask questions about maternal Vitamin D supplements, infant diet, maternal and infant sun exposure and sun Protective behaviours as in our PREVIOUS work,15for example, number of hours spent in the sun per day, during summer or winter, weekends and holidays, will be collected for mother and child.']	[('INCOMPLETE_EVIDENCE', 264)]	1	[('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 155, 'vitamin D'), ('GO_0019230', 'proprioception', 232, 'protective')]
S79-PMC4691762	PMC4691762	12/2015	S79-PMC4691762	['it will MODEL the POTENTIAL cost-effectiveness of routine infant Vitamin D supplementation compared to no supplementation, ASSUMING australia-wide implementation.']	[('INCOMPLETE_EVIDENCE', 8), ('INCOMPLETE_EVIDENCE', 18), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 123)]	3	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 73, 'D')]
S94-PMC4691762	PMC4691762	12/2015	S94-PMC4691762	['a 30% reduction in the prevalence of Food allergy ATTRIBUTED to Vitamin D supplementation represents a clinically IMPORTANT reduction on a population level.']	[('SUPERFICIAL_RELATIONSHIP', 50), ('IMPORTANT_CONSIDERATION', 114)]	2	[('CHEBI_33290', 'food', 37, 'food'), ('CHEBI_27300', 'vitamin D', 64, 'vitamin D')]
S106-PMC4691762	PMC4691762	12/2015	S106-PMC4691762	['we will not be monitoring Serum 25(Oh)D for safety reasons nor considering the association between 25(Oh)D and outcome frequency given that 400\u2005Iu HAS BEEN SHOWN to be SAFE in term babies,1926preterm infants27and is the current RECOMMENDED dose in the usa, canada, the uk and europe.18\n\ndiscussion\nthe results of the vitality trial will determine WHETHER Vitamin D supplementation has a ROLE in optimising infant Immune health in the first year of Life, reducing the risk of allergic disease and Respiratory diseases.']	[('INCOMPLETE_EVIDENCE', 147), ('IMPORTANT_CONSIDERATION', 168), ('FUTURE_WORK', 228), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 347), ('SUPERFICIAL_RELATIONSHIP', 387)]	5	[('UBERON_0001977', 'blood serum', 26, 'serum'), ('CHEBI_71657', 'versiconol acetate', 32, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 32, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 99, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 99, '25(OH)D'), ('CHEBI_17883', 'hydrogen chloride', 144, 'IU'), ('CHEBI_27300', 'vitamin D', 355, 'vitamin D'), ('UBERON_0002405', 'immune system', 413, 'immune'), ('UBERON_0000104', 'life cycle', 448, 'life'), ('UBERON_0001004', 'respiratory system', 496, 'respiratory')]
S107-PMC4691762	PMC4691762	12/2015	S107-PMC4691762	['furthermore FINDINGS will provide EVIDENCE to inform GUIDELINES for Vitamin D supplementation of infants.']	[('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 34), ('PROBABLE_UNDERSTANDING', 53)]	3	[('CHEBI_27300', 'vitamin D', 68, 'vitamin D')]
S108-PMC4691762	PMC4691762	12/2015	S108-PMC4691762	['this will be the FIRST population-based trial of Postnatal infant Vitamin D supplementation sufficiently powered to address the IMPACT on any disease outcome including allergic disease, lris and bone health.']	[('INCOMPLETE_EVIDENCE', 17), ('SUPERFICIAL_RELATIONSHIP', 128)]	2	[('GO_0007567', 'parturition', 49, 'postnatal'), ('CHEBI_27300', 'vitamin D', 66, 'vitamin D')]
S111-PMC4691762	PMC4691762	12/2015	S111-PMC4691762	['furthermore we are uniquely placed internationally TO ASSESS the ROLE of Vitamin D in Early Life development since australia does not currently RECOMMEND universal infant Vitamin D supplementation and is one of the few countries where there is no routine fortification of the Food chain supply.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 51), ('SUPERFICIAL_RELATIONSHIP', 65), ('FUTURE_WORK', 144)]	3	[('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('UBERON_0001847', 'lobule of pinna', 86, 'early life'), ('CHEBI_27300', 'vitamin D', 171, 'vitamin D'), ('CHEBI_33290', 'food', 276, 'food')]
S113-PMC4691762	PMC4691762	12/2015	S113-PMC4691762	['restricting the trial to infants with Vitamin D deficiency would REQUIRE a smaller trial, HOWEVER it would be UNETHICAL to randomise these infants to placebo thereby not treating with Vitamin D. the use of Vitamin D supplements in the placebo group is ANOTHER POTENTIAL ISSUE HOWEVER we are collecting sufficient data regarding Feeding practices, Supplement use and sun exposure to account for this.']	[('FUTURE_WORK', 65), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 90), ('DIFFICULT_TASK', 110), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 252), ('INCOMPLETE_EVIDENCE', 260), ('PROBLEM_COMPLICATION', 270), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 276)]	7	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 184, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 206, 'vitamin D'), ('GO_0007631', 'feeding behavior', 328, 'feeding'), ('CHEBI_16158', 'steroid sulfate', 347, 'supplement')]
S118-PMC4691762	PMC4691762	12/2015	S118-PMC4691762	['it acts by inducing Antimicrobial peptides in Epithelial Cells, Neutrophils and Macrophages28And increases transcription of the innate Immune protein (hcap-18) which is capable of killing a wide variety of Viral and bacterial pathogens.29THESE FINDINGS are SUPPORTED by the observation that Vitamin D receptor polymorphisms (which decrease the bioavailability of Vitamin D to the cell) are ASSOCIATED with more SEVERE bronchiolitis30and that defective Control Of Vitamin D receptor-Mediated Cell Signalling PREDISPOSES to SEVERE Respiratory syncytial Virus bronchiolitis.31\n\nconclusions\ninternational enthusiasm for supplemental Vitamin D has OUTPACED AVAILABLE EVIDENCE on its EFFECTIVENESS32AND in fact ARGUMENT for routine supplementation is in equipoise.']	[('INCOMPLETE_EVIDENCE', 236), ('INCOMPLETE_EVIDENCE', 257), ('SUPERFICIAL_RELATIONSHIP', 390), ('IMPORTANT_CONSIDERATION', 411), ('SUPERFICIAL_RELATIONSHIP', 507), ('IMPORTANT_CONSIDERATION', 522), ('ANOMALY_CURIOUS_FINDING', 643), ('ANOMALY_CURIOUS_FINDING', 643), ('INCOMPLETE_EVIDENCE', 652), ('SUPERFICIAL_RELATIONSHIP', 678), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 705)]	11	[('CHEBI_65381', 'albizoside C', 20, 'antimicrobial'), ('CL_0000066', 'epithelial cell', 46, 'epithelial cells'), ('UBERON_0000483', 'epithelium', 46, 'epithelial'), ('CL_0000775', 'neutrophil', 64, 'neutrophils'), ('CL_0000091', 'Kupffer cell', 80, 'macrophages28and'), ('UBERON_0002405', 'immune system', 135, 'immune'), ('NCBITaxon_1', 'root', 206, 'viral'), ('CHEBI_27300', 'vitamin D', 291, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 363, 'vitamin D'), ('GO_0060070', 'canonical Wnt signaling pathway', 452, 'control of ... -mediated cell signalling'), ('CHEBI_27300', 'vitamin D', 463, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 529, 'respiratory'), ('NCBITaxon_1', 'root', 551, 'virus'), ('CHEBI_27300', 'vitamin D', 629, 'vitamin D')]
S119-PMC4691762	PMC4691762	12/2015	S119-PMC4691762	['if FOUND to be both efficacious and cost-effective, Vitamin D infant supplementation would provide a readily available, low harm INTERVENTION that would optimise infant Immune health in the first year of Life and significantly reduce the population BURDEN of allergic disease.']	[('ANOMALY_CURIOUS_FINDING', 3), ('INCOMPLETE_EVIDENCE', 3), ('SUPERFICIAL_RELATIONSHIP', 129), ('IMPORTANT_CONSIDERATION', 249)]	4	[('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('UBERON_0002405', 'immune system', 169, 'immune'), ('UBERON_0000104', 'life cycle', 204, 'life')]
S120-PMC4691762	PMC4691762	12/2015	S120-PMC4691762	['the vitality trial will also enable a FUTURE evaluation of WHETHER Postnatal Vitamin D supplementation is ASSOCIATED with IMPROVED bone health in later childhood—the historical basis of widespread Postnatal Vitamin D supplementation, which REMAINS essentially UNTESTED.']	[('FUTURE_WORK', 38), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 59), ('SUPERFICIAL_RELATIONSHIP', 106), ('IMPORTANT_CONSIDERATION', 122), ('INCOMPLETE_EVIDENCE', 240), ('INCOMPLETE_EVIDENCE', 260)]	6	[('GO_0007567', 'parturition', 67, 'postnatal'), ('CHEBI_27300', 'vitamin D', 77, 'vitamin D'), ('GO_0007567', 'parturition', 197, 'postnatal'), ('CHEBI_27300', 'vitamin D', 207, 'vitamin D')]
S96-PMC4714725	PMC4714725	1/2016	S96-PMC4714725	['ab, a Micronutrients and Herbal supplements\nthere is NO CLEAR EVIDENCE that dietary supplementation with Vitamins, Minerals, herbs, or spices CAN improve diabetes, and there MAY BE safety CONCERNS regarding the long-term use of antioxidant supplements such as Vitamins E and C and Carotene.c Alcohol\nadults with diabetes who drink alcohol SHOULD do so in moderation (no more than one drink per day for Adult women and no more than two drinks per day for Adult men).c\nAlcohol Consumption MAY place People with diabetes at INCREASED risk for delayed hypoglycemia, ESPECIALLY IF taking Insulin or Insulin secretagogues.']	[('FULL_UNKNOWN', 53), ('PROBABLE_UNDERSTANDING', 56), ('INCOMPLETE_EVIDENCE', 142), ('INCOMPLETE_EVIDENCE', 174), ('PROBLEM_COMPLICATION', 188), ('FUTURE_WORK', 339), ('INCOMPLETE_EVIDENCE', 487), ('IMPORTANT_CONSIDERATION', 521), ('ANOMALY_CURIOUS_FINDING', 562), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 573)]	10	[('CHEBI_34850', 'milrinone lactate', 6, 'Micronutrients'), ('NCBITaxon_7955', 'Danio rerio', 25, 'herbal'), ('CHEBI_33277', 'gamma-tocotrienol', 105, 'vitamins'), ('CHEBI_46751', 'quinolizidine', 115, 'minerals'), ('CHEBI_27300', 'vitamin D', 260, 'vitamins E'), ('CHEBI_18245', 'carboxylato group', 275, 'C'), ('PR_000004900', 'complement C3', 275, 'C'), ('CHEBI_23042', 'carotene', 281, 'carotene'), ('CHEBI_30879', 'alcohol', 292, 'Alcohol'), ('UBERON_0007023', 'adult organism', 402, 'adult'), ('UBERON_0007023', 'adult organism', 454, 'adult'), ('CHEBI_30879', 'alcohol', 467, 'Alcohol'), ('GO_0007631', 'feeding behavior', 475, 'consumption'), ('NCBITaxon_10088', 'Mus <genus>', 497, 'people'), ('PR_000045358', 'insulin family protein', 583, 'insulin'), ('PR_000045358', 'insulin family protein', 594, 'insulin')]
S0-PMC4719746	PMC4719746	1/2016	S0-PMC4719746	['Vitamin D deficiency and supplementation in Pregnancy in a multiethnic population-based cohort\n\nabstract\n\nbackground\nTO INVESTIGATE ethnic DIFFERENCES in Vitamin D levels during Pregnancy, assess RISK factors for Vitamin D deficiency and explore the EFFECT of Vitamin D supplementation in women with deficiency in early Pregnancy.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 117), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 139), ('SUPERFICIAL_RELATIONSHIP', 196), ('SUPERFICIAL_RELATIONSHIP', 250)]	4	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 44, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 154, 'vitamin D'), ('GO_0007565', 'female pregnancy', 178, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 213, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 260, 'vitamin D'), ('GO_0007565', 'female pregnancy', 320, 'pregnancy')]
S7-PMC4719746	PMC4719746	1/2016	S7-PMC4719746	['ethnicity, education, season and intake of Vitamin D were independently ASSOCIATED with 25(Oh)D. at gw 28, the mean 25(Oh)d had increased from 23 (sd:7.8) to 47 (27) nmol/l ( p \u2009<\u20090.01) in women who were RECOMMENDED Vitamin D supplementation, with small or no change in women with sufficient Vitamin D levels at baseline.']	[('SUPERFICIAL_RELATIONSHIP', 72), ('FUTURE_WORK', 204)]	2	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 88, '25(OH)D'), ('CHEBI_51686', 'haematoxylin', 118, '(OH'), ('CHEBI_27300', 'vitamin D', 216, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 292, 'vitamin D')]
S9-PMC4719746	PMC4719746	1/2016	S9-PMC4719746	['the Serum levels of 25(Oh)D increased significantly from gw 15 to 28 in Vitamin D deficient women who received a RECOMMENDATION for supplementation.']	[('FUTURE_WORK', 113)]	1	[('UBERON_0001977', 'blood serum', 4, 'serum'), ('CHEBI_71657', 'versiconol acetate', 20, '25(OH)D'), ('PR_000010220', 'mannose-binding protein C', 22, '('), ('PR_000006444', 'diacylglycerol kinase delta', 26, 'D'), ('CHEBI_27300', 'vitamin D', 72, 'vitamin D')]
S10-PMC4719746	PMC4719746	1/2016	S10-PMC4719746	['this RECOMMENDATION of Vitamin D supplementation increased Vitamin D levels in deficient women.']	[('FUTURE_WORK', 5)]	1	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 59, 'vitamin D')]
S15-PMC4719746	PMC4719746	1/2016	S15-PMC4719746	['there are FEW population-based STUDIES exploring Vitamin D deficiency in Pregnancy in today’s multiethnic europe, and LITTLE IS KNOWN about the IMPACT of socioeconomic status or the EFFECT of Vitamin D supplements [9,10].']	[('INCOMPLETE_EVIDENCE', 10), ('FULL_UNKNOWN', 118), ('SUPERFICIAL_RELATIONSHIP', 144), ('SUPERFICIAL_RELATIONSHIP', 182)]	4	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('GO_0007565', 'female pregnancy', 73, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 192, 'vitamin D')]
S18-PMC4719746	PMC4719746	1/2016	S18-PMC4719746	['HOWEVER, the current state of evidence SUGGESTS unclear benefits of routine Vitamin D supplementation for most maternal or child health outcomes [17].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 39)]	2	[('CHEBI_27300', 'vitamin D', 76, 'vitamin D')]
S20-PMC4719746	PMC4719746	1/2016	S20-PMC4719746	['DESPITE the CONTROVERSIES RELATED to adverse outcomes, and LACK OF EVIDENCE of clear benefits of routine supplementation, most western countries RECOMMEND Vitamin D supplementation during Pregnancy.']	[('ANOMALY_CURIOUS_FINDING', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 12), ('SUPERFICIAL_RELATIONSHIP', 26), ('INCOMPLETE_EVIDENCE', 59), ('FUTURE_WORK', 145)]	5	[('CHEBI_27300', 'vitamin D', 155, 'vitamin D'), ('GO_0007565', 'female pregnancy', 188, 'pregnancy')]
S21-PMC4719746	PMC4719746	1/2016	S21-PMC4719746	['the AIMS of THIS PAPER were TO INVESTIGATE ethnic DIFFERENCES in Vitamin D levels during Pregnancy, ASSESS RISK FACTORS for Vitamin D deficiency and explore the EFFECT of Vitamin D supplementation in women identified with low values during early Pregnancy.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 12), ('QUESTION_ANSWERED_BY_THIS_WORK', 28), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 50), ('QUESTION_ANSWERED_BY_THIS_WORK', 100), ('SUPERFICIAL_RELATIONSHIP', 107), ('SUPERFICIAL_RELATIONSHIP', 161)]	7	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('GO_0007565', 'female pregnancy', 89, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 171, 'vitamin'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 179, 'D'), ('GO_0007565', 'female pregnancy', 246, 'pregnancy')]
S47-PMC4719746	PMC4719746	1/2016	S47-PMC4719746	['all participants were asked about their Intake of Vitamin D supplements including Prenatal Vitamins during the past two weeks at both visits, and self-reported intake was categorized AS “ Vitamin D ≥10\xa0μg/day” and “no or Vitamin D <10\xa0μg/day”.']	[('PROBABLE_UNDERSTANDING', 183)]	1	[('GO_0007631', 'feeding behavior', 40, 'intake'), ('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('GO_0007565', 'female pregnancy', 82, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 91, 'vitamins'), ('CHEBI_27300', 'vitamin D', 188, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 221, 'vitamin D')]
S50-PMC4719746	PMC4719746	1/2016	S50-PMC4719746	['the RECOMMENDATION of Vitamin D supplementation\npre-planned, and ACCORDING TO the protocol, women with 25(Oh)D less than the laboratory’s lower reference range (<37\xa0nmol/l) at Gestational week 15 were provided with written information describing their 25(Oh)D D concentration, and they were RECOMMENDED to consult their general practitioner (gp) for treatment.']	[('FUTURE_WORK', 4), ('INCOMPLETE_EVIDENCE', 65), ('FUTURE_WORK', 291)]	3	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 103, '25(OH)D'), ('GO_0007565', 'female pregnancy', 176, 'gestational'), ('CHEBI_29156', 'Gly-tRNA(Gly)', 252, '25(OH)D D'), ('PR_000007367', 'fibrosin-1-like protein', 252, '25(OH)D D')]
S54-PMC4719746	PMC4719746	1/2016	S54-PMC4719746	['we have NO INFORMATION on the exact dose of Vitamin D supplements taken if SELF-REPORTED intake was >10\xa0μg/day.']	[('FULL_UNKNOWN', 8), ('INCOMPLETE_EVIDENCE', 75)]	2	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D')]
S63-PMC4719746	PMC4719746	1/2016	S63-PMC4719746	['explanatory linear regression models were performed TO ASSESS the relationship between ethnicity and the concentration of 25(Oh)D, both at inclusion and in Gestational week 28, accounting for the following POTENTIAL CONFOUNDING FACTORS: Gestational week, age, parity, season, education, Vitamin D supplements and pre-Pregnancy bmi.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 52), ('INCOMPLETE_EVIDENCE', 206), ('PROBLEM_COMPLICATION', 216)]	3	[('CHEBI_71657', 'versiconol acetate', 122, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 128, 'D'), ('GO_0007565', 'female pregnancy', 156, 'gestational'), ('GO_0007565', 'female pregnancy', 237, 'gestational'), ('CHEBI_27300', 'vitamin D', 287, 'vitamin D'), ('GO_0007565', 'female pregnancy', 317, 'pregnancy')]
S75-PMC4719746	PMC4719746	1/2016	S75-PMC4719746	['about two thirds of western european and east asian women reported using Vitamin D supplements regularly at inclusion COMPARED TO 50\xa0% of OTHER ethnic groups.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 118), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 138)]	2	[('CHEBI_27300', 'vitamin D', 73, 'vitamin D')]
S78-PMC4719746	PMC4719746	1/2016	S78-PMC4719746	['aincluding 3 women from usa and canada\nbincomplete data on the variables BECAUSE of MISSING values for 6–12 women\nat Gestational week 28, the proportion of south asian and middle eastern women who had used Vitamin D supplements ≥10\xa0μg/day over the past two weeks was higher than at Gestational week 15 ( p \u2009<\u20090.01 and p \u2009<\u20090.05, respectively).']	[('PROBLEM_COMPLICATION', 73), ('PROBLEM_COMPLICATION', 84)]	2	[('GO_0007565', 'female pregnancy', 117, 'gestational'), ('CHEBI_27300', 'vitamin D', 206, 'vitamin D'), ('GO_0007565', 'female pregnancy', 282, 'gestational')]
S87-PMC4719746	PMC4719746	1/2016	S87-PMC4719746	['crude mean (sd) Vitamin D [25(Oh)D in nmol/l] levels according to POTENTIAL explanatory factorsat inclusionat Gestational week 28 n \u2009=\u2009748 n \u2009=\u2009748mean(sd)mean(sd)overall mean 25(Oh)d50(27)59(29)age at inclusion\u2009\u2009\u2009≤30\xa0years47(25)55(27)\u2009\u2009\u2009>30\xa0years54(28)62(30)parity (para 0 ref)53(26)61(29)\u2009\u2009\u2009para 152(28)59(27)\u2009\u2009\u2009para ≥242(25)52(30)western europe (ref)69(24)72(28)\u2009\u2009\u2009south asia32(19)46(23)\u2009\u2009\u2009middle east34(20)51(29)\u2009\u2009\u2009sub-saharan africa38(18)45(25)\u2009\u2009\u2009east asia51(17)53(19)\u2009\u2009\u2009other56(21)63(26)season of Blood sample\u2009\u2009\u2009summer56(29)60(29)\u2009\u2009\u2009winter46(24)57(27)education level (>12\xa0years ref)60(27)67(27)\u2009\u2009\u200910-12 years46(25)56(29)\u2009\u2009\u2009<10\xa0years37(20)44(23)Vitamin D supplements\u2009\u2009\u2009≥10\xa0μga57(26)61(28)\u2009\u2009\u2009no or <10\xa0μg42(26)53(29)pre-Pregnancy bmi; kg/m2(normal weight (<25) ref)51(27)59(29)\u2009\u2009\u2009overweight (≥25/<30)51(27)61(31)\u2009\u2009\u2009obesity (≥30)48(24)54(24)\naintake of ≥10\xa0μg Vitamin D daily past two weeks\n\ncaption (fig): fig.']	[('INCOMPLETE_EVIDENCE', 66)]	1	[('CHEBI_28384', 'vitamin K', 16, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 16, 'Vitamin D'), ('CHEBI_71657', 'versiconol acetate', 27, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 27, '25 ... OH ... D'), ('GO_0007565', 'female pregnancy', 110, 'gestational'), ('CHEBI_30778', 'gallic acid', 176, '25(OH)'), ('UBERON_0000178', 'blood', 503, 'blood'), ('CHEBI_28384', 'vitamin K', 650, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 724, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 863, 'vitamin D')]
S90-PMC4719746	PMC4719746	1/2016	S90-PMC4719746	['in addition, education, Intake of Vitamin D supplements and season were INDEPENDENTLY ASSOCIATED with 25(Oh)D concentrations at inclusion.']	[('SUPERFICIAL_RELATIONSHIP', 72), ('SUPERFICIAL_RELATIONSHIP', 86)]	2	[('GO_0007631', 'feeding behavior', 24, 'intake'), ('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 102, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 102, '25(OH ... D')]
S95-PMC4719746	PMC4719746	1/2016	S95-PMC4719746	"['=\u20090.24independent variabler2adj.b95\xa0% cib95\xa0% cir2adj.b95\xa0% cib95\xa0% cilowerupperlowerupperlowerupperloweruppergestational week at inclusion (<15 ref)−0.0010.01ᅟ≥15−0.56−4.43.3 −6.4−10−2.3**−4.6−8.3−0.92* age at inclusion0.03 0.940.551.3** 0.14−0.210.490.03 1.10.641.5**0.700.261.1** parity (para 0 ref)0.020.01ᅟpara1−1.2−5.43.10.24−3.13.6−2.8−7.41.8 −4.4−8.7−0.22* ᅟpara ≥2 −11−17−6.3** −3.2−7.61.3 −9.3−15−3.8** −5.4−110.25geographic region (western europe ref)0.380.16ᅟsouth asia −37−40−33**−28−33−23**−26−31−21**−17−23−11** ᅟmiddle east −34−39−30**−24−29−18**−21−26−15**−9.5−16−2.9** ᅟsub-saharan africa −31−37−25**−20−27−13**−26−34−19**−12−20−3.1** ᅟeast asia −17−24−10**−11−18−3.9**−19−28−11**−11−20−1.6* ᅟother −13−19−6.4**−7.6−14−0.90*−9.0−17−1.3* −1.4−9.66.9season (summer ref)0.030.01ᅟwinter −9.9−14−6.1**−5.2−8.9−1.4**−5.7−9.8−1.6** −1.3−6.13.4geographic region*seasona−11−16−4.8**−15−22−7.4** education level (>12 y ref)0.110.08ᅟ10-12 year −14−18−10**−3.7−7.1−0.30*−11−15−6.8** −1.8−6.12.5ᅟ<10\xa0year −23−28−17**−5.2−10−0.31*−23−29−17**−8.6−15−2.5** Vitamin D supplements (≥10μgbref)0.080.02ᅟno or <10\xa0μg −15−19−11**−11−14−7.7**−8.2−13−3.8**−9.8−14−5.8** pre-Pregnancy bmi (<25\xa0kg/m2ref)−0.001−0.001ᅟ≥25\xa0kg/m2−0.76−4.73.2−0.11−4.44.2\nathe EFFECT of season on 25(Oh)d differed by ethnicity: the interaction term is ""1"" for records with both non-western and winter and ""0"" for western and summer (ref)\nbintake of ≥10\xa0μg Vitamin D daily past two weeks\nbold numbers indicate p \u2009<\u20090.05 (* p \u2009<\u20090.05, ** p \u2009<\u20090.01)\n\nVitamin D status at Gestational week 28\nat the beginning of the third trimester, the prevalence of 25(Oh)D <50\xa0nmol/l among the largest ethnic minority groups was lower than at study inclusion: south asia: 62\xa0%, the middle east: 58\xa0% and sub-saharan africa: 63\xa0%.']"	[('SUPERFICIAL_RELATIONSHIP', 1248)]	1	[('CHEBI_28384', 'vitamin K', 1059, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 1168, 'pregnancy'), ('CHEBI_30778', 'gallic acid', 1268, '25(OH)'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1268, '25(OH'), ('CHEBI_27300', 'vitamin D', 1427, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 1435, 'D'), ('CHEBI_28384', 'vitamin K', 1519, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 1539, 'gestational'), ('CHEBI_71657', 'versiconol acetate', 1618, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 1618, '25 ... OH ... D')]
S99-PMC4719746	PMC4719746	1/2016	S99-PMC4719746	['in addition, age, parity, education, intake of Vitamin D supplementation and Gestational week at inclusion were independently ASSOCIATED with 25(Oh)D concentrations.']	[('SUPERFICIAL_RELATIONSHIP', 126)]	1	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('GO_0007565', 'female pregnancy', 77, 'gestational'), ('CHEBI_71657', 'versiconol acetate', 142, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 148, 'D')]
S104-PMC4719746	PMC4719746	1/2016	S104-PMC4719746	['ONLY 37\xa0% of these women reported an intake of ≥10\xa0μg/day of Vitamin D supplements, BUT at Gestational week 28, this proportion had increased to 73\xa0% ( p \u2009<\u20090.01).']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 0), ('ANOMALY_CURIOUS_FINDING', 84)]	3	[('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('GO_0007565', 'female pregnancy', 91, 'gestational')]
S129-PMC4719746	PMC4719746	1/2016	S129-PMC4719746	['HOWEVER, 73\xa0% reported use of ≥10\xa0μg/day of Vitamin D supplements at the post-test, and only 3.5\xa0% STILL had severe deficiency, COMPARED TO 20\xa0% at inclusion.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 99), ('ANOMALY_CURIOUS_FINDING', 128)]	4	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D')]
S134-PMC4719746	PMC4719746	1/2016	S134-PMC4719746	['most studies that we IDENTIFIED were cross-sectional, and FEW adjusted for Intake of Vitamin D supplements, education, parity and seasonal variance [5,29].']	[('INCOMPLETE_EVIDENCE', 21), ('INCOMPLETE_EVIDENCE', 58)]	2	[('GO_0007631', 'feeding behavior', 75, 'intake'), ('CHEBI_27300', 'vitamin D', 85, 'vitamin D')]
S139-PMC4719746	PMC4719746	1/2016	S139-PMC4719746	['our data also INDICATED that low SELF-REPORTED Intake of Vitamin D supplements was an INDEPENDENT RISK FACTOR for Vitamin D deficiency, also FOUND in an irish study [3].']	[('INCOMPLETE_EVIDENCE', 14), ('INCOMPLETE_EVIDENCE', 33), ('SUPERFICIAL_RELATIONSHIP', 86), ('SUPERFICIAL_RELATIONSHIP', 98), ('INCOMPLETE_EVIDENCE', 141)]	5	[('GO_0007631', 'feeding behavior', 47, 'intake'), ('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D')]
S141-PMC4719746	PMC4719746	1/2016	S141-PMC4719746	['the DEBATE about the OPTIMAL dose of Vitamin D supplementation during Pregnancy is ONGOING.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 4), ('IMPORTANT_CONSIDERATION', 21), ('IMPORTANT_CONSIDERATION', 83)]	3	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('GO_0007565', 'female pregnancy', 70, 'pregnancy')]
S142-PMC4719746	PMC4719746	1/2016	S142-PMC4719746	['GUIDELINES from scandinavia and uk RECOMMEND all Pregnant women supplement intake with 10\xa0μg (400\xa0iu) Vitamin D daily to prevent Vitamin D deficiency [21,34,35].']	[('PROBABLE_UNDERSTANDING', 0), ('FUTURE_WORK', 35)]	2	[('GO_0007565', 'female pregnancy', 49, 'pregnant'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 129, 'vitamin D')]
S147-PMC4719746	PMC4719746	1/2016	S147-PMC4719746	['SEVERAL STUDIES among Pregnant women have SHOWED a marked increase in 25(Oh)D with daily supplements of Vitamin D [11,24,43,44].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 42)]	2	[('GO_0007565', 'female pregnancy', 22, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 70, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 104, 'vitamin D')]
S150-PMC4719746	PMC4719746	1/2016	S150-PMC4719746	['in women who were RECOMMENDED daily Vitamin D supplements of 20\xa0μg or 30\xa0μg due to low values in early Pregnancy, we OBSERVED an increase in self-reported use of supplements at the follow-up visit.']	[('FUTURE_WORK', 18), ('INCOMPLETE_EVIDENCE', 117)]	2	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('GO_0007565', 'female pregnancy', 103, 'pregnancy')]
S157-PMC4719746	PMC4719746	1/2016	S157-PMC4719746	['supplementation with a higher dose of Vitamin D than 20\xa0μg or 30\xa0μg would LIKELY be sufficient to achieve acceptable 25(Oh)D concentration in Pregnancy.']	[('PROBABLE_UNDERSTANDING', 74)]	1	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 117, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 117, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 142, 'pregnancy')]
S159-PMC4719746	PMC4719746	1/2016	S159-PMC4719746	['ethnic minority background, low intake of Supplements, low education and winter season were INDEPENDENT RISK FACTORS for Vitamin D deficiency.']	[('SUPERFICIAL_RELATIONSHIP', 92), ('SUPERFICIAL_RELATIONSHIP', 104)]	2	[('CHEBI_33341', 'titanium atom', 42, 'supplements'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin D')]
S160-PMC4719746	PMC4719746	1/2016	S160-PMC4719746	['after identifying participants with low 25(Oh)D values at study inclusion, and RECOMMENDING treatment with daily moderate doses of Vitamin D, the daily intake of Supplements significantly increased and the prevalence of severe Vitamin D deficiency was substantially reduced.']	[('FUTURE_WORK', 79)]	1	[('CHEBI_71657', 'versiconol acetate', 40, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 162, 'supplements'), ('CHEBI_27300', 'vitamin D', 227, 'vitamin D')]
S137-PMC4728620	PMC4728620	1/2016	S137-PMC4728620	['furthermore, a trial that provided a teaspoonful of cod Liver oil (free of Vitamin A and D) from 9 to 12 month of age FOUND an increase in voluntary attention in a free play test after the intervention, ESPECIALLY in boys, compared with un-supplemented children [73].']	[('INCOMPLETE_EVIDENCE', 118), ('ANOMALY_CURIOUS_FINDING', 203)]	2	[('UBERON_0002107', 'liver', 56, 'liver'), ('CHEBI_27300', 'vitamin D', 75, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 83, 'A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 89, 'D')]
S23-PMC4729160	PMC4729160	1/2016	S23-PMC4729160	['they FOUND Antenatal Vitamin A supplementation decreased anemia [4,5], Preterm Delivery [5,6], Intrauterine growth retardation [6], low Birth weight [4], deformity [7], preeclampsia/eclampsia [8,9], poor infant growth [4], neonatal and infant mortality [4,10], and maternal mortality [10,11].']	[('INCOMPLETE_EVIDENCE', 5)]	1	[('GO_0007567', 'parturition', 11, 'antenatal'), ('CHEBI_27300', 'vitamin D', 21, 'vitamin A'), ('GO_0007565', 'female pregnancy', 71, 'preterm'), ('GO_0007567', 'parturition', 79, 'delivery'), ('UBERON_0022293', 'reproductive gland secretion', 95, 'intrauterine'), ('GO_0007567', 'parturition', 136, 'birth')]
S100-PMC4729160	PMC4729160	1/2016	S100-PMC4729160	['the PRESENT STUDY SHOWED that Retinol concentrations of anemia and Pregnant women with Vitamin A supplements were higher than no anemia and Pregnant women without Vitamin A supplements.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('INCOMPLETE_EVIDENCE', 18)]	2	[('CHEBI_26536', 'retinoic acid', 30, 'retinol'), ('GO_0007565', 'female pregnancy', 67, 'pregnant'), ('CHEBI_27300', 'vitamin D', 87, 'vitamin A'), ('GO_0007565', 'female pregnancy', 140, 'pregnant'), ('CHEBI_27300', 'vitamin D', 163, 'vitamin A')]
S108-PMC4729160	PMC4729160	1/2016	S108-PMC4729160	['this MAY REFLECT a TRUE reduction in Vitamin A stores with increasing Gestation, as PROPOSED by a large trial of weekly Vitamin A supplementation in bangladesh [24].']	[('INCOMPLETE_EVIDENCE', 5), ('PROBABLE_UNDERSTANDING', 9), ('PROBABLE_UNDERSTANDING', 19), ('INCOMPLETE_EVIDENCE', 84)]	4	[('CHEBI_27300', 'vitamin D', 37, 'vitamin A'), ('GO_0007565', 'female pregnancy', 70, 'gestation'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin A')]
S18-PMC4764019	PMC4764019	1/2016	S18-PMC4764019	['the eurodiab STUDY5SHOWED that 7 european centers that practiced regular Vitamin D supplementation during infancy had a 33% lower incidence of juvenile diabetes prior to age 15 years than centers that DID NOT ENCOURAGE regular supplementation.']	[('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 201), ('FUTURE_WORK', 209)]	3	[('CHEBI_27300', 'vitamin D', 73, 'vitamin D')]
S59-PMC4764019	PMC4764019	1/2016	S59-PMC4764019	['in the final analysis, the underlying HYPOTHESIS is not that Vitamin D supplementation will reduce the disease BURDEN of dm1, preeclampsia, ms, schizophrenia, or the OTHER disorders listed, RATHER, the RELEVANT HYPOTHESIS is, INSTEAD, that it is precisely Vitamin D inadequacy that increases or aggravates the disease BURDEN of these varied outcomes.']	[('INCOMPLETE_EVIDENCE', 38), ('IMPORTANT_CONSIDERATION', 111), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 166), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 190), ('IMPORTANT_CONSIDERATION', 202), ('INCOMPLETE_EVIDENCE', 211), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 226), ('IMPORTANT_CONSIDERATION', 318)]	8	[('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 256, 'vitamin D')]
S0-PMC4770602	PMC4770602	1/2016	S0-PMC4770602	['EFFECT of Vitamin D supplementation in the reduce RISK of Preeclampsia in nulliparous women\n\nabstract\n\nbackground:\nthe exact ROLE of Vitamin D in the development and severity of Preeclampsia is STILL UNCLEAR.']	[('SUPERFICIAL_RELATIONSHIP', 0), ('IMPORTANT_CONSIDERATION', 50), ('SUPERFICIAL_RELATIONSHIP', 125), ('FULL_UNKNOWN', 194)]	4	[('CHEBI_27300', 'vitamin D', 10, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 58, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 133, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 178, 'preeclampsia')]
S1-PMC4770602	PMC4770602	1/2016	S1-PMC4770602	['the AIM of the PRESENT STUDY was TO INVESTIGATE the ASSOCIATION between Vitamin D supplement and Preeclampsia in Pregnant women.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 15), ('QUESTION_ANSWERED_BY_THIS_WORK', 33), ('SUPERFICIAL_RELATIONSHIP', 52)]	4	[('CHEBI_27300', 'vitamin D', 72, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 97, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 113, 'pregnant')]
S9-PMC4770602	PMC4770602	1/2016	S9-PMC4770602	['conclusion:\nIN SUMMARY, our results DEMONSTRATED that Vitamin D supplementation during the third Trimester of Pregnancy; DESPITE the non-significant ASSOCIATION between Vitamin D supplementation and preeclampsia, reduce the risk of preeclampsia.']	[('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 36), ('ANOMALY_CURIOUS_FINDING', 121), ('SUPERFICIAL_RELATIONSHIP', 149)]	4	[('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 97, 'trimester'), ('GO_0007565', 'female pregnancy', 110, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin D')]
S23-PMC4770602	PMC4770602	1/2016	S23-PMC4770602	['[518]\nbased ON the ROLE of maternal Vitamin D deficiency, AS a POTENTIAL in DEPENDENT RISK FACTOR for Preeclampsia, Vitamin D supplementation in early Pregnancy REMAINS a POSSIBLE intervention and POSSIBLE improved Pregnancy outcomes through PREVENTION or delay of Preeclampsia.']	[('ANOMALY_CURIOUS_FINDING', 12), ('ANOMALY_CURIOUS_FINDING', 12), ('SUPERFICIAL_RELATIONSHIP', 19), ('PROBABLE_UNDERSTANDING', 58), ('INCOMPLETE_EVIDENCE', 63), ('SUPERFICIAL_RELATIONSHIP', 76), ('SUPERFICIAL_RELATIONSHIP', 86), ('INCOMPLETE_EVIDENCE', 161), ('INCOMPLETE_EVIDENCE', 171), ('INCOMPLETE_EVIDENCE', 197), ('SUPERFICIAL_RELATIONSHIP', 242)]	11	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 102, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin D'), ('GO_0007565', 'female pregnancy', 151, 'pregnancy'), ('GO_0007565', 'female pregnancy', 215, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 265, 'preeclampsia')]
S24-PMC4770602	PMC4770602	1/2016	S24-PMC4770602	['furthermore, because Vitamin D supplementation is simple and cost-effective with a low LIKELIHOOD of toxicity, increased supplementation in Pregnant women is RECOMMEND previously.']	[('PROBABLE_UNDERSTANDING', 87), ('FUTURE_WORK', 158)]	2	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('GO_0007565', 'female pregnancy', 140, 'pregnant')]
S25-PMC4770602	PMC4770602	1/2016	S25-PMC4770602	['and FURTHER prospective longitudinal STUDIES or randomized controlled trials to assess the POTENTIAL EFFECT of Vitamin D supplementation on adverse Pregnancy outcomes are SUGGESTED.']	[('FUTURE_WORK', 4), ('INCOMPLETE_EVIDENCE', 91), ('SUPERFICIAL_RELATIONSHIP', 101), ('INCOMPLETE_EVIDENCE', 171)]	4	[('CHEBI_27300', 'vitamin D', 111, 'vitamin D'), ('GO_0007565', 'female pregnancy', 148, 'pregnancy')]
S26-PMC4770602	PMC4770602	1/2016	S26-PMC4770602	['THUS, THIS STUDY was AIMED TO EXAMINE the IMPACT of Vitamin D supplementation in reduction of RISK of Preeclampsia in nulliparous women in a randomized controlled trial.']	[('PROBABLE_UNDERSTANDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 6), ('QUESTION_ANSWERED_BY_THIS_WORK', 21), ('QUESTION_ANSWERED_BY_THIS_WORK', 27), ('SUPERFICIAL_RELATIONSHIP', 42), ('IMPORTANT_CONSIDERATION', 94)]	6	[('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 102, 'preeclampsia')]
S46-PMC4770602	PMC4770602	1/2016	S46-PMC4770602	['infant Birth weight in case group who received Vitamin D supplementation was higher than control group, result of independent sample t-test SHOWS that this difference in the mean of infant Birth weight between groups was statistically significant.']	[('INCOMPLETE_EVIDENCE', 140)]	1	[('GO_0007567', 'parturition', 7, 'birth'), ('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('GO_0007567', 'parturition', 189, 'birth')]
S58-PMC4770602	PMC4770602	1/2016	S58-PMC4770602	['cases included 68 pregnant women who received supplementation contain Vitamin D (600 iu/d) and control group included 70 pregnant women who received supplementation without Vitamin D. differences between both groups were not statistically significant ( p -value = 0.84)\n\ndiscussion\nEVIDENCE TO EVALUATE the effectiveness of Vitamin D in Pregnancy is no enough and much of what we KNOW comes from observational RATHER than experimental design, THEREFORE, AT PRESENT Vitamin D supplementation is NOT routinely offered to all pregnant women.']	[('INCOMPLETE_EVIDENCE', 282), ('QUESTION_ANSWERED_BY_THIS_WORK', 291), ('INCOMPLETE_EVIDENCE', 380), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 410), ('PROBABLE_UNDERSTANDING', 443), ('INCOMPLETE_EVIDENCE', 454), ('ANOMALY_CURIOUS_FINDING', 494)]	7	[('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 173, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 324, 'vitamin D'), ('GO_0007565', 'female pregnancy', 337, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 465, 'vitamin D')]
S59-PMC4770602	PMC4770602	1/2016	S59-PMC4770602	['[19] in the PRESENT STUDY, we ASSESSED the EFFECT of Vitamin D supplementation in reduction of risk of Preeclampsia in nulliparous women.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 12), ('QUESTION_ANSWERED_BY_THIS_WORK', 30), ('SUPERFICIAL_RELATIONSHIP', 43)]	3	[('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 103, 'preeclampsia')]
S60-PMC4770602	PMC4770602	1/2016	S60-PMC4770602	['our results SHOWED that the frequency of Preeclampsia in case group, who received Vitamin D supplementation, was lower than control group but this difference between case and control groups was not statistically significant.']	[('INCOMPLETE_EVIDENCE', 12)]	1	[('GO_0007128', 'meiotic prophase I', 41, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 82, 'vitamin D')]
S64-PMC4770602	PMC4770602	1/2016	S64-PMC4770602	['[3] in the norwegian mother and child cohort study, the ASSOCIATION between Intake of Vitamin D during Pregnancy and the risk of Preeclampsia in 23,423 Nulliparous Pregnant women was ESTIMATED and authors OBSERVED 27% reduction in risk of Preeclampsia after Vitamin D supplementation in these women.']	[('SUPERFICIAL_RELATIONSHIP', 56), ('INCOMPLETE_EVIDENCE', 183), ('INCOMPLETE_EVIDENCE', 205)]	3	[('GO_0007631', 'feeding behavior', 76, 'intake'), ('CHEBI_27300', 'vitamin D', 86, 'vitamin D'), ('GO_0007565', 'female pregnancy', 103, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 129, 'preeclampsia'), ('GO_0046662', 'regulation of oviposition', 152, 'nulliparous'), ('GO_0007565', 'female pregnancy', 164, 'pregnant'), ('GO_0007128', 'meiotic prophase I', 239, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 258, 'vitamin D')]
S65-PMC4770602	PMC4770602	1/2016	S65-PMC4770602	"[""[8] investigators in ANOTHER cohort STUDY REPORTED that the risk of Preeclampsia in the female offspring's first Pregnancy reduced after regular supplementation with Vitamin D in the first year of Life.""]"	[('INCOMPLETE_EVIDENCE', 21), ('INCOMPLETE_EVIDENCE', 42)]	2	[('GO_0007128', 'meiotic prophase I', 68, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 113, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 166, 'vitamin D'), ('UBERON_0000104', 'life cycle', 197, 'life')]
S66-PMC4770602	PMC4770602	1/2016	S66-PMC4770602	['[20] also, ROLE of Vitamin D in the PREVENTION of Preeclampsia is SUPPORTED by two clinical TRIALS, HOWEVER, in one of these STUDIES as an uncontrolled trial, supplementation with a multivitamin/Mineral supplement and halibut Liver oil provided at 20 week Gestation reduced the odds of Preeclampsia.']	[('SUPERFICIAL_RELATIONSHIP', 11), ('SUPERFICIAL_RELATIONSHIP', 36), ('INCOMPLETE_EVIDENCE', 66), ('FUTURE_WORK', 92), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 100), ('INCOMPLETE_EVIDENCE', 125)]	6	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 50, 'preeclampsia'), ('CHEBI_46662', 'mineral', 195, 'mineral'), ('UBERON_0002107', 'liver', 226, 'liver'), ('GO_0007565', 'female pregnancy', 256, 'gestation'), ('GO_0007128', 'meiotic prophase I', 286, 'preeclampsia')]
S67-PMC4770602	PMC4770602	1/2016	S67-PMC4770602	['[21] in other study,400 women at 20-24 week Gestation randomized to Vitamin D and Calcium supplements or no treatment, results of this study SHOWS that in the treated group reduction occurred in the incidence of Preeclampsia compared with the untreated group THOUGH this was not statistically significant.']	[('INCOMPLETE_EVIDENCE', 141), ('ANOMALY_CURIOUS_FINDING', 259)]	2	[('GO_0007565', 'female pregnancy', 44, 'gestation'), ('CHEBI_27300', 'vitamin D', 68, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 82, 'calcium'), ('GO_0007128', 'meiotic prophase I', 212, 'preeclampsia')]
S70-PMC4770602	PMC4770602	1/2016	S70-PMC4770602	['[23] in the PRESENT STUDY infant Birth weight in women who received Vitamin D supplementation, was significantly more than control group.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 12)]	1	[('GO_0007567', 'parturition', 33, 'birth'), ('CHEBI_27300', 'vitamin D', 68, 'vitamin D')]
S75-PMC4770602	PMC4770602	1/2016	S75-PMC4770602	['[22] IN CONTRAST WITH our results OTHER study SHOWED that low Birth weight is NOTED in infants of mothers supplemented with Vitamin D.\nwe THINKS that some POSSIBLE LIMITATIONS of the present study that SHOULD BE addressed and noted in FUTURE STUDIES are included; unmeasured sun exposure, maternal baseline 25-Oh-D and Preconception, physical activity, local area and early Pregnancy dietary Intake to HELP realize the EFFECT of these FACTORS.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 5), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 34), ('INCOMPLETE_EVIDENCE', 46), ('ANOMALY_CURIOUS_FINDING', 78), ('INCOMPLETE_EVIDENCE', 138), ('INCOMPLETE_EVIDENCE', 155), ('INCOMPLETE_EVIDENCE', 164), ('FUTURE_WORK', 202), ('FUTURE_WORK', 235), ('FUTURE_WORK', 402), ('SUPERFICIAL_RELATIONSHIP', 419), ('SUPERFICIAL_RELATIONSHIP', 435)]	12	[('GO_0007567', 'parturition', 62, 'birth'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D'), ('CHEBI_46744', 'DDT-2,3-dihydrodiol', 307, '25-OH-D'), ('PR_000000164', 'BMP2', 309, '-OH'), ('PR_000006444', 'diacylglycerol kinase delta', 313, 'D'), ('GO_0007565', 'female pregnancy', 319, 'preconception'), ('GO_0007565', 'female pregnancy', 374, 'pregnancy'), ('GO_0007631', 'feeding behavior', 392, 'intake')]
S78-PMC4770602	PMC4770602	1/2016	S78-PMC4770602	['THEREFORE, ADDITIONAL well-designed, prospective, randomized TRIALS of supplementation with good sample size that control for dietary exposure will BE NECESSARY to determine a POTENTIAL ROLE for Vitamin D in the PREVENTION of Preeclampsia.']	[('PROBABLE_UNDERSTANDING', 0), ('FUTURE_WORK', 11), ('FUTURE_WORK', 148), ('INCOMPLETE_EVIDENCE', 176), ('SUPERFICIAL_RELATIONSHIP', 186), ('SUPERFICIAL_RELATIONSHIP', 212)]	6	[('CHEBI_27300', 'vitamin D', 195, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 226, 'preeclampsia')]
S79-PMC4770602	PMC4770602	1/2016	S79-PMC4770602	['in CONCLUSION, results of the PRESENT STUDY DEMONSTRATED that Vitamin D supplementation during the third Trimester of Pregnancy; reduce the RISK of Preeclampsia HOWEVER, this was not statistically significant.']	[('INCOMPLETE_EVIDENCE', 3), ('QUESTION_ANSWERED_BY_THIS_WORK', 30), ('INCOMPLETE_EVIDENCE', 44), ('IMPORTANT_CONSIDERATION', 140), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 161)]	5	[('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 105, 'trimester'), ('GO_0007565', 'female pregnancy', 118, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 148, 'preeclampsia')]
S80-PMC4770602	PMC4770602	1/2016	S80-PMC4770602	['and FURTHER TRIALS ARE NEEDED to FURTHER CLARIFY the EFFECT of calcium supplementation, Vitamin D supplementation, or both on reduce the incidence of Preeclampsia.']	[('FUTURE_WORK', 4), ('FUTURE_WORK', 12), ('FUTURE_WORK', 33), ('SUPERFICIAL_RELATIONSHIP', 53)]	4	[('CHEBI_27300', 'vitamin D', 88, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 150, 'preeclampsia')]
S76-PMC4772030	PMC4772030	1/2016	S76-PMC4772030	['mff as an additional Food ration in the basic Food basket increased estimated daily intakes, in particular for Vitamin A, b-Vitamins (Thiamine, riboflavin and Nicotinamide), Ascorbic Acid, zinc and iron, while the supplementary oil ration for Pregnant women ESPECIALLY improved the intakes of Tocopherols (table 2).']	[('ANOMALY_CURIOUS_FINDING', 258)]	1	[('CHEBI_33290', 'food', 21, 'food'), ('CHEBI_33290', 'food', 46, 'food'), ('CHEBI_27300', 'vitamin D', 111, 'vitamin A'), ('CHEBI_33277', 'gamma-tocotrienol', 124, 'vitamins'), ('CHEBI_26948', 'vitamin B1', 134, 'thiamine'), ('CHEBI_17154', 'nicotinamide', 159, 'nicotinamide'), ('CHEBI_22652', 'ascorbic acid', 174, 'ascorbic acid'), ('GO_0007565', 'female pregnancy', 243, 'pregnant'), ('CHEBI_27013', 'tocopherol', 293, 'tocopherols')]
S100-PMC4778858	PMC4778858	3/2016	S100-PMC4778858	['HOWEVER, CAUTION for too much Vitamin D supplementation SHOULD BE raised AS ONE STUDY DETERMINED higher concentrations of neonatal 25-Ohd are POSSIBLY ASSOCIATED with an elevated risk of becoming overweight in Adult Life [26].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 9), ('FUTURE_WORK', 56), ('PROBABLE_UNDERSTANDING', 73), ('INCOMPLETE_EVIDENCE', 76), ('QUESTION_ANSWERED_BY_THIS_WORK', 86), ('INCOMPLETE_EVIDENCE', 142), ('SUPERFICIAL_RELATIONSHIP', 151)]	8	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('CHEBI_72765', 'verruculogen', 131, '25-OHD'), ('UBERON_0000113', 'post-juvenile adult stage', 210, 'adult life')]
S102-PMC4778858	PMC4778858	3/2016	S102-PMC4778858	['as addressed PREVIOUSLY by our group [12] and others [27], obese women MAY REQUIRE larger amounts of Vitamin D supplementation compared to normal weight women to provide their neonates with sufficient levels of Vitamin D. YET the definition of neonatal Vitamin D sufficiency has NOT BEEN DETERMINED.']	[('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 71), ('IMPORTANT_CONSIDERATION', 75), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 222), ('ANOMALY_CURIOUS_FINDING', 222), ('FULL_UNKNOWN', 279)]	6	[('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 211, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 253, 'vitamin D')]
S106-PMC4778858	PMC4778858	3/2016	S106-PMC4778858	['THUS, well-designed, interventional studies, with both neonatal and longitudinal follow up outcomes, are NECESSARY in order to provide improved RECOMMENDATIONS for Vitamin D supplementation in Pregnancy.']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 105), ('FUTURE_WORK', 144)]	3	[('CHEBI_27300', 'vitamin D', 164, 'vitamin D'), ('GO_0007565', 'female pregnancy', 193, 'pregnancy')]
S119-PMC4778858	PMC4778858	3/2016	S119-PMC4778858	['furthermore, supplementation of Vitamin D during Pregnancy CONFOUNDS the outcomes.']	[('PROBLEM_COMPLICATION', 59)]	1	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('GO_0007565', 'female pregnancy', 49, 'pregnancy')]
S130-PMC4778858	PMC4778858	3/2016	S130-PMC4778858	['information on Prenatal Vitamin use or additional Vitamin D supplementation within this cohort WAS NOT COLLECTED.']	[('INCOMPLETE_EVIDENCE', 95), ('INCOMPLETE_EVIDENCE', 99)]	2	[('GO_0007565', 'female pregnancy', 15, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 24, 'vitamin'), ('CHEBI_27300', 'vitamin D', 50, 'vitamin D')]
S87-PMC4784858	PMC4784858	3/2016	S87-PMC4784858	['EVEN IF national GUIDELINES RECOMMEND the use of dietary supplements to meet REQUIREMENTS for some Nutrients (Folate, Vitamin D, iron or Iodine) during Pregnancy, Nutrient intakes from dietary supplements were not included in the pandiet calculation, like in other studies using diet quality indexes for Pregnancy [11–13].']	[('ANOMALY_CURIOUS_FINDING', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 5), ('PROBABLE_UNDERSTANDING', 17), ('FUTURE_WORK', 28), ('IMPORTANT_CONSIDERATION', 77)]	5	[('CHEBI_33284', 'nutrient', 99, 'nutrients'), ('CHEBI_30863', '5-azaorotic acid', 110, 'folate'), ('CHEBI_27300', 'vitamin D', 118, 'vitamin D'), ('CHEBI_24859', 'iodine atom', 137, 'iodine'), ('GO_0007565', 'female pregnancy', 152, 'pregnancy'), ('CHEBI_33284', 'nutrient', 163, 'nutrient'), ('GO_0007565', 'female pregnancy', 304, 'pregnancy')]
S16-PMC4785305	PMC4785305	3/2016	S16-PMC4785305	['caption (boxed-text)\nstrengths and limitations of this study\n\nTHIS is the FIRST randomised controlled trial (rct) in the middle east directly addressing the applicability of the institute of medicine RECOMMENDATIONS in this specific population, and assessing the EFFECT of Vitamin D supplementation on neonatal bone Mineral content.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 62), ('INCOMPLETE_EVIDENCE', 74), ('FUTURE_WORK', 200), ('SUPERFICIAL_RELATIONSHIP', 263)]	4	[('CHEBI_27300', 'vitamin D', 273, 'vitamin D'), ('CHEBI_46662', 'mineral', 316, 'mineral')]
S19-PMC4785305	PMC4785305	3/2016	S19-PMC4785305	['the findings of this trial will help guide the public health policymaker regarding Vitamin D supplementation in Pregnant women and will allow a step forward in EVIDENCE-BASED RECOMMENDATIONS SPECIFIC to the middle east.']	[('INCOMPLETE_EVIDENCE', 160), ('FUTURE_WORK', 175), ('FUTURE_WORK', 191)]	3	[('CHEBI_27300', 'vitamin D', 83, 'vitamin D'), ('GO_0007565', 'female pregnancy', 112, 'pregnant')]
S20-PMC4785305	PMC4785305	3/2016	S20-PMC4785305	['results derived from Nutrient rct, specifically Vitamin D supplementation, SUFFER from several CONFOUNDING FACTORS RELATED to the baseline status, intake of OTHER Nutrients, such as calcium and proteins, and sun exposure, which are DIFFICULT to quantify accurately.']	[('IMPORTANT_CONSIDERATION', 75), ('PROBLEM_COMPLICATION', 95), ('SUPERFICIAL_RELATIONSHIP', 115), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 157), ('DIFFICULT_TASK', 232)]	5	[('CHEBI_33284', 'nutrient', 21, 'nutrient'), ('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('CHEBI_33284', 'nutrient', 163, 'nutrients')]
S22-PMC4785305	PMC4785305	3/2016	S22-PMC4785305	['WHILE the total Calcitriol levels double in the first trimester, free Calcitriol levels do not increase until the third trimester and remain so until Lactation.24conversely, Parathyroid hormone (pth) levels decrease early on and increase back to mid-normal range by term.2the total calcium level decreases during Pregnancy, due to haemodilution, WHILE the ionised calcium level remains stable.2vitamin D binding proteins also increase during Pregnancy secondary to high Oestrogen levels,45but the 25-Hydroxyvitamin D (25(Oh)D) level, the single best nutritional INDICATOR of Vitamin D status,6remains stable.7the changes in Calcitriol levels led to the description of Pregnancy as a state of ‘absorptive hypercalciuria’.12the above Adaptive physiology is KEY to SAFETY CONSIDERATIONS when using Vitamin D supplementation during Pregnancy, as well as to determining key biochemical and hormonal parameters to be monitored.']	[('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 346), ('SUPERFICIAL_RELATIONSHIP', 562), ('IMPORTANT_CONSIDERATION', 755), ('IMPORTANT_CONSIDERATION', 762), ('IMPORTANT_CONSIDERATION', 769)]	6	[('CHEBI_17823', 'calcitriol', 16, 'calcitriol'), ('CHEBI_17823', 'calcitriol', 70, 'calcitriol'), ('GO_0007595', 'lactation', 150, 'lactation'), ('UBERON_0001132', 'parathyroid gland', 174, 'parathyroid'), ('GO_0007565', 'female pregnancy', 313, 'pregnancy'), ('PR_000006444', 'diacylglycerol kinase delta', 402, 'D'), ('GO_0007565', 'female pregnancy', 442, 'pregnancy'), ('CHEBI_50114', 'estrogen', 470, 'oestrogen'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 497, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 518, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 575, 'vitamin D'), ('CHEBI_17823', 'calcitriol', 624, 'calcitriol'), ('GO_0007565', 'female pregnancy', 668, 'pregnancy'), ('GO_0018888', '3-chloroacrylic acid metabolic process', 732, 'adaptive'), ('CHEBI_27300', 'vitamin D', 795, 'vitamin D'), ('GO_0007565', 'female pregnancy', 828, 'pregnancy')]
S24-PMC4785305	PMC4785305	3/2016	S24-PMC4785305	"[""ASSOCIATION between maternal Vitamin D level and neonatal adverse outcomes\nlow maternal 25(Oh)D levels were RECENTLY LINKED to fetal programming, and were found TO be ASSOCIATED with adverse events in neonates, resulting in small for Gestational age (sga) at Birth,1923and also later on during childhood, leading to reduced muscle and bone mass in offspring at 4 and 9\u2005years.2425this MAY BE EXPLAINED by the fact that maternal Vitamin D is ESSENTIAL for fetal Musculoskeletal integrity, as it Regulates neonatal bone accrual, POSSIBLY through specific proteins that are responsible for Placental Calcium Transport.26RECENTLY, data from the southampton women's survey (sws) SHOWED that maternal 25(Oh)D level is significantly CORRELATED with Placental Amino Acid transporters Expression, that mediate the Transport Of various Nutrients to the fetus.27furthermore, maternal Vitamin D MAY INFLUENCE the fetal muscle motor Unit size, and CONSEQUENTLY muscle mass and strength after Birth.25it is NOTEWORTHY that fetal bone development is one of the PREDICTORS of peak bone mass, Adult bone Mineral content and Hip geometry, THUS CORRELATING with fracture risk later in Life.2628\n\nVitamin d replacement guidelines during Pregnancy\nthe guidelines regarding Vitamin D replacement or supplementation during Pregnancy VARY substantially.""]"	[('SUPERFICIAL_RELATIONSHIP', 0), ('INCOMPLETE_EVIDENCE', 108), ('SUPERFICIAL_RELATIONSHIP', 117), ('QUESTION_ANSWERED_BY_THIS_WORK', 161), ('SUPERFICIAL_RELATIONSHIP', 167), ('INCOMPLETE_EVIDENCE', 384), ('ANOMALY_CURIOUS_FINDING', 388), ('PROBABLE_UNDERSTANDING', 391), ('IMPORTANT_CONSIDERATION', 440), ('INCOMPLETE_EVIDENCE', 526), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 614), ('INCOMPLETE_EVIDENCE', 673), ('SUPERFICIAL_RELATIONSHIP', 725), ('INCOMPLETE_EVIDENCE', 882), ('SUPERFICIAL_RELATIONSHIP', 886), ('PROBABLE_UNDERSTANDING', 934), ('ANOMALY_CURIOUS_FINDING', 992), ('SUPERFICIAL_RELATIONSHIP', 1045), ('PROBABLE_UNDERSTANDING', 1120), ('SUPERFICIAL_RELATIONSHIP', 1125), ('DIFFICULT_TASK', 1309)]	21	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 88, '25(OH)D'), ('GO_0007565', 'female pregnancy', 234, 'gestational'), ('GO_0007567', 'parturition', 259, 'birth'), ('CHEBI_27300', 'vitamin D', 427, 'vitamin D'), ('UBERON_0002204', 'musculoskeletal system', 460, 'musculoskeletal'), ('GO_0065007', 'biological regulation', 493, 'regulates'), ('UBERON_0001987', 'placenta', 586, 'placental'), ('GO_0006816', 'calcium ion transport', 596, 'calcium transport'), ('CHEBI_71657', 'versiconol acetate', 694, '25(OH)D'), ('UBERON_0001987', 'placenta', 741, 'placental'), ('CHEBI_82880', 'N-acyltetradecaphytosphingosine', 751, 'amino acid'), ('GO_0010467', 'gene expression', 775, 'expression'), ('GO_0006415', 'translational termination', 804, 'transport of ... nutrients'), ('CHEBI_33284', 'nutrient', 825, 'nutrients'), ('CHEBI_27300', 'vitamin D', 872, 'vitamin D'), ('UBERON_0002105', 'vestibulo-auditory system', 919, 'unit'), ('GO_0007567', 'parturition', 978, 'birth'), ('UBERON_0007023', 'adult organism', 1075, 'adult'), ('CHEBI_46662', 'mineral', 1086, 'mineral'), ('UBERON_0001464', 'hip', 1106, 'hip'), ('UBERON_0000104', 'life cycle', 1165, 'life'), ('CHEBI_33229', 'vitamin (role)', 1176, 'Vitamin'), ('GO_0007565', 'female pregnancy', 1216, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 1251, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1299, 'pregnancy')]
S25-PMC4785305	PMC4785305	3/2016	S25-PMC4785305	['the 2010 institute of medicine (iom) report on dietary reference intakes for Calcium and Vitamin D RECOMMENDED 600\u2005iu to Pregnant women as the recommended daily allowance (rda), the rda being the dose that is projected to allow at least 97.5% of the Pregnant women population to reach the DESIRABLE target 25(Oh)D level ≥50\u2005nmol/l.29this RECOMMENDATION was BASED ON OBSERVATIONAL studies, NONE of which were conducted in the middle east.29CONVERSELY, the Endocrine society 2011 GUIDELINES RECOMMENDED that 1500–2000\u2005iu daily of Vitamin D is NEEDED to reach a target 25(Oh)D level ≥75\u2005nmol/l (a RECOMMENDATION that was graded as weak with moderate quality of evidence).30the american college of obstetricians and gynecologists (acog) does not RECOMMEND screening for Vitamin D level in Pregnancy, and abides by the iom RECOMMENDATIONS.31moreover, the who 2012 guidelines on Vitamin D replacement during Pregnancy DID NOT RECOMMEND vitamin D supplementation as part of Prenatal care.32this was based ON a meta-analysis of Vitamin D trials during Pregnancy, which IDENTIFIED a LIMITED NUMBER of high-quality studies DEMONSTRATING a beneficial EFFECT of supplementation on maternal and neonatal outcomes, and CONCLUDED that FURTHER randomised controlled trials (rcts) ARE NEEDED.33in the uk, HOWEVER, Pregnant women are CONSIDERED AT RISK of Vitamin D deficiency, and supplementation with 400\u2005iu daily is REQUIRED.34\nit is NOT CLEAR WHETHER any of the above RECOMMENDED doses are applicable to non-western populations, with lower baseline Vitamin D levels, such as in lebanon and other middle eastern countries.']	[('FUTURE_WORK', 99), ('IMPORTANT_CONSIDERATION', 289), ('FUTURE_WORK', 338), ('INCOMPLETE_EVIDENCE', 357), ('INCOMPLETE_EVIDENCE', 366), ('INCOMPLETE_EVIDENCE', 389), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 437), ('PROBABLE_UNDERSTANDING', 478), ('FUTURE_WORK', 489), ('FUTURE_WORK', 541), ('IMPORTANT_CONSIDERATION', 541), ('FUTURE_WORK', 594), ('FUTURE_WORK', 742), ('FUTURE_WORK', 818), ('INCOMPLETE_EVIDENCE', 912), ('FUTURE_WORK', 920), ('ANOMALY_CURIOUS_FINDING', 998), ('ANOMALY_CURIOUS_FINDING', 998), ('INCOMPLETE_EVIDENCE', 1061), ('INCOMPLETE_EVIDENCE', 1074), ('INCOMPLETE_EVIDENCE', 1113), ('SUPERFICIAL_RELATIONSHIP', 1140), ('INCOMPLETE_EVIDENCE', 1205), ('FUTURE_WORK', 1220), ('FUTURE_WORK', 1264), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1288), ('IMPORTANT_CONSIDERATION', 1316), ('INCOMPLETE_EVIDENCE', 1316), ('IMPORTANT_CONSIDERATION', 1327), ('IMPORTANT_CONSIDERATION', 1401), ('FULL_UNKNOWN', 1419), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1429), ('FUTURE_WORK', 1454)]	33	[('CHEBI_31341', 'calcium dihydroxide', 77, 'Calcium'), ('CHEBI_28384', 'vitamin K', 89, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 89, 'Vitamin'), ('GO_0007565', 'female pregnancy', 121, 'pregnant'), ('GO_0007565', 'female pregnancy', 250, 'pregnant'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 309, 'OH)D'), ('PR_000013502', 'parvalbumin alpha', 311, ')D'), ('UBERON_0005063', 'left ventricular compact myocardium', 455, 'Endocrine'), ('CHEBI_27300', 'vitamin D', 528, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 566, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 566, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 766, 'vitamin D'), ('GO_0007565', 'female pregnancy', 785, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 873, 'vitamin D'), ('GO_0007565', 'female pregnancy', 902, 'pregnancy'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 938, 'D'), ('GO_0007565', 'female pregnancy', 967, 'prenatal'), ('CHEBI_27300', 'vitamin D', 1020, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1044, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1297, 'pregnant'), ('CHEBI_27300', 'vitamin D', 1338, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1535, 'vitamin D')]
S26-PMC4785305	PMC4785305	3/2016	S26-PMC4785305	['indeed, the who Pregnancy guidelines clearly STATED that “Vitamin D supplementation will PROBABLY have the most BENEFIT in populations of poor countries, those with darker skin colour and in populations with a high prevalence of Vitamin D deficiency.']	[('INCOMPLETE_EVIDENCE', 45), ('PROBABLE_UNDERSTANDING', 89), ('IMPORTANT_CONSIDERATION', 112)]	3	[('GO_0007565', 'female pregnancy', 16, 'pregnancy'), ('CHEBI_28384', 'vitamin K', 58, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 229, 'vitamin D')]
S28-PMC4785305	PMC4785305	3/2016	S28-PMC4785305	['rcts of Vitamin D supplementation during Pregnancy\ntwo landmark rcts HAVE BEEN conducted in the usa35and the uk.36hollis et al 35SHOWED that in Pregnant women in the usa, with a baseline 25(Oh)D level around 60\u2005nmol/l, a Vitamin dose of 4000\u2005iu daily allowed 82% of participants to reach a 25(Oh)D level of 80\u2005nmol/l, WHILE ONLY 70% and 50% reached this TARGET in the intermediate (2000\u2005iu daily) and low (400\u2005iu daily) doses, respectively.']	[('INCOMPLETE_EVIDENCE', 69), ('INCOMPLETE_EVIDENCE', 127), ('ANOMALY_CURIOUS_FINDING', 318), ('ANOMALY_CURIOUS_FINDING', 324), ('FUTURE_WORK', 354)]	5	[('CHEBI_27300', 'vitamin D', 8, 'vitamin D'), ('GO_0007565', 'female pregnancy', 41, 'pregnancy'), ('GO_0007565', 'female pregnancy', 144, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 187, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 187, '25(OH)D'), ('CHEBI_33229', 'vitamin (role)', 221, 'vitamin'), ('CHEBI_71657', 'versiconol acetate', 290, '25(OH)D')]
S29-PMC4785305	PMC4785305	3/2016	S29-PMC4785305	['cooper et al 36SHOWED that Vitamin D supplementation of 1000\u2005iu daily, COMPARED TO placebo, in Pregnant women in the uk allowed a significant increase in bone Mineral content (bmc) of neonates, HOWEVER, ONLY when they were Born in winter.']	[('INCOMPLETE_EVIDENCE', 13), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 71), ('ANOMALY_CURIOUS_FINDING', 194), ('ANOMALY_CURIOUS_FINDING', 203)]	4	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('GO_0007565', 'female pregnancy', 95, 'pregnant'), ('CHEBI_46662', 'mineral', 159, 'Mineral'), ('GO_0007567', 'parturition', 223, 'born')]
S30-PMC4785305	PMC4785305	3/2016	S30-PMC4785305	['ONE STUDY from india, comparing non-intervention to Vitamin D supplementation groups, with the dose being DEPENDENT on 25(Oh)D levels at 20\u2005weeks Gestation, SHOWED that Vitamin D supplementation resulted in a significant difference in the achieved 25(Oh)D level at Delivery (43.1 (81.3) nmol/l in the former group versus 56.8 (47.5) nmol/l in the latter group).37hollis et al 36and sablok et al 37SHOWED that Vitamin D supplementation decreased the RISK of Preterm labour, Gestational diabetes and hypertensive complications (all combined).']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 106), ('INCOMPLETE_EVIDENCE', 157), ('INCOMPLETE_EVIDENCE', 395), ('IMPORTANT_CONSIDERATION', 449)]	5	[('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 119, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 125, 'D'), ('GO_0007565', 'female pregnancy', 146, 'gestation'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 248, '25(OH)D'), ('GO_0007567', 'parturition', 265, 'delivery'), ('CHEBI_27300', 'vitamin D', 409, 'vitamin D'), ('GO_0007565', 'female pregnancy', 457, 'preterm'), ('GO_0007565', 'female pregnancy', 473, 'gestational')]
S31-PMC4785305	PMC4785305	3/2016	S31-PMC4785305	['in the middle east and north africa region, there are FEW RECENT rcts that attempted to determine the OPTIMAL regimen of Vitamin D replacement in healthy Pregnant women.38–41WITH the exception of soheilykhah et al 40who ASSESSED the EFFECT of Vitamin D supplementation on Insulin resistance, the primary outcomes in THESE studies were MOSTLY maternal and neonatal 25(Oh)D levels (seeonline supplementary appendix1).']	[('INCOMPLETE_EVIDENCE', 54), ('INCOMPLETE_EVIDENCE', 58), ('IMPORTANT_CONSIDERATION', 102), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 172), ('INCOMPLETE_EVIDENCE', 220), ('SUPERFICIAL_RELATIONSHIP', 233), ('INCOMPLETE_EVIDENCE', 316), ('PROBABLE_UNDERSTANDING', 335)]	8	[('CHEBI_27300', 'vitamin D', 121, 'vitamin D'), ('GO_0007565', 'female pregnancy', 154, 'pregnant'), ('CHEBI_27300', 'vitamin D', 243, 'vitamin D'), ('PR_000045358', 'insulin family protein', 272, 'insulin'), ('CHEBI_71657', 'versiconol acetate', 364, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 364, '25 ... OH ... D')]
S32-PMC4785305	PMC4785305	3/2016	S32-PMC4785305	['none of the other clinically IMPORTANT outcomes, such as neonatal size and OTHER anthropometric measurements, neonatal bmc, gdm and c-section rates, were evaluated as primary outcomes in any of these trials (seeonline supplementary appendix1).10.1136/bmjopen-2015-010818.supp1\n\nwe therefore compiled a registry of all ongoing Vitamin D trials in Pregnancy, as captured by their registration on clinicaltrial.gov42(seeonline supplementary appendix2).']	[('IMPORTANT_CONSIDERATION', 29), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 75)]	2	[('CHEBI_27300', 'vitamin D', 326, 'vitamin D'), ('GO_0007565', 'female pregnancy', 346, 'pregnancy')]
S34-PMC4785305	PMC4785305	3/2016	S34-PMC4785305	['ONLY two of the ONGOING trials are being conducted in the middle east, one in iran and one in israel, start supplementation in the third Trimester and use Vitamin D doses of 7000\u2005iu and 2000\u2005iu daily, respectively.']	[('INCOMPLETE_EVIDENCE', 0), ('IMPORTANT_CONSIDERATION', 16)]	2	[('GO_0009294', 'DNA mediated transformation', 137, 'trimester'), ('CHEBI_27300', 'vitamin D', 155, 'vitamin D')]
S35-PMC4785305	PMC4785305	3/2016	S35-PMC4785305	['these latter studies AIM at assessing the EFFECT of Vitamin D supplementation on offspring calcium status, maternal and infant Vitamin D status and bone status (by quantitative ultrasound) at 1\u2005year.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 21), ('SUPERFICIAL_RELATIONSHIP', 42)]	2	[('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 127, 'vitamin D')]
S86-PMC4785305	PMC4785305	3/2016	S86-PMC4785305	['Vitamin D supplementation ≤200\u2005iu daily.ii\nexclusion criteria:\n25(Oh)D level <25\u2005nmol/l, AS it would be UNETHICAL to randomise Pregnant women to the low dose of Vitamin D, and 25(Oh)D level >75\u2005nmol/l (30\u2005ng/ml), as Vitamin D supplementation with routine Prenatal multivitamins would be sufficient.']	[('PROBABLE_UNDERSTANDING', 89), ('DIFFICULT_TASK', 104)]	2	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_71657', 'versiconol acetate', 63, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 63, '25(OH)D'), ('GO_0007565', 'female pregnancy', 127, 'pregnant'), ('CHEBI_27300', 'vitamin D', 161, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 176, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 182, 'D'), ('CHEBI_27300', 'vitamin D', 216, 'vitamin D'), ('GO_0007565', 'female pregnancy', 255, 'prenatal')]
S120-PMC4785305	PMC4785305	3/2016	S120-PMC4785305	['CONSIDERING that each 100\u2005iu Vitamin D supplementation increases the level by 1.7\u2005nmol/l,49the EXPECTED levels reached in the low-dose and high-dose arms would be 67\u2005nmol/l and 106\u2005nmol/l, respectively.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 95)]	2	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D')]
S130-PMC4785305	PMC4785305	3/2016	S130-PMC4785305	['they SHOWED a significant difference of 6\u2005g (sd 10\u2005g) in neonatal mean bmc in the Vitamin D supplemented group, compared to placebo, in the winter season.36for a 90% power and a type i error of 2.5%, considering an sd of bmc of 10\u2005g, to detect a 6\u2005g difference in bmc between high-dose and low-dose groups, 69 participants per arm are needed.']	[('INCOMPLETE_EVIDENCE', 5)]	1	[('CHEBI_27300', 'vitamin D', 82, 'vitamin D')]
S157-PMC4785305	PMC4785305	3/2016	S157-PMC4785305	['it is NOTEWORTHY that high doses of Vitamin D (up to 4000\u2005iu daily) HAVE BEEN used in PREVIOUS TRIALS conducted during Pregnancy with no reported adverse events (seeonline supplementary appendix1).']	[('ANOMALY_CURIOUS_FINDING', 6), ('INCOMPLETE_EVIDENCE', 68), ('INCOMPLETE_EVIDENCE', 86)]	3	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('GO_0007565', 'female pregnancy', 119, 'pregnancy')]
S168-PMC4785305	PMC4785305	3/2016	S168-PMC4785305	['furthermore, GIVEN the LACK OF EVIDENCE-BASED guidelines that define the OPTIMAL rda for Vitamin D supplementation during Pregnancy in our population, and the LIMITED NUMBER of randomised clinical trials completed so far in our region, this trial will fill an IMPORTANT KNOWLEDGE GAP.']	[('PROBABLE_UNDERSTANDING', 13), ('INCOMPLETE_EVIDENCE', 23), ('IMPORTANT_CONSIDERATION', 73), ('INCOMPLETE_EVIDENCE', 159), ('IMPORTANT_CONSIDERATION', 260), ('FULL_UNKNOWN', 270)]	6	[('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('GO_0007565', 'female pregnancy', 122, 'pregnancy')]
S172-PMC4785305	PMC4785305	3/2016	S172-PMC4785305	['the findings of this trial will help guide the public health policymaker regarding Vitamin D supplementation in Pregnant women and will allow a step forward in EVIDENCE-BASED RECOMMENDATIONS SPECIFIC to the middle east.']	[('INCOMPLETE_EVIDENCE', 160), ('FUTURE_WORK', 175), ('FUTURE_WORK', 191)]	3	[('CHEBI_27300', 'vitamin D', 83, 'vitamin D'), ('GO_0007565', 'female pregnancy', 112, 'pregnant')]
S174-PMC4785305	PMC4785305	3/2016	S174-PMC4785305	['FINDINGS from our trial, and SIMILAR TO results derived from Nutrient rcts, are PRONE to the CONFOUNDING effect of several FACTORS.52indeed, the baseline 25(Oh)D level, the dietary Intake of Vitamin D and OTHER Nutrients, such as Calcium and proteins, sun exposure and others, REMAIN IMPORTANT PREDICTORS AFFECTING the response to Vitamin D supplementation, but are very DIFFICULT to quantify accurately.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 29), ('PROBABLE_UNDERSTANDING', 80), ('PROBLEM_COMPLICATION', 93), ('SUPERFICIAL_RELATIONSHIP', 123), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 205), ('INCOMPLETE_EVIDENCE', 277), ('IMPORTANT_CONSIDERATION', 284), ('SUPERFICIAL_RELATIONSHIP', 294), ('SUPERFICIAL_RELATIONSHIP', 305), ('DIFFICULT_TASK', 371)]	11	[('CHEBI_33284', 'nutrient', 61, 'nutrient'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 157, 'OH)D'), ('GO_0007631', 'feeding behavior', 181, 'intake'), ('CHEBI_27300', 'vitamin D', 191, 'vitamin D'), ('CHEBI_33284', 'nutrient', 211, 'nutrients'), ('CHEBI_22313', 'alkaline earth metal atom', 230, 'calcium'), ('CHEBI_27300', 'vitamin D', 331, 'vitamin D')]
S25-PMC4800340	PMC4800340	5/2016	S25-PMC4800340	"[""THIS STUDY SUGGESTS that low sunlight and PRESUMABLY suboptimal Vitamin D status at Birth is ASSOCIATED with Food Allergy Development in childhood.30a large scale population-based study in australia SHOWED that infants with low Serum 25-Hydroxyvitamin (Oh) D3Levels (≤50 nmol/l) had almost 12 times and 4 times higher risk of developing Peanut and egg allergies, respectively, in the first year of Life THAN infants with adequate Serum Vitamin D level.31HOWEVER, ANOTHER STUDY conducted in germany DEMONSTRATED that 25(Oh)D3Concentration in Pregnant women's Serum and in Cord Blood were positively ASSOCIATED with increased risk of Food Allergy Development among children in the first 2 years.32a RECENT randomized double-blind controlled TRIAL SHOWED that maternal Vitamin D3Supplementation for 6 weeks during Lactation increased the risk of Food allergy diagnosis by 3.42 times [95% confidence interval (ci)=1.02–11.77] among children of supplementation group compared to control group by 2 years of age.33due to lack OF robustly designed studies, a causal ASSOCIATION between Vitamin D status during Prenatal and Neonatal Period and Food allergy Development In Children remains INCONCLUSIVE.""]"	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 11), ('PROBABLE_UNDERSTANDING', 42), ('SUPERFICIAL_RELATIONSHIP', 93), ('INCOMPLETE_EVIDENCE', 199), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 403), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 452), ('INCOMPLETE_EVIDENCE', 463), ('INCOMPLETE_EVIDENCE', 498), ('SUPERFICIAL_RELATIONSHIP', 598), ('INCOMPLETE_EVIDENCE', 697), ('INCOMPLETE_EVIDENCE', 739), ('INCOMPLETE_EVIDENCE', 745), ('ANOMALY_CURIOUS_FINDING', 1020), ('SUPERFICIAL_RELATIONSHIP', 1059), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1181)]	16	[('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('GO_0007567', 'parturition', 84, 'birth'), ('CHEBI_33290', 'food', 109, 'food'), ('GO_0048467', 'gynoecium development', 109, 'food allergy development'), ('UBERON_0001977', 'blood serum', 228, 'serum'), ('CHEBI_60346', 'alpha-Kdo-(2->8)-alpha-Kdo-OAll', 234, '25-hydroxyvitamin (OH) D3levels'), ('NCBITaxon_10088', 'Mus <genus>', 337, 'peanut'), ('UBERON_0000104', 'life cycle', 398, 'life'), ('UBERON_0001977', 'blood serum', 430, 'serum'), ('CHEBI_27300', 'vitamin D', 436, 'vitamin D'), ('CHEBI_74304', '(6Z,9Z,12Z,15Z,18Z,21Z)-3-oxotetracosahexaenoyl-CoA(4-)', 516, '25(OH)D3concentration'), ('GO_0007565', 'female pregnancy', 541, 'pregnant'), ('UBERON_0001977', 'blood serum', 558, 'serum'), ('UBERON_0009472', 'axilla', 571, 'cord blood'), ('CHEBI_33290', 'food', 632, 'food'), ('GO_0048467', 'gynoecium development', 632, 'food allergy development'), ('CHEBI_52915', 'phosphatediyl group', 766, 'vitamin D3supplementation'), ('GO_0007595', 'lactation', 811, 'lactation'), ('CHEBI_33290', 'food', 843, 'food'), ('CHEBI_27300', 'vitamin D', 1079, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1103, 'prenatal'), ('UBERON_0007221', 'neonate stage', 1116, 'neonatal period'), ('CHEBI_33290', 'food', 1136, 'food'), ('GO_0030163', 'protein catabolic process', 1149, 'development in children')]
S28-PMC4811441	PMC4811441	3/2016	S28-PMC4811441	['SO FAR, controlled intervention trials sufficiently powered for pe are lacking [9], but one SMALL STUDY conducted REPORTS no effects of Vitamin D supplementation on pe [10].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 92), ('INCOMPLETE_EVIDENCE', 114)]	3	[('CHEBI_27300', 'vitamin D', 136, 'vitamin D')]
S14-PMC4829940	PMC4829940	5/2016	S14-PMC4829940	['low 25(Oh)D levels HAVE BEEN ASSOCIATED with a range of adverse conditions, from Pregnancy outcomes to childhood illnesses and chronic disease including osteoporosis, cancer and Cardiovascular disease in Adulthood[3], ALTHOUGH randomized controlled trials of Vitamin D supplements do NOT SUPPORT causality for Extra-Skeletal outcomes[4],[5].']	[('INCOMPLETE_EVIDENCE', 19), ('SUPERFICIAL_RELATIONSHIP', 29), ('ANOMALY_CURIOUS_FINDING', 218), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 284)]	4	[('CHEBI_71657', 'versiconol acetate', 4, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 4, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 81, 'pregnancy'), ('UBERON_0004535', 'cardiovascular system', 178, 'cardiovascular'), ('UBERON_0000113', 'post-juvenile adult stage', 204, 'adulthood'), ('CHEBI_27300', 'vitamin D', 259, 'vitamin D'), ('UBERON_0001431', 'distal carpal bone 2', 310, 'extra-skeletal')]
S20-PMC4829940	PMC4829940	5/2016	S20-PMC4829940	['ALTHOUGH two RECENT randomized controlled trials observed SUGGESTIVE reductions in the incidence of asthma and recurrent wheezing following Vitamin D supplementation during Pregnancy[12],[13], the primary endpoints were not statistically significant.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 58)]	4	[('CHEBI_27300', 'vitamin D', 140, 'vitamin D'), ('GO_0007565', 'female pregnancy', 173, 'pregnancy')]
S127-PMC4829940	PMC4829940	5/2016	S127-PMC4829940	['HOWEVER, a FEW other STUDIES have explored RELATIONSHIPS between Vitamin D supplementation or circulating 25(Oh)D and methylation at a few Cpg Sites in two to four candidate Genes in Adults[18],[46], and one Genome-wide Dna Methylation study explored ASSOCIATION with Vitamin D deficiency in african children[17].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 11), ('SUPERFICIAL_RELATIONSHIP', 43), ('SUPERFICIAL_RELATIONSHIP', 251)]	4	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 106, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 106, '25(OH)D'), ('SO_0000036', 'matrix_attachment_site', 139, 'CpG sites'), ('SO_0000704', 'gene', 174, 'genes'), ('UBERON_0007023', 'adult organism', 183, 'adults'), ('SO_0001026', 'genome', 208, 'genome'), ('GO_0006306', 'DNA methylation', 220, 'DNA methylation'), ('CHEBI_27300', 'vitamin D', 268, 'vitamin D')]
S136-PMC4832516	PMC4832516	10/2015	S136-PMC4832516	['similarly, NO information was AVAILABLE on maternal residential location, individually-measured sunshine exposure, or Vitamin D supplementation during Pregnancy, HOWEVER EVEN the youngest participant in the uk biobank (aged 38 in our analysis) was Conceived during a time when Gestational Vitamin D supplementation was not RECOMMENDED in the uk.']	[('FULL_UNKNOWN', 11), ('ANOMALY_CURIOUS_FINDING', 162), ('ANOMALY_CURIOUS_FINDING', 170), ('FUTURE_WORK', 323)]	4	[('CHEBI_27300', 'vitamin D', 118, 'vitamin D'), ('GO_0007565', 'female pregnancy', 151, 'pregnancy'), ('GO_0070268', 'cornification', 248, 'conceived'), ('GO_0007565', 'female pregnancy', 277, 'gestational'), ('CHEBI_27300', 'vitamin D', 289, 'vitamin D')]
S122-PMC4843009	PMC4843009	4/2016	S122-PMC4843009	['CONVERSELY, Vitamin D supplementation HAS BEEN REPORTED to counteract depressive symptoms515253.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 38), ('INCOMPLETE_EVIDENCE', 47)]	3	[('CHEBI_27300', 'vitamin D', 12, 'vitamin D')]
S124-PMC4843009	PMC4843009	4/2016	S124-PMC4843009	['CONVERSELY Vitamin D supplementation decreases the RISK to develop psychotic-like symptoms44.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('IMPORTANT_CONSIDERATION', 51)]	2	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D')]
S156-PMC4846845	PMC4846845	4/2016	S156-PMC4846845	['a RECENT meta-analysis did NOT see a positive change in ptb, lbw, pre-eclampsia, and Gestational diabetes rates with Vitamin D supplementation, THOUGH they did CONCLUDE that Vitamin D has “PLAUSIBLE EFFECTS” on many Perinatal outcomes [119].']	[('INCOMPLETE_EVIDENCE', 2), ('ANOMALY_CURIOUS_FINDING', 27), ('ANOMALY_CURIOUS_FINDING', 144), ('INCOMPLETE_EVIDENCE', 160), ('INCOMPLETE_EVIDENCE', 189), ('SUPERFICIAL_RELATIONSHIP', 199)]	6	[('GO_0007565', 'female pregnancy', 85, 'gestational'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 174, 'vitamin D'), ('GO_0036268', 'swimming', 216, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 216, 'perinatal')]
S97-PMC4859539	PMC4859539	5/2016	S97-PMC4859539	"[""in MODELS 1 and 4, there was also a TREND NOTED with the child’s percent fat being positively ASSOCIATED with Cathelicidin (beta = 0.028, p = 0.052 and beta = 0.025, p = 0.087).10.1371/journal.pone.0152711.t003\n\ncaption (table-wrap): table 3\nmultivariable linear regression models assessing factors associated with natural logarithm for Cathelicidin.model 1 \xa0\xa0independent variablesbetase1p valuerace/ethnicity\xa0\xa0black-0.0390.230.864white---------hispanic-0.1490.2000.459genderfemale---------male0.3180.16 0.047 age0.1450.065 0.028 percent fat0.0280.0140.052child's current 25(Oh)D-0.0050.010.598 model 2 \xa0\xa0\xa0independent variablesbetasep valuerace/ethnicityblack0.0350.210.868white---------hispanic-0.1490.210.470genderfemale---------male0.2750.170.104age0.2120.07 0.004 percent fat0.0250.020.087child's 25(Oh)D at Birth-0.0030.010.748 model 3 \xa0\xa0\xa0independent variablesbetasep valuerace/ethnicity\xa0\xa0black0.0410.180.821white---------hispanic-0.1220.160.458genderfemale---------male0.0910.140.507age0.1550.07 0.023 percent fat0.0120.010.359maternal 25(Oh)D throughout Pregnancy<-0.000100.999 model 4 \xa0\xa0\xa0independent variablesbetasep valuerace/ethnicity\xa0\xa0black0.0460.1990.816white---------hispanic-0.0800.1850.669genderfemale---------male0.3180.158 0.047 age0.1510.064 0.021 percent fat0.0260.010.069maternal 25(Oh)D 1-month before Delivery0.0030.010.606\n1se represents standard error\n\ndiscussion\nin THIS STUDY of healthy children whose mothers had participated in a Vitamin D supplementation trial during Pregnancy, DESPITE DIFFERENCES in both maternal and childhood Vitamin D status, there were no significant differences in Cathelicidin concentration between the three racial/ethnic groups studied.""]"	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 3), ('INCOMPLETE_EVIDENCE', 36), ('ANOMALY_CURIOUS_FINDING', 42), ('SUPERFICIAL_RELATIONSHIP', 94), ('QUESTION_ANSWERED_BY_THIS_WORK', 1391), ('ANOMALY_CURIOUS_FINDING', 1508), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1516)]	7	[('CHEBI_3364', 'Canthiumine', 110, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 110, 'cathelicidin'), ('CHEBI_3461', 'Casuarictin', 337, 'Cathelicidin'), ('CHEBI_71657', 'versiconol acetate', 572, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 572, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 801, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 807, 'D'), ('GO_0007567', 'parturition', 812, 'birth'), ('CHEBI_71657', 'versiconol acetate', 1042, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 1048, 'D'), ('GO_0007565', 'female pregnancy', 1061, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 1300, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1300, '25(OH)D'), ('GO_0007567', 'parturition', 1323, 'delivery0'), ('CHEBI_27300', 'vitamin D', 1458, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1497, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 1559, 'vitamin D'), ('CHEBI_3364', 'Canthiumine', 1618, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 1618, 'cathelicidin')]
S115-PMC4874157	PMC4874157	5/2016	S115-PMC4874157	['several other STUDIES SUGGEST that, WHENEVER POSSIBLE, Interferon Β treatment SHOULD BE discontinued prior to Conception.21–28HOWEVER, SIMILAR women in OTHER STUDIES continued to receive treatment modalities throughout Pregnancy.1015–19\ninitially, Vitamin D was given as a supplement to address the paucity women MAY SUFFER from during Pregnancy,29and to attend to the Vitamin D deficiency in the general lebanese population.30more RECENT STUDIES have also SHOWN that maintaining adequate levels of Vitamin D during Pregnancy MIGHT have a PROTECTIVE EFFECT and lower the risk of developing Postpartum relapses.31\npsychological support was CRUCIAL in maintaining the mental well-Being of the mother.32some women exhibited signs of anxiety and depression.']	[('INCOMPLETE_EVIDENCE', 14), ('INCOMPLETE_EVIDENCE', 22), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 36), ('INCOMPLETE_EVIDENCE', 45), ('FUTURE_WORK', 78), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 124), ('INCOMPLETE_EVIDENCE', 135), ('INCOMPLETE_EVIDENCE', 152), ('INCOMPLETE_EVIDENCE', 313), ('IMPORTANT_CONSIDERATION', 317), ('INCOMPLETE_EVIDENCE', 432), ('INCOMPLETE_EVIDENCE', 457), ('INCOMPLETE_EVIDENCE', 526), ('SUPERFICIAL_RELATIONSHIP', 539), ('SUPERFICIAL_RELATIONSHIP', 550), ('IMPORTANT_CONSIDERATION', 639)]	16	[('CHEBI_76163', 'isoxicam', 55, 'interferon β'), ('PR_000008918', 'interferon alpha-5', 55, 'interferon β'), ('GO_0007620', 'copulation', 110, 'conception'), ('GO_0007565', 'female pregnancy', 219, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 248, 'vitamin D'), ('GO_0007565', 'female pregnancy', 336, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 369, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 499, 'vitamin D'), ('GO_0007565', 'female pregnancy', 516, 'pregnancy'), ('GO_0007565', 'female pregnancy', 590, 'postpartum'), ('GO_0016441', 'posttranscriptional gene silencing', 677, '-being')]
S97-PMC4877864	PMC4877864	6/2015	S97-PMC4877864	['OTHER STUDIES HAVE REPORTED similar improvements in autistic children supplemented with Vitamin B6, Folate, and Vitamin C [30].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 14)]	2	[('CHEBI_33237', 'vitamin D4', 88, 'vitamin B6'), ('CHEBI_30863', '5-azaorotic acid', 100, 'folate'), ('CHEBI_27300', 'vitamin D', 112, 'vitamin C')]
S81-PMC4889866	PMC4889866	5/2016	S81-PMC4889866	['PRELIMINARY analysis was also performed on maternal innate Immune function; the result SHOWED no correlation between maternal Vitamin D status and cytokine response to tlr ligands in maternal Mononuclear cells (supplement 1) (see supplementary material available online athttp://dx.doi.org/10.1155/2016/8175898).']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 87)]	2	[('UBERON_0002405', 'immune system', 59, 'immune'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D'), ('CL_0000100', 'motor neuron', 192, 'mononuclear'), ('GO_0031097', 'medial cortex', 192, 'mononuclear')]
S101-PMC4889866	PMC4889866	5/2016	S101-PMC4889866	['in vitro studies HAVE also SHOWN direct Vitamin D supplementation in culture Human cells to upregulate Il-10 secretion [3,21–24].']	[('INCOMPLETE_EVIDENCE', 17)]	1	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('NCBITaxon_9606', 'Homo sapiens', 77, 'human'), ('PR_000001470', 'interleukin-28B', 103, 'IL-10')]
S103-PMC4889866	PMC4889866	5/2016	S103-PMC4889866	['BECAUSE direct Vitamin D supplementation DEEMED to increase Il-10 Production, our result SUGGESTED a reduced Il-10 response to Tlr Stimulation with higher Vitamin D concentration.']	[('PROBABLE_UNDERSTANDING', 0), ('PROBABLE_UNDERSTANDING', 41), ('INCOMPLETE_EVIDENCE', 89)]	3	[('CHEBI_27300', 'vitamin D', 15, 'vitamin D'), ('GO_0032613', 'interleukin-10 production', 60, 'IL-10 production'), ('PR_000001470', 'interleukin-28B', 60, 'IL-10'), ('PR_000001470', 'interleukin-28B', 109, 'IL-10'), ('GO_0031295', 'T cell costimulation', 127, 'TLR stimulation'), ('CHEBI_27300', 'vitamin D', 155, 'vitamin D')]
S113-PMC4889866	PMC4889866	5/2016	S113-PMC4889866	['HOWEVER, most studies that SHOWED PROTECTIVE EFFECT of Vitamin D against Respiratory diseases were of interventional studies that used supplementary Vitamin D and DID NOT measure Serum Vitamin D level.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 27), ('SUPERFICIAL_RELATIONSHIP', 34), ('SUPERFICIAL_RELATIONSHIP', 45), ('INCOMPLETE_EVIDENCE', 163)]	5	[('CHEBI_27300', 'vitamin D', 55, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 73, 'respiratory'), ('CHEBI_27300', 'vitamin D', 149, 'vitamin D'), ('UBERON_0001977', 'blood serum', 179, 'serum'), ('CHEBI_27300', 'vitamin D', 185, 'vitamin D')]
S129-PMC4889866	PMC4889866	5/2016	S129-PMC4889866	['the result SHOWED no correlation between maternal Vitamin D status and neonatal Tlr9 triggered cytokine response (supplement 2), THOUGH such conclusion NEEDED to be INTERPRETED with CAUTION for the null CORRELATION MIGHT be DUE TO LACK OF POWER OWING TO SMALL number of test samples.']	[('INCOMPLETE_EVIDENCE', 11), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 129), ('ANOMALY_CURIOUS_FINDING', 129), ('FUTURE_WORK', 152), ('FULL_UNKNOWN', 165), ('INCOMPLETE_EVIDENCE', 182), ('SUPERFICIAL_RELATIONSHIP', 203), ('INCOMPLETE_EVIDENCE', 215), ('PROBLEM_COMPLICATION', 224), ('INCOMPLETE_EVIDENCE', 231), ('PROBLEM_COMPLICATION', 231), ('PROBLEM_COMPLICATION', 245), ('INCOMPLETE_EVIDENCE', 254)]	13	[('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('PR_000001155', 'Toll-like receptor 4', 80, 'TLR9')]
S2806-PMC4896250	PMC4896250	4/2016	S2806-PMC4896250	['FURTHER RESEARCH SHOULD BE focused on Vitamin D supplementation for the PREVENTION of childhood asthma.']	[('FUTURE_WORK', 0), ('FUTURE_WORK', 17), ('SUPERFICIAL_RELATIONSHIP', 72)]	3	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D')]
S3550-PMC4896250	PMC4896250	4/2016	S3550-PMC4896250	['data regarding the magnitude of Vitamin D deficiency among exclusively breastfed infants in kenya IS NEEDED to inform supplementation policies.']	[('FUTURE_WORK', 98)]	1	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D')]
S3562-PMC4896250	PMC4896250	4/2016	S3562-PMC4896250	['a policy on Vitamin D supplementation is RECOMMENDED in this population to mitigate the IMPACT of Vitamin D deficiency especially on chronic non-communicable diseases.']	[('FUTURE_WORK', 41), ('SUPERFICIAL_RELATIONSHIP', 88)]	2	[('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 98, 'vitamin D')]
S4493-PMC4896250	PMC4896250	4/2016	S4493-PMC4896250	['for PREVENTION and treatment of asthma, an intervention study in asthmatic children with low serum Vitamin D level, and a Vitamin D study ASSESSED the OPTIMAL delivery and safety of its supplementation IS NEEDED.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 138), ('IMPORTANT_CONSIDERATION', 151), ('FUTURE_WORK', 202)]	4	[('CHEBI_27300', 'vitamin D', 99, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 122, 'vitamin D')]
S6132-PMC4896250	PMC4896250	4/2016	S6132-PMC4896250	['SINCE THESE studies were very HETEROGENEOUS and the retrospective or the observational cohort studies, large randomized controlled TRIALS ARE NEEDED to determine WHETHER Vitamin D supplementation MAY BE beneficial in the PREVENTION of ar.']	[('PROBLEM_COMPLICATION', 0), ('INCOMPLETE_EVIDENCE', 6), ('DIFFICULT_TASK', 30), ('FUTURE_WORK', 131), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 162), ('INCOMPLETE_EVIDENCE', 196), ('SUPERFICIAL_RELATIONSHIP', 221)]	7	[('CHEBI_27300', 'vitamin D', 170, 'vitamin D')]
S8292-PMC4896250	PMC4896250	4/2016	S8292-PMC4896250	['objective\nwe AIMED TO INVESTIGATE WHETHER Vitamin D insufficiency in asthmatic Adults ASSOCIATES with atopy, poor asthma Control, and more frequent Respiratory Tract infections, and WHETHER these patients CAN BENEFIT from Vitamin D supplementation.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 13), ('QUESTION_ANSWERED_BY_THIS_WORK', 19), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 34), ('SUPERFICIAL_RELATIONSHIP', 86), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 182), ('INCOMPLETE_EVIDENCE', 205), ('IMPORTANT_CONSIDERATION', 209)]	7	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('UBERON_0007023', 'adult organism', 79, 'adults'), ('GO_0065007', 'biological regulation', 121, 'control'), ('UBERON_0000065', 'respiratory tract', 148, 'respiratory tract'), ('CHEBI_27300', 'vitamin D', 222, 'vitamin D')]
S149-PMC4897157	PMC4897157	5/2016	S149-PMC4897157	['finally, there is a LACK OF research on the EFFECT FACTOR for amount of sun exposure and Vitamin D status such as clothes and Vitamin D supplements.']	[('INCOMPLETE_EVIDENCE', 20), ('SUPERFICIAL_RELATIONSHIP', 44), ('SUPERFICIAL_RELATIONSHIP', 51)]	3	[('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D')]
S100-PMC4903143	PMC4903143	5/2016	S100-PMC4903143	['because of widespread Vitamin D INSUFFICIENCY in many population groups and INCONSISTENT response to fixed doses of Vitamin D supplementation, the authors RECOMMEND testing for 25(Oh)d levels and SUITABLE intervention as REQUIRED [76].']	[('IMPORTANT_CONSIDERATION', 32), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 76), ('FUTURE_WORK', 155), ('IMPORTANT_CONSIDERATION', 196), ('IMPORTANT_CONSIDERATION', 221)]	5	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin D'), ('CHEBI_30778', 'gallic acid', 177, '25(OH)')]
S168-PMC4908484	PMC4908484	6/2016	S168-PMC4908484	['(2003) FIRST SUGGESTED a POSSIBLE use of Vitamin D supplementation, after reporting that systemic administration of Vitamin D attenuates iron‐induced oxidative injuries in the Rat locus coeruleus.']	[('INCOMPLETE_EVIDENCE', 7), ('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 25)]	3	[('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin D'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 176, 'rat')]
S176-PMC4908484	PMC4908484	6/2016	S176-PMC4908484	['the results SUPPORT the POTENTIAL use of Vitamin D supplementation as a therapeutic STRATEGY in neurodegeneration disorders.']	[('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 24), ('FUTURE_WORK', 84)]	3	[('CHEBI_27300', 'vitamin D', 41, 'vitamin D')]
S272-PMC4910255	PMC4910255	6/2016	S272-PMC4910255	['other outcomes\ncomparison of follow-ups did NOT confirm the impression of transiently lower systolic Blood pressure at 2.5\xa0years in the nepal janakpur trial, or of improved Lung function in children SEEN in a similar trial of Vitamin A supplementation from nepal sarlahi [66].']	[('ANOMALY_CURIOUS_FINDING', 44), ('INCOMPLETE_EVIDENCE', 199)]	2	[('UBERON_0000178', 'blood', 101, 'blood'), ('UBERON_0002048', 'lung', 173, 'lung'), ('CHEBI_27300', 'vitamin D', 226, 'vitamin A')]
S135-PMC4910734	PMC4910734	6/2015	S135-PMC4910734	['MANY of the Micronutrients STUDIES HAVE BEEN BASED ON Plasma and Urinary clinical results, which SUGGEST the elevation of Lipid Peroxide-generated Aldehydes (Hne, mda)84–86as well as deficiencies in antioxidants, such as Vitamin E, Sulfur-containing Compounds, such as cysteine, methionine, and Gsh,119carnitine,120biotin,121and ( n -3) pufas.122given the depressed levels of Sulfur-containing Compounds in asd Individuals, it is NOT SURPRISING that these children are more sensitive than neurotypicals to the exposure of mercury and other heavy metals.78the antioxidant supplements, which SHOW symptom improvements include, but are not limited to Ubiquinol,123nac,124carnosine, and Vitamin C.125other Micronutrients, including b1,126B6-Mg2+,127Folate, Vitamin E, Retinol, and Zn2+, HAVE BEEN selected for a variety of reasons RELATING to the INVOLVEMENT in abnormal Metabolic pathways IMPLICATED in asd,1even THOUGH the clinical assays do not always show a deficiency in asd Individuals compared to neurotypical controls.119with all of the single Micronutrient STUDIES, there are CONFLICTING results regarding efficacy.119there are a FEW STUDIES, which utilize broad-spectrum Micronutrient supplementation and report improvements in clinical BIOMARKERS and/or various autism-rating scales.76,121,128the broad-spectrum Micronutrient STUDIES are very PROMISING BECAUSE all DEMONSTRATE a significant CORRELATION between nutritional deficiencies and severity of autistic symptoms.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 27), ('INCOMPLETE_EVIDENCE', 35), ('INCOMPLETE_EVIDENCE', 45), ('INCOMPLETE_EVIDENCE', 97), ('PROBABLE_UNDERSTANDING', 430), ('ANOMALY_CURIOUS_FINDING', 434), ('INCOMPLETE_EVIDENCE', 590), ('INCOMPLETE_EVIDENCE', 783), ('SUPERFICIAL_RELATIONSHIP', 827), ('SUPERFICIAL_RELATIONSHIP', 843), ('SUPERFICIAL_RELATIONSHIP', 886), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 910), ('ANOMALY_CURIOUS_FINDING', 910), ('INCOMPLETE_EVIDENCE', 1062), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1081), ('INCOMPLETE_EVIDENCE', 1135), ('SUPERFICIAL_RELATIONSHIP', 1243), ('INCOMPLETE_EVIDENCE', 1333), ('PROBABLE_UNDERSTANDING', 1350), ('PROBABLE_UNDERSTANDING', 1360), ('INCOMPLETE_EVIDENCE', 1372), ('SUPERFICIAL_RELATIONSHIP', 1398)]	23	[('CHEBI_33839', 'macromolecule', 12, 'micronutrients'), ('UBERON_0001969', 'blood plasma', 54, 'plasma'), ('UBERON_0001088', 'urine', 65, 'urinary'), ('CHEBI_48107', 'nitric acid', 122, 'lipid peroxide'), ('CHEBI_17478', 'aldehyde', 147, 'aldehydes'), ('CHEBI_17759', 'cholesta-5,7-dien-3beta-ol', 158, 'HNE'), ('CHEBI_27300', 'vitamin D', 221, 'vitamin E'), ('CHEBI_36933', 'oxygen-19 atom', 232, 'sulfur'), ('CHEBI_36357', 'polyatomic entity', 250, 'compounds'), ('CHEBI_16856', 'glutathione', 295, 'GSH'), ('CHEBI_36933', 'oxygen-19 atom', 376, 'sulfur'), ('CHEBI_36357', 'polyatomic entity', 394, 'compounds'), ('NCBITaxon_1', 'root', 411, 'individuals'), ('CHEBI_17976', 'ubiquinol', 648, 'ubiquinol'), ('CHEBI_27300', 'vitamin D', 683, 'vitamin C'), ('CHEBI_33839', 'macromolecule', 702, 'micronutrients'), ('CHEBI_73173', '2,4-DB', 731, '126B6'), ('CHEBI_6636', 'magnesium dichloride', 737, 'Mg2+,'), ('CHEBI_75275', 'tetradecyl sulfonic acid', 742, '127folate'), ('CHEBI_27300', 'vitamin D', 753, 'vitamin E'), ('CHEBI_26536', 'retinoic acid', 764, 'retinol'), ('CHEBI_29105', 'zinc(2+)', 777, 'Zn2+,'), ('GO_0008152', 'metabolic process', 867, 'metabolic'), ('NCBITaxon_1', 'root', 976, 'individuals'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 1048, 'micronutrient'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 1177, 'micronutrient'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 1319, 'micronutrient')]
S243-PMC4910734	PMC4910734	6/2015	S243-PMC4910734	['additionally, Sulfur-containing antioxidants, such as Taurine and Nac, are superior to Vitamin C and form the ESSENTIAL core of any supplementation plan to counteract Aldehyde toxicity or oxidative stress.L-Carnitine, BUT NOT Acetyl-Carnitine, is LIKELY beneficial for many and can be included.']	[('IMPORTANT_CONSIDERATION', 110), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 218), ('PROBABLE_UNDERSTANDING', 247)]	3	[('CHEBI_36933', 'oxygen-19 atom', 14, 'sulfur'), ('CHEBI_15891', 'taurine', 54, 'taurine'), ('CHEBI_7421', 'NAC', 66, 'NAC'), ('CHEBI_27300', 'vitamin D', 87, 'vitamin C'), ('CHEBI_17478', 'aldehyde', 167, 'aldehyde'), ('CHEBI_86085', '(Z)-p-coumaroylagmatine', 205, 'l-carnitine'), ('CHEBI_17387', 'O-acylcarnitine', 226, 'acetyl-carnitine')]
S42-PMC4924183	PMC4924183	6/2016	S42-PMC4924183	['grieger and clifton, provide updated EVIDENCE from epidemiological and rcts on the IMPACT of dietary and supplemental intakes of Omega-3 Long-Chain polyunsaturated Fatty Acids, zinc, Folate, iron, Calcium, and Vitamin D, as well as dietary patterns, on infant Birth weight [16].']	[('INCOMPLETE_EVIDENCE', 37), ('SUPERFICIAL_RELATIONSHIP', 83)]	2	[('CHEBI_76261', '1-nitropropane', 129, 'omega-3 long-chain'), ('CHEBI_35366', 'fatty acid', 164, 'fatty acids'), ('CHEBI_30863', '5-azaorotic acid', 183, 'folate'), ('CHEBI_22313', 'alkaline earth metal atom', 197, 'calcium'), ('CHEBI_27300', 'vitamin D', 210, 'vitamin D'), ('GO_0007567', 'parturition', 260, 'birth')]
S0-PMC4930210	PMC4930210	7/2016	S0-PMC4930210	['the current recommended Vitamin D intake guideline for diet and supplements during Pregnancy is not adequate to achieve Vitamin D sufficiency for most Pregnant women\n\nabstract\n\nbackground\nthe aims of THIS STUDY were TO DETERMINE IF Pregnant women consumed the RECOMMENDED Vitamin D through diet alone or through diet and supplements, and if they achieved the current reference range Vitamin D status when their reported dietary intake met the current RECOMMENDATIONS.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 200), ('QUESTION_ANSWERED_BY_THIS_WORK', 216), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 229), ('FUTURE_WORK', 260), ('FUTURE_WORK', 451)]	5	[('CHEBI_28384', 'vitamin K', 24, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 83, 'Pregnancy'), ('CHEBI_28384', 'vitamin K', 120, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 151, 'Pregnant'), ('GO_0007565', 'female pregnancy', 232, 'pregnant'), ('CHEBI_27300', 'vitamin D', 272, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 383, 'vitamin D')]
S7-PMC4930210	PMC4930210	7/2016	S7-PMC4930210	['there was a significant RELATIONSHIP between maternal reported dietary Vitamin D intake (diet and supplement) and 25(Oh)D and 3-Epi-25(Oh)D3Concentrations in an adjusted linear regression model.']	[('SUPERFICIAL_RELATIONSHIP', 24)]	1	[('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 114, '25(OH)D'), ('CHEBI_34304', 'fenobucarb', 126, '3-epi-25'), ('CHEBI_73735', 'gadoterate', 135, 'OH)D3concentrations')]
S10-PMC4930210	PMC4930210	7/2016	S10-PMC4930210	['there is also EVIDENCE that Pregnancy RISKS MAY BE mitigated by Vitamin D supplementation, ALTHOUGH the optimal daily dose is NOT CLEAR [2].']	[('INCOMPLETE_EVIDENCE', 14), ('IMPORTANT_CONSIDERATION', 38), ('INCOMPLETE_EVIDENCE', 44), ('ANOMALY_CURIOUS_FINDING', 91), ('FULL_UNKNOWN', 126)]	5	[('GO_0007565', 'female pregnancy', 28, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 64, 'vitamin D')]
S18-PMC4930210	PMC4930210	7/2016	S18-PMC4930210	['HOWEVER, the daily use of Vitamin D supplements CONTRIBUTED to a better 25-Hydroxycholecalciferol (25(Oh)D) status [8].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('SUPERFICIAL_RELATIONSHIP', 48)]	2	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('CHEBI_50545', 'trans-isoeugenol', 72, '25-hydroxycholecalciferol'), ('CHEBI_71657', 'versiconol acetate', 99, '25(OH)D')]
S19-PMC4930210	PMC4930210	7/2016	S19-PMC4930210	['a combined analysis of two randomized clinical trials of 494 Pregnant women taking 400, 2000, and 4000 iu/day Vitamin D during Pregnancy SHOWED that Vitamin D supplementation of 4000 iu/day was more EFFECTIVE in achieving Serum concentrations ≥ 80 nmol/l than 400 and 2000 iu/day in all women and their neonates REGARDLESS OF race, SUGGESTING that the current dietary RECOMMENDATION in the absence of supplementation in Pregnancy MAY not be OPTIMAL [9].']	[('INCOMPLETE_EVIDENCE', 137), ('SUPERFICIAL_RELATIONSHIP', 199), ('INCOMPLETE_EVIDENCE', 312), ('INCOMPLETE_EVIDENCE', 332), ('FUTURE_WORK', 368), ('INCOMPLETE_EVIDENCE', 430), ('IMPORTANT_CONSIDERATION', 441)]	7	[('GO_0007565', 'female pregnancy', 61, 'pregnant'), ('CHEBI_27300', 'vitamin D', 110, 'vitamin D'), ('GO_0007565', 'female pregnancy', 127, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 149, 'vitamin D'), ('UBERON_0001977', 'blood serum', 222, 'serum'), ('GO_0007565', 'female pregnancy', 420, 'pregnancy')]
S21-PMC4930210	PMC4930210	7/2016	S21-PMC4930210	['a RECENT systematic REVIEW of Vitamin D supplementation in Pregnancy CONCLUDED that EVIDENCE is currently INSUFFICIENT TO SUPPORT DEFINITE clinical RECOMMENDATIONS regarding Vitamin D supplementation in Pregnancy.']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 20), ('INCOMPLETE_EVIDENCE', 69), ('INCOMPLETE_EVIDENCE', 84), ('INCOMPLETE_EVIDENCE', 106), ('PROBLEM_COMPLICATION', 106), ('PROBABLE_UNDERSTANDING', 130), ('FUTURE_WORK', 148)]	8	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0007565', 'female pregnancy', 59, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 174, 'vitamin D'), ('GO_0007565', 'female pregnancy', 203, 'pregnancy')]
S28-PMC4930210	PMC4930210	7/2016	S28-PMC4930210	['our AIMS in the CURRENT STUDY were TO DETERMINE: a) if Pregnant women were Consuming the RECOMMENDED Vitamin D through diet alone or through diet and supplements, and b) IF Pregnant women can achieve the current reference range Vitamin D status when their reported dietary intake of Vitamin D met the current RECOMMENDATIONS.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 16), ('QUESTION_ANSWERED_BY_THIS_WORK', 35), ('FUTURE_WORK', 89), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 170), ('FUTURE_WORK', 309)]	6	[('GO_0007565', 'female pregnancy', 55, 'pregnant'), ('GO_0007631', 'feeding behavior', 75, 'consuming'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('GO_0007565', 'female pregnancy', 173, 'pregnant'), ('CHEBI_27300', 'vitamin D', 228, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 283, 'vitamin D')]
S42-PMC4930210	PMC4930210	7/2016	S42-PMC4930210	['maternal supplement intake questionnaire (siq)\nfollowing enrollment, the maternal supplement intake questionnaire (siq) was administered by a trained nutrition professional to each participant once during each trimester of Pregnancy and once at 3 months Postpartum to determine current natural health product (nhp) use including Vitamin D. the siq was designed specifically for the apron study and was initially used in a pilot study that included of fifty women in the apron study who completed the questionnaire during their first and second visits TO assess efficacy and the detail of information obtained [15].']	[('QUESTION_ANSWERED_BY_THIS_WORK', 551)]	1	[('GO_0007565', 'female pregnancy', 223, 'pregnancy'), ('GO_0007565', 'female pregnancy', 254, 'postpartum'), ('CHEBI_27300', 'vitamin D', 329, 'vitamin D')]
S73-PMC4930210	PMC4930210	7/2016	S73-PMC4930210	['a multiple linear regression analysis was used to examine the ASSOCIATION between women’s Plasma 25(Oh)D (D2+ D3) concentration and their reported dietary Vitamin D intake in supplements and diet adjusted for the potential covariates of maternal age, maternal bmi at second trimester, season (summer from may 01-oct 31 and winter from nov 01-apr 30), and race (caucasian vs .']	[('SUPERFICIAL_RELATIONSHIP', 62)]	1	[('UBERON_0001969', 'blood plasma', 90, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 97, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 97, '25(OH ... D'), ('CHEBI_29108', 'calcium(2+)', 106, 'D2+'), ('PR_000002019', 'MHC class II histocompatibility antigen beta chain DRB1', 106, 'D2'), ('PR_000001177', 'D(2) dopamine receptor', 110, 'D3'), ('CHEBI_27300', 'vitamin D', 155, 'vitamin D')]
S86-PMC4930210	PMC4930210	7/2016	S86-PMC4930210	['REPORTED dietary Vitamin D intake (diet and supplements) .table 3shows the reported intake from diet and supplements for all the trimesters of Pregnancy.']	[('INCOMPLETE_EVIDENCE', 0)]	1	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('GO_0007565', 'female pregnancy', 143, 'pregnancy')]
S119-PMC4930210	PMC4930210	7/2016	S119-PMC4930210	['Plasma 3-Epi-25(Oh)D3Was significantly ASSOCIATED with reported Vitamin D intake from supplements BUT not diet (data not shown).']	[('SUPERFICIAL_RELATIONSHIP', 39), ('ANOMALY_CURIOUS_FINDING', 98)]	2	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('CHEBI_73839', 'D-Leu-D-Leu', 7, '3-epi-25(OH)D3was'), ('PR_000008528', 'hairy/enhancer-of-split related with YRPW motif protein 1', 13, '25(OH ... D3was'), ('CHEBI_27300', 'vitamin D', 64, 'vitamin D')]
S126-PMC4930210	PMC4930210	7/2016	S126-PMC4930210	['discussion\nTO OUR KNOWLEDGE, THIS is the largest STUDY TO date to SHOW 44% of Pregnant women with a higher socioeconomic status reported Vitamin D intake (diet and supplements) not meeting the dietary reference intakes (dri) recomendations.']	[('PROBABLE_UNDERSTANDING', 11), ('QUESTION_ANSWERED_BY_THIS_WORK', 29), ('QUESTION_ANSWERED_BY_THIS_WORK', 49), ('QUESTION_ANSWERED_BY_THIS_WORK', 55), ('INCOMPLETE_EVIDENCE', 66)]	5	[('GO_0007565', 'female pregnancy', 78, 'pregnant'), ('CHEBI_27300', 'vitamin D', 137, 'vitamin D')]
S128-PMC4930210	PMC4930210	7/2016	S128-PMC4930210	['we also FOUND that 20% of Pregnant women had Vitamin D concentraion <75 nmol/l, DESPITE more than half of these women reporting taking more than 600 iu/day of Vitamin D (the current rda) BASED ON their REPORTED intake from diet and supplements.']	[('INCOMPLETE_EVIDENCE', 8), ('ANOMALY_CURIOUS_FINDING', 80), ('INCOMPLETE_EVIDENCE', 187), ('INCOMPLETE_EVIDENCE', 202)]	4	[('GO_0007565', 'female pregnancy', 26, 'pregnant'), ('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 159, 'vitamin D')]
S133-PMC4930210	PMC4930210	7/2016	S133-PMC4930210	['in THE CURRENT STUDY, we SHOWED that Pregnant women are taking small amounts of Vitamin D from Food and beverages in their diet (<200 iu/day), and they are relying on supplemental sources of Vitamin D to meet the current dris.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('INCOMPLETE_EVIDENCE', 25)]	2	[('GO_0007565', 'female pregnancy', 37, 'pregnant'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin D'), ('CHEBI_33290', 'food', 95, 'food'), ('CHEBI_27300', 'vitamin D', 191, 'vitamin D')]
S137-PMC4930210	PMC4930210	7/2016	S137-PMC4930210	['another RECENT american longitudinal STUDY of 193 Pregnant women from mid-Pregnancy to Birth SHOWED Consuming a Prenatal Vitamin D supplement (334 iu/day) did not PREVENT precipitous drops in maternal Plasma 25(Oh)D concentration [28].']	[('INCOMPLETE_EVIDENCE', 8), ('INCOMPLETE_EVIDENCE', 37), ('INCOMPLETE_EVIDENCE', 93), ('SUPERFICIAL_RELATIONSHIP', 163)]	4	[('GO_0007565', 'female pregnancy', 50, 'pregnant'), ('GO_0007565', 'female pregnancy', 74, 'pregnancy'), ('GO_0007567', 'parturition', 87, 'birth'), ('GO_0007631', 'feeding behavior', 100, 'consuming'), ('GO_0007565', 'female pregnancy', 112, 'prenatal'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 201, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 208, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 208, '25(OH)D')]
S138-PMC4930210	PMC4930210	7/2016	S138-PMC4930210	['IN FACT, randomized clinical trials of 2000 and 4000 iu/day Vitamin D during Pregnancy HAVE SHOWN that Vitamin D supplementation of 4000 iu/day was more EFFECTIVE in achieving Serum concentrations ≥80 nmol/l of Vitamin D [9].']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 87), ('SUPERFICIAL_RELATIONSHIP', 153)]	3	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('GO_0007565', 'female pregnancy', 77, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 103, 'vitamin D'), ('UBERON_0001977', 'blood serum', 176, 'serum'), ('CHEBI_27300', 'vitamin D', 211, 'vitamin D')]
S142-PMC4930210	PMC4930210	7/2016	S142-PMC4930210	['ALTHOUGH PREVIOUS STUDIES HAVE SHOWN FACTORS like age, season, and Vitamin D supplementation AFFECT 3-Epi-25(Oh)D3[29,30], in OUR STUDY the ONLY FACTOR positively CORRELATED with level of the 3-Epi-25(Oh)D3Was Vitamin D intake.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 9), ('INCOMPLETE_EVIDENCE', 26), ('SUPERFICIAL_RELATIONSHIP', 37), ('SUPERFICIAL_RELATIONSHIP', 93), ('QUESTION_ANSWERED_BY_THIS_WORK', 126), ('ANOMALY_CURIOUS_FINDING', 140), ('INCOMPLETE_EVIDENCE', 140), ('SUPERFICIAL_RELATIONSHIP', 145), ('SUPERFICIAL_RELATIONSHIP', 163)]	10	[('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('CHEBI_76629', '2-lysophosphatidic acid', 100, '3-epi-25(OH)D3'), ('PR_000001177', 'D(2) dopamine receptor', 112, 'D3'), ('CHEBI_73839', 'D-Leu-D-Leu', 192, '3-epi-25(OH)D3was'), ('PR_000012979', 'DNA-directed DNA/RNA polymerase mu', 204, 'D3was'), ('CHEBI_27300', 'vitamin D', 210, 'vitamin D')]
S143-PMC4930210	PMC4930210	7/2016	S143-PMC4930210	['the fact that season significantly AFFECTED 25(Oh)D concentration BUT NOT 3-epi-25(oh)d3suggests that Vitamin D supplements COULD BE a source for 3-Epi-25(Oh)D3As SHOWN in a PREVIOUS STUDY [30].']	[('SUPERFICIAL_RELATIONSHIP', 35), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 66), ('INCOMPLETE_EVIDENCE', 124), ('INCOMPLETE_EVIDENCE', 163), ('INCOMPLETE_EVIDENCE', 174)]	5	"[('CHEBI_71657', 'versiconol acetate', 44, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 50, 'D'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin D'), ('CHEBI_63219', ""alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-[alpha-D-Gal-(1->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc-(1->6)]-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-Cer"", 146, '3-epi-25(OH)D3as'), ('PR_000006270', 'triokinase/FMN cyclase', 158, 'D3as')]"
S4-PMC4934634	PMC4934634	11/2015	S4-PMC4934634	['Vitamin D is found naturally in only a few foods THUS supplementation CAN provide an accessible and effective way to raise Vitamin D status when dietary intakes and sunlight exposure are low.']	[('PROBABLE_UNDERSTANDING', 49), ('INCOMPLETE_EVIDENCE', 70)]	2	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 123, 'vitamin D')]
S6-PMC4934634	PMC4934634	11/2015	S6-PMC4934634	['the EFFECT of Vitamin D supplementation during Pregnancy and early Life on maternal and infant outcomes will be of particular FOCUS in this review.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 126)]	2	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('GO_0007565', 'female pregnancy', 47, 'pregnancy'), ('UBERON_0000104', 'life cycle', 67, 'life')]
S8-PMC4934634	PMC4934634	11/2015	S8-PMC4934634	['introduction\nWHILE the beneficial EFFECTS of Vitamin D supplementation with respect to reducing the RISK of rickets HAS BEEN recognized for close to 100 years, there is increasing concern that rickets in young children is reemerging in numerous countries [1,2].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 13), ('SUPERFICIAL_RELATIONSHIP', 34), ('IMPORTANT_CONSIDERATION', 100), ('INCOMPLETE_EVIDENCE', 116)]	4	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D')]
S19-PMC4934634	PMC4934634	11/2015	S19-PMC4934634	['rickets will not be discussed in this review (readers are referred to a review on this topic by elder and bishop, 2014 [5]) as this paper is FOCUSED on RECENT LITERATURE regarding the IMPORTANCE of maternal Vitamin D status on Pregnancy and infant outcomes, with an EMPHASIS on supplementation trials.healthcare-03-01097-t001_table 1\n\ncaption (table-wrap): table 1\n\ndesignation of Vitamin D status based on circulating Vitamin D levels by the u.s. institute of medicine (iom) and the Endocrine society.Vitamin D statusiomendocrine societydeficiency<12 ng/ml (30 nmol/l)<20 ng/ml (50 nmol/l)insufficiency12–20 ng/ml (30–50 nmol/l)21–29 ng/ml (52.5–72.5 nmol/l)sufficiency>20 ng/ml (50 nmol/l)>30 ng/ml (75 nmol/l)toxicity>50 ng/ml (125 nmol/l)>150 ng/ml (375 nmol/l)\n\n2.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 141), ('INCOMPLETE_EVIDENCE', 152), ('IMPORTANT_CONSIDERATION', 184), ('IMPORTANT_CONSIDERATION', 266)]	4	[('CHEBI_27300', 'vitamin D', 207, 'vitamin D'), ('GO_0007565', 'female pregnancy', 227, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 381, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 419, 'vitamin D'), ('UBERON_0005063', 'left ventricular compact myocardium', 484, 'Endocrine'), ('CHEBI_28384', 'vitamin K', 502, 'Vitamin D')]
S32-PMC4934634	PMC4934634	11/2015	S32-PMC4934634	['BASED ON lower circulating 25(Oh)D concentrations at a given Vitamin D supplement level in obese and overweight subjects compared to normal weight subjects, ekwaru and coworkers RECENTLY RECOMMENDED that “Vitamin D supplementation be 2–3 times higher for obese subjects and 1.5 times higher for overweight subjects relative to normal weight subjects” [10].']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 178), ('FUTURE_WORK', 187)]	3	[('CHEBI_71657', 'versiconol acetate', 27, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 27, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 205, 'vitamin D')]
S51-PMC4934634	PMC4934634	11/2015	S51-PMC4934634	['the reductions in fertility CAN be restored by Vitamin D supplementation.']	[('INCOMPLETE_EVIDENCE', 28)]	1	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D')]
S57-PMC4934634	PMC4934634	11/2015	S57-PMC4934634	['supplementation with Estrogen was able to prevent the histological changes to vdr-null male Testis and normalize follicular stimulating hormone (fsh), and Luteinizing hormone (lh) levels, INDICATING Vitamin D MIGHT have a contributing ROLE in Spermatogenesis and Male Fertility.']	[('INCOMPLETE_EVIDENCE', 188), ('INCOMPLETE_EVIDENCE', 209), ('SUPERFICIAL_RELATIONSHIP', 235)]	3	[('CHEBI_50114', 'estrogen', 21, 'estrogen'), ('UBERON_0000473', 'testis', 92, 'testis'), ('GO_0001905', 'activation of membrane attack complex', 155, 'luteinizing'), ('CHEBI_27300', 'vitamin D', 199, 'vitamin D'), ('GO_0007283', 'spermatogenesis', 243, 'spermatogenesis'), ('GO_0007141', 'male meiosis I', 263, 'male fertility')]
S82-PMC4934634	PMC4934634	11/2015	S82-PMC4934634	['a supplementation trial involving 128 Vitamin D insufficient (<30 ng/ml, as classified by the authors) iranian women six to eight weeks prior to undergoing freeze-thaw Embryo transfer FOUND no differences in Pregnancy rates between women receiving 50,000 iu Vitamin D/week compared to women receiving Placebo [33].']	[('INCOMPLETE_EVIDENCE', 184)]	1	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('UBERON_0000922', 'embryo', 168, 'embryo'), ('GO_0007565', 'female pregnancy', 208, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 258, 'vitamin D'), ('CHEBI_26130', 'biological pigment', 301, 'placebo')]
S89-PMC4934634	PMC4934634	11/2015	S89-PMC4934634	['ALTHOUGH the amount of Vitamin D provided through the Supplement is lower than the current rdas set by EITHER the iom or Endocrine society, this study SHOULD provide new INSIGHTS into HOW Periconceptional dietary interventions CAN IMPACT Female and Male Fertility, a RESEARCH area that is presently LACKING.']	[('ANOMALY_CURIOUS_FINDING', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 103), ('FUTURE_WORK', 151), ('INCOMPLETE_EVIDENCE', 170), ('EXPLICIT_QUESTION', 184), ('INCOMPLETE_EVIDENCE', 227), ('SUPERFICIAL_RELATIONSHIP', 231), ('INCOMPLETE_EVIDENCE', 267), ('INCOMPLETE_EVIDENCE', 299)]	9	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('CHEBI_16158', 'steroid sulfate', 54, 'supplement'), ('UBERON_0005063', 'left ventricular compact myocardium', 121, 'Endocrine'), ('GO_0007565', 'female pregnancy', 188, 'periconceptional'), ('GO_0007601', 'visual perception', 238, 'female ...'), ('GO_0007141', 'male meiosis I', 249, 'male fertility')]
S111-PMC4934634	PMC4934634	11/2015	S111-PMC4934634	['the THEORY that Vitamin D supplementation CAN help normalize Blood Glucose levels and reduce the incidence of Gestational diabetes is an active AREA of research.']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 42), ('FUTURE_WORK', 144)]	3	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('UBERON_0000178', 'blood', 61, 'blood'), ('CHEBI_17234', 'glucose', 67, 'glucose'), ('GO_0007565', 'female pregnancy', 110, 'gestational')]
S116-PMC4934634	PMC4934634	11/2015	S116-PMC4934634	['the EFFECTS of Vitamin D supplementation (400 iu /day Vitamin D3) on Insulin and Glucose Metabolism were observed in healthy, Pregnant women in their 25th week of Gestation [45].']	[('SUPERFICIAL_RELATIONSHIP', 4)]	1	[('CHEBI_27300', 'vitamin D', 15, 'vitamin D'), ('CHEBI_33279', 'vitamin D5', 54, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 54, 'vitamin D3'), ('GO_0007631', 'feeding behavior', 69, 'insulin ...'), ('PR_000045358', 'insulin family protein', 69, 'insulin'), ('CHEBI_17234', 'glucose', 81, 'glucose'), ('GO_0006006', 'glucose metabolic process', 81, 'glucose metabolism'), ('GO_0007565', 'female pregnancy', 126, 'pregnant'), ('GO_0007565', 'female pregnancy', 163, 'gestation')]
S123-PMC4934634	PMC4934634	11/2015	S123-PMC4934634	['with regard to Pregnancy outcome, there were no cases of polyhydramnios (the accumulation of excess Amniotic Fluid) in the Vitamin D group compared to 17.4% in the placebo group, and a marked reduction of hyperbilirubinemia in infants from the Vitamin D supplemented group (27.3%) COMPARED TO the placebo group (60.9%) was REPORTED ( p = 0.02) [47].']	[('ANOMALY_CURIOUS_FINDING', 281), ('INCOMPLETE_EVIDENCE', 323)]	2	[('GO_0007565', 'female pregnancy', 15, 'pregnancy'), ('UBERON_0000173', 'amniotic fluid', 100, 'amniotic fluid'), ('CHEBI_27300', 'vitamin D', 123, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 244, 'vitamin D')]
S124-PMC4934634	PMC4934634	11/2015	S124-PMC4934634	['these data SUGGEST a positive EFFECT of Vitamin D supplementation on Pregnancy outcomes in women with Gestational diabetes.']	[('INCOMPLETE_EVIDENCE', 11), ('SUPERFICIAL_RELATIONSHIP', 30)]	2	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('GO_0007565', 'female pregnancy', 69, 'pregnancy'), ('GO_0007565', 'female pregnancy', 102, 'gestational')]
S126-PMC4934634	PMC4934634	11/2015	S126-PMC4934634	[', INVESTIGATED the EFFECTS of Vitamin D co-supplemented with Calcium on Metabolic parameters in women diagnosed with Gestational diabetes starting in their 24th–28th week of Gestation.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 2), ('SUPERFICIAL_RELATIONSHIP', 19)]	2	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 61, 'calcium'), ('GO_0008152', 'metabolic process', 72, 'metabolic'), ('GO_0007565', 'female pregnancy', 117, 'gestational'), ('GO_0007565', 'female pregnancy', 174, 'gestation')]
S129-PMC4934634	PMC4934634	11/2015	S129-PMC4934634	['IN AGREEMENT WITH ANOTHER STUDY by the same group [45], Vitamin D plus calcium supplementation improved fasting Plasma Glucose, serum Insulin, homa-ir, hdl, and ldl in women with Gestational diabetes compared TO placebo.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 18), ('QUESTION_ANSWERED_BY_THIS_WORK', 209)]	3	[('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 112, 'plasma'), ('CHEBI_17234', 'glucose', 119, 'glucose'), ('PR_000045358', 'insulin family protein', 134, 'insulin'), ('GO_0007565', 'female pregnancy', 179, 'gestational')]
S131-PMC4934634	PMC4934634	11/2015	S131-PMC4934634	['GIVEN the heightened response with co-supplementation, it SUGGESTS that the EFFECTS of Vitamin D on Gestational diabetes MIGHT be enhanced with the use of Calcium.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 58), ('SUPERFICIAL_RELATIONSHIP', 76), ('INCOMPLETE_EVIDENCE', 121)]	4	[('CHEBI_27300', 'vitamin D', 87, 'vitamin D'), ('GO_0007565', 'female pregnancy', 100, 'gestational'), ('CHEBI_22313', 'alkaline earth metal atom', 155, 'calcium')]
S132-PMC4934634	PMC4934634	11/2015	S132-PMC4934634	['WHILE Vitamin D supplementation to women with Gestational diabetes improved Metabolic parameters, what IS NEEDED are clinical trials investigating the extent to WHICH Vitamin D supplementation decreases adverse Perinatal outcomes ASSOCIATED with Gestational diabetes including macrosomia, Respiratory distress, and Postnatal hypoglycemia.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('FUTURE_WORK', 103), ('EXPLICIT_QUESTION', 161), ('SUPERFICIAL_RELATIONSHIP', 230)]	4	[('CHEBI_27300', 'vitamin D', 6, 'vitamin D'), ('GO_0007565', 'female pregnancy', 46, 'gestational'), ('GO_0008152', 'metabolic process', 76, 'metabolic'), ('CHEBI_27300', 'vitamin D', 167, 'vitamin D'), ('GO_0036268', 'swimming', 211, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 211, 'perinatal'), ('GO_0007565', 'female pregnancy', 246, 'gestational'), ('UBERON_0001004', 'respiratory system', 289, 'respiratory'), ('GO_0007567', 'parturition', 315, 'postnatal')]
S133-PMC4934634	PMC4934634	11/2015	S133-PMC4934634	['to test the dose response EFFECT of Vitamin D on Glucose Metabolism, doses of 200 iu/day, 50,000 iu/monthly, or 50,000 iu/biweekly Vitamin D3Were chosen to supplement healthy (non-Gestational diabetes), Pregnant women with severe Vitamin D deficiency (7.6 ± 6.3 ng/ml) from the 12th week of Gestation to Delivery [49].']	[('SUPERFICIAL_RELATIONSHIP', 26)]	1	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('CHEBI_17234', 'glucose', 49, 'glucose'), ('GO_0006006', 'glucose metabolic process', 49, 'glucose metabolism'), ('CHEBI_73706', 'bromosuccinate', 131, 'vitamin D3were'), ('PR_000017209', 'utrophin', 131, 'vitamin D3were'), ('GO_0007565', 'female pregnancy', 180, 'gestational'), ('GO_0007565', 'female pregnancy', 203, 'pregnant'), ('CHEBI_27300', 'vitamin D', 230, 'vitamin D'), ('GO_0007565', 'female pregnancy', 291, 'gestation'), ('GO_0007567', 'parturition', 304, 'delivery')]
S145-PMC4934634	PMC4934634	11/2015	S145-PMC4934634	[', INVESTIGATED the ASSOCIATION of circulating maternal 1,25(Oh)2D levels on Preeclampsia and the EFFECT of Vitamin D supplementation on Placental Cytokine Production in Rats [57].']	[('QUESTION_ANSWERED_BY_THIS_WORK', 2), ('SUPERFICIAL_RELATIONSHIP', 19), ('SUPERFICIAL_RELATIONSHIP', 97)]	3	[('CHEBI_82784', 'PVP38-Ag NP', 55, '1,25(OH)2D'), ('GO_0007128', 'meiotic prophase I', 76, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin D'), ('UBERON_0001987', 'placenta', 136, 'placental'), ('GO_0001814', 'negative regulation of antibody-dependent cellular cytotoxicity', 146, 'cytokine production'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 169, 'rats')]
S149-PMC4934634	PMC4934634	11/2015	S149-PMC4934634	['TO INVESTIGATE the EFFECT of Vitamin D supplementation on Blood pressure and Circulating T Cells, the Rats induced by reduced Uterine perfusion pressure (rupp), a MODEL of preeclampsia, were administered Vitamin D2Or Vitamin D3On Gestation days 14–18 [57].']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('SUPERFICIAL_RELATIONSHIP', 19), ('INCOMPLETE_EVIDENCE', 163)]	3	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('UBERON_0000178', 'blood', 58, 'blood'), ('CL_0000080', 'circulating cell', 77, 'circulating'), ('CL_0000084', 'T cell', 89, 'T cells'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 102, 'rats'), ('UBERON_0000995', 'uterus', 126, 'uterine'), ('CHEBI_27329', 'xanthosine phosphate', 204, 'vitamin D2or'), ('PR_000017209', 'utrophin', 204, 'vitamin D2or'), ('CHEBI_63460', 'parkeol', 217, 'vitamin D3on'), ('PR_000017209', 'utrophin', 217, 'vitamin D3on'), ('GO_0007565', 'female pregnancy', 230, 'gestation')]
S164-PMC4934634	PMC4934634	11/2015	S164-PMC4934634	['THUS, it is NOT SURPRISING that this study FOUND no effect of the Vitamin D supplementation on incidences of Preterm Birth, Preeclampsia, or small for Gestation age SINCE 23% of participants had persistent Serum 25(Oh)D below 10 ng/ml which IS CONSIDERED Vitamin D deficiency status by both the iom and endocrine society (table 1).']	[('PROBABLE_UNDERSTANDING', 0), ('PROBABLE_UNDERSTANDING', 12), ('INCOMPLETE_EVIDENCE', 43), ('PROBABLE_UNDERSTANDING', 165), ('INCOMPLETE_EVIDENCE', 241)]	5	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('GO_0007565', 'female pregnancy', 109, 'preterm birth'), ('GO_0007128', 'meiotic prophase I', 124, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 151, 'gestation'), ('UBERON_0001977', 'blood serum', 206, 'serum'), ('CHEBI_71657', 'versiconol acetate', 212, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 212, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 255, 'vitamin D')]
S166-PMC4934634	PMC4934634	11/2015	S166-PMC4934634	[', provided Vitamin D supplement doses DEPENDING ON baseline level of Serum 25(Oh)D levels or placebo [62].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 38)]	1	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('UBERON_0001977', 'blood serum', 69, 'serum'), ('CHEBI_71657', 'versiconol acetate', 75, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 75, '25(OH)D')]
S168-PMC4934634	PMC4934634	11/2015	S168-PMC4934634	['infants of mothers receiving Vitamin D supplementation were more LIKELY to reach Vitamin D sufficiency at Birth compare to infants of non-supplemented mothers (46.2% vs. 14%, respectively), HOWEVER, over half of the infants in the Supplement group still had suboptimal Vitamin D status.']	[('PROBABLE_UNDERSTANDING', 65), ('ANOMALY_CURIOUS_FINDING', 190)]	2	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('GO_0007567', 'parturition', 106, 'birth'), ('CHEBI_16158', 'steroid sulfate', 231, 'supplement'), ('CHEBI_27300', 'vitamin D', 269, 'vitamin D')]
S171-PMC4934634	PMC4934634	11/2015	S171-PMC4934634	['Vitamin D supplementation is a low cost intervention strategy and ADDITIONAL clinical TRIALS powered to determine the EFFECTS of Vitamin D on Preeclampsia PREVENTION and treatment ARE clearly WARRANTED.']	[('FUTURE_WORK', 66), ('SUPERFICIAL_RELATIONSHIP', 118), ('SUPERFICIAL_RELATIONSHIP', 155), ('FUTURE_WORK', 180)]	4	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 129, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 142, 'preeclampsia')]
S192-PMC4934634	PMC4934634	11/2015	S192-PMC4934634	['one randomized controlled trial INVESTIGATED the EFFECTS of Prenatal Vitamin D supplementation on Respiratory outcomes in children at three years of age.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 32), ('SUPERFICIAL_RELATIONSHIP', 49)]	2	[('GO_0007565', 'female pregnancy', 60, 'prenatal'), ('CHEBI_27300', 'vitamin D', 69, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 98, 'respiratory')]
S199-PMC4934634	PMC4934634	11/2015	S199-PMC4934634	['ALTHOUGH Cord Blood 25(Oh)D levels were significantly higher in the supplemented children compared TO the control group, ONLY a small percentage of offspring receiving daily Vitamin D (13%) or bolus Vitamin D (3%) had Cord Blood Vitamin D levels ≥ 50 nmol/l.']	[('ANOMALY_CURIOUS_FINDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 99), ('ANOMALY_CURIOUS_FINDING', 121)]	3	[('UBERON_0009472', 'axilla', 9, 'cord blood'), ('CHEBI_71657', 'versiconol acetate', 20, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 20, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 174, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 199, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 218, 'cord'), ('UBERON_0000178', 'blood', 223, 'blood'), ('CHEBI_27300', 'vitamin D', 229, 'vitamin D')]
S201-PMC4934634	PMC4934634	11/2015	S201-PMC4934634	['children will be followed for three years for Respiratory health outcomes and the data will provide a better look into the EFFECTS of a higher dose Vitamin D supplement on allergic outcomes.']	[('SUPERFICIAL_RELATIONSHIP', 123)]	1	[('UBERON_0001004', 'respiratory system', 46, 'respiratory'), ('CHEBI_27300', 'vitamin D', 148, 'vitamin D')]
S203-PMC4934634	PMC4934634	11/2015	S203-PMC4934634	['in an on-GOING TRIAL (Vitamin D antenatal asthma reduction trial, vdaart) the INFLUENCE of Vitamin D supplementation beginning in the second Trimester on different infant allergic disease risk at three years of age is being explored [76].']	[('INCOMPLETE_EVIDENCE', 8), ('SUPERFICIAL_RELATIONSHIP', 78)]	2	[('CHEBI_28384', 'vitamin K', 22, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 141, 'trimester')]
S209-PMC4934634	PMC4934634	11/2015	S209-PMC4934634	[', REPORTED that supplementing both mother/infant pairs with Vitamin D from the third trimester to 6 months Postnatal reduced the amount of primary care visits for acute respiratory infection [77].']	[('INCOMPLETE_EVIDENCE', 2)]	1	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('GO_0007567', 'parturition', 107, 'postnatal')]
S212-PMC4934634	PMC4934634	11/2015	S212-PMC4934634	['SINCE THE study LOOKED AT the number of visits RATHER than confirmed diagnosis of infection, THIS STUDY SUGGESTS infant Vitamin D supplementation in addition to Prenatal supplementation MIGHT be BENEFICIAL in reducing health care visits for acute Respiratory infections.']	[('PROBLEM_COMPLICATION', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 6), ('INCOMPLETE_EVIDENCE', 16), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 47), ('QUESTION_ANSWERED_BY_THIS_WORK', 93), ('INCOMPLETE_EVIDENCE', 104), ('INCOMPLETE_EVIDENCE', 186), ('SUPERFICIAL_RELATIONSHIP', 195)]	8	[('CHEBI_27300', 'vitamin D', 120, 'vitamin D'), ('GO_0007565', 'female pregnancy', 161, 'prenatal'), ('UBERON_0001004', 'respiratory system', 247, 'respiratory')]
S225-PMC4934634	PMC4934634	11/2015	S225-PMC4934634	['risk of toxicity\nthe causes of Vitamin D intoxication from high dietary intakes CAN result from errors in fortification dosages, manufacturing mistakes of over-the-counter supplements, or misunderstanding doctor recommendations.']	[('INCOMPLETE_EVIDENCE', 80)]	1	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D')]
S234-PMC4934634	PMC4934634	11/2015	S234-PMC4934634	['STILL, SOME professionals fear that with the increase in supplementation rates, there COULD BE a rise in Vitamin D toxicity.']	[('ANOMALY_CURIOUS_FINDING', 0), ('IMPORTANT_CONSIDERATION', 0), ('INCOMPLETE_EVIDENCE', 7), ('INCOMPLETE_EVIDENCE', 86)]	4	[('CHEBI_27300', 'vitamin D', 105, 'vitamin D')]
S251-PMC4934634	PMC4934634	11/2015	S251-PMC4934634	['data regarding long-term high dose Vitamin D supplementation in women of Childbearing age are LACKING.']	[('FULL_UNKNOWN', 94)]	1	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('GO_0007129', 'homologous chromosome pairing at meiosis', 73, 'childbearing')]
S253-PMC4934634	PMC4934634	11/2015	S253-PMC4934634	['also, studies powered TO DETERMINE the EFFECT of separate ethnic groups’ varying baseline Vitamin D levels on 25(Oh)D levels after different Vitamin D supplementation doses will provide more concrete INFORMATION for individualized RECOMMENDATIONS during Pregnancy.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 22), ('SUPERFICIAL_RELATIONSHIP', 39), ('INCOMPLETE_EVIDENCE', 200), ('FUTURE_WORK', 231)]	4	[('CHEBI_27300', 'vitamin D', 90, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 110, '25(OH)D'), ('PR_000011040', 'nuclear receptor coactivator 1', 112, '(OH)D'), ('CHEBI_27300', 'vitamin D', 141, 'vitamin D'), ('GO_0007565', 'female pregnancy', 254, 'pregnancy')]
S255-PMC4934634	PMC4934634	11/2015	S255-PMC4934634	['the women in both groups had mean baseline levels considered Vitamin D deficient THUS supplementing higher amounts than 1200 iu/day would be needed to achieve sufficiency for this population.']	[('PROBABLE_UNDERSTANDING', 81)]	1	[('CHEBI_27300', 'vitamin D', 61, 'vitamin D')]
S261-PMC4934634	PMC4934634	11/2015	S261-PMC4934634	['ALTHOUGH both single and daily doses of Vitamin D3Seem to be SAFE, CAUTION SHOULD BE CONSIDERED when supplementing at these high doses in Pregnant women, PARTICULARLY if baseline Vitamin D status is sufficient.']	[('ANOMALY_CURIOUS_FINDING', 0), ('IMPORTANT_CONSIDERATION', 61), ('FUTURE_WORK', 67), ('INCOMPLETE_EVIDENCE', 67), ('FUTURE_WORK', 75), ('FUTURE_WORK', 85), ('ANOMALY_CURIOUS_FINDING', 154), ('IMPORTANT_CONSIDERATION', 154)]	8	[('CHEBI_64387', 'thiosultap(1-)', 40, 'vitamin D3seem'), ('GO_0007565', 'female pregnancy', 138, 'pregnant'), ('CHEBI_27300', 'vitamin D', 179, 'vitamin D')]
S262-PMC4934634	PMC4934634	11/2015	S262-PMC4934634	['a one-time, Oral bolus of Vitamin D is an EFFECTIVE way to treat Vitamin D deficiency AS 25(Oh)D levels quickly rise following supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 42), ('PROBABLE_UNDERSTANDING', 86)]	2	[('UBERON_0000165', 'mouth', 12, 'oral'), ('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 89, '25(OH)D')]
S265-PMC4934634	PMC4934634	11/2015	S265-PMC4934634	['it is not COMPLETELY known HOW large, acute increases in circulating 25(Oh)D levels immediately following supplementation CAN AFFECT a fetus/infant, who are VULNERABLE to Vitamin D toxicity at this time in development.']	[('PROBABLE_UNDERSTANDING', 10), ('EXPLICIT_QUESTION', 27), ('INCOMPLETE_EVIDENCE', 122), ('SUPERFICIAL_RELATIONSHIP', 126), ('IMPORTANT_CONSIDERATION', 157)]	5	[('CHEBI_71657', 'versiconol acetate', 69, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 69, '25 ... OH ... D'), ('CHEBI_27300', 'vitamin D', 171, 'vitamin D')]
S266-PMC4934634	PMC4934634	11/2015	S266-PMC4934634	['as PREVIOUSLY mentioned, short-term studies GENERALLY AGREE with its SAFETY BUT long-term STUDIES ARE NEEDED to address the QUESTION of WHETHER large bolus Vitamin D supplementation during Pregnancy is ASSOCIATED with any adverse health outcomes in the offspring later in Life.']	[('INCOMPLETE_EVIDENCE', 3), ('PROBABLE_UNDERSTANDING', 44), ('INCOMPLETE_EVIDENCE', 54), ('IMPORTANT_CONSIDERATION', 69), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 76), ('FUTURE_WORK', 90), ('EXPLICIT_QUESTION', 124), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 136), ('EXPLICIT_QUESTION', 136), ('SUPERFICIAL_RELATIONSHIP', 202)]	10	[('CHEBI_27300', 'vitamin D', 156, 'vitamin D'), ('GO_0007565', 'female pregnancy', 189, 'pregnancy'), ('UBERON_0000104', 'life cycle', 272, 'life')]
S276-PMC4934634	PMC4934634	11/2015	S276-PMC4934634	['higher Vitamin D supplement arms were able to sustain higher infant Vitamin D Serum levels at 12 months when compared to 400 iu/day, which AGREES WITH a study by grant et al.']	[('INCOMPLETE_EVIDENCE', 139)]	1	[('CHEBI_27300', 'vitamin D', 7, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 68, 'vitamin D'), ('UBERON_0001977', 'blood serum', 78, 'serum')]
S279-PMC4934634	PMC4934634	11/2015	S279-PMC4934634	['ALTHOUGH numerous cases of newborn Vitamin D toxicity HAVE BEEN REPORTED over the past 80 years, toxicity is RARE when compared to the number of newborns receiving Vitamin D supplementation [95,96,97,98].']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 54), ('INCOMPLETE_EVIDENCE', 109)]	3	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 164, 'vitamin D')]
S280-PMC4934634	PMC4934634	11/2015	S280-PMC4934634	['a RECENT case report on an exclusively Breastfed four-month old infant receiving over the counter liquid Vitamin D supplementation SHOWED 25(Oh)D levels of 294 ng/ml, severe hypercalcemia, hypercalciuria, and nephrocalcinosis [95].']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 131)]	2	[('GO_0007567', 'parturition', 39, 'breastfed'), ('CHEBI_27300', 'vitamin D', 105, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 138, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 144, 'D')]
S288-PMC4934634	PMC4934634	11/2015	S288-PMC4934634	['also, loss of function mutations in 24-hydroylase was found to be a risk factor for idiopathic infantile hypercalcemia making those infants more susceptible to Vitamin D toxicity EVEN at lower Vitamin D supplementation doses [86], THUS genetics CAN play a ROLE in both Vitamin D deficiency and toxicity.']	[('ANOMALY_CURIOUS_FINDING', 179), ('PROBABLE_UNDERSTANDING', 231), ('INCOMPLETE_EVIDENCE', 245), ('SUPERFICIAL_RELATIONSHIP', 256)]	4	[('CHEBI_27300', 'vitamin D', 160, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 193, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 269, 'vitamin D')]
S296-PMC4934634	PMC4934634	11/2015	S296-PMC4934634	['additional fortification or supplementation STRATEGIES WOULD BE NEEDED to reach rda levels of Vitamin D intake CONSISTENTLY, especially in Individuals with low intakes of fish/seafood or fortified dairy foods, other fortified foods (e.g., breakfast cereals) and beverages”.']	[('FUTURE_WORK', 44), ('FUTURE_WORK', 55), ('PROBABLE_UNDERSTANDING', 111)]	3	[('CHEBI_27300', 'vitamin D', 94, 'vitamin D'), ('NCBITaxon_1', 'root', 139, 'individuals')]
S303-PMC4934634	PMC4934634	11/2015	S303-PMC4934634	['Vitamin D supplementation/fortification HAS also BEEN met with OPPOSITION [107] DUE TO CONCERNS that Vitamin D is a hormone and SHOULD BE treated as such including addressing efficacy, dose and side effects.']	[('INCOMPLETE_EVIDENCE', 40), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 63), ('PROBLEM_COMPLICATION', 80), ('PROBLEM_COMPLICATION', 87), ('FUTURE_WORK', 128)]	5	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin D')]
S305-PMC4934634	PMC4934634	11/2015	S305-PMC4934634	['OTHER CONCERNS are the INSUFFICIENT EVIDENCE to determine the EFFECTS of Vitamin D supplementation/fortification on bone health and fracture incidence and that fda RECOMMENDATIONS to include Vitamin D on Food labels MAY ENCOURAGE fortification of Vitamin D in products that would not otherwise necessarily be RECOMMENDED, and lastly, that there is SOME EVIDENCE for POSSIBLE adverse consequences to Vitamin D fortification [107].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('PROBLEM_COMPLICATION', 6), ('INCOMPLETE_EVIDENCE', 23), ('SUPERFICIAL_RELATIONSHIP', 62), ('FUTURE_WORK', 164), ('INCOMPLETE_EVIDENCE', 216), ('FUTURE_WORK', 220), ('FUTURE_WORK', 309), ('INCOMPLETE_EVIDENCE', 348), ('INCOMPLETE_EVIDENCE', 366)]	10	[('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 191, 'vitamin D'), ('CHEBI_33290', 'food', 204, 'food'), ('CHEBI_27300', 'vitamin D', 247, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 399, 'vitamin D')]
S306-PMC4934634	PMC4934634	11/2015	S306-PMC4934634	['WHILE the ESSENTIALITY of adequate Vitamin D during Pregnancy is not DISPUTED, CONTROVERSY exists over the RECOMMENDED dietary intake levels, the mathematical approaches to calculating that level, and the endpoints used to determine REQUIREMENTS; the concentrations of circulating 25(Oh)D that denote deficiency, insufficiency and adequacy status; and WHETHER race, body weight or OTHER factors SHOULD BE TAKEN into account when making dietary RECOMMENDATIONS, similarly, it is NOT CLEAR WHAT Vitamin D supplementation regimens are most EFFECTIVE during Pregnancy; WHETHER mother, child OR both SHOULD BE supplemented; and WHETHER there are long-term CONSEQUENCES of supplementation.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('IMPORTANT_CONSIDERATION', 10), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 69), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 79), ('FUTURE_WORK', 107), ('IMPORTANT_CONSIDERATION', 233), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 352), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 381), ('FUTURE_WORK', 395), ('IMPORTANT_CONSIDERATION', 405), ('FUTURE_WORK', 444), ('FULL_UNKNOWN', 478), ('EXPLICIT_QUESTION', 488), ('SUPERFICIAL_RELATIONSHIP', 537), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 565), ('FUTURE_WORK', 595), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 623), ('PROBLEM_COMPLICATION', 651)]	18	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('GO_0007565', 'female pregnancy', 52, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 281, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 281, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 493, 'vitamin D'), ('GO_0007565', 'female pregnancy', 554, 'pregnancy')]
S19-PMC4944244	PMC4944244	7/2016	S19-PMC4944244	['attention also MUST BE given to those who have dark skin, less skin exposed to sunlight and obese because they have a higher RISK of Vitamin D deficiency warranting Vitamin D supplement, mainly during Pregnancy and Lactation [11].']	[('IMPORTANT_CONSIDERATION', 15), ('IMPORTANT_CONSIDERATION', 125)]	2	[('CHEBI_27300', 'vitamin D', 133, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 165, 'vitamin D'), ('GO_0007565', 'female pregnancy', 201, 'pregnancy'), ('GO_0007595', 'lactation', 215, 'lactation')]
S21-PMC4944244	PMC4944244	7/2016	S21-PMC4944244	['[12] REVEALED that ethnic minorities (asian) SHOULD BE RECOMMENDED for biochemical screening in early Pregnancy, followed by supplement if low levels of Vitamin D was FOUND.']	[('INCOMPLETE_EVIDENCE', 5), ('FUTURE_WORK', 45), ('FUTURE_WORK', 55), ('INCOMPLETE_EVIDENCE', 167)]	4	[('GO_0007565', 'female pregnancy', 102, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 153, 'vitamin D')]
S24-PMC4944244	PMC4944244	7/2016	S24-PMC4944244	['three IMPORTANT sources of Vitamin D are sunlight, Vitamin D supplements and Food.']	[('IMPORTANT_CONSIDERATION', 6)]	1	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('CHEBI_33290', 'food', 77, 'food')]
S75-PMC4944244	PMC4944244	7/2016	S75-PMC4944244	['caption (table-wrap): table 1\n\nsocio-demographic, Antenatal, skin characteristics and Vitamin D intake of first trimester Pregnant women ( n \u2009=\u2009396)independent variablesnpercentmean\u2009±\u2009sd /\xa0median (iqr 25\xa0%, 75\xa0%)a) socio-demographic factors\u2003age (year)28.06\u2009±\u20094.09 (min\u2009=\u200918, max\u2009=\u200940)\u2003ethnic groups\u2003\u2003malay30777.5\u2003\u2003chinese4411.2\u2003\u2003indian358.8\u2003\u2003others102.5\u2003educational status\u2003\u2003primary school164.0\u2003\u2003secondary school14937.6\u2003\u2003tertiary school23158.4\u2003working status\u2003\u2003working30176.0\u2003\u2003not working9524.0\u2003household members3 (2,4) (min\u2009=\u20092, max\u2009=\u200912)\u2003household income per monthrm3500 (2800,5000) (min\u2009=\u2009rm900, max\u2009=\u2009rm20 000)b) factors related to Antenatal\u2003Week Of Pregnancy10 (8,12) (min\u2009=\u20094, max\u2009=\u200912)\u2003gravidity2 (1,3) (min\u2009=\u20091, max\u2009=\u20099)\u2003parity0 (0,1) (min\u2009=\u20090, max\u2009=\u20096)\u2003smoking status\u2003\u2003yes30.8\u2003\u2003no39399.2\u2003last child Birth\u2003\u2003≤ 2\xa0years12461.1\u2003\u2003>2\xa0years7938.9\u2003\u2003not applicable (first Pregnancy)193\u2003still breastfeeding\u2003\u2003yes4122.9\u2003\u2003no13879.1\u2003\u2003not applicable (no child)217\u2003body mass index (bmi) before Pregnancy(kg/m2)22.69 (19.95, 26.36) (min\u2009=\u200914.29, max\u2009=\u200953.90)\u2003weight at first Antenatal visit (kg)57.70 (49.60,68.00) (min\u2009=\u200933.00, max\u2009=\u2009148.70)c) factors related to skin\u2003fitzpatrick skin classification\u2003\u2003skin type i -ii10326.0\u2003\u2003skin type iii17343.7\u2003\u2003skin type iv-vi12030.3\u2003Melanin indices (using mexameter 18) (0-999.000)302.17 (245.00, 302.17) (min\u2009=\u2009133.33, max\u2009=\u2009949.33)\u2003sun protection score (0-8)5 (4,5) (min\u2009=\u20090, max\u2009=\u20097)\u2003the length of time exposed to sunlight (minutes per week)37.50 (0,150) (min\u2009=\u20090, max\u2009=\u20091680)d) factors related to Vitamin D intake\u2003intake of Vitamin D in Food (iu/day)202.16 (124.94, 334.62) (min\u2009=\u200913.50, max\u2009=\u20091523.12)\u2003the number of respondents taking Antenatal Supplements\u2003\u2003taking Supplements containing Vitamin D4411.1\u2003\u2003taking supplements without Vitamin D intake61.5\u2003\u2003not taking supplement34687.4\u2003Calcium and Vitamin D supplement\u2003\u2003no38697.5\u2003\u2003yes102.5\u2003intake of Vitamin D from Food and supplements (iu/day)220.04 (137.88, 376.45) (min\u2009=\u200915.10, max\u2009=\u20091523.12)\u2003the level of Vitamin D taken from Food and supplements (iu/day)\u2003\u2003<200\xa0iu/day17844.90\u2003\u2003≥200\xa0iu/day21855.10\n\ncaption (table-wrap): table 2\n\nSerum Vitamin D (25(Oh)D) concentrations among first Trimester Pregnant women ( n \u2009=\u2009396)Serum Vitamin dnpercentmedian (iqr 25\xa0%, 75\xa0%)Serum concentration of 25 (Oh)D nmol/l27.11 (19.87,36.99) (min\u2009=\u20097.50, max\u2009=\u2009121.43)Serum concentration of 25 (Oh) D nmol/l (categorized)\u2003<25.00\xa0nmol/l17443.9\u200325-49.99\xa0nmol/l18446.5\u200350-74.99\xa0nmol/l338.3\u2003≥75\xa0nmol/l51.3serum concentration of 25 (Oh) D nmol/l (categorized)\u2003<50\xa0nmol/l35890.4\u2003≥50\xa0nmol/l389.6\ntable\xa03shows the association between each independent variable with hypovitaminosis d. age, ethnicity, education level, fitzpatrick classification, Melanin indices, sun protection score and Intake of Vitamin D from Food have ASSOCIATION with hypovitaminosis D ( p \u2009<\u20090.05).']	[('SUPERFICIAL_RELATIONSHIP', 2779)]	1	[('GO_0007567', 'parturition', 50, 'antenatal'), ('CHEBI_27300', 'vitamin D', 86, 'vitamin D'), ('GO_0007565', 'female pregnancy', 122, 'pregnant'), ('GO_0003410', 'anterior rotation of the optic cup', 634, 'antenatal Week of pregnancy10'), ('GO_0007567', 'parturition', 806, 'Birth'), ('GO_0007565', 'female pregnancy', 869, 'pregnancy'), ('GO_0007565', 'female pregnancy', 984, 'pregnancy'), ('GO_0007567', 'parturition', 1064, 'antenatal'), ('CHEBI_25179', 'melanins', 1260, 'Melanin'), ('CHEBI_27300', 'vitamin D', 1528, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1555, 'vitamin D'), ('CHEBI_33290', 'food', 1568, 'food'), ('GO_0007567', 'parturition', 1667, 'antenatal'), ('CHEBI_33341', 'titanium atom', 1677, 'supplements'), ('CHEBI_33341', 'titanium atom', 1697, 'supplements'), ('CHEBI_72741', '2-arachidonyl-sn-glycero-3-phosphoethanolamine', 1720, 'vitamin D4411'), ('CHEBI_27300', 'vitamin D', 1764, 'vitamin D'), ('CHEBI_31341', 'calcium dihydroxide', 1815, 'Calcium'), ('CHEBI_27300', 'vitamin D', 1827, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1879, 'vitamin D'), ('CHEBI_33290', 'food', 1894, 'food'), ('CHEBI_27300', 'vitamin D', 1989, 'vitamin D'), ('CHEBI_33290', 'food', 2010, 'food'), ('UBERON_0001977', 'blood serum', 2114, 'Serum'), ('CHEBI_27300', 'vitamin D', 2120, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 2131, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 2131, '25 ... OH ... D'), ('GO_0009294', 'DNA mediated transformation', 2167, 'trimester'), ('GO_0007565', 'female pregnancy', 2177, 'pregnant'), ('UBERON_0001977', 'blood serum', 2203, 'Serum'), ('CHEBI_33229', 'vitamin (role)', 2209, 'vitamin'), ('UBERON_0001977', 'blood serum', 2249, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 2272, '25 (OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 2272, '25'), ('PR_000006444', 'diacylglycerol kinase delta', 2279, 'D'), ('UBERON_0001977', 'blood serum', 2333, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 2356, '25 (OH) D'), ('CHEBI_71657', 'versiconol acetate', 2489, '25 (OH) D'), ('CHEBI_25179', 'melanins', 2702, 'melanin'), ('GO_0007631', 'feeding behavior', 2744, 'intake'), ('CHEBI_27300', 'vitamin D', 2754, 'vitamin D'), ('CHEBI_33290', 'food', 2769, 'food'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 2812, 'D')]
S79-PMC4944244	PMC4944244	7/2016	S79-PMC4944244	['HOWEVER, in order to prevent the occurrence of multicollinearity, Melanin index, Vitamin D intake from Food and supplements, and the level of Vitamin D in foods and Supplements (iu/day) were not included in the multivariable analysis.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0)]	1	[('CHEBI_25179', 'melanins', 66, 'melanin'), ('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('CHEBI_33290', 'food', 103, 'food'), ('CHEBI_27300', 'vitamin D', 142, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 165, 'supplements')]
S100-PMC4944244	PMC4944244	7/2016	S100-PMC4944244	['this is IN LINE WITH OUR STUDY, where the PREVALENCE of hypovitaminosis D (25 (Oh) D Serum <50\xa0nmol/l) in the first trimester was high (90.4\xa0%) and only 11.1\xa0% took supplements containing Vitamin D. moreover, most of them had just started the Supplements and the results MAY not have AFFECTED their Vitamin D status yet.']	[('INCOMPLETE_EVIDENCE', 8), ('QUESTION_ANSWERED_BY_THIS_WORK', 21), ('IMPORTANT_CONSIDERATION', 42), ('INCOMPLETE_EVIDENCE', 271), ('SUPERFICIAL_RELATIONSHIP', 284)]	5	[('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 72, 'D'), ('CHEBI_71657', 'versiconol acetate', 75, '25 (OH) D'), ('PR_000003010', 'moesin isoform 1', 78, '(OH ... D'), ('UBERON_0001977', 'blood serum', 85, 'serum'), ('CHEBI_27300', 'vitamin D', 188, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 243, 'supplements'), ('CHEBI_27300', 'vitamin D', 299, 'vitamin D')]
S118-PMC4944244	PMC4944244	7/2016	S118-PMC4944244	['LACK of Vitamin D was not found in Pregnant women who consumed Antenatal Vitamin supplements.']	[('PROBLEM_COMPLICATION', 0)]	1	[('CHEBI_27300', 'vitamin D', 8, 'vitamin D'), ('GO_0007565', 'female pregnancy', 35, 'pregnant'), ('GO_0007567', 'parturition', 63, 'antenatal'), ('CHEBI_33229', 'vitamin (role)', 73, 'vitamin')]
S122-PMC4944244	PMC4944244	7/2016	S122-PMC4944244	['their study was SIMILAR TO ours, where intake of Vitamin D supplement or Prenatal Vitamins containing Vitamin D in the first trimester was not associated with adequate Serum 25(Oh)D level.']	[('INCOMPLETE_EVIDENCE', 16)]	1	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('GO_0007565', 'female pregnancy', 73, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 82, 'vitamins'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin D'), ('UBERON_0001977', 'blood serum', 168, 'serum'), ('CHEBI_33010', 'chromide(1-)', 176, '(OH)D')]
S123-PMC4944244	PMC4944244	7/2016	S123-PMC4944244	['this was DUE TO ONLY 11.1\xa0% respondents took Vitamin D supplements or Antenatal Vitamin supplements containing Vitamin D in the first Trimester.']	[('PROBLEM_COMPLICATION', 9), ('INCOMPLETE_EVIDENCE', 16)]	2	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('GO_0007567', 'parturition', 70, 'antenatal'), ('CHEBI_33229', 'vitamin (role)', 80, 'vitamin'), ('CHEBI_27300', 'vitamin D', 111, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 134, 'trimester')]
S217-PMC4944244	PMC4944244	7/2016	S217-PMC4944244	['[22] also CLAIMED that there was a significant difference in Serum 25(Oh)D between Pregnant women who took 400\xa0iu or more Vitamin D as Supplements during the Antenatal period and Pregnant women who took\u2009<\u2009400\xa0iu/day or none (or 0.19; 95\xa0% ci: 0.06 to 0.56, p <0.01).']	[('INCOMPLETE_EVIDENCE', 10)]	1	[('UBERON_0001977', 'blood serum', 61, 'serum'), ('CHEBI_71657', 'versiconol acetate', 67, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 67, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 83, 'pregnant'), ('CHEBI_27300', 'vitamin D', 122, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 135, 'supplements'), ('GO_0007567', 'parturition', 158, 'antenatal'), ('UBERON_0001760', 'frontal sinus', 158, 'antenatal'), ('GO_0007565', 'female pregnancy', 179, 'pregnant')]
S227-PMC4944244	PMC4944244	7/2016	S227-PMC4944244	['Calcium supplement with Vitamin D SHOULD BE given earlier to those who do not Consume adequate milk during Pregnancy to prevent adverse health EFFECTS to the mother and fetus.']	[('FUTURE_WORK', 34), ('SUPERFICIAL_RELATIONSHIP', 143)]	2	[('CHEBI_31341', 'calcium dihydroxide', 0, 'Calcium'), ('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('GO_0007631', 'feeding behavior', 78, 'consume'), ('GO_0007565', 'female pregnancy', 107, 'pregnancy')]
S4-PMC4949006	PMC4949006	7/2016	S4-PMC4949006	['Folic Acid SHOULD BE supplemented prior to Conception and continued through AT LEAST the first 28 days of fetal Life to prevent Neural Tube defects, and Vitamin C SHOULD be given to women who smoke to lower the incidence of asthma and wheezing in the children.']	[('FUTURE_WORK', 11), ('PROBABLE_UNDERSTANDING', 76), ('FUTURE_WORK', 163)]	3	[('CHEBI_30751', 'formic acid', 0, 'Folic acid'), ('GO_0007620', 'copulation', 43, 'conception'), ('UBERON_0000104', 'life cycle', 112, 'life'), ('UBERON_0001049', 'neural tube', 128, 'neural tube'), ('CHEBI_27300', 'vitamin D', 153, 'vitamin C')]
S11-PMC4949006	PMC4949006	7/2016	S11-PMC4949006	['Folic Acid, Iodine, and Calcium in all Pregnant women and Vitamin C in smokers are the ONLY Supplements SO FAR SHOWN to be of value for routine use.']	[('INCOMPLETE_EVIDENCE', 87), ('INCOMPLETE_EVIDENCE', 104), ('INCOMPLETE_EVIDENCE', 111)]	3	[('CHEBI_30751', 'formic acid', 0, 'Folic acid'), ('CHEBI_24859', 'iodine atom', 12, 'iodine'), ('CHEBI_22313', 'alkaline earth metal atom', 24, 'calcium'), ('GO_0007565', 'female pregnancy', 39, 'pregnant'), ('CHEBI_27300', 'vitamin D', 58, 'vitamin C'), ('CHEBI_33341', 'titanium atom', 92, 'supplements')]
S132-PMC4949006	PMC4949006	7/2016	S132-PMC4949006	['supplementation does prevent and cure this condition.93–95all studies to date fail to show any significant EFFECTS of Vitamin A supplementation on Pregnancy outcomes for mother or fetus.96more than 10,000 iu of Vitamin A supplementation per day (4 times the recommended daily allowance) increases the risk of cleft lip or palate, Hydrocephalus, and Heart defects.']	[('SUPERFICIAL_RELATIONSHIP', 107)]	1	[('CHEBI_27300', 'vitamin D', 118, 'vitamin A'), ('GO_0007565', 'female pregnancy', 147, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 211, 'vitamin A'), ('UBERON_4100114', 'anterior distal condyle of femur', 330, 'hydrocephalus'), ('UBERON_0000948', 'heart', 349, 'heart')]
S136-PMC4949006	PMC4949006	7/2016	S136-PMC4949006	['Vitamin B6Supplementation HAS BEEN shown in 3 SMALL STUDIES to give a modest gain in Birth weight.99Vitamin C supplementation has not been shown to be of value in improving Pregnancy outcomes,99but HAS SHOWN value for PREVENTION of wheezing and asthma in the children of smokers.100\n\nVitamin E\nONE STUDY CORRELATED risk of wheeze inversely to the level of Vitamin E as well as a linear RELATIONSHIP between the level and the forced Expiratory volume at 1 minute.101NO OTHER STUDIES APPEAR to support OR REFUTE this.']	[('INCOMPLETE_EVIDENCE', 26), ('INCOMPLETE_EVIDENCE', 46), ('INCOMPLETE_EVIDENCE', 198), ('SUPERFICIAL_RELATIONSHIP', 218), ('INCOMPLETE_EVIDENCE', 294), ('SUPERFICIAL_RELATIONSHIP', 304), ('SUPERFICIAL_RELATIONSHIP', 386), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 462), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 468), ('INCOMPLETE_EVIDENCE', 468), ('ANOMALY_CURIOUS_FINDING', 482), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 500), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 503)]	13	[('CHEBI_10122', 'Zizyphine F', 0, 'Vitamin B6supplementation'), ('PR_000017279', 'testis-specific basic protein Y 1', 0, 'Vitamin B6supplementation'), ('GO_0007567', 'parturition', 85, 'birth'), ('CHEBI_65430', 'ardisiphenol A', 98, '99Vitamin C'), ('PR_000004900', 'complement C3', 108, 'C'), ('GO_0007565', 'female pregnancy', 173, 'pregnancy'), ('CHEBI_28384', 'vitamin K', 284, 'Vitamin E'), ('CHEBI_27300', 'vitamin D', 356, 'vitamin E'), ('GO_0010467', 'gene expression', 432, 'expiratory')]
S145-PMC4949006	PMC4949006	7/2016	S145-PMC4949006	['HOWEVER, when Vitamin D deficiency is identified during Pregnancy, supplementation with up to 1000 to 2000 iu/d is CONSIDERED SAFE by MOST EXPERTS.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 115), ('IMPORTANT_CONSIDERATION', 126), ('PROBABLE_UNDERSTANDING', 134), ('PROBABLE_UNDERSTANDING', 139)]	5	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('GO_0007565', 'female pregnancy', 56, 'pregnancy')]
S148-PMC4949006	PMC4949006	7/2016	S148-PMC4949006	['SOME STUDIES REPORT higher long-bone density in fetuses of women with adequate amounts of Vitamin D,115,116but the numbers are SMALL.117the general RECOMMENDATION is 1000 to 2000 mg/d of supplementation, BUT there are no AGREED-UPON levels for sufficiency or insufficiency in Pregnancy.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 127), ('FUTURE_WORK', 148), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 204), ('INCOMPLETE_EVIDENCE', 221)]	6	[('CHEBI_27300', 'vitamin D', 90, 'vitamin D'), ('GO_0007565', 'female pregnancy', 276, 'pregnancy')]
S149-PMC4949006	PMC4949006	7/2016	S149-PMC4949006	['THERE ARE NO STUDIES clearly SHOWING DIFFERENCES in maternal outcomes or fetal survival, Birth weight, or Gestational length relative to Vitamin D,118but studies on bone health (and Lung function and asthma at age 6 years119) SUPPORT a level of AT LEAST 50 nmol/l, which implies a need for some supplementation for all Pregnant women.120–123\n\nCalcium\nwomen lose 3% to 5% of their bone mass while Lactating but rapidly regain it within 6 months after weaning.']	[('FULL_UNKNOWN', 0), ('INCOMPLETE_EVIDENCE', 10), ('INCOMPLETE_EVIDENCE', 29), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 37), ('INCOMPLETE_EVIDENCE', 226), ('PROBABLE_UNDERSTANDING', 245)]	6	[('GO_0007567', 'parturition', 89, 'birth'), ('GO_0007565', 'female pregnancy', 106, 'gestational'), ('CHEBI_27300', 'vitamin D', 137, 'vitamin D'), ('UBERON_0002048', 'lung', 182, 'lung'), ('GO_0007565', 'female pregnancy', 319, 'pregnant'), ('CHEBI_31341', 'calcium dihydroxide', 343, 'Calcium'), ('GO_0007594', 'puparial adhesion', 396, 'lactating')]
S194-PMC4949006	PMC4949006	7/2016	S194-PMC4949006	['there is GOOD EVIDENCE for supplementation with Vitamin C in Pregnant women who smoke.']	[('PROBABLE_UNDERSTANDING', 9)]	1	[('CHEBI_27300', 'vitamin D', 48, 'vitamin C'), ('GO_0007565', 'female pregnancy', 61, 'pregnant')]
S195-PMC4949006	PMC4949006	7/2016	S195-PMC4949006	['there is NO GOOD current EVIDENCE to SHOW value in supplementation for iron and vitamins A, B6, B12, A, e, or D at this time, ALTHOUGH there are many SUGGESTIVE STUDIES for Vitamin D. all Pregnant women SHOULD BE ENCOURAGED to eat a balanced diet rich in fresh or frozen fruits and vegetables, high-quality Carbohydrates including whole grains, and with a good mix of proteins from beans, lean meats, fish, and seafood.']	[('FULL_UNKNOWN', 9), ('INCOMPLETE_EVIDENCE', 25), ('INCOMPLETE_EVIDENCE', 37), ('ANOMALY_CURIOUS_FINDING', 126), ('INCOMPLETE_EVIDENCE', 150), ('FUTURE_WORK', 203), ('FUTURE_WORK', 213)]	7	[('PR_000004370', 'asialoglycoprotein receptor 2', 89, 'A'), ('PR_000004690', 'B-cell lymphoma/leukemia 11A', 92, 'B6'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 96, 'B12'), ('PR_000004370', 'asialoglycoprotein receptor 2', 101, 'A'), ('PR_000006444', 'diacylglycerol kinase delta', 110, 'D'), ('CHEBI_27300', 'vitamin D', 173, 'vitamin D'), ('GO_0007565', 'female pregnancy', 188, 'pregnant'), ('CHEBI_16646', 'carbohydrate', 307, 'carbohydrates')]
S70-PMC4958285	PMC4958285	7/2016	S70-PMC4958285	[')39351008.55\n\nHerbals, homeopathic and dietary medications\nwith respect to herbals, homeopathic and dietary medications, there were a total of 4462 calls, with the majority of these inquiries being unspecified ( n \u2009=\u2009492), this was closely followed by inquires RELATED to Caffeine Consumption ( n \u2009=\u2009415), zinc ( n \u2009=\u2009246), and Vitamin C ( n \u2009=\u2009205) supplements.']	[('SUPERFICIAL_RELATIONSHIP', 261)]	1	[('CHEBI_35581', 'indole', 14, 'Herbals'), ('CHEBI_27732', 'caffeine', 272, 'caffeine'), ('GO_0007631', 'feeding behavior', 281, 'consumption'), ('CHEBI_27300', 'vitamin D', 328, 'vitamin C')]
S60-PMC4969253	PMC4969253	8/2016	S60-PMC4969253	['a series of nine trials have BEEN RECENTLY reviewed to determine the IMPACT of Vitamin A supplementation in PREVENTING mortality and short- and long-term morbidities in very low Birth weight infants [21].']	[('ANOMALY_CURIOUS_FINDING', 29), ('INCOMPLETE_EVIDENCE', 34), ('SUPERFICIAL_RELATIONSHIP', 69), ('SUPERFICIAL_RELATIONSHIP', 108)]	4	[('CHEBI_27300', 'vitamin D', 79, 'vitamin A'), ('GO_0007567', 'parturition', 178, 'birth')]
S61-PMC4969253	PMC4969253	8/2016	S61-PMC4969253	['a meta-analysis of these data [21] SHOWED that at 36\xa0weeks of age, there was a significant reduction in oxygen use in the preterm infants treated with Vitamin A supplementation COMPARED TO the control (placebo) group, ALTHOUGH ONLY a TREND towards reduction of death or chronic Lung disease was observed.']	[('INCOMPLETE_EVIDENCE', 35), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 177), ('ANOMALY_CURIOUS_FINDING', 218), ('ANOMALY_CURIOUS_FINDING', 227), ('INCOMPLETE_EVIDENCE', 234)]	5	[('CHEBI_27300', 'vitamin D', 151, 'vitamin A'), ('UBERON_0002048', 'lung', 278, 'lung')]
S65-PMC4969253	PMC4969253	8/2016	S65-PMC4969253	['no adverse effects due to Vitamin A supplementation were REPORTED in these trials [21].']	[('INCOMPLETE_EVIDENCE', 57)]	1	[('CHEBI_27300', 'vitamin D', 26, 'vitamin A')]
S79-PMC4969253	PMC4969253	8/2016	S79-PMC4969253	['these EFFECTS CAN be PREVENTED or alleviated by proper Vitamin A supplementation during Gestation [25].']	[('SUPERFICIAL_RELATIONSHIP', 6), ('INCOMPLETE_EVIDENCE', 14), ('SUPERFICIAL_RELATIONSHIP', 21)]	3	[('CHEBI_27300', 'vitamin D', 55, 'vitamin A'), ('GO_0007565', 'female pregnancy', 88, 'gestation')]
S13-PMC4971719	PMC4971719	8/2016	S13-PMC4971719	['FUTURE INVESTIGATIONS SHOULD study WHETHER Vitamin D supplementation in early Pregnancy MAY PREVENT Perinatal depressive symptoms.']	[('FUTURE_WORK', 0), ('FUTURE_WORK', 22), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 35), ('INCOMPLETE_EVIDENCE', 88), ('SUPERFICIAL_RELATIONSHIP', 92)]	5	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('GO_0007565', 'female pregnancy', 78, 'pregnancy'), ('GO_0036268', 'swimming', 100, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 100, 'perinatal')]
S167-PMC4971719	PMC4971719	8/2016	S167-PMC4971719	['IF randomized studies SHOW a benefit for Vitamin D for PREVENTION or treatment of Perinatal depression, supplementation MAY benefit maternal fetal and neonatal health [49,50].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 22), ('SUPERFICIAL_RELATIONSHIP', 55), ('INCOMPLETE_EVIDENCE', 120)]	4	[('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('GO_0036268', 'swimming', 82, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 82, 'perinatal')]
S170-PMC4971719	PMC4971719	8/2016	S170-PMC4971719	['IMPORTANT FUTURE AREAS OF RESEARCH would INCLUDE randomized controlled trials of Vitamin D supplementation for women who are screen for depression RISK in early Pregnancy and who are found to have low Vitamin D levels.']	[('FUTURE_WORK', 0), ('IMPORTANT_CONSIDERATION', 0), ('FUTURE_WORK', 10), ('FUTURE_WORK', 41), ('IMPORTANT_CONSIDERATION', 147)]	5	[('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('GO_0007565', 'female pregnancy', 161, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 201, 'vitamin D')]
S7-PMC4973215	PMC4973215	8/2016	S7-PMC4973215	['conclusion:\nidentification of RISK FACTORS (black race, medicaid status, obesity and lack of Prenatal Vitamin use) CAN LEAD TO OPPORTUNITIES for targeted Prenatal Vitamin supplementation to reduce the risk of neonatal Vitamin D deficiency and sga status.']	[('SUPERFICIAL_RELATIONSHIP', 30), ('INCOMPLETE_EVIDENCE', 115), ('PROBABLE_UNDERSTANDING', 119), ('FUTURE_WORK', 127)]	4	[('GO_0007565', 'female pregnancy', 93, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 102, 'vitamin'), ('GO_0007565', 'female pregnancy', 154, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 163, 'vitamin'), ('CHEBI_27300', 'vitamin D', 218, 'vitamin D')]
S10-PMC4973215	PMC4973215	8/2016	S10-PMC4973215	['THUS, levels of neonates at Birth depend entirely on that of the mother and, ACCORDINGLY, SEVERAL STUDIES have CONSISTENTLY CORRELATED Cord Blood 25(Oh)D levels to those of their mothers.1,2,3,4,5,6in addition, maternal Vitamin D deficiency HAS BEEN LINKED to decreased fetal growth and Birth size in OBSERVATIONAL studies.7,8,9\nmaternal Vitamin D deficiency is PREVALENT, the extent of which CAN be INFLUENCED by many variables including skin pigmentation, sun exposure, season, age, Vitamin supplementation and obesity.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 77), ('INCOMPLETE_EVIDENCE', 90), ('PROBABLE_UNDERSTANDING', 111), ('SUPERFICIAL_RELATIONSHIP', 124), ('INCOMPLETE_EVIDENCE', 241), ('SUPERFICIAL_RELATIONSHIP', 250), ('INCOMPLETE_EVIDENCE', 301), ('IMPORTANT_CONSIDERATION', 362), ('INCOMPLETE_EVIDENCE', 393), ('SUPERFICIAL_RELATIONSHIP', 400)]	11	[('GO_0007567', 'parturition', 28, 'birth'), ('UBERON_0002240', 'spinal cord', 135, 'cord'), ('UBERON_0000178', 'blood', 140, 'blood'), ('CHEBI_71657', 'versiconol acetate', 146, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 220, 'vitamin D'), ('GO_0007567', 'parturition', 287, 'birth'), ('CHEBI_27300', 'vitamin D', 338, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 485, 'vitamin')]
S12-PMC4973215	PMC4973215	8/2016	S12-PMC4973215	['far FEWER STUDIES have EXAMINED the RELATIONSHIP between Cord Blood Vitamin D levels, which MAY more ACCURATELY REFLECT fetal levels of Vitamin D, and neonatal outcomes.14,24GIVEN the racial DISPARITIES SEEN in both Vitamin D deficiency and Perinatal outcomes, Vitamin D HAS BEEN PROPOSED as part of the EXPLANATION for this DISPARITY, PARTICULARLY with regard to fetal growth and sga.8\nINCREASED AWARENESS of the GROWING PREVALENCE of maternal Vitamin D deficiency has LED TO an URGENT NEED for CONSIDERATION of supplementation during Pregnancy.']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 23), ('SUPERFICIAL_RELATIONSHIP', 36), ('INCOMPLETE_EVIDENCE', 92), ('PROBABLE_UNDERSTANDING', 101), ('SUPERFICIAL_RELATIONSHIP', 112), ('PROBABLE_UNDERSTANDING', 174), ('IMPORTANT_CONSIDERATION', 191), ('INCOMPLETE_EVIDENCE', 203), ('INCOMPLETE_EVIDENCE', 271), ('INCOMPLETE_EVIDENCE', 280), ('PROBABLE_UNDERSTANDING', 304), ('IMPORTANT_CONSIDERATION', 325), ('IMPORTANT_CONSIDERATION', 336), ('IMPORTANT_CONSIDERATION', 387), ('INCOMPLETE_EVIDENCE', 414), ('IMPORTANT_CONSIDERATION', 422), ('SUPERFICIAL_RELATIONSHIP', 470), ('IMPORTANT_CONSIDERATION', 480), ('FUTURE_WORK', 487), ('FUTURE_WORK', 496)]	21	[('UBERON_0002240', 'spinal cord', 57, 'cord'), ('UBERON_0000178', 'blood', 62, 'blood'), ('CHEBI_27300', 'vitamin D', 68, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 216, 'vitamin D'), ('GO_0036268', 'swimming', 241, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 241, 'perinatal'), ('CHEBI_27300', 'vitamin D', 261, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 445, 'vitamin D'), ('GO_0007565', 'female pregnancy', 536, 'pregnancy')]
S13-PMC4973215	PMC4973215	8/2016	S13-PMC4973215	['ALTHOUGH studies HAVE SHOWN that supplementation increases maternal and Cord Blood Vitamin D levels, changes in clinical outcomes HAVE NOT yet BEEN WELL PROVEN.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 17), ('INCOMPLETE_EVIDENCE', 130)]	3	[('UBERON_0002240', 'spinal cord', 72, 'cord'), ('UBERON_0000178', 'blood', 77, 'blood'), ('CHEBI_27300', 'vitamin D', 83, 'vitamin D')]
S14-PMC4973215	PMC4973215	8/2016	S14-PMC4973215	['THUS, sufficient EVIDENCE is LACKING at this time to RECOMMEND routine Vitamin D supplementation during Pregnancy.12HOWEVER, identification of specific RISK FACTORS for Vitamin D deficiency and the additive EFFECTS of these RISK FACTORS MAY LEAD TO OPPORTUNITIES for targeted supplementation with improved outcomes.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 17), ('FUTURE_WORK', 53), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 116), ('SUPERFICIAL_RELATIONSHIP', 152), ('SUPERFICIAL_RELATIONSHIP', 207), ('SUPERFICIAL_RELATIONSHIP', 224), ('INCOMPLETE_EVIDENCE', 237), ('SUPERFICIAL_RELATIONSHIP', 241), ('FUTURE_WORK', 249)]	10	[('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('GO_0007565', 'female pregnancy', 104, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin D')]
S17-PMC4973215	PMC4973215	8/2016	S17-PMC4973215	['our GOAL was TO IDENTIFY specific high-risk subsets of Pregnant women who MAY BENEFIT from Vitamin D supplementation IN ORDER TO mitigate adverse Perinatal outcomes such as sga.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 13), ('INCOMPLETE_EVIDENCE', 74), ('IMPORTANT_CONSIDERATION', 78), ('QUESTION_ANSWERED_BY_THIS_WORK', 117)]	5	[('GO_0007565', 'female pregnancy', 55, 'pregnant'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('GO_0036268', 'swimming', 146, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 146, 'perinatal')]
S62-PMC4973215	PMC4973215	8/2016	S62-PMC4973215	['ALTHOUGH the prevalence of Vitamin D deficiency in black mothers and neonates is WELL KNOWN, DEBATE exists as to the RELATIONSHIP between race, Vitamin D deficiency and sga.12,14,15,17,18we EXAMINED this RELATIONSHIP in conjunction with additional maternal characteristics in order TO IDENTIFY groups of Pregnant women who could BENEFIT MOST from Vitamin D supplementation.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 81), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 93), ('SUPERFICIAL_RELATIONSHIP', 117), ('QUESTION_ANSWERED_BY_THIS_WORK', 190), ('SUPERFICIAL_RELATIONSHIP', 204), ('QUESTION_ANSWERED_BY_THIS_WORK', 282), ('IMPORTANT_CONSIDERATION', 329), ('PROBABLE_UNDERSTANDING', 337)]	9	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D'), ('GO_0007565', 'female pregnancy', 304, 'pregnant'), ('CHEBI_27300', 'vitamin D', 347, 'vitamin D')]
S94-PMC4973215	PMC4973215	8/2016	S94-PMC4973215	['Vitamin D supplementation during Pregnancy HAS BEEN SHOWN to positively AFFECT Cord Blood Vitamin D levels at Birth.43,44studies of Vitamin D supplementation during Pregnancy THUS FAR HAVE SHOWN CONFLICTING results with respect to Birth weight and reduction of sga.43,45,46,47,48adequately powered and randomized controlled trials of vitamin d supplementation during Pregnancy ARE NEEDED TO ASSESS the IMPACT of supplementation on sga as well as the APPROPRIATE dose and timing of supplementation.']	[('INCOMPLETE_EVIDENCE', 43), ('SUPERFICIAL_RELATIONSHIP', 72), ('INCOMPLETE_EVIDENCE', 175), ('INCOMPLETE_EVIDENCE', 184), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 195), ('FUTURE_WORK', 377), ('FUTURE_WORK', 388), ('SUPERFICIAL_RELATIONSHIP', 402), ('IMPORTANT_CONSIDERATION', 450)]	9	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 33, 'pregnancy'), ('UBERON_0002240', 'spinal cord', 79, 'cord'), ('UBERON_0000178', 'blood', 84, 'blood'), ('CHEBI_27300', 'vitamin D', 90, 'vitamin D'), ('GO_0007567', 'parturition', 110, 'birth'), ('CHEBI_27300', 'vitamin D', 132, 'vitamin D'), ('GO_0007565', 'female pregnancy', 165, 'pregnancy'), ('GO_0007567', 'parturition', 231, 'birth'), ('GO_0007565', 'female pregnancy', 367, 'pregnancy')]
S96-PMC4973215	PMC4973215	8/2016	S96-PMC4973215	['if Vitamin D supplementation does not occur during Pregnancy, it MAY BE IMPERATIVE to identify and offer additional supplementation beyond the routinely recommended 400\u2009iu per day for all infants.28\nthere were several LIMITATIONS to our study.']	[('FUTURE_WORK', 65), ('IMPORTANT_CONSIDERATION', 72), ('INCOMPLETE_EVIDENCE', 218)]	3	[('CHEBI_27300', 'vitamin D', 3, 'vitamin D'), ('GO_0007565', 'female pregnancy', 51, 'pregnancy')]
S104-PMC4973215	PMC4973215	8/2016	S104-PMC4973215	['we IDENTIFIED additive and modifiable maternal RISK FACTORS that WOULD BENEFIT MOST from risk reduction and targeted Vitamin D supplementation.']	[('INCOMPLETE_EVIDENCE', 3), ('SUPERFICIAL_RELATIONSHIP', 47), ('FUTURE_PREDICTION', 65), ('IMPORTANT_CONSIDERATION', 71), ('PROBABLE_UNDERSTANDING', 79)]	5	[('CHEBI_27300', 'vitamin D', 117, 'vitamin D')]
S14-PMC4975901	PMC4975901	8/2016	S14-PMC4975901	['ACCORDING TO the centers for disease control and prevention (cdc), APPROXIMATELY 34\xa0% of women aged 20–39 used a dietary supplement containing Folic Acid and 30\xa0% reported using supplemental Vitamin D in 2003–2006 [2].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 67)]	2	[('CHEBI_30751', 'formic acid', 143, 'folic acid'), ('CHEBI_27300', 'vitamin D', 191, 'vitamin D')]
S44-PMC4976416	PMC4976416	7/2016	S44-PMC4976416	['[30] the antioxidant supplementation through Vitamins E and C and the Mineral zinc HAS BEEN seen to APPARENTLY enhance the antioxidant protection against oxidative stress and allow less time for wound Healing.']	[('INCOMPLETE_EVIDENCE', 83), ('ANOMALY_CURIOUS_FINDING', 100)]	2	[('CHEBI_27300', 'vitamin D', 45, 'vitamins E'), ('PR_000004900', 'complement C3', 60, 'C'), ('CHEBI_46662', 'mineral', 70, 'mineral'), ('GO_0007605', 'sensory perception of sound', 201, 'healing')]
S77-PMC4976416	PMC4976416	7/2016	S77-PMC4976416	['[58]\n\nvitamin e intake during pregnancy and childhood\nVitamin E supplements in Pregnancy USUALLY contain only small doses of Vitamin E, ALTHOUGH adverse EFFECTS have not been OBSERVED EVEN at higher doses.']	[('INCOMPLETE_EVIDENCE', 89), ('ANOMALY_CURIOUS_FINDING', 136), ('SUPERFICIAL_RELATIONSHIP', 153), ('INCOMPLETE_EVIDENCE', 175), ('ANOMALY_CURIOUS_FINDING', 184)]	5	[('CHEBI_28384', 'vitamin K', 54, 'Vitamin E'), ('GO_0007565', 'female pregnancy', 79, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin E')]
S0-PMC4979151	PMC4979151	8/2016	S0-PMC4979151	['Prenatal high-dose Vitamin D3Supplementation has balanced EFFECTS on Cord Blood th1 and th2 Responses\n\nabstract\n\nbackground\nantenatal Vitamin D3(vitd3) supplementation significantly increases maternal and neonatal 25-Hydroxyvitamin D3(25(Oh)D3) concentration, YET the EFFECT of an improvement in maternal-fetal Vitamin D status on the neonatal immune response is UNCLEAR.']	[('SUPERFICIAL_RELATIONSHIP', 58), ('ANOMALY_CURIOUS_FINDING', 260), ('SUPERFICIAL_RELATIONSHIP', 268), ('FULL_UNKNOWN', 363)]	4	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_52915', 'phosphatediyl group', 19, 'vitamin D3supplementation'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 19, 'vitamin D3supplementation'), ('UBERON_0002240', 'spinal cord', 69, 'cord'), ('UBERON_0000178', 'blood', 74, 'blood'), ('GO_0060033', 'anatomical structure regression', 92, 'responses'), ('CHEBI_33279', 'vitamin D5', 134, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 134, 'vitamin D3'), ('CHEBI_63991', '15-epi-lipoxin B4', 214, '25-hydroxyvitamin D3'), ('PR_000001177', 'D(2) dopamine receptor', 232, 'D3'), ('CHEBI_62946', 'ammonium sulfate', 235, '25(OH)D3'), ('PR_000001177', 'D(2) dopamine receptor', 241, 'D3'), ('CHEBI_27300', 'vitamin D', 311, 'vitamin D')]
S13-PMC4979151	PMC4979151	8/2016	S13-PMC4979151	['there is NO CONSENSUS on the cutoff value for Vitamin D deficiency and the optimum dosage for supplementation during Pregnancy REMAINS CONTROVERSIAL.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 9), ('INCOMPLETE_EVIDENCE', 127), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 135)]	3	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('GO_0007565', 'female pregnancy', 117, 'pregnancy')]
S114-PMC4979151	PMC4979151	8/2016	S114-PMC4979151	['discussion\nwe PREVIOUSLY SHOWED that supplementation with vitd3during the 3rd trimester of Pregnancy improved maternal and Cord Blood Vitamin D status [18] and reduction of antibacterial peptide ll-37 in Monocytes [20].']	[('INCOMPLETE_EVIDENCE', 14), ('INCOMPLETE_EVIDENCE', 25)]	2	[('GO_0007565', 'female pregnancy', 91, 'pregnancy'), ('UBERON_0002240', 'spinal cord', 123, 'cord'), ('UBERON_0000178', 'blood', 128, 'blood'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin D'), ('CL_0000576', 'monocyte', 204, 'monocytes')]
S117-PMC4979151	PMC4979151	8/2016	S117-PMC4979151	['there is a SCARCITY of in vivo data in Humans during Pregnancy SHOWING EFFECTS of Vitamin D supplementation on neonatal Immune function.']	[('INCOMPLETE_EVIDENCE', 11), ('INCOMPLETE_EVIDENCE', 63), ('SUPERFICIAL_RELATIONSHIP', 71)]	3	[('NCBITaxon_9606', 'Homo sapiens', 39, 'humans'), ('GO_0007565', 'female pregnancy', 53, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 82, 'vitamin D'), ('UBERON_0002405', 'immune system', 120, 'immune')]
S146-PMC4979151	PMC4979151	8/2016	S146-PMC4979151	['down-regulation of Genes in the Tcr Complex, T Cell co-stimulatory Molecules and Major Histocompatibility Complexes (T Cell Adaptive Immunity) in the vitd group SUGGESTS suppression of T Cell Signaling Pathway by Vitamin D. induction of Cd2, Cd40Lg and Il-12Rb2 Expression that are IMPORTANT in T and Nk Cell function and inflammatory responses, and down-regulation of receptors for these ligands SUGGEST balanced responses to in vivo vitd3supplementation that would be expected to mitigate MAJOR downstream effects.']	[('DIFFICULT_TASK', 36), ('INCOMPLETE_EVIDENCE', 161), ('IMPORTANT_CONSIDERATION', 282), ('INCOMPLETE_EVIDENCE', 397), ('IMPORTANT_CONSIDERATION', 491)]	5	[('SO_0000704', 'gene', 19, 'genes'), ('GO_0042101', 'T cell receptor complex', 32, 'TCR complex'), ('CL_0000084', 'T cell', 45, 'T cell'), ('CHEBI_36357', 'polyatomic entity', 67, 'molecules'), ('GO_0042611', 'MHC protein complex', 81, 'major histocompatibility complexes'), ('CL_0000084', 'T cell', 117, 'T cell'), ('GO_0002456', 'T cell mediated immunity', 117, 'T cell adaptive immunity'), ('CL_0000084', 'T cell', 185, 'T cell'), ('GO_0002770', 'T cell inhibitory signaling pathway', 185, 'T cell signaling pathway'), ('CHEBI_27300', 'vitamin D', 213, 'vitamin D'), ('PR_000001204', 'C-C chemokine receptor type 8', 237, 'CD2'), ('PR_000001309', 'CD70 molecule', 242, 'CD40LG'), ('PR_000008990', 'interleukin-1 family member 9', 253, 'IL-12RB2'), ('GO_0010467', 'gene expression', 262, 'expression'), ('CL_0000909', 'CD8-positive, alpha-beta memory T cell', 295, 'T ...'), ('CL_0000623', 'natural killer cell', 301, 'NK cell'), ('GO_0005634', 'nucleus', 301, 'NK')]
S69-PMC4982007	PMC4982007	8/2016	S69-PMC4982007	['n \u2009=\u20095832: age 4\xa0years \u2003n \u2009=\u20095191; age 8\xa0years \u2003n \u2009=\u20097339; age 16\xa0yearsmaternal Gestational weight gain (kg)3 categories of weight gain1: less than recommended2: as recommended3: more than recommendedpre-Pregnancy weight (kg)school entry assessment score-4\xa0yearsiq- wechsler intelligence scale for children -iii-8\xa0yearsadequate final exam results-16\xa0yearschildren of women gained weight\u2009<\u2009expected-↓ school entry assessment score (-0.075 sd) and adequate final-exam results (or\u2009=\u20090.88); ↑weight gain - early and mid Pregnancy -↑school entry assessment score (0.072 and 0.077 sd)↑ weight gain in all three periods of Pregnancy-↑ iq at 8\xa0years (0.070 to 0.078 sd) and ↑pre-Pregnancy weight-↓ school entry assessment score (-0.004 sd/kg), iq (-0.004 sd) and the odds (or\u2009=\u20090.99) of achieving adequate final exam resultsconfounders adjusted for: the child’s sex, current age, ma; me, parity, pre-Pregnancy bmi, smoking and mode of Delivery16 medium\nbmi body mass index, qs quality score, rb risk of bias, ga Gestational age, ma maternal age, bwt Birthweight, ses socio-economic status, me maternal education, pe paternal education, miq maternal intelligence, he home environment, ms maternal smoking, bf breast-feeding, dm maternal diabetes, pih Pregnancy induced hypertension\n\ncaption (table-wrap): table 3\n\nsummary of the studies examining ASSOCIATIONS of maternal Vitamin D status with offspring Cognitive functionauthor, year, sample size, age, country, study designnutrientcognitive functionresults after adjustment for confoundersqs and rb20gale c; 2008 \u2003n \u2009=\u2009178\u2003age 9\xa0years\u2003uk\u2003prospective longitudinalserum Vitamin D concentrations assessed at 28-42 weeks Gestation21.2\xa0% had <27.5\xa0nmol/l28.3\xa0% had 27.5-50\xa0nmol/lwechsler abbreviated scale of intelligencefull-scale, verbal or performance iqno association between Vitamin D concentrations and offspring iq (full-scale, verbal or performance)confounders adjusted for: unadjusted16 medium21whitehouse ajo; 2012\u2003age 5\xa0years ( n \u2009=\u2009534)\u2003age 10\xa0years ( n \u2009=\u2009474)\u2003australia\u2003prospective longitudinalserum Vitamin D concentrations assessed at 18\xa0weeks Gestation25.2\xa0% mothers had insufficiency (≤46\xa0nmol/l)(lowest quartile)peabody picture vocabulary test Receptive Languagechildren of mothers with Vitamin D insufficiency (lowest quartile (≤46\xa0nmol/l) were at INCREASED RISK (or\u2009=\u20091.97) of Language impairment compared to children of mothers without insufficiency (highest quartile (≥72\xa0nmol/l; or\u2009=\u20091.00)confounders adjusted for: ma, ms, parity, family income, season of maternal Blood sampling13 medium22morales\xa0e; 2012 \u2003n \u2009=\u20091820\u2003age 11-23 months\u2003spain\u2003prospective population based\u2003cohort studyplasma Vitamin D concentrations assessed during 12-23 weeks Gestation19.5\xa0% mothers had deficiency (<20\xa0ng/ml)31.5\xa0% had insufficiency (20-30\xa0ng/ml)bayley scales of infant development (mental (mdi) and psychomotor (pdi) developmental score)a positive linear ASSOCIATION between Vitamin D concentrations and mdi and pdiper 10\xa0ng/ml increase in Vitamin D concentrations mdi and pdi score increased by β\u2009=\u20090.79 and β\u2009=\u20090.88 points respectivelycompared to infants of deficient mothers, infants of mothers with normal level scored higher mdi (β\u2009=\u20092.60) and pdi (β\u2009=\u20092.32) points respectivelyconfounders adjusted for: the child’s sex, bwt, area of study, maternal country of origin, ma, parity, Pre-Pregnancy bmi, ses, me, ms, Alcohol and season15 medium\nqs quality score, rb risk of bias, ma maternal age, bwt Birthweight, me Maternal education, ms maternal smoking, bmi body mass index, ses socio-economic status\n\ncaption (table-wrap): table 4\n\nsummary of the studies examining ASSOCIATIONS of maternal Folate status with offspring Cognitive functionauthor, year, sample size, age, country, study designnutrientcognitive functionresults after adjustment for confoundersqs and rb23wu btf; 2012 \u2003n \u2009=\u2009154\u2003age 18 months\u2003canada\u2003prospectiveplasma Folate and thcy concentrations assessed at 16 and 36\xa0weeks Gestationno Folate deficiency (plasma Folate <6.8\xa0nmol/l)high thcy not reportedbayley scales of infant developmentreceptive language, expressive language, Cognitive skills, fine motor and gross motorno ASSOCIATION of Folate and thcy with Cognitive functionconfounders adjusted for: the child’s sex, bf, ethnicity, ma, miq, maternal Fatty Acid level13 medium24tamura t; 2005 \u2003n \u2009=\u2009355\u2003age 5\xa0years\u2003usa\u2003prospective\u2003mothers participated in zinc supplementation trial during Pregnancyred cell and Plasma Folate concentrations – 19, 26 and 37\xa0weeks Gestation and thcy concentrations-26 and 37\xa0weekslow Folate-(Plasma Folate <11\xa0nmol/l)19\xa0weeks- 7.4\xa0%; 26\xa0weeks- 8.2\xa0%; 37\xa0weeks- 14.0\xa0%Red Cell Folate <430\xa0nmol/l)19\xa0weeks- 7.2\xa0%; 26\xa0weeks- 3.8\xa0%; 37\xa0weeks- 3.3\xa0%high thcy (thcy\u2009>\u20097\xa0μmol/l)26\xa0weeks- 8.4\xa0%; 37\xa0weeks- 22.1\xa0%differential ability scale (verbal, nonverbal and general iq), Visual and Auditory sequential Memory (Visual and Auditory Memory span)knox cube (attention span and Short-Term Memory)gross motor scale (gross Motor Development and grooved pegboard (manipulative dexterity)no difference in the mental and psychomotor developmental scores between children of mothers with normal and deficient Folate and thcy groups.']	[('SUPERFICIAL_RELATIONSHIP', 1338), ('IMPORTANT_CONSIDERATION', 2306), ('SUPERFICIAL_RELATIONSHIP', 2901), ('SUPERFICIAL_RELATIONSHIP', 3617), ('SUPERFICIAL_RELATIONSHIP', 4142)]	5	[('GO_0007565', 'female pregnancy', 80, 'gestational'), ('GO_0007565', 'female pregnancy', 204, 'pregnancy'), ('GO_0007565', 'female pregnancy', 516, 'pregnancy'), ('GO_0007565', 'female pregnancy', 616, 'pregnancy'), ('GO_0007565', 'female pregnancy', 671, 'pregnancy'), ('GO_0007565', 'female pregnancy', 892, 'pregnancy'), ('GO_0007567', 'parturition', 927, 'delivery16'), ('GO_0007565', 'female pregnancy', 1004, 'gestational'), ('GO_0007596', 'blood coagulation', 1042, 'birthweight'), ('GO_0007565', 'female pregnancy', 1242, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 1363, 'vitamin D'), ('GO_0050890', 'cognition', 1395, 'cognitive'), ('CHEBI_27300', 'vitamin D', 1611, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1660, 'gestation21'), ('CHEBI_27300', 'vitamin D', 1818, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 2052, 'vitamin D'), ('GO_0007565', 'female pregnancy', 2098, 'gestation25'), ('GO_0000724', 'double-strand break repair via homologous recombination', 2201, 'Receptive languageChildren'), ('CHEBI_27300', 'vitamin D', 2244, 'vitamin D'), ('GO_0006266', 'DNA ligation', 2336, 'language'), ('UBERON_0000178', 'blood', 2527, 'blood'), ('CHEBI_27300', 'vitamin D', 2650, 'vitamin D'), ('GO_0007565', 'female pregnancy', 2703, 'gestation19'), ('CHEBI_27300', 'vitamin D', 2921, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 2986, 'vitamin D'), ('GO_0007568', 'aging', 3332, 'pre'), ('GO_0007565', 'female pregnancy', 3336, 'pregnancy'), ('CHEBI_30879', 'alcohol', 3364, 'alcohol'), ('GO_0007596', 'blood coagulation', 3448, 'birthweight'), ('GO_0007618', 'mating', 3464, 'maternal'), ('CHEBI_30863', '5-azaorotic acid', 3642, 'folate'), ('GO_0050890', 'cognition', 3671, 'cognitive'), ('CHEBI_30863', '5-azaorotic acid', 3881, 'folate'), ('GO_0007565', 'female pregnancy', 3940, 'gestationNo'), ('CHEBI_30863', '5-azaorotic acid', 3952, 'folate'), ('CHEBI_30863', '5-azaorotic acid', 3978, 'folate'), ('GO_0050890', 'cognition', 4095, 'cognitive'), ('CHEBI_30863', '5-azaorotic acid', 4157, 'folate'), ('GO_0050890', 'cognition', 4178, 'cognitive'), ('CHEBI_35366', 'fatty acid', 4272, 'fatty acid'), ('GO_0007605', 'sensory perception of sound', 4410, 'pregnancyRed'), ('UBERON_0001969', 'blood plasma', 4432, 'plasma'), ('CHEBI_30863', '5-azaorotic acid', 4439, 'folate'), ('GO_0007565', 'female pregnancy', 4483, 'gestation'), ('CHEBI_30863', '5-azaorotic acid', 4536, 'folate'), ('UBERON_0001969', 'blood plasma', 4544, 'plasma'), ('CHEBI_30863', '5-azaorotic acid', 4551, 'folate'), ('CL_0000232', 'erythrocyte', 4619, 'Red cell'), ('CHEBI_30863', '5-azaorotic acid', 4628, 'folate'), ('GO_0007601', 'visual perception', 4819, 'Visual'), ('GO_0006754', 'ATP biosynthetic process', 4830, 'Auditory ...'), ('GO_0007613', 'memory', 4850, 'Memory'), ('GO_0007601', 'visual perception', 4858, 'visual'), ('GO_0007605', 'sensory perception of sound', 4869, 'auditory'), ('GO_0007613', 'memory', 4878, 'memory'), ('GO_0007608', 'sensory perception of smell', 4920, 'short-term memory'), ('GO_0009653', 'anatomical structure morphogenesis', 4963, 'motor development'), ('CHEBI_30863', '5-azaorotic acid', 5145, 'folate')]
S75-PMC4982007	PMC4982007	8/2016	S75-PMC4982007	['m; 2010 \u2003n \u2009=\u20099983 14\xa0years \u2003n \u2009=\u200910474 16\xa0years\u2003finland\u2003prospective Birth cohort studyhb concentrations at 3rd 7th and 9th Gestational monthsanaemiaschool performance14\xa0years- self report16\xa0years- school report↑maternal hb at 9\xa0months-↑ total school performance score (β\u2009=\u20090.03) and theory score at 14\xa0years and total score at 16\xa0years offspring of mothers with anaemia –low school scores (or\u2009=\u2009-0.05 at 14\xa0years and (or\u2009=\u2009-0.06) at 16\xa0yearsconfounders adjusted for: the child’s sex, bwt, Pregnancy wanted or not, me, social class, parity, marital status, ms, maternal mental health status18 low40davidson pw; 2008 \u2003n \u2009=\u2009229\u2003age 5, 9, 25and 30\xa0months\u2003republic of seychelles\u2003longitudinal cohort studyiron- total body stores at 14-24 weeks of Gestation assessed before the start of iron supplementationbayley scales of infant development: mental development index (mdi) and psychomotor development index (pdi) (9 and 30\xa0months)infant Cognition (fagan infantest-novelty preference) and Visual expectation paradigm –Visual recognition Memory (9 and 25\xa0months)a-not-b and delayed spatial alternation: inhibition, Working Memory, Planning and attention (25\xa0months)no association between maternal iron stores and Cognitive function at any age.confounders adjusted for: the child’s sex, bwt, ma, ses, he, miq and both parents living with the child (yes/no)19 low41lewis sj; 2013 \u2003n \u2009=\u2009~3,500\u2003age 8\xa0years\u2003uk\u2003population based prospective birth cohorthb concentrationsbefore 18\xa0weekshb <11.0\xa0g/dl -8\xa0%after 28\xa0weekshb <11.0\xa0g/dl -30\xa0%wechsler intelligence scale for children-iii- full- scale iqno ASSOCIATION between maternal hb and child’s iqconfounders adjusted for: ga, me, the child’s genotype, Iron supplementation, population stratification15 medium42tran td; 2013 \u2003n \u2009=\u2009378\u2003age 6\xa0months\u2003vietnam\u2003population based prospective cohort studyiron deficiency anaemia (hb <11.0\xa0g/dl and Serum ferritin <15\xa0ng/ml) during 12-28 weeks of Gestation-16\xa0%bayley scales of infant and toddler development-iii edition-Cognitive scoreinfants of anaemic mothers scored 11.6 points (0.77sd) lower in bsid Cognitive scores compared to infants of non-anaemic mothers.confounders adjusted for: parity, ma, me, wealth index, the child’s Birth and current weight, family support, bf.18 low43zhou sj; 2006 \u2003n \u2009=\u2009302\u2003age 4\xa0years; australia\u2003double blind randomized controlled trialiron Supplements (20\xa0mg/day) or placebo from 20\xa0weeks Gestation until deliverycompliance-86\xa0%stanford binet intelligence scale – iq (Verbal Reasoning, Visual Reasoning, Quantitative Reasoning and Short-Term Memory)no difference between the children of supplement group and placebo group in the mean score of composite iq or any subscales iq or in the proportion of children whose iq fell 1 or 2 sd below the mean.confounders adjusted for: sex, Birth order, Gestational age, ma, me, pe, he, bf20 low44li q; 2009 \u2003n \u2009=\u20091305\u2003age 3, 6 and 12\xa0months\u2003double blind cluster randomized controlled trial\u2003china3 intervention groups (all received Folic Acid)Folic Acid alone400\xa0μg ( n \u2009=\u2009471)-controliron 60\xa0mg\u2009+\u2009Folic Acid400\xa0μg ( n \u2009=\u2009438)multiple Micronutrients ((b Vitamins (1,2,3 6 and 12), Vitamin A, d, c, e and minerals (zinc, Iodine, copper, Selenium)\u2009+\u2009iron 30\xa0mg\u2009+\u2009400\xa0μg Folic Acid)) ( n \u2009=\u2009396)daily supplementation from enrolment until Delivery; inadequate information about compliancebayley scales of Infant Development :mental (md) and Psychomotor Development (pd)no significant difference in infants md and pd score at 3 and 6\xa0months and pd score at 12\xa0months between Supplement groupsmean md score among children of multiple Micronutrient group increased by 1 to 1.22 points COMPARED to children of Folic Acid alone, or Folic Acid\u2009+\u2009Iron group at 12\xa0monthsconfounders adjusted for: infants age, sex, Gestational age, apgar score, bwt, infant health, maternal age and bmi, parental education, occupation, ses, number of tablets consumed19 low\nqs quality score , rb risk of bias , hb haemoglobin , ga Gestational age , ma maternal age , bwt birthweight , ses socio-economic status , me maternal education , pe paternal education , miq maternal intelligence , he home environment , ms maternal smoking , bf breast-feeding , bmi body mass index\n\ncaption (table-wrap): table 7\n\nsummary of the studies examining ASSOCIATIONS of maternal Carbohydrate/protein with offspring Cognitive functionauthor, year, sample size, age, country, study designnutrientcognitive functionresults after adjustment for confoundersqs and rb45alderman h; 2014 \u2003n \u2009=\u20096774\u2003age 16-22 years\u2003double blind cluster randomized controlled trial\u2003gambiacarbohydrate/protein supplementsintervention group:2 biscuits daily (1015\xa0kcal Carbohydrate and 22\xa0g protein) from 20\xa0weeks of Gestation to Deliverycontrol group: same Supplements for 20\xa0weeks during Postpartum but not during Pregnancyno information about complianceraven’s progressive matrices- nonverbal reasoning abilitythe mill hill vocabulary testthe backward and forward digit-span testschooling achievement (questionnaire)no difference in any of the Cognitive test scores or schooling achievement between children whose mothers received thesupplements during Pregnancy and children whose mothers received Supplements during Postpartum.confounders adjusted for: the child’s sex, age, ga, me, pe, maternal height, parity, season of Birth, language and village allocation19 low\nqs quality score, rb risk of bias, ga Gestational age, me Maternal education, pe paternal education\n\nmaternal anthropometry (table\xa02)\nall were observational studies and from developed countries [8–19].']	[('SUPERFICIAL_RELATIONSHIP', 1587), ('ANOMALY_CURIOUS_FINDING', 3631), ('SUPERFICIAL_RELATIONSHIP', 4262)]	3	[('GO_0007567', 'parturition', 69, 'Birth'), ('GO_0007565', 'female pregnancy', 124, 'gestational'), ('GO_0007565', 'female pregnancy', 490, 'pregnancy'), ('GO_0007565', 'female pregnancy', 742, 'gestation'), ('GO_0050890', 'cognition', 933, 'cognition'), ('GO_0007601', 'visual perception', 984, 'Visual'), ('GO_0007601', 'visual perception', 1013, 'visual ...'), ('GO_0007613', 'memory', 1032, 'memory'), ('GO_0007631', 'feeding behavior', 1109, 'working memory'), ('GO_0006260', 'DNA replication', 1125, 'planning'), ('GO_0050890', 'cognition', 1207, 'cognitive'), ('CHEBI_24870', 'ion', 1689, 'iron'), ('UBERON_0001977', 'blood serum', 1876, 'serum'), ('GO_0007565', 'female pregnancy', 1924, 'gestation'), ('GO_0050890', 'cognition', 1998, 'cognitive'), ('GO_0050890', 'cognition', 2082, 'cognitive'), ('GO_0007567', 'parturition', 2210, 'birth'), ('CHEBI_33341', 'titanium atom', 2355, 'supplements'), ('GO_0007565', 'female pregnancy', 2404, 'gestation'), ('GO_0016055', 'Wnt signaling pathway', 2483, 'verbal reasoning'), ('GO_0007602', 'phototransduction', 2501, 'visual reasoning'), ('GO_0031028', 'septation initiation signaling', 2519, 'quantitative reasoning'), ('GO_0007608', 'sensory perception of smell', 2546, 'short-term memory'), ('GO_0007567', 'parturition', 2794, 'birth'), ('GO_0007565', 'female pregnancy', 2807, 'gestational'), ('CHEBI_30751', 'formic acid', 2985, 'folic acid'), ('CHEBI_30751', 'formic acid', 2996, 'Folic acid'), ('CHEBI_52727', 'ethyl nile blue A', 3051, 'folic acid400'), ('CHEBI_33839', 'macromolecule', 3088, 'micronutrients'), ('CHEBI_33277', 'gamma-tocotrienol', 3107, 'vitamins'), ('CHEBI_27300', 'vitamin D', 3134, 'vitamin A'), ('CHEBI_24859', 'iodine atom', 3173, 'iodine'), ('CHEBI_27568', 'selenium atom', 3189, 'selenium'), ('CHEBI_30751', 'formic acid', 3221, 'folic acid'), ('GO_0007567', 'parturition', 3288, 'delivery'), ('GO_0060119', 'inner ear receptor cell development', 3354, 'Infant Development'), ('GO_0035210', 'prepupal development', 3390, 'Psychomotor development'), ('CHEBI_16158', 'steroid sulfate', 3523, 'supplement'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 3581, 'micronutrient'), ('CHEBI_30751', 'formic acid', 3655, 'folic acid'), ('CHEBI_30751', 'formic acid', 3676, 'folic acid'), ('CHEBI_24870', 'ion', 3689, 'iron'), ('GO_0007565', 'female pregnancy', 3756, 'gestational'), ('GO_0007565', 'female pregnancy', 3955, 'gestational'), ('CHEBI_16730', 'chloramphenicol 3-acetate', 4287, 'carbohydrate'), ('GO_0050890', 'cognition', 4323, 'cognitive'), ('CHEBI_16730', 'chloramphenicol 3-acetate', 4649, 'carbohydrate'), ('GO_0007565', 'female pregnancy', 4697, 'gestation'), ('GO_0051607', 'defense response to virus', 4710, 'deliveryControl'), ('CHEBI_33341', 'titanium atom', 4738, 'supplements'), ('GO_0007565', 'female pregnancy', 4770, 'postpartum'), ('GO_0007605', 'sensory perception of sound', 4796, 'pregnancyNo'), ('GO_0050890', 'cognition', 5027, 'cognitive'), ('GO_0007565', 'female pregnancy', 5136, 'pregnancy'), ('CHEBI_33341', 'titanium atom', 5182, 'supplements'), ('GO_0007565', 'female pregnancy', 5201, 'postpartum'), ('GO_0007567', 'parturition', 5307, 'birth'), ('GO_0007565', 'female pregnancy', 5390, 'gestational'), ('GO_0007618', 'mating', 5410, 'maternal')]
S337-PMC4989298	PMC4989298	8/2016	S337-PMC4989298	['in RECENT YEARS a POSSIBLE ROLE in PREVENTION HAS BEEN ATTRIBUTED to Vitamin D. indeed, OBSERVATIONAL and cohort studies have DOCUMENTED the existence of a CORRELATION between vitamin d intake (from dietary sources or supplementation) in Pregnant women and children and the risk of wheezing, asthma or Food allergy later in Life.']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 18), ('SUPERFICIAL_RELATIONSHIP', 27), ('SUPERFICIAL_RELATIONSHIP', 35), ('INCOMPLETE_EVIDENCE', 46), ('SUPERFICIAL_RELATIONSHIP', 55), ('INCOMPLETE_EVIDENCE', 88), ('INCOMPLETE_EVIDENCE', 126), ('SUPERFICIAL_RELATIONSHIP', 156)]	9	[('CHEBI_27300', 'vitamin D', 69, 'vitamin D'), ('GO_0007565', 'female pregnancy', 238, 'pregnant'), ('CHEBI_33290', 'food', 302, 'food'), ('UBERON_0000104', 'life cycle', 324, 'life')]
S362-PMC4989298	PMC4989298	8/2016	S362-PMC4989298	['the study conclusions were that there was not SUFFICIENT evidence to establish a causal CONNECTION; there were also NO RANDOMISED clinical trial (rct) on the effect of supplementation of Vitamin D and risk of asthma.']	[('IMPORTANT_CONSIDERATION', 46), ('SUPERFICIAL_RELATIONSHIP', 88), ('FULL_UNKNOWN', 116)]	3	[('CHEBI_27300', 'vitamin D', 187, 'vitamin D')]
S365-PMC4989298	PMC4989298	8/2016	S365-PMC4989298	['one SHOWED no correlation and the other 5 FOUND an inverse RELATIONSHIP between Vitamin D intake (through diet or supplementation) or Vitamin D levels in Umbilical Cord blood and the incidence of asthma or wheezing at 1–3 or 5\xa0years of age.']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 42), ('SUPERFICIAL_RELATIONSHIP', 59)]	3	[('CHEBI_27300', 'vitamin D', 80, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin D'), ('UBERON_0002331', 'umbilical cord', 154, 'umbilical cord')]
S368-PMC4989298	PMC4989298	8/2016	S368-PMC4989298	['in 2013, a randomised, controlled study by goldring and co-workers studied 113 children receiving Prenatal supplementation of Vitamin D. no effect on atopy, risk of atopic dermatitis, Pulmonary function and exhaled Nitric Oxide was FOUND [125].']	[('INCOMPLETE_EVIDENCE', 232)]	1	[('GO_0007565', 'female pregnancy', 98, 'prenatal'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D'), ('UBERON_0002048', 'lung', 184, 'pulmonary'), ('CHEBI_16480', 'nitric oxide', 215, 'nitric oxide')]
S376-PMC4989298	PMC4989298	8/2016	S376-PMC4989298	['the use of Vitamin D supplementation for the primary PREVENTION of allergic diseases REMAINS an attractive TOPIC of study, BUT CURRENT KNOWLEDGE and AVAILABLE EVIDENCE does not warrant its RECOMMENDATION [129].']	[('SUPERFICIAL_RELATIONSHIP', 53), ('INCOMPLETE_EVIDENCE', 85), ('IMPORTANT_CONSIDERATION', 107), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 123), ('INCOMPLETE_EVIDENCE', 127), ('INCOMPLETE_EVIDENCE', 149), ('FUTURE_WORK', 189)]	7	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D')]
S379-PMC4989298	PMC4989298	8/2016	S379-PMC4989298	['on BASIS of the AVAILABLE EVIDENCE, the use of Vitamin D supplementation is not RECOMMENDED for the primary prevention of allergic disease.']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 16), ('FUTURE_WORK', 80)]	3	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D')]
S39-PMC4990268	PMC4990268	8/2016	S39-PMC4990268	['the interventions considered by this review are outlined intable 1(numbered to correspond to the sections of the paper where they are addressed).10.1371/journal.pone.0160562.t001\n\ncaption (table-wrap): table 1\ninterventions addressed in THIS review.Nutritioninfectionobstetrical and other• immediate & exclusive breastfeeding• deworming• advance distribution of Misoprostol for use immediately after Childbirth for preventing post-Partum hemorrhage• antenatal Iron supplementation & anemia screening & treatment• intermittent presumptive treatment of malaria & use of Insecticide-treated nets• pre-eclampsia screening & treatment• multi-Micronutrient supplementation• Tetanus Toxoid• clean Delivery practices• Calcium supplementation• advance distribution of Chlorhexidine for application to the Umbilical Cord Stump• thermal care• antenatal Vitamin A supplementation• syphilis screening & treatment• Birth preparedness & complication readiness• advance distribution of Vitamin A for administration to the newborn• hiv screening/ pmtct• tobacco, alcohol use• Iodized Salt use• Family Planning• balanced protein-energy supplementation\n\neffects modified by context\nfor each of these INTERVENTIONS, the review addresses: 1) EVIDENCE on EFFECTS with regard to mortality and other IMPORTANT endpoints and 2) variation in expected EFFECTS by context.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 237), ('SUPERFICIAL_RELATIONSHIP', 1181), ('INCOMPLETE_EVIDENCE', 1221), ('SUPERFICIAL_RELATIONSHIP', 1233), ('IMPORTANT_CONSIDERATION', 1276), ('SUPERFICIAL_RELATIONSHIP', 1325)]	6	[('GO_0012501', 'programmed cell death', 249, 'NutritionInfectionObstetrical'), ('CHEBI_63610', 'misoprostol', 362, 'misoprostol'), ('GO_0007623', 'circadian rhythm', 400, 'childbirth'), ('GO_0007567', 'parturition', 431, 'partum'), ('UBERON_0001013', 'adipose tissue', 431, 'partum'), ('CHEBI_24870', 'ion', 460, 'iron'), ('CHEBI_24852', 'insecticide', 568, 'insecticide'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 637, 'micronutrient'), ('CHEBI_32848', 'serine residue', 668, 'Tetanus'), ('CHEBI_29238', 'tritium atom', 676, 'toxoid'), ('GO_0007567', 'parturition', 690, 'delivery'), ('CHEBI_31341', 'calcium dihydroxide', 710, 'Calcium'), ('CHEBI_3647', 'chlorpromazine', 759, 'chlorhexidine'), ('UBERON_0010270', 'filum terminale externum', 796, 'umbilical cord stump'), ('CHEBI_27300', 'vitamin D', 842, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 850, 'A'), ('GO_0007567', 'parturition', 901, 'Birth'), ('CHEBI_27300', 'vitamin D', 970, 'vitamin A'), ('CHEBI_31721', 'Irsogladine maleate', 1059, 'Iodized salt'), ('GO_0006437', 'tyrosyl-tRNA aminoacylation', 1077, 'Family Planning')]
S224-PMC4990268	PMC4990268	8/2016	S224-PMC4990268	['multi-Micronutrient supplementation\nvarious Micronutrients HAVE BEEN investigated for their ROLE in Pregnancy outcomes (Iron, Folic Acid, Calcium, magnesium, zinc, Vitamin A/ B-Carotene, Vitamin D3, Iodine, Omega-3 Fatty Acids, and others).']	[('INCOMPLETE_EVIDENCE', 59), ('SUPERFICIAL_RELATIONSHIP', 92)]	2	[('CHEBI_6956', 'Mitragynine', 6, 'Micronutrient'), ('CHEBI_33839', 'macromolecule', 44, 'micronutrients'), ('GO_0007565', 'female pregnancy', 100, 'pregnancy'), ('CHEBI_24870', 'ion', 120, 'iron'), ('CHEBI_30751', 'formic acid', 126, 'folic acid'), ('CHEBI_22313', 'alkaline earth metal atom', 138, 'calcium'), ('CHEBI_27300', 'vitamin D', 164, 'vitamin A'), ('CHEBI_27793', 'beta-carotene 5,6-epoxide', 175, 'B-carotene'), ('CHEBI_33279', 'vitamin D5', 187, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 187, 'vitamin D3'), ('CHEBI_24859', 'iodine atom', 199, 'iodine'), ('CHEBI_79370', 'ibho#10', 207, 'omega-3'), ('CHEBI_35366', 'fatty acid', 215, 'fatty acids')]
S295-PMC4990268	PMC4990268	8/2016	S295-PMC4990268	['as with all supplementation STRATEGIES to prevent the COMPLICATIONS ASSOCIATED with Micronutrient deficiencies, the IMPACT of supplementation in the Antenatal Period will DEPEND ON the overall Vitamin A status of the population and the special demands that Pregnancy makes on Vitamin A reserves.']	[('FUTURE_WORK', 28), ('IMPORTANT_CONSIDERATION', 54), ('PROBLEM_COMPLICATION', 54), ('SUPERFICIAL_RELATIONSHIP', 68), ('SUPERFICIAL_RELATIONSHIP', 116), ('SUPERFICIAL_RELATIONSHIP', 171)]	6	[('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 84, 'micronutrient'), ('GO_0007567', 'parturition', 149, 'antenatal'), ('UBERON_0006721', 'alisphenoid bone', 149, 'antenatal period'), ('CHEBI_27300', 'vitamin D', 193, 'vitamin A'), ('GO_0007565', 'female pregnancy', 257, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 276, 'vitamin A')]
S297-PMC4990268	PMC4990268	8/2016	S297-PMC4990268	['IN FACT, the CURRENT EVIDENCE provides SOME SUPPORT for this RELATED to Vitamin A supplementation during Pregnancy.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 39), ('INCOMPLETE_EVIDENCE', 44), ('SUPERFICIAL_RELATIONSHIP', 61)]	5	[('CHEBI_27300', 'vitamin D', 72, 'vitamin A'), ('GO_0007565', 'female pregnancy', 105, 'pregnancy')]
S298-PMC4990268	PMC4990268	8/2016	S298-PMC4990268	['one additional ISSUE for Vitamin A supplementation in Pregnancy is that high doses of Retinol are a WELL-KNOWN Teratogen IF provided early in Gestation[102].']	[('PROBLEM_COMPLICATION', 15), ('PROBABLE_UNDERSTANDING', 100), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 121)]	3	[('CHEBI_27300', 'vitamin D', 25, 'vitamin A'), ('GO_0007565', 'female pregnancy', 54, 'pregnancy'), ('CHEBI_26536', 'retinoic acid', 86, 'retinol'), ('CHEBI_50117', 'phenylglyoxylyl-CoA', 111, 'teratogen'), ('GO_0007565', 'female pregnancy', 142, 'gestation')]
S314-PMC4990268	PMC4990268	8/2016	S314-PMC4990268	['IN SUMMARY, there is CONFLICTING EVIDENCE for benefit of Vitamin A or Β-Carotene supplementation on maternal mortality.']	[('INCOMPLETE_EVIDENCE', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 21), ('INCOMPLETE_EVIDENCE', 33)]	3	[('CHEBI_27300', 'vitamin D', 57, 'vitamin A'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 70, 'β-carotene')]
S317-PMC4990268	PMC4990268	8/2016	S317-PMC4990268	['there was NO EVIDENCE that Antenatal Vitamin A supplementation reduced infant mortality, Stillbirth, Preterm Birth or increased Birthweight[19,101,107–110].']	[('INCOMPLETE_EVIDENCE', 10)]	1	[('GO_0007567', 'parturition', 27, 'antenatal'), ('CHEBI_27300', 'vitamin D', 37, 'vitamin A'), ('GO_0001966', 'thigmotaxis', 89, 'stillbirth'), ('GO_0007565', 'female pregnancy', 101, 'preterm birth'), ('GO_0007596', 'blood coagulation', 128, 'birthweight')]
S319-PMC4990268	PMC4990268	8/2016	S319-PMC4990268	['overall, there is NO CONSISTENT EVIDENCE that Antenatal Vitamin A supplementation improves growth of infants through the first year of Life[101].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 18), ('INCOMPLETE_EVIDENCE', 21)]	2	[('GO_0007567', 'parturition', 46, 'antenatal'), ('CHEBI_27300', 'vitamin D', 56, 'vitamin A'), ('UBERON_0000104', 'life cycle', 135, 'life')]
S323-PMC4990268	PMC4990268	8/2016	S323-PMC4990268	['night blindness in Pregnancy: a stratified analysis of the nepal trial SHOWED significantly higher infant mortality for children Born to women who were night blind during Pregnancy and that Antenatal Vitamin A supplementation attenuated this risk[111].']	[('INCOMPLETE_EVIDENCE', 71)]	1	[('GO_0007565', 'female pregnancy', 19, 'Pregnancy'), ('GO_0007567', 'parturition', 129, 'born'), ('GO_0007565', 'female pregnancy', 171, 'pregnancy'), ('GO_0007567', 'parturition', 190, 'antenatal'), ('CHEBI_27300', 'vitamin D', 200, 'vitamin A')]
S326-PMC4990268	PMC4990268	8/2016	S326-PMC4990268	['maternal hiv infection: there is NO CONSISTENT EVIDENCE that Antenatal Vitamin A supplementation reduces RISK of Mother-To-child-Transmission Of Hiv (mtct) BUT there is significant heterogeneity in trial results [101].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 33), ('INCOMPLETE_EVIDENCE', 33), ('IMPORTANT_CONSIDERATION', 105), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 156)]	4	[('GO_0007567', 'parturition', 61, 'antenatal'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin A'), ('GO_0007533', 'mating type switching', 113, 'mother-to ... transmission of HIV')]
S332-PMC4990268	PMC4990268	8/2016	S332-PMC4990268	['newborn Vitamin A advance distribution\nas mentioned in the section on Antenatal Vitamin A supplementation, almost 20 million women are Vitamin A deficient, with PARTICULARLY high prevalence in south and southeast asia[101].']	[('ANOMALY_CURIOUS_FINDING', 161), ('IMPORTANT_CONSIDERATION', 161)]	2	[('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 8, 'Vitamin A'), ('GO_0007567', 'parturition', 70, 'antenatal'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 135, 'vitamin A')]
S336-PMC4990268	PMC4990268	8/2016	S336-PMC4990268	['MULTIPLE STUDIES have DEMONSTRATED that Vitamin A supplementation among children 6 months to 5 years of age in populations with endemic Vitamin A deficiency CAN reduce mortality[116].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 22), ('INCOMPLETE_EVIDENCE', 157)]	3	[('CHEBI_27300', 'vitamin D', 40, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin A')]
S338-PMC4990268	PMC4990268	8/2016	S338-PMC4990268	['SUPPORTING this VIEW, there was NO EVIDENCE of benefit of Vitamin A supplementation on mortality among children under 6 months[117] until humphrey et al.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 16), ('INCOMPLETE_EVIDENCE', 32)]	3	[('CHEBI_27300', 'vitamin D', 58, 'vitamin A')]
S343-PMC4990268	PMC4990268	8/2016	S343-PMC4990268	['evidence: the studies identified for this review FOUND VARYING results of Vitamin A supplementation on infant mortality.']	[('INCOMPLETE_EVIDENCE', 49), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 55)]	2	[('CHEBI_27300', 'vitamin D', 74, 'vitamin A')]
S354-PMC4990268	PMC4990268	8/2016	S354-PMC4990268	['among hiv positive women in zimbabwe, there was NO EVIDENCE for IMPACT of Vitamin A supplementation for mothers and/or their newborns on mortality[127].']	[('INCOMPLETE_EVIDENCE', 48), ('SUPERFICIAL_RELATIONSHIP', 64)]	2	[('CHEBI_27300', 'vitamin D', 74, 'vitamin A')]
S355-PMC4990268	PMC4990268	8/2016	S355-PMC4990268	['a trial in guinea-bissau SHOWED that Vitamin A supplementation (25,000 iu at Birth) was not significantly associated with mortality (rr = 1.08, 95% ci: 0.79–1.47)[122].']	[('INCOMPLETE_EVIDENCE', 25)]	1	[('CHEBI_27300', 'vitamin D', 37, 'vitamin A'), ('GO_0007567', 'parturition', 77, 'birth')]
S361-PMC4990268	PMC4990268	8/2016	S361-PMC4990268	['conclusion: pooling results across all rcts SHOWS no benefit from newborn Vitamin A supplementation on early infant mortality.']	[('INCOMPLETE_EVIDENCE', 44)]	1	[('CHEBI_27300', 'vitamin D', 74, 'vitamin A')]
S1116-PMC4990268	PMC4990268	8/2016	S1116-PMC4990268	['intable 6below, we have offered very brief comments on such implementation CONSIDERATIONS.10.1371/journal.pone.0160562.t006\n\ncaption (table-wrap): table 6\n“best buy” ratings for interventions reviewed.interventionpopulation impactease of Deliverycommentsbreastfeeding—early initiation ✓ ☺large magnitude EFFECT on newborn mortalityiron/ anemia ✓✓✓ ☺LIKELY a significant mortality EFFECT, BUT EVIDENCE is WEAK; clear benefit however for iugr multi-Micronutrient supplementation✓ ☺ ALTHOUGH iugr is reduced , in many low income settings there MAY BE no net benefit; under SOME conditions there MAY BE net harm Calcium ✓✓✓😐 large magnitude EFFECTS but significant logistical barriers at currently recommended dose antenatal Vitamin A ☺ no effects on our outcomes of interest Postnatal Vitamin A ✓ ☺EVIDENCE for IMPACT on early infant deaths in Vitamin-A deficient populationsiodine ✓ ☺major benefit in ↓’d burden of Cognitive disabilitybalanced protein-energy supplementation ✓✓✓😐 significant benefits, but cost & logistical challenges limit scalability deworming ☺ no effects on our outcomes of interest iptp/itns ✓✓✓✓ ☺large magnitude EFFECTS in malarious areastetanus Toxoid ✓ ☺in most settings, coverage is now relatively high; this NEEDS to be sustainedchlorhexidine advance distribution ✓ ☺large magnitude EFFECT on newborn mortality in high nmr populationssyphilis screening & treatment ✓✓✓ ☺relatively inexpensive and straightforward diagnostics and treatmentpmtct ✓😐 high population effective coverage REQUIRES robust services and systemsmisoprostol advance distribution ✓ ☺to ensure SAFETY, Delivery strategy NEEDS to reliably ensure counseling on correct timing of use (i.e.']	[('IMPORTANT_CONSIDERATION', 75), ('SUPERFICIAL_RELATIONSHIP', 304), ('PROBABLE_UNDERSTANDING', 349), ('SUPERFICIAL_RELATIONSHIP', 380), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 388), ('INCOMPLETE_EVIDENCE', 392), ('INCOMPLETE_EVIDENCE', 404), ('ANOMALY_CURIOUS_FINDING', 480), ('INCOMPLETE_EVIDENCE', 541), ('INCOMPLETE_EVIDENCE', 570), ('INCOMPLETE_EVIDENCE', 592), ('SUPERFICIAL_RELATIONSHIP', 637), ('INCOMPLETE_EVIDENCE', 795), ('SUPERFICIAL_RELATIONSHIP', 808), ('SUPERFICIAL_RELATIONSHIP', 1134), ('FUTURE_WORK', 1234), ('SUPERFICIAL_RELATIONSHIP', 1309), ('IMPORTANT_CONSIDERATION', 1508), ('IMPORTANT_CONSIDERATION', 1590), ('FUTURE_WORK', 1616), ('IMPORTANT_CONSIDERATION', 1616)]	21	[('GO_0031078', 'histone deacetylase activity (H3-K14 specific)', 238, 'DeliveryCommentsBreastfeeding'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 447, 'micronutrient'), ('CHEBI_31341', 'calcium dihydroxide', 608, 'Calcium'), ('CHEBI_77082', 'O-adipoylcarnitine(1-)', 616, '✓✓✓😐'), ('CHEBI_33233', 'fundamental particle', 721, 'vitamin A ☺'), ('PR_000021995', 'dual specificity mitogen-activated protein kinase kinase 4 phosphorylated form', 721, 'vitamin A ☺'), ('GO_0007567', 'parturition', 772, 'Postnatal'), ('CHEBI_27300', 'vitamin D', 782, 'vitamin A'), ('CHEBI_33229', 'vitamin (role)', 841, 'vitamin'), ('PR_000027594', 'histone H3', 841, 'vitamin-A'), ('GO_0050890', 'cognition', 913, 'cognitive'), ('CHEBI_29238', 'tritium atom', 1168, 'toxoid'), ('GO_0007567', 'parturition', 1598, 'delivery')]
S1153-PMC4990268	PMC4990268	8/2016	S1153-PMC4990268	['DEPENDING ON the setting, this COULD BE supplemented by clinical preventive interventions that CAN be put into operation at the time of home Births, NOTABLY the use of Misoprostol for prevention of pph, application of Chlorhexidine to the Umbilical Cord Stump and newborn Vitamin A supplementation.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 31), ('INCOMPLETE_EVIDENCE', 95), ('IMPORTANT_CONSIDERATION', 149)]	4	[('GO_0007567', 'parturition', 141, 'births'), ('CHEBI_63610', 'misoprostol', 168, 'misoprostol'), ('CHEBI_3647', 'chlorpromazine', 218, 'chlorhexidine'), ('UBERON_0010270', 'filum terminale externum', 239, 'umbilical cord stump'), ('CHEBI_27300', 'vitamin D', 272, 'vitamin A')]
S1184-PMC4990268	PMC4990268	8/2016	S1184-PMC4990268	['BUT current RECOMMENDED dose imposes IMPORTANT logistical DIFFICULTIES.antenatal vitamin aroutine supplementation not indicated BUT in Vitamin A deficient populations screening for night blindness and treating such cases with Vitamin A CAN be RECOMMENDED.Postnatal vitamin abenefit expected in Vitamin A deficient populations (e.g.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('FUTURE_WORK', 12), ('IMPORTANT_CONSIDERATION', 37), ('DIFFICULT_TASK', 58), ('PROBLEM_COMPLICATION', 58), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 128), ('INCOMPLETE_EVIDENCE', 236), ('FUTURE_WORK', 243)]	8	[('CHEBI_27300', 'vitamin D', 135, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 226, 'vitamin A'), ('GO_0007567', 'parturition', 255, 'Postnatal'), ('CHEBI_27300', 'vitamin D', 294, 'vitamin A')]
S150-PMC4990280	PMC4990280	8/2016	S150-PMC4990280	['the mm supplement of unicef/who/unu contained IMPORTANT antioxidants such as Vitamin E, Vitamin C and Selenium which are KNOWN to reduce inflammatory responses.']	[('IMPORTANT_CONSIDERATION', 46), ('INCOMPLETE_EVIDENCE', 121)]	2	[('CHEBI_27300', 'vitamin D', 77, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 88, 'vitamin C'), ('CHEBI_27568', 'selenium atom', 102, 'selenium')]
S154-PMC4990280	PMC4990280	8/2016	S154-PMC4990280	['a study in nepal DEMONSTRATED that maternal Vitamin A supplementation enhanced natural Antibody concentrations in children at preadolescent age (9 to 13 years); the authors POSTULATED that pre-Natal supplementation lead TO a higher reservoir and sustained natural immunity in these children [37].']	[('INCOMPLETE_EVIDENCE', 17), ('INCOMPLETE_EVIDENCE', 173), ('QUESTION_ANSWERED_BY_THIS_WORK', 220)]	3	[('CHEBI_27300', 'vitamin D', 44, 'vitamin A'), ('GO_0042571', 'immunoglobulin complex, circulating', 87, 'antibody'), ('GO_0007567', 'parturition', 193, 'natal')]
S0-PMC4992225	PMC4992225	8/2016	S0-PMC4992225	['a randomized controlled trial of Vitamin D supplementation on Perinatal depression: in iranian Pregnant mothers\n\nabstract\n\nbackground\nMood disorders in Pregnancy and Post-Partum Period are common and CONSIDERED as a PUBLIC HEALTH ISSUE.']	[('IMPORTANT_CONSIDERATION', 200), ('IMPORTANT_CONSIDERATION', 216), ('IMPORTANT_CONSIDERATION', 230)]	3	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('GO_0036268', 'swimming', 62, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 62, 'perinatal'), ('GO_0007565', 'female pregnancy', 95, 'pregnant'), ('GO_0065007', 'biological regulation', 134, 'Mood'), ('GO_0007565', 'female pregnancy', 152, 'pregnancy'), ('GO_0007565', 'female pregnancy', 166, 'post-partum'), ('UBERON_0001699', 'sensory root of facial nerve', 171, 'partum period')]
S38-PMC4992225	PMC4992225	8/2016	S38-PMC4992225	['SEVERAL STUDIES have REVEALED that Vitamin D supplementation can raise Vitamin D reserves gradually, according to baseline concentration of Vitamin D, dose and duration of Consumption [16–18].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 21)]	2	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 140, 'vitamin D'), ('GO_0007631', 'feeding behavior', 172, 'consumption')]
S39-PMC4992225	PMC4992225	8/2016	S39-PMC4992225	['IN ACCORDANCE to a GUIDELINE by holick et al., 6–8 weeks Consumption of a high dose Vitamin D supplement are ESSENTIAL to obtain an adequate Blood reserves of Vitamin D [19].']	[('INCOMPLETE_EVIDENCE', 0), ('PROBABLE_UNDERSTANDING', 19), ('IMPORTANT_CONSIDERATION', 109)]	3	[('GO_0007631', 'feeding behavior', 57, 'consumption'), ('CHEBI_27300', 'vitamin D', 84, 'vitamin D'), ('UBERON_0000178', 'blood', 141, 'blood'), ('CHEBI_27300', 'vitamin D', 159, 'vitamin D')]
S94-PMC4992225	PMC4992225	8/2016	S94-PMC4992225	['intervention in the Supplement consumer (Vitamin D) group: in 2007 and 2010, the canadian pediatric association RECOMMENDED a daily amount of 2000\xa0iu of Vitamin D for Pregnant and breast-feeding women [47,46].']	[('FUTURE_WORK', 112)]	1	[('CHEBI_16158', 'steroid sulfate', 20, 'supplement'), ('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 153, 'vitamin D'), ('GO_0007565', 'female pregnancy', 167, 'pregnant')]
S105-PMC4992225	PMC4992225	8/2016	S105-PMC4992225	['the multivitamin supplementations contained 200–400\xa0iu of Vitamin D.\n\nsample size and statistical analysis\nwe COULD NOT FIND a similar study to use its means for determining the sample size.']	[('FULL_UNKNOWN', 110)]	1	[('CHEBI_27300', 'vitamin D', 58, 'vitamin D')]
S194-PMC4992225	PMC4992225	8/2016	S194-PMC4992225	['in the PRESENT STUDY, the mean Vitamin D concentrations in Vitamin D group were significantly higher after taking 2000\xa0iu of Vitamin D supplementation per day for AT LEAST 8 weeks.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 7), ('PROBABLE_UNDERSTANDING', 163)]	2	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin D')]
S196-PMC4992225	PMC4992225	8/2016	S196-PMC4992225	['IN CONTRAST, in the PREVIOUS STUDIES 2000\xa0iu Vitamin D supplementation was more sufficient to increase Serum 25-Hydroxyvitamin D concentrations up to the adequate amount (≥32\xa0ng/ml) [18,57,58].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 20)]	2	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('UBERON_0001977', 'blood serum', 103, 'serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 109, '25-hydroxyvitamin D')]
S197-PMC4992225	PMC4992225	8/2016	S197-PMC4992225	['in those studies, Vitamin D supplementations started at the end of the first trimester or at the beginning of the second Trimester and their participants had higher initial 25-hydroxyvitamin d concentrations COMPARED TO the participants in OUR STUDY.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 208), ('QUESTION_ANSWERED_BY_THIS_WORK', 240)]	2	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 121, 'trimester')]
S232-PMC4992225	PMC4992225	8/2016	S232-PMC4992225	['the Vitamin D and control groups were SIMILAR regarding to general characteristics EXCEPT FOR two variables: unplanned Pregnancy and using other Supplements OUT OF THE STUDY’S PROTOCOL.']	[('SUPERFICIAL_RELATIONSHIP', 38), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 83), ('PROBLEM_COMPLICATION', 157)]	3	[('CHEBI_27300', 'vitamin D', 4, 'vitamin D'), ('GO_0007565', 'female pregnancy', 119, 'pregnancy'), ('CHEBI_33341', 'titanium atom', 145, 'supplements')]
S237-PMC4992225	PMC4992225	8/2016	S237-PMC4992225	['the control group consumed extra supplements such as Calcium more frequently, NONETHELESS this group had significantly higher depression scores compared to Vitamin D group.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 78)]	1	[('CHEBI_22313', 'alkaline earth metal atom', 53, 'calcium'), ('CHEBI_27300', 'vitamin D', 156, 'vitamin D')]
S238-PMC4992225	PMC4992225	8/2016	S238-PMC4992225	['PREVIOUS clinical TRIALS, in which Vitamin D supplementations were consumed during Pregnancy [18,58], HAVE NOT EVALUATED the Antenatal and Postnatal depression disorders.']	[('INCOMPLETE_EVIDENCE', 0), ('FULL_UNKNOWN', 102), ('FULL_UNKNOWN', 107)]	3	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('GO_0007565', 'female pregnancy', 83, 'pregnancy'), ('GO_0007567', 'parturition', 125, 'antenatal'), ('GO_0007567', 'parturition', 139, 'postnatal')]
S274-PMC4992225	PMC4992225	8/2016	S274-PMC4992225	['meaning that over time, depression scores decreased much more in the Vitamin D group in comparison to control group and this SHOWS the POSSIBLE EFFECTS of the Vitamin D3Supplementation.']	[('INCOMPLETE_EVIDENCE', 125), ('INCOMPLETE_EVIDENCE', 135), ('SUPERFICIAL_RELATIONSHIP', 144)]	3	[('CHEBI_27300', 'vitamin D', 69, 'vitamin D'), ('CHEBI_52915', 'phosphatediyl group', 159, 'vitamin D3supplementation')]
S113-PMC4993554	PMC4993554	8/2016	S113-PMC4993554	['Vitamins and other supplements in Pregnancy\nwomen’s awareness about the RECOMMENDATIONS for Supplements in Pregnancy was explored, including vitamins and other RECOMMENDED supplements (Folic Acid and Iodine), as well as those Vitamins for which there were DANGERS ASSOCIATED with excessive doses (Vitamin A, Vitamin D, and Vitamin B6).']	[('FUTURE_WORK', 72), ('FUTURE_WORK', 160), ('IMPORTANT_CONSIDERATION', 256), ('SUPERFICIAL_RELATIONSHIP', 264)]	4	[('CHEBI_28371', 'vitamin K epoxide', 0, 'Vitamins'), ('GO_0007565', 'female pregnancy', 34, 'pregnancy'), ('CHEBI_33341', 'titanium atom', 92, 'supplements'), ('GO_0007565', 'female pregnancy', 107, 'pregnancy'), ('CHEBI_30751', 'formic acid', 185, 'folic acid'), ('CHEBI_24859', 'iodine atom', 200, 'iodine'), ('CHEBI_33277', 'gamma-tocotrienol', 226, 'vitamins'), ('CHEBI_27300', 'vitamin D', 297, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 305, 'A'), ('CHEBI_27300', 'vitamin D', 308, 'vitamin D'), ('CHEBI_33237', 'vitamin D4', 323, 'vitamin B6'), ('PR_000004690', 'B-cell lymphoma/leukemia 11A', 331, 'B6')]
S18-PMC4996336	PMC4996336	12/2015	S18-PMC4996336	['two of THESE STUDIES INVOLVED Calcium supplementation,16,17one INVOLVED supplementation with Calcium plus Vitamin D,18two INVOLVED supplementation with zinc,19,20and one included four intervention arms in females of Childbearing age (i.e.']	[('INCOMPLETE_EVIDENCE', 7), ('SUPERFICIAL_RELATIONSHIP', 21), ('SUPERFICIAL_RELATIONSHIP', 63), ('SUPERFICIAL_RELATIONSHIP', 122)]	4	[('CHEBI_22313', 'alkaline earth metal atom', 30, 'calcium'), ('CHEBI_22313', 'alkaline earth metal atom', 93, 'calcium'), ('CHEBI_27300', 'vitamin D', 106, 'vitamin D'), ('GO_0007129', 'homologous chromosome pairing at meiosis', 216, 'childbearing')]
S23-PMC4997421	PMC4997421	8/2016	S23-PMC4997421	['THEREFORE, the OBJECTIVE of THIS STUDY was to use nhanes data to EXAMINE the Retinol status of women of Childbearing age in the united states, and TO ASSESS the IMPACT of poverty and race, as well as OTHER INDICATORS that have NOT previously BEEN EXAMINED in this population, including Food security and use of supplemental nutrition assistance programs (snap), on Vitamin A status.']	[('PROBABLE_UNDERSTANDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 15), ('QUESTION_ANSWERED_BY_THIS_WORK', 28), ('QUESTION_ANSWERED_BY_THIS_WORK', 65), ('QUESTION_ANSWERED_BY_THIS_WORK', 147), ('SUPERFICIAL_RELATIONSHIP', 161), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 200), ('SUPERFICIAL_RELATIONSHIP', 206), ('FULL_UNKNOWN', 227)]	9	[('CHEBI_26536', 'retinoic acid', 77, 'retinol'), ('GO_0007129', 'homologous chromosome pairing at meiosis', 104, 'childbearing'), ('CHEBI_33290', 'food', 286, 'food'), ('CHEBI_27300', 'vitamin D', 365, 'vitamin A')]
S6-PMC4997567	PMC4997567	8/2016	S6-PMC4997567	['the RISK FACTORS were low socioeconomic status, insufficient family income, poor housing conditions, lack of exposure to sunlight DUE TO cultural practices, sole Breast feeding, and inadequate supplementation of Vitamin D to the children and the Pregnant women.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('PROBLEM_COMPLICATION', 130)]	2	[('UBERON_0000310', 'breast', 162, 'breast'), ('CHEBI_27300', 'vitamin D', 212, 'vitamin D'), ('GO_0007565', 'female pregnancy', 246, 'pregnant')]
S11-PMC4997567	PMC4997567	8/2016	S11-PMC4997567	['the risk factors contributing to Vitamin D deficiency rickets in the egyptian children include the low socioeconomic status, the limited exposure to sunlight due TO housing conditions and cultural practices, and the exclusive or prolonged Breast-feeding without Vitamin D supplements.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 162)]	1	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('UBERON_0000310', 'breast', 239, 'breast'), ('CHEBI_27300', 'vitamin D', 262, 'vitamin D')]
S54-PMC4997567	PMC4997567	8/2016	S54-PMC4997567	['as regards to the maternal Gestational conditions, the mothers of 175 cases (70%) had more than 3 Pregnancies, compared TO the mothers of 23 controls (9.2%); of 140 cases (56%) has less than 2-year interval between the Pregnancies, compared TO those of 14 controls (5.6%); of 200 cases (80%) exposed to less than half an hour a day, compared to the mothers of 50 controls (20%); of 155 (62%) with no Food rich in Vitamin D, nor calcium, nor Vitamin D supplementation during Pregnancy, compared TO those of 10 controls (4%).']	[('QUESTION_ANSWERED_BY_THIS_WORK', 120), ('QUESTION_ANSWERED_BY_THIS_WORK', 241), ('QUESTION_ANSWERED_BY_THIS_WORK', 494)]	3	[('GO_0007565', 'female pregnancy', 27, 'gestational'), ('GO_0007565', 'female pregnancy', 98, 'pregnancies'), ('GO_0007565', 'female pregnancy', 219, 'pregnancies'), ('CHEBI_33290', 'food', 400, 'food'), ('CHEBI_27300', 'vitamin D', 413, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 441, 'vitamin D'), ('GO_0007565', 'female pregnancy', 474, 'pregnancy')]
S78-PMC4997567	PMC4997567	8/2016	S78-PMC4997567	['maternally, repeated Pregnancies more than 3 gravida (70%), shortened Pregnancy free intervals to less than 2 years (56%), lack OF adequate sunlight exposure to less than half an hour (80%), and inadequate maternal Gestational supplementation of Calcium and Vitamin D (62%) were contributing RISK FACTORS.']	[('ANOMALY_CURIOUS_FINDING', 128), ('SUPERFICIAL_RELATIONSHIP', 292)]	2	[('GO_0007565', 'female pregnancy', 21, 'pregnancies'), ('GO_0007565', 'female pregnancy', 70, 'pregnancy'), ('GO_0007565', 'female pregnancy', 215, 'gestational'), ('CHEBI_22313', 'alkaline earth metal atom', 246, 'calcium'), ('CHEBI_27300', 'vitamin D', 258, 'vitamin D')]
S82-PMC4997567	PMC4997567	8/2016	S82-PMC4997567	['(2008) [14], and bakeit and megeid (2012) [13] who REPORTED deficient maternal geastational supplementation of Calcium and Vitamin D as a cause of infantile Vitamin D deficiency rickets.']	[('INCOMPLETE_EVIDENCE', 51)]	1	[('CHEBI_22313', 'alkaline earth metal atom', 111, 'calcium'), ('CHEBI_27300', 'vitamin D', 123, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 157, 'vitamin D')]
S93-PMC4997567	PMC4997567	8/2016	S93-PMC4997567	['(1992) [20] who OBSERVED that the Breast- Fed infant with insufficiency Intake of Vitamin D supplement are susceptible to nutritional rickets.']	[('INCOMPLETE_EVIDENCE', 16)]	1	[('UBERON_0000310', 'breast', 34, 'breast'), ('GO_0007631', 'feeding behavior', 42, 'fed'), ('GO_0007631', 'feeding behavior', 72, 'intake'), ('CHEBI_27300', 'vitamin D', 82, 'vitamin D')]
S94-PMC4997567	PMC4997567	8/2016	S94-PMC4997567	['hollis and wagner (2004) [21] NOTICED that ALTHOUGH Breast Milk is adequate for growth and bone mineralization in the first year of Life, it is lacking adequate concentration of Vitamin D. THEREFORE, Vitamin D supplementation MUST BE NECESSARY for Breast-Fed infants.']	[('ANOMALY_CURIOUS_FINDING', 30), ('ANOMALY_CURIOUS_FINDING', 43), ('PROBABLE_UNDERSTANDING', 189), ('IMPORTANT_CONSIDERATION', 226), ('IMPORTANT_CONSIDERATION', 234)]	5	[('UBERON_0000310', 'breast', 52, 'breast'), ('UBERON_0001913', 'milk', 59, 'milk'), ('UBERON_0000104', 'life cycle', 132, 'life'), ('CHEBI_27300', 'vitamin D', 178, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 200, 'vitamin D'), ('UBERON_0000310', 'breast', 248, 'breast'), ('GO_0007631', 'feeding behavior', 255, 'fed')]
S101-PMC4997567	PMC4997567	8/2016	S101-PMC4997567	['the RISK FACTORS included low socioeconomic status, nutritionally Vitamin D deficient mothers, and prolonged Breast Feeding without Vitamin D supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 4)]	1	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('GO_0007567', 'parturition', 109, 'breast'), ('GO_0007631', 'feeding behavior', 116, 'feeding'), ('CHEBI_27300', 'vitamin D', 132, 'vitamin D')]
S103-PMC4997567	PMC4997567	8/2016	S103-PMC4997567	['several RISK FACTORS had IMPORTANT CONTRIBUTIONS, including low socio-economic status represented by low family income, low standard of education, poor housing conditions, lack of exposure to sunlight, nutritional status of mother, and prolonged Breast-Feeding without Vitamin D supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 8), ('IMPORTANT_CONSIDERATION', 25), ('SUPERFICIAL_RELATIONSHIP', 35)]	3	[('GO_0007567', 'parturition', 246, 'breast-'), ('UBERON_0000310', 'breast', 246, 'breast'), ('GO_0007631', 'feeding behavior', 253, 'feeding'), ('CHEBI_27300', 'vitamin D', 269, 'vitamin D')]
S1-PMC5014971	PMC5014971	8/2016	S1-PMC5014971	['RECOMMENDATIONS for adequate levels of circulating 25-Hydroxyvitamin D and appropriate Vitamin D supplementation during Pregnancy DIFFER between the institute of medicine and the Endocrine society.']	[('FUTURE_WORK', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 130)]	2	[('CHEBI_62218', '23,24-dihydrocucurbitacin D', 51, '25-hydroxyvitamin D'), ('CHEBI_27300', 'vitamin D', 87, 'vitamin D'), ('GO_0007565', 'female pregnancy', 120, 'pregnancy'), ('UBERON_0005063', 'left ventricular compact myocardium', 179, 'Endocrine')]
S4-PMC5014971	PMC5014971	8/2016	S4-PMC5014971	['a majority INDICATED that Vitamin D insufficiency was a PROBLEM in their patient population (68.4%) and that most of their Pregnant patients would BENEFIT from vitamin D supplementation (66.3%).']	[('INCOMPLETE_EVIDENCE', 11), ('IMPORTANT_CONSIDERATION', 56), ('PROBLEM_COMPLICATION', 56), ('IMPORTANT_CONSIDERATION', 147)]	4	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('GO_0007565', 'female pregnancy', 123, 'pregnant'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 168, 'D')]
S5-PMC5014971	PMC5014971	8/2016	S5-PMC5014971	['half (52.5%) would RECOMMEND Vitamin D supplementation during Pregnancy to some patients, BUT ONLY 16.8% to all.']	[('FUTURE_WORK', 19), ('ANOMALY_CURIOUS_FINDING', 90)]	2	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('GO_0007565', 'female pregnancy', 62, 'pregnancy')]
S7-PMC5014971	PMC5014971	8/2016	S7-PMC5014971	['physicians who indicated that Vitamin D status was a PROBLEM in their patient population were more LIKELY to screen routinely (32.8% versus 9.7%, p = 0.002) and believe their patients would BENEFIT from supplementation (91.2% versus 16.1%, p = 0.001).']	[('IMPORTANT_CONSIDERATION', 53), ('PROBABLE_UNDERSTANDING', 99), ('IMPORTANT_CONSIDERATION', 190)]	3	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D')]
S14-PMC5014971	PMC5014971	8/2016	S14-PMC5014971	['the IMPORTANCE of dietary Vitamin D, both naturally occurring in foods and via supplements added to foods (e.g., fortified Milk) or Consumed directly, has increased.']	[('IMPORTANT_CONSIDERATION', 4)]	1	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('UBERON_0001913', 'milk', 123, 'milk'), ('GO_0007631', 'feeding behavior', 132, 'consumed')]
S26-PMC5014971	PMC5014971	8/2016	S26-PMC5014971	['the two groups also RECOMMEND DIFFERENT levels of Vitamin D supplementation, IN LARGE PART DUE TO the DIFFERENT stable levels of circulating 25-Oh-D they are attempting to obtain.']	[('FUTURE_WORK', 20), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 30), ('INCOMPLETE_EVIDENCE', 77), ('PROBABLE_UNDERSTANDING', 91), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 102)]	5	[('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('CHEBI_46744', 'DDT-2,3-dihydrodiol', 141, '25-OH-D')]
S27-PMC5014971	PMC5014971	8/2016	S27-PMC5014971	['low to moderate quality evidence exists for a PROTECTIVE EFFECT of Vitamin D supplementation during Pregnancy for a number of Pregnancy outcomes, including Preeclampsia, being small for Gestational age, and Preterm labor [20].']	[('SUPERFICIAL_RELATIONSHIP', 46), ('SUPERFICIAL_RELATIONSHIP', 57)]	2	[('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('GO_0007565', 'female pregnancy', 100, 'pregnancy'), ('GO_0007565', 'female pregnancy', 126, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 156, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 186, 'gestational'), ('GO_0007565', 'female pregnancy', 207, 'preterm')]
S33-PMC5014971	PMC5014971	8/2016	S33-PMC5014971	['Vitamin D supplementation during Pregnancy is GENERALLY CONSIDERED SAFE, THOUGH rigorous studies on high doses of Vitamin D supplementation are LACKING [25].']	[('PROBABLE_UNDERSTANDING', 46), ('INCOMPLETE_EVIDENCE', 56), ('IMPORTANT_CONSIDERATION', 67), ('ANOMALY_CURIOUS_FINDING', 73), ('INCOMPLETE_EVIDENCE', 144)]	5	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 33, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D')]
S34-PMC5014971	PMC5014971	8/2016	S34-PMC5014971	['results from a RECENT STUDY INDICATE that Vitamin D supplementation during Pregnancy with up to 4,000\u2009iu/day is SAFE and EFFECTIVE [26].']	[('INCOMPLETE_EVIDENCE', 15), ('INCOMPLETE_EVIDENCE', 28), ('IMPORTANT_CONSIDERATION', 112), ('SUPERFICIAL_RELATIONSHIP', 121)]	4	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('GO_0007565', 'female pregnancy', 75, 'pregnancy')]
S37-PMC5014971	PMC5014971	8/2016	S37-PMC5014971	['the PURPOSE of THIS STUDY was TO ASSESS the practice, knowledge, and opinions of practicing obstetrician-gynecologists regarding screening for Vitamin D status and Vitamin D supplementation of their Pregnant patients.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 15), ('QUESTION_ANSWERED_BY_THIS_WORK', 30)]	3	[('CHEBI_27300', 'vitamin D', 143, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 164, 'vitamin D'), ('GO_0007565', 'female pregnancy', 199, 'pregnant')]
S43-PMC5014971	PMC5014971	8/2016	S43-PMC5014971	['the survey contained questions on physician and patient population demographics, physician opinion regarding health CONCERNS associated with Vitamin D deficiency/insufficiency, and practice patterns regarding screening and supplementing Pregnant women.']	[('IMPORTANT_CONSIDERATION', 116)]	1	[('CHEBI_27300', 'vitamin D', 141, 'vitamin D'), ('GO_0007565', 'female pregnancy', 237, 'pregnant')]
S63-PMC5014971	PMC5014971	8/2016	S63-PMC5014971	['less than half (45.5%) had read acog committee opinion 495 (co 495) on Vitamin D during Pregnancy, and opinion was split evenly among these physicians on WHETHER this committee opinion had changed their practice regarding Vitamin D screening and supplementation during Pregnancy.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 154)]	1	[('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('GO_0007565', 'female pregnancy', 88, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 222, 'vitamin D'), ('GO_0007565', 'female pregnancy', 269, 'pregnancy')]
S64-PMC5014971	PMC5014971	8/2016	S64-PMC5014971	['a majority responded that Vitamin D insufficiency was a PROBLEM in their patient population (68.3%) and that most of their patients would BENEFIT from taking a Vitamin D supplement (66.3%).']	[('IMPORTANT_CONSIDERATION', 56), ('PROBLEM_COMPLICATION', 56), ('IMPORTANT_CONSIDERATION', 138)]	3	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 160, 'vitamin D')]
S68-PMC5014971	PMC5014971	8/2016	S68-PMC5014971	['a majority of respondents considered Vitamin D supplementation during Pregnancy (82.1%) to be SAFE.']	[('IMPORTANT_CONSIDERATION', 94)]	1	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('GO_0007565', 'female pregnancy', 70, 'pregnancy')]
S82-PMC5014971	PMC5014971	8/2016	S82-PMC5014971	['about half of respondents RECOMMEND additional Vitamin D supplementation to their Pregnant patients (always = 16.8%, often = 11.9%, and sometimes = 23.8%).']	[('FUTURE_WORK', 26)]	1	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('GO_0007565', 'female pregnancy', 82, 'pregnant')]
S83-PMC5014971	PMC5014971	8/2016	S83-PMC5014971	['physicians who considered Vitamin D insufficiency a PROBLEM among their patients were more LIKELY to think that most of their Pregnant patients would BENEFIT from taking Vitamin D supplements (91.2% versus 16.1%; p< 0.001).']	[('IMPORTANT_CONSIDERATION', 52), ('PROBABLE_UNDERSTANDING', 91), ('IMPORTANT_CONSIDERATION', 150)]	3	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('GO_0007565', 'female pregnancy', 126, 'pregnant'), ('CHEBI_27300', 'vitamin D', 170, 'vitamin D')]
S87-PMC5014971	PMC5014971	8/2016	S87-PMC5014971	['regarding the level of circulating 25-Hydroxyvitamin D below which there is CONCERN for Vitamin D deficiency, respondents were ROUGHLY split between below 20\u2009ng/ml (50\u2009nmol/l) and 32\u2009ng/ml (80\u2009nmol/l) AS the level at which they would RECOMMEND a higher supplementation dose of vitamin d (46.5% versus 40.6%).']	[('IMPORTANT_CONSIDERATION', 76), ('PROBABLE_UNDERSTANDING', 127), ('PROBABLE_UNDERSTANDING', 201), ('FUTURE_WORK', 234)]	4	[('CHEBI_62218', '23,24-dihydrocucurbitacin D', 35, '25-hydroxyvitamin D'), ('CHEBI_27300', 'vitamin D', 88, 'vitamin D')]
S90-PMC5014971	PMC5014971	8/2016	S90-PMC5014971	['physicians who indicated that Vitamin D insufficiency is a PROBLEM in their patient population were more LIKELY to agree or strongly agree that Vitamin D supplementation during Pregnancy is safe and that all Pregnant women SHOULD BE screened.']	[('IMPORTANT_CONSIDERATION', 59), ('PROBABLE_UNDERSTANDING', 105), ('FUTURE_WORK', 223)]	3	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D'), ('GO_0007565', 'female pregnancy', 177, 'pregnancy'), ('GO_0007565', 'female pregnancy', 208, 'pregnant')]
S92-PMC5014971	PMC5014971	8/2016	S92-PMC5014971	['these physicians were also more LIKELY to disagree with the following statements: Vitamin D supplementation during Pregnancy is GENERALLY not NECESSARY, they are not CONCERNED about Vitamin D deficiency in their Pregnant patients, Pregnant women taking Prenatal Vitamins are at low RISK for Vitamin D deficiency, and most of my Pregnant patients will get enough vitamin d through sun exposure and diet (table 3).']	[('PROBABLE_UNDERSTANDING', 32), ('PROBABLE_UNDERSTANDING', 128), ('IMPORTANT_CONSIDERATION', 142), ('IMPORTANT_CONSIDERATION', 166), ('IMPORTANT_CONSIDERATION', 282)]	5	[('CHEBI_27300', 'vitamin D', 82, 'vitamin D'), ('GO_0007565', 'female pregnancy', 115, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 182, 'vitamin D'), ('GO_0007565', 'female pregnancy', 212, 'pregnant'), ('GO_0007565', 'female pregnancy', 231, 'pregnant'), ('GO_0007565', 'female pregnancy', 253, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 262, 'vitamins'), ('CHEBI_27300', 'vitamin D', 291, 'vitamin D'), ('GO_0007565', 'female pregnancy', 328, 'pregnant')]
S94-PMC5014971	PMC5014971	8/2016	S94-PMC5014971	['discussion\nthe results of THIS STUDY SUGGEST that practicing obstetrician-gynecologists GENERALLY are SOMEWHAT CONCERNED about the Vitamin D status of their Pregnant patients and consider Vitamin D supplementation during Pregnancy to be SAFE.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 26), ('INCOMPLETE_EVIDENCE', 37), ('PROBABLE_UNDERSTANDING', 88), ('INCOMPLETE_EVIDENCE', 102), ('IMPORTANT_CONSIDERATION', 111), ('IMPORTANT_CONSIDERATION', 237)]	6	[('CHEBI_27300', 'vitamin D', 131, 'vitamin D'), ('GO_0007565', 'female pregnancy', 157, 'pregnant'), ('CHEBI_27300', 'vitamin D', 188, 'vitamin D'), ('GO_0007565', 'female pregnancy', 221, 'pregnancy')]
S95-PMC5014971	PMC5014971	8/2016	S95-PMC5014971	"[""the greater the CONCERN is over their patients' Vitamin D status, the more LIKELY the physician is to RECOMMEND supplementation.""]"	[('PROBLEM_COMPLICATION', 16), ('PROBABLE_UNDERSTANDING', 75), ('FUTURE_WORK', 102)]	3	[('CHEBI_27300', 'vitamin D', 48, 'vitamin D')]
S98-PMC5014971	PMC5014971	8/2016	S98-PMC5014971	['there was a LACK OF CONSENSUS regarding the APPROPRIATE level of Vitamin D supplementation during Pregnancy and the value of circulating 25-Hydroxyvitamin D, below which there is CONCERN regarding Vitamin D insufficiency.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 12), ('INCOMPLETE_EVIDENCE', 12), ('IMPORTANT_CONSIDERATION', 44), ('IMPORTANT_CONSIDERATION', 179), ('PROBLEM_COMPLICATION', 179)]	5	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('GO_0007565', 'female pregnancy', 98, 'pregnancy'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 137, '25-hydroxyvitamin D'), ('CHEBI_27300', 'vitamin D', 197, 'vitamin D')]
S100-PMC5014971	PMC5014971	8/2016	S100-PMC5014971	['there is CONTINUING CONTROVERSY over the APPROPRIATE levels of Vitamin D supplementation and of the levels of circulating 25-Hydroxyvitamin D that represent good health.']	[('FUTURE_WORK', 9), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 20), ('IMPORTANT_CONSIDERATION', 41)]	3	[('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 122, '25-hydroxyvitamin D')]
S101-PMC5014971	PMC5014971	8/2016	S101-PMC5014971	['the result has been CONFLICTING RECOMMENDATIONS from the iom [14,15] and the Endocrine society [19], ESPECIALLY CONCERNING Vitamin D supplementation and APPROPRIATE levels of circulating 25-Oh-D during Pregnancy (table 4).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 20), ('FUTURE_WORK', 32), ('IMPORTANT_CONSIDERATION', 101), ('IMPORTANT_CONSIDERATION', 112), ('IMPORTANT_CONSIDERATION', 153)]	5	[('UBERON_0005063', 'left ventricular compact myocardium', 77, 'Endocrine'), ('CHEBI_27300', 'vitamin D', 123, 'vitamin D'), ('CHEBI_46744', 'DDT-2,3-dihydrodiol', 187, '25-OH-D'), ('GO_0007565', 'female pregnancy', 202, 'pregnancy')]
S110-PMC5014971	PMC5014971	8/2016	S110-PMC5014971	['on a CAUTIONARY NOTE, the EVIDENCE for positive BENEFITS of circulating levels of 25-Oh-D and Vitamin D supplementation above those from iom can hardly be called definitive.']	[('IMPORTANT_CONSIDERATION', 5), ('IMPORTANT_CONSIDERATION', 16), ('INCOMPLETE_EVIDENCE', 26), ('IMPORTANT_CONSIDERATION', 48)]	4	[('CHEBI_46744', 'DDT-2,3-dihydrodiol', 82, '25-OH-D'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin D')]
S132-PMC5014971	PMC5014971	8/2016	S132-PMC5014971	['ALTHOUGH few screen most of their Pregnant patients for Vitamin D status, most would RECOMMEND Vitamin D supplementation EVEN without screening.']	[('ANOMALY_CURIOUS_FINDING', 0), ('FUTURE_WORK', 85), ('ANOMALY_CURIOUS_FINDING', 121)]	3	[('GO_0007565', 'female pregnancy', 34, 'pregnant'), ('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 95, 'vitamin D')]
S105-PMC5024431	PMC5024431	9/2016	S105-PMC5024431	['Eating Out less/Eat at home morei want to only dine out for 1 meal a weekeat more at home\u2003evening/night time Eating (e.g., healthier and/or restricting)no Eating after 8:00pmlimit snacks at night\u2003follow\xa0canada’s Food guidefollow canada’s Food guide\u2003follow \ufeffvegetarian/vegan dietseat mostly vegan\u2003follow\xa0fad diets (not gluten free)more alkaline and less Acidic Foods\u2003gluten free (includes wheat free)follow celiac diet\u2003follow\xa0other plans (includes fodmap guidelines, Heart healthy, diabetes, optifast®, weight watchers®, dash, dietitian meal plans, weight lifting, Pregnancy diet, unspecified diet plans)following the dietitian’s plan, eat only my shakes this week, follow diet, follow diabetes diet\u2003glycemic indexkeep a low glycemic index diet\u2003clean Eating (includes unprocessed, whole, fresh, raw, natural foods)Eating cleaner, eat as much raw as possible, to eat fresh Food\u2003supplementstake 600-800 iu Vitamin D daily\u2003planning and preparing Food†cook dinner from scratch a minimum of 3 times per week, plan 4–5 smaller meals per daybetter Planning and Preparing Of Food, plan healthy meals, plan meals\u2003goals describing when Food is Eaten or not Eaten/Eating patternseat breakfast, Lunch, dinner & snack every day, not to eat in between mealseat more regularly, try not to snack so much throughout the day\u2003breakfasteating healthy breakfastincorporate cereal or smoothies more often for breakfast\u2003psychological aspects of Eatingdon’t binge, drink Water or 0 cal drink when hungry, stop emotional eatingto Control Food Intake, respect Food AS a means of nutrition and to satisfy hunger\u2003general Eating improvementseat healthy meals and snacks, eat the RECOMMENDED dv of Minerals and Vitamins, eat a variety of foodseat healthy, eat a balanced diet, eat right to avoid ibs symptoms\noverall, there were n\u2009= \u20091,986, n\u2009= \u2009614, n\u2009= \u2009233, and n\u2009= \u20091,134 daily, weekly, monthly, and one-time write your own goal statements, respectively (excluding irrelevant to health/Nonsense goals); these goals were RARELY tracked.']	[('PROBABLE_UNDERSTANDING', 1538), ('FUTURE_WORK', 1649), ('INCOMPLETE_EVIDENCE', 1993)]	3	[('GO_0006897', 'endocytosis', 0, 'Eating out'), ('GO_0018888', '3-chloroacrylic acid metabolic process', 16, 'Eat'), ('GO_0051318', 'G1 phase', 109, 'eating'), ('GO_0051318', 'G1 phase', 155, 'eating'), ('CHEBI_33290', 'food', 212, 'Food'), ('CHEBI_33290', 'food', 238, 'food'), ('CHEBI_37527', 'acid', 353, 'acidic'), ('CHEBI_33290', 'food', 360, 'foods'), ('UBERON_0000948', 'heart', 466, 'heart'), ('GO_0007565', 'female pregnancy', 564, 'pregnancy'), ('GO_0051318', 'G1 phase', 750, 'eating'), ('GO_0007568', 'aging', 813, 'Eating'), ('CHEBI_33290', 'food', 871, 'food'), ('CHEBI_27300', 'vitamin D', 903, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 911, 'D'), ('CHEBI_33290', 'food', 942, 'food'), ('GO_0006260', 'DNA replication', 1040, 'planning'), ('GO_0007565', 'female pregnancy', 1053, 'preparing of food'), ('CHEBI_33290', 'food', 1066, 'food'), ('CHEBI_33290', 'food', 1125, 'food'), ('GO_0036268', 'swimming', 1133, 'eaten'), ('GO_0036268', 'swimming', 1146, 'eaten'), ('GO_0051318', 'G1 phase', 1152, 'eating'), ('UBERON_0010164', 'collection of hairs', 1182, 'Lunch'), ('GO_0050957', 'equilibrioception', 1421, 'eatingDon'), ('CHEBI_15377', 'water', 1446, 'water'), ('GO_0065007', 'biological regulation', 1504, 'control'), ('CHEBI_33290', 'food', 1512, 'food'), ('GO_0007631', 'feeding behavior', 1512, 'food intake'), ('CHEBI_33290', 'food', 1533, 'food'), ('GO_0051318', 'G1 phase', 1592, 'eating'), ('CHEBI_46751', 'quinolizidine', 1667, 'minerals'), ('CHEBI_33277', 'gamma-tocotrienol', 1680, 'vitamins'), ('GO_0001967', 'suckling behavior', 1959, 'nonsense')]
S71-PMC5024513	PMC5024513	9/2016	S71-PMC5024513	['caption (table-wrap): table 2\n\ncharacteristics of included studiesstudy informationparticipantssupplementsmeasurementqualitystudycountrystudy designstudy groupsnumberageinclusion criteriaexclusion criteriasupplement type and dosenumber with available dataestimated compliance: n (%)data collection method (s)time period(s)quality ratingbaker et.al (2009) [23]ukcross-sectional studyna50014–18singleton Pregnancy, age 14–18, Gestational age\u2009<\u2009=20\xa0weeksinability to provide informed consent, preeclampsia, Clotting disorders, hiv/aids, haemoglobinopathies, diabetes, Renal disease, hypertension, multiple Gestations, history of 3=\u2009>\u2009previous Miscarriagespreconception folic acid49834 (6.9)24\xa0h recall (multiple)third Trimester+Folic Acid in early pregnancy498220 (44.2)Iron in early pregnancy49839 (7.8)multivitamins in early pregnancy49819 (3.8)Folic Acid only in 3rd trimester2905 (1.7)Iron and Folic Acid in 3rd trimester29013 (4.5)Iron only in 3rd trimester29042 (14.5)multivitamins in 3rd trimester2907 (2.4)castillo-duran et.al (2001) [43]chilerctzinc supplemented24916.4 (mean)beginning Prenatal visits before 20\xa0weeks Gestation, aged <19 at estimated due dateadolescents whose background included chronic diseases, Drug abuse, mental retardation, illiteracy or Pregnancy due to incest or rape20\xa0mg Zinc Sulphate dailyintervention group - 249at least 50\xa0% compliance24\xa0h Recall (multiple)second and third Trimester+placebo25840\xa0mg Iron Sulphateall participants - 507chan et.al (2006) [24]usarctcontrol group, 2 intervention groups excluded from review*2315–17enrolled before 20\xa0weeks Gestationhypertension, diabetes, Renal or Liver disease, alcohol or tobacco use, using medicines effecting Ca Metabolismno additional supplements reportedfood diary (weighing not mentioned)second and third Trimester−/+chang et.al (2003) [37]usaretrospective chart reviewna91812–17self-reported racial group as african-american; singleton Pregnancybirth results not AVAILABLE DUE TO abortion, Miscarriage or transfer of care90\xa0mg Carbonyl Iron daily plus additional up to 120\xa0mg for those classified as anaemic918not reportednot reportedsecond and third Trimester+dawson et.al (2000) [35]usarctone-a-day without iron2016–20aged 16–20, less than 16\xa0weeks Gestation, no Iron supplementation for previous 30\xa0dayshypertension; diabetes; other medical problems; haemoglobin <11\xa0g/dl; haematocrit <30\xa0%vitamin a 5000\xa0iu, Vitamin D 400\xa0iu, Vitamin E 10\xa0mg, Vitamin C 60\xa0mg, Folic Acid 0.4\xa0mg, Thiamine 1.5\xa0mg, riboflavin 1.7\xa0mg, niacin 20\xa0mg, Pyridoxine 2\xa0mg, Vitamin B- 6\xa0mg, Pantothenic Acid 10\xa0mg20not reportedvenous Blood samplesecond and third Trimester and Delivery−/+one-a-day with iron2018\xa0mg iron, vitamin a 5000\xa0iu, Vitamin D 400\xa0iu, Vitamin E 10\xa0mg, Vitamin C 60\xa0mg, Folic Acid 0.4\xa0mg, Thiamine 1.5\xa0mg, riboflavin 1.7\xa0mg, Niacin 20\xa0mg, Pyridoxine 2\xa0mg, Vitamin B- 6\xa0mg, pantothenic Acid 10\xa0mg20derbyshire (2009) [39]ukcross-sectional studyna2015–19attending Antenatal classes or community clinicsincomplete diarynone reportedfood diary unweighedthird Trimester+gadowsky et.al (1995) [42]canadacross-sectional studyna5814–19not reportednot reportedfolic Acid mean 479\xa0μg/day5882\xa0%Venous Blood samplethird trimester+Elemental Iron mean 31.5\xa0mg/daycyanocobalamin (B12) mean 2.24\xa0μg/dgiddens et.al (2000) [27]usarct (subset from a larger study)na5913–18singleton Pregnancies, between 13 and 19\xa0weeks Gestationnot REPORTEDREPORTED that any contribution from Supplements was not included in analysisfood diary weighedmean over Pregnancy−/+ginde et.al (2010) [32]usasecondary analysis of cross sectional surveyna8413–19not reportednot reportedsome participants taking Vitamin D Supplementsnot reportednot reportedvenous Blood samplemean over Pregnancy+gutierrez et.al (1999) [28]usacross-sectional studyna4613–18self-identified ethnicity as mexican american, primigravida, 13–18 years of agehistory of Miscarriage or health problems, involved in competitive athletic performances or heavy exercise, planned to move away during study periodnone reported24\xa0h recall (single)second and third Trimester+iannotti et.al (2005) [36]usacross-sectional studyna8013–18self-reported racial group as african-american; singleton Pregnancynot reportednone reported10\xa0ml Venous Blood samplesecond and third trimesters+job et.al (1995) [41]australiacross-sectional studyna3513–19not reportednot reportednone REPORTED24\xa0h recallmean over Pregnancy+lee et.al (2013) [25]usacross-sectional studyna15613–18age 18 or under, carrying a single fetus, 12–30 weeks Gestation at recruitmentnot REPORTEDREPORTED that any CONTRIBUTION from Supplements was not included in analysis24\xa0h recall (multiple)<23\xa0weeks Gestation, 23–30 weeks Gestation and mean over Pregnancy+mcguire et.al.']	[('INCOMPLETE_EVIDENCE', 1954), ('PROBLEM_COMPLICATION', 1964), ('INCOMPLETE_EVIDENCE', 3401), ('INCOMPLETE_EVIDENCE', 4377), ('INCOMPLETE_EVIDENCE', 4553), ('SUPERFICIAL_RELATIONSHIP', 4579)]	6	[('GO_0007565', 'female pregnancy', 402, 'pregnancy'), ('GO_0007565', 'female pregnancy', 424, 'gestational'), ('GO_0050817', 'coagulation', 504, 'clotting'), ('UBERON_0002113', 'kidney', 565, 'renal'), ('GO_0007565', 'female pregnancy', 603, 'gestations'), ('GO_0050788', 'sequestering of mercury', 640, 'miscarriagesPreconception'), ('GO_0009294', 'DNA mediated transformation', 715, 'trimester'), ('CHEBI_30751', 'formic acid', 725, 'Folic acid'), ('CHEBI_24870', 'ion', 767, 'Iron'), ('CHEBI_30751', 'formic acid', 844, 'Folic acid'), ('CHEBI_24870', 'ion', 886, 'Iron'), ('CHEBI_30751', 'formic acid', 895, 'folic acid'), ('CHEBI_24870', 'ion', 933, 'Iron'), ('GO_0007565', 'female pregnancy', 1092, 'prenatal'), ('GO_0007565', 'female pregnancy', 1124, 'gestation'), ('CHEBI_23888', 'drug', 1221, 'drug'), ('GO_0007565', 'female pregnancy', 1267, 'pregnancy'), ('CHEBI_10127', 'zonisamide', 1304, 'Zinc sulphate'), ('GO_0060033', 'anatomical structure regression', 1376, 'recall'), ('GO_0009294', 'DNA mediated transformation', 1410, 'trimester'), ('CHEBI_83530', 'atenolol-desisopropyl', 1436, 'iron sulphateAll'), ('GO_0051866', 'general adaptation syndrome', 1589, 'gestationHypertension'), ('UBERON_0002113', 'kidney', 1622, 'renal'), ('UBERON_0002107', 'liver', 1631, 'liver'), ('CHEBI_32588', 'potassium chloride', 1696, 'Ca'), ('GO_0008152', 'metabolic process', 1699, 'metabolismNo'), ('GO_0009294', 'DNA mediated transformation', 1795, 'trimester'), ('GO_0007605', 'sensory perception of sound', 1927, 'pregnancyBirth'), ('GO_0046660', 'female sex differentiation', 1981, 'miscarriage'), ('CHEBI_30255', 'sulfidocarbonate(.1-)', 2018, 'carbonyl iron'), ('GO_0009294', 'DNA mediated transformation', 2142, 'trimester'), ('GO_0007565', 'female pregnancy', 2242, 'gestation'), ('CHEBI_24870', 'ion', 2256, 'iron'), ('CHEBI_27300', 'vitamin D', 2403, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 2421, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 2438, 'vitamin C'), ('CHEBI_30751', 'formic acid', 2455, 'folic acid'), ('CHEBI_26948', 'vitamin B1', 2474, 'thiamine'), ('CHEBI_16410', 'pyridoxamine', 2524, 'pyridoxine'), ('CHEBI_27300', 'vitamin D', 2541, 'vitamin B'), ('CHEBI_7916', 'pantothenic acid', 2558, 'pantothenic acid'), ('UBERON_0000178', 'blood', 2601, 'blood'), ('GO_0009294', 'DNA mediated transformation', 2630, 'trimester'), ('GO_0007567', 'parturition', 2644, 'delivery'), ('CHEBI_27300', 'vitamin D', 2707, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 2725, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 2742, 'vitamin C'), ('CHEBI_30751', 'formic acid', 2759, 'folic acid'), ('CHEBI_26948', 'vitamin B1', 2778, 'thiamine'), ('CHEBI_7542', 'neurotensin', 2814, 'niacin'), ('CHEBI_16410', 'pyridoxamine', 2828, 'pyridoxine'), ('CHEBI_27300', 'vitamin D', 2845, 'vitamin B'), ('CHEBI_37527', 'acid', 2874, 'acid'), ('GO_0007567', 'parturition', 2950, 'antenatal'), ('GO_0009294', 'DNA mediated transformation', 3043, 'trimester'), ('CHEBI_37527', 'acid', 3145, 'Acid'), ('UBERON_0001638', 'vein', 3171, 'Venous'), ('UBERON_0000178', 'blood', 3178, 'blood'), ('CHEBI_4779', 'emedastine', 3206, 'Elemental'), ('CHEBI_24870', 'ion', 3216, 'Iron'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 3253, 'B12'), ('GO_0007565', 'female pregnancy', 3351, 'pregnancies'), ('GO_0007565', 'female pregnancy', 3388, 'gestationNot'), ('CHEBI_33341', 'titanium atom', 3445, 'supplements'), ('GO_0007565', 'female pregnancy', 3513, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 3653, 'vitamin D'), ('CHEBI_46978', 'thiazinemonocarboxylic acid', 3663, 'supplementsNot'), ('UBERON_0000178', 'blood', 3705, 'blood'), ('GO_0007565', 'female pregnancy', 3727, 'pregnancy'), ('GO_0046660', 'female sex differentiation', 3887, 'miscarriage'), ('GO_0009294', 'DNA mediated transformation', 4074, 'trimester'), ('GO_0006915', 'apoptotic process', 4201, 'pregnancyNot'), ('UBERON_0001638', 'vein', 4241, 'Venous'), ('UBERON_0000178', 'blood', 4248, 'blood'), ('GO_0007565', 'female pregnancy', 4406, 'pregnancy'), ('GO_0007565', 'female pregnancy', 4525, 'gestation'), ('CHEBI_33341', 'titanium atom', 4597, 'supplements'), ('GO_0007565', 'female pregnancy', 4669, 'gestation'), ('GO_0007565', 'female pregnancy', 4692, 'gestation'), ('GO_0007565', 'female pregnancy', 4716, 'pregnancy')]
S83-PMC5028238	PMC5028238	10/2016	S83-PMC5028238	['in addition, BENEFITS from Prenatal Vitamin D supplementation are also Modulated by geographic location and OTHER FACTORS.47THEREFORE biological mechanisms that maximize Vitamin D production and absorption would be selected for in the north.']	[('IMPORTANT_CONSIDERATION', 13), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 108), ('SUPERFICIAL_RELATIONSHIP', 114), ('ANOMALY_CURIOUS_FINDING', 122), ('ANOMALY_CURIOUS_FINDING', 122), ('ANOMALY_CURIOUS_FINDING', 122)]	6	[('GO_0007565', 'female pregnancy', 27, 'prenatal'), ('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('GO_0065007', 'biological regulation', 71, 'modulated'), ('CHEBI_27300', 'vitamin D', 170, 'vitamin D')]
S201-PMC5028238	PMC5028238	10/2016	S201-PMC5028238	"[""COMMENT on Vitamin D3's in-direct inhibition of Dhcr7\nOF NOTE, Vitamin D (Cholecalciferol) decreases the Dhcr7 activity through an indirect mechanism.54there HAS BEEN SOME SPECULATION on the POSSIBILITY of Teratogenic AFFECTS resulting from high doses of Vitamin D when taken as a Prenatal supplement.89HOWEVER, a RECENT REVIEW of Vitamin D supplementation among Pregnant women FOUND that Vitamin D supplementation MAY reduce the RISK of pre-eclampsia, low Birth weight, Preterm Birth90,91and adverse Kidney outcomes in offspring.92BECAUSE the mechanism of Vitamin D3's inhibition of Dhcr7 is indirect (UNLIKE our studied Pharmacological Dhcr7 Inhibitors) it is LIKELY to be MEDIATED through a COMPLEX pathway with many INTERACTING feedback loops.""]"	[('INCOMPLETE_EVIDENCE', 0), ('ANOMALY_CURIOUS_FINDING', 54), ('INCOMPLETE_EVIDENCE', 158), ('INCOMPLETE_EVIDENCE', 167), ('INCOMPLETE_EVIDENCE', 172), ('INCOMPLETE_EVIDENCE', 191), ('SUPERFICIAL_RELATIONSHIP', 218), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 301), ('INCOMPLETE_EVIDENCE', 314), ('INCOMPLETE_EVIDENCE', 378), ('INCOMPLETE_EVIDENCE', 415), ('IMPORTANT_CONSIDERATION', 430), ('PROBABLE_UNDERSTANDING', 530), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 603), ('PROBABLE_UNDERSTANDING', 662), ('SUPERFICIAL_RELATIONSHIP', 675), ('DIFFICULT_TASK', 694), ('SUPERFICIAL_RELATIONSHIP', 720)]	18	[('CHEBI_33279', 'vitamin D5', 11, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 11, 'vitamin D3'), ('PR_000006474', 'ATP-dependent RNA helicase A', 48, 'DHCR7'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('CHEBI_52550', 'theopalauamide', 74, 'cholecalciferol'), ('PR_000006474', 'ATP-dependent RNA helicase A', 105, 'DHCR7'), ('CHEBI_50905', 'teratogenic agent', 206, 'teratogenic'), ('GO_0031649', 'heat generation', 206, 'teratogenic'), ('CHEBI_27300', 'vitamin D', 255, 'vitamin D'), ('GO_0007565', 'female pregnancy', 281, 'prenatal'), ('CHEBI_27300', 'vitamin D', 331, 'vitamin D'), ('GO_0007565', 'female pregnancy', 363, 'pregnant'), ('CHEBI_27300', 'vitamin D', 389, 'vitamin D'), ('GO_0007567', 'parturition', 457, 'birth'), ('GO_0007565', 'female pregnancy', 471, 'preterm'), ('GO_0042633', 'hair cycle', 479, 'birth90'), ('UBERON_0002113', 'kidney', 501, 'kidney'), ('CHEBI_33279', 'vitamin D5', 557, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 557, 'vitamin D3'), ('PR_000006474', 'ATP-dependent RNA helicase A', 584, 'DHCR7'), ('CHEBI_52217', 'pharmaceutical', 622, 'pharmacological'), ('PR_000006474', 'ATP-dependent RNA helicase A', 638, 'DHCR7'), ('CHEBI_35222', 'inhibitor', 644, 'inhibitors')]
S202-PMC5028238	PMC5028238	10/2016	S202-PMC5028238	['studies involving moderate Prenatal Vitamin D supplementation HAVE REPORTED no adverse EFFECTS.89THEREFORE, we would not expect Vitamin D to result in slos-RELATED Teratogenic EFFECTS, ALTHOUGH ADDITIONAL STUDIES would BE NEEDED to ascertain the EFFECTS of large doses of Prenatal Vitamin D supplementation.']	[('INCOMPLETE_EVIDENCE', 62), ('SUPERFICIAL_RELATIONSHIP', 87), ('PROBABLE_UNDERSTANDING', 95), ('PROBABLE_UNDERSTANDING', 95), ('SUPERFICIAL_RELATIONSHIP', 156), ('SUPERFICIAL_RELATIONSHIP', 176), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 185), ('FUTURE_WORK', 194), ('FUTURE_WORK', 205), ('FUTURE_WORK', 219), ('SUPERFICIAL_RELATIONSHIP', 246)]	11	[('GO_0007565', 'female pregnancy', 27, 'prenatal'), ('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 128, 'vitamin D'), ('CHEBI_50905', 'teratogenic agent', 164, 'teratogenic'), ('GO_0007565', 'female pregnancy', 272, 'prenatal'), ('CHEBI_27300', 'vitamin D', 281, 'vitamin D')]
S112-PMC5029041	PMC5029041	9/2016	S112-PMC5029041	['multiple Micronutrient supplements decrease lbw, fgr and stillbirths [69]; HOWEVER, WHETHER deficiencies of Micronutrients such as zinc, Calcium and Vitamin A INTERACT with malaria in Pregnancy REMAINS UNCLEAR [70].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 75), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 84), ('SUPERFICIAL_RELATIONSHIP', 159), ('FULL_UNKNOWN', 194)]	4	[('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 9, 'micronutrient'), ('CHEBI_33839', 'macromolecule', 108, 'micronutrients'), ('CHEBI_22313', 'alkaline earth metal atom', 137, 'calcium'), ('CHEBI_27300', 'vitamin D', 149, 'vitamin A'), ('GO_0007565', 'female pregnancy', 184, 'pregnancy')]
S80-PMC5030591	PMC5030591	9/2016	S80-PMC5030591	"[""caption (table-wrap): table 4\n\nthemes and elements relating to specific Conception and Pregnancy information for women with rheumatoid arthritis and their familiessaying : information that should be discussed by health professionals doing : actions that SHOULD BE undertaken by health professionals review of current Medications in relation to safety during Conception and Pregnancy (100%) prior to Conception and Pregnancy, review current Medication(s) and discuss:\nmedications vary with respect to their SAFETY during Pregnancy and RISKS related to Fertility, Ovulation, Conception and Miscarriage\nSOME Medicines used in ra care MAY have EFFECTS on Fertility, Conception and Pregnancy process, for example, regular Nsaids MAY impair fertility and ASSOCIATED RISKS with fetus\nit is IMPORTANT to time Conceptionprovide GUIDANCE as to WHERE to obtain reliable information about SAFETY of Medicines in Pregnancywhere current Medication(s) is (are) contraindicated for Conception/Pregnancy the following SHOULD BE discussed with the patient:\nthere are SAFE Medication options pre, during (including Delivery) and Postpregnancy (including Breast feeding)\ntiming is IMPORTANT in RELATION to ceasing or switching of current Medications and allowing for washout periods prior to Conception\nthere is a need for close supervision/monitoring by a rheumatologist when discontinuing current Medications prior to Pregnancy, including CONSIDERING POTENTIAL NEED for disease stabilisation on new treatment prior to Conception and Pregnancydiscuss IMPACT of ra pathology on Pregnancy and Pregnancy on ra (100%) there are DIFFERENT SCENARIOS regarding ra disease activity during Pregnancy (eg, POSSIBLE remission/low disease activity)discuss: ra-related pain management options during Pregnancyconception MAY take longer compared with women who do not have rathere is a need to balance disease Control with maternal and fetal health and safetyra MAY AFFECT Pregnancy and Pregnancy MAY AFFECT ra, and there are POSSIBLE adverse outcomes where risks are identified (eg, Prematurity)there are significant risks ASSOCIATED with active or uncontrolled ra for the mother and baby, ESPECIALLY irreversible Joint damage and functional impairmentpregnancy MAY change a patient’s health outlook in the futurethe size of the baby MAY BE smaller than women without ra and MAY also be Delivered pre-term discuss IMPORTANT elements of Preconception care RELEVANT to patient (97.1%) it is IMPORTANT to achieve optimal disease control prior to considering Pregnancy—Planning Conception is preferable after patients achieve and maintain low disease activityencourage and facilitate early discussions with all health practitioners involved in care about family planning to allow for adequate preparationthere is a CRITICAL need for a planned Pregnancy RATHER than an unplanned Pregnancyreview Prenatal nutrition, including need for dietary/vitamin supplements (ie, Folic Acid, calcium, Vitamin D, Iodine, iron)history of previous Attempts To Conceive/Pregnancies or Pregnancy-related complications (eg, Miscarriage) and other relevant patient history (such as smoking/Illicit Drug use history, family history of hereditary issues) MAY AFFECT Pregnancyundertake RELEVANT health checks such as immunisation status (eg, rubella, varicella, pertussis), Sexually Transmitted disease screening, pap test, screening for other Autoimmune disorders that MAY IMPACT on Pregnancyweight management and appropriate exercise are very IMPORTANTCONSIDER the NEED for review of diabetes or impaired Glucose tolerance if RISK factors are present (eg, on Steroid medication or overweight/obese)it is IMPORTANT to manage comorbid conditions, such as diabetes and hypertensionsome women MAY NEED to avoid Conception during a flarera disease activity MAY or MAY not improve with Pregnancy and there is a LIKELIHOOD of Postpartum flares importance of maintaining optimistic outlook and providing positive messages (97.1%) Pregnancy and Breast feeding success rates are near normal in women with mild to moderate ra nowadays (where appropriate for the patient's clinical status)ra is not a BARRIER to Pregnancystrategies to address anxiety, stress and depression (if relevant) are IMPORTANT, such as mindfulness meditation need for close monitoring of a patient prior to and during Pregnancy, where indicated (94.1%) it is IMPORTANCE to have a healthcare team with expertise in Autoimmune disorders for SOME women with radetermine THE NEED for high-level obstetric care during a Pregnancy (where indicated), including the need for Anaesthetic inputsome women REQUIRE closer monitoring of their Pregnancy and this is USUALLY proportional to disease activity, comorbidities and maternal historyassess the REQUIREMENTS for any extra treatment or monitoring prior to, or during, Pregnancyit is IMPORTANT to develop a Pregnancy plan, which includes different options for management of ra and support for different scenariosvaginal Delivery MAY NOT always BE POSSIBLE, depending on condition of the patient's Hips.""]"	[('FUTURE_WORK', 254), ('IMPORTANT_CONSIDERATION', 506), ('IMPORTANT_CONSIDERATION', 534), ('INCOMPLETE_EVIDENCE', 600), ('INCOMPLETE_EVIDENCE', 631), ('SUPERFICIAL_RELATIONSHIP', 640), ('INCOMPLETE_EVIDENCE', 724), ('SUPERFICIAL_RELATIONSHIP', 749), ('IMPORTANT_CONSIDERATION', 760), ('IMPORTANT_CONSIDERATION', 783), ('FUTURE_WORK', 819), ('EXPLICIT_QUESTION', 834), ('IMPORTANT_CONSIDERATION', 877), ('FUTURE_WORK', 1001), ('IMPORTANT_CONSIDERATION', 1049), ('IMPORTANT_CONSIDERATION', 1161), ('SUPERFICIAL_RELATIONSHIP', 1174), ('FUTURE_WORK', 1421), ('IMPORTANT_CONSIDERATION', 1421), ('INCOMPLETE_EVIDENCE', 1433), ('SUPERFICIAL_RELATIONSHIP', 1532), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1605), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1615), ('INCOMPLETE_EVIDENCE', 1677), ('INCOMPLETE_EVIDENCE', 1788), ('INCOMPLETE_EVIDENCE', 1929), ('SUPERFICIAL_RELATIONSHIP', 1933), ('INCOMPLETE_EVIDENCE', 1964), ('SUPERFICIAL_RELATIONSHIP', 1968), ('INCOMPLETE_EVIDENCE', 1993), ('SUPERFICIAL_RELATIONSHIP', 2091), ('IMPORTANT_CONSIDERATION', 2158), ('INCOMPLETE_EVIDENCE', 2230), ('INCOMPLETE_EVIDENCE', 2302), ('INCOMPLETE_EVIDENCE', 2343), ('IMPORTANT_CONSIDERATION', 2382), ('SUPERFICIAL_RELATIONSHIP', 2423), ('IMPORTANT_CONSIDERATION', 2457), ('IMPORTANT_CONSIDERATION', 2779), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 2817), ('INCOMPLETE_EVIDENCE', 3196), ('SUPERFICIAL_RELATIONSHIP', 3200), ('IMPORTANT_CONSIDERATION', 3226), ('INCOMPLETE_EVIDENCE', 3410), ('SUPERFICIAL_RELATIONSHIP', 3414), ('IMPORTANT_CONSIDERATION', 3485), ('INCOMPLETE_EVIDENCE', 3507), ('SUPERFICIAL_RELATIONSHIP', 3568), ('IMPORTANT_CONSIDERATION', 3646), ('INCOMPLETE_EVIDENCE', 3731), ('FUTURE_WORK', 3735), ('IMPORTANT_CONSIDERATION', 3735), ('INCOMPLETE_EVIDENCE', 3794), ('INCOMPLETE_EVIDENCE', 3801), ('PROBABLE_UNDERSTANDING', 3847), ('DIFFICULT_TASK', 4131), ('IMPORTANT_CONSIDERATION', 4222), ('IMPORTANT_CONSIDERATION', 4364), ('INCOMPLETE_EVIDENCE', 4444), ('INCOMPLETE_EVIDENCE', 4472), ('IMPORTANT_CONSIDERATION', 4600), ('INCOMPLETE_EVIDENCE', 4657), ('IMPORTANT_CONSIDERATION', 4744), ('IMPORTANT_CONSIDERATION', 4831), ('INCOMPLETE_EVIDENCE', 4976), ('DIFFICULT_TASK', 4980)]	66	[('GO_0007631', 'feeding behavior', 72, 'conception ...'), ('GO_0007565', 'female pregnancy', 87, 'pregnancy'), ('CHEBI_25441', 'mycothiols', 317, 'medications'), ('GO_0007620', 'copulation', 358, 'conception'), ('GO_0007565', 'female pregnancy', 373, 'pregnancy'), ('GO_0007620', 'copulation', 399, 'conception'), ('GO_0007565', 'female pregnancy', 414, 'pregnancy'), ('CHEBI_60211', 'compound Z', 440, 'medication'), ('GO_0007565', 'female pregnancy', 520, 'pregnancy'), ('GO_0009566', 'fertilization', 551, 'fertility'), ('GO_0030728', 'ovulation', 562, 'ovulation'), ('GO_0007620', 'copulation', 573, 'conception'), ('GO_0046660', 'female sex differentiation', 588, 'miscarriage'), ('CHEBI_25179', 'melanins', 605, 'medicines'), ('GO_0009566', 'fertilization', 651, 'fertility'), ('GO_0007620', 'copulation', 662, 'conception'), ('GO_0007565', 'female pregnancy', 677, 'pregnancy'), ('CHEBI_16039', 'ITP', 717, 'NSAIDs'), ('GO_0070268', 'cornification', 801, 'conceptionProvide'), ('CHEBI_25179', 'melanins', 887, 'medicines'), ('GO_0000712', 'resolution of meiotic recombination intermediates', 900, 'pregnancyWhere'), ('CHEBI_60211', 'compound Z', 923, 'medication'), ('GO_0007620', 'copulation', 966, 'conception'), ('GO_0007565', 'female pregnancy', 977, 'pregnancy'), ('CHEBI_60211', 'compound Z', 1054, 'medication'), ('GO_0007567', 'parturition', 1096, 'delivery'), ('GO_0007565', 'female pregnancy', 1110, 'postpregnancy'), ('UBERON_0000310', 'breast', 1135, 'breast'), ('CHEBI_25441', 'mycothiols', 1218, 'medications'), ('GO_0007620', 'copulation', 1272, 'conception'), ('CHEBI_25441', 'mycothiols', 1379, 'medications'), ('GO_0007565', 'female pregnancy', 1400, 'pregnancy'), ('GO_0007620', 'copulation', 1500, 'conception'), ('GO_0006915', 'apoptotic process', 1515, 'pregnancyDiscuss'), ('GO_0007565', 'female pregnancy', 1558, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1572, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1662, 'pregnancy'), ('GO_0007602', 'phototransduction', 1768, 'pregnancyConception'), ('GO_0065007', 'biological regulation', 1877, 'control'), ('GO_0007565', 'female pregnancy', 1940, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1954, 'pregnancy'), ('GO_0007565', 'female pregnancy', 2051, 'prematurity'), ('UBERON_0004905', 'articulation', 2182, 'joint'), ('GO_0007567', 'parturition', 2355, 'delivered'), ('GO_0007565', 'female pregnancy', 2404, 'preconception'), ('GO_0007565', 'female pregnancy', 2523, 'pregnancy'), ('GO_0006260', 'DNA replication', 2533, 'planning'), ('GO_0007620', 'copulation', 2542, 'conception'), ('GO_0007565', 'female pregnancy', 2807, 'pregnancy'), ('GO_0006412', 'translation', 2842, 'pregnancyReview'), ('GO_0007565', 'female pregnancy', 2858, 'prenatal'), ('CHEBI_30751', 'formic acid', 2930, 'folic acid'), ('CHEBI_27300', 'vitamin D', 2951, 'vitamin D'), ('CHEBI_24859', 'iodine atom', 2962, 'iodine'), ('GO_0000380', 'alternative mRNA splicing, via spliceosome', 2995, 'attempts to conceive'), ('GO_0007565', 'female pregnancy', 3016, 'pregnancies'), ('GO_0007565', 'female pregnancy', 3031, 'pregnancy'), ('GO_0046660', 'female sex differentiation', 3068, 'miscarriage'), ('CHEBI_35704', 'N(2)-acetyl-L-lysine', 3133, 'illicit drug'), ('GO_0051610', 'serotonin uptake', 3207, 'pregnancyUndertake'), ('GO_0019095', 'pole plasm mitochondrial rRNA localization', 3314, 'sexually transmitted'), ('UBERON_0001442', 'skeleton of manus', 3384, 'autoimmune'), ('GO_0006412', 'translation', 3424, 'pregnancyWeight'), ('CHEBI_17234', 'glucose', 3547, 'glucose'), ('CHEBI_35341', 'steroid', 3601, 'steroid'), ('GO_0007620', 'copulation', 3749, 'conception'), ('GO_0007565', 'female pregnancy', 3822, 'pregnancy'), ('GO_0007565', 'female pregnancy', 3861, 'postpartum'), ('GO_0007565', 'female pregnancy', 3964, 'Pregnancy'), ('UBERON_0000310', 'breast', 3978, 'breast'), ('GO_0006915', 'apoptotic process', 4142, 'pregnancyStrategies'), ('GO_0007565', 'female pregnancy', 4323, 'pregnancy'), ('UBERON_0001442', 'skeleton of manus', 4419, 'autoimmune'), ('GO_0007565', 'female pregnancy', 4520, 'pregnancy'), ('CHEBI_38867', 'anaesthetic', 4572, 'anaesthetic'), ('GO_0007565', 'female pregnancy', 4635, 'pregnancy'), ('GO_0007565', 'female pregnancy', 4816, 'pregnancyIt'), ('GO_0007565', 'female pregnancy', 4854, 'pregnancy'), ('GO_0007567', 'parturition', 4967, 'delivery'), ('UBERON_0000988', 'pons', 5044, 'hips')]
S1-PMC5035678	PMC5035678	4/2016	S1-PMC5035678	['objectives\nwe report the FIRST STUDY of the IMPACT of Prenatal Vitamin D supplementation on Postpartum dysglycemia in gdm patients in a randomized clinical trial.']	[('INCOMPLETE_EVIDENCE', 25), ('SUPERFICIAL_RELATIONSHIP', 44)]	2	[('GO_0007565', 'female pregnancy', 54, 'prenatal'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('GO_0007565', 'female pregnancy', 92, 'postpartum')]
S9-PMC5035678	PMC5035678	4/2016	S9-PMC5035678	['conclusions\nALTHOUGH the high Vitamin D supplementation dose in the PRESENT STUDY (compared to the 400 iu/day dose USUALLY recommended for Pregnancy) SAFELY increases the Serum 25Ohd, in gdm cases, the higher dose does not affect the plasma Glucose level or Insulin resistance at short term follow-up after Delivery.']	[('ANOMALY_CURIOUS_FINDING', 12), ('QUESTION_ANSWERED_BY_THIS_WORK', 68), ('INCOMPLETE_EVIDENCE', 115), ('IMPORTANT_CONSIDERATION', 150)]	4	"[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0007565', 'female pregnancy', 139, 'pregnancy'), ('UBERON_0001977', 'blood serum', 171, 'serum'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 177, '25OHD'), ('CHEBI_17234', 'glucose', 241, 'glucose'), ('PR_000045358', 'insulin family protein', 258, 'insulin'), ('GO_0007567', 'parturition', 307, 'delivery')]"
S23-PMC5035678	PMC5035678	4/2016	S23-PMC5035678	['a RECENT STUDY SHOWED that post-Parturition Vitamin D supplementation MAY PREVENT the progression of Insulin resistance in patients with a recent history of gdm (16).']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 15), ('INCOMPLETE_EVIDENCE', 70), ('SUPERFICIAL_RELATIONSHIP', 74)]	4	[('GO_0019230', 'proprioception', 32, 'parturition'), ('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('PR_000045358', 'insulin family protein', 101, 'insulin')]
S26-PMC5035678	PMC5035678	4/2016	S26-PMC5035678	['objectives\nwe THEREFORE SOUGHT TO EXPLORE the EFFECT of Vitamin D supplementation in women with gdm and hypovitaminosis D, both on post-Partum Glucose levels and Insulin resistance, in a randomized clinical trial.']	[('PROBABLE_UNDERSTANDING', 14), ('QUESTION_ANSWERED_BY_THIS_WORK', 24), ('QUESTION_ANSWERED_BY_THIS_WORK', 31), ('SUPERFICIAL_RELATIONSHIP', 46)]	4	[('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 120, 'D'), ('GO_0007567', 'parturition', 136, 'partum'), ('CHEBI_17234', 'glucose', 143, 'glucose'), ('PR_000045358', 'insulin family protein', 162, 'insulin')]
S109-PMC5035678	PMC5035678	4/2016	S109-PMC5035678	['discussion\nTO OUR KNOWLEDGE, THIS is the FIRST STUDY TO EVALUATE the EFFECTS of Vitamin D supplementation during Pregnancy on Glucose Metabolism shortly after Delivery.']	[('PROBABLE_UNDERSTANDING', 11), ('QUESTION_ANSWERED_BY_THIS_WORK', 29), ('INCOMPLETE_EVIDENCE', 41), ('QUESTION_ANSWERED_BY_THIS_WORK', 47), ('QUESTION_ANSWERED_BY_THIS_WORK', 53), ('SUPERFICIAL_RELATIONSHIP', 69)]	6	[('CHEBI_27300', 'vitamin D', 80, 'vitamin D'), ('GO_0007565', 'female pregnancy', 113, 'pregnancy'), ('CHEBI_17234', 'glucose', 126, 'glucose'), ('GO_0006006', 'glucose metabolic process', 126, 'glucose metabolism'), ('GO_0007567', 'parturition', 159, 'delivery')]
S110-PMC5035678	PMC5035678	4/2016	S110-PMC5035678	['OUR STUDY DEMONSTRATES that high dose Vitamin D supplementation during Pregnancy in women with gdm and impairment of 25Ohd concentration has no effect on post-Partum Plasma Glucose and Insulin resistance.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 10)]	2	"[('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('GO_0007565', 'female pregnancy', 71, 'pregnancy'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 117, '25OHD'), ('GO_0007567', 'parturition', 159, 'partum'), ('UBERON_0001969', 'blood plasma', 166, 'plasma'), ('CHEBI_17234', 'glucose', 173, 'glucose'), ('PR_000045358', 'insulin family protein', 185, 'insulin')]"
S115-PMC5035678	PMC5035678	4/2016	S115-PMC5035678	['HOWEVER, there is SCARCE INFORMATION about the EFFECT of Vitamin D supplementation on Glucose Metabolism, especially during Pregnancy and after Delivery.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 18), ('SUPERFICIAL_RELATIONSHIP', 47)]	3	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('CHEBI_17234', 'glucose', 86, 'glucose'), ('GO_0006006', 'glucose metabolic process', 86, 'glucose metabolism'), ('GO_0007565', 'female pregnancy', 124, 'pregnancy'), ('GO_0007567', 'parturition', 144, 'delivery')]
S117-PMC5035678	PMC5035678	4/2016	S117-PMC5035678	['(26) REVEALED a positive EFFECT of co-supplementation with Vitamin D and Calcium on Insulin resistance during Pregnancy.']	[('INCOMPLETE_EVIDENCE', 5), ('SUPERFICIAL_RELATIONSHIP', 25)]	2	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 73, 'calcium'), ('PR_000045358', 'insulin family protein', 84, 'insulin'), ('GO_0007565', 'female pregnancy', 110, 'pregnancy')]
S132-PMC5035678	PMC5035678	4/2016	S132-PMC5035678	['they FOUND that high dose supplementation for a mean of 14 weeks during Pregnancy was not beneficial to the patients’ plasma Glucose level or Insulin resistance during Pregnancy, BUT that their babies BENEFITTED from the supplementation with decreased neonatal hypovitaminosis D. the authors CONCLUDED that the commencement of Vitamin D supplementation MAY HAVE been too late to cause any observable EFFECTS on Β-Cell function, and they SUGGESTED that earlier supplementation, EVEN before Pregnancy, MIGHT be EFFECTIVE.']	[('INCOMPLETE_EVIDENCE', 5), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 179), ('IMPORTANT_CONSIDERATION', 201), ('INCOMPLETE_EVIDENCE', 292), ('INCOMPLETE_EVIDENCE', 353), ('IMPORTANT_CONSIDERATION', 357), ('SUPERFICIAL_RELATIONSHIP', 400), ('INCOMPLETE_EVIDENCE', 437), ('ANOMALY_CURIOUS_FINDING', 477), ('INCOMPLETE_EVIDENCE', 500), ('SUPERFICIAL_RELATIONSHIP', 509)]	11	[('GO_0007565', 'female pregnancy', 72, 'pregnancy'), ('CHEBI_17234', 'glucose', 125, 'glucose'), ('PR_000045358', 'insulin family protein', 142, 'insulin'), ('GO_0007565', 'female pregnancy', 168, 'pregnancy'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 277, 'D'), ('CHEBI_27300', 'vitamin D', 327, 'vitamin D'), ('CL_0000623', 'natural killer cell', 411, 'β-cell'), ('GO_0007565', 'female pregnancy', 489, 'pregnancy')]
S133-PMC5035678	PMC5035678	4/2016	S133-PMC5035678	['in OUR STUDY, over a median interval of 26 weeks between commencement of Vitamin D supplements and ogtt measurements, high dose Vitamin D LED TO maternal and neonatal 25Ohd level increases, but not to the predicted EFFECTS on Glucose level and Insulin resistance.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('SUPERFICIAL_RELATIONSHIP', 138), ('SUPERFICIAL_RELATIONSHIP', 215)]	3	"[('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 128, 'vitamin D'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 167, '25OHD'), ('CHEBI_17234', 'glucose', 226, 'glucose'), ('PR_000045358', 'insulin family protein', 244, 'insulin')]"
S135-PMC5035678	PMC5035678	4/2016	S135-PMC5035678	['as mentioned by yap, this result MAY INDICATE that it is actually dysglycemia that leads to defects in Liver Hydroxylation of Vitamin D.\nVitamin D supplementation has diverse EFFECTS on the non-Pregnant population.']	[('INCOMPLETE_EVIDENCE', 33), ('INCOMPLETE_EVIDENCE', 37), ('SUPERFICIAL_RELATIONSHIP', 175)]	3	[('UBERON_0002107', 'liver', 103, 'liver'), ('GO_0044444', 'cytoplasmic part', 109, 'hydroxylation'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 137, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 194, 'pregnant')]
S137-PMC5035678	PMC5035678	4/2016	S137-PMC5035678	['(30) REPORTED that daily 4,000 iu Vitamin D3 supplementation for 6 months (720,000 iu total) significantly decreased Insulin resistance in south asian women with Vitamin D deficiency and Insulin resistance.']	[('INCOMPLETE_EVIDENCE', 5)]	1	[('CHEBI_33279', 'vitamin D5', 34, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 34, 'vitamin D3'), ('PR_000045358', 'insulin family protein', 117, 'insulin'), ('CHEBI_27300', 'vitamin D', 162, 'vitamin D'), ('PR_000045358', 'insulin family protein', 187, 'insulin')]
S142-PMC5035678	PMC5035678	4/2016	S142-PMC5035678	['THUS, the effectiveness of longer periods of supplementation with Vitamin D is DOUBTFUL.']	[('PROBABLE_UNDERSTANDING', 0), ('PROBLEM_COMPLICATION', 79)]	2	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D')]
S143-PMC5035678	PMC5035678	4/2016	S143-PMC5035678	['in ANOTHER STUDY of the non-Pregnant population, and CONSISTENT with our results, davidson and colleagues FOUND that a mean supplement dose of 88,865 iu Vitamin D per week, in 56 subjects with hypovitaminosis D and pre-diabetes, had no effect on Insulin resistance and plasma Glucose levels at 3, 6, 9, and 12 months after intervention, compared to 53 subjects in a placebo group (31).']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 53), ('INCOMPLETE_EVIDENCE', 106)]	3	[('GO_0007565', 'female pregnancy', 28, 'pregnant'), ('CHEBI_27300', 'vitamin D', 153, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 209, 'D'), ('PR_000045358', 'insulin family protein', 246, 'insulin'), ('CHEBI_17234', 'glucose', 276, 'glucose')]
S144-PMC5035678	PMC5035678	4/2016	S144-PMC5035678	['in THIS STUDY, application of a proper dose and duration of Vitamin D supplementation LED TO a rapid increase in 25Ohd, up to near 70 ng/ml, which was maintained for the duration of the study.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('SUPERFICIAL_RELATIONSHIP', 86)]	2	"[('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 113, '25OHD')]"
S150-PMC5035678	PMC5035678	4/2016	S150-PMC5035678	['the study was DESIGNED to detect any EFFECTS of Vitamin D on Insulin resistance by allowing for adequate time between the start of supplementation and the measurement of outcomes, and with the FEWEST number of patients lost to follow up.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 14), ('SUPERFICIAL_RELATIONSHIP', 37), ('INCOMPLETE_EVIDENCE', 193)]	3	[('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('PR_000045358', 'insulin family protein', 61, 'insulin')]
S157-PMC5035678	PMC5035678	4/2016	S157-PMC5035678	['we DID NOT adjust the supplementation dose of Vitamin D3 based on the patient’s weight in order to provide an appropriate volume of distribution of Vitamin D in every patient, and the results would have been more reliable by calculating the proper dose for each Individual.']	[('INCOMPLETE_EVIDENCE', 3)]	1	[('CHEBI_33279', 'vitamin D5', 46, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 46, 'vitamin D3'), ('CHEBI_27300', 'vitamin D', 148, 'vitamin D'), ('NCBITaxon_1', 'root', 262, 'individual')]
S160-PMC5035678	PMC5035678	4/2016	S160-PMC5035678	['IN SPITE of these LIMITATIONS, THIS is currently the ONLY study in the literature that evaluates the INFLUENCE of Vitamin D supplementation during Pregnancy on Postpartum dysglycemia.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 18), ('QUESTION_ANSWERED_BY_THIS_WORK', 31), ('INCOMPLETE_EVIDENCE', 53), ('SUPERFICIAL_RELATIONSHIP', 101)]	5	[('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('GO_0007565', 'female pregnancy', 147, 'pregnancy'), ('GO_0007565', 'female pregnancy', 160, 'postpartum')]
S161-PMC5035678	PMC5035678	4/2016	S161-PMC5035678	['in conclusion, Prenatal Vitamin D supplementation in patients with gdm and hypovitaminosis D SAFELY and significantly increases maternal and neonatal Serum 25Ohd.']	[('IMPORTANT_CONSIDERATION', 93)]	1	"[('GO_0007565', 'female pregnancy', 15, 'prenatal'), ('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 91, 'D'), ('UBERON_0001977', 'blood serum', 150, 'serum'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 156, '25OHD')]"
S109-PMC5039809	PMC5039809	10/2016	S109-PMC5039809	['PREVIOUS intervention STUDIES have NOT CONSISTENTLY DEMONSTRATED that Prenatal Vitamin A supplementation CAN increase Birth size.']	[('INCOMPLETE_EVIDENCE', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 35), ('INCOMPLETE_EVIDENCE', 52), ('INCOMPLETE_EVIDENCE', 105)]	4	[('GO_0007565', 'female pregnancy', 70, 'prenatal'), ('CHEBI_27300', 'vitamin D', 79, 'vitamin A'), ('GO_0007567', 'parturition', 118, 'birth')]
S59-PMC5045784	PMC5045784	10/2016	S59-PMC5045784	['SIMILARLY, a RECENT interventional TRIAL of three dosing regimens for Vitamin D supplementation in extremely preterm infants FOUND no association between Vitamin D status and Respiratory outcomes.17\nthe IMPORTANCE of Vitamin D status in pediatric Respiratory health is SUPPORTED by large epidemiologic studies of term infants SHOWING an ASSOCIATION between suboptimal Vitamin D status and wheezing.4,18in addition, Animal studies demonstrate an IMPORTANT biologic ROLE for Vitamin D in Lung Development and Maturation, including Differentiation Of Type Ii Pneumocytes, Surfactant Phospholipid synthesis and secretion,19as well as an immunomodulatory ROLE in Epithelial Cells, Neutrophils and Macrophages.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 125), ('IMPORTANT_CONSIDERATION', 203), ('INCOMPLETE_EVIDENCE', 269), ('INCOMPLETE_EVIDENCE', 326), ('SUPERFICIAL_RELATIONSHIP', 337), ('IMPORTANT_CONSIDERATION', 445), ('SUPERFICIAL_RELATIONSHIP', 464), ('SUPERFICIAL_RELATIONSHIP', 650)]	10	[('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 154, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 175, 'respiratory'), ('CHEBI_27300', 'vitamin D', 217, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 247, 'respiratory'), ('CHEBI_27300', 'vitamin D', 368, 'vitamin D'), ('NCBITaxon_33208', 'Metazoa', 415, 'animal'), ('CHEBI_27300', 'vitamin D', 473, 'vitamin D'), ('GO_0035180', 'larval wandering behavior', 486, 'lung development ... maturation'), ('UBERON_0002048', 'lung', 486, 'lung'), ('GO_0007620', 'copulation', 529, 'differentiation of ...'), ('CL_0002063', 'type II pneumocyte', 548, 'type II pneumocytes'), ('CHEBI_53015', 'N(6)-carboxymethyl-L-lysine residue', 569, 'surfactant phospholipid'), ('CL_0000066', 'epithelial cell', 658, 'epithelial cells'), ('UBERON_0000483', 'epithelium', 658, 'epithelial'), ('CL_0000775', 'neutrophil', 676, 'neutrophils'), ('CL_0000235', 'macrophage', 692, 'macrophages')]
S60-PMC5045784	PMC5045784	10/2016	S60-PMC5045784	['finally, interventional Animal and Human studies provide STRONG EVIDENCE for a beneficial ROLE of Vitamin D supplementation in Pulmonary outcomes.7,20\nthe ROLE of Vitamin D status in the development of bpd REMAINS incompletely understood.']	[('INCOMPLETE_EVIDENCE', 57), ('PROBABLE_UNDERSTANDING', 57), ('SUPERFICIAL_RELATIONSHIP', 90), ('SUPERFICIAL_RELATIONSHIP', 155), ('INCOMPLETE_EVIDENCE', 206)]	5	[('NCBITaxon_33208', 'Metazoa', 24, 'animal'), ('NCBITaxon_9606', 'Homo sapiens', 35, 'human'), ('CHEBI_27300', 'vitamin D', 98, 'vitamin D'), ('UBERON_0002048', 'lung', 127, 'pulmonary'), ('CHEBI_27300', 'vitamin D', 163, 'vitamin D')]
S77-PMC5045784	PMC5045784	10/2016	S77-PMC5045784	[', wagner et al.30,31and others have DEMONSTRATED that Vitamin D status at Birth is modifiable through maternal supplementation during Pregnancy.']	[('INCOMPLETE_EVIDENCE', 36)]	1	[('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('GO_0007567', 'parturition', 74, 'birth'), ('GO_0007565', 'female pregnancy', 134, 'pregnancy')]
S78-PMC5045784	PMC5045784	10/2016	S78-PMC5045784	['two RECENTLY published large intervention trials of additional Vitamin D supplementation during Pregnancy in the united states32and europe33showed TRENDS but no significant decreases in the incidence of childhood wheezing and asthma in the first 3 years of Life among the offspring.']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 147)]	2	[('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('GO_0007565', 'female pregnancy', 96, 'pregnancy'), ('UBERON_0000104', 'life cycle', 257, 'life')]
S85-PMC5045784	PMC5045784	10/2016	S85-PMC5045784	['the adequacy of current Postnatal nutritional supplementation of Vitamin D HAS RECENTLY BEEN assessed in Preterm infants in the united states and in europe.']	[('INCOMPLETE_EVIDENCE', 75)]	1	[('GO_0007567', 'parturition', 24, 'postnatal'), ('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('GO_0007565', 'female pregnancy', 105, 'preterm')]
S86-PMC5045784	PMC5045784	10/2016	S86-PMC5045784	['mccarthy et al.29REPORTED that in a cohort of 274 preterm infants (<32 weeks) in ireland, levels of 25(Oh)D REMAINED under 20\u2009ng\u2009ml−1in 78% of subjects DESPITE 18 days on average of enteral Feeding and Vitamin D supplementation.29a RECENT intervention TRIAL by fort et al.17DEMONSTRATED that biochemical Vitamin D deficiency among EXTREMELY preterm infants CAN be reduced by additional supplementation with 200 units of Vitamin D daily, and PREVENTED by additional supplementation with 800 units of Vitamin D daily17and these two regimens were FOUND TO BE SAFE.']	[('INCOMPLETE_EVIDENCE', 15), ('INCOMPLETE_EVIDENCE', 108), ('ANOMALY_CURIOUS_FINDING', 152), ('INCOMPLETE_EVIDENCE', 232), ('PROBABLE_UNDERSTANDING', 272), ('PROBABLE_UNDERSTANDING', 272), ('IMPORTANT_CONSIDERATION', 331), ('INCOMPLETE_EVIDENCE', 357), ('SUPERFICIAL_RELATIONSHIP', 441), ('ANOMALY_CURIOUS_FINDING', 544), ('IMPORTANT_CONSIDERATION', 556)]	11	[('CHEBI_71657', 'versiconol acetate', 100, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 106, 'D'), ('GO_0007631', 'feeding behavior', 190, 'feeding'), ('CHEBI_27300', 'vitamin D', 202, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 304, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 420, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 499, 'vitamin D')]
S87-PMC5045784	PMC5045784	10/2016	S87-PMC5045784	['there are several LIMITATIONS in OUR STUDY, including its SMALL sample size, risk of selection bias and lack of data on Prenatal Vitamin D supplementation and maternal 25(Oh)D levels.']	[('INCOMPLETE_EVIDENCE', 18), ('QUESTION_ANSWERED_BY_THIS_WORK', 33), ('INCOMPLETE_EVIDENCE', 58)]	3	[('GO_0007565', 'female pregnancy', 120, 'prenatal'), ('CHEBI_27300', 'vitamin D', 129, 'vitamin D'), ('CHEBI_33010', 'chromide(1-)', 170, '(OH)D')]
S93-PMC5045784	PMC5045784	10/2016	S93-PMC5045784	['given the LIMITATIONS of a MODEST sample size of our study, we PROPOSE that our data combined with others for a meta-analysis MAY BE WARRANTED before CONSIDERATION of interventional trials of Vitamin D supplementation.']	[('INCOMPLETE_EVIDENCE', 10), ('INCOMPLETE_EVIDENCE', 27), ('INCOMPLETE_EVIDENCE', 63), ('INCOMPLETE_EVIDENCE', 126), ('FUTURE_WORK', 133), ('FUTURE_WORK', 150)]	6	[('CHEBI_27300', 'vitamin D', 192, 'vitamin D')]
S11-PMC5051327	PMC5051327	9/2016	S11-PMC5051327	['IF OUR FINDINGS are SUPPORTED by FURTHER STUDIES, PREFERABLY on SEVERE Birth asphyxia, Vitamin D supplementation/sun exposure in Pregnancy MAY lower the risk of subsequent Birth asphyxia.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('INCOMPLETE_EVIDENCE', 20), ('FUTURE_WORK', 33), ('PROBABLE_UNDERSTANDING', 50), ('IMPORTANT_CONSIDERATION', 64), ('INCOMPLETE_EVIDENCE', 139)]	7	[('GO_0007567', 'parturition', 71, 'birth'), ('CHEBI_27300', 'vitamin D', 87, 'vitamin D'), ('GO_0007565', 'female pregnancy', 129, 'pregnancy'), ('GO_0007567', 'parturition', 172, 'birth')]
S17-PMC5051327	PMC5051327	9/2016	S17-PMC5051327	['introduction\nVitamin D is NECESSARY for optimal Skeletal function and deficiency is RELATED to rachitis.1\nit is, HOWEVER, IMPORTANT for bone Metabolism, as well as for optimal function of Striated and Smooth Muscle strength including Heart Muscle, and is RELATED to Postnatal muscle strength.2vitamin D supplementation has a positive IMPACT on muscle strength on Individuals with Vitamin D deficiency.134THE institute of medicine (iom), usa RECOMMENDS daily nutritional intake of Vitamin D of 600\u2005u, BUT OTHERS RECOMMEND higher doses.56a RECENT swedish STUDY SHOWED that the mean nutritional intake of Vitamin D was <200\u2005u/day.7ALTHOUGH Vitamin D is found in low amounts in the diet, mainly in oily fish and egg, the primary source of Vitamin D for Humans is skin conversion to Vitamin D from solar ultraviolet radiation.1pregnant women residing at high latitudes are AT RISK of Vitamin D deficiency BECAUSE of low solar intensity, especially during the winter months.18vitamin D deficiency is common in the nordic countries, ESPECIALLY among those not exposing themselves to the sun.8since fetal Vitamin D levels are directly RELATED to that of their mothers there is also a high LIKELIHOOD of fetal Vitamin D deficiency in our population.9\nBirth asphyxia is ASSOCIATED with Cardiovascular dysfunction, including low Ventricular output, lower left Ventricular Ejection fraction and increased troponin levels.1011congestive Heart failure MAY occur in severe cases of asphyxia.12intrauterine fetal distress is RELATED to an increase in Blood pressure, redistribution and a change in fetal Heart rate pattern.']	[('IMPORTANT_CONSIDERATION', 26), ('SUPERFICIAL_RELATIONSHIP', 84), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 113), ('IMPORTANT_CONSIDERATION', 122), ('SUPERFICIAL_RELATIONSHIP', 255), ('SUPERFICIAL_RELATIONSHIP', 334), ('INCOMPLETE_EVIDENCE', 401), ('FUTURE_WORK', 441), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 500), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 504), ('FUTURE_WORK', 511), ('INCOMPLETE_EVIDENCE', 538), ('INCOMPLETE_EVIDENCE', 559), ('ANOMALY_CURIOUS_FINDING', 627), ('IMPORTANT_CONSIDERATION', 868), ('PROBABLE_UNDERSTANDING', 900), ('ANOMALY_CURIOUS_FINDING', 1026), ('SUPERFICIAL_RELATIONSHIP', 1127), ('PROBABLE_UNDERSTANDING', 1181), ('SUPERFICIAL_RELATIONSHIP', 1260), ('INCOMPLETE_EVIDENCE', 1438), ('SUPERFICIAL_RELATIONSHIP', 1509)]	22	[('CHEBI_28384', 'vitamin K', 13, 'Vitamin D'), ('UBERON_0004288', 'skeleton', 48, 'skeletal'), ('GO_0008152', 'metabolic process', 141, 'metabolism'), ('UBERON_0002435', 'striatum', 188, 'striated'), ('UBERON_0001135', 'smooth muscle tissue', 201, 'smooth muscle'), ('UBERON_0001133', 'cardiac muscle tissue', 234, 'heart muscle'), ('GO_0007567', 'parturition', 266, 'postnatal'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 301, 'D'), ('NCBITaxon_1', 'root', 363, 'individuals'), ('CHEBI_27300', 'vitamin D', 380, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 480, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 602, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 637, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 735, 'vitamin D'), ('NCBITaxon_9606', 'Homo sapiens', 749, 'humans'), ('CHEBI_27300', 'vitamin D', 778, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 879, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 978, 'D'), ('CHEBI_27300', 'vitamin D', 1097, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1201, 'vitamin D'), ('GO_0007567', 'parturition', 1242, 'Birth'), ('UBERON_0004535', 'cardiovascular system', 1276, 'cardiovascular'), ('UBERON_0002082', 'cardiac ventricle', 1318, 'ventricular'), ('UBERON_0002082', 'cardiac ventricle', 1349, 'ventricular'), ('UBERON_0000970', 'eye', 1361, 'ejection'), ('UBERON_0000948', 'heart', 1424, 'heart'), ('UBERON_0000178', 'blood', 1535, 'blood'), ('UBERON_0000948', 'heart', 1588, 'heart')]
S54-PMC5051327	PMC5051327	9/2016	S54-PMC5051327	['IN FACT, the ONLY study PREVIOUSLY addressing THIS topic was performed in southern china, where Vitamin D deficiency is relatively UNCOMMON and no RELATION to Birth asphyxia was FOUND.19two randomised controlled studies of Antenatal Vitamin D supplementation REPORTED lower apgar score at 1 and 5\u2005min, respectively.2021in addition, in the latter study REPORTED, 13% of Vitamin D deficient newborn had apgar score at 5\u2005min <7, as compared TO 1.1% among those who were sufficient.21our observational study design disables us from investigating a causal RELATION between Vitamin D levels and fetal distress/Birth asphyxia.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 24), ('QUESTION_ANSWERED_BY_THIS_WORK', 46), ('INCOMPLETE_EVIDENCE', 131), ('SUPERFICIAL_RELATIONSHIP', 147), ('INCOMPLETE_EVIDENCE', 178), ('INCOMPLETE_EVIDENCE', 259), ('INCOMPLETE_EVIDENCE', 352), ('QUESTION_ANSWERED_BY_THIS_WORK', 438), ('SUPERFICIAL_RELATIONSHIP', 551)]	11	[('CHEBI_27300', 'vitamin D', 96, 'vitamin D'), ('GO_0007567', 'parturition', 159, 'birth'), ('GO_0007567', 'parturition', 223, 'antenatal'), ('CHEBI_27300', 'vitamin D', 233, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 369, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 568, 'vitamin D'), ('GO_0007567', 'parturition', 604, 'birth')]
S83-PMC5051327	PMC5051327	9/2016	S83-PMC5051327	['IF OTHER groups REPRODUCE our FINDINGS and a causal RELATIONSHIP CAN be established, we MIGHT be in a position to lower the risk of fetal distress/Birth asphyxia with Vitamin D supplementation/sun exposure in Pregnancy.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 3), ('INCOMPLETE_EVIDENCE', 16), ('INCOMPLETE_EVIDENCE', 30), ('SUPERFICIAL_RELATIONSHIP', 52), ('INCOMPLETE_EVIDENCE', 65), ('INCOMPLETE_EVIDENCE', 88)]	7	[('GO_0007567', 'parturition', 147, 'birth'), ('CHEBI_27300', 'vitamin D', 167, 'vitamin D'), ('GO_0007565', 'female pregnancy', 209, 'pregnancy')]
S250-PMC5062906	PMC5062906	10/2016	S250-PMC5062906	['ALTHOUGH Vitamin D deficiency HAS BEEN LINKED to adverse Pregnancy/Birth outcomes [14,46–52], there is currently NO STANDARD practice of screening women for Vitamin D deficiency during Pregnancy nor are there standard RECOMMENDATIONS beyond Prenatal Vitamins for supplementation during this CRITICAL time [53,54].']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 30), ('SUPERFICIAL_RELATIONSHIP', 39), ('INCOMPLETE_EVIDENCE', 113), ('FUTURE_WORK', 218), ('IMPORTANT_CONSIDERATION', 291)]	6	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007608', 'sensory perception of smell', 57, 'pregnancy ...'), ('GO_0007567', 'parturition', 67, 'birth'), ('CHEBI_27300', 'vitamin D', 157, 'vitamin D'), ('GO_0007565', 'female pregnancy', 185, 'pregnancy'), ('GO_0007565', 'female pregnancy', 241, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 250, 'vitamins')]
S0-PMC5064894	PMC5064894	10/2016	S0-PMC5064894	['maternal Vitamin D supplementation during Pregnancy and Lactation to prevent acute Respiratory infections in infancy in dhaka, bangladesh (mdari trial): protocol for a prospective cohort study nested within a randomized controlled trial\n\nabstract\n\nbackground\nearly Infancy is a HIGH-RISK period for SEVERE acute Respiratory infection (ari), PARTICULARLY in low-income countries with resource-limited Health Systems.']	[('IMPORTANT_CONSIDERATION', 278), ('IMPORTANT_CONSIDERATION', 299), ('IMPORTANT_CONSIDERATION', 341)]	3	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007565', 'female pregnancy', 42, 'pregnancy'), ('GO_0007595', 'lactation', 56, 'lactation'), ('UBERON_0001004', 'respiratory system', 83, 'respiratory'), ('UBERON_0000023', 'wing', 265, 'infancy'), ('UBERON_0001004', 'respiratory system', 312, 'respiratory'), ('UBERON_0002423', 'hepatobiliary system', 400, 'health systems')]
S9-PMC5064894	PMC5064894	10/2016	S9-PMC5064894	['we HYPOTHESIZE that among infants 0–6 months of age, the incidence of microbiologically-confirmed viral ari will be significantly lower in infants whose mothers received high-dose Prenatal/Postpartum Vitamin D supplements versus placebo.']	[('INCOMPLETE_EVIDENCE', 3)]	1	[('GO_0007565', 'female pregnancy', 180, 'prenatal'), ('GO_0007565', 'female pregnancy', 189, 'postpartum'), ('CHEBI_27300', 'vitamin D', 200, 'vitamin D')]
S11-PMC5064894	PMC5064894	10/2016	S11-PMC5064894	['discussion\nIF SHOWN to reduce the RISK of viral ari in infancy, integration of maternal Prenatal/Postpartum Vitamin D supplementation into Antenatal Care programs in south asia may be a FEASIBLE primary preventive STRATEGY to reduce THE BURDEN of ari-ASSOCIATED morbidity and mortality in young infants.']	[('INCOMPLETE_EVIDENCE', 11), ('IMPORTANT_CONSIDERATION', 34), ('PROBABLE_UNDERSTANDING', 186), ('FUTURE_WORK', 214), ('IMPORTANT_CONSIDERATION', 233), ('SUPERFICIAL_RELATIONSHIP', 251)]	6	[('GO_0007565', 'female pregnancy', 88, 'prenatal'), ('GO_0007565', 'female pregnancy', 97, 'postpartum'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin D'), ('GO_0007608', 'sensory perception of smell', 139, 'antenatal care')]
S28-PMC5064894	PMC5064894	10/2016	S28-PMC5064894	['DESPITE these SUGGESTIVE results from observational studies, there HAVE BEEN FEW prospective randomized controlled trials examining the IMPACT of Vitamin D supplementation on RISK of ari in children.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 14), ('INCOMPLETE_EVIDENCE', 67), ('INCOMPLETE_EVIDENCE', 77), ('SUPERFICIAL_RELATIONSHIP', 136), ('IMPORTANT_CONSIDERATION', 175)]	7	[('CHEBI_27300', 'vitamin D', 146, 'vitamin D')]
S32-PMC5064894	PMC5064894	10/2016	S32-PMC5064894	['the FIRST randomized trial of Prenatal Vitamin D supplementation on childhood wheeze was RECENTLY published [25].']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 89)]	2	[('GO_0007565', 'female pregnancy', 30, 'prenatal'), ('CHEBI_27300', 'vitamin D', 39, 'vitamin D')]
S37-PMC5064894	PMC5064894	10/2016	S37-PMC5064894	['first, THERE HAVE BEEN NO STUDIES examining the EFFECT of Prenatal Vitamin D supplementation on a primary outcome of laboratory-confirmed Viral Respiratory infections in the first 6\xa0months of Life, a high-risk period for both Vitamin D deficiency and Respiratory Tract infections.']	[('FULL_UNKNOWN', 7), ('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 23), ('SUPERFICIAL_RELATIONSHIP', 48)]	4	[('GO_0007565', 'female pregnancy', 58, 'prenatal'), ('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('NCBITaxon_1', 'root', 138, 'viral'), ('UBERON_0001004', 'respiratory system', 144, 'respiratory'), ('UBERON_0000104', 'life cycle', 192, 'life'), ('CHEBI_27300', 'vitamin D', 226, 'vitamin D'), ('UBERON_0000065', 'respiratory tract', 251, 'respiratory tract')]
S39-PMC5064894	PMC5064894	10/2016	S39-PMC5064894	['third, THERE HAVE BEEN NO STUDIES assessing the ASSOCIATION between Vitamin D supplementation and quantitative Nasal carriage of streptococcus pneumoniae (pneumococcus), the most IMPORTANT cause of bacterial lrti in young children worldwide.']	[('FULL_UNKNOWN', 7), ('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 23), ('SUPERFICIAL_RELATIONSHIP', 48), ('IMPORTANT_CONSIDERATION', 179)]	5	[('CHEBI_27300', 'vitamin D', 68, 'vitamin D'), ('UBERON_0000004', 'nose', 111, 'nasal')]
S42-PMC5064894	PMC5064894	10/2016	S42-PMC5064894	['THIS STUDY is integrated into a randomized clinical trial of maternal Vitamin D supplementation for which the primary outcome is length at one year of age (maternal Vitamin D for infant Growth (mdig) trial, clinicaltrials.org identifier nct01924013), currently underway in dhaka, bangladesh and funded by the bill and melinda gates foundation (achieving health growth platform grant opp1066764) [30].']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0)]	1	[('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 165, 'Vitamin D'), ('GO_0006099', 'tricarboxylic acid cycle', 186, 'Growth')]
S43-PMC5064894	PMC5064894	10/2016	S43-PMC5064894	['we HYPOTHESIZE that among infants 0–6 months, the incidence of microbiologically confirmed ari will be significantly lower in infants of mothers who received a relatively high dose of Vitamin D (28,000\xa0iu/week) during Pregnancy plus continued Postpartum supplementation (to 6\xa0months Postpartum) compared to mothers who received placebo throughout the Prenatal and Postpartum periods.']	[('INCOMPLETE_EVIDENCE', 3)]	1	[('CHEBI_27300', 'vitamin D', 184, 'vitamin D'), ('GO_0007565', 'female pregnancy', 218, 'pregnancy'), ('GO_0007565', 'female pregnancy', 243, 'postpartum'), ('GO_0007565', 'female pregnancy', 283, 'postpartum'), ('GO_0007565', 'female pregnancy', 351, 'prenatal'), ('GO_0007565', 'female pregnancy', 364, 'postpartum')]
S44-PMC5064894	PMC5064894	10/2016	S44-PMC5064894	['if a significantly decreased incidence of microbiologically confirmed ari is FOUND, we will further assess for EFFECT of lower doses of Prenatal maternal Vitamin D supplementation.']	[('INCOMPLETE_EVIDENCE', 77), ('SUPERFICIAL_RELATIONSHIP', 111)]	2	[('GO_0007565', 'female pregnancy', 136, 'prenatal'), ('CHEBI_27300', 'vitamin D', 154, 'vitamin D')]
S45-PMC5064894	PMC5064894	10/2016	S45-PMC5064894	['we AIM to quantify the EFFECT of maternal Vitamin D supplementation on the relative incidence of, a) microbiologically confirmed ari (primary outcome); b) ari due to influenza (a&b) and Rsv; c) clinical ari; and, d) s. pneumococcus nasal carriage density.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('SUPERFICIAL_RELATIONSHIP', 23)]	2	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 186, 'RSV')]
S160-PMC5064894	PMC5064894	10/2016	S160-PMC5064894	['we anticipate that the EFFECT of maternal Vitamin D supplementation will be incremental with increasing dose, such that the greatest EFFECT size (vs. placebo) will be observed in the highest dose Vitamin D group with Postpartum continuation (group e in fig.']	[('SUPERFICIAL_RELATIONSHIP', 23), ('SUPERFICIAL_RELATIONSHIP', 133)]	2	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 196, 'vitamin D'), ('GO_0007565', 'female pregnancy', 217, 'postpartum')]
S163-PMC5064894	PMC5064894	10/2016	S163-PMC5064894	['THIS will TEST the core mechanistic HYPOTHESIS that IMPROVEMENTS in Vitamin D status via maternal Vitamin D supplementation reduce the RISK of ari among infants in dhaka.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 10), ('INCOMPLETE_EVIDENCE', 36), ('FUTURE_WORK', 52), ('IMPORTANT_CONSIDERATION', 135)]	5	[('CHEBI_27300', 'vitamin D', 68, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 98, 'vitamin D')]
S168-PMC5064894	PMC5064894	10/2016	S168-PMC5064894	['we thus maintain 80\xa0% power to address the QUESTION of WHETHER maternal Vitamin D supplementation CAN reduce the rate of microbiologically-confirmed acute Respiratory infections, while simultaneously being able to address WHETHER lower doses are also EFFECTIVE, and TO INVESTIGATE WHETHER a dose–response RELATIONSHIP exists, thereby SUPPORTING the biological PLAUSIBILITY and robustness of inferences.']	[('EXPLICIT_QUESTION', 43), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 55), ('EXPLICIT_QUESTION', 55), ('INCOMPLETE_EVIDENCE', 98), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 222), ('SUPERFICIAL_RELATIONSHIP', 251), ('QUESTION_ANSWERED_BY_THIS_WORK', 266), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 281), ('SUPERFICIAL_RELATIONSHIP', 305), ('INCOMPLETE_EVIDENCE', 334), ('INCOMPLETE_EVIDENCE', 360)]	11	[('CHEBI_27300', 'vitamin D', 72, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 155, 'respiratory')]
S185-PMC5064894	PMC5064894	10/2016	S185-PMC5064894	['a specific pairwise comparison between the 28,000\xa0iu/week Prenatal\u2009+\u2009Postpartum group (group e) will be compared to 28,000\xa0iu/week without Postpartum supplementation (group d) TO IDENTIFY the IMPACT of continuing Vitamin D supplementation in the Postpartum period.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 176), ('SUPERFICIAL_RELATIONSHIP', 192)]	2	[('GO_0007565', 'female pregnancy', 58, 'prenatal'), ('GO_0007565', 'female pregnancy', 69, 'postpartum'), ('GO_0007565', 'female pregnancy', 139, 'postpartum'), ('CHEBI_27300', 'vitamin D', 213, 'vitamin D'), ('GO_0007565', 'female pregnancy', 246, 'postpartum')]
S193-PMC5064894	PMC5064894	10/2016	S193-PMC5064894	['discussion\nthe mdari study in dhaka, bangladesh leverages the infrastructure of a large randomized placebo controlled, dose-ranging trial of maternal Vitamin D supplementation during Pregnancy and Lactation in bangladesh TO TEST the HYPOTHESIS that maternal Vitamin D supplementation CAN decrease infant Respiratory infections during the HIGH RISK first 6\xa0months of infancy.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 221), ('INCOMPLETE_EVIDENCE', 233), ('INCOMPLETE_EVIDENCE', 284), ('IMPORTANT_CONSIDERATION', 338)]	4	[('CHEBI_27300', 'vitamin D', 150, 'vitamin D'), ('GO_0007565', 'female pregnancy', 183, 'pregnancy'), ('GO_0007595', 'lactation', 197, 'lactation'), ('CHEBI_27300', 'vitamin D', 258, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 304, 'respiratory')]
S194-PMC5064894	PMC5064894	10/2016	S194-PMC5064894	['IF SHOWN to reduce the RISK of ari in infancy, integration of maternal Prenatal/Postpartum Vitamin D supplementation into Antenatal Care programs in south asia MAY BE a FEASIBLE primary preventive STRATEGY to reduce THE BURDEN of ari-associated morbidity and mortality in young infants.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 0), ('IMPORTANT_CONSIDERATION', 23), ('INCOMPLETE_EVIDENCE', 160), ('PROBABLE_UNDERSTANDING', 169), ('FUTURE_WORK', 197), ('IMPORTANT_CONSIDERATION', 216)]	7	[('GO_0007565', 'female pregnancy', 71, 'prenatal'), ('GO_0007565', 'female pregnancy', 80, 'postpartum'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('GO_0007608', 'sensory perception of smell', 122, 'antenatal care')]
S120-PMC5084016	PMC5084016	10/2016	S120-PMC5084016	['the Endogenous Synthesis Of Vitamin D requires exposure to ultraviolet radiation with a wavelength between 290 and 315 nm, and is INFLUENCED by several FACTORS, RELATED to both the Individual’s characteristics (such as sex and phenotype, weight), and environmental factors (the degree of physical activity, latitude, season, time of exposure to sunlight, pollution, use of sunscreens and supplements).']	[('SUPERFICIAL_RELATIONSHIP', 130), ('SUPERFICIAL_RELATIONSHIP', 152), ('SUPERFICIAL_RELATIONSHIP', 161)]	3	[('GO_0009790', 'embryo development', 4, 'endogenous'), ('GO_0030474', 'spindle pole body duplication', 15, 'synthesis of vitamin D'), ('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 36, 'D'), ('NCBITaxon_1', 'root', 181, 'individual')]
S132-PMC5084016	PMC5084016	10/2016	S132-PMC5084016	['DESPITE the LACK OF CONSENSUS on adequate intakes among DIFFERENT countries (table 3), supplementation with Vitamin D is RECOMMENDED for all Pregnant women at a dose of 600 iu/day (15 µg/day) [57].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 12), ('INCOMPLETE_EVIDENCE', 12), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 56), ('FUTURE_WORK', 121)]	6	[('CHEBI_27300', 'vitamin D', 108, 'vitamin D'), ('GO_0007565', 'female pregnancy', 141, 'pregnant')]
S10-PMC5084041	PMC5084041	10/2016	S10-PMC5084041	['the DETERMINANTS of season-corrected change in 25(Oh)D were origin, sun-Seeking behaviour, clothing style, dietary Vitamin D intake, Vitamin D supplementation and recent travel <35° n. in CONCLUSION, season-corrected 25(Oh)D concentration increased during Pregnancy and DEPENDED PARTLY on lifestyle FACTORS.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('INCOMPLETE_EVIDENCE', 188), ('SUPERFICIAL_RELATIONSHIP', 270), ('INCOMPLETE_EVIDENCE', 279), ('SUPERFICIAL_RELATIONSHIP', 299)]	5	[('CHEBI_71657', 'versiconol acetate', 47, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 53, 'D'), ('GO_0007601', 'visual perception', 72, 'seeking'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 133, 'vitamin'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 141, 'D'), ('CHEBI_71657', 'versiconol acetate', 217, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 217, '25(OH)D'), ('GO_0007565', 'female pregnancy', 256, 'pregnancy')]
S23-PMC5084041	PMC5084041	10/2016	S23-PMC5084041	['such analyses of 25(Oh)D concentrations during Pregnancy SHOW that Vitamin D status between early and late Pregnancy tracks moderately and that change DEPENDS ON supplement use, Gestational weight gain and physical activity [12].']	[('INCOMPLETE_EVIDENCE', 57), ('SUPERFICIAL_RELATIONSHIP', 151)]	2	[('CHEBI_71657', 'versiconol acetate', 17, '25(OH)D'), ('GO_0007565', 'female pregnancy', 47, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('GO_0007565', 'female pregnancy', 107, 'pregnancy'), ('GO_0007565', 'female pregnancy', 178, 'gestational')]
S69-PMC5084041	PMC5084041	10/2016	S69-PMC5084041	['variables included in multivariate analyses were selected on the basis of biological PLAUSIBILITY; the POTENTIAL DETERMINANTS of Vitamin D deficiency at t1 were season, Clothing style, recent travel to <35° n, sun-seeking behaviour, Vitamin D supplement use (including multivitamin supplements containing Vitamin D), Vitamin D intake (from oily fish and Milk), origin, bmi at t1, tobacco use at t1 and age.']	[('INCOMPLETE_EVIDENCE', 85), ('INCOMPLETE_EVIDENCE', 103), ('SUPERFICIAL_RELATIONSHIP', 113)]	3	[('CHEBI_27300', 'vitamin D', 129, 'vitamin D'), ('UBERON_2002051', 'scale circulus', 169, 'clothing'), ('CHEBI_27300', 'vitamin D', 233, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 305, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 317, 'vitamin D'), ('UBERON_0001913', 'milk', 354, 'milk')]
S96-PMC5084041	PMC5084041	10/2016	S96-PMC5084041	['in a multivariable logistic regression analysis, DETERMINANTS relating to odds of 25(Oh)D concentrations <30 nmol/l at t1 were of non-north european origin, sampling in spring, never exposing skin when sunny, no Vitamin D supplementation, lower dietary Vitamin D intake and lower age (table 2).']	[('SUPERFICIAL_RELATIONSHIP', 49)]	1	[('CHEBI_71657', 'versiconol acetate', 82, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 82, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 212, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 253, 'vitamin D')]
S97-PMC5084041	PMC5084041	10/2016	S97-PMC5084041	['among the subgroup ( n = 316) of women Born in africa and asia, DETERMINANTS of 25(Oh)D concentrations <30 nmol/l were not taking Vitamin D supplements, never exposing skin when sunny and lower age (table 2).']	[('SUPERFICIAL_RELATIONSHIP', 64)]	1	[('GO_0007567', 'parturition', 39, 'born'), ('CHEBI_71657', 'versiconol acetate', 80, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 80, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D')]
S106-PMC5084041	PMC5084041	10/2016	S106-PMC5084041	['a season-corrected analysis of change in 25(Oh)D SHOWED that the DETERMINANTS of change in 25(Oh)D during Pregnancy were origin, sun-Seeking behaviour, clothing style, dietary Vitamin D intake at t3, Vitamin D supplementation at t3 and having travelled to <35° n in the past six months (adjusted r2= 0.186) (table 3).']	[('INCOMPLETE_EVIDENCE', 49), ('SUPERFICIAL_RELATIONSHIP', 65)]	2	[('CHEBI_71657', 'versiconol acetate', 41, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 47, 'D'), ('CHEBI_71657', 'versiconol acetate', 91, '25(OH)D'), ('GO_0007565', 'female pregnancy', 106, 'pregnancy'), ('GO_0007601', 'visual perception', 133, 'seeking'), ('CHEBI_27300', 'vitamin D', 176, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 200, 'vitamin D')]
S107-PMC5084041	PMC5084041	10/2016	S107-PMC5084041	['Gestational weight gain, bmi and age were not significantly associated with change in 25(Oh)D. in the subgroup of women Born in africa and asia, only Vitamin D supplementation at t3 was a DETERMINANT of season-corrected change in Vitamin D status during Pregnancy (adjusted r2= 0.115) (table 3).']	[('SUPERFICIAL_RELATIONSHIP', 188)]	1	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('CHEBI_71657', 'versiconol acetate', 86, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 86, '25(OH)D'), ('GO_0007567', 'parturition', 120, 'born'), ('CHEBI_27300', 'vitamin D', 150, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 230, 'vitamin D'), ('GO_0007565', 'female pregnancy', 254, 'pregnancy')]
S123-PMC5084041	PMC5084041	10/2016	S123-PMC5084041	['this MAY PARTLY be EXPLAINED by less Vitamin D supplement use in late Pregnancy than in early Pregnancy.']	[('INCOMPLETE_EVIDENCE', 5), ('INCOMPLETE_EVIDENCE', 9), ('PROBABLE_UNDERSTANDING', 19)]	3	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('GO_0007565', 'female pregnancy', 70, 'pregnancy'), ('GO_0007565', 'female pregnancy', 94, 'pregnancy')]
S124-PMC5084041	PMC5084041	10/2016	S124-PMC5084041	['in OUR STUDY, the proportion of women using Vitamin D supplements was SIMILAR at t1 and t3, but IT IS POSSIBLE that supplement use CONTRIBUTED to the increase in 25(Oh)D if supplementation was initiated shortly before t1.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('SUPERFICIAL_RELATIONSHIP', 70), ('INCOMPLETE_EVIDENCE', 96), ('SUPERFICIAL_RELATIONSHIP', 131)]	4	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 162, '25(OH)D')]
S136-PMC5084041	PMC5084041	10/2016	S136-PMC5084041	['we FOUND that DETERMINANTS of change in season-corrected Vitamin D status were RELATED to sun exposure (sun-Seeking behaviour, clothing style, and travel <35° n), Vitamin D intake (dietary and supplementary) and origin.']	[('INCOMPLETE_EVIDENCE', 3), ('SUPERFICIAL_RELATIONSHIP', 14), ('SUPERFICIAL_RELATIONSHIP', 79)]	3	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('GO_0007568', 'aging', 107, '-seeking'), ('CHEBI_27300', 'vitamin D', 163, 'vitamin D')]
S138-PMC5084041	PMC5084041	10/2016	S138-PMC5084041	['moon et al SHOWED that Vitamin D supplementation is RELATED to changes in 25(Oh)D between the first and the third trimester, which SUPPORTS OUR FINDINGS [12].']	[('INCOMPLETE_EVIDENCE', 11), ('SUPERFICIAL_RELATIONSHIP', 52), ('INCOMPLETE_EVIDENCE', 131), ('QUESTION_ANSWERED_BY_THIS_WORK', 140)]	4	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 74, '25(OH)D')]
S141-PMC5084041	PMC5084041	10/2016	S141-PMC5084041	['we FOUND that the ONLY DETERMINANT of change in the subgroup Born in africa and asia was Vitamin D supplement use.']	[('INCOMPLETE_EVIDENCE', 3), ('ANOMALY_CURIOUS_FINDING', 18), ('SUPERFICIAL_RELATIONSHIP', 23)]	3	[('GO_0007567', 'parturition', 61, 'born'), ('CHEBI_27300', 'vitamin D', 89, 'vitamin D')]
S82-PMC5085625	PMC5085625	9/2016	S82-PMC5085625	['in our opinion, SOME DISCREPANCIES between the results of PREVIOUS STUDIES MAY result from LACK OF adjustment for Vitamin D supplementation and season of the Blood sampling.']	[('INCOMPLETE_EVIDENCE', 16), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 21), ('INCOMPLETE_EVIDENCE', 58), ('INCOMPLETE_EVIDENCE', 75), ('PROBLEM_COMPLICATION', 91)]	5	[('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('UBERON_0000178', 'blood', 158, 'blood')]
S125-PMC5085625	PMC5085625	9/2016	S125-PMC5085625	['CONSEQUENTLY, these authors RECOMMENDED to conduct a well-designed randomized controlled trial to examine the exact ROLE of Vitamin D supplementation in the PREVENTION of Gdm [49].']	[('PROBABLE_UNDERSTANDING', 0), ('FUTURE_WORK', 28), ('SUPERFICIAL_RELATIONSHIP', 116), ('SUPERFICIAL_RELATIONSHIP', 157)]	4	[('CHEBI_27300', 'vitamin D', 124, 'vitamin D'), ('GO_0070477', 'endospore core', 171, 'GDM')]
S66-PMC5093678	PMC5093678	10/2016	S66-PMC5093678	['the control group will be provided with the usual Antenatal dietary advice as per nice guidelines on Antenatal care, weight management in Pregnancy and hypertension in Pregnancy.15–17Folic Acid and Vitamin D supplementation will be provided as per national RECOMMENDATIONS for all participants.']	[('FUTURE_WORK', 257)]	1	[('GO_0007567', 'parturition', 50, 'antenatal'), ('GO_0007567', 'parturition', 101, 'antenatal'), ('GO_0007565', 'female pregnancy', 138, 'pregnancy'), ('GO_0007565', 'female pregnancy', 168, 'pregnancy'), ('CHEBI_39159', '(S)-trichostatic acid', 181, '17Folic acid'), ('CHEBI_27300', 'vitamin D', 198, 'vitamin D')]
S83-PMC5095257	PMC5095257	11/2016	S83-PMC5095257	['TO EXPLORE the POSSIBLE EFFECT of uvb radiation exposure, which IS KNOWN to INFLUENCE Vitamin D status, on the seasonality pattern OBSERVED in aad, we compared monthly ors (supplemental figure 1) dividing the cohort into 2 groups according to geographical latitude.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 15), ('SUPERFICIAL_RELATIONSHIP', 24), ('INCOMPLETE_EVIDENCE', 64), ('SUPERFICIAL_RELATIONSHIP', 76), ('INCOMPLETE_EVIDENCE', 131)]	6	[('CHEBI_27300', 'vitamin D', 86, 'vitamin D')]
S154-PMC5100620	PMC5100620	10/2016	S154-PMC5100620	['no such effects on Lipids were FOUND in the nepal trial that included multiple Micronutrient supplements and allocated Vitamin A only as control.19\n\nGlucose Metabolism\nchildren of mothers receiving mms had significantly lower fasting Glucose levels as compared with those allocated to the standard fe60f.']	[('INCOMPLETE_EVIDENCE', 31)]	1	[('CHEBI_18059', 'lipid', 19, 'lipids'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 79, 'micronutrient'), ('CHEBI_27300', 'vitamin D', 119, 'vitamin A'), ('CHEBI_17234', 'glucose', 149, 'Glucose'), ('GO_0006006', 'glucose metabolic process', 149, 'Glucose metabolism'), ('CHEBI_17234', 'glucose', 234, 'glucose')]
S22-PMC5118763	PMC5118763	12/2016	S22-PMC5118763	['ALTHOUGH PREVIOUS reports from this trial SHOWED a high prevalence of anemia, zinc, and Vitamin B-12 deficiencies in early Pregnancy among the women in the trial (14), there was no differential effect of using the mmn regimen on women’s hemoglobin concentration compared with standard Iron–Folic Acid supplementation regimens (11).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 9), ('INCOMPLETE_EVIDENCE', 42)]	4	[('CHEBI_27300', 'vitamin D', 88, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 88, 'vitamin B-12'), ('GO_0007565', 'female pregnancy', 123, 'pregnancy'), ('CHEBI_24870', 'ion', 285, 'iron'), ('CHEBI_30751', 'formic acid', 290, 'folic acid')]
S107-PMC5118763	PMC5118763	12/2016	S107-PMC5118763	['this was CONFIRMED by regression analyses when evaluating dose-response over the full range of capsule Intake because there were no linear associations between the number of Capsules taken and Plasma concentration of Vitamin B-12 for any of the Micronutrient supplementation types (results not shown).']	[('INCOMPLETE_EVIDENCE', 9)]	1	[('GO_0007631', 'feeding behavior', 103, 'intake'), ('CHEBI_23042', 'carotene', 174, 'capsules'), ('UBERON_0001969', 'blood plasma', 193, 'plasma'), ('CHEBI_27300', 'vitamin D', 217, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 217, 'vitamin B-12'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 245, 'micronutrient')]
S160-PMC5118763	PMC5118763	12/2016	S160-PMC5118763	['a positive EFFECT of mmn supplementation on maternal Plasma Vitamin B-12 HAS also BEEN observed among Pregnant women in nepal (17).']	[('SUPERFICIAL_RELATIONSHIP', 11), ('INCOMPLETE_EVIDENCE', 73)]	2	[('UBERON_0001969', 'blood plasma', 53, 'plasma'), ('CHEBI_27300', 'vitamin D', 60, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 60, 'vitamin B-12'), ('GO_0007565', 'female pregnancy', 102, 'pregnant')]
S161-PMC5118763	PMC5118763	12/2016	S161-PMC5118763	['DESPITE supplementation, Plasma Vitamin B-12 decreased from early to late Gestation for all 3 Micronutrient types in OUR STUDY.']	[('ANOMALY_CURIOUS_FINDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 117)]	2	[('UBERON_0001969', 'blood plasma', 25, 'plasma'), ('CHEBI_27300', 'vitamin D', 32, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 32, 'vitamin B-12'), ('GO_0007565', 'female pregnancy', 74, 'gestation'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 94, 'micronutrient')]
S7-PMC5129897	PMC5129897	10/2016	S7-PMC5129897	['NEVERTHELESS, national policy changes are JUSTIFIED to improve Vitamin D status of canadians through promotion of SAFE sun exposure messages, Vitamin D supplement use, and/or facilitation of Food fortification.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('IMPORTANT_CONSIDERATION', 42), ('IMPORTANT_CONSIDERATION', 42), ('IMPORTANT_CONSIDERATION', 114)]	4	[('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 142, 'vitamin D'), ('CHEBI_33290', 'food', 191, 'food')]
S78-PMC5129897	PMC5129897	10/2016	S78-PMC5129897	['a clinical trial involving 8- to 12-year-old schoolchildren in japan receiving 1200 iu/d of Vitamin D3Found a significant reduction in incidence of type a influenza for those who had not been taking Vitamin D supplements (relative risk = 0.36 [95% ci, 0.17–0.79]).33a study in mongolia involving children near 10\xa0y of age with a baseline 25(Oh)D concentration of 18\xa0nmol/l (95% ci, 13–25\xa0nmol/l) FOUND that giving them a loading dose of Vitamin D3Followed by 300 iu/d of Vitamin D, which raised the 25(Oh)D concentration to 47\xa0nmol/l (95% ci, 39–57\xa0nmol/l), resulted in a 3-month adjusted relative risk of acute Respiratory Tract infections (aris) of 0.50 (95% ci, 0.28–0.88).34that study SHOWS that People with low 25(Oh)D concentrations have significant reductions in aris with modest increases in 25(Oh)D concentrations.']	[('INCOMPLETE_EVIDENCE', 396), ('INCOMPLETE_EVIDENCE', 689)]	2	[('CHEBI_59712', 'squarate', 92, 'vitamin D3found'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 92, 'vitamin D3found'), ('CHEBI_27300', 'vitamin D', 199, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 338, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 338, '25(OH)D'), ('CHEBI_83261', 'pyribencarb', 437, 'vitamin D3followed'), ('CHEBI_27300', 'vitamin D', 471, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 499, '25(OH)D'), ('UBERON_0000065', 'respiratory tract', 612, 'respiratory tract'), ('NCBITaxon_10088', 'Mus <genus>', 700, 'people'), ('CHEBI_71657', 'versiconol acetate', 716, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 800, '25(OH)D')]
S93-PMC5129897	PMC5129897	10/2016	S93-PMC5129897	['a RECENT PAPER by EXPERTS in ms ESTIMATED that Vitamin D supplementation COULD PREVENT 40% of ms cases.63using that value, the total economic BURDEN of ms in canada could eventually be reduced by $1.5\xa0billion.']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 9), ('PROBABLE_UNDERSTANDING', 18), ('INCOMPLETE_EVIDENCE', 32), ('INCOMPLETE_EVIDENCE', 73), ('SUPERFICIAL_RELATIONSHIP', 79), ('IMPORTANT_CONSIDERATION', 142)]	7	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D')]
S99-PMC5129897	PMC5129897	10/2016	S99-PMC5129897	['Vitamin D supplementation CAN improve osteoporosis and reduce fractures.26the classical ROLE of Vitamin D is to help with calcium absorption and Metabolism, leading to strong Bones.']	[('INCOMPLETE_EVIDENCE', 26), ('SUPERFICIAL_RELATIONSHIP', 88)]	2	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin D'), ('GO_0008152', 'metabolic process', 145, 'metabolism'), ('UBERON_0001474', 'bone element', 175, 'bones')]
S105-PMC5129897	PMC5129897	10/2016	S105-PMC5129897	['Dental services cost about $12.6\xa0billion per year in canada.70for children aged 3–14\xa0years, SEVERAL Vitamin D supplementation trials were conducted in the united states and great britain between 1928 and 1942.71for an average supplementation of ABOUT 600 iu/d, the rate of Dental caries decreased by half (relative risk = 0.51[95% ci, 0.40–0.65]).']	[('INCOMPLETE_EVIDENCE', 92), ('INCOMPLETE_EVIDENCE', 245)]	2	[('UBERON_0001091', 'calcareous tooth', 0, 'Dental'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin D'), ('UBERON_0001091', 'calcareous tooth', 273, 'dental')]
S107-PMC5129897	PMC5129897	10/2016	S107-PMC5129897	['Tooth loss was reduced by 40% in the elderly over a 2-year period with Vitamin D and Calcium supplementation.73\nMOUNTING EVIDENCE INDICATES that Vitamin D reduces risk of major depression disorder (mdd) as well as treats it.']	[('INCOMPLETE_EVIDENCE', 112), ('INCOMPLETE_EVIDENCE', 130)]	2	[('UBERON_0001091', 'calcareous tooth', 0, 'Tooth'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 85, 'calcium'), ('CHEBI_27300', 'vitamin D', 145, 'vitamin D')]
S118-PMC5129897	PMC5129897	10/2016	S118-PMC5129897	"[""“the CURRENTLY AVAILABLE results INDICATE that Vitamin D supplementation during Pregnancy reduces the RISK of Preterm Birth, low Birth weight, Dental caries of infancy, and neonatal infectious diseases such as Respiratory infections and sepsis.”81furthermore, with UNFOLDING RESEARCH into fetal origins of pediatric and Adult disease, EVIDENCE increasingly INDICATES that Gestational Vitamin D indices MAY determine health in later Life.82for example, an INTERESTING cohort study CORRELATING maternal Vitamin D levels at 18\xa0weeks' Pregnancy and health outcomes of progeny FOUND that Gestational Vitamin D deficiency was ASSOCIATED with a higher risk of impaired Lung Development in 6-year-old offspring, Neurocognitive difficulties at age 10\xa0years, increased risk of Eating disorders in Adolescence, and lower peak bone mass at 20\xa0y.83\na RECENT STUDY CONCLUDED that Vitamin D is reduces exacerbations of asthma.84\n\nall-cause mortality rate\ngarland and colleagues85presented a meta-analysis of 32 prospective observational studies that investigated all-cause mortality rate with respect to 25(Oh)D concentration at time of enrollment.""]"	[('INCOMPLETE_EVIDENCE', 5), ('INCOMPLETE_EVIDENCE', 33), ('IMPORTANT_CONSIDERATION', 102), ('INCOMPLETE_EVIDENCE', 265), ('INCOMPLETE_EVIDENCE', 335), ('INCOMPLETE_EVIDENCE', 357), ('INCOMPLETE_EVIDENCE', 402), ('ANOMALY_CURIOUS_FINDING', 455), ('SUPERFICIAL_RELATIONSHIP', 480), ('INCOMPLETE_EVIDENCE', 572), ('SUPERFICIAL_RELATIONSHIP', 620), ('INCOMPLETE_EVIDENCE', 838), ('INCOMPLETE_EVIDENCE', 851)]	13	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('GO_0007565', 'female pregnancy', 80, 'pregnancy'), ('GO_0007565', 'female pregnancy', 110, 'preterm'), ('GO_0007567', 'parturition', 118, 'birth'), ('GO_0007567', 'parturition', 129, 'birth'), ('UBERON_0001091', 'calcareous tooth', 143, 'dental'), ('UBERON_0001004', 'respiratory system', 210, 'respiratory'), ('UBERON_0007023', 'adult organism', 320, 'adult'), ('GO_0007565', 'female pregnancy', 372, 'gestational'), ('CHEBI_27300', 'vitamin D', 384, 'vitamin D'), ('UBERON_0000104', 'life cycle', 432, 'life'), ('CHEBI_27300', 'vitamin D', 501, 'vitamin D'), ('GO_0007565', 'female pregnancy', 531, 'pregnancy'), ('GO_0007565', 'female pregnancy', 583, 'gestational'), ('CHEBI_27300', 'vitamin D', 595, 'vitamin D'), ('GO_0030324', 'lung development', 662, 'lung development'), ('UBERON_0002048', 'lung', 662, 'lung'), ('GO_0050905', 'neuromuscular process', 704, 'neurocognitive'), ('GO_0051318', 'G1 phase', 767, 'eating'), ('GO_0048848', 'neurohypophysis morphogenesis', 787, 'adolescence'), ('CHEBI_27300', 'vitamin D', 866, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 1089, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 1089, '25(OH ... D')]
S176-PMC5129897	PMC5129897	10/2016	S176-PMC5129897	['the results of observational studies are GENERALLY not well-SUPPORTED by clinical trials of Vitamin D supplementation.94the primary REASON for that lack OF support SEEMS TO be that the trials were NOT WELL DESIGNED, being based LARGELY on the guidelines for Pharmaceutical Drugs RATHER than for Nutrients.2another WORRISOME POINT is that clinical trials have BEEN much more successful when baseline 25(Oh)D concentrations were low.']	[('PROBABLE_UNDERSTANDING', 41), ('INCOMPLETE_EVIDENCE', 60), ('PROBABLE_UNDERSTANDING', 132), ('ANOMALY_CURIOUS_FINDING', 153), ('ANOMALY_CURIOUS_FINDING', 164), ('INCOMPLETE_EVIDENCE', 197), ('INCOMPLETE_EVIDENCE', 228), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 279), ('IMPORTANT_CONSIDERATION', 314), ('IMPORTANT_CONSIDERATION', 324), ('ANOMALY_CURIOUS_FINDING', 359)]	11	[('CHEBI_27300', 'vitamin D', 92, 'vitamin D'), ('CHEBI_52217', 'pharmaceutical', 258, 'pharmaceutical'), ('CHEBI_23888', 'drug', 273, 'drugs'), ('CHEBI_33284', 'nutrient', 295, 'nutrients'), ('CHEBI_71657', 'versiconol acetate', 399, '25(OH)D')]
S178-PMC5129897	PMC5129897	10/2016	S178-PMC5129897	['ANOTHER LIMITATION of clinical trials is that they are of short duration—GENERALLY a few months to a few years—YET chronic diseases MAY develop slowly over decades, and the half-life of Vitamin D is about 3\xa0weeks, requiring several months of supplementation to show benefit.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 8), ('PROBABLE_UNDERSTANDING', 73), ('ANOMALY_CURIOUS_FINDING', 111), ('INCOMPLETE_EVIDENCE', 132)]	5	[('CHEBI_27300', 'vitamin D', 186, 'vitamin D')]
S184-PMC5129897	PMC5129897	10/2016	S184-PMC5129897	['supplements are RECOMMENDED BECAUSE getting Vitamin D from foods alone is hard.']	[('FUTURE_WORK', 16), ('PROBABLE_UNDERSTANDING', 28)]	2	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D')]
S192-PMC5129897	PMC5129897	10/2016	S192-PMC5129897	['one was a meta-analysis of observational studies.104the OTHER was a study of cancer incidence by occupation in nordic countries.49\n\nconclusions\nmany People living in canada do not have OPTIMAL 25(Oh)D concentrations AS a result of limited solar uvb exposure and/or not obtaining enough Vitamin D from Food or supplements.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 56), ('IMPORTANT_CONSIDERATION', 185), ('PROBABLE_UNDERSTANDING', 216)]	3	[('NCBITaxon_10088', 'Mus <genus>', 149, 'people'), ('CHEBI_71657', 'versiconol acetate', 193, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 193, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 286, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 294, 'D'), ('CHEBI_33290', 'food', 301, 'food')]
S10-PMC5146866	PMC5146866	12/2016	S10-PMC5146866	['OUR FINDINGS RAISE a QUESTION regarding the adequacy of the aap RECOMMENDED Vitamin D supplementation REQUIREMENTS without knowing the infant’s Vitamin D status at Birth.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('EXPLICIT_QUESTION', 13), ('EXPLICIT_QUESTION', 21), ('FUTURE_WORK', 64), ('IMPORTANT_CONSIDERATION', 102)]	5	[('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D'), ('GO_0007567', 'parturition', 164, 'birth')]
S91-PMC5146866	PMC5146866	12/2016	S91-PMC5146866	['COMPARABLE to PREVIOUS reports we FOUND no difference between the cb Vitamin D status and maternal multivitamin supplementation [30,32].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 14), ('INCOMPLETE_EVIDENCE', 34)]	3	[('CHEBI_27300', 'vitamin D', 69, 'vitamin D')]
S107-PMC5146866	PMC5146866	12/2016	S107-PMC5146866	['our data SHOULD ENCOURAGE pediatricians to supplement infants with Vitamin D ESPECIALLY CONSIDERING the REPORTED POOR COMPLIANCE with the aap’s RECOMMENDATIONS by both, pediatricians and parents [38].']	[('FUTURE_WORK', 9), ('FUTURE_WORK', 16), ('IMPORTANT_CONSIDERATION', 77), ('IMPORTANT_CONSIDERATION', 88), ('PROBABLE_UNDERSTANDING', 88), ('INCOMPLETE_EVIDENCE', 104), ('IMPORTANT_CONSIDERATION', 113), ('PROBLEM_COMPLICATION', 113), ('PROBLEM_COMPLICATION', 118), ('FUTURE_WORK', 144)]	10	[('CHEBI_27300', 'vitamin D', 67, 'vitamin D')]
S108-PMC5146866	PMC5146866	12/2016	S108-PMC5146866	['moreover, DUE TO the high LIKELIHOOD of Vitamin D insufficiency/deficiency at Birth, FURTHER STUDIES MAY be REQUIRED to determine the ROLE of implementing Vitamin D supplementation with respect to the cb Vitamin D status.']	[('PROBLEM_COMPLICATION', 10), ('PROBABLE_UNDERSTANDING', 26), ('FUTURE_WORK', 85), ('INCOMPLETE_EVIDENCE', 101), ('IMPORTANT_CONSIDERATION', 108), ('SUPERFICIAL_RELATIONSHIP', 134)]	6	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('GO_0007567', 'parturition', 78, 'birth'), ('CHEBI_27300', 'vitamin D', 155, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 204, 'vitamin D')]
S0-PMC5155676	PMC5155676	12/2016	S0-PMC5155676	['DETERMINANTS of the maternal 25-Hydroxyvitamin D response to Vitamin D supplementation during Pregnancy\n\nabstract\n\ncontext:\ncurrent approaches to Antenatal Vitamin D supplementation do NOT ACCOUNT for interindividual differences in 25-Hydroxyvitamin D (25(Oh)D) response.']	[('SUPERFICIAL_RELATIONSHIP', 0), ('INCOMPLETE_EVIDENCE', 185)]	2	"[('CHEBI_27844', ""2',3'-cyclic AMP"", 29, '25-Hydroxyvitamin D'), ('CHEBI_28384', 'vitamin K', 61, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 61, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 94, 'Pregnancy'), ('GO_0007567', 'parturition', 146, 'antenatal'), ('CHEBI_27300', 'vitamin D', 156, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 232, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 253, '25(OH)D')]"
S18-PMC5155676	PMC5155676	12/2016	S18-PMC5155676	['indeed MANY national GUIDELINES RECOMMEND universal Antenatal Vitamin D supplementation to prevent Vitamin D INSUFFICIENCY (7–9).']	[('INCOMPLETE_EVIDENCE', 7), ('PROBABLE_UNDERSTANDING', 21), ('FUTURE_WORK', 32), ('IMPORTANT_CONSIDERATION', 109)]	4	[('GO_0007567', 'parturition', 52, 'antenatal'), ('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 99, 'vitamin D')]
S20-PMC5155676	PMC5155676	12/2016	S20-PMC5155676	['ALTHOUGH Vitamin D supplementation CAN improve maternal 25(Oh)D status (10), LITTLE IS KNOWN about HOW maternal characteristics MIGHT INFLUENCE the 25(Oh)d achieved after supplementation.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 35), ('FULL_UNKNOWN', 77), ('EXPLICIT_QUESTION', 99), ('INCOMPLETE_EVIDENCE', 128), ('SUPERFICIAL_RELATIONSHIP', 134)]	6	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 56, '25(OH)D'), ('CHEBI_30778', 'gallic acid', 148, '25(OH)')]
S21-PMC5155676	PMC5155676	12/2016	S21-PMC5155676	['in nonpregnant Adults, baseline 25(Oh)D concentration, body weight/adiposity and age are IMPORTANT DETERMINANTS of the incremental rise in 25(Oh)D after Vitamin D supplementation (13,14).']	[('IMPORTANT_CONSIDERATION', 89), ('SUPERFICIAL_RELATIONSHIP', 99)]	2	[('UBERON_0007023', 'adult organism', 15, 'adults'), ('CHEBI_71657', 'versiconol acetate', 32, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 32, '25(OH'), ('PR_000006444', 'diacylglycerol kinase delta', 38, 'D'), ('CHEBI_30778', 'gallic acid', 139, '25(OH)'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 145, 'D'), ('CHEBI_27300', 'vitamin D', 153, 'vitamin D')]
S22-PMC5155676	PMC5155676	12/2016	S22-PMC5155676	['during Pregnancy, maternal hemodilution is ACCOMPANIED by a number OF physiological changes to both Vitamin D Metabolism (15) and maternal body composition (16); such adaptations MIGHT lead to DIFFERENCES in the DETERMINANTS of response to Vitamin D supplementation between Pregnant and nonpregnant women.']	[('SUPERFICIAL_RELATIONSHIP', 43), ('ANOMALY_CURIOUS_FINDING', 67), ('INCOMPLETE_EVIDENCE', 179), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 193), ('SUPERFICIAL_RELATIONSHIP', 212)]	5	[('GO_0007565', 'female pregnancy', 7, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin D'), ('GO_0007601', 'visual perception', 100, 'vitamin D'), ('GO_0008152', 'metabolic process', 110, 'metabolism'), ('CHEBI_27300', 'vitamin D', 240, 'vitamin D'), ('GO_0007565', 'female pregnancy', 274, 'pregnant')]
S23-PMC5155676	PMC5155676	12/2016	S23-PMC5155676	['clinically, understanding HOW Individuals respond COULD LEAD to individualized Antenatal counseling regarding Vitamin D supplementation to ensure Vitamin D repletion is achieved without increasing the RISK of Vitamin D toxicity.']	[('EXPLICIT_QUESTION', 26), ('INCOMPLETE_EVIDENCE', 50), ('SUPERFICIAL_RELATIONSHIP', 56), ('IMPORTANT_CONSIDERATION', 201)]	4	[('NCBITaxon_1', 'root', 30, 'individuals'), ('GO_0007567', 'parturition', 79, 'antenatal'), ('CHEBI_27300', 'vitamin D', 110, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 146, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 209, 'vitamin D')]
S24-PMC5155676	PMC5155676	12/2016	S24-PMC5155676	['we THEREFORE undertook THIS STUDY TO DETERMINE maternal characteristics ASSOCIATED with achieved 25(Oh)D after Antenatal Vitamin D supplementation in the context of a double-blind, randomized, placebo-controlled trial.']	[('PROBABLE_UNDERSTANDING', 3), ('QUESTION_ANSWERED_BY_THIS_WORK', 23), ('QUESTION_ANSWERED_BY_THIS_WORK', 34), ('SUPERFICIAL_RELATIONSHIP', 72)]	4	[('CHEBI_71657', 'versiconol acetate', 97, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 103, 'D'), ('GO_0007567', 'parturition', 111, 'antenatal'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin D')]
S75-PMC5155676	PMC5155676	12/2016	S75-PMC5155676	['percentage of women achieving Vitamin D replete status (>50 nmol/l) according to randomization group and season of Deliveryseason of Deliveryplacebo1000 iu/d Cholecalciferol p comparing randomization groupswinter (december–may)13.975.0<.001summer (june–november)54.290.1<.001 p comparing seasons<.001<.001\n\ndeterminants of maternal 25(Oh)D at 34 weeks of Gestation\nin univariate analysis, maternal age, baseline 25(Oh)D, season of Delivery and compliance with study Medication were significantly ASSOCIATED with 34 week 25(Oh)D in both the Placebo and Vitamin D supplementation groups (table 3).']	[('SUPERFICIAL_RELATIONSHIP', 496)]	1	[('CHEBI_28384', 'vitamin K', 30, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 30, 'Vitamin D'), ('GO_0006260', 'DNA replication', 115, 'DeliverySeason'), ('GO_0006260', 'DNA replication', 133, 'DeliveryPlacebo1000'), ('CHEBI_16113', 'cholesterol', 158, 'Cholecalciferol'), ('CHEBI_71657', 'versiconol acetate', 332, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 332, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 355, 'gestation'), ('CHEBI_71657', 'versiconol acetate', 412, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 415, 'OH ... D'), ('GO_0007567', 'parturition', 431, 'delivery'), ('CHEBI_60211', 'compound Z', 466, 'medication'), ('CHEBI_71657', 'versiconol acetate', 520, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 520, '25(OH)D'), ('CHEBI_26130', 'biological pigment', 540, 'placebo'), ('CHEBI_27300', 'vitamin D', 552, 'vitamin D')]
S82-PMC5155676	PMC5155676	12/2016	S82-PMC5155676	['in multiple linear regression analysis, maternal factors significantly ASSOCIATED with greater 25(Oh)D at 34 weeks of Gestation in the Vitamin D supplementation group were lower Pregnancy weight gain (kg) (β = −0.81; 95% confidence interval [ci] −1.39, −0.22; p = .007), higher compliance (%) (β = 0.28; 95%ci 0.072, 0.48; p = .008), higher early Pregnancy 25(Oh)D (nmol/l) (β = 0.28; 95%ci 0.16, 0.40; p< .001), and summer Delivery (summer vs winter) (β = 10.51; 95%ci 6.40, 14.63; p< .001) (figure 2a).']	[('SUPERFICIAL_RELATIONSHIP', 71)]	1	[('CHEBI_71657', 'versiconol acetate', 95, '25(OH)D'), ('GO_0007565', 'female pregnancy', 118, 'gestation'), ('CHEBI_27300', 'vitamin D', 135, 'vitamin D'), ('GO_0007565', 'female pregnancy', 178, 'pregnancy'), ('GO_0007565', 'female pregnancy', 347, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 357, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 357, '25(OH)D'), ('GO_0007567', 'parturition', 424, 'delivery')]
S98-PMC5155676	PMC5155676	12/2016	S98-PMC5155676	['however, gaining less weight during Pregnancy, having a higher 25(Oh)D in early Pregnancy, Delivering in summer and having higher compliance with supplementation were INDEPENDENTLY ASSOCIATED with achieving a greater 25(Oh)D concentration in late Pregnancy among women randomized to Vitamin D supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 167), ('SUPERFICIAL_RELATIONSHIP', 181)]	2	[('GO_0007565', 'female pregnancy', 36, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 63, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 63, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 80, 'pregnancy'), ('GO_0006900', 'vesicle budding from membrane', 91, 'delivering'), ('CHEBI_71657', 'versiconol acetate', 217, '25(OH)D'), ('GO_0007565', 'female pregnancy', 247, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 283, 'vitamin D')]
S99-PMC5155676	PMC5155676	12/2016	S99-PMC5155676	['THUS, those women who are AT RISK of Vitamin D insufficiency in early Pregnancy, gain greater weight, and Deliver in winter MIGHT NEED supplementation with a higher dose of Cholecalciferol to achieve SIMILAR 25(Oh)D concentrations.']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 26), ('INCOMPLETE_EVIDENCE', 124), ('IMPORTANT_CONSIDERATION', 130), ('SUPERFICIAL_RELATIONSHIP', 200)]	5	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('GO_0007565', 'female pregnancy', 70, 'pregnancy'), ('GO_0007567', 'parturition', 106, 'deliver'), ('CHEBI_52550', 'theopalauamide', 173, 'cholecalciferol'), ('CHEBI_71657', 'versiconol acetate', 208, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 214, 'D')]
S100-PMC5155676	PMC5155676	12/2016	S100-PMC5155676	['HOWEVER, when Vitamin D replete status was considered as the outcome, ONLY non-white maternal ethnicity and Delivery in winter were significant PREDICTORS of Vitamin D nonreplete status after supplementation.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 70), ('SUPERFICIAL_RELATIONSHIP', 144)]	3	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('GO_0007567', 'parturition', 108, 'delivery'), ('CHEBI_27300', 'vitamin D', 158, 'vitamin D')]
S101-PMC5155676	PMC5155676	12/2016	S101-PMC5155676	['TO OUR KNOWLEDGE, the factors which determine the response to Vitamin D supplementation in Pregnancy have not previously been assessed.']	[('PROBABLE_UNDERSTANDING', 0)]	1	[('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('GO_0007565', 'female pregnancy', 91, 'pregnancy')]
S105-PMC5155676	PMC5155676	12/2016	S105-PMC5155676	['metaanalysis of Vitamin D supplementation STUDIES has SUGGESTED that over 50% of the variance in 25(Oh)D increment in response to supplementation is explained by body weight (13).']	[('INCOMPLETE_EVIDENCE', 42), ('INCOMPLETE_EVIDENCE', 54)]	2	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 97, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 103, 'D')]
S108-PMC5155676	PMC5155676	12/2016	S108-PMC5155676	['weight gain in Pregnancy REPRESENTS NOT ONLY increased fat mass BUT ALSO Feto-Placental Tissues and hemodilution (16); our data, THEREFORE, SUGGEST that overall volume of dilution, and not just adiposity, MAY BE IMPORTANT for response to Vitamin D supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 25), ('ANOMALY_CURIOUS_FINDING', 36), ('ANOMALY_CURIOUS_FINDING', 64), ('PROBABLE_UNDERSTANDING', 129), ('INCOMPLETE_EVIDENCE', 140), ('INCOMPLETE_EVIDENCE', 205), ('IMPORTANT_CONSIDERATION', 212)]	7	[('GO_0007565', 'female pregnancy', 15, 'pregnancy'), ('UBERON_0000981', 'femur', 73, 'feto'), ('UBERON_0002483', 'trabecular bone tissue', 78, 'placental tissues'), ('CHEBI_27300', 'vitamin D', 238, 'vitamin D')]
S113-PMC5155676	PMC5155676	12/2016	S113-PMC5155676	['IMPORTANTLY, the difference between the 25(Oh)D achieved at 34 weeks of Gestation in women randomized to Placebo compared with Cholecalciferol decreased with increasing baseline 25(Oh)D. this is CONSISTENT with PREVIOUS STUDIES in Adults, which HAVE SHOWN that the incremental response to Vitamin D supplementation is higher in Vitamin D insufficient than replete subjects (13,14) and that the increase in 25(Oh)D relative to supplementation dose is negatively ASSOCIATED with dose of vitamin D supplement (26).']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 195), ('INCOMPLETE_EVIDENCE', 211), ('INCOMPLETE_EVIDENCE', 245), ('SUPERFICIAL_RELATIONSHIP', 461)]	5	[('CHEBI_71657', 'versiconol acetate', 40, '25(OH)D'), ('GO_0007565', 'female pregnancy', 72, 'gestation'), ('CHEBI_26130', 'biological pigment', 105, 'placebo'), ('CHEBI_52550', 'theopalauamide', 127, 'cholecalciferol'), ('CHEBI_33010', 'chromide(1-)', 180, '(OH)D'), ('UBERON_0007023', 'adult organism', 231, 'adults'), ('CHEBI_27300', 'vitamin D', 289, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 328, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 406, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 412, 'D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 493, 'D')]
S117-PMC5155676	PMC5155676	12/2016	S117-PMC5155676	['similarly, non-white ethnicity was ASSOCIATED with a higher risk of not achieving Vitamin D replete status in the supplemented women.']	[('SUPERFICIAL_RELATIONSHIP', 35)]	1	[('CHEBI_27300', 'vitamin D', 82, 'vitamin D')]
S120-PMC5155676	PMC5155676	12/2016	S120-PMC5155676	['maternal age was also positively ASSOCIATED in univariate analyses with 25(Oh)D achieved at 34 weeks of Gestation in women who received Vitamin D supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 33)]	1	[('CHEBI_71657', 'versiconol acetate', 72, '25(OH)D'), ('GO_0007565', 'female pregnancy', 104, 'gestation'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin D')]
S123-PMC5155676	PMC5155676	12/2016	S123-PMC5155676	['data from healthy and hospitalized Adults have SIMILARLY SHOWN that older Individuals achieve a higher 25(Oh)D after Vitamin D supplementation (13,32).']	[('INCOMPLETE_EVIDENCE', 47), ('SUPERFICIAL_RELATIONSHIP', 47)]	2	[('UBERON_0007023', 'adult organism', 35, 'adults'), ('NCBITaxon_1', 'root', 74, 'individuals'), ('CHEBI_71657', 'versiconol acetate', 103, '25(OH)D'), ('PR_000010220', 'mannose-binding protein C', 105, '('), ('PR_000006444', 'diacylglycerol kinase delta', 109, 'D'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin D')]
S124-PMC5155676	PMC5155676	12/2016	S124-PMC5155676	['AS such, young Pregnant women MIGHT PARTICULARLY REQUIRE ADVICE on the need for, and compliance with, Vitamin D supplementation.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 30), ('ANOMALY_CURIOUS_FINDING', 36), ('IMPORTANT_CONSIDERATION', 36), ('FUTURE_WORK', 49), ('IMPORTANT_CONSIDERATION', 49), ('FUTURE_WORK', 57)]	7	[('GO_0007565', 'female pregnancy', 15, 'pregnant'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin D')]
S125-PMC5155676	PMC5155676	12/2016	S125-PMC5155676	['ALTHOUGH OUR FINDINGS are NOVEL, and MAY enable the development of individualized ADVICE for Antenatal Vitamin D supplementation, there are a NUMBER OF LIMITATIONS which SHOULD BE CONSIDERED in the INTERPRETATION of this study.']	[('ANOMALY_CURIOUS_FINDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 9), ('FULL_UNKNOWN', 26), ('INCOMPLETE_EVIDENCE', 37), ('FUTURE_WORK', 82), ('INCOMPLETE_EVIDENCE', 142), ('INCOMPLETE_EVIDENCE', 152), ('PROBLEM_COMPLICATION', 152), ('FUTURE_WORK', 170), ('FUTURE_WORK', 180), ('INCOMPLETE_EVIDENCE', 198)]	11	[('GO_0007567', 'parturition', 93, 'antenatal'), ('CHEBI_27300', 'vitamin D', 103, 'vitamin D')]
S127-PMC5155676	PMC5155676	12/2016	S127-PMC5155676	['as baseline 25(Oh)D was ASSOCIATED with the LIKELIHOOD of achieving Vitamin D replete status, it is LIKELY that women with very low levels of 25(Oh)D at baseline will require a higher supplementation dose to achieve Vitamin D repletion.']	[('SUPERFICIAL_RELATIONSHIP', 24), ('PROBABLE_UNDERSTANDING', 44), ('PROBABLE_UNDERSTANDING', 100)]	3	[('CHEBI_71657', 'versiconol acetate', 12, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 68, 'vitamin D'), ('CHEBI_33010', 'chromide(1-)', 144, '(OH)D'), ('CHEBI_27300', 'vitamin D', 216, 'vitamin D')]
S131-PMC5155676	PMC5155676	12/2016	S131-PMC5155676	['thirdly, we DID NOT examine Genetic determinants of the response to Vitamin D supplementation.']	[('INCOMPLETE_EVIDENCE', 12)]	1	[('SO_0000704', 'gene', 28, 'genetic'), ('CHEBI_27300', 'vitamin D', 68, 'vitamin D')]
S132-PMC5155676	PMC5155676	12/2016	S132-PMC5155676	['it HAS BEEN demonstrated PREVIOUSLY that the incremental rise in 25(Oh)D after supplementation DIFFERS by Single Nucleotide Polymorphisms in Vitamin D Binding Protein (33,34) and 25-hydroxylase Genes (33).']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 25), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 95)]	3	[('CHEBI_71657', 'versiconol acetate', 65, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 65, '25(OH ... D'), ('SO_0000694', 'SNP', 106, 'single nucleotide polymorphisms'), ('CHEBI_27300', 'vitamin D', 141, 'vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 141, 'vitamin D binding protein'), ('SO_0000704', 'gene', 194, 'genes')]
S133-PMC5155676	PMC5155676	12/2016	S133-PMC5155676	['ALTHOUGH this Genetic information CAN enable a more COMPREHENSIVE understanding of the biochemical response to Vitamin D supplementation, the current inability to undertake genotyping on a widespread population basis means this additional information WOULD NOT ALLOW for alterations to current clinical PRACTICE regarding Vitamin D supplementation in Pregnancy.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 34), ('PROBABLE_UNDERSTANDING', 52), ('DIFFICULT_TASK', 251), ('INCOMPLETE_EVIDENCE', 303)]	6	[('SO_0000704', 'gene', 14, 'genetic'), ('CHEBI_27300', 'vitamin D', 111, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 322, 'vitamin D'), ('GO_0007565', 'female pregnancy', 351, 'pregnancy')]
S137-PMC5155676	PMC5155676	12/2016	S137-PMC5155676	['AS SUCH, personalized Vitamin D supplementation ADVICE MIGHT become part of future Antenatal care.']	[('PROBABLE_UNDERSTANDING', 0), ('FUTURE_WORK', 48), ('INCOMPLETE_EVIDENCE', 55)]	3	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('GO_0007567', 'parturition', 83, 'antenatal')]
S41-PMC5167470	PMC5167470	12/2016	S41-PMC5167470	['this was followed by Vitamin 25-Oh-D3 deficiency in 40.5% of patients, B12 deficiency in 22.6%, Vitamin A in 7.7%, Calcium in 6.6%, Vitamin E in 6% and Folic Acid in 5.4%.5in another RECENT prospective STUDY that followed 49 women who got Pregnant after bs, progressively decreasing levels of Vitamins A, D, b12, and iron were OBSERVED over the course of Pregnancy, DESPITE correct compliance with oral supplements, before and during Gestation.']	[('INCOMPLETE_EVIDENCE', 183), ('INCOMPLETE_EVIDENCE', 327), ('ANOMALY_CURIOUS_FINDING', 366)]	3	[('CHEBI_85670', 'N-oleoyl-sn-glycero-3-phosphoethanolamine', 21, 'vitamin 25-OH-D3'), ('CHEBI_27778', 'abequose', 71, 'B12'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 71, 'B12'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin A'), ('CHEBI_22313', 'alkaline earth metal atom', 115, 'calcium'), ('CHEBI_27300', 'vitamin D', 132, 'vitamin E'), ('CHEBI_30751', 'formic acid', 152, 'folic acid'), ('GO_0007565', 'female pregnancy', 239, 'pregnant'), ('CHEBI_27300', 'vitamin D', 293, 'vitamins A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 302, 'A'), ('PR_000006444', 'diacylglycerol kinase delta', 305, 'D'), ('GO_0007565', 'female pregnancy', 355, 'pregnancy'), ('GO_0007565', 'female pregnancy', 434, 'gestation')]
S114-PMC5240436	PMC5240436	1/2017	S114-PMC5240436	['a PREVIOUS STUDY that provided combined Vitamin A and zinc supplementation to children in ghana LED TO a reduction in the RISK of clinical malaria episodes [46] possibly DUE TO the synergistic EFFECTS of Vitamin A and zinc on Immune function [47].']	[('INCOMPLETE_EVIDENCE', 2), ('SUPERFICIAL_RELATIONSHIP', 96), ('IMPORTANT_CONSIDERATION', 122), ('PROBABLE_UNDERSTANDING', 170), ('SUPERFICIAL_RELATIONSHIP', 193)]	5	[('CHEBI_27300', 'vitamin D', 40, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 204, 'vitamin A'), ('UBERON_0002405', 'immune system', 226, 'immune')]
S116-PMC5240436	PMC5240436	1/2017	S116-PMC5240436	['the LACK OF treatment response DESPITE the provision of adequate doses of Vitamin A and zinc in mmn and sq-lns and reasonable adherence to supplementation [24] COULD HAVE been due to dietary factors inhibiting zinc absorption [48] or haemodilution in the latter half of Pregnancy lowering levels of Retinol binding protein resulting in functional Vitamin A deficiency [49].']	[('INCOMPLETE_EVIDENCE', 4), ('ANOMALY_CURIOUS_FINDING', 31), ('INCOMPLETE_EVIDENCE', 160), ('IMPORTANT_CONSIDERATION', 166)]	4	[('CHEBI_27300', 'vitamin D', 74, 'vitamin A'), ('GO_0007565', 'female pregnancy', 270, 'pregnancy'), ('CHEBI_26536', 'retinoic acid', 299, 'retinol'), ('CHEBI_27300', 'vitamin D', 347, 'vitamin A')]
S120-PMC5240436	PMC5240436	1/2017	S120-PMC5240436	['FURTHER clinical TRIALS supplementing single Nutrients (efas, Vitamin A or zinc) MAY BE CRUCIAL in isolating the IMPACT of each Nutrient on maternal infections.']	[('FUTURE_WORK', 0), ('INCOMPLETE_EVIDENCE', 81), ('IMPORTANT_CONSIDERATION', 88), ('SUPERFICIAL_RELATIONSHIP', 113)]	4	[('CHEBI_33284', 'nutrient', 45, 'nutrients'), ('CHEBI_27300', 'vitamin D', 62, 'vitamin A'), ('CHEBI_33284', 'nutrient', 128, 'nutrient')]
S36-PMC5264377	PMC5264377	7/2016	S36-PMC5264377	['EVEN THOUGH tian FOUND a positive ASSOCIATION between maternal Vitamin D levels and infant weight at Birth, Vitamin D supplementation for Pregnant women with low Serum levels of 25(Oh)D3 failed to improve Birth weight outcomes.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 17), ('SUPERFICIAL_RELATIONSHIP', 34)]	3	[('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('GO_0007567', 'parturition', 101, 'birth'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin D'), ('GO_0007565', 'female pregnancy', 138, 'pregnant'), ('UBERON_0001977', 'blood serum', 162, 'serum'), ('CHEBI_32029', 'potassium acetate', 180, '(OH)D3'), ('PR_000001904', 'platelet endothelial cell adhesion molecule', 183, ')D3'), ('GO_0007567', 'parturition', 205, 'birth')]
S37-PMC5264377	PMC5264377	7/2016	S37-PMC5264377	['IN FACT, the benefits ASSOCIATED with Gestational Vitamin D supplementation are debatable, and MORE RESEARCH IS WARRANTED (dalgard et al ., 2016;dressler et al ., 2016).']	[('ANOMALY_CURIOUS_FINDING', 0), ('SUPERFICIAL_RELATIONSHIP', 22), ('FUTURE_WORK', 95)]	3	[('GO_0007565', 'female pregnancy', 38, 'gestational'), ('CHEBI_27300', 'vitamin D', 50, 'vitamin D')]
S39-PMC5310660	PMC5310660	1/2017	S39-PMC5310660	['this latter plays a significant ROLE, SINCE increased Serum Vitamin D concentration is ASSOCIATED with a decreased risk of multiple sclerosis [10,11], and Vitamin D supplementation during the first year of Life is ASSOCIATED with a significantly decreased risk of type 1 diabetes [12].']	[('SUPERFICIAL_RELATIONSHIP', 32), ('PROBABLE_UNDERSTANDING', 38), ('SUPERFICIAL_RELATIONSHIP', 87), ('SUPERFICIAL_RELATIONSHIP', 214)]	4	[('UBERON_0001977', 'blood serum', 54, 'serum'), ('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 155, 'vitamin D'), ('UBERON_0000104', 'life cycle', 206, 'life')]
S103-PMC5318550	PMC5318550	2/2017	S103-PMC5318550	['as shown in the correlation matrix (see onlinesupplementary table s1), child spring Birth negatively CORRELATED with nulliparity (r=−0.03, p=0.008), maternal mid-Pregnancy and Cord Blood Vitamin D Plasma concentrations (r=−0.11, p=0.01 and r=−0.12, p<0.001), child relative age compared with peers in school (r=−0.17, p<0.001) and positively CORRELATED with maternal crp concentrations (r=0.05, p=0.001) and presence of fever in mid-Pregnancy (r=0.06, p=0.001).10.1136/bmjopen-2016-012406.supp3\n\nnext, we tested the change of the association between season of Birth and iq with addition of possible covariates to the basic model, each in a separate model (see onlinesupplementary table s2).']	[('SUPERFICIAL_RELATIONSHIP', 101), ('SUPERFICIAL_RELATIONSHIP', 342)]	2	[('GO_0007567', 'parturition', 84, 'birth'), ('GO_0007565', 'female pregnancy', 162, 'pregnancy'), ('UBERON_0002240', 'spinal cord', 176, 'cord'), ('UBERON_0000178', 'blood', 181, 'blood'), ('CHEBI_27300', 'vitamin D', 187, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 197, 'plasma'), ('GO_0007565', 'female pregnancy', 433, 'pregnancy'), ('GO_0007567', 'parturition', 560, 'birth')]
S93-PMC5325195	PMC5325195	2/2017	S93-PMC5325195	['cbhvs also actively promoted facility-based delivery.10.1371/journal.pone.0170739.t001\n\ncaption (table-wrap): table 1\ncbhv messages to Pregnant women transmitted through pictorial counselling cards.1 importance of Antenatal clinic attendance for Pregnant women 2 importance of screening tests, including hiv in Pregnancy 3 importance of intermittent preventive therapy for malaria in Pregnancy using Sulphadoxine-Pyrimethamine tablets 4 importance of skilled attendance in Labor and Postpartum care 5 importance of an Insecticide-treated net and HOW to use it at home 6 types of Food, importance of an adequate and balanced diet in Pregnancy, and Vitamin A supplementation for children 7 the IMPORTANCE of iron and Folic Acid during Pregnancy 8 importance of using Misoprostol tablets after Delivery Of the Baby and HOW to use it 9 the IMPORTANCE of Chlorhexidine gel for Cord care and HOW to apply it on the Cord; avoiding use of POTENTIALLY harmful substances to the Cord 10 the care for low Birth weight babies with kangaroo care 11 HOW to prepare the Oral rehydration Solution (ors) for diarrheal diseases in children under 5 years, and the IMPORTANCE of ors.']	[('EXPLICIT_QUESTION', 546), ('IMPORTANT_CONSIDERATION', 692), ('EXPLICIT_QUESTION', 816), ('IMPORTANT_CONSIDERATION', 836), ('EXPLICIT_QUESTION', 886), ('INCOMPLETE_EVIDENCE', 931), ('EXPLICIT_QUESTION', 1036), ('IMPORTANT_CONSIDERATION', 1145)]	8	[('GO_0007565', 'female pregnancy', 135, 'pregnant'), ('GO_0007567', 'parturition', 214, 'antenatal'), ('GO_0007565', 'female pregnancy', 246, 'pregnant'), ('GO_0007565', 'female pregnancy', 311, 'pregnancy'), ('GO_0007565', 'female pregnancy', 384, 'pregnancy'), ('CHEBI_9329', 'sulfadoxine', 400, 'Sulphadoxine'), ('CHEBI_16610', 'spermidine', 413, 'pyrimethamine'), ('GO_0007612', 'learning', 473, 'labor'), ('GO_0007565', 'female pregnancy', 483, 'postpartum'), ('CHEBI_24852', 'insecticide', 518, 'insecticide'), ('CHEBI_33290', 'food', 579, 'food'), ('GO_0007565', 'female pregnancy', 632, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 647, 'vitamin A'), ('CHEBI_30751', 'formic acid', 715, 'folic acid'), ('GO_0007565', 'female pregnancy', 733, 'pregnancy'), ('CHEBI_63610', 'misoprostol', 765, 'misoprostol'), ('GO_0046697', 'decidualization', 791, 'delivery of ... baby'), ('CHEBI_3647', 'chlorpromazine', 850, 'chlorhexidine'), ('UBERON_0002240', 'spinal cord', 872, 'cord'), ('UBERON_0002240', 'spinal cord', 909, 'cord'), ('UBERON_0002240', 'spinal cord', 969, 'cord'), ('GO_0007567', 'parturition', 994, 'birth'), ('UBERON_0000978', 'leg', 1055, 'Oral'), ('CHEBI_75958', 'solution', 1072, 'Solution')]
S44-PMC5332602	PMC5332602	3/2017	S44-PMC5332602	['additionally, Serum Vitamin A, Vitamin E, and Selenium levels were significantly increased at the end of the experiment in protein-deficient groups but not in protein-sufficient groups, SUGGESTIVE of a positive “30-day response” (as seen in Vitamin A-deficient children [17]) to supplementation of these Micronutrients in the diet.']	[('INCOMPLETE_EVIDENCE', 186)]	1	[('UBERON_0001977', 'blood serum', 14, 'serum'), ('CHEBI_27300', 'vitamin D', 20, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 31, 'vitamin E'), ('CHEBI_27568', 'selenium atom', 46, 'selenium'), ('CHEBI_27300', 'vitamin D', 241, 'vitamin A'), ('CHEBI_33839', 'macromolecule', 304, 'micronutrients')]
S92-PMC5340372	PMC5340372	3/2017	S92-PMC5340372	['infants who were exclusively Breastfed or had high levels of skin pigmentation, INADEQUATE sunlight exposure, or INADEQUATE Vitamin supplement are AT RISK of a Vitamin D deficiency [26].']	[('IMPORTANT_CONSIDERATION', 80), ('IMPORTANT_CONSIDERATION', 113), ('IMPORTANT_CONSIDERATION', 147)]	3	[('GO_0007567', 'parturition', 29, 'breastfed'), ('CHEBI_33229', 'vitamin (role)', 124, 'vitamin'), ('CHEBI_27300', 'vitamin D', 160, 'vitamin D')]
S126-PMC5340372	PMC5340372	3/2017	S126-PMC5340372	['in a randomized control TRIAL, a Vitamin D supplement CAN EVEN decrease the RISK of seasonal flu in children [50].']	[('INCOMPLETE_EVIDENCE', 24), ('INCOMPLETE_EVIDENCE', 54), ('ANOMALY_CURIOUS_FINDING', 58), ('IMPORTANT_CONSIDERATION', 76)]	4	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D')]
S10-PMC5351212	PMC5351212	3/2017	S10-PMC5351212	['conclusions\nthis work RAISES the POSSIBILITY that early dietary supplementation with Vitamin D MAY open NEW AVENUES for a successful attenuation or EVEN PREVENTION of Neurodevelopmental disorders following maternal inflammation during Pregnancy.']	[('EXPLICIT_QUESTION', 22), ('INCOMPLETE_EVIDENCE', 33), ('INCOMPLETE_EVIDENCE', 95), ('FULL_UNKNOWN', 104), ('FUTURE_WORK', 108), ('ANOMALY_CURIOUS_FINDING', 148), ('SUPERFICIAL_RELATIONSHIP', 153)]	7	[('CHEBI_27300', 'vitamin D', 85, 'vitamin D'), ('GO_0007399', 'nervous system development', 167, 'neurodevelopmental'), ('GO_0007565', 'female pregnancy', 235, 'pregnancy')]
S8-PMC5368580	PMC5368580	4/2017	S8-PMC5368580	['circadian variance was significant except for fat-adjusted Vitamins A and E, with a higher CONTRIBUTION to total variance with supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 91)]	1	[('CHEBI_27300', 'vitamin D', 59, 'vitamins A'), ('PR_000004480', 'V-type proton ATPase catalytic subunit A', 59, 'vitamins A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 74, 'E')]
S11-PMC5368580	PMC5368580	4/2017	S11-PMC5368580	['acute supplementation EFFECTS were FOUND for Thiamin, riboflavin, and Vitamins B-6 and a at 2–4 h postdosing, with 0.1–6.17% passing into Milk.']	[('SUPERFICIAL_RELATIONSHIP', 22), ('INCOMPLETE_EVIDENCE', 35)]	2	[('CHEBI_26948', 'vitamin B1', 45, 'thiamin'), ('CHEBI_27300', 'vitamin D', 70, 'vitamins B'), ('UBERON_0001913', 'milk', 138, 'milk')]
S30-PMC5368580	PMC5368580	4/2017	S30-PMC5368580	['samples were analyzed for Retinol (Vitamin A), Tocopherol (Vitamin E), Thiamin (Vitamin B-1), riboflavin (Vitamin B-2), Nicotinamide (Vitamin B-3), Vitamin B-6, and Vitamin B-12 to examine 1 ) within-Feeding variation, 2 ) Circadian variation and contributions DUE TO subject variability, 3 ) acute short-term EFFECTS of maternal supplementation on milk Vitamin concentrations, and 4 ) the OPTIMAL time for collection to determine which Milk samples best represented the daily median Vitamin concentrations in Milk.']	[('PROBLEM_COMPLICATION', 261), ('SUPERFICIAL_RELATIONSHIP', 310), ('IMPORTANT_CONSIDERATION', 390)]	3	[('CHEBI_26536', 'retinoic acid', 26, 'retinol'), ('CHEBI_27300', 'vitamin D', 35, 'vitamin A'), ('CHEBI_27013', 'tocopherol', 47, 'tocopherol'), ('CHEBI_27300', 'vitamin D', 59, 'vitamin E'), ('CHEBI_26948', 'vitamin B1', 71, 'thiamin'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin B'), ('PR_000000037', 'BMP receptor type-2', 88, 'B'), ('PR_000003770', 'all-trans-retinol dehydrogenase [NAD(+)] ADH4', 90, '1'), ('CHEBI_27300', 'vitamin D', 106, 'vitamin B'), ('CHEBI_17154', 'nicotinamide', 120, 'nicotinamide'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 134, 'vitamin B-3'), ('CHEBI_27300', 'vitamin D', 148, 'vitamin B'), ('PR_000017255', 'Vang-like protein 1', 148, 'vitamin B-6'), ('CHEBI_27300', 'vitamin D', 165, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 165, 'vitamin B-12'), ('GO_0007631', 'feeding behavior', 200, 'feeding'), ('GO_0051216', 'cartilage development', 223, 'circadian'), ('CHEBI_33229', 'vitamin (role)', 354, 'vitamin'), ('UBERON_0001913', 'milk', 437, 'milk'), ('CHEBI_33229', 'vitamin (role)', 484, 'vitamin'), ('UBERON_0001913', 'milk', 510, 'milk')]
S106-PMC5368580	PMC5368580	4/2017	S106-PMC5368580	['however, the CONTRIBUTION of the Circadian variation to the total variance was <10% for all Vitamins, but increased CONSIDERABLY with maternal supplementation for riboflavin (36%) and Vitamin B-6 (23%) ( table 2 , supplemental table 2 ).']	[('SUPERFICIAL_RELATIONSHIP', 13), ('ANOMALY_CURIOUS_FINDING', 116)]	2	[('GO_0051216', 'cartilage development', 33, 'circadian'), ('CHEBI_33277', 'gamma-tocotrienol', 92, 'vitamins'), ('CHEBI_27300', 'vitamin D', 184, 'vitamin B'), ('PR_000017255', 'Vang-like protein 1', 184, 'vitamin B-6')]
S127-PMC5368580	PMC5368580	4/2017	S127-PMC5368580	['niacin and Vitamin E both SHOWED significantly lower concentrations on days when supplements were consumed.']	[('INCOMPLETE_EVIDENCE', 26)]	1	[('CHEBI_27300', 'vitamin D', 11, 'vitamin E')]
S128-PMC5368580	PMC5368580	4/2017	S128-PMC5368580	['no effects of acute supplementation were FOUND for Vitamin B-12 and efatconcentrations.']	[('INCOMPLETE_EVIDENCE', 41)]	1	[('CHEBI_27300', 'vitamin D', 51, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 51, 'vitamin B-12')]
S136-PMC5368580	PMC5368580	4/2017	S136-PMC5368580	['EVEN THOUGH the increase in all 4 Vitamins was significant and substantial from both doses, ONLY 0.05–0.35% of Thiamin, 0.54–0.6% of riboflavin, 1.0–1.14% of Vitamin B-6, and 4.85–6.17% of Vitamin A in the supplements were Secreted into the Breast Milk and subsequently available to the infant ( table 3 ).']	[('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 92)]	2	[('CHEBI_33277', 'gamma-tocotrienol', 34, 'vitamins'), ('CHEBI_26948', 'vitamin B1', 111, 'thiamin'), ('CHEBI_27300', 'vitamin D', 158, 'vitamin B'), ('CHEBI_27300', 'vitamin D', 189, 'vitamin A'), ('GO_0046903', 'secretion', 223, 'secreted'), ('UBERON_0000310', 'breast', 241, 'breast'), ('UBERON_0001913', 'milk', 248, 'milk')]
S138-PMC5368580	PMC5368580	4/2017	S138-PMC5368580	['HOWEVER, when compared with their adequate intakes, ONLY 2.3–11.1% of Thiamin, 2.8–7.9% of riboflavin, and 8.6–22.3% of Vitamin A were transferred to the milk via maternal supplement, whereas 30.7–98.9% of the adequate intake was provided by maternal Vitamin B-6 supplementation.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 52)]	3	[('CHEBI_26948', 'vitamin B1', 70, 'thiamin'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 251, 'vitamin B'), ('PR_000017255', 'Vang-like protein 1', 251, 'vitamin B-6')]
S175-PMC5368580	PMC5368580	4/2017	S175-PMC5368580	['without supplementation, the morning hours (0900–0959) and early afternoon hours (1500–1559) were also acceptable for sample collection based on their lower variation in Vitamin concentrations, WHEREAS increases in the concentration of riboflavin and Vitamin B-6 in milk during the early afternoon on days 2 and 3 reflected acute EFFECTS of maternal supplementation.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 194), ('SUPERFICIAL_RELATIONSHIP', 330)]	2	[('CHEBI_33229', 'vitamin (role)', 170, 'vitamin'), ('CHEBI_27300', 'vitamin D', 251, 'vitamin B'), ('PR_000017255', 'Vang-like protein 1', 251, 'vitamin B-6')]
S180-PMC5368580	PMC5368580	4/2017	S180-PMC5368580	['the acute response of riboflavin and Vitamin B-6 also enabled the ESTIMATE of 1 ) a maximum dose of these Vitamins in the milk during maternal supplementation and, subsequently, 2 ) a maximum amount provided to the infant.']	[('INCOMPLETE_EVIDENCE', 66)]	1	[('CHEBI_27300', 'vitamin D', 37, 'vitamin B'), ('PR_000017255', 'Vang-like protein 1', 37, 'vitamin B-6'), ('CHEBI_33277', 'gamma-tocotrienol', 106, 'vitamins')]
S188-PMC5368580	PMC5368580	4/2017	S188-PMC5368580	['moreover, we FOUND that the acute EFFECTS of maternal supplementation REMAINED significant for riboflavin and Vitamin B-6 in the fasting Milk samples 24 h after supplementation compared with day 1, and that the Vitamins were not Secreted into Milk at the same rate throughout a day during maternal supplementation, resulting in a bolus dose of ≤35% of the adequate intake for Vitamin B-6 during a single Feeding, WHEREAS the bolus dose for riboflavin during a single Feeding only provided ∼11% of the adequate intake.']	[('INCOMPLETE_EVIDENCE', 13), ('SUPERFICIAL_RELATIONSHIP', 34), ('INCOMPLETE_EVIDENCE', 70), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 413)]	4	[('CHEBI_27300', 'vitamin D', 110, 'vitamin B'), ('PR_000017255', 'Vang-like protein 1', 110, 'vitamin B-6'), ('UBERON_0001913', 'milk', 137, 'milk'), ('CHEBI_33277', 'gamma-tocotrienol', 211, 'vitamins'), ('GO_0046903', 'secretion', 229, 'secreted'), ('UBERON_0001913', 'milk', 243, 'milk'), ('CHEBI_27300', 'vitamin D', 376, 'vitamin B'), ('PR_000017255', 'Vang-like protein 1', 376, 'vitamin B-6'), ('GO_0007631', 'feeding behavior', 404, 'feeding'), ('GO_0007631', 'feeding behavior', 467, 'feeding')]
S126-PMC5371920	PMC5371920	3/2017	S126-PMC5371920	['the RECENT uk-based TRIAL of Vitamin D supplementation—maternal Vitamin D osteoporosis study (mavidos), tested the HYPOTHESIS that maternal Antenatal Vitamin D supplementation LEADS to increased offspring bone Mineral content.']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 20), ('INCOMPLETE_EVIDENCE', 115), ('SUPERFICIAL_RELATIONSHIP', 176)]	4	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 64, 'Vitamin D'), ('GO_0007567', 'parturition', 140, 'antenatal'), ('CHEBI_27300', 'vitamin D', 150, 'vitamin D'), ('CHEBI_46662', 'mineral', 210, 'mineral')]
S131-PMC5371920	PMC5371920	3/2017	S131-PMC5371920	['thus, in a pre-specified analysis, amongst winter births, neonates Delivered to mothers allocated Vitamin D supplements had more than 0.5 sd greater whole body bmc than did neonates Born to placebo mothers ( p = 0.004); the INTERACTION between season and treatment was also statistically significant ( p = 0.04) [44].']	[('SUPERFICIAL_RELATIONSHIP', 224)]	1	[('GO_0007567', 'parturition', 67, 'delivered'), ('CHEBI_27300', 'vitamin D', 98, 'vitamin D'), ('GO_0007567', 'parturition', 182, 'born')]
S135-PMC5371920	PMC5371920	3/2017	S135-PMC5371920	['IN CONTRAST, 25(Oh)D concentrations in mothers allocated to Vitamin D supplementation rose REGARDLESS OF season of Delivery.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 91)]	2	[('CHEBI_71657', 'versiconol acetate', 13, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 19, 'D'), ('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('GO_0007567', 'parturition', 115, 'delivery')]
S137-PMC5371920	PMC5371920	3/2017	S137-PMC5371920	['Vitamin D supplementation APPEARED SAFE; THESE FINDINGS SUPPORT current RECOMMENDATIONS in uk and elsewhere, and MAY SUGGEST the basis for more stratified approaches to Vitamin D supplementation in Pregnancy.']	[('ANOMALY_CURIOUS_FINDING', 26), ('IMPORTANT_CONSIDERATION', 35), ('INCOMPLETE_EVIDENCE', 41), ('INCOMPLETE_EVIDENCE', 56), ('FUTURE_WORK', 72), ('INCOMPLETE_EVIDENCE', 113), ('INCOMPLETE_EVIDENCE', 117)]	7	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin D'), ('GO_0007565', 'female pregnancy', 198, 'pregnancy')]
S0-PMC5372327	PMC5372327	3/2017	S0-PMC5372327	['towards EVIDENCE-BASED Vitamin D supplementation in infants: Vitamin D intervention in infants (vidi) — study design and methods of a randomised controlled double-blinded intervention study\n\nabstract\n\nbackground\nVitamin D is IMPORTANT for bone mass accrual during growth.']	[('INCOMPLETE_EVIDENCE', 8), ('IMPORTANT_CONSIDERATION', 225)]	2	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 212, 'Vitamin D')]
S2-PMC5372327	PMC5372327	3/2017	S2-PMC5372327	['MANY countries apply Vitamin D supplementation STRATEGIES in infants, but the guidelines are NOT BASED ON scientific EVIDENCE and AIM at PREVENTION of rickets.']	[('INCOMPLETE_EVIDENCE', 0), ('FUTURE_WORK', 47), ('INCOMPLETE_EVIDENCE', 93), ('FUTURE_WORK', 130), ('SUPERFICIAL_RELATIONSHIP', 137)]	5	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D')]
S3-PMC5372327	PMC5372327	3/2017	S3-PMC5372327	['it REMAINS UNCLEAR WHETHER the RECOMMENDED doses are sufficient for the wide array of OTHER EFFECTS of Vitamin D. the vidi trial performed in finland is the FIRST large randomised controlled study for evaluation of the EFFECTS of different Vitamin D supplemental doses in infancy on:\nbone strength\ninfections and immunity\nallergy, atopy and asthma\nCognitive development\nGenetic Regulation Of Mineral Homeostasis\n\nmethods/design\nvidi, a randomised controlled double-blinded single-centre intervention study is conducted in infants from the age of 2\xa0weeks to 24\xa0months.']	[('FULL_UNKNOWN', 3), ('INCOMPLETE_EVIDENCE', 3), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 19), ('FUTURE_WORK', 31), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 86), ('SUPERFICIAL_RELATIONSHIP', 92), ('INCOMPLETE_EVIDENCE', 157), ('SUPERFICIAL_RELATIONSHIP', 219)]	8	[('CHEBI_27300', 'vitamin D', 103, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 240, 'vitamin D'), ('GO_0050890', 'cognition', 348, 'cognitive'), ('SO_0000704', 'gene', 370, 'genetic'), ('GO_1900046', 'regulation of hemostasis', 378, 'regulation of ... homeostasis'), ('CHEBI_46662', 'mineral', 392, 'mineral')]
S6-PMC5372327	PMC5372327	3/2017	S6-PMC5372327	['discussion\nthe study ENABLES evaluation of short and long term EFFECTS of supplemental Vitamin D on growth, Immune functions and Skeletal and developmental parameters in infants, and the EFFECTS of Genetic FACTORS therein.']	[('PROBABLE_UNDERSTANDING', 21), ('SUPERFICIAL_RELATIONSHIP', 63), ('SUPERFICIAL_RELATIONSHIP', 187), ('SUPERFICIAL_RELATIONSHIP', 206)]	4	[('CHEBI_27300', 'vitamin D', 87, 'vitamin D'), ('UBERON_0002405', 'immune system', 108, 'immune'), ('UBERON_0004288', 'skeleton', 129, 'skeletal'), ('SO_0000704', 'gene', 198, 'genetic')]
S7-PMC5372327	PMC5372327	3/2017	S7-PMC5372327	['the results enable institution of EVIDENCE-BASED guidelines for Vitamin D supplementation in infancy.']	[('INCOMPLETE_EVIDENCE', 34)]	1	[('CHEBI_27300', 'vitamin D', 64, 'vitamin D')]
S30-PMC5372327	PMC5372327	3/2017	S30-PMC5372327	['in healthy children aged 8–17 years with S-25-Ohd levels above 50\xa0nmol/l, no effect of Vitamin D supplementation on bmd is seen [14], and the RELATIONSHIP between bmd and s-25-Ohd is INCONSISTENT in infants and young children [15].']	[('SUPERFICIAL_RELATIONSHIP', 142), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 183)]	2	[('CHEBI_86929', 'S b G-5,5-G b S A CH2', 41, 'S-25-OHD'), ('PR_000000036', 'BMP receptor type-1B', 42, '-25'), ('CHEBI_27300', 'vitamin D', 87, 'vitamin D'), ('CHEBI_72765', 'verruculogen', 173, '25-OHD')]
S32-PMC5372327	PMC5372327	3/2017	S32-PMC5372327	['in Vitamin D deficient children, Vitamin D supplementation improved growth velocity and PREVENTED stunted growth [18,19].']	[('SUPERFICIAL_RELATIONSHIP', 88)]	1	[('CHEBI_27300', 'vitamin D', 3, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 33, 'vitamin D')]
S48-PMC5372327	PMC5372327	3/2017	S48-PMC5372327	['HOWEVER, findings have NOT been CONSISTENT [39] and RECENT STUDIES on Prenatal Vitamin D supplementation have not demonstrated an EFFECT on wheezing at 3\xa0years of age [40,41].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 23), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 32), ('INCOMPLETE_EVIDENCE', 52), ('SUPERFICIAL_RELATIONSHIP', 130)]	5	[('GO_0007565', 'female pregnancy', 70, 'prenatal'), ('CHEBI_27300', 'vitamin D', 79, 'vitamin D')]
S52-PMC5372327	PMC5372327	3/2017	S52-PMC5372327	['Vitamin D trials are RARE and they have not been able to SUPPORT beneficial EFFECTS of Vitamin D supplementation on Cognitive functions among Adults [47,48].']	[('INCOMPLETE_EVIDENCE', 21), ('INCOMPLETE_EVIDENCE', 57), ('SUPERFICIAL_RELATIONSHIP', 76)]	3	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 87, 'vitamin D'), ('GO_0050890', 'cognition', 116, 'cognitive'), ('UBERON_0007023', 'adult organism', 142, 'adults')]
S58-PMC5372327	PMC5372327	3/2017	S58-PMC5372327	['Genetic Regulation Of Mineral Homeostasis\nS-25-Ohd concentration has high heritability (28–80%), which EXPLAINS differences in responses to Vitamin D supplementation [53].']	[('PROBABLE_UNDERSTANDING', 103)]	1	[('SO_0000704', 'gene', 0, 'Genetic'), ('GO_1900046', 'regulation of hemostasis', 8, 'regulation of ... homeostasis'), ('CHEBI_46662', 'mineral', 22, 'mineral'), ('CHEBI_86929', 'S b G-5,5-G b S A CH2', 42, 'S-25-OHD'), ('CHEBI_27300', 'vitamin D', 140, 'vitamin D')]
S64-PMC5372327	PMC5372327	3/2017	S64-PMC5372327	['vdr polymorphisms together with Vitamin D supplementation AFFECT bone Mineral accrual SUGGESTING that Vitamin D supplementation COULD BE used to change the developmental trajectory and induce phenotype with lowered risk for chronic disease or disorder [59,60].']	[('SUPERFICIAL_RELATIONSHIP', 58), ('INCOMPLETE_EVIDENCE', 86), ('INCOMPLETE_EVIDENCE', 128)]	3	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('CHEBI_46662', 'mineral', 70, 'mineral'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin D')]
S66-PMC5372327	PMC5372327	3/2017	S66-PMC5372327	['overall AIMS and research questions\nthe AIM of the STUDY is TO INVESTIGATE long-term health benefits of early Vitamin D supplementation with a dose ensuring effective concentration of 25-Ohd.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 8), ('QUESTION_ANSWERED_BY_THIS_WORK', 40), ('QUESTION_ANSWERED_BY_THIS_WORK', 51), ('QUESTION_ANSWERED_BY_THIS_WORK', 60)]	4	[('CHEBI_27300', 'vitamin D', 110, 'vitamin D'), ('CHEBI_72765', 'verruculogen', 184, '25-OHD')]
S68-PMC5372327	PMC5372327	3/2017	S68-PMC5372327	['we HYPOTHESISE that a higher Vitamin D supplementation to infants between 2\xa0weeks and 24\xa0months of age will increase bone strength and decrease the frequency of infections.']	[('INCOMPLETE_EVIDENCE', 3), ('QUESTION_ANSWERED_BY_THIS_WORK', 3)]	2	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D')]
S122-PMC5372327	PMC5372327	3/2017	S122-PMC5372327	['discussion\nTO THE BEST OF OUR KNOWLEDGE, THIS is the largest and MOST COMPREHENSIVE randomised intervention STUDY TO ASSESS the EFFECTS of Vitamin D supplementation on Skeletal and extra Skeletal outcomes in infants.']	[('PROBABLE_UNDERSTANDING', 11), ('QUESTION_ANSWERED_BY_THIS_WORK', 41), ('PROBABLE_UNDERSTANDING', 65), ('QUESTION_ANSWERED_BY_THIS_WORK', 108), ('QUESTION_ANSWERED_BY_THIS_WORK', 114), ('SUPERFICIAL_RELATIONSHIP', 128)]	6	[('CHEBI_27300', 'vitamin D', 139, 'vitamin D'), ('UBERON_0004288', 'skeleton', 168, 'skeletal'), ('UBERON_0004288', 'skeleton', 187, 'skeletal')]
S123-PMC5372327	PMC5372327	3/2017	S123-PMC5372327	['to date, epidemiological studies and randomised intervention trials have DEMONSTRATED CONFLICTING results on, for example, the EFFECT of Vitamin D supplementation on childhood infections and on Neurocognitive functioning.']	[('INCOMPLETE_EVIDENCE', 73), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 86), ('SUPERFICIAL_RELATIONSHIP', 127)]	3	[('CHEBI_27300', 'vitamin D', 137, 'vitamin D'), ('GO_0050905', 'neuromuscular process', 194, 'neurocognitive')]
S136-PMC5372327	PMC5372327	3/2017	S136-PMC5372327	['in addition, the study is designed to have control over the most common sources of Vitamin D.\nIF the results from the vidi-trial CONFIRM the connections between the increased dose of Vitamin D and the primary outcomes, the health benefits gained by a population-wide supplementation with higher Vitamin D dose — a simple and low-cost INTERVENTION — are obvious.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 94), ('INCOMPLETE_EVIDENCE', 129), ('SUPERFICIAL_RELATIONSHIP', 334)]	3	[('CHEBI_27300', 'vitamin D', 83, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 183, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 295, 'vitamin D')]
S177-PMC5384134	PMC5384134	4/2017	S177-PMC5384134	['Vitamin A and zinc supplementation) are OFTEN prioritised over behaviour-change and health promotion-based approaches (e.g.']	[('PROBABLE_UNDERSTANDING', 40)]	1	[('CHEBI_27300', 'vitamin D', 0, 'vitamin A')]
S7-PMC5385921	PMC5385921	4/2017	S7-PMC5385921	['because Gestational Vitamin D deficiency is readily preventable with SAFE, inexpensive and readily available supplementation, this RISK FACTOR WARRANTS CLOSER SCRUTINY.']	[('IMPORTANT_CONSIDERATION', 69), ('SUPERFICIAL_RELATIONSHIP', 131), ('FUTURE_WORK', 143), ('FUTURE_WORK', 152)]	4	[('GO_0007565', 'female pregnancy', 8, 'gestational'), ('CHEBI_27300', 'vitamin D', 20, 'vitamin D')]
S142-PMC5385921	PMC5385921	4/2017	S142-PMC5385921	['it is FEASIBLE that a SAFE, inexpensive and PUBLICALLY acceptable Vitamin D supplementation in AT-RISK groups MAY reduce the PREVALENCE of this RISK FACTOR.']	[('PROBABLE_UNDERSTANDING', 6), ('IMPORTANT_CONSIDERATION', 22), ('IMPORTANT_CONSIDERATION', 44), ('IMPORTANT_CONSIDERATION', 95), ('INCOMPLETE_EVIDENCE', 110), ('IMPORTANT_CONSIDERATION', 125), ('SUPERFICIAL_RELATIONSHIP', 144)]	7	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D')]
S143-PMC5385921	PMC5385921	4/2017	S143-PMC5385921	['just as Prenatal Folate supplementation has reduced the incidence of spina bifida, we SPECULATE that Prenatal Vitamin D supplementation MAY reduce the incidence of asd.']	[('INCOMPLETE_EVIDENCE', 86), ('INCOMPLETE_EVIDENCE', 136)]	2	[('GO_0007565', 'female pregnancy', 8, 'prenatal'), ('CHEBI_30863', '5-azaorotic acid', 17, 'folate'), ('GO_0007565', 'female pregnancy', 101, 'prenatal'), ('CHEBI_27300', 'vitamin D', 110, 'vitamin D')]
S5-PMC5405075	PMC5405075	4/2017	S5-PMC5405075	['ALTHOUGH, the results of rcts SHOWED a POTENTIAL ASSOCIATION with asthma-RELATED phenotypes RATHER than asthma per se , the low toxicity of Vitamin D supplements make it TEMPTING to SPECULATE that Pregnant women at a high RISK of obtaining a child with asthma MAY BE benefited, ESPECIALLY if they are Vitamin D deficient.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 30), ('INCOMPLETE_EVIDENCE', 39), ('SUPERFICIAL_RELATIONSHIP', 49), ('SUPERFICIAL_RELATIONSHIP', 73), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 92), ('INCOMPLETE_EVIDENCE', 170), ('INCOMPLETE_EVIDENCE', 182), ('IMPORTANT_CONSIDERATION', 222), ('INCOMPLETE_EVIDENCE', 260), ('ANOMALY_CURIOUS_FINDING', 278)]	12	[('CHEBI_27300', 'vitamin D', 140, 'vitamin D'), ('GO_0007565', 'female pregnancy', 197, 'pregnant'), ('CHEBI_27300', 'vitamin D', 301, 'vitamin D')]
S14-PMC5405075	PMC5405075	4/2017	S14-PMC5405075	['in THIS mini-REVIEW ARTICLE, we AIM to present the CURRENT KNOWLEDGE as it EMERGES from studies FOCUSED on the IMPACT of maternal Vitamin D status and Vitamin d supplementation on the Development Of Asthma in early childhood.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('QUESTION_ANSWERED_BY_THIS_WORK', 13), ('QUESTION_ANSWERED_BY_THIS_WORK', 32), ('INCOMPLETE_EVIDENCE', 51), ('INCOMPLETE_EVIDENCE', 75), ('QUESTION_ANSWERED_BY_THIS_WORK', 96), ('SUPERFICIAL_RELATIONSHIP', 111)]	7	[('CHEBI_27300', 'vitamin D', 130, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 151, 'vitamin'), ('GO_0009602', 'detection of symbiont', 184, 'development of asthma')]
S58-PMC5405075	PMC5405075	4/2017	S58-PMC5405075	['caption (table-wrap): table 1\n\nrandomized control trials on Vitamin D supplementation during Pregnancy and asthma/wheezing .referencecountry and enrollment periodstudy populationintervention armsnumber/age of children at outcome assessmentintake of intervention from/untileffect on median Vitamin D levels (ng/ml)outcomes of interestmain FINDINGSGOLDRING et al.']	[('INCOMPLETE_EVIDENCE', 338)]	1	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('GO_0007565', 'female pregnancy', 93, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 289, 'vitamin D')]
S89-PMC5405075	PMC5405075	4/2017	S89-PMC5405075	['moreover, it HAS BEEN PROPOSED that studies SHOULD focus on Vitamin D status in early Pregnancy and supplementary administration SHOULD BE initiated from the first Trimester of Gestation in order to observe the OPTIMAL EFFECT on RISK of childhood asthma, THOUGH EVIDENCE from chawes et al.’s clinical trial DID NOT CONFIRM this NOTION (75).']	[('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 22), ('FUTURE_WORK', 44), ('FUTURE_WORK', 129), ('IMPORTANT_CONSIDERATION', 211), ('SUPERFICIAL_RELATIONSHIP', 219), ('IMPORTANT_CONSIDERATION', 229), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 255), ('ANOMALY_CURIOUS_FINDING', 255), ('INCOMPLETE_EVIDENCE', 262), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 307), ('INCOMPLETE_EVIDENCE', 328)]	12	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('GO_0007565', 'female pregnancy', 86, 'pregnancy'), ('GO_0009294', 'DNA mediated transformation', 164, 'trimester'), ('GO_0007565', 'female pregnancy', 177, 'gestation')]
S102-PMC5405075	PMC5405075	4/2017	S102-PMC5405075	['HOWEVER, given the RATHER low toxicity of such a Supplement, Pregnant women at a high risk of obtaining a child with asthma MAY BE benefited, especially IF they are Vitamin D deficient.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 19), ('INCOMPLETE_EVIDENCE', 124), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 153)]	4	[('CHEBI_16158', 'steroid sulfate', 49, 'supplement'), ('GO_0007565', 'female pregnancy', 61, 'pregnant'), ('CHEBI_27300', 'vitamin D', 165, 'vitamin D')]
S64-PMC5410409	PMC5410409	4/2017	S64-PMC5410409	['the CONFLICTING results MAY reflect Genetic variability in the general population in the Metabolism and allergy preventive EFFECTS of Vitamin D supplementation in the child [67].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 4), ('INCOMPLETE_EVIDENCE', 24), ('SUPERFICIAL_RELATIONSHIP', 123)]	3	[('SO_0000704', 'gene', 36, 'genetic'), ('GO_0008152', 'metabolic process', 89, 'metabolism'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin D')]
S192-PMC5410409	PMC5410409	4/2017	S192-PMC5410409	['there are no rcts done on Vitamin D supplementation in allergy PREVENTION.']	[('SUPERFICIAL_RELATIONSHIP', 63)]	1	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D')]
S193-PMC5410409	PMC5410409	4/2017	S193-PMC5410409	['also, the 2 cohort studies on Vitamin D supplementation have CONFLICTING results.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 61)]	1	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D')]
S194-PMC5410409	PMC5410409	4/2017	S194-PMC5410409	['in 1 large Birth cohort STUDY, regular Vitamin D supplementation was ASSOCIATED with the risk of developing atopy (odds ratio [or], 1.66) and allergic rhinitis (or, 1.46) than those who received it irregularly or none at all [75].']	[('INCOMPLETE_EVIDENCE', 3), ('SUPERFICIAL_RELATIONSHIP', 69)]	2	[('GO_0007567', 'parturition', 11, 'birth'), ('CHEBI_27300', 'vitamin D', 39, 'vitamin D')]
S112-PMC5414300	PMC5414300	5/2017	S112-PMC5414300	['children aged 6–59\xa0months receive Vitamin A supplements during biannual national Vitamin A campaigns, ALTHOUGH coverage is unsatisfactory [11].']	[('ANOMALY_CURIOUS_FINDING', 102)]	1	[('CHEBI_27300', 'vitamin D', 34, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 81, 'vitamin A')]
S0-PMC5418719	PMC5418719	5/2017	S0-PMC5418719	['efficacy and SAFETY of early supplementation with 800\xa0iu of Vitamin D in very preterm infants followed by underlying levels of Vitamin D at Birth\n\nabstract\n\nbackground\nto determine the EFFICACY and SAFETY of early supplementation with 800\xa0iu of Vitamin D in very low Birth weight (vlbw) infants.']	[('IMPORTANT_CONSIDERATION', 13), ('SUPERFICIAL_RELATIONSHIP', 185), ('IMPORTANT_CONSIDERATION', 198)]	3	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 127, 'vitamin D'), ('GO_0007567', 'parturition', 140, 'birth'), ('CHEBI_27300', 'vitamin D', 245, 'vitamin D'), ('GO_0007567', 'parturition', 267, 'birth')]
S6-PMC5418719	PMC5418719	5/2017	S6-PMC5418719	['conclusion\nCONSIDERING the EFFICACY and SAFETY of Vitamin D supplementation in THIS STUDY, Vitamin D intake of 800\xa0iu/day MAY enhance Vitamin D status during early hospitalization in vlbw infants with 25 Ohd concentrations\u2009<\u200910\xa0ng/ml at Birth.']	[('PROBABLE_UNDERSTANDING', 11), ('SUPERFICIAL_RELATIONSHIP', 27), ('IMPORTANT_CONSIDERATION', 40), ('QUESTION_ANSWERED_BY_THIS_WORK', 79), ('INCOMPLETE_EVIDENCE', 122)]	5	"[('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin D'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 201, '25 OHD'), ('GO_0007567', 'parturition', 237, 'birth')]"
S13-PMC5418719	PMC5418719	5/2017	S13-PMC5418719	['the european GUIDELINE on daily Vitamin D supplementation RECOMMEND 800 to 1000\xa0iu/day for preterm infants, WHILE western countries RECOMMEND 400\xa0iu/day [3].']	[('PROBABLE_UNDERSTANDING', 13), ('FUTURE_WORK', 58), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 108), ('FUTURE_WORK', 132)]	4	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D')]
S19-PMC5418719	PMC5418719	5/2017	S19-PMC5418719	['the AIM of THIS STUDY was TO DETERMINE WHETHER daily Vitamin D supplementation with a high dose of 800\xa0iu is SAFE and EFFECTIVE to increase the proportion of vlbw infants with 25(Oh)D\u2009>\u200930\xa0ng/ml, from 2\xa0weeks of age until hospital discharge.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 11), ('QUESTION_ANSWERED_BY_THIS_WORK', 26), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 39), ('IMPORTANT_CONSIDERATION', 109), ('SUPERFICIAL_RELATIONSHIP', 118)]	6	[('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 176, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 176, '25(OH)D')]
S33-PMC5418719	PMC5418719	5/2017	S33-PMC5418719	['we determined the efficacy and SAFETY of early supplementation with 800\xa0iu Vitamin D.\n\noutcome measures\nthe primary outcome measured the proportion of Vitamin D sufficiency (>30\xa0ng/ml) at 32 and 36\xa0weeks pma and was analyzed by Cord Blood 25(Oh)D levels (<10\xa0ng/ml versus\u2009≥\u200910\xa0ng/ml) at Birth.']	[('IMPORTANT_CONSIDERATION', 31)]	1	[('CHEBI_27300', 'vitamin D', 75, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 151, 'vitamin D'), ('UBERON_0009472', 'axilla', 228, 'cord blood'), ('CHEBI_71657', 'versiconol acetate', 239, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 239, '25(OH)D'), ('GO_0007567', 'parturition', 287, 'birth')]
S89-PMC5418719	PMC5418719	5/2017	S89-PMC5418719	['discussion\nTHIS PROSPECTIVE STUDY was PLANNED TO DETERMINE WHETHER 800\xa0iu Vitamin D supplementation from 2\xa0weeks of age is SAFE and EFFECTIVE to reach sufficient Vitamin D levels at 36\xa0weeks pma in vlbw infants.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 11), ('QUESTION_ANSWERED_BY_THIS_WORK', 38), ('QUESTION_ANSWERED_BY_THIS_WORK', 46), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 59), ('IMPORTANT_CONSIDERATION', 123), ('SUPERFICIAL_RELATIONSHIP', 132)]	6	[('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 162, 'vitamin D')]
S90-PMC5418719	PMC5418719	5/2017	S90-PMC5418719	['among vlbw infants with 25(Oh)D concentrations\u2009<\u200910\xa0ng/ml at Birth, none had an excess level of 25(Oh)D >80\xa0ng/ml after 800\xa0iu Vitamin D supplementation, ALTHOUGH 35% of infants with Vitamin D deficiency from Birth were still Vitamin D insufficient at 36\xa0weeks pma.']	[('ANOMALY_CURIOUS_FINDING', 154)]	1	[('CHEBI_71657', 'versiconol acetate', 24, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 30, 'D'), ('GO_0007567', 'parturition', 61, 'birth'), ('CHEBI_71657', 'versiconol acetate', 96, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 102, 'D'), ('CHEBI_27300', 'vitamin D', 127, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 183, 'vitamin D'), ('GO_0007567', 'parturition', 209, 'birth'), ('CHEBI_27300', 'vitamin D', 226, 'vitamin D')]
S91-PMC5418719	PMC5418719	5/2017	S91-PMC5418719	['the response to Vitamin D supplementation was DEPENDENT on the baseline Vitamin D stores at Birth.']	[('SUPERFICIAL_RELATIONSHIP', 46)]	1	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 72, 'vitamin D'), ('GO_0007567', 'parturition', 92, 'birth')]
S101-PMC5418719	PMC5418719	5/2017	S101-PMC5418719	['preterm infants with radiologic evidence of rickets or high alkaline phosphatase (>800\xa0iu/l) are GENERALLY given the upper intake total of 800\xa0iu/day of Vitamin D. DESPITE Vitamin D supplementation, it is DIFFICULT to maintain the RECOMMENDED daily Vitamin D intake from dietary in preterm infants, and there are FEW EVIDENCE-based data to support Vitamin D supplementation to meet a desired Serum 25(Oh)D ACCORDING to Vitamin D status at Birth in preterm infants.']	[('PROBABLE_UNDERSTANDING', 97), ('ANOMALY_CURIOUS_FINDING', 164), ('DIFFICULT_TASK', 205), ('FUTURE_WORK', 231), ('INCOMPLETE_EVIDENCE', 313), ('SUPERFICIAL_RELATIONSHIP', 406)]	6	[('CHEBI_27300', 'vitamin D', 153, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 172, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 249, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 348, 'vitamin D'), ('UBERON_0001977', 'blood serum', 392, 'serum'), ('CHEBI_71657', 'versiconol acetate', 398, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 401, 'OH ... D'), ('CHEBI_27300', 'vitamin D', 419, 'vitamin D'), ('GO_0007567', 'parturition', 439, 'birth')]
S103-PMC5418719	PMC5418719	5/2017	S103-PMC5418719	['CONSISTENT with PREVIOUS reports about a dose-response EFFECT of Vitamin D supplementation [2,23], we OBSERVED that early supplementation with 800\xa0iu Vitamin D safely achieved an 88% PROBABILITY of Vitamin D sufficiency at 36 pma in the MAJORITY of infants with Cord-Blood levels of 25(Oh)D\u2009≥\u200910\xa0ng/ml.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 16), ('SUPERFICIAL_RELATIONSHIP', 55), ('INCOMPLETE_EVIDENCE', 102), ('PROBABLE_UNDERSTANDING', 183), ('PROBABLE_UNDERSTANDING', 237)]	6	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 150, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 198, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 262, 'cord'), ('UBERON_0000178', 'blood', 267, 'blood'), ('CHEBI_71657', 'versiconol acetate', 283, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 283, '25(OH ... D')]
S104-PMC5418719	PMC5418719	5/2017	S104-PMC5418719	['ALTHOUGH a number of Vitamin D deficiency was significantly lower after supplementation than before supplementation in the PRESENT STUDY, supplementation with 800\xa0iu MIGHT not be sufficient to achieve optimal Vitamin D levels in preterm infants with UNDERLYING level of Vitamin D deficiency from Birth.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 123), ('INCOMPLETE_EVIDENCE', 166), ('SUPERFICIAL_RELATIONSHIP', 250)]	5	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 209, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 270, 'vitamin D'), ('GO_0007567', 'parturition', 296, 'birth')]
S105-PMC5418719	PMC5418719	5/2017	S105-PMC5418719	['the DIFFERENT response to Vitamin D supplementation COULD BE EXPLAINED by vdr Gene polymorphism INVOLVED in Vitamin D Receptor, which results in Vitamin D deficiency at 36 pma in SOME babies after supplementation [24].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 4), ('INCOMPLETE_EVIDENCE', 52), ('ANOMALY_CURIOUS_FINDING', 58), ('PROBABLE_UNDERSTANDING', 61), ('SUPERFICIAL_RELATIONSHIP', 96), ('INCOMPLETE_EVIDENCE', 179)]	6	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('SO_0000704', 'gene', 78, 'gene'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin D'), ('PR_000001683', 'vasopressin V2 receptor', 108, 'vitamin D receptor'), ('CHEBI_27300', 'vitamin D', 145, 'vitamin D')]
S107-PMC5418719	PMC5418719	5/2017	S107-PMC5418719	['HOWEVER, RECOMMENDED oral Vitamin D supplementation to attain adequate Serum 25(Oh)D concentrations has not been recognized in vlbw infants with underlying level of Vitamin D deficiency from Birth.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('FUTURE_WORK', 9)]	2	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('UBERON_0001977', 'blood serum', 71, 'serum'), ('CHEBI_71657', 'versiconol acetate', 77, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 83, 'D'), ('CHEBI_27300', 'vitamin D', 165, 'vitamin D'), ('GO_0007567', 'parturition', 191, 'birth')]
S109-PMC5418719	PMC5418719	5/2017	S109-PMC5418719	['[23] reported that daily supplementation of Vitamin D in doses of 800\xa0iu compared with 400\xa0iu APPEARS to reduce the prevalence of Vitamin D deficiency at 40\xa0weeks pma in preterm infants of 28 to 34\xa0weeks Gestation.']	[('ANOMALY_CURIOUS_FINDING', 94)]	1	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D'), ('GO_0007565', 'female pregnancy', 204, 'gestation')]
S110-PMC5418719	PMC5418719	5/2017	S110-PMC5418719	['a randomized controlled trial in 100 infants with Gestational age between 23 and 27\xa0weeks DEMONSTRATED that the 800\xa0iu/d dose of Vitamin D supplementation PREVENTED Vitamin D deficiency, without toxicity, with concentrations above the desired 25(Oh)D range of 20–60\xa0ng/ml in the majority of infants on day 28 [2].']	[('INCOMPLETE_EVIDENCE', 90), ('SUPERFICIAL_RELATIONSHIP', 155)]	2	[('GO_0007565', 'female pregnancy', 50, 'gestational'), ('CHEBI_27300', 'vitamin D', 129, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 165, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 243, '25(OH)D')]
S132-PMC5418719	PMC5418719	5/2017	S132-PMC5418719	['during Vitamin D supplementation, preterm infants REQUIRE close monitoring of Serum calcium, Phosphorus, Urinary Calcium Excretion, Urinary P Excretion and Renal Calcification, frequently detected by ultrasonography.']	[('IMPORTANT_CONSIDERATION', 50)]	1	[('CHEBI_27300', 'vitamin D', 7, 'vitamin D'), ('UBERON_0001977', 'blood serum', 78, 'serum'), ('CHEBI_35885', 'secondary phosphine', 93, 'phosphorus'), ('GO_0060073', 'micturition', 105, 'urinary'), ('UBERON_0001088', 'urine', 105, 'urinary'), ('GO_0036161', 'calcitonin secretion', 113, 'calcium excretion'), ('GO_0060073', 'micturition', 132, 'urinary'), ('UBERON_0001088', 'urine', 132, 'urinary'), ('GO_0007568', 'aging', 140, 'P excretion'), ('UBERON_0002113', 'kidney', 156, 'renal'), ('GO_0051301', 'cell division', 162, 'calcification')]
S137-PMC5418719	PMC5418719	5/2017	S137-PMC5418719	['conclusion\nTHIS STUDY FOCUSED on SAFETY and response to the early initiation of oral Vitamin D supplementation followed by underlying level of Vitamin D at Birth in vlbw infants.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 11), ('QUESTION_ANSWERED_BY_THIS_WORK', 22), ('IMPORTANT_CONSIDERATION', 33)]	3	[('CHEBI_27300', 'vitamin D', 85, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 143, 'vitamin D'), ('GO_0007567', 'parturition', 156, 'birth')]
S138-PMC5418719	PMC5418719	5/2017	S138-PMC5418719	['CONSIDERING the EFFICACY and SAFETY of Vitamin D supplementation in THIS STUDY, Vitamin D intake of 800\xa0iu per day MAY optimize Vitamin D levels during early hospitalization in vlbw infants.']	[('IMPORTANT_CONSIDERATION', 0), ('INCOMPLETE_EVIDENCE', 0), ('PROBABLE_UNDERSTANDING', 0), ('SUPERFICIAL_RELATIONSHIP', 16), ('IMPORTANT_CONSIDERATION', 29), ('QUESTION_ANSWERED_BY_THIS_WORK', 68), ('INCOMPLETE_EVIDENCE', 115)]	7	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 128, 'vitamin D')]
S140-PMC5418719	PMC5418719	5/2017	S140-PMC5418719	['longitudinal extension of this study and randomized controlled STUDIES ARE REQUIRED to explore the efficacy and clinical benefits of daily supplementation of Vitamin D in dose of 800\xa0iu in a larger cohort.']	[('FUTURE_WORK', 63), ('FUTURE_WORK', 71), ('IMPORTANT_CONSIDERATION', 75)]	3	[('CHEBI_27300', 'vitamin D', 158, 'vitamin D')]
S14-PMC5426325	PMC5426325	4/2017	S14-PMC5426325	['CONSEQUENTLY, the Vitamin D status will then depend more on diet, supplementation and/or fortification alone.']	[('PROBABLE_UNDERSTANDING', 0)]	1	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D')]
S27-PMC5426325	PMC5426325	4/2017	S27-PMC5426325	['we DID NOT identify OTHER abrupt societal changes during 1983–1988 that POTENTIALLY COULD INFLUENCE our results, neither in relation to fortification practices in other Food products for Consumption(31,32), nor in relation to Margarine intake in the danish population(33)or in relation to national RECOMMENDATIONS for Vitamin D supplementation to Pregnant women or infants.']	[('INCOMPLETE_EVIDENCE', 3), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 20), ('INCOMPLETE_EVIDENCE', 72), ('INCOMPLETE_EVIDENCE', 84), ('SUPERFICIAL_RELATIONSHIP', 90), ('FUTURE_WORK', 298)]	6	[('CHEBI_33290', 'food', 169, 'food'), ('GO_0007631', 'feeding behavior', 187, 'consumption'), ('CHEBI_6784', 'mestranol', 226, 'margarine'), ('CHEBI_27300', 'vitamin D', 318, 'vitamin D'), ('GO_0007565', 'female pregnancy', 347, 'pregnant')]
S120-PMC5426325	PMC5426325	4/2017	S120-PMC5426325	['also, in the danish national Birth cohort, mid-Pregnancy maternal supplementation with >10 µg Vitamin D/d was ASSOCIATED with a 30 % higher risk of offspring Forearm fractures(37).']	[('SUPERFICIAL_RELATIONSHIP', 110)]	1	[('GO_0007567', 'parturition', 29, 'Birth'), ('GO_0007565', 'female pregnancy', 47, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin D'), ('UBERON_0002386', 'forelimb zeugopod', 158, 'forearm')]
S143-PMC5426325	PMC5426325	4/2017	S143-PMC5426325	['intervention studies with supplementation of Vitamin D in Pregnancy are currently ONGOING(9,55).']	[('IMPORTANT_CONSIDERATION', 82)]	1	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('GO_0007565', 'female pregnancy', 58, 'pregnancy')]
S30-PMC5436890	PMC5436890	5/2017	S30-PMC5436890	['the KEY STRATEGIES of the nns includes growth monitoring and promotion, ENCOURAGING behaviour change to improve good nutritional practices, Vitamin A supplementation, zinc supplementation during treatment of diarrhoea and Iron/Folic Acid supplementation for Pregnant women.']	[('IMPORTANT_CONSIDERATION', 4), ('FUTURE_WORK', 8), ('FUTURE_WORK', 72)]	3	[('CHEBI_27300', 'vitamin D', 140, 'vitamin A'), ('CHEBI_24870', 'ion', 222, 'iron'), ('CHEBI_30751', 'formic acid', 227, 'folic acid'), ('GO_0007565', 'female pregnancy', 258, 'pregnant')]
S131-PMC5445675	PMC5445675	6/2017	S131-PMC5445675	['the general Food basket caloric content was reduced in 2004, BUT certain Micronutrients via mff increased, PARTICULARLY Vitamin A, Thiamin, riboflavin, Vitamin C, iron, and calcium (supplemental table 1).']	[('ANOMALY_CURIOUS_FINDING', 61), ('ANOMALY_CURIOUS_FINDING', 107)]	2	[('CHEBI_33290', 'food', 12, 'food'), ('CHEBI_33839', 'macromolecule', 73, 'micronutrients'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin A'), ('CHEBI_26948', 'vitamin B1', 131, 'thiamin'), ('CHEBI_27300', 'vitamin D', 152, 'vitamin C')]
S135-PMC5445675	PMC5445675	6/2017	S135-PMC5445675	['the positive IMPACT on sga in 2004 was ASSOCIATED with significant increases (>50%) in Vitamin A, Thiamin, Nicotinamide, riboflavin, Vitamin C, iron, and Calcium, and a small reduction in Folic Acid (supplemental table 1).']	[('SUPERFICIAL_RELATIONSHIP', 13), ('SUPERFICIAL_RELATIONSHIP', 39)]	2	[('CHEBI_27300', 'vitamin D', 87, 'vitamin A'), ('CHEBI_26948', 'vitamin B1', 98, 'thiamin'), ('CHEBI_17154', 'nicotinamide', 107, 'nicotinamide'), ('CHEBI_27300', 'vitamin D', 133, 'vitamin C'), ('CHEBI_22313', 'alkaline earth metal atom', 154, 'calcium'), ('CHEBI_30751', 'formic acid', 188, 'folic acid')]
S27-PMC5474873	PMC5474873	6/2017	S27-PMC5474873	['mcgrath and colleagues REPORTED that “both low and high concentrations of neonatal Vitamin D were ASSOCIATED with INCREASED RISK of schizophrenia.” SIMILARLY, absence of supplementation with Vitamin d before the age of one was FOUND TO BE ASSOCIATED with later schizophrenia in males (19).']	[('INCOMPLETE_EVIDENCE', 23), ('SUPERFICIAL_RELATIONSHIP', 98), ('IMPORTANT_CONSIDERATION', 114), ('SUPERFICIAL_RELATIONSHIP', 148), ('ANOMALY_CURIOUS_FINDING', 227), ('SUPERFICIAL_RELATIONSHIP', 239)]	6	[('CHEBI_27300', 'vitamin D', 83, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 191, 'vitamin')]
S75-PMC5485024	PMC5485024	3/2017	S75-PMC5485024	['parental smoking, bmi status, or diet (Vitamin D, Omega‐3 Fatty Acids, Omega‐6 Fatty Acids or dietary supplements) at age 8 years DID NOT influence the OBSERVED or and were not included in the final model.']	[('INCOMPLETE_EVIDENCE', 130), ('INCOMPLETE_EVIDENCE', 152)]	2	"[('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('CHEBI_75908', ""5'-CTGC-3' dsDNA oligonucleotide"", 50, 'omega‐3 fatty acids'), ('CHEBI_75908', ""5'-CTGC-3' dsDNA oligonucleotide"", 71, 'omega‐6 fatty acids')]"
S108-PMC5485024	PMC5485024	3/2017	S108-PMC5485024	['after additional adjustment for dietary supplement use and dietary intakes of Omega‐3, Omega‐6 Fatty Acids and Vitamin D at 8 years of age similar results were OBSERVED (oradj0.70, 95% ci 0.55–0.90).']	[('INCOMPLETE_EVIDENCE', 160)]	1	[('CHEBI_30823', 'oleate', 78, 'omega'), ('CHEBI_37972', 'phosphorus-32 atom', 84, '3'), ('CHEBI_30823', 'oleate', 87, 'omega'), ('CHEBI_52026', 'amorpha-4,11-diene', 93, '6'), ('CHEBI_35366', 'fatty acid', 95, 'fatty acids'), ('CHEBI_27300', 'vitamin D', 111, 'vitamin D')]
S131-PMC5487839	PMC5487839	3/2016	S131-PMC5487839	['an increased risk of malformations events has NOT been OBSERVED in Humans (LIMITED DATA) [360]cvitamin dthe ROLE for Vitamin D supplementation in Pregnancy is CONTROVERSIAL, BUT there is NO EVIDENCE of a reduction in adverse Pregnancy outcomes (e.g., Preeclampsia, Stillbirth, neonatal death) [361] or improvement in bone Mineral content in children in studies in which supplementation was given INDEPENDENTLY from Blood levels [362].']	[('FULL_UNKNOWN', 46), ('INCOMPLETE_EVIDENCE', 75), ('SUPERFICIAL_RELATIONSHIP', 108), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 159), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 174), ('INCOMPLETE_EVIDENCE', 187), ('SUPERFICIAL_RELATIONSHIP', 396)]	7	[('NCBITaxon_9606', 'Homo sapiens', 67, 'humans'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin D'), ('GO_0007565', 'female pregnancy', 146, 'pregnancy'), ('GO_0007565', 'female pregnancy', 225, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 251, 'preeclampsia'), ('GO_0001966', 'thigmotaxis', 265, 'stillbirth'), ('CHEBI_46662', 'mineral', 322, 'mineral'), ('UBERON_0000178', 'blood', 415, 'blood')]
S17-PMC5489519	PMC5489519	6/2017	S17-PMC5489519	['evidently, randomized controlled clinical trials INDICATED the beneficial ROLE of maternal Vitamin D supplementation on the Vitamin D status of breastfed infants14,15.']	[('INCOMPLETE_EVIDENCE', 49), ('SUPERFICIAL_RELATIONSHIP', 74)]	2	[('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D')]
S89-PMC5489519	PMC5489519	6/2017	S89-PMC5489519	['Vitamin D supplementation of mothers results in Vitamin D sufficiency in Breast-Fed infants13, THUS POTENTIALLY Modulating the Immune signature of maternal Breast Milk to her recipient infant.']	[('PROBABLE_UNDERSTANDING', 95), ('INCOMPLETE_EVIDENCE', 100)]	2	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('UBERON_0000310', 'breast', 73, 'breast'), ('GO_0007631', 'feeding behavior', 80, 'fed'), ('GO_0065007', 'biological regulation', 112, 'modulating'), ('UBERON_0002405', 'immune system', 127, 'immune'), ('UBERON_0001348', 'brown adipose tissue', 156, 'breast milk')]
S108-PMC5489519	PMC5489519	6/2017	S108-PMC5489519	['also, these studies MAY have IMPLICATIONS regarding Vitamin D supplemention during Lactation.']	[('INCOMPLETE_EVIDENCE', 20), ('IMPORTANT_CONSIDERATION', 29)]	2	[('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('GO_0007595', 'lactation', 83, 'lactation')]
S73-PMC5510234	PMC5510234	7/2017	S73-PMC5510234	['this finding SUGGESTS then a LINK between Vitamin A deficiency and an INCREASED RISK of infant exposure to hiv during Vaginal Delivery.48,57later on, this was NOT CONFIRMED by other studies from the developped countries.61,62a cochrane review on Vitamin A supplementation and mtct of hiv was published in 2011, by wiysonge et al .']	[('INCOMPLETE_EVIDENCE', 13), ('SUPERFICIAL_RELATIONSHIP', 29), ('IMPORTANT_CONSIDERATION', 70), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 159)]	4	[('CHEBI_27300', 'vitamin D', 42, 'vitamin A'), ('UBERON_0001987', 'placenta', 118, 'vaginal'), ('GO_0007567', 'parturition', 126, 'delivery'), ('CHEBI_27300', 'vitamin D', 246, 'vitamin A')]
S76-PMC5510234	PMC5510234	7/2017	S76-PMC5510234	['the fifth study FOCUSED on post-Natal Vitamin A supplementation and enrolled 4495 hiv-infected women.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 16)]	1	[('GO_0007567', 'parturition', 32, 'natal'), ('CHEBI_27300', 'vitamin D', 38, 'vitamin A')]
S78-PMC5510234	PMC5510234	7/2017	S78-PMC5510234	['the authors REPORTED that EVEN in regions where Vitamin A deficiency is a PUBLIC HEALTH CONCERN, Vitamin A supplementation for PREVENTION of Prenatal mtct is not RECOMMENDED.58finally a RECENT REVIEW done on the vitamin a supplementation for the reduction of the RISK of mother-to-child transmission of hiv, REPORTED that early observational studies FOUND an ASSOCIATION between Vitamin A deficiency and increased rates of mtct of hiv.']	[('INCOMPLETE_EVIDENCE', 12), ('ANOMALY_CURIOUS_FINDING', 26), ('IMPORTANT_CONSIDERATION', 74), ('SUPERFICIAL_RELATIONSHIP', 127), ('FUTURE_WORK', 162), ('INCOMPLETE_EVIDENCE', 186), ('IMPORTANT_CONSIDERATION', 263), ('INCOMPLETE_EVIDENCE', 308), ('INCOMPLETE_EVIDENCE', 350), ('SUPERFICIAL_RELATIONSHIP', 359)]	10	[('CHEBI_27300', 'vitamin D', 48, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 97, 'vitamin A'), ('GO_0007565', 'female pregnancy', 141, 'prenatal'), ('CHEBI_27300', 'vitamin D', 379, 'vitamin A')]
S2-PMC5513133	PMC5513133	7/2017	S2-PMC5513133	['evidence of the ROLE of Vitamin D status and supplementation in the etiology and PREVENTION of pe is reviewed in THIS ARTICLE along with identification of research gaps to inform FUTURE STUDIES.']	[('SUPERFICIAL_RELATIONSHIP', 16), ('SUPERFICIAL_RELATIONSHIP', 81), ('QUESTION_ANSWERED_BY_THIS_WORK', 113), ('FUTURE_WORK', 179)]	4	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D')]
S5-PMC5513133	PMC5513133	7/2017	S5-PMC5513133	['clinical trials TO DATE HAVE BEEN unable to show an INDEPENDENT EFFECT of Vitamin D supplementation in PREVENTING pe.']	[('INCOMPLETE_EVIDENCE', 16), ('INCOMPLETE_EVIDENCE', 24), ('SUPERFICIAL_RELATIONSHIP', 52), ('SUPERFICIAL_RELATIONSHIP', 64), ('SUPERFICIAL_RELATIONSHIP', 103)]	5	[('CHEBI_27300', 'vitamin D', 74, 'vitamin D')]
S6-PMC5513133	PMC5513133	7/2017	S6-PMC5513133	['conclusions\nthe included clinical trials do not show an independent effect of Vitamin D supplementation in PREVENTING pe; HOWEVER, ISSUES with dose, timing, and duration of supplementation HAVE NOT BEEN COMPLETELY ADDRESSED.']	[('SUPERFICIAL_RELATIONSHIP', 107), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 122), ('PROBLEM_COMPLICATION', 131), ('IMPORTANT_CONSIDERATION', 189), ('INCOMPLETE_EVIDENCE', 194)]	5	[('CHEBI_27300', 'vitamin D', 78, 'vitamin D')]
S82-PMC5513133	PMC5513133	7/2017	S82-PMC5513133	['role of Vitamin D and Vitamin D Receptor (vdr) in Calcium Homeostasis\nthe EFFECTS of Calcium supplementation on Pregnancy-induced hypertensive disorders are well characterized.']	[('SUPERFICIAL_RELATIONSHIP', 74)]	1	[('CHEBI_27300', 'vitamin D', 8, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('PR_000001683', 'vasopressin V2 receptor', 22, 'vitamin D receptor'), ('GO_0050817', 'coagulation', 50, 'calcium'), ('GO_0042592', 'homeostatic process', 58, 'homeostasis'), ('CHEBI_22313', 'alkaline earth metal atom', 85, 'calcium'), ('GO_0007565', 'female pregnancy', 112, 'pregnancy')]
S92-PMC5513133	PMC5513133	7/2017	S92-PMC5513133	['methods\n\nsearch strategy\nthe review protocol was designed a priori to answer the QUESTION, “WHAT are the EFFECTS of Vitamin D concentrations and supplementation during Pregnancy on pre-eclampsia in women?” we conducted a literature search using medline electronic databases (via pubmed) to identify published studies until february 2015.']	[('EXPLICIT_QUESTION', 81), ('EXPLICIT_QUESTION', 92), ('SUPERFICIAL_RELATIONSHIP', 105)]	3	[('CHEBI_27300', 'vitamin D', 116, 'vitamin D'), ('GO_0007565', 'female pregnancy', 168, 'pregnancy')]
S101-PMC5513133	PMC5513133	7/2017	S101-PMC5513133	['the inclusion criteria for this review were availability of an abstract, clinical data on Vitamin D concentrations and/or supplementation in ASSOCIATION with pih outcomes in any global setting, and subjects that included Pregnant participants aged 18\xa0years and above without other medical co-morbidities.']	[('SUPERFICIAL_RELATIONSHIP', 141)]	1	[('CHEBI_27300', 'vitamin D', 90, 'vitamin D'), ('GO_0007565', 'female pregnancy', 221, 'pregnant')]
S118-PMC5513133	PMC5513133	7/2017	S118-PMC5513133	['HOWEVER, when CONSIDERING total Vitamin D intake (diet + supplement) of 15–20\xa0μg/d compared to less than 5\xa0μg/d, there was an adjusted or of 0.76 (95% ci 0.60–0.95) for diagnosis with pe [77].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('IMPORTANT_CONSIDERATION', 14)]	2	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D')]
S129-PMC5513133	PMC5513133	7/2017	S129-PMC5513133	['germany, 2–14 [85]case control20 – women with peat Delivery43 – healthy Pregnant controls\u2003mohaghegh et al., iran, 2015 [89]case control41 -- women with pe 50 – healthy Pregnant controlstime of labor\u2003powe, usa, 2010 [86]nested case control39 -- developed pe 131 – healthy Pregnant controls1st Trimester\u2003robinson et al., usa, 2010 [25]case control50 -- women with eospe29\xa0weeks Gestation100 – healthy Pregnant controls\u2003schneuer et al., australia, 2014 [114]nested case control5109 Pregnant women (223 with pe and 29/223 with eospe)10–14\xa0weeks Gestation\u2003singla et al., india, 2015 [87]case control74 -- nulliparous women with pe>30\xa0weeks Gestation100 -- healthy nulliparous controls\u2003ullah et al., bangladesh, 2013 [82]case control33 -- women with pe>20\xa0weeks Gestation79 – normal Pregnancy controls\u2003wetta et al., uk, 2013 [96]case control100 -women with pe15–21\xa0weeks Gestation200 – healthy Pregnant controls\u2003woodham et al., usa, 2011 [15]nested case control41 – women with severe pe2nd trimester121 – uncomplicated birth controls\u2003xu et al., usa, 2014 [53]case control100 – women with pe≤ 24\xa0weeks Gestation100 – uncomplicated Birth controls\u2003yu et al., uk, 2012 [115]case control60 –late pe11–13\xa0weeks Gestation30 –early pe1000 – healthy controlsretrospective cohort study\u2003alvarez-fernandez et al., spain, 2014 [90]retrospective cohort257 -- women attending obstetric triage with suspicion of pe1st trimester and 20\xa0weeks of Gestation\u2003scholl et al., usa, 2013 [78]retrospective cohort1141 -- low income and minority Pregnant womenentry to care (mean 13.7\xa0±\xa05.7\xa0weeks)prospective cohort studies\u2003burris et al., usa, 2014 [94]prospective cohort1591 -- Pregnant women16.4–36.9\xa0weeks Gestation\u2003haugen et al., norway, 2000 [77]prospective cohort23,423 -- Pregnant womenvitamin D intake at weeks 15, 22, and 30 Gestation\u2003shand et al., canada, 2010 [37]prospective cohort221 -- women at risk for pe10–20\xa0weeks Gestation\u2003wei et al., canda 2012 [60]prospective cohort697 -- Pregnant women receiving Vitamin C and e supplementation for the PREVENTION of pe12–18\xa0weeks Gestation, 24-26 weeks Gestation\u2003wei, canada, 2013 [14]prospective cohort697 -- Pregnant women receiving Vitamin C and e supplementation for the PREVENTION of pe24–26\xa0weeks Gestation\u2003zhou, china, 2014 [116]prospective cohort74 – women with pe16–20 weeks\xa0Gestation\n\ncaption (table-wrap): table 3\n\nASSOCIATION between Vitamin D and pre-eclampsia (pe) in observational studiesauthor, location, yearkey findingsresultsaugust et al., usa, 1992 [88]↓ 1,25Oh2D in women with pe vs chronic htn and normal women1,25 Oh2D levels:pe: 37.8 +/− 15\xa0pg/ml chronic htn: 75 +/− 15\xa0pg/ml ( p \xa0<\xa00.05); normal women: 65 +/− 10\xa0pg/ml ( p \xa0<\xa00.05)fernandez- alonzo et al., spain, 2012 [97]↔ Pe and 25(Oh)D levels25(Oh)D: <49.9\xa0nmol/l: 28.6% (2/7 women); 49.9–74.9\xa0nmol/l: 42.9% (3/7 women); ≥ 74.9\xa0nmol/l: 28.6% (2/7 women) ( p \xa0=\xa00.91)pena hr, et al.']	[('SUPERFICIAL_RELATIONSHIP', 2026), ('SUPERFICIAL_RELATIONSHIP', 2199), ('SUPERFICIAL_RELATIONSHIP', 2350)]	3	[('GO_0007567', 'parturition', 51, 'delivery43'), ('GO_0007565', 'female pregnancy', 72, 'pregnant'), ('GO_0007565', 'female pregnancy', 168, 'pregnant'), ('GO_0007565', 'female pregnancy', 271, 'pregnant'), ('GO_0009294', 'DNA mediated transformation', 292, 'trimester'), ('GO_0007565', 'female pregnancy', 376, 'gestation100'), ('GO_0007565', 'female pregnancy', 399, 'pregnant'), ('GO_0007565', 'female pregnancy', 479, 'pregnant'), ('GO_0007565', 'female pregnancy', 541, 'gestation'), ('GO_0007565', 'female pregnancy', 635, 'gestation100'), ('GO_0007565', 'female pregnancy', 756, 'gestation79'), ('GO_0007565', 'female pregnancy', 777, 'pregnancy'), ('GO_0007565', 'female pregnancy', 865, 'gestation200'), ('GO_0007565', 'female pregnancy', 888, 'pregnant'), ('GO_0007565', 'female pregnancy', 1095, 'gestation100'), ('GO_0007567', 'parturition', 1124, 'birth'), ('GO_0007565', 'female pregnancy', 1199, 'gestation30'), ('GO_0007565', 'female pregnancy', 1422, 'gestation'), ('GO_0007565', 'female pregnancy', 1513, 'pregnant'), ('GO_0007565', 'female pregnancy', 1646, 'pregnant'), ('GO_0007565', 'female pregnancy', 1676, 'gestation'), ('GO_0007565', 'female pregnancy', 1746, 'pregnant'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 1768, 'D'), ('GO_0007565', 'female pregnancy', 1801, 'gestation'), ('GO_0007565', 'female pregnancy', 1899, 'gestation'), ('GO_0007565', 'female pregnancy', 1961, 'pregnant'), ('CHEBI_27300', 'vitamin D', 1986, 'vitamin C'), ('GO_0007565', 'female pregnancy', 2054, 'gestation'), ('GO_0007565', 'female pregnancy', 2077, 'gestation'), ('GO_0007565', 'female pregnancy', 2134, 'pregnant'), ('CHEBI_27300', 'vitamin D', 2159, 'vitamin C'), ('GO_0007565', 'female pregnancy', 2227, 'gestation'), ('GO_0007565', 'female pregnancy', 2308, 'gestation'), ('CHEBI_27300', 'vitamin D', 2370, 'vitamin D'), ('CHEBI_72639', '13-HODE', 2501, '25OH2D'), ('CHEBI_72639', '13-HODE', 2558, '25 OH2D'), ('CHEBI_51383', 'hydridocarbon(3.)', 2724, 'PE'), ('CHEBI_71657', 'versiconol acetate', 2731, '25(OH)D'), ('CHEBI_33010', 'chromide(1-)', 2747, '(OH)D')]
S132-PMC5513133	PMC5513133	7/2017	S132-PMC5513133	['germany, 2–14 [85]↓ 25(Oh)D levels in pe in summer compared to controls, 1,25(Oh)2D ↓ only in winter25(Oh)D: pe:18.2\xa0±\xa017.1; control: 49.2\xa0±\xa029.2\xa0ng/ml, ( p \xa0<\xa00.001); 1,25(Oh)2D: 291\xa0±\xa0217 vs 612.3\xa0±\xa0455\xa0pmol/ml ( p \xa0<\xa00.05)mohaghegh et al., iran, 2015 [89]↓ mean 25(Oh)D in pe compared to Pregnant controls without pe25(Oh)D:Pe: 37.9\xa0±\xa033.9\xa0nmol/lcontrols: 58.2\xa0±\xa038.2\xa0nmol/l( p \xa0=\xa00.001)powe, usa, 2010 [86]↔ women with pe and controls with 25(Oh)D\xa0<\xa015.0\xa0nmol/ladjusted or: 1.3595% ci: 0.40 to 4.50robinson et al., usa, 2010 [25]↑ eospe in women with maternal 25(Oh)D levels <=19.6\xa0nmol/l compared to levels >19.6\xa0nmol/lor: 3.6095% ci: 1.71–7.58( p \xa0<\xa00.001)schneuer et al., australia, 2014 [114]↔ pe or eospe and low 25(Oh)D (< 25\xa0nmol/l)adjusted or- all pe: 0.4695% ci: 0.19–1.10adjusted or- eospe: 1.4095% ci: 0.20 to 9.89singla et al., india, 2015 [87]↓ mean Serum Vitamin D in women with pe vs controlspe: 24.2\xa0±\xa012.4\xa0nmol/l controls: 36.9\xa0±\xa016.7\xa0nmol/l;( p \xa0=\xa00.0001)ullah et al., bangladesh, 2013 [82]↑ pe per 25\xa0nmol/l decrease in 25(Oh)D leveladjusted or: 1.6695% ci: 1.05–3.02wetta et al., uk, 2013 [96]↔ between pe and 25-Oh D\xa0<\xa030\xa0ng/ml and <37.4\xa0nmol/l<30\xa0ng/ml adjusted or: 1.195% ci: 0.6–2.0adjusted or: 1.4 (<37.4\xa0nmol/l)95% ci: 0.7–3.0woodham et al., usa, 2011 [15]↓ severe pe in women with 10\xa0nmol/l increase in maternal 25(Oh)D leveladjusted or: 0.6295% ci: 0.51–0.76xu et al., usa, 2014 [53]↑ pe in women with Vitamin D deficiency (<37.5\xa0nmol/l)or: 4.495% ci: 1.8–10.8yu et al., uk, 2012 [115]↔ Serum Vitamin D raw values in pe and controls25(Oh)D levels: controls: 46.8\xa0nmol/l (27.8–70.0;)early pe: 32.2\xa0nmol/l (22.7–50.4); late pe: 39.2\xa0nmol/l (22.1–63.0) ( p \xa0=\xa00.231)alvarez-fernandez et al., spain, 2014 [90]↑ pe in women with 25(Oh)D levels <50\xa0nmol/l compared TO levels >50\xa0nmol/l after 20\xa0weeks of Gestationor: 4.695% ci:1.4–15( p \xa0=\xa00.010)scholl et al., usa, 2013 [78]↑ pe in women with 25(Oh)D\xa0<\xa049.9\xa0nmol/l and hyperparathyroidismadjusted or: 2.8695% ci: 1.28–6.41burris et al., usa, 2014 [94]↔ Pe and 25(Oh)D levels compared at each 25\xa0nmol/l increase in 25 (Oh)Dadjusted or: 1.1495% ci: 0.77–1.67haugen et al., norway, 2000 [77]↓ pe in women taking 10–15 mcg/d as compared with no supplementsadjusted or: 0.7395% ci: 0.58–0.92shand et al., canada, 2010 [37]↔ pe and 25(Oh)D levels <37.5\xa0nmol/ladjusted or: 0.9195% ci: 0.31–2.62wei et al., canda 2012 [60]↔ Pe and 25(Oh)D\xa0<\xa050\xa0nmol/ladjusted or: 1.2495% ci: 0.58–2.67( p \xa0=\xa00.58)wei, canada, 2013 [14]↑ pe and women with ↓ pigf levels and maternal 25(Oh)d\xa0<\xa050\xa0nmol/ladjusted or: 2.9795% ci: 1.23–7.20zhou, china, 2014 [116]↔ pe and 25(Oh)D levels25(Oh)D levelsgroup a ( n \xa0=\xa013): 41.4\xa0±\xa06.5\xa0nmol/l; group b ( n \xa0=\xa036): 62.1\xa0±\xa07.0\xa0nmol/l; group c ( n \xa0=\xa025): 89.6\xa0±\xa013.0\xa0nmol/l; ( p \xa0=\xa00.900)\na case-cohort study of women from 12 different united states (us) sites whose vitamin D levels were measured at ≤26\xa0weeks of Gestation SHOWED that 25(Oh)D levels greater than 50\xa0nmol/l were ASSOCIATED with a 40% reduction in risk for severe pe (0.65 [95% ci 0.43 to 0.98]), although there was no reduction in absolute and relative risk for the milder clinical subtypes of pe when 25(Oh)D levels were greater than 50\xa0nmol/l [79].']	[('QUESTION_ANSWERED_BY_THIS_WORK', 1791), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 2293), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 2609), ('INCOMPLETE_EVIDENCE', 2914), ('SUPERFICIAL_RELATIONSHIP', 2969)]	5	"[('CHEBI_71657', 'versiconol acetate', 20, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 26, 'D'), ('CHEBI_73285', ""3-iodo-4-aminobenzyl-5'-N-methylcarboxamidoadenosine"", 75, '25(OH)2D ↓'), ('CHEBI_33010', 'chromide(1-)', 102, '(OH)D'), ('CHEBI_82784', 'PVP38-Ag NP', 168, '1,25(OH)2D'), ('CHEBI_71657', 'versiconol acetate', 265, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 265, '25'), ('PR_000011614', 'opioid growth factor receptor', 268, 'OH'), ('PR_000006444', 'diacylglycerol kinase delta', 271, 'D'), ('GO_0007565', 'female pregnancy', 291, 'pregnant'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 322, 'OH)D'), ('CHEBI_51383', 'hydridocarbon(3.)', 327, 'PE'), ('CHEBI_71657', 'versiconol acetate', 444, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 444, '25(OH)D'), ('CHEBI_33010', 'chromide(1-)', 566, '(OH)D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 725, 'OH)D'), ('UBERON_0001977', 'blood serum', 867, 'serum'), ('CHEBI_27300', 'vitamin D', 873, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 1043, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 1043, '25(OH ... D'), ('CHEBI_72765', 'verruculogen', 1134, '25-OH D'), ('CHEBI_71657', 'versiconol acetate', 1343, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1343, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 1434, 'vitamin D'), ('UBERON_0001977', 'blood serum', 1519, 'serum'), ('CHEBI_27300', 'vitamin D', 1525, 'vitamin D'), ('CHEBI_33010', 'chromide(1-)', 1566, '(OH)D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 1759, 'OH)D'), ('GO_0007565', 'female pregnancy', 1830, 'gestationOR'), ('CHEBI_71657', 'versiconol acetate', 1920, '25(OH)D'), ('CHEBI_51383', 'hydridocarbon(3.)', 2030, 'PE'), ('CHEBI_71657', 'versiconol acetate', 2037, '25(OH)D'), ('CHEBI_982', '2-Aceto-2-hydroxybutanoate', 2091, '25 (OH)DAdjusted'), ('CHEBI_71657', 'versiconol acetate', 2303, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 2303, '25(OH)D'), ('CHEBI_51383', 'hydridocarbon(3.)', 2393, 'PE'), ('CHEBI_71657', 'versiconol acetate', 2400, '25(OH)D'), ('CHEBI_63056', 'zinc cation', 2534, '25(OH'), ('CHEBI_71657', 'versiconol acetate', 2619, '25(OH)D'), ('CHEBI_33010', 'chromide(1-)', 2635, '(OH)D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 2865, 'D'), ('GO_0007565', 'female pregnancy', 2904, 'gestation'), ('CHEBI_71657', 'versiconol acetate', 2926, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 3159, '25(OH)D')]"
S166-PMC5513133	PMC5513133	7/2017	S166-PMC5513133	['in a 50-year-old controlled trial of 5644 women, olsen & secher ASSESSED the PREVENTIVE EFFECT of a multi-Vitamin Mineral supplement, which included iron, Calcium, Iodine, manganese, copper, Vitamin B Complex, Vitamin C, and 260\xa0mg/day of calcium and halibut Liver oil containing 2500\xa0iu/g Vitamin D per day.']	[('INCOMPLETE_EVIDENCE', 64), ('SUPERFICIAL_RELATIONSHIP', 77), ('SUPERFICIAL_RELATIONSHIP', 88)]	3	[('CHEBI_46674', 'lizardite', 106, 'vitamin mineral'), ('CHEBI_22313', 'alkaline earth metal atom', 155, 'calcium'), ('CHEBI_24859', 'iodine atom', 164, 'iodine'), ('CHEBI_75427', 'deuterated fatty acid', 191, 'vitamin B complex'), ('CHEBI_27300', 'vitamin D', 210, 'vitamin C'), ('UBERON_0002107', 'liver', 259, 'liver'), ('CHEBI_27300', 'vitamin D', 290, 'vitamin D')]
S170-PMC5513133	PMC5513133	7/2017	S170-PMC5513133	['caption (table-wrap): table 4\n\nASSOCIATION of Vitamin D supplementation and Pregnancy-induced hypertension (pih) outcomes in clinical trialsauthor, location, yearstudy designsubjectsinterventionkey findingsresultsolsen and secher, denmark, 1990 [91]randomized controlled clinical trial5644 Pregnant women2500\xa0iu Vitamin D supplement versus no Supplement at week 20 of Pregnancy↓ pe31.5% reduction in the odds ( p \xa0<\xa00.005)olsen et al., europe, 2000 [98]randomized placebo controlled clinical trial386 women who previously experienced pih2.7\xa0g N-3 Fatty Acids/day given from 33\xa0weeks until Delivery vs Olive Oil placebo↔ pih recurrence riskor\xa0=\xa00.9895% ci: 0.63–1.53\n\nevidence that SUGGESTS no association between maternal Vitamin D deficiency and pe\nWHILE the PRECEDING STUDIES SUPPORT a LINK between Vitamin D deficiency during Pregnancy and risk of pe, SOME STUDIES present CONFLICTING EVIDENCE (tables2and3).']	[('SUPERFICIAL_RELATIONSHIP', 31), ('INCOMPLETE_EVIDENCE', 681), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 750), ('INCOMPLETE_EVIDENCE', 760), ('INCOMPLETE_EVIDENCE', 778), ('SUPERFICIAL_RELATIONSHIP', 788), ('INCOMPLETE_EVIDENCE', 855), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 876), ('INCOMPLETE_EVIDENCE', 888)]	9	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('GO_0007565', 'female pregnancy', 76, 'pregnancy'), ('GO_0007565', 'female pregnancy', 290, 'pregnant'), ('CHEBI_27300', 'vitamin D', 312, 'vitamin D'), ('CHEBI_16158', 'steroid sulfate', 343, 'supplement'), ('GO_0007565', 'female pregnancy', 368, 'pregnancy'), ('GO_0007567', 'parturition', 377, '↓'), ('CHEBI_30256', 'thiocarbonyl group', 543, 'n-3'), ('CHEBI_35366', 'fatty acid', 547, 'fatty acids'), ('GO_0007567', 'parturition', 589, 'delivery'), ('CHEBI_50695', 'monobactam', 601, 'olive oil'), ('CHEBI_27300', 'vitamin D', 722, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 801, 'vitamin D'), ('GO_0007565', 'female pregnancy', 829, 'pregnancy')]
S177-PMC5513133	PMC5513133	7/2017	S177-PMC5513133	['RETROSPECTIVELY ANALYZED Vitamin D status and the risk of pe in 697 nulliparous women with singleton Pregnancies in a randomized, placebo-controlled trial of vitamin c and e supplementation for the PREVENTION of pe.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 16), ('SUPERFICIAL_RELATIONSHIP', 198)]	3	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('GO_0007565', 'female pregnancy', 101, 'pregnancies')]
S221-PMC5513133	PMC5513133	7/2017	S221-PMC5513133	['maternal dietary intake of Vitamin D from Foods or supplements MAY also VARY.']	[('INCOMPLETE_EVIDENCE', 63), ('DIFFICULT_TASK', 72)]	2	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('CHEBI_33290', 'food', 42, 'foods')]
S223-PMC5513133	PMC5513133	7/2017	S223-PMC5513133	['the use of cod Liver oil as a Food supplement in some diets presents a CHALLENGE in determining an isolated EFFECT of Vitamin D supplementation.']	[('DIFFICULT_TASK', 71), ('SUPERFICIAL_RELATIONSHIP', 108)]	2	[('UBERON_0002107', 'liver', 15, 'liver'), ('CHEBI_33290', 'food', 30, 'food'), ('CHEBI_27300', 'vitamin D', 118, 'vitamin D')]
S229-PMC5513133	PMC5513133	7/2017	S229-PMC5513133	['in a cochrane review of Vitamin D supplementation for women during Pregnancy, women who received Vitamin D and Calcium supplementation had a lower RISK of pre-eclampsia than those not receiving any intervention (rr 0.51; 95% ci 0.32 to 0.80; three trials, 1114 women, moderate quality), YET an increased risk for Preterm Birth (rr\xa0=\xa01.57; 95% ci: 1.02–2.43; three studies, 798 women, moderate quality).']	[('IMPORTANT_CONSIDERATION', 147), ('ANOMALY_CURIOUS_FINDING', 287)]	2	[('CHEBI_28384', 'vitamin K', 24, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 67, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 97, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 111, 'calcium'), ('GO_0007565', 'female pregnancy', 313, 'preterm birth')]
S231-PMC5513133	PMC5513133	7/2017	S231-PMC5513133	['the ROLE of Fish Oils in pe REMAINS UNCERTAIN and SIMILARLY poses a CHALLENGE in determining an isolated EFFECT of Vitamin D supplementation, UNLESS studies are designed such that they CONSIDER this.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('INCOMPLETE_EVIDENCE', 28), ('FULL_UNKNOWN', 36), ('SUPERFICIAL_RELATIONSHIP', 50), ('DIFFICULT_TASK', 68), ('SUPERFICIAL_RELATIONSHIP', 105), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 142), ('FUTURE_WORK', 142), ('INCOMPLETE_EVIDENCE', 185)]	9	[('CHEBI_39279', 'halomethane', 12, 'fish oils'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin D')]
S247-PMC5513133	PMC5513133	7/2017	S247-PMC5513133	['RECENTLY, participants in the Vitamin D for antenatal asthma (vdaart) randomized double-blind placebo controlled trial took a daily dose of 4000\xa0iu Vitamin D supplementation plus a multivitamin with 400\xa0iu Vitamin D or placebo (placebo pill plus a multi-Vitamin with 400\xa0iu Vitamin D daily) TO ASSESS the EFFECT of Vitamin D supplementation on the frequency of pe among Pregnant women with a high risk for atopic disease [110].']	[('INCOMPLETE_EVIDENCE', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 291), ('SUPERFICIAL_RELATIONSHIP', 305)]	3	[('CHEBI_28384', 'vitamin K', 30, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 148, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 206, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 254, 'vitamin'), ('CHEBI_27300', 'vitamin D', 274, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 315, 'vitamin D'), ('GO_0007565', 'female pregnancy', 370, 'pregnant')]
S249-PMC5513133	PMC5513133	7/2017	S249-PMC5513133	['SUGGESTS a POTENTIAL for a ROLE for the frequency and timing of Vitamin D supplementation and risk for pe, given that the total intake greater than 800\xa0iu/day did not reduce RISK.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 11), ('SUPERFICIAL_RELATIONSHIP', 27), ('IMPORTANT_CONSIDERATION', 174)]	4	[('CHEBI_27300', 'vitamin D', 64, 'vitamin D')]
S254-PMC5513133	PMC5513133	7/2017	S254-PMC5513133	['BUT this Vitamin D level was maintained in ONLY 74% of Pregnancies in the supplementation group by weeks 32 to 38 of Gestation, SUGGESTING that supplementation at EVEN earlier time-points or before Pregnancy MAY BE NECESSARY to maintain sufficient Vitamin D levels that are PROTECTIVE against pe.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 43), ('INCOMPLETE_EVIDENCE', 128), ('ANOMALY_CURIOUS_FINDING', 163), ('INCOMPLETE_EVIDENCE', 208), ('IMPORTANT_CONSIDERATION', 215), ('SUPERFICIAL_RELATIONSHIP', 274)]	8	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007565', 'female pregnancy', 55, 'pregnancies'), ('GO_0007565', 'female pregnancy', 117, 'gestation'), ('GO_0007565', 'female pregnancy', 198, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 248, 'vitamin D')]
S261-PMC5513133	PMC5513133	7/2017	S261-PMC5513133	['replication of findings using a uniform set of definitions for pe and clinical subtypes CAN inform the use of Vitamin D supplementation for the PREVENTION of pe.']	[('INCOMPLETE_EVIDENCE', 88), ('SUPERFICIAL_RELATIONSHIP', 144)]	2	[('CHEBI_27300', 'vitamin D', 110, 'vitamin D')]
S265-PMC5513133	PMC5513133	7/2017	S265-PMC5513133	['DESPITE the clear ASSOCIATION of Serum deficiency with pe, a better understanding of the variable IMPACT of supplementation IS NEEDED to identify POTENTIAL of Genetic and environmental INTERACTIONS, as well as pre-Conception data TO IDENTIFY the CRITICAL time window for therapeutic potential of Vitamin D, if any.']	[('ANOMALY_CURIOUS_FINDING', 0), ('SUPERFICIAL_RELATIONSHIP', 18), ('SUPERFICIAL_RELATIONSHIP', 98), ('FUTURE_WORK', 124), ('INCOMPLETE_EVIDENCE', 146), ('SUPERFICIAL_RELATIONSHIP', 185), ('QUESTION_ANSWERED_BY_THIS_WORK', 230), ('IMPORTANT_CONSIDERATION', 246)]	8	[('UBERON_0001977', 'blood serum', 33, 'serum'), ('SO_0000704', 'gene', 159, 'genetic'), ('GO_0007620', 'copulation', 214, 'conception'), ('CHEBI_27300', 'vitamin D', 296, 'vitamin D')]
S267-PMC5513133	PMC5513133	7/2017	S267-PMC5513133	['results from Vitamin D supplementation during Pregnancy did not show a statistically significant independent EFFECT of Vitamin D on the RISK of pe and pih.']	[('SUPERFICIAL_RELATIONSHIP', 109), ('IMPORTANT_CONSIDERATION', 136)]	2	[('CHEBI_27300', 'vitamin D', 13, 'vitamin D'), ('GO_0007565', 'female pregnancy', 46, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 119, 'vitamin D')]
S268-PMC5513133	PMC5513133	7/2017	S268-PMC5513133	['at this time, our UNDERSTANDING of an IDEAL supplementation dose of Vitamin D to reduce pih REMAINS INCOMPLETE.']	[('INCOMPLETE_EVIDENCE', 18), ('IMPORTANT_CONSIDERATION', 38), ('INCOMPLETE_EVIDENCE', 92)]	3	[('CHEBI_27300', 'vitamin D', 68, 'vitamin D')]
S85-PMC5523023	PMC5523023	7/2017	S85-PMC5523023	['in SEVERAL STUDIES, the supplementation with a Nutraceutical of Antioxidants and Anti-Inflammatory Compounds (e.g., Curcumin, zinc, Selenium, Vitamin D) was ASSOCIATED with reduction of Airway inflammation, as documented by a decrease in fractional exhaled Nitric Oxide (feno) (48) or prolonged time to exacerbation (49).']	[('INCOMPLETE_EVIDENCE', 3), ('SUPERFICIAL_RELATIONSHIP', 157)]	2	[('CHEBI_50733', 'nutraceutical', 47, 'nutraceutical'), ('CHEBI_60641', 'methyl 5-aminolevulinate hydrochloride', 64, 'antioxidants'), ('CHEBI_22485', 'glucosamine oligosaccharide', 81, 'anti-inflammatory compounds'), ('CHEBI_3962', 'curcumin', 116, 'curcumin'), ('CHEBI_27568', 'selenium atom', 132, 'selenium'), ('CHEBI_27300', 'vitamin D', 142, 'vitamin D'), ('UBERON_0001005', 'respiratory airway', 186, 'airway'), ('CHEBI_16480', 'nitric oxide', 257, 'nitric oxide')]
S97-PMC5523023	PMC5523023	7/2017	S97-PMC5523023	['Prenatal supplementation of Vitamin C and E improved Pulmonary functions of newborns of smoking mothers (59), BUT in a large placebo-controlled study, this EFFECT was not confirmed (60).']	[('ANOMALY_CURIOUS_FINDING', 110), ('SUPERFICIAL_RELATIONSHIP', 156)]	2	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_27300', 'vitamin D', 28, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 42, 'E'), ('UBERON_0002048', 'lung', 53, 'pulmonary')]
S0-PMC5524288	PMC5524288	7/2017	S0-PMC5524288	['maternal 25(Oh)D concentrations ≥40 ng/ml ASSOCIATED with 60% lower Preterm Birth RISK among general obstetrical patients at an urban medical center\n\nabstract\n\nbackground\nGIVEN the HIGH RATE of Preterm Birth (ptb) nationwide and data from rcts DEMONSTRATING risk reduction with Vitamin D supplementation, the medical university of south carolina (musc) implemented a NEW standard of care for Pregnant women to receive Vitamin D testing and supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 42), ('IMPORTANT_CONSIDERATION', 82), ('INCOMPLETE_EVIDENCE', 171), ('IMPORTANT_CONSIDERATION', 181), ('INCOMPLETE_EVIDENCE', 244), ('FULL_UNKNOWN', 367)]	6	[('CHEBI_71657', 'versiconol acetate', 9, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 9, '25(OH)D'), ('GO_0007565', 'female pregnancy', 68, 'preterm birth'), ('GO_0007565', 'female pregnancy', 194, 'preterm birth'), ('CHEBI_27300', 'vitamin D', 278, 'vitamin D'), ('GO_0007565', 'female pregnancy', 392, 'pregnant'), ('CHEBI_27300', 'vitamin D', 418, 'vitamin D')]
S18-PMC5524288	PMC5524288	7/2017	S18-PMC5524288	['Serum 25(Oh)D concentration captures the EFFECT of multiple Vitamin D input sources (Supplement, sun, and Food) and makes provision for inter-individual VARIABILITY in dose response [11].']	[('SUPERFICIAL_RELATIONSHIP', 41), ('DIFFICULT_TASK', 153)]	2	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 6, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 6, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('CHEBI_16158', 'steroid sulfate', 85, 'supplement'), ('CHEBI_33290', 'food', 106, 'food')]
S24-PMC5524288	PMC5524288	7/2017	S24-PMC5524288	['trials, the medical university of south carolina (musc) INITIATED a NEW standard of care for Pregnant women that included routine Vitamin D testing and supplementation in september 2015.']	[('INCOMPLETE_EVIDENCE', 56), ('FULL_UNKNOWN', 68)]	2	[('GO_0007565', 'female pregnancy', 93, 'pregnant'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D')]
S126-PMC5524288	PMC5524288	7/2017	S126-PMC5524288	['additionally, using Serum 25(Oh)D concentration is a BETTER INDICATOR of Vitamin D status and statistically more powerful than using reported Intake BECAUSE it ACCOUNTS FOR all Vitamin D input sources (sun exposure, Food, and Supplements) and makes provision for inter-Individual VARIABILITY in Vitamin D dose response.']	[('PROBABLE_UNDERSTANDING', 53), ('SUPERFICIAL_RELATIONSHIP', 60), ('PROBABLE_UNDERSTANDING', 149), ('INCOMPLETE_EVIDENCE', 160), ('DIFFICULT_TASK', 280)]	5	[('UBERON_0001977', 'blood serum', 20, 'serum'), ('CHEBI_71657', 'versiconol acetate', 26, '25(OH)D'), ('PR_000011040', 'nuclear receptor coactivator 1', 28, '(OH'), ('PR_000006444', 'diacylglycerol kinase delta', 32, 'D'), ('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('GO_0007631', 'feeding behavior', 142, 'intake'), ('CHEBI_27300', 'vitamin D', 177, 'vitamin D'), ('CHEBI_33290', 'food', 216, 'food'), ('CHEBI_33341', 'titanium atom', 226, 'supplements'), ('NCBITaxon_1', 'root', 269, 'individual'), ('CHEBI_27300', 'vitamin D', 295, 'vitamin D')]
S131-PMC5524288	PMC5524288	7/2017	S131-PMC5524288	['FURTHER evaluation of the Vitamin D testing and supplementation protocol is PLANNED.']	[('FUTURE_WORK', 0), ('FUTURE_WORK', 76)]	2	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D')]
S12-PMC5537904	PMC5537904	7/2017	S12-PMC5537904	['APPROXIMATELY 33% of Pregnant women in the united states have Vitamin D deficiency, defined as 25-Hydroxyvitamin D (25Ohd) < 50 nmol/l, EVEN THOUGH 73% report using Vitamin D-containing Prenatal supplements [2].']	[('INCOMPLETE_EVIDENCE', 0), ('ANOMALY_CURIOUS_FINDING', 136)]	2	"[('GO_0007565', 'female pregnancy', 21, 'pregnant'), ('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 95, '25-hydroxyvitamin D'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 116, '25OHD'), ('CHEBI_27300', 'vitamin D', 165, 'vitamin D'), ('GO_0007565', 'female pregnancy', 186, 'prenatal')]"
S14-PMC5537904	PMC5537904	7/2017	S14-PMC5537904	['Prenatal Vitamin D deficiency HAS BEEN ASSOCIATED with pre-term Birth [4,5], low birthweight [5,6], and small for Gestational age offspring [5,6,7], WHILE Prenatal Vitamin D supplementation HAS BEEN SHOWN to increase offspring Birth weight and length [8].']	[('INCOMPLETE_EVIDENCE', 30), ('SUPERFICIAL_RELATIONSHIP', 39), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 149), ('INCOMPLETE_EVIDENCE', 190)]	4	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007567', 'parturition', 64, 'birth'), ('GO_0007565', 'female pregnancy', 114, 'gestational'), ('GO_0007565', 'female pregnancy', 155, 'prenatal'), ('CHEBI_27300', 'vitamin D', 164, 'vitamin D'), ('GO_0007567', 'parturition', 227, 'birth')]
S17-PMC5537904	PMC5537904	7/2017	S17-PMC5537904	['WHILE NUMEROUS STUDIES HAVE REPORTED that higher maternal Vitamin D intake (from Food and/or dietary supplements) is ASSOCIATED with increased Prenatal and/or cord Blood 25(Oh)D levels [14,15,16,17], it is NOT CLEAR WHETHER this TRANSLATES TO an EFFECT on neonatal adiposity.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 6), ('INCOMPLETE_EVIDENCE', 23), ('SUPERFICIAL_RELATIONSHIP', 117), ('FULL_UNKNOWN', 206), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 216), ('SUPERFICIAL_RELATIONSHIP', 229), ('SUPERFICIAL_RELATIONSHIP', 246)]	8	[('CHEBI_27300', 'vitamin D', 58, 'vitamin D'), ('CHEBI_33290', 'food', 81, 'food'), ('GO_0007565', 'female pregnancy', 143, 'prenatal'), ('UBERON_0000178', 'blood', 164, 'blood'), ('CHEBI_71657', 'versiconol acetate', 170, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 176, 'D')]
S20-PMC5537904	PMC5537904	7/2017	S20-PMC5537904	['there is also a notable LACK OF study on body composition during infancy, a time in which Postnatal exposures (infant Vitamin D supplementation, Vitamin D-fortified formula use) MAY also play a PIVOTAL ROLE in Adiposity Development.']	[('INCOMPLETE_EVIDENCE', 24), ('INCOMPLETE_EVIDENCE', 178), ('IMPORTANT_CONSIDERATION', 194), ('SUPERFICIAL_RELATIONSHIP', 202)]	4	[('GO_0007567', 'parturition', 90, 'postnatal'), ('CHEBI_27300', 'vitamin D', 118, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 145, 'vitamin D'), ('GO_0060612', 'adipose tissue development', 210, 'adiposity development')]
S55-PMC5537904	PMC5537904	7/2017	S55-PMC5537904	['dose) for each Supplement, and used manufacturer data on Nutrient composition to ESTIMATE average daily dose of Vitamin D from dietary supplements (iu/day) during Pregnancy.']	[('INCOMPLETE_EVIDENCE', 81)]	1	[('CHEBI_16158', 'steroid sulfate', 15, 'supplement'), ('CHEBI_33284', 'nutrient', 57, 'nutrient'), ('CHEBI_27300', 'vitamin D', 112, 'vitamin D'), ('GO_0007565', 'female pregnancy', 163, 'pregnancy')]
S68-PMC5537904	PMC5537904	7/2017	S68-PMC5537904	['we ESTIMATED weeks of daily Vitamin D supplement use for offspring by summing the weeks of daily Vitamin D use (when reported by the mother as an “other” Supplement) and weeks of daily multivitamin use, AS infant multivitamin supplements typically contain Vitamin D [42].']	[('INCOMPLETE_EVIDENCE', 3), ('PROBABLE_UNDERSTANDING', 203)]	2	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 97, 'vitamin D'), ('CHEBI_16158', 'steroid sulfate', 154, 'supplement'), ('CHEBI_27300', 'vitamin D', 256, 'vitamin D')]
S144-PMC5537904	PMC5537904	7/2017	S144-PMC5537904	['randomized clinical trials HAVE SHOWN that Prenatal Vitamin D supplementation increases both maternal 25(Oh)D and offspring birthweight [8].']	[('INCOMPLETE_EVIDENCE', 27)]	1	[('GO_0007565', 'female pregnancy', 43, 'prenatal'), ('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 102, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 105, 'OH ... D')]
S151-PMC5537904	PMC5537904	7/2017	S151-PMC5537904	['OUR finding that the ASSOCIATION between Cord Blood 25(Oh)D and Birthweight varies according to maternal bmi MUST BE REPLICATED in OTHER studies, including intervention trials, TO DETERMINE IF Vitamin D supplementation RECOMMENDATIONS to modify Birthweight SHOULD BE bmi-specific.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('SUPERFICIAL_RELATIONSHIP', 21), ('IMPORTANT_CONSIDERATION', 109), ('INCOMPLETE_EVIDENCE', 117), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 131), ('QUESTION_ANSWERED_BY_THIS_WORK', 177), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 190), ('FUTURE_WORK', 219), ('FUTURE_WORK', 257)]	9	[('UBERON_0009472', 'axilla', 41, 'cord blood'), ('CHEBI_71657', 'versiconol acetate', 52, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 52, '25(OH)D'), ('GO_0007596', 'blood coagulation', 64, 'birthweight'), ('CHEBI_27300', 'vitamin D', 193, 'vitamin D'), ('GO_0007596', 'blood coagulation', 245, 'birthweight')]
S166-PMC5537904	PMC5537904	7/2017	S166-PMC5537904	['these data are IN AGREEMENT with results of Prenatal Vitamin D supplementation trials, which REPORTED that EVEN with supplementation, women with non-white race/ethnicity, higher pre-Pregnancy bmis, and winter Deliveries had lower 25(Oh)D levels in Pregnancy [15,61].']	[('INCOMPLETE_EVIDENCE', 15), ('INCOMPLETE_EVIDENCE', 93), ('ANOMALY_CURIOUS_FINDING', 107)]	3	[('GO_0007565', 'female pregnancy', 44, 'prenatal'), ('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('GO_0007565', 'female pregnancy', 182, 'pregnancy'), ('GO_0007567', 'parturition', 209, 'deliveries'), ('CHEBI_71657', 'versiconol acetate', 230, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 230, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 248, 'pregnancy')]
S179-PMC5537904	PMC5537904	7/2017	S179-PMC5537904	['we were ONLY able to use crude ESTIMATES of offspring Intake of Vitamin D Postnatally from formula or infant supplements, which MAY have prevented us from detecting ASSOCIATIONS between 25(Oh)D at Birth and 5-month body composition that varied by Postnatal Vitamin D intake.']	[('INCOMPLETE_EVIDENCE', 8), ('INCOMPLETE_EVIDENCE', 31), ('INCOMPLETE_EVIDENCE', 128), ('SUPERFICIAL_RELATIONSHIP', 165)]	4	[('GO_0007631', 'feeding behavior', 54, 'intake'), ('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('GO_0007565', 'female pregnancy', 74, 'postnatally'), ('CHEBI_71657', 'versiconol acetate', 186, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 192, 'D'), ('GO_0007567', 'parturition', 197, 'birth'), ('GO_0007567', 'parturition', 247, 'postnatal'), ('CHEBI_27300', 'vitamin D', 257, 'vitamin D')]
S18-PMC5539754	PMC5539754	8/2017	S18-PMC5539754	['HOWEVER, the MAJORITY of Vitamin D supplementation intervention trials in Pregnancy have not had a SIGNIFICANT IMPACT on maternal and offspring health [10].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('PROBABLE_UNDERSTANDING', 13), ('IMPORTANT_CONSIDERATION', 99)]	3	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('GO_0007565', 'female pregnancy', 74, 'pregnancy')]
S51-PMC5539754	PMC5539754	8/2017	S51-PMC5539754	['information about the quantity of Vitamin D within supplements was NOT COLLECTED.']	[('INCOMPLETE_EVIDENCE', 67)]	1	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D')]
S157-PMC5539754	PMC5539754	8/2017	S157-PMC5539754	['winter-time supplementation of 1000\xa0iu/day Vitamin D is an EFFECTIVE STRATEGY to improve 25Ohd in Pregnancy [45].']	[('PROBABLE_UNDERSTANDING', 59)]	1	"[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 89, '25OHD'), ('GO_0007565', 'female pregnancy', 98, 'pregnancy')]"
S160-PMC5539754	PMC5539754	8/2017	S160-PMC5539754	['thus, RECOMMENDATIONS for Vitamin D supplementation to improve Glucose Homeostasis in Pregnancy CANNOT BE made BASED ON our results.']	[('FUTURE_WORK', 6), ('INCOMPLETE_EVIDENCE', 96), ('PROBABLE_UNDERSTANDING', 111)]	3	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('CHEBI_17234', 'glucose', 63, 'glucose'), ('GO_0042593', 'glucose homeostasis', 63, 'glucose homeostasis'), ('GO_0007565', 'female pregnancy', 86, 'pregnancy')]
S73-PMC5540678	PMC5540678	7/2017	S73-PMC5540678	"[""additional separate adjustment for maternal Intake of Vitamin E, zinc, selenium, n-3 Pufas, n-6 Pufas, and total fruits and vegetables in Pregnancy DID NOT substantially alter the main findings (data not shown), nor did additional separate adjustment for child's free Sugar intake at age 3\u2005years (supplementary table e3).""]"	[('INCOMPLETE_EVIDENCE', 148)]	1	[('GO_0007631', 'feeding behavior', 44, 'intake'), ('CHEBI_27300', 'vitamin D', 54, 'vitamin E'), ('CHEBI_86926', 'S a S b S', 85, 'PUFAs'), ('CHEBI_86926', 'S a S b S', 96, 'PUFAs'), ('GO_0007565', 'female pregnancy', 138, 'pregnancy'), ('CHEBI_24870', 'ion', 268, 'sugar')]
S0-PMC5546866	PMC5546866	8/2017	S0-PMC5546866	['response to antenatal Cholecalciferol supplementation is ASSOCIATED with common Vitamin D–related Genetic variants\n\nabstract\n\ncontext:\nSingle-Nucleotide Polymorphisms (Snps) in Genes RELATED to Vitamin D Metabolism HAVE BEEN ASSOCIATED with Serum 25-Hydroxyvitamin D [25(Oh)D] concentration, BUT these RELATIONSHIPS have NOT BEEN EXAMINED following Antenatal Cholecalciferol supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 57), ('SUPERFICIAL_RELATIONSHIP', 183), ('INCOMPLETE_EVIDENCE', 215), ('SUPERFICIAL_RELATIONSHIP', 225), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 292), ('SUPERFICIAL_RELATIONSHIP', 302), ('FULL_UNKNOWN', 321)]	7	[('CHEBI_16113', 'cholesterol', 22, 'Cholecalciferol'), ('CHEBI_28384', 'vitamin K', 80, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 80, 'Vitamin D'), ('SO_0000704', 'gene', 98, 'Genetic'), ('SO_0000694', 'SNP', 135, 'Single-nucleotide polymorphisms'), ('SO_0000694', 'SNP', 168, 'SNPs'), ('SO_0000704', 'gene', 177, 'genes'), ('CHEBI_27300', 'vitamin D', 194, 'vitamin D'), ('GO_0018977', '1,1,1-trichloro-2,2-bis-(4-chlorophenyl)ethane metabolic process', 202, 'D metabolism'), ('UBERON_0001977', 'blood serum', 241, 'serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 247, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 268, '25(OH)D'), ('GO_0007567', 'parturition', 349, 'antenatal'), ('CHEBI_52550', 'theopalauamide', 359, 'cholecalciferol')]
S11-PMC5546866	PMC5546866	8/2017	S11-PMC5546866	['conclusions:\nGenetic variation in Dhcr7 , which encodes 7-Dehyrocholesterol reductase in the Epidermal Vitamin D Biosynthesis pathway, APPEARS to modify baseline 25(Oh)D. IN CONTRAST, the response to Antenatal Cholecalciferol supplementation was ASSOCIATED with Snps in Cyp2R1 , which MAY alter 25-hydroxylase activity, and gc , which MAY AFFECT Vitamin D binding Protein Synthesis or Metabolite affinity.']	[('ANOMALY_CURIOUS_FINDING', 135), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 171), ('SUPERFICIAL_RELATIONSHIP', 246), ('INCOMPLETE_EVIDENCE', 285), ('INCOMPLETE_EVIDENCE', 335), ('SUPERFICIAL_RELATIONSHIP', 339)]	6	[('SO_0000704', 'gene', 13, 'Genetic'), ('PR_000006474', 'ATP-dependent RNA helicase A', 34, 'DHCR7'), ('CHEBI_17500', '7alpha-hydroxycholesterol', 56, '7-dehyrocholesterol'), ('UBERON_0007376', 'outer epithelium', 93, 'epidermal'), ('CHEBI_27300', 'vitamin D', 103, 'vitamin D'), ('GO_0042368', 'vitamin D biosynthetic process', 103, 'vitamin D biosynthesis'), ('PR_000006444', 'diacylglycerol kinase delta', 111, 'D'), ('CHEBI_71657', 'versiconol acetate', 162, '25(OH)D'), ('GO_0007567', 'parturition', 200, 'antenatal'), ('CHEBI_52550', 'theopalauamide', 210, 'cholecalciferol'), ('SO_0000694', 'SNP', 262, 'SNPs'), ('PR_000006110', 'cytochrome P450 27, mitochondrial', 270, 'CYP2R1'), ('CHEBI_27300', 'vitamin D', 346, 'vitamin D'), ('GO_0006412', 'translation', 364, 'protein synthesis'), ('CHEBI_39382', 'flufenoxuron', 385, 'metabolite')]
S12-PMC5546866	PMC5546866	8/2017	S12-PMC5546866	['abstract:teaser\nASSOCIATIONS between Snps in the Vitamin D Metabolism pathway and 25(Oh)D were ASSESSED before and after Antenatal Vitamin D supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 16), ('QUESTION_ANSWERED_BY_THIS_WORK', 95)]	2	[('SO_0000694', 'SNP', 37, 'SNPs'), ('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 49, 'vitamin D metabolism'), ('PR_000006444', 'diacylglycerol kinase delta', 57, 'D'), ('CHEBI_71657', 'versiconol acetate', 82, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 88, 'D'), ('GO_0007567', 'parturition', 121, 'antenatal'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D')]
S14-PMC5546866	PMC5546866	8/2017	S14-PMC5546866	['antenatal Vitamin D supplementation is now RECOMMENDED for all Pregnant women in many national GUIDELINES (1–3) AS SEVERE maternal Vitamin D deficiency CAN result in symptomatic neonatal hypocalcemia (4).']	[('FUTURE_WORK', 43), ('PROBABLE_UNDERSTANDING', 95), ('PROBABLE_UNDERSTANDING', 112), ('IMPORTANT_CONSIDERATION', 115), ('INCOMPLETE_EVIDENCE', 152)]	5	[('CHEBI_27300', 'vitamin D', 10, 'vitamin D'), ('GO_0007565', 'female pregnancy', 63, 'pregnant'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D')]
S21-PMC5546866	PMC5546866	8/2017	S21-PMC5546866	['several of these Snps have been ASSOCIATED with the Serum 25(Oh)D increase in response to Vitamin D supplementation in SMALL STUDIES (9–11).']	[('SUPERFICIAL_RELATIONSHIP', 32), ('INCOMPLETE_EVIDENCE', 119)]	2	[('SO_0000694', 'SNP', 17, 'SNPs'), ('UBERON_0001977', 'blood serum', 52, 'serum'), ('CHEBI_71657', 'versiconol acetate', 58, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 58, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 90, 'vitamin D')]
S26-PMC5546866	PMC5546866	8/2017	S26-PMC5546866	['CONSIDERING this and the physiological changes to the Vitamin D pathway in Pregnancy, it is THEREFORE POSSIBLE that the Genetic variants ASSOCIATED with baseline Serum 25(Oh)d status and the response to supplementation also differ between the Pregnant and nonpregnant state.']	[('PROBABLE_UNDERSTANDING', 0), ('PROBABLE_UNDERSTANDING', 92), ('INCOMPLETE_EVIDENCE', 102), ('SUPERFICIAL_RELATIONSHIP', 137)]	4	[('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('GO_0007565', 'female pregnancy', 75, 'pregnancy'), ('SO_0000704', 'gene', 120, 'genetic'), ('UBERON_0001977', 'blood serum', 162, 'serum'), ('CHEBI_30778', 'gallic acid', 168, '25(OH)'), ('GO_0007565', 'female pregnancy', 243, 'pregnant')]
S27-PMC5546866	PMC5546866	8/2017	S27-PMC5546866	['we THEREFORE undertook THIS STUDY TO DETERMINE WHETHER Snps within the Vitamin D Metabolism pathway KNOWN to modify Vitamin D status are also ASSOCIATED with the response to Antenatal Vitamin d supplementation.']	[('PROBABLE_UNDERSTANDING', 3), ('QUESTION_ANSWERED_BY_THIS_WORK', 23), ('QUESTION_ANSWERED_BY_THIS_WORK', 34), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 47), ('INCOMPLETE_EVIDENCE', 100), ('SUPERFICIAL_RELATIONSHIP', 142)]	6	[('SO_0000694', 'SNP', 55, 'SNPs'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 71, 'vitamin D metabolism'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin D'), ('GO_0007567', 'parturition', 174, 'antenatal'), ('CHEBI_33229', 'vitamin (role)', 184, 'vitamin')]
S118-PMC5546866	PMC5546866	8/2017	S118-PMC5546866	['discussion\nTHIS STUDY ASSESSED the RELATIONSHIPS between common Genetic variants and the response to Vitamin D supplementation in Pregnancy; rs12785878 in dhcr7 was ASSOCIATED with 25(Oh)D status in early Pregnancy prior to Vitamin D supplementation, WHEREAS rs10741657 in Cyp2R1 and rs2282679 in gc were ASSOCIATED with both the achieved and change in 25(Oh)D concentration following supplementation with 1000 iu/d Cholecalciferol.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 11), ('QUESTION_ANSWERED_BY_THIS_WORK', 22), ('SUPERFICIAL_RELATIONSHIP', 35), ('SUPERFICIAL_RELATIONSHIP', 165), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 251), ('SUPERFICIAL_RELATIONSHIP', 305)]	6	[('SO_0000704', 'gene', 64, 'genetic'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('GO_0007565', 'female pregnancy', 130, 'pregnancy'), ('CHEBI_30778', 'gallic acid', 181, '25(OH)'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 187, 'D'), ('GO_0007565', 'female pregnancy', 205, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 224, 'vitamin D'), ('PR_000006110', 'cytochrome P450 27, mitochondrial', 273, 'CYP2R1'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 356, 'OH)D'), ('CHEBI_52550', 'theopalauamide', 416, 'cholecalciferol')]
S127-PMC5546866	PMC5546866	8/2017	S127-PMC5546866	['the published gwas (8,22) DID NOT stratify Individuals by Vitamin D supplement usage, which COULD ACCOUNT FOR differing ASSOCIATIONS before and after supplementation in our cohort, or the differing FINDINGS MIGHT REFLECT the LOWER POWER in our study.']	[('INCOMPLETE_EVIDENCE', 26), ('INCOMPLETE_EVIDENCE', 92), ('PROBABLE_UNDERSTANDING', 98), ('SUPERFICIAL_RELATIONSHIP', 120), ('INCOMPLETE_EVIDENCE', 198), ('INCOMPLETE_EVIDENCE', 207), ('SUPERFICIAL_RELATIONSHIP', 213), ('INCOMPLETE_EVIDENCE', 225)]	8	[('NCBITaxon_1', 'root', 43, 'individuals'), ('CHEBI_27300', 'vitamin D', 58, 'vitamin D')]
S129-PMC5546866	PMC5546866	8/2017	S129-PMC5546866	['the Dhcr7 Gene encodes 7-Dhc reductase, which converts 7-Dhc back to Cholesterol, thereby reducing the availability of 7-Dhc for conversion to previtamin d. the ASSOCIATION of this Snp with only baseline 25(Oh)D is biologically CONSISTENT with the NOTION that the relative proportion of 25(Oh)D obtained from Vitamin D Biosynthesis in the skin AS OPPOSED TO dietary intake is lower following supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 161), ('INCOMPLETE_EVIDENCE', 228), ('INCOMPLETE_EVIDENCE', 248), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 344)]	4	[('PR_000006474', 'ATP-dependent RNA helicase A', 4, 'DHCR7'), ('SO_0000704', 'gene', 10, 'gene'), ('CHEBI_17759', 'cholesta-5,7-dien-3beta-ol', 23, '7-DHC'), ('CHEBI_17759', 'cholesta-5,7-dien-3beta-ol', 55, '7-DHC'), ('CHEBI_16113', 'cholesterol', 69, 'cholesterol'), ('CHEBI_17759', 'cholesta-5,7-dien-3beta-ol', 119, '7-DHC'), ('SO_0000694', 'SNP', 181, 'SNP'), ('CHEBI_71657', 'versiconol acetate', 204, '25(OH)D'), ('CHEBI_63056', 'zinc cation', 287, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 293, 'D'), ('CHEBI_27300', 'vitamin D', 309, 'vitamin D'), ('GO_0042368', 'vitamin D biosynthetic process', 309, 'vitamin D biosynthesis')]
S132-PMC5546866	PMC5546866	8/2017	S132-PMC5546866	['we FOUND that the rs10741657 Snp was not associated with baseline 25(Oh)D BUT was ASSOCIATED with the response to Gestational Vitamin D supplementation, THEREFORE SUGGESTING that this Snp ONLY modifies 25(Oh)D status when the substrate is more readily available and that at the baseline measurement, saturation of the enzyme had not been reached.']	[('INCOMPLETE_EVIDENCE', 3), ('ANOMALY_CURIOUS_FINDING', 74), ('SUPERFICIAL_RELATIONSHIP', 82), ('PROBABLE_UNDERSTANDING', 153), ('INCOMPLETE_EVIDENCE', 163), ('ANOMALY_CURIOUS_FINDING', 188)]	6	[('SO_0000694', 'SNP', 29, 'SNP'), ('CHEBI_71657', 'versiconol acetate', 66, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 66, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 114, 'gestational'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D'), ('SO_0000694', 'SNP', 184, 'SNP'), ('CHEBI_71657', 'versiconol acetate', 202, '25(OH)D')]
S134-PMC5546866	PMC5546866	8/2017	S134-PMC5546866	['BECAUSE the g Allele at rs10741657, which was more frequent in our population, was ASSOCIATED with lower 25(Oh)D following supplementation, it COULD BE POSTULATED that this Allele previously conferred an evolutionary advantage to prevent Vitamin D toxicity.']	[('PROBLEM_COMPLICATION', 0), ('SUPERFICIAL_RELATIONSHIP', 83), ('INCOMPLETE_EVIDENCE', 143), ('INCOMPLETE_EVIDENCE', 152)]	4	[('SO_0001023', 'allele', 14, 'allele'), ('CHEBI_71657', 'versiconol acetate', 105, '25(OH)D'), ('SO_0001023', 'allele', 173, 'allele'), ('CHEBI_27300', 'vitamin D', 238, 'vitamin D')]
S137-PMC5546866	PMC5546866	8/2017	S137-PMC5546866	['we SIMILARLY FOUND that the c Allele was ASSOCIATED with lower achieved 25(Oh)D following Antenatal Vitamin D supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 3), ('INCOMPLETE_EVIDENCE', 13), ('SUPERFICIAL_RELATIONSHIP', 41)]	3	[('SO_0001023', 'allele', 30, 'allele'), ('CHEBI_71657', 'versiconol acetate', 72, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 75, 'OH ... D'), ('GO_0007567', 'parturition', 90, 'antenatal'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin D')]
S151-PMC5546866	PMC5546866	8/2017	S151-PMC5546866	['OUR FINDINGS SUGGEST that analysis of Snps MAY have an IMPORTANT ROLE in identifying high-risk categories of Individuals who are LIKELY to REQUIRE higher doses of Vitamin D to achieve repletion, and STUDIES ARE NEEDED to establish clinical approaches to Vitamin D supplementation that are centered on individual characteristics.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 43), ('IMPORTANT_CONSIDERATION', 55), ('SUPERFICIAL_RELATIONSHIP', 65), ('PROBABLE_UNDERSTANDING', 129), ('IMPORTANT_CONSIDERATION', 139), ('FUTURE_WORK', 199)]	8	[('SO_0000694', 'SNP', 38, 'SNPs'), ('NCBITaxon_1', 'root', 109, 'individuals'), ('CHEBI_27300', 'vitamin D', 163, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 254, 'vitamin D')]
S68-PMC5576167	PMC5576167	8/2017	S68-PMC5576167	['Folic Acid was FOUND TO BE the most common dietary supplements used among Pregnant women (95.9%; n \xa0=\xa094) followed by iron, calcium and Vitamin D (88.8, 81.6 and 41%, respectively).']	[('ANOMALY_CURIOUS_FINDING', 15)]	1	[('CHEBI_30751', 'formic acid', 0, 'Folic acid'), ('GO_0007565', 'female pregnancy', 74, 'pregnant'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin D')]
S64-PMC5579643	PMC5579643	8/2017	S64-PMC5579643	['HOWEVER, clinical trials on Vitamin D supplementation in children and the POSSIBLE ROLE in preventing Food allergy are LACKING.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 74), ('SUPERFICIAL_RELATIONSHIP', 83), ('FULL_UNKNOWN', 119)]	4	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('CHEBI_33290', 'food', 102, 'food')]
S65-PMC5579643	PMC5579643	8/2017	S65-PMC5579643	['a systematic review of Vitamin D supplementation for the PREVENTION of allergic diseases FOUND NO EVIDENCES about the PROTECTIVE ROLE of this Nutrient in children, but the CURRENTLY available data are poor [24].']	[('SUPERFICIAL_RELATIONSHIP', 57), ('INCOMPLETE_EVIDENCE', 89), ('INCOMPLETE_EVIDENCE', 95), ('SUPERFICIAL_RELATIONSHIP', 118), ('SUPERFICIAL_RELATIONSHIP', 129), ('INCOMPLETE_EVIDENCE', 172)]	6	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('CHEBI_33284', 'nutrient', 142, 'nutrient')]
S66-PMC5587553	PMC5587553	9/2017	S66-PMC5587553	['ON THE OTHER HAND, Antenatal supplementation was FOUND EFFECTIVE when they had iron (n\u2009=\u200910, d 0.05, 95% ci 0.002–0.10, p\u2009=\u20090.04), Vitamins B1, B2, b3, B12(n\u2009=\u200910, d 0.05, 95% ci 0.01–0.10, p\u2009=\u20090.02), and Vitamin C (n\u2009=\u20099, d 0.07, 95% ci 0.02–0.12, p\u2009=\u20090.004).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 49), ('SUPERFICIAL_RELATIONSHIP', 55)]	3	[('GO_0007567', 'parturition', 19, 'antenatal'), ('CHEBI_34993', 'talampicillin hydrochloride', 131, 'vitamins B1'), ('PR_000004693', 'Bcl-2-like protein 10', 140, 'B1'), ('PR_000004693', 'Bcl-2-like protein 10', 144, 'B2'), ('CHEBI_27778', 'abequose', 152, 'B12'), ('CHEBI_27300', 'vitamin D', 205, 'vitamin C')]
S8-PMC5623264	PMC5623264	9/2017	S8-PMC5623264	['six interventions were ASSOCIATED with a decreased RISK of lbw: oral supplementation with (1) Vitamin A, (2) low-dose Calcium, (3) zinc, (4) multiple Micronutrients (mmn), nutritional education and provision of preventive Antimalarials.']	[('SUPERFICIAL_RELATIONSHIP', 23), ('IMPORTANT_CONSIDERATION', 51)]	2	[('CHEBI_27300', 'vitamin D', 94, 'vitamin A'), ('CHEBI_22313', 'alkaline earth metal atom', 118, 'calcium'), ('CHEBI_33839', 'macromolecule', 150, 'micronutrients'), ('CHEBI_22580', 'anthraquinone', 222, 'antimalarials')]
S73-PMC5623264	PMC5623264	9/2017	S73-PMC5623264	['twenty-two studies ASSESSED the EFFECT of the INTERVENTIONS on ptb.24–43 45 46all systematic reviews included individually\xa0rcts,24–469 cluster-rcts24 30–32 35 36 38 42 45and 10\xa0both rcts and quasi-rcts.24 26 29–32 43–46the number of included trials per review ranged from 241to 61 trials.30the number of included participants in the reviews ranged from 603 participants41to over 310\u2009000 participants.24supplementation with Vitamins was reported in five reviews,24–26 45 46supplementation with Minerals in eight reviews27–34and mmn supplementation was assessed in three reviews.35–37there was one review on protein supplementation and nutritional education38and two reviews REPORTED on marine oil and Fatty Acid supplementation.39 40one review evaluated reduced Salt intake,41one deworming42and two reviews preventive Antimalarial drugs.43 44\n\nmethodological quality of the included reviews\nsixteen reviews were of high quality.24–26 28–33 36 38 39 42 43 45 46six reviews were assessed to be of moderate quality.27 34 37 40 41 44only one included review had a score of three and, therefore, was judged to be of low methodological quality (table 1).35\n\neffects of interventions\n\noral supplementation with Vitamins alone or in combination\nfive systematic reviews INVESTIGATED the EFFECT of oral supplementation with Vitamin A,24vitamin C45Or Vitamin E during Pregnancy46And oral Folic Acid supplementation25 26during the Periconceptional period and Pregnancy (see\xa0onlinesupplementary table 6).']	[('INCOMPLETE_EVIDENCE', 19), ('SUPERFICIAL_RELATIONSHIP', 32), ('SUPERFICIAL_RELATIONSHIP', 46), ('INCOMPLETE_EVIDENCE', 673), ('QUESTION_ANSWERED_BY_THIS_WORK', 1260), ('SUPERFICIAL_RELATIONSHIP', 1277)]	6	[('CHEBI_33277', 'gamma-tocotrienol', 423, 'vitamins'), ('CHEBI_46751', 'quinolizidine', 493, 'minerals'), ('CHEBI_35366', 'fatty acid', 700, 'fatty acid'), ('CHEBI_24866', 'salt', 761, 'salt'), ('CHEBI_67261', '(Z)-2,3-dehydroadipyl-CoA(5-)', 817, 'antimalarial'), ('CHEBI_33277', 'gamma-tocotrienol', 1203, 'vitamins'), ('CHEBI_27300', 'vitamin D', 1313, 'vitamin A'), ('CHEBI_528968', '1-O-(alpha-D-galactopyranosyl)-N-(8-phenyloctanoyl)phytosphingosine', 1333, 'C45or'), ('PR_000001309', 'CD70 molecule', 1333, 'C45or'), ('CHEBI_27300', 'vitamin D', 1339, 'vitamin E'), ('GO_0006412', 'translation', 1356, 'pregnancy46and'), ('CHEBI_30751', 'formic acid', 1376, 'folic acid'), ('UBERON_0001844', 'cochlea', 1418, 'periconceptional'), ('GO_0007565', 'female pregnancy', 1446, 'pregnancy')]
S74-PMC5623264	PMC5623264	9/2017	S74-PMC5623264	['Vitamin A\na review including 19 rcts, quasi-rcts and cluster-rcts randomising over 310\u2009000 Pregnant women living in areas with endemic Vitamin A deficiency or in areas with adequate Intake assessed the EFFECT of Vitamin A supplementation or one of its derivatives alone or in combination with other supplements on lbw and ptb.24vitamin a alone compared with placebo or no treatment did not reduce lbw or ptb.']	[('SUPERFICIAL_RELATIONSHIP', 202)]	1	[('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'Vitamin A'), ('GO_0007565', 'female pregnancy', 91, 'pregnant'), ('CHEBI_27300', 'vitamin D', 135, 'vitamin A'), ('GO_0007631', 'feeding behavior', 182, 'intake'), ('CHEBI_27300', 'vitamin D', 212, 'vitamin A')]
S78-PMC5623264	PMC5623264	9/2017	S78-PMC5623264	['Vitamin E\ntwenty-one rcts and quasi-rcts randomising 22\u2009129 Pregnant women living in areas with inadequate Vitamin E intake or areas with PRESUMED adequate intake were included in this review.46any Vitamin E supplementation did not reduce ptb, sga or iugr.']	[('PROBABLE_UNDERSTANDING', 138)]	1	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin E'), ('PR_000017279', 'testis-specific basic protein Y 1', 0, 'Vitamin E'), ('GO_0007565', 'female pregnancy', 60, 'pregnant'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 198, 'vitamin E')]
S93-PMC5623264	PMC5623264	9/2017	S93-PMC5623264	['multiple Micronutrient supplementation\nthe EFFECT of mmn supplementation on lbw, ptb and sga was assessed in three reviews (see\xa0onlinesupplementary table 8).35–37mmn supplementation provided one RECOMMENDED daily nutrient intake of Vitamin A, vitamin B1, vitamin B2, niacin, vitamin B6, Vitamin B12, Folic Acid, Vitamin C, vitamin d, Vitamin E, copper, Selenium and Iodine with iron and zinc to Pregnant women.47a significant reduction of lbw in the range of 11%–14%\u2009and a significant reduction of sga in the range of 10%–17%\u2009could BE observed following mmn supplementation in all three reviews.']	[('SUPERFICIAL_RELATIONSHIP', 43), ('FUTURE_WORK', 195), ('ANOMALY_CURIOUS_FINDING', 532)]	3	"[('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 9, 'micronutrient'), ('CHEBI_27300', 'vitamin D', 232, 'vitamin A'), ('CHEBI_27718', ""alpha-Fuc-(1->2)-[alpha-Fuc-(1->2)-beta-Gal-(1->3)-alpha-GalNAc-(1->3)]-beta-Gal-(1->4)-beta-GlcNAc-(1->3)-beta-Gal-(1->4)-beta-Glc-(1<->1')-Cer"", 251, 'B1'), ('CHEBI_18245', 'carboxylato group', 263, 'B2'), ('CHEBI_51231', 'DAPI', 283, 'B6'), ('CHEBI_33279', 'vitamin D5', 287, 'vitamin B12'), ('CHEBI_30751', 'formic acid', 300, 'folic acid'), ('CHEBI_27300', 'vitamin D', 312, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 334, 'vitamin E'), ('CHEBI_27568', 'selenium atom', 353, 'selenium'), ('CHEBI_24859', 'iodine atom', 366, 'iodine'), ('GO_0007565', 'female pregnancy', 395, 'pregnant')]"
S108-PMC5623264	PMC5623264	9/2017	S108-PMC5623264	['vitamin a supplementation with other Micronutrients (Iron\xa0+\xa0Folate) compared with Micronutrient supplementation without Vitamin A had a positive EFFECT and reduced the risk of lbw by 33%.24HOWEVER, THESE FINDINGS are from a study involving only hiv-positive women and when comparing Vitamin A supplementation alone versus placebo or no treatment, a reduction of lbw could NOT be OBSERVED.']	[('SUPERFICIAL_RELATIONSHIP', 145), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 187), ('INCOMPLETE_EVIDENCE', 198), ('FULL_UNKNOWN', 372)]	4	[('CHEBI_33839', 'macromolecule', 37, 'micronutrients'), ('CHEBI_24870', 'ion', 53, 'iron'), ('CHEBI_30863', '5-azaorotic acid', 60, 'folate'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 82, 'micronutrient'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 283, 'vitamin A')]
S121-PMC5623264	PMC5623264	9/2017	S121-PMC5623264	['piso et al FOUND that Vitamin C supplementation during Pregnancy increased the RISK of ptb and magnesium supplementation decreased the RISK of ptb, lbw and sga.15HOWEVER, the cochrane reviews from which data were extracted had previously been updated and new studies had been added resulting in changed conclusions.']	[('INCOMPLETE_EVIDENCE', 11), ('IMPORTANT_CONSIDERATION', 79), ('IMPORTANT_CONSIDERATION', 135), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 160)]	4	[('CHEBI_27300', 'vitamin D', 22, 'vitamin C'), ('GO_0007565', 'female pregnancy', 55, 'pregnancy')]
S122-PMC5623264	PMC5623264	9/2017	S122-PMC5623264	['currently, there is NO EVIDENCE that magnesium or Vitamin C supplementation during Pregnancy positively or negatively AFFECT the RISK of ptb, lbw or sga.']	[('INCOMPLETE_EVIDENCE', 20), ('SUPERFICIAL_RELATIONSHIP', 118), ('IMPORTANT_CONSIDERATION', 129)]	3	[('CHEBI_27300', 'vitamin D', 50, 'vitamin C'), ('GO_0007565', 'female pregnancy', 83, 'pregnancy')]
S0-PMC5634602	PMC5634602	10/2017	S0-PMC5634602	['randomized trial of two doses of Vitamin D3In preterm infants <32 weeks: dose IMPACT on achieving desired Serum 25(Oh)D3In a nicu population\n\nabstract\n\nbackground\nRECOMMENDATIONS for Vitamin D supplementation for preterm infants span a WIDE range of doses.']	[('SUPERFICIAL_RELATIONSHIP', 78), ('FUTURE_WORK', 163), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 236)]	3	[('CHEBI_33229', 'vitamin (role)', 33, 'vitamin D3in'), ('PR_000017209', 'utrophin', 33, 'vitamin D3in'), ('UBERON_0001977', 'blood serum', 106, 'serum'), ('PR_000001883', 'lysosome-associated membrane protein', 112, '25(OH)D3in'), ('CHEBI_27300', 'vitamin D', 183, 'vitamin D')]
S1-PMC5634602	PMC5634602	10/2017	S1-PMC5634602	['response to Vitamin D supplementation and IMPACT on outcomes in preterm infants is NOT WELL UNDERSTOOD.']	[('SUPERFICIAL_RELATIONSHIP', 42), ('FULL_UNKNOWN', 83)]	2	[('CHEBI_27300', 'vitamin D', 12, 'vitamin D')]
S14-PMC5634602	PMC5634602	10/2017	S14-PMC5634602	['MANY aspects of clinical application of Vitamin D supplementation in the smallest preterm infants NEED additional SUPPORTIVE EVIDENCE.']	[('INCOMPLETE_EVIDENCE', 0), ('FUTURE_WORK', 98), ('INCOMPLETE_EVIDENCE', 114), ('FUTURE_WORK', 125)]	4	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D')]
S19-PMC5634602	PMC5634602	10/2017	S19-PMC5634602	['the authors of THIS PAPER HOWEVER, CONCLUDE that doses of supplementation of Vitamin D SHOULD ensure 25(Oh)D levels of 75 nmol/l to maintain Skeletal health.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 15), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 26), ('INCOMPLETE_EVIDENCE', 35), ('FUTURE_WORK', 87)]	4	[('CHEBI_27300', 'vitamin D', 77, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 101, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 107, 'D'), ('UBERON_0004288', 'skeleton', 141, 'skeletal')]
S23-PMC5634602	PMC5634602	10/2017	S23-PMC5634602	['the endocrine society also RECOMMENDS a target level of >75 nmol/l and espghan an EVEN higher target of >80 nmol/l.10.1371/journal.pone.0185950.t001\n\ncaption (table-wrap): table 1\nrecommendations for Vitamin D supplementation.recommending bodypatient agerecommended supplementationrecommended target Serum levelcommentsyear of publication american academy of pediatrics—section of breastfeeding and committee on nutrition healthy infants Birth– 12 months of age400 iu daily>50 nmol/l (targeting bone health)*begin soon after Birth, in the first few days of Life.']	[('FUTURE_WORK', 27), ('ANOMALY_CURIOUS_FINDING', 82)]	2	[('CHEBI_27300', 'vitamin D', 200, 'vitamin D'), ('UBERON_0001977', 'blood serum', 300, 'Serum'), ('GO_0007567', 'parturition', 438, 'birth'), ('GO_0007567', 'parturition', 525, 'birth'), ('UBERON_0000104', 'life cycle', 557, 'life')]
S26-PMC5634602	PMC5634602	10/2017	S26-PMC5634602	['preterm infants2008[2]Endocrine society healthy infants 0–1 year400–1000 iu>75 nmol/l (for non-Skeletal benefits)0–1 Vitamin D deficient (<50 nmol/l) 2000 iu/D for 6 weeks followed by maintenance dosing2011[9]\nvery LITTLE data is available regarding response to Vitamin D supplementation in the smallest and youngest infants (<1200 grams at Birth), a population that MIGHT see the most BENEFIT from normalized Vitamin D status.']	[('INCOMPLETE_EVIDENCE', 215), ('INCOMPLETE_EVIDENCE', 367), ('IMPORTANT_CONSIDERATION', 386)]	3	[('UBERON_0005063', 'left ventricular compact myocardium', 22, 'Endocrine'), ('UBERON_0004288', 'skeleton', 95, 'skeletal'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 158, 'D'), ('CHEBI_27300', 'vitamin D', 262, 'vitamin D'), ('GO_0007567', 'parturition', 341, 'birth'), ('CHEBI_27300', 'vitamin D', 410, 'vitamin D')]
S28-PMC5634602	PMC5634602	10/2017	S28-PMC5634602	['another trial evaluating placebo, 200 iu and 800 iu daily Vitamin D supplement evaluated levels at 36 weeks and days of Respiratory support, SHOWING PREVENTION of Vitamin D deficiency with the 800 iu dose, and an improvement in Serum levels with the 200 iu dose as compared to placebo, but no difference in days alive or in Respiratory support [11].']	[('INCOMPLETE_EVIDENCE', 141), ('SUPERFICIAL_RELATIONSHIP', 149)]	2	[('CHEBI_27300', 'vitamin D', 58, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 120, 'respiratory'), ('CHEBI_27300', 'vitamin D', 163, 'vitamin D'), ('UBERON_0001977', 'blood serum', 228, 'serum'), ('UBERON_0001004', 'respiratory system', 324, 'respiratory')]
S33-PMC5634602	PMC5634602	10/2017	S33-PMC5634602	['MANY STUDIES in the united states and abroad have DOCUMENTED maternal status to be SUBOPTIMAL and have CALLED for national programs to improve maternal Vitamin D status with increased supplementation dose and frequency [18–26].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 50), ('IMPORTANT_CONSIDERATION', 83), ('IMPORTANT_CONSIDERATION', 103), ('IMPORTANT_CONSIDERATION', 103)]	5	[('CHEBI_27300', 'vitamin D', 152, 'vitamin D')]
S40-PMC5634602	PMC5634602	10/2017	S40-PMC5634602	['additionally, we will EVALUATE response to supplementation in the subset of infants weighing <1200 grams AS there is MINIMAL information available regarding response to Vitamin D supplementation in this specific high-risk group.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 22), ('PROBABLE_UNDERSTANDING', 105), ('INCOMPLETE_EVIDENCE', 117)]	3	[('CHEBI_27300', 'vitamin D', 169, 'vitamin D')]
S66-PMC5634602	PMC5634602	10/2017	S66-PMC5634602	['Gestational age, Birth anthropometrics and in hospital growth are presented intable 2.10.1371/journal.pone.0185950.t002\n\ncaption (table-wrap): table 2\nGestational age, Birth anthropometrics and in hospital growth by Vitamin D3Supplementation group.variable400 iu800 iup-valuenmedianiqrnmedianiqr Birth weight, grams 161405.5270161392.56321.00 Birth weight %ile 1633301639.5390.33 Gestational age at delivery 163121630.355.350.75 Birth length, cm 16395.51639.510.10.94 Birth length %ile 1615241624.536.50.36 Birth Head circumference, cm 1627.521627.54.150.66 Birth hc %ile 162051163940.50.71 weight at 36 weeks, grams 142378.5393122542472.50.23 weight %ile 36 weeks 1418201227.5310.14 length at 36 weeks, cm 14432.21245.753.650.09 length %ile 36 weeks 1411151228450.06 hc at 36 weeks, cm 1432.13.51233.252.050.75 hc %ile 36 weeks 1430.562124429.50.52\n\n25Ohd changes by Vitamin D dose\nCord Blood 25(Oh)D3Levels were significantly CORRELATED with Gestational age (r = 0.40, p = 0.04), but had no CORRELATION with sex or race.']	[('SUPERFICIAL_RELATIONSHIP', 928), ('SUPERFICIAL_RELATIONSHIP', 993)]	2	"[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('GO_0007567', 'parturition', 17, 'birth'), ('GO_0007565', 'female pregnancy', 151, 'Gestational'), ('GO_0007567', 'parturition', 168, 'birth'), ('CHEBI_52915', 'phosphatediyl group', 216, 'vitamin D3supplementation'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 216, 'vitamin D3supplementation'), ('GO_0007567', 'parturition', 296, 'Birth'), ('GO_0007567', 'parturition', 343, 'Birth'), ('GO_0007565', 'female pregnancy', 380, 'Gestational'), ('GO_0007567', 'parturition', 429, 'Birth'), ('GO_0007567', 'parturition', 468, 'Birth'), ('GO_0007567', 'parturition', 507, 'Birth'), ('UBERON_0000033', 'head', 513, 'head'), ('GO_0007567', 'parturition', 558, 'Birth'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 851, '25OHD'), ('CHEBI_27300', 'vitamin D', 868, 'vitamin D'), ('UBERON_0000948', 'heart', 883, 'Cord'), ('UBERON_0000178', 'blood', 888, 'blood'), ('CHEBI_51924', 'ethyl 2-cyanoacetoacetate', 894, '25(OH)D3levels'), ('PR_000006775', 'cytoplasmic dynein 2 heavy chain 1', 900, 'D3levels'), ('GO_0007565', 'female pregnancy', 944, 'gestational')]"
S84-PMC5634602	PMC5634602	10/2017	S84-PMC5634602	['we SHOWED significant improvements in Vitamin D status between the groups supplemented with 400 iu and 800 iu at four weeks of age.']	[('INCOMPLETE_EVIDENCE', 3)]	1	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D')]
S89-PMC5634602	PMC5634602	10/2017	S89-PMC5634602	['a notable DIFFERENCE between THIS STUDY and ours is that in natarajan’s intervention the dose of Vitamin D supplementation was reduced to ACCOUNT FOR dietary intake of vitamin D and the total intake of Vitamin D was 400 iu or 800 iu.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 10), ('QUESTION_ANSWERED_BY_THIS_WORK', 29), ('PROBABLE_UNDERSTANDING', 138)]	3	[('CHEBI_27300', 'vitamin D', 97, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 176, 'D'), ('CHEBI_27300', 'vitamin D', 202, 'vitamin D')]
S90-PMC5634602	PMC5634602	10/2017	S90-PMC5634602	['in OUR STUDY supplementation of Vitamin D was in addition to dietary Vitamin D leading to greater total daily intake.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3)]	1	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 69, 'vitamin D')]
S125-PMC5634602	PMC5634602	10/2017	S125-PMC5634602	['supplementation of these patients with Vitamin D would NOT BE ADVISABLE.']	[('IMPORTANT_CONSIDERATION', 55), ('FUTURE_WORK', 62)]	2	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D')]
S131-PMC5634602	PMC5634602	10/2017	S131-PMC5634602	['these infants are the HIGHEST RISK infants and are in need of additional evaluation of Vitamin D status and response to supplementation.']	[('IMPORTANT_CONSIDERATION', 22)]	1	[('CHEBI_27300', 'vitamin D', 87, 'vitamin D')]
S144-PMC5634602	PMC5634602	10/2017	S144-PMC5634602	['EVIDENCE continues to mount in SUPPORT of this supplementation of preterm infants with Vitamin D early in hospitalization [44].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 31)]	2	[('CHEBI_27300', 'vitamin D', 87, 'vitamin D')]
S150-PMC5634602	PMC5634602	10/2017	S150-PMC5634602	['the OPTIMAL dose of Vitamin D supplementation for preterm infants during the early Neonatal Period WARRANTS FURTHER INVESTIGATION, but it is REASONABLE and SAFE to RECOMMEND daily supplementation in addition to dietary intake with 800 iu of Vitamin D to high-risk preterm infants while hospitalized in the nicu in order to TARGET a level of 25(Oh)D that is >75 nmol/l, AS we HAVE SHOWN this to improve bone health defined by dexa in this AT-RISK population.']	[('IMPORTANT_CONSIDERATION', 4), ('FUTURE_WORK', 99), ('PROBABLE_UNDERSTANDING', 141), ('IMPORTANT_CONSIDERATION', 156), ('FUTURE_WORK', 164), ('FUTURE_WORK', 323), ('PROBABLE_UNDERSTANDING', 369), ('INCOMPLETE_EVIDENCE', 375), ('IMPORTANT_CONSIDERATION', 438)]	9	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('UBERON_0007221', 'neonate stage', 83, 'neonatal period'), ('CHEBI_27300', 'vitamin D', 241, 'vitamin D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 344, 'OH)D')]
S44-PMC5640793	PMC5640793	9/2017	S44-PMC5640793	"[""the lancet 's 2013 maternal and child nutrition series RECOMMENDS ten nutrition-specific INTERVENTIONS, including sufficient and diverse Foods for adolescent girls and women; iron, Folic Acid, and Calcium supplementation in Pregnancy; good infant and young child Feeding practices; Vitamin A, iron, and preventive zinc supplementation for children; and treatment for moderate and severe acute malnutrition.5strikingly HOWEVER, expanding the coverage of these nutrition-specific INTERVENTIONS to 90% of mothers and children would only reduce stunting by an ESTIMATED 20%.5larger reductions than these REQUIRE increasing access to family Planning, health services for Pregnant women and children, investments in Water and sanitation, social safety nets, girls' education, and women's empowerment.6a pragmatic approach to design community STRATEGIES for stunting reduction MIGHT THEREFORE be to prioritise action on immediate determinants (infection control, nutrition, and care in the first 1000 days) while providing an enabling social environment for changes in more distal determinants, for example by sharing information about health, nutrition, and sanitation entitlements, and bolstering women's agency.""]"	[('FUTURE_WORK', 55), ('SUPERFICIAL_RELATIONSHIP', 89), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 418), ('ANOMALY_CURIOUS_FINDING', 418), ('SUPERFICIAL_RELATIONSHIP', 478), ('INCOMPLETE_EVIDENCE', 556), ('FUTURE_WORK', 600), ('IMPORTANT_CONSIDERATION', 600), ('FUTURE_WORK', 836), ('INCOMPLETE_EVIDENCE', 870), ('PROBABLE_UNDERSTANDING', 876)]	11	[('CHEBI_33290', 'food', 137, 'foods'), ('CHEBI_30751', 'formic acid', 181, 'folic acid'), ('CHEBI_22313', 'alkaline earth metal atom', 197, 'calcium'), ('GO_0007565', 'female pregnancy', 224, 'pregnancy'), ('GO_0007631', 'feeding behavior', 263, 'feeding'), ('CHEBI_27300', 'vitamin D', 282, 'vitamin A'), ('GO_0006260', 'DNA replication', 636, 'planning'), ('GO_0007565', 'female pregnancy', 666, 'pregnant'), ('CHEBI_15377', 'water', 710, 'water')]
S0-PMC5659607	PMC5659607	10/2017	S0-PMC5659607	['Prenatal Vitamin D supplementation reduces RISK of asthma/recurrent wheeze in early childhood: a combined analysis of two randomized controlled trials\n\nabstract\n\nbackground\nwe RECENTLY published two independent randomized controlled trials of Vitamin D supplementation during Pregnancy, both INDICATING a >20% reduced risk of asthma/recurrent wheeze in the offspring by 3 years of age.']	[('IMPORTANT_CONSIDERATION', 43), ('INCOMPLETE_EVIDENCE', 176), ('INCOMPLETE_EVIDENCE', 292)]	3	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 243, 'vitamin D'), ('GO_0007565', 'female pregnancy', 276, 'pregnancy')]
S13-PMC5659607	PMC5659607	10/2017	S13-PMC5659607	['conclusions\nthis combined analysis SHOWS that Vitamin D supplementation during Pregnancy results in a significant reduced risk of asthma/recurrent wheeze in the offspring, ESPECIALLY among women with 25(Oh)D level ≥ 30 ng/ml at randomization, where the risk was almost halved.']	[('INCOMPLETE_EVIDENCE', 35), ('ANOMALY_CURIOUS_FINDING', 172)]	2	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('GO_0007565', 'female pregnancy', 79, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 200, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 200, '25(OH)D')]
S19-PMC5659607	PMC5659607	10/2017	S19-PMC5659607	['THEREFORE, we RECENTLY conducted two independent randomized controlled trials (rcts) of increased Vitamin D supplementation during Pregnancy to prevent childhood asthma/recurrent wheeze in the offspring by age 3 years: the Vitamin D antenatal asthma reduction trial (vdaart[7]) and the copenhagen prospective studies on asthma in childhood 2010 (copsac2010[8]).']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 14)]	2	[('CHEBI_27300', 'vitamin D', 98, 'vitamin D'), ('GO_0007565', 'female pregnancy', 131, 'pregnancy'), ('CHEBI_28384', 'vitamin K', 223, 'Vitamin D')]
S21-PMC5659607	PMC5659607	10/2017	S21-PMC5659607	['a recent meta-analysis SUGGESTED that INSUFFICIENT power DUE TO an OVERESTIMATION of the treatment effect MAY HAVE BEEN one of the ISSUES for the non-significance of the FINDINGS[11], BUT we HYPOTHESIZED that maternal 25(Oh)D level at trial entry MAY also have INFLUENCED the EFFECT of the Vitamin D supplementation[12].']	[('INCOMPLETE_EVIDENCE', 23), ('INCOMPLETE_EVIDENCE', 38), ('PROBLEM_COMPLICATION', 38), ('PROBLEM_COMPLICATION', 57), ('PROBLEM_COMPLICATION', 67), ('INCOMPLETE_EVIDENCE', 106), ('INCOMPLETE_EVIDENCE', 110), ('PROBLEM_COMPLICATION', 131), ('INCOMPLETE_EVIDENCE', 170), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 184), ('INCOMPLETE_EVIDENCE', 191), ('INCOMPLETE_EVIDENCE', 247), ('SUPERFICIAL_RELATIONSHIP', 261), ('SUPERFICIAL_RELATIONSHIP', 276)]	14	[('CHEBI_71657', 'versiconol acetate', 218, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 224, 'D'), ('CHEBI_27300', 'vitamin D', 290, 'vitamin D')]
S68-PMC5659607	PMC5659607	10/2017	S68-PMC5659607	['HOWEVER, a literature search REVEALED one additional trial of Vitamin D supplementation in Pregnancy and subsequent asthma/recurrent wheeze performed by goldring et al., which DIFFERED markedly from our trials by enrolling 180 women at Pregnancy week 27 and randomizing them to either no Vitamin D, 800 iu Ergocalciferol daily until Delivery or a single oral bolus of 200,000 iu Cholecalciferol[22].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 29), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 176)]	3	[('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('GO_0007565', 'female pregnancy', 91, 'pregnancy'), ('GO_0007565', 'female pregnancy', 236, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 288, 'vitamin D'), ('CHEBI_4910', 'etomidate', 306, 'ergocalciferol'), ('GO_0007567', 'parturition', 333, 'delivery'), ('CHEBI_52550', 'theopalauamide', 379, 'cholecalciferol')]
S113-PMC5659607	PMC5659607	10/2017	S113-PMC5659607	['Lower Respiratory Tract infections (lrti) are analyzed by poisson regression model.Vitamin D vs.placeboipdor (95% ci)asthma/ recurrent wheeze0.75 (0.57–0.97)p = 0.03total Ige > median0.93 (0.73–1.18)p = 0.43specific Ige > 0.35ku/l1.05 (0.77–1.43)p = 0.78eczema0.91 (0.71–1.18)p = 0.47lrti0.92 (0.75–1.14)p = 0.44\n\ndiscussion\nin THIS combined analysis of the two largest rcts to date of Vitamin D supplementation during Pregnancy, we SHOWED that the supplementation resulted in a significant and clinically IMPORTANT 26% reduced risk of asthma/recurrent wheeze in the offspring until age 3, with a more pronounced 46% reduced risk if the women had 25(Oh)d level ≥30ng/ml at trial entry.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 328), ('INCOMPLETE_EVIDENCE', 433), ('IMPORTANT_CONSIDERATION', 506)]	3	[('UBERON_0004905', 'articulation', 0, 'Lower respiratory tract'), ('CHEBI_28384', 'vitamin K', 83, 'Vitamin D'), ('GO_0071743', 'IgE immunoglobulin complex, circulating', 171, 'IgE'), ('GO_0071743', 'IgE immunoglobulin complex, circulating', 216, 'IgE'), ('CHEBI_27300', 'vitamin D', 386, 'vitamin D'), ('GO_0007565', 'female pregnancy', 419, 'pregnancy'), ('CHEBI_63056', 'zinc cation', 647, '25(OH')]
S114-PMC5659607	PMC5659607	10/2017	S114-PMC5659607	['these results UNDERLINE that Vitamin D supplementation during Pregnancy MAY BE an IMPORTANT FACTOR in the PREVENTION of childhood asthma.']	[('PROBABLE_UNDERSTANDING', 14), ('INCOMPLETE_EVIDENCE', 72), ('IMPORTANT_CONSIDERATION', 82), ('SUPERFICIAL_RELATIONSHIP', 92), ('SUPERFICIAL_RELATIONSHIP', 106)]	5	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('GO_0007565', 'female pregnancy', 62, 'pregnancy')]
S118-PMC5659607	PMC5659607	10/2017	S118-PMC5659607	['this resulted in more power to detect TRUE EFFECTS of the Vitamin D supplementation than the individual intent-to-treat analyses, illustrated by a similar overall effect estimate in the analyses, which now reached statistical SIGNIFICANCE.']	[('PROBABLE_UNDERSTANDING', 38), ('SUPERFICIAL_RELATIONSHIP', 43), ('IMPORTANT_CONSIDERATION', 226)]	3	[('CHEBI_27300', 'vitamin D', 58, 'vitamin D')]
S120-PMC5659607	PMC5659607	10/2017	S120-PMC5659607	['DESPITE these DIFFERENCES, the trials SIMILARLY SHOWED that the Vitamin D supplementation resulted in significantly increased post-interventional 25(Oh)D levels in the mothers.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 14), ('SUPERFICIAL_RELATIONSHIP', 38), ('INCOMPLETE_EVIDENCE', 48)]	5	[('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 146, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 146, '25(OH ... D')]
S130-PMC5659607	PMC5659607	10/2017	S130-PMC5659607	['furthermore, including a third trial of Vitamin D supplementation in the meta-analysis, which intervened at a later Pregnancy stage (week 27) and with a much lower dose (800 iu/day) [22] also SHOWED an overall PROTECTIVE EFFECT of Vitamin D on Development Of Asthma/recurrent Wheeze.']	[('INCOMPLETE_EVIDENCE', 192), ('SUPERFICIAL_RELATIONSHIP', 210), ('SUPERFICIAL_RELATIONSHIP', 221)]	3	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('GO_0007565', 'female pregnancy', 116, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 231, 'vitamin D'), ('GO_0009602', 'detection of symbiont', 244, 'development of asthma'), ('GO_0006386', 'termination of RNA polymerase III transcription', 276, 'wheeze')]
S132-PMC5659607	PMC5659607	10/2017	S132-PMC5659607	['a recent meta-analysis SUPPORTS our finding of a significant reduction in asthma/wheeze from Prenatal Vitamin D supplementation[11].']	[('INCOMPLETE_EVIDENCE', 23)]	1	[('GO_0007565', 'female pregnancy', 93, 'prenatal'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin D')]
S135-PMC5659607	PMC5659607	10/2017	S135-PMC5659607	['to explore that ISSUE, we performed the combined analyses stratified for the women’s 25(Oh)D level at trial entry, which SHOWED that the Vitamin D supplement resulted in a significantly reduced RISK of asthma/recurrent wheeze in the offspring of women with 25(Oh)D ≥ 30 ng/ml, BUT a much SMALLER and statistically non-significant EFFECT among women with 25(Oh)D < 30 ng/ml.']	[('PROBLEM_COMPLICATION', 16), ('INCOMPLETE_EVIDENCE', 121), ('IMPORTANT_CONSIDERATION', 194), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 277), ('INCOMPLETE_EVIDENCE', 288), ('SUPERFICIAL_RELATIONSHIP', 330)]	6	[('CHEBI_71657', 'versiconol acetate', 85, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 91, 'D'), ('CHEBI_27300', 'vitamin D', 137, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 257, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 257, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 354, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 354, '25(OH)D')]
S136-PMC5659607	PMC5659607	10/2017	S136-PMC5659607	['this FINDING is CONTRARY to what MANY have SUGGESTED that ONLY those who are deficient in Vitamin D would BENEFIT from supplementation.']	[('INCOMPLETE_EVIDENCE', 5), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 16), ('INCOMPLETE_EVIDENCE', 33), ('INCOMPLETE_EVIDENCE', 43), ('ANOMALY_CURIOUS_FINDING', 58), ('IMPORTANT_CONSIDERATION', 106)]	6	[('CHEBI_27300', 'vitamin D', 90, 'vitamin D')]
S140-PMC5659607	PMC5659607	10/2017	S140-PMC5659607	['THEREFORE, initiating the supplementation at 10–18 weeks’ Gestation in vdaart and in particular at 22–26 weeks’ Gestation in copsac2010was PRESUMABLY too late to achieve a maximal EFFECT of Vitamin D on fetal Lung Development.']	[('PROBABLE_UNDERSTANDING', 0), ('PROBABLE_UNDERSTANDING', 139), ('SUPERFICIAL_RELATIONSHIP', 180)]	3	[('GO_0007565', 'female pregnancy', 58, 'gestation'), ('GO_0007565', 'female pregnancy', 112, 'gestation'), ('CHEBI_27300', 'vitamin D', 190, 'vitamin D'), ('GO_0030324', 'lung development', 209, 'lung development'), ('UBERON_0002048', 'lung', 209, 'lung')]
S141-PMC5659607	PMC5659607	10/2017	S141-PMC5659607	['in addition, AS Human fertility is also INFLUENCED by Vitamin D[29,30], it MAY EVEN be worthwhile to TARGET supplementation before Conception to optimize Implantation of the Fertilized Egg and assure sufficient Vitamin D for Lung and Immune Development from the very beginning of Life.']	[('PROBABLE_UNDERSTANDING', 13), ('SUPERFICIAL_RELATIONSHIP', 40), ('INCOMPLETE_EVIDENCE', 75), ('ANOMALY_CURIOUS_FINDING', 79), ('FUTURE_WORK', 101)]	5	[('NCBITaxon_9606', 'Homo sapiens', 16, 'human'), ('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('GO_0007620', 'copulation', 131, 'conception'), ('GO_0007566', 'embryo implantation', 154, 'implantation'), ('GO_0009566', 'fertilization', 174, 'fertilized'), ('CL_0000025', 'egg cell', 185, 'egg'), ('UBERON_0007379', 'shelled egg', 185, 'egg'), ('CHEBI_27300', 'vitamin D', 211, 'vitamin D'), ('GO_0006266', 'DNA ligation', 225, 'lung ...'), ('UBERON_0002048', 'lung', 225, 'lung'), ('GO_0001822', 'kidney development', 234, 'immune development'), ('UBERON_0002405', 'immune system', 234, 'immune'), ('UBERON_0000104', 'life cycle', 280, 'life')]
S144-PMC5659607	PMC5659607	10/2017	S144-PMC5659607	['we OBSERVED that the Vitamin D supplement resulted in a significant increase in post-interventional maternal 25(Oh)D level in both trials, BUT levels ≥ 30 ng/ml were ONLY achieved in 75% of the supplemented mothers in vdaart and 82% in copsac2010underscoring that too low a dose MAY have attenuated the trial results in both trials but to a greater extent in vdaart POSSIBLY because of the increased african american enrollment.']	[('INCOMPLETE_EVIDENCE', 3), ('ANOMALY_CURIOUS_FINDING', 139), ('INCOMPLETE_EVIDENCE', 166), ('INCOMPLETE_EVIDENCE', 279), ('INCOMPLETE_EVIDENCE', 366)]	5	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 109, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 109, '25(OH ... D')]
S145-PMC5659607	PMC5659607	10/2017	S145-PMC5659607	['the LACK OF effect of the Vitamin D supplement among women with low 25(Oh)D levels at trial entry also SUGGESTS that the dose MIGHT have been too low to reverse developmental changes caused by insufficient Vitamin D exposure before the supplementation was initiated.']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 103), ('INCOMPLETE_EVIDENCE', 126)]	3	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 68, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 74, 'D'), ('CHEBI_27300', 'vitamin D', 206, 'vitamin D')]
S148-PMC5659607	PMC5659607	10/2017	S148-PMC5659607	['this is CONSISTENT with a RECENT rct SHOWING no effect on Cat specific Ige levels, WHEREAS decreased house-Dust Mite specific Ige was SHOWN in the offspring of mothers supplemented with Vitamin D during Pregnancy[31].']	[('INCOMPLETE_EVIDENCE', 8), ('INCOMPLETE_EVIDENCE', 26), ('INCOMPLETE_EVIDENCE', 37), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 83), ('INCOMPLETE_EVIDENCE', 134)]	5	[('NCBITaxon_33208', 'Metazoa', 58, 'cat'), ('GO_0071743', 'IgE immunoglobulin complex, circulating', 71, 'IgE'), ('NCBITaxon_10088', 'Mus <genus>', 107, 'dust'), ('NCBITaxon_10088', 'Mus <genus>', 112, 'mite'), ('GO_0071743', 'IgE immunoglobulin complex, circulating', 126, 'IgE'), ('CHEBI_27300', 'vitamin D', 186, 'vitamin D'), ('GO_0007565', 'female pregnancy', 203, 'pregnancy')]
S151-PMC5659607	PMC5659607	10/2017	S151-PMC5659607	['combining this KNOWLEDGE with OUR FINDINGS from THIS combined analysis, SHOWING that Vitamin D supplementation has a PROTECTIVE EFFECT on childhood asthma/recurrent wheeze, makes Vitamin D a very PROMISING Nutrient for FUTURE PREVENTION of Immune-mediated disorders.']	[('FUTURE_WORK', 15), ('QUESTION_ANSWERED_BY_THIS_WORK', 30), ('QUESTION_ANSWERED_BY_THIS_WORK', 48), ('INCOMPLETE_EVIDENCE', 72), ('SUPERFICIAL_RELATIONSHIP', 117), ('SUPERFICIAL_RELATIONSHIP', 128), ('PROBABLE_UNDERSTANDING', 196), ('FUTURE_WORK', 219), ('SUPERFICIAL_RELATIONSHIP', 226)]	9	[('CHEBI_27300', 'vitamin D', 85, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 179, 'vitamin D'), ('CHEBI_33284', 'nutrient', 206, 'nutrient'), ('UBERON_0002405', 'immune system', 240, 'immune')]
S152-PMC5659607	PMC5659607	10/2017	S152-PMC5659607	['FUTURE STUDIES SHOULD explore the OPTIMAL timing and level of Vitamin D supplementation during Pregnancy.']	[('FUTURE_WORK', 0), ('FUTURE_WORK', 15), ('IMPORTANT_CONSIDERATION', 34)]	3	[('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('GO_0007565', 'female pregnancy', 95, 'pregnancy')]
S153-PMC5659607	PMC5659607	10/2017	S153-PMC5659607	['conclusion\nthis combined analysis SHOWS a significant and clinically IMPORTANT 26% PROTECTIVE EFFECT of Vitamin D supplementation during Pregnancy on the RISK of asthma/recurrent wheeze in the offspring, with a more pronounced risk reduction of 46% in women with 25(Oh)D level ≥ 30 ng/ml at trial entry.']	[('INCOMPLETE_EVIDENCE', 34), ('IMPORTANT_CONSIDERATION', 69), ('SUPERFICIAL_RELATIONSHIP', 83), ('SUPERFICIAL_RELATIONSHIP', 94), ('IMPORTANT_CONSIDERATION', 154)]	5	[('CHEBI_27300', 'vitamin D', 104, 'vitamin D'), ('GO_0007565', 'female pregnancy', 137, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 263, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 263, '25(OH)D')]
S6-PMC5664622	PMC5664622	9/2017	S6-PMC5664622	['THEREFORE, summer improves the levels of Vitamin D in the body but does not guarantee the RECOMMENDED concentration and supplementation throughout the whole year is ESSENTIAL.']	[('PROBABLE_UNDERSTANDING', 0), ('FUTURE_WORK', 90), ('IMPORTANT_CONSIDERATION', 165)]	3	[('CHEBI_27300', 'vitamin D', 41, 'vitamin D')]
S15-PMC5664622	PMC5664622	9/2017	S15-PMC5664622	['AS dietary sources of Vitamin D have FAILED to meet the RECOMMENDED levels for years [12,13], Vitamin D concentration is in fact enhanced by supplementation and exposure to sunlight [2,5].']	[('PROBABLE_UNDERSTANDING', 0), ('DIFFICULT_TASK', 37), ('FUTURE_WORK', 56)]	3	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin D')]
S35-PMC5664622	PMC5664622	9/2017	S35-PMC5664622	['the content of Vitamin D in Vitamin/Mineral supplements for Pregnant women, as well as single-component Vitamin D preparations, was ESTIMATED on the BASIS of our earlier analysis [14].']	[('INCOMPLETE_EVIDENCE', 132), ('INCOMPLETE_EVIDENCE', 149)]	2	[('CHEBI_27300', 'vitamin D', 15, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 28, 'vitamin'), ('CHEBI_46662', 'mineral', 36, 'mineral'), ('GO_0007565', 'female pregnancy', 60, 'pregnant'), ('CHEBI_27300', 'vitamin D', 104, 'vitamin D')]
S39-PMC5664622	PMC5664622	9/2017	S39-PMC5664622	['statistical analysis\na multivariate regression analysis was used TO INVESTIGATE the relationship between maternal Vitamin D concentration and selected baseline characteristics (Vitamin D consumption, use of dietary supplements, season, maternal age and education, gravidity, bmi, weight gain, diabetes, hypertension, smoking, use of sun screen, exposure to sun).']	[('QUESTION_ANSWERED_BY_THIS_WORK', 65)]	1	[('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 177, 'vitamin D')]
S65-PMC5664622	PMC5664622	9/2017	S65-PMC5664622	['other factors RELATED to Serum Vitamin D concentration\nmultivariate regression analysis REVEALED that, apart from the season of the year, Vitamin D concentration was AFFECTED by the following FACTORS: maternal use of Vitamin D supplements, weight gain in Pregnancy, Gestational diabetes mellitus (gdm), and—in case of Cord Blood—also with Maternal age.']	[('SUPERFICIAL_RELATIONSHIP', 14), ('INCOMPLETE_EVIDENCE', 88), ('SUPERFICIAL_RELATIONSHIP', 166), ('SUPERFICIAL_RELATIONSHIP', 192)]	4	[('UBERON_0001977', 'blood serum', 25, 'Serum'), ('CHEBI_28384', 'vitamin K', 31, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 31, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 138, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 217, 'vitamin D'), ('GO_0007565', 'female pregnancy', 255, 'pregnancy'), ('GO_0007565', 'female pregnancy', 266, 'gestational'), ('UBERON_0002240', 'spinal cord', 318, 'cord'), ('UBERON_0000178', 'blood', 323, 'blood'), ('GO_0007618', 'mating', 339, 'maternal')]
S93-PMC5664622	PMC5664622	9/2017	S93-PMC5664622	['DUE TO the fact that weather conditions, including the increasingly common heat waves which prevent exposure to sun, remain beyond Human control, supplementation SEEMS TO BE the BEST method of preventing Vitamin D insufficiency.']	[('PROBLEM_COMPLICATION', 0), ('ANOMALY_CURIOUS_FINDING', 162), ('IMPORTANT_CONSIDERATION', 178)]	3	[('NCBITaxon_9606', 'Homo sapiens', 131, 'human'), ('CHEBI_27300', 'vitamin D', 204, 'vitamin D')]
S94-PMC5664622	PMC5664622	9/2017	S94-PMC5664622	['REGARDLESS, DESPITE Vitamin/Mineral supplementation in Pregnancy, maternal intake of Vitamin D REMAINS below the RECOMMENDED levels, MOSTLY BECAUSE 75% of the multi-component Supplements for Pregnant women which are available in poland contain small amount of Vitamin D (5–10 µg) [14], as compared to the recommended dose of 37.5–50 µg [8].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 12), ('INCOMPLETE_EVIDENCE', 95), ('FUTURE_WORK', 113), ('PROBABLE_UNDERSTANDING', 133), ('PROBABLE_UNDERSTANDING', 140)]	6	[('CHEBI_33229', 'vitamin (role)', 20, 'vitamin'), ('CHEBI_46662', 'mineral', 28, 'mineral'), ('GO_0007565', 'female pregnancy', 55, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 85, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 175, 'supplements'), ('GO_0007565', 'female pregnancy', 191, 'pregnant'), ('CHEBI_27300', 'vitamin D', 260, 'vitamin D')]
S113-PMC5664622	PMC5664622	9/2017	S113-PMC5664622	['it is MOST PROBABLY the result of the fact that gdm women in this sample more OFTEN used single-component Vitamin D preparations, or even several supplements at once, as compared to healthy women (35.8% vs. 11.5%, respectively).']	[('PROBABLE_UNDERSTANDING', 6), ('PROBABLE_UNDERSTANDING', 11), ('PROBABLE_UNDERSTANDING', 78)]	3	[('CHEBI_27300', 'vitamin D', 106, 'vitamin D')]
S116-PMC5664622	PMC5664622	9/2017	S116-PMC5664622	['the absence of a correlation between Blood Vitamin D levels and its intake from the diet (no supplementation) is MOST PROBABLY a direct result of low Vitamin D Intake (2.1 µg/day), which is CONSISTENT with REPORTS of other authors at a daily Intake of 0.8 µg [12].']	[('PROBABLE_UNDERSTANDING', 113), ('PROBABLE_UNDERSTANDING', 118), ('INCOMPLETE_EVIDENCE', 190), ('INCOMPLETE_EVIDENCE', 206)]	4	[('UBERON_0000178', 'blood', 37, 'blood'), ('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 150, 'vitamin D'), ('GO_0007631', 'feeding behavior', 160, 'intake'), ('GO_0007631', 'feeding behavior', 242, 'intake')]
S1-PMC5679631	PMC5679631	11/2017	S1-PMC5679631	['we INVESTIGATED WHETHER maternal Vitamin D supplemention, maternal Plasma 25-Hydroxyvitamin D concentration, OR direct supplementation of the infant INFLUENCES key bacterial taxa within microbiota of one month old infants.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 16), ('SUPERFICIAL_RELATIONSHIP', 149)]	3	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 67, 'plasma'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 74, '25-hydroxyvitamin D')]
S12-PMC5679631	PMC5679631	11/2017	S12-PMC5679631	['difficile were ASSOCIATED with Vitamin D supplementation of Breast Fed infants whose mothers were more LIKELY to adhere to an alternative lifestyle in terms of, e .']	[('SUPERFICIAL_RELATIONSHIP', 15), ('PROBABLE_UNDERSTANDING', 103)]	2	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D'), ('UBERON_0000310', 'breast', 60, 'breast'), ('GO_0007631', 'feeding behavior', 67, 'fed')]
S15-PMC5679631	PMC5679631	11/2017	S15-PMC5679631	['given that Intestinal Microbiotic Homeostasis MAY BE an IMPORTANT FACTOR in the PREVENTION of Immune mediated diseases and that Vitamin D status is a MODIFIABLE FACTOR, FURTHER INVESTIGATION of the IMPACT of Postnatal Vitamin D supplementation SHOULD BE conducted in older infants.']	[('INCOMPLETE_EVIDENCE', 46), ('IMPORTANT_CONSIDERATION', 56), ('SUPERFICIAL_RELATIONSHIP', 66), ('SUPERFICIAL_RELATIONSHIP', 80), ('IMPORTANT_CONSIDERATION', 150), ('SUPERFICIAL_RELATIONSHIP', 161), ('FUTURE_WORK', 169), ('SUPERFICIAL_RELATIONSHIP', 198), ('FUTURE_WORK', 244)]	9	[('UBERON_0000160', 'intestine', 11, 'intestinal'), ('CHEBI_75293', 'methyltrioctylammonium', 22, 'microbiotic'), ('GO_0055074', 'calcium ion homeostasis', 22, 'microbiotic homeostasis'), ('UBERON_0002405', 'immune system', 94, 'immune'), ('CHEBI_27300', 'vitamin D', 128, 'vitamin D'), ('GO_0007567', 'parturition', 208, 'postnatal'), ('CHEBI_27300', 'vitamin D', 218, 'vitamin D')]
S26-PMC5679631	PMC5679631	11/2017	S26-PMC5679631	['GIVEN that Vitamin D status is a MODIFIABLE FACTOR which MAY INFLUENCE Intestinal Microbiotic Homeostasis, which in turn is INDICATED to be IMPORTANT in the prevention of Immune mediated diseases, we INVESTIGATED WHETHER maternal use of multivitamin supplements containing Vitamin D, maternal Vitamin D status (25 Hydroxyvitamin D (25(Oh)D), OR administration of Vitamin D supplement to the baby INFLUENCES the presence and abundance of several key bacterial taxa of the infant Gut microbiota.']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 33), ('SUPERFICIAL_RELATIONSHIP', 44), ('INCOMPLETE_EVIDENCE', 57), ('SUPERFICIAL_RELATIONSHIP', 61), ('INCOMPLETE_EVIDENCE', 124), ('IMPORTANT_CONSIDERATION', 140), ('QUESTION_ANSWERED_BY_THIS_WORK', 200), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 213), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 342), ('SUPERFICIAL_RELATIONSHIP', 396)]	11	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('UBERON_0000160', 'intestine', 71, 'intestinal'), ('CHEBI_75293', 'methyltrioctylammonium', 82, 'microbiotic'), ('GO_0055074', 'calcium ion homeostasis', 82, 'microbiotic homeostasis'), ('UBERON_0002405', 'immune system', 171, 'immune'), ('CHEBI_27300', 'vitamin D', 273, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 293, 'vitamin D'), ('CHEBI_67828', 'rel-(3aR,4S,6aS,7R,9aR,10aS)-10a-Hydroxy-7-isopropyl-1,4,9a-trimethyl-4,5,6,6a,7,8,9,9a,10,10a-decahydro-3aH-dicyclopenta[a,d]cycloocten-3-one', 311, '25 hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 332, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 363, 'vitamin D'), ('UBERON_0001555', 'digestive tract', 478, 'gut')]
S36-PMC5679631	PMC5679631	11/2017	S36-PMC5679631	['data regarding POSSIBLE CONFOUNDERS and Vitamin D exposure through Supplement use was assessed from questionnaires sent to all parents at 34 weeks of Gestation, the time of Fecal sampling and 3 months Postpartum, respectively.']	[('INCOMPLETE_EVIDENCE', 15), ('PROBLEM_COMPLICATION', 24)]	2	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('CHEBI_16158', 'steroid sulfate', 67, 'supplement'), ('GO_0007565', 'female pregnancy', 150, 'gestation'), ('UBERON_0000922', 'embryo', 173, 'fecal'), ('GO_0007565', 'female pregnancy', 201, 'postpartum')]
S78-PMC5679631	PMC5679631	11/2017	S78-PMC5679631	['the analyses concerning Vitamin D supplementation of the Breast Fed infant included 616 Individuals after omitting infants receiving formula (n = 208), both Breast Milk and formula (n = 87) and lack OF information regarding Feeding (n = 2).']	[('ANOMALY_CURIOUS_FINDING', 199)]	1	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('UBERON_0000310', 'breast', 57, 'breast'), ('GO_0007631', 'feeding behavior', 64, 'fed'), ('NCBITaxon_1', 'root', 88, 'individuals'), ('UBERON_0000310', 'breast', 157, 'breast'), ('UBERON_0001913', 'milk', 164, 'milk'), ('GO_0007631', 'feeding behavior', 224, 'feeding')]
S84-PMC5679631	PMC5679631	11/2017	S84-PMC5679631	['the characteristics of the Breast Fed children were fairly SIMILAR between the children receiving Vitamin D supplementation and those who did not, except that mothers who were recruited in the conventional recruitment group were more LIKELY to give their child Vitamin D supplementation than those in the alternative recruitment group.']	[('SUPERFICIAL_RELATIONSHIP', 59), ('PROBABLE_UNDERSTANDING', 234)]	2	[('GO_0007567', 'parturition', 27, 'breast fed'), ('UBERON_0000310', 'breast', 27, 'breast'), ('CHEBI_27300', 'vitamin D', 98, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 261, 'vitamin D')]
S85-PMC5679631	PMC5679631	11/2017	S85-PMC5679631	['there was also a minor difference in that parents with more children TENDED not to supplement their infant with Vitamin D. in terms of use of multivitamin supplements containing Vitamin D, by the mother, those in the conventional group were more represented in the none and highest categories of supplementation with approximately equal representation of recruitment groups occuring in the < 10 μg category.']	[('SUPERFICIAL_RELATIONSHIP', 69)]	1	[('CHEBI_27300', 'vitamin D', 112, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 178, 'vitamin D')]
S88-PMC5679631	PMC5679631	11/2017	S88-PMC5679631	['during seasons of both high and low cutaneous Production Of Vitamin D, the mean maternal Plasma 25(Oh)D concentrations were significantly greater in mothers who used Vitamin D containing supplements COMPARED TO those who did not.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 199)]	1	[('GO_0018240', 'protein S-linked glycosylation via cysteine', 46, 'production of vitamin D'), ('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 89, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 96, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 96, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 166, 'vitamin D')]
S89-PMC5679631	PMC5679631	11/2017	S89-PMC5679631	['use of multivitamin supplements containing Vitamin D and maternal obesity were ASSOCIATED with maternal 25(Oh)D level during both low and high seasons, WHILE recruitment group was significantly ASSOCIATED with 25(Oh)D concentration ONLY during the high season.10.1371/journal.pone.0188011.t002\n\ncaption (table-wrap): table 2\nmean maternal 25(Oh)D concentration according to season of Blood sampling and use of multivitamin supplements containing Vitamin D.Blood sampling in high season of cutaneous Vitamin D productionblood sampling in low season of cutaneous Vitamin D production maternal use of multivitamin supplement containing Vitamin Dmaternal Plasma 25(Oh)d nmol/lmaternal Plasma 25(Oh)D nmol/l no (mean (sd))45.2 (17.0)30.1 (13.5)yes (mean (sd))53.3 (17.8)40.9 (16.1)p value&p = 0.000p = 0.000model # beta (95% ci)beta (95% ci) constant52.7 (47.7, 57.7)34.6 (29.5, 39.7)maternal use of multivitamin supplement containing Vitamin D (yes vs .']	[('SUPERFICIAL_RELATIONSHIP', 79), ('ANOMALY_CURIOUS_FINDING', 152), ('SUPERFICIAL_RELATIONSHIP', 194), ('INCOMPLETE_EVIDENCE', 232)]	4	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 104, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 104, '25(OH ... D'), ('CHEBI_71657', 'versiconol acetate', 210, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 210, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 339, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 339, '25 ... OH ... D'), ('UBERON_0000178', 'blood', 384, 'blood'), ('CHEBI_27300', 'vitamin D', 446, 'vitamin D'), ('UBERON_0000178', 'blood', 456, 'Blood'), ('CHEBI_27300', 'vitamin D', 499, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 561, 'vitamin D'), ('CHEBI_61716', 'alpha-Kdo-CH2OH-(2->4)-alpha-Kdo', 633, 'vitamin DMaternal'), ('UBERON_0001969', 'blood plasma', 651, 'Plasma'), ('CHEBI_63056', 'zinc cation', 658, '25(OH'), ('UBERON_0001969', 'blood plasma', 681, 'Plasma'), ('CHEBI_71657', 'versiconol acetate', 688, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 930, 'vitamin D')]
S92-PMC5679631	PMC5679631	11/2017	S92-PMC5679631	['conventional recruitment group -4.6 (-7.8, -1.4) -3.1 (-6.4, 0.3)\nhigh season = april–october, low season = november–march; overweight = body mass index > 90thpercentile;\n&unpaired t-test;\n#regression coefficients (beta) from multivariable linear regression analysis INDICATE the difference in maternal Plasma 25(Oh)D in nmol/l between the group of mothers taking multivitamin supplement containing Vitamin D and those who did not while controlling for the other factors in the model\n\nmaternal Vitamin D intake through use of multivitamin supplements containing Vitamin d\nmaternal use of multivitamin supplements containing Vitamin D was not associated with the prevalence of any of the bacteria in both the unadjusted and adjusted analyses (data not shown).']	[('INCOMPLETE_EVIDENCE', 267)]	1	[('UBERON_0001969', 'blood plasma', 303, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 310, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 310, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 399, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 494, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 562, 'vitamin'), ('CHEBI_27300', 'vitamin D', 624, 'vitamin D')]
S93-PMC5679631	PMC5679631	11/2017	S93-PMC5679631	['there was a statistically significant negative linear TREND between categories of maternal Vitamin D supplementation and counts of bifidobacterium spp.']	[('INCOMPLETE_EVIDENCE', 54)]	1	[('CHEBI_27300', 'vitamin D', 91, 'vitamin D')]
S96-PMC5679631	PMC5679631	11/2017	S96-PMC5679631	['the trend for bifidobacteria REMAINED statistically significant following correction for multiple testing using the fdr.10.1371/journal.pone.0188011.t003\n\ncaption (table-wrap): table 3\nassociation between maternal use of multivitamin supplements containing Vitamin D and log10colony forming units of bacterial species or groups in infants colonized with the respective bacteria.maternal use of multivitamin supplements containing vitamin dmaternal multivitamin supplementation containing Vitamin dbacteria&nunadjusted b (95% ci)#adjusted b (95% ci)none bifidobacterium spp.']	[('INCOMPLETE_EVIDENCE', 29)]	1	[('CHEBI_27300', 'vitamin D', 257, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 488, 'vitamin')]
S105-PMC5679631	PMC5679631	11/2017	S105-PMC5679631	['600 (reference)0 (reference)quintile 2680.01 (-0.21, 0.24)0.01 (-0.21, 0.22)quintile 349-0.11 (-0.35, 0.14)-0.18 (-0.41, 0.06)quintile 4510.02 (-0.22, 0.26)0.04 (-0.20, 0.28)quintile 558-0.06 (-0.30, 0.17)0.08 (-0.17, 0.33)p for linear trendp = 0.459\n&number of children colonized;\n#adjusted for: place and mode of Delivery, number of siblings, recruitment group, total bacterial counts, sex, vaginitis during the last month of Pregnancy, mode of infant nutrition and season of Blood sampling; quintile 5 is the highest quintile;\n* remained statistically significant after correction with fdr (q < 0.05)\n\nVitamin D supplementation of the infant\nthere was no influence of Vitamin D supplementation of the infant during the first month of Life on the prevalence of any of the bacterial species or groups (data not shown).table 5shows the ASSOCIATION between Vitamin D supplementation of the infant in the first month of Life and the log10cfus of the different bacteria in children colonized with the respective bacterial group or species (for a visualisation of the data in univariable boxplots see alsos3 fig).10.1371/journal.pone.0188011.t005\n\ncaption (table-wrap): table 5\nassociation between Vitamin D supplementation of the infant and log10colony forming units/g Feces of bacterial species or groups in Breast Fed infants (n = 616) colonized with the respective bacteria.Vitamin D supplement use of Breast feeding infantsvitamin D supplementationbacteria&nunadjusted b (95% ci)#adjusted b (95% ci)no use bifidobacterium spp.']	[('SUPERFICIAL_RELATIONSHIP', 836)]	1	[('GO_0007567', 'parturition', 315, 'delivery'), ('GO_0007565', 'female pregnancy', 428, 'pregnancy'), ('UBERON_0000178', 'blood', 478, 'blood'), ('CHEBI_28384', 'vitamin K', 605, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 671, 'vitamin D'), ('UBERON_0000104', 'life cycle', 737, 'life'), ('CHEBI_27300', 'vitamin D', 856, 'vitamin D'), ('UBERON_0000104', 'life cycle', 918, 'life'), ('CHEBI_27300', 'vitamin D', 1194, 'vitamin D'), ('UBERON_0001988', 'feces', 1266, 'feces'), ('GO_0007567', 'parturition', 1306, 'breast'), ('UBERON_0000310', 'breast', 1306, 'breast'), ('GO_0007631', 'feeding behavior', 1313, 'fed'), ('CHEBI_28384', 'vitamin K', 1374, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 1374, 'Vitamin'), ('UBERON_0000310', 'breast', 1402, 'Breast'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 1432, 'D')]
S114-PMC5679631	PMC5679631	11/2017	S114-PMC5679631	['difficile were ASSOCIATED with Vitamin D supplementation in the alternative group (b = -1.45 log10cfu/g Feces; 95% ci: -2.63, -0.28) with no association found in the conventional group (b = 0.49; 95% ci: -0.71, 1.69).']	[('SUPERFICIAL_RELATIONSHIP', 15)]	1	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D'), ('UBERON_0001988', 'feces', 104, 'feces')]
S134-PMC5679631	PMC5679631	11/2017	S134-PMC5679631	['in Humans, a study investigating variation in diet and microbial composition of the Intestinal Tract between 52 african americans and 46 caucasian americans FOUND DISCORDANT Vitamin D supplementation practices and differences between the counts of bacteroidetes in the Fecal samples between the two groups [28].']	[('INCOMPLETE_EVIDENCE', 157), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 163)]	2	[('NCBITaxon_9606', 'Homo sapiens', 3, 'humans'), ('UBERON_0001555', 'digestive tract', 84, 'intestinal tract'), ('CHEBI_27300', 'vitamin D', 174, 'vitamin D'), ('UBERON_0000922', 'embryo', 269, 'fecal')]
S135-PMC5679631	PMC5679631	11/2017	S135-PMC5679631	['in a cross sectional analysis of 98 Adults examining enterotype partitioning in RELATION to Nutrient Consumption (Food frequency questionnaire), Vitamin D supplement use and Vitamin D from dairy sources were found to be ASSOCIATED with enterotypes.']	[('SUPERFICIAL_RELATIONSHIP', 80), ('SUPERFICIAL_RELATIONSHIP', 220)]	2	[('UBERON_0007023', 'adult organism', 36, 'adults'), ('CHEBI_33284', 'nutrient', 92, 'nutrient'), ('GO_0007631', 'feeding behavior', 101, 'consumption'), ('CHEBI_33290', 'food', 114, 'food'), ('CHEBI_27300', 'vitamin D', 145, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 174, 'vitamin D')]
S138-PMC5679631	PMC5679631	11/2017	S138-PMC5679631	['the INFLUENCE of direct Vitamin D supplementation of the child DIFFERED between the two recruitment groups SUGGESTING that lifestyle factors are Modulating the ASSOCIATION between Vitamin D and the Intestinal bacterial Taxa.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 63), ('INCOMPLETE_EVIDENCE', 107), ('SUPERFICIAL_RELATIONSHIP', 160)]	4	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('GO_0065007', 'biological regulation', 145, 'modulating'), ('CHEBI_27300', 'vitamin D', 180, 'vitamin D'), ('UBERON_0000160', 'intestine', 198, 'intestinal'), ('NCBITaxon_10088', 'Mus <genus>', 219, 'taxa')]
S146-PMC5679631	PMC5679631	11/2017	S146-PMC5679631	['in a FUTURE STUDY, it would be PREFERABLE to investigate the IMPACT of Postnatal Vitamin D supplementation in older infants whose 25(Oh)D concentrations have reached a steady state.']	[('FUTURE_WORK', 5), ('PROBABLE_UNDERSTANDING', 31), ('SUPERFICIAL_RELATIONSHIP', 61)]	3	[('GO_0007567', 'parturition', 71, 'postnatal'), ('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 130, '25(OH)D')]
S151-PMC5679631	PMC5679631	11/2017	S151-PMC5679631	['the number of infants not administered Vitamin D supplementation was low because it is standard PRACTICE to supplement Breast Fed children with Vitamin D, and the lower prevalence of colonization with these bacteria also CONTRIBUTED to this LIMITATION.']	[('INCOMPLETE_EVIDENCE', 96), ('SUPERFICIAL_RELATIONSHIP', 221), ('INCOMPLETE_EVIDENCE', 241)]	3	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('GO_0007567', 'parturition', 119, 'breast'), ('UBERON_0000310', 'breast', 119, 'breast'), ('GO_0007631', 'feeding behavior', 126, 'fed'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D')]
S159-PMC5679631	PMC5679631	11/2017	S159-PMC5679631	['TO OUR KNOWLEDGE, THIS is the FIRST report of a large scale observational study INDICATING that Prenatal Vitamin D exposure, AS measured either by maternal use of multivitamin supplements containing Vitamin D, or 25(Oh)D quintiles, INFLUENCES several IMPORTANT bacterial taxa within the infant Gut.']	[('PROBABLE_UNDERSTANDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 18), ('INCOMPLETE_EVIDENCE', 30), ('INCOMPLETE_EVIDENCE', 80), ('PROBABLE_UNDERSTANDING', 125), ('SUPERFICIAL_RELATIONSHIP', 232), ('IMPORTANT_CONSIDERATION', 251)]	7	[('GO_0007565', 'female pregnancy', 96, 'prenatal'), ('CHEBI_27300', 'vitamin D', 105, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 199, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 213, '25(OH)D'), ('UBERON_0001555', 'digestive tract', 294, 'gut')]
S161-PMC5679631	PMC5679631	11/2017	S161-PMC5679631	['the INFLUENCE of Postnatal Vitamin D supplementation MERITS to BE analyzed in a larger group of older infants and with extensive microbial profiling approach.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('FUTURE_WORK', 53), ('IMPORTANT_CONSIDERATION', 53), ('ANOMALY_CURIOUS_FINDING', 63)]	4	[('GO_0007567', 'parturition', 17, 'postnatal'), ('CHEBI_27300', 'vitamin D', 27, 'vitamin D')]
S163-PMC5679631	PMC5679631	11/2017	S163-PMC5679631	['in infants colonized with the respective bacteria in RELATION to maternal multivitamin supplementation containing Vitamin D.\n(docx)\n\ncaption (media)\n\nclick here for additional data file.']	[('SUPERFICIAL_RELATIONSHIP', 53)]	1	[('CHEBI_27300', 'vitamin D', 114, 'vitamin D')]
S168-PMC5679631	PMC5679631	11/2017	S168-PMC5679631	['in infants colonized with the respective bacteria in RELATION to Vitamin D supplement use of breastfed infants.']	[('SUPERFICIAL_RELATIONSHIP', 53)]	1	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D')]
S24-PMC5682869	PMC5682869	11/2017	S24-PMC5682869	['supplementation of Vitamin A is SUGGESTED to be restricted only to areas where Vitamin A deficiency is a substantial PUBLIC HEALTH PROBLEM.']	[('INCOMPLETE_EVIDENCE', 32), ('IMPORTANT_CONSIDERATION', 117), ('IMPORTANT_CONSIDERATION', 131), ('PROBLEM_COMPLICATION', 131)]	4	[('CHEBI_27300', 'vitamin D', 19, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 79, 'vitamin A')]
S26-PMC5682869	PMC5682869	11/2017	S26-PMC5682869	['Vitamin B6, zinc, multi-Nutrient supplements and Vitamin D supplementation are NOT ADVOCATED as routine procedure.']	[('ANOMALY_CURIOUS_FINDING', 79), ('FUTURE_WORK', 83)]	2	[('CHEBI_27306', 'vitamin B6', 0, 'Vitamin B6'), ('PR_000017269', 'ventral anterior homeobox 2', 0, 'Vitamin B6'), ('CHEBI_33284', 'nutrient', 24, 'nutrient'), ('CHEBI_27300', 'vitamin D', 49, 'vitamin D')]
S46-PMC5682869	PMC5682869	11/2017	S46-PMC5682869	['HOWEVER, still a well-balanced ovo-lacto vegetarian diet USUALLY enables good Nutrient status in Pregnancy, when supplemented with Vitamin D, Folic Acid, Iodine, iron, Vitamin B12 and zinc, and, in cases of a fish-free diet, with Dha [19].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 57)]	2	[('CHEBI_33284', 'nutrient', 78, 'nutrient'), ('GO_0007565', 'female pregnancy', 97, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D'), ('CHEBI_30751', 'formic acid', 142, 'folic acid'), ('CHEBI_24859', 'iodine atom', 154, 'iodine'), ('CHEBI_33279', 'vitamin D5', 168, 'vitamin B12'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 176, 'B12'), ('CHEBI_17874', 'dihydrozeatin', 230, 'DHA')]
S21-PMC5697969	PMC5697969	12/2017	S21-PMC5697969	['the IMPACTS of Micronutrient supplements, such as Iron and Folic Acid (ifa) (7), calcium (8), Vitamin A (9), and zinc (10), on maternal and child health outcomes are well DOCUMENTED.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('INCOMPLETE_EVIDENCE', 171)]	2	[('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 15, 'micronutrient'), ('CHEBI_24870', 'ion', 50, 'iron'), ('CHEBI_30751', 'formic acid', 59, 'folic acid'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin A')]
S0-PMC5706533	PMC5706533	11/2017	S0-PMC5706533	['Vitamin D supplementation during Pregnancy: state of the evidence from a systematic review of randomised trials\n\nabstract\nobjectives \xa0TO ESTIMATE the EFFECTS of Vitamin D supplementation during Pregnancy on 11 maternal and 27 neonatal/infant outcomes; TO DETERMINE frequencies at which trial outcome data were missing, unreported, or inconsistently reported; and to project the POTENTIAL contributions of registered ongoing or planned trials.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 134), ('INCOMPLETE_EVIDENCE', 137), ('SUPERFICIAL_RELATIONSHIP', 150), ('QUESTION_ANSWERED_BY_THIS_WORK', 252), ('INCOMPLETE_EVIDENCE', 378)]	5	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 33, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 161, 'vitamin D'), ('GO_0007565', 'female pregnancy', 194, 'pregnancy')]
S18-PMC5706533	PMC5706533	11/2017	S18-PMC5706533	['beyond its established INFLUENCE on bone growth and Calcium Homeostasis,1vitamin D and its RELATED Metabolites have HYPOTHESISED EFFECTS on the risk of Cardiovascular diseases,2cancer,3respiratory infections,4asthma,5conditions RELATED to Pregnancy (such as pre-eclampsia, Gestational diabetes), and Birth outcomes.6concern that Vitamin D deficiency is a global PUBLIC HEALTH PROBLEM HAS BEEN sparked by numerous REPORTS of the high proportion of Individuals in studies throughout the world who have relatively low Serum/Plasma concentrations of 25-hydroxyvitamin d (25(Oh)D),7the conventional circulating BIOMARKER of Vitamin D status.8there HAS BEEN particular ATTENTION to the high prevalence of vitamin d deficiency in Pregnant women and newborns.7\nin 2010, dietary reference intakes for Vitamin D for canada and the us from the institute of medicine were based solely on bone health—particularly in young children (for instance, rickets) and older Adults (for instance, osteoporosis).1considerable SKEPTICISM was cast onto the LINK between Vitamin D and Extraskeletal health conditions or the POTENTIAL benefits (versus risks) of intakes larger than the recommended dietary allowance (600 iu/day for MOST children and Adults).1THE institute’s report DID NOT RECOMMEND higher intakes during Pregnancy and Lactation.1a 2016 update of the cochrane collaboration systematic review and meta-analysis of trials of Vitamin D in Pregnancy (versus placebo or no Supplement), HOWEVER, TENTATIVELY CONCLUDED that Prenatal Vitamin D supplementation “MAY reduce the risk of pre-eclampsia, low birthweight and Preterm Birth.”6other RECENT systematic reviews that included trials with active control arms (in which participants received Vitamin D) ACKNOWLEDGED the POTENTIAL EFFECT of Vitamin D on fetal growth910but DID NOT FIND evidence of EFFECTS on OTHER maternal, fetal, or infant outcomes.91011citing the 2016 cochrane review,6the world health organization guidelines for Antenatal care ADVISE against routine Vitamin D supplementation in Pregnancy.12dietary and supplementation RECOMMENDATIONS, HOWEVER, vary widely across other professional organisations (appendix 1), and there REMAINS a LACK OF CONSENSUS on target health outcomes, indications for Prenatal supplementation, or EVIDENCE BASED regimens for supplement dose (or fortification STRATEGIES).']	[('SUPERFICIAL_RELATIONSHIP', 23), ('SUPERFICIAL_RELATIONSHIP', 91), ('INCOMPLETE_EVIDENCE', 116), ('SUPERFICIAL_RELATIONSHIP', 129), ('SUPERFICIAL_RELATIONSHIP', 228), ('IMPORTANT_CONSIDERATION', 362), ('IMPORTANT_CONSIDERATION', 376), ('PROBLEM_COMPLICATION', 376), ('INCOMPLETE_EVIDENCE', 384), ('INCOMPLETE_EVIDENCE', 413), ('SUPERFICIAL_RELATIONSHIP', 606), ('INCOMPLETE_EVIDENCE', 643), ('IMPORTANT_CONSIDERATION', 663), ('INCOMPLETE_EVIDENCE', 663), ('IMPORTANT_CONSIDERATION', 1003), ('SUPERFICIAL_RELATIONSHIP', 1032), ('INCOMPLETE_EVIDENCE', 1098), ('PROBABLE_UNDERSTANDING', 1205), ('INCOMPLETE_EVIDENCE', 1231), ('INCOMPLETE_EVIDENCE', 1255), ('FUTURE_WORK', 1263), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1471), ('INCOMPLETE_EVIDENCE', 1480), ('INCOMPLETE_EVIDENCE', 1492), ('INCOMPLETE_EVIDENCE', 1543), ('INCOMPLETE_EVIDENCE', 1623), ('INCOMPLETE_EVIDENCE', 1738), ('PROBABLE_UNDERSTANDING', 1738), ('INCOMPLETE_EVIDENCE', 1755), ('SUPERFICIAL_RELATIONSHIP', 1765), ('INCOMPLETE_EVIDENCE', 1807), ('SUPERFICIAL_RELATIONSHIP', 1832), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1843), ('FUTURE_WORK', 1983), ('FUTURE_WORK', 2075), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 2092), ('ANOMALY_CURIOUS_FINDING', 2092), ('INCOMPLETE_EVIDENCE', 2177), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 2187), ('INCOMPLETE_EVIDENCE', 2187), ('INCOMPLETE_EVIDENCE', 2277), ('FUTURE_WORK', 2339)]	42	[('GO_0055073', 'cadmium ion homeostasis', 52, 'calcium homeostasis'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 81, 'D'), ('CHEBI_25212', 'metabolite', 99, 'metabolites'), ('UBERON_0004535', 'cardiovascular system', 152, 'cardiovascular'), ('GO_0007565', 'female pregnancy', 239, 'pregnancy'), ('GO_0007565', 'female pregnancy', 273, 'gestational'), ('GO_0007567', 'parturition', 300, 'birth'), ('CHEBI_27300', 'vitamin D', 329, 'vitamin D'), ('NCBITaxon_1', 'root', 447, 'individuals'), ('UBERON_0001977', 'blood serum', 515, 'serum'), ('UBERON_0001969', 'blood plasma', 521, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 567, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 619, 'vitamin D'), ('GO_0007565', 'female pregnancy', 723, 'pregnant'), ('CHEBI_27300', 'vitamin D', 792, 'vitamin D'), ('UBERON_0007023', 'adult organism', 953, 'adults'), ('CHEBI_27300', 'vitamin D', 1045, 'vitamin D'), ('UBERON_0001431', 'distal carpal bone 2', 1059, 'extraskeletal'), ('UBERON_0007023', 'adult organism', 1223, 'adults'), ('GO_0007565', 'female pregnancy', 1295, 'pregnancy'), ('GO_0007595', 'lactation', 1309, 'lactation'), ('CHEBI_27300', 'vitamin D', 1413, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1426, 'pregnancy'), ('CHEBI_16158', 'steroid sulfate', 1458, 'supplement'), ('GO_0007565', 'female pregnancy', 1507, 'prenatal'), ('CHEBI_27300', 'vitamin D', 1516, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1601, 'preterm birth'), ('CHEBI_27300', 'vitamin D', 1727, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1775, 'vitamin D'), ('GO_0007567', 'parturition', 1968, 'antenatal'), ('CHEBI_27300', 'vitamin D', 2006, 'vitamin D'), ('GO_0007565', 'female pregnancy', 2035, 'pregnancy'), ('GO_0007565', 'female pregnancy', 2248, 'prenatal')]
S20-PMC5706533	PMC5706533	11/2017	S20-PMC5706533	['we SPECIFICALLY AIMED to estimate the EFFECTS of Vitamin D supplementation during Pregnancy on maternal, neonatal, and infant outcomes, taking into consideration the quality of AVAILABLE evidence and heterogeneity across studies; determine frequencies at which relevant outcome variable data were missing, unreported, or inconsistently reported among trials that were otherwise eligible for inclusion; and IDENTIFY ONGOING or PLANNED STUDIES of Vitamin D supplementation during Pregnancy to project the state of EVIDENCE that COULD accrue in the next decade.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('QUESTION_ANSWERED_BY_THIS_WORK', 16), ('SUPERFICIAL_RELATIONSHIP', 38), ('INCOMPLETE_EVIDENCE', 177), ('FUTURE_WORK', 406), ('IMPORTANT_CONSIDERATION', 415), ('FUTURE_WORK', 426), ('INCOMPLETE_EVIDENCE', 434), ('INCOMPLETE_EVIDENCE', 512), ('INCOMPLETE_EVIDENCE', 526)]	10	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('GO_0007565', 'female pregnancy', 82, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 445, 'vitamin D'), ('GO_0007565', 'female pregnancy', 478, 'pregnancy')]
S46-PMC5706533	PMC5706533	11/2017	S46-PMC5706533	['when multiple comparisons from the same trial were included in the same meta-analysis, we divided the control group sample size corresponding to each comparison by the number of intervention arms to avoid double counting participants.14\nwe conducted subgroup meta-analyses according to a priori defined sources of potential clinical and methodological heterogeneity17: control arm type (Placebo versus Vitamin D containing active control); dosing frequency (regular versus bolus); baseline Vitamin D status categorised as low (mean 25(Oh)D <30 nmol/l) versus sufficient (≥30 nmol/l), based on maternal mean 25(Oh)D in the control group at enrolment (“initial baseline”) or at/near delivery (“modified baseline,” which THEORETICALLY takes into account the effect of active control supplementation); intervention dose (among regular dose trials), defined as low (<2000 iu/day) versus high (≥2000 iu/day).']	[('INCOMPLETE_EVIDENCE', 718)]	1	[('CHEBI_26130', 'biological pigment', 387, 'placebo'), ('CHEBI_27300', 'vitamin D', 402, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 490, 'vitamin D'), ('CHEBI_63056', 'zinc cation', 532, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 538, 'D'), ('CHEBI_71657', 'versiconol acetate', 607, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 613, 'D')]
S80-PMC5706533	PMC5706533	11/2017	S80-PMC5706533	['figures are number (percentage) unless stated otherwisecharacteristicall trialsregular dose trials*Bolus dose trials*trials4337†8†intervention arms55469participants enrolled:\u2003total840676871031\u2003median within individual trials (min-max)133 (16-1134)133 (16-1134)118 (50-235)meta-analyses to which each trial contributed:\u2003median maternal outcomes (min-max)2 (0-6)2 (0-6)2 (0-4)\u2003median newborn/infant outcomes (min-max)3 (0-17)3 (0-17)4 (0-7)\u2003trials that DID not contribute data to any meta-analyses2 (4.7)2 (5.4)0 (0.0)geographical region:\u2003europe7 (16.3)7 (18.9)2 (25.0)\u2003south east asia6 (14.0)2 (5.4)4 (50.0)\u2003americas5 (11.6)5 (13.5)0 (0.0)\u2003eastern mediterranean21 (48.8)19 (51.4)2 (25.0)\u2003western pacific4 (9.3)4 (10.8)0 (0.0)health status at enrolment:\u2003generally healthy37 (86.0)33 (89.2)6 (75.0)\u2003Gestational diabetes4 (9.3)2 (5.4)2 (25.0)\u2003hypocalcaemia1 (2.3)1 (2.7)\u2003multiple sclerosis1 (2.3)1 (2.7)0 (0.0)baseline Vitamin D status‡:\u2003mean 25(Oh)D <30 nmol/l10 (23.3)9 (24.3)2 (25.0)\u2003mean 25(Oh)D ≥30 nmol/l23 (53.5)20 (54.1)3 (37.5)\u2003not reported10 (23.3)8 (21.6)3 (37.5)type of Vitamin D§:\u2003d24 (7.3)3 (6.5)1 (11.1)\u2003d348 (87.3)40 (87.0)8 (88.9)\u2003not reported3 (5.5)3 (6.5)0 (0.0)supplementation frequency§:\u2003daily31 (56.4)31 (67.4)—\u2003weekly5 (9.1)5 (10.9)—\u2003every 2 weeks6 (10.9)6 (13.0)—\u2003monthly3 (5.5)3 (6.5)—\u2003 every 2 months1 (1.8)1 (2.2)—\u2003single dose3 (5.5)—3 (33.3)\u2003two doses4 (7.3)—4 (44.4)\u2003other2 (3.6)—2 (22.2)intervention dose§¶:\u2003median (min-max)2000 (200-7543)2000 (200-7543)—\u2003regular dose <2000 iu/day24 (52.2)24 (52.2)—\u2003regular dose ≥2000 iu/day22 (47.8)22 (47.8)—control intervention type:\u2003placebo29 (67.4)23 (62.2)8 (100.0)\u2003active14 (32.6)14 (37.8)0 (0.0)median Vitamin D dose in active control arms (min-max)400 (200-600)400 (200-600)—timing of initiation of supplementation§:\u20031st trimester19 (34.5)18 (39.1)1 (11.1)\u20032nd trimester30 (54.5)24 (52.2)6 (66.7)\u20033rd trimester5 (9.1)3 (6.5)2 (22.2)\u2003not reported1 (1.8)1 (2.2)0 (0.0)\n*regular dosing refers to regimens in which Supplement was administered at least three times at regular frequency throughout Pregnancy (daily, weekly, every 2 weeks, monthly, or every 2 months ); bolus dosing refers to interventions administered either once or twice during intervention period.']	[('ANOMALY_CURIOUS_FINDING', 451)]	1	[('NCBITaxon_10088', 'Mus <genus>', 99, 'Bolus'), ('GO_0007565', 'female pregnancy', 796, 'Gestational'), ('CHEBI_27300', 'vitamin D', 915, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 939, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 988, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 1078, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1671, 'vitamin D'), ('CHEBI_16158', 'steroid sulfate', 1981, 'supplement'), ('GO_0007565', 'female pregnancy', 2062, 'pregnancy')]
S89-PMC5706533	PMC5706533	11/2017	S89-PMC5706533	['no published trials were conducted in africa, THOUGH one large trial in tanzania (n=2300) is ongoing and projected to be completed and published before 2024\n\ncaption (fig)\n\nfig 3 \xa0effective equivalent daily Vitamin D dose (iu/day) versus maternal baseline mean 25-Hydroxyvitamin D (25(Oh)D) concentration (nmol/l) in published Prenatal Vitamin D supplementation trials with regular dosing regimens (29 trials; 36 comparisons).']	[('ANOMALY_CURIOUS_FINDING', 46)]	1	[('CHEBI_27300', 'vitamin D', 207, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 261, '25-hydroxyvitamin D'), ('CHEBI_30778', 'gallic acid', 282, '25(OH)'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 288, 'D'), ('GO_0007565', 'female pregnancy', 327, 'prenatal'), ('CHEBI_27300', 'vitamin D', 336, 'vitamin D')]
S98-PMC5706533	PMC5706533	11/2017	S98-PMC5706533	['caption (table-wrap): table 2\n\npooled risk ratios from primary meta-analyses of EFFECTS of Vitamin D supplementation during Pregnancy on maternal and neonatal/infant outcomesoutcomestrials reporting eligible outcometrials included*intervention-control comparisons included*participants included*risk ratio (95% ci)i2(%) maternal pre-eclampsia3337061.09 (0.43 to 2.76)67†Gestational hypertension2225641.69 (0.73 to 3.92)0gestational diabetes55510300.65 (0.39 to 1.08)45stillbirth16161946060.75 (0.51 to 1.13)0caesarean section17161832401.02 (0.93 to 1.12)0preterm labor4447760.52 (0.26 to 1.05)51hypercalcaemia4111753.11 (0.87 to 11.08)—hypercalciuria2111603.00 (0.12 to 72.56)—hypocalcaemia2112000.05†(0.01 to 0.18)—admission to hospital55517760.97 (0.69 to 1.35)0 neonatal/infant Preterm Birth14131537571.00 (0.77 to 1.30)0low Birth weight87711560.74 (0.47 to 1.16)47small for Gestational age5577410.60†(0.40 to 0.90)0congenital malformations54425090.93 (0.61 to 1.42)0neonatal death53412020.48 (0.16 to 1.49)0.0hypercalcaemia111730.97 (0.31 to 3.08)—hypocalcaemia2111260.10 (0.01 to 1.83)—admission to Neonatal Intensive Care unit55619970.92 (0.66 to 1.28)21respiratory infections (general)1122230.97 (0.77 to 1.23)0upper Respiratory Tract infections2243890.91 (0.77 to 1.06)0lower Respiratory Tract infections44617690.97 (0.84 to 1.12)0asthma or recurrent/persistent wheeze by age 3 years22213870.81†(0.67 to 0.98)0\n*intervention-control group comparisons with zero events in both groups excluded from primary meta-analyses.']	[('SUPERFICIAL_RELATIONSHIP', 80)]	1	[('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('GO_0007565', 'female pregnancy', 124, 'pregnancy'), ('GO_0007565', 'female pregnancy', 370, 'Gestational'), ('GO_0007128', 'meiotic prophase I', 781, 'Preterm'), ('GO_0043174', 'nucleoside salvage', 789, 'birth14131537571'), ('GO_0007567', 'parturition', 828, 'birth'), ('GO_0007565', 'female pregnancy', 878, 'gestational'), ('UBERON_0001759', 'vagus nerve', 1104, 'neonatal'), ('UBERON_0001007', 'digestive system', 1113, 'intensive care'), ('UBERON_0000065', 'respiratory tract', 1224, 'respiratory tract'), ('UBERON_0000065', 'respiratory tract', 1284, 'respiratory tract')]
S107-PMC5706533	PMC5706533	11/2017	S107-PMC5706533	['biochemical safety outcomes (hypercalcaemia, hypercalciuria, hypocalcaemia) were RARE; ONLY four trials met our minimum criteria for case definitions and methods of ascertainment based on routine monitoring of maternal Serum calcium (table 2; tables s9-s11in appendix 10), YET ignoring the these criteria did not change the inference that there was no significant EFFECT of Vitamin D supplementation on the RISK of hypercalcaemia, which is a primary INDICATOR of toxicity of Vitamin D supplementation (table s9 and fig s18 in Appendix 10).']	[('INCOMPLETE_EVIDENCE', 81), ('INCOMPLETE_EVIDENCE', 87), ('ANOMALY_CURIOUS_FINDING', 273), ('SUPERFICIAL_RELATIONSHIP', 364), ('IMPORTANT_CONSIDERATION', 407), ('SUPERFICIAL_RELATIONSHIP', 450)]	6	[('UBERON_0001977', 'blood serum', 219, 'serum'), ('CHEBI_27300', 'vitamin D', 374, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 475, 'vitamin D'), ('UBERON_0001154', 'vermiform appendix', 526, 'appendix')]
S109-PMC5706533	PMC5706533	11/2017	S109-PMC5706533	['pooling of 37 comparisons INDICATED that Prenatal Vitamin D supplementation (versus low dose, no Vitamin D, or placebo) increased mean Birth weight by an average of 58 g (fig 4).']	[('INCOMPLETE_EVIDENCE', 26)]	1	[('GO_0007565', 'female pregnancy', 41, 'prenatal'), ('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 97, 'vitamin D'), ('GO_0007567', 'parturition', 135, 'birth')]
S115-PMC5706533	PMC5706533	11/2017	S115-PMC5706533	['caption (fig)\n\nfig 4 \xa0a: weighted mean differences (wmds) and b: cumulative wmds for effect of Prenatal Vitamin D supplementation on mean Birth weight (g), ESTIMATED with random effects meta-analysis, based on 37 intervention-control comparisons in 30 randomised controlled trials of regular or bolus regimen Vitamin D at any dose in studies published by september 2017\nCONSISTENT with the pooled EFFECT on mean Birth weight—but in a smaller subset of only seven comparisons—vitamin d reduced the risk of small for Gestational age (sga) (table 2; table s14 and fig s30 in appendix 10).']	[('INCOMPLETE_EVIDENCE', 156), ('INCOMPLETE_EVIDENCE', 370), ('SUPERFICIAL_RELATIONSHIP', 397)]	3	[('GO_0007565', 'female pregnancy', 95, 'prenatal'), ('CHEBI_27300', 'vitamin D', 104, 'vitamin D'), ('GO_0007567', 'parturition', 138, 'birth'), ('CHEBI_27300', 'vitamin D', 309, 'vitamin D'), ('GO_0007567', 'parturition', 412, 'birth'), ('GO_0007565', 'female pregnancy', 515, 'gestational')]
S121-PMC5706533	PMC5706533	11/2017	S121-PMC5706533	['the pooled estimate from two high quality regular dose trials in high income countries (total 1387 participants) INDICATED that Prenatal Vitamin D supplementation significantly decreased the RISK of persistent/recurrent wheeze in offspring by age 3 years (table 2; fig s51 in appendix 10).']	[('INCOMPLETE_EVIDENCE', 113), ('IMPORTANT_CONSIDERATION', 191)]	2	[('GO_0007565', 'female pregnancy', 128, 'prenatal'), ('CHEBI_27300', 'vitamin D', 137, 'vitamin D')]
S145-PMC5706533	PMC5706533	11/2017	S145-PMC5706533	['discussion\nthough trials of Prenatal Vitamin D supplementation are being published at an ACCELERATING pace, randomised controlled trials published up to 2017 were GENERALLY SMALL, low quality, and RARELY designed to examine clinical outcomes.']	[('IMPORTANT_CONSIDERATION', 89), ('PROBABLE_UNDERSTANDING', 163), ('INCOMPLETE_EVIDENCE', 173), ('INCOMPLETE_EVIDENCE', 197)]	4	[('GO_0007565', 'female pregnancy', 28, 'prenatal'), ('CHEBI_27300', 'vitamin D', 37, 'vitamin D')]
S155-PMC5706533	PMC5706533	11/2017	S155-PMC5706533	['for example, Prenatal Vitamin D supplementation in deficient women modifies neonatal Calcium Homeostasis,31BUT clinical CORRELATES (such as symptomatic infant hypocalcaemia) were RARE and infrequently ascertained across trials.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 105), ('SUPERFICIAL_RELATIONSHIP', 120), ('INCOMPLETE_EVIDENCE', 179)]	3	[('GO_0007565', 'female pregnancy', 13, 'prenatal'), ('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('GO_0055073', 'cadmium ion homeostasis', 85, 'calcium homeostasis')]
S156-PMC5706533	PMC5706533	11/2017	S156-PMC5706533	['NONETHELESS, there was no EVIDENCE of any specific harms to mothers or fetuses attributable to Vitamin D supplementation within the range of reported doses.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 26)]	2	[('CHEBI_27300', 'vitamin D', 95, 'vitamin D')]
S163-PMC5706533	PMC5706533	11/2017	S163-PMC5706533	['MANY of the REPORTED doses, HOWEVER, DID NOT yield EFFECTS on maternal 25(Oh)D that would be expected BASED ON Vitamin D pharmacokinetics.3637the muted dose-25(Oh)D RELATION COULD BE ATTRIBUTED to high baseline 25(Oh)D, low precision of 25(Oh)D assays, low rates of adherence to supplementation regimens, or lower than labeled Vitamin D content of the Supplements.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 12), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 28), ('INCOMPLETE_EVIDENCE', 37), ('SUPERFICIAL_RELATIONSHIP', 51), ('QUESTION_ANSWERED_BY_THIS_WORK', 102), ('ANOMALY_CURIOUS_FINDING', 108), ('SUPERFICIAL_RELATIONSHIP', 165), ('INCOMPLETE_EVIDENCE', 174), ('SUPERFICIAL_RELATIONSHIP', 183)]	10	[('CHEBI_71657', 'versiconol acetate', 71, '25(OH)D'), ('PR_000003010', 'moesin isoform 1', 73, '(OH ... D'), ('CHEBI_27300', 'vitamin D', 111, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 157, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 211, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 237, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 327, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 352, 'supplements')]
S173-PMC5706533	PMC5706533	11/2017	S173-PMC5706533	['although we intend to update this review regularly (the platform for FUTURE real time dissemination is STILL TO BE DETERMINED), we project LIMITED aggregate gains from the 35 MOSTLY SMALL TRIALS of Prenatal Vitamin D supplementation trials that are registered as completed, ongoing, or planned.']	[('FUTURE_WORK', 69), ('FULL_UNKNOWN', 103), ('INCOMPLETE_EVIDENCE', 139), ('INCOMPLETE_EVIDENCE', 175), ('INCOMPLETE_EVIDENCE', 182)]	5	[('GO_0007565', 'female pregnancy', 198, 'prenatal'), ('CHEBI_27300', 'vitamin D', 207, 'vitamin D')]
S176-PMC5706533	PMC5706533	11/2017	S176-PMC5706533	['in the meantime, we ENDORSE the NOTION that WHENEVER feasible, investigators SHOULD report all clinically IMPORTANT outcomes, EVEN in SMALL trials that are individually UNDERPOWERED to detect EFFECTS on such outcomes.45\njohn ioannidis RECENTLY REMARKED that “systematic reviews MAY SOMETIMES be most helpful IF, INSTEAD of focusing on the summary of the evidence, HIGHLIGHT the BIASES that are INVOLVED and what NEEDS to be done to remedy the state-of-the-EVIDENCE in the given field.”46we conclude that there is currently INSUFFICIENT EVIDENCE to guide RECOMMENDATIONS for Prenatal Vitamin D supplementation.']	[('INCOMPLETE_EVIDENCE', 20), ('INCOMPLETE_EVIDENCE', 32), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 44), ('FUTURE_WORK', 77), ('IMPORTANT_CONSIDERATION', 106), ('ANOMALY_CURIOUS_FINDING', 126), ('INCOMPLETE_EVIDENCE', 134), ('PROBLEM_COMPLICATION', 169), ('SUPERFICIAL_RELATIONSHIP', 192), ('INCOMPLETE_EVIDENCE', 235), ('ANOMALY_CURIOUS_FINDING', 244), ('ANOMALY_CURIOUS_FINDING', 244), ('INCOMPLETE_EVIDENCE', 278), ('INCOMPLETE_EVIDENCE', 282), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 308), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 312), ('INCOMPLETE_EVIDENCE', 364), ('PROBLEM_COMPLICATION', 378), ('SUPERFICIAL_RELATIONSHIP', 394), ('FUTURE_WORK', 412), ('INCOMPLETE_EVIDENCE', 456), ('INCOMPLETE_EVIDENCE', 523), ('FUTURE_WORK', 554)]	23	[('GO_0007565', 'female pregnancy', 574, 'prenatal'), ('CHEBI_27300', 'vitamin D', 583, 'vitamin D')]
S177-PMC5706533	PMC5706533	11/2017	S177-PMC5706533	['cautious PROJECTIONS for the next decade SUGGEST that we will eventually know more about Vitamin D in Pregnancy THAN we do now, BUT in the absence of a coordinated effort and funding to conduct large new trials, SOME of the most CRITICAL QUESTIONS about the effectiveness of Prenatal Vitamin D supplementation will PROBABLY REMAIN unanswered in the foreseeable FUTURE.']	[('FUTURE_WORK', 9), ('FUTURE_WORK', 9), ('INCOMPLETE_EVIDENCE', 41), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 112), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 128), ('INCOMPLETE_EVIDENCE', 212), ('IMPORTANT_CONSIDERATION', 229), ('EXPLICIT_QUESTION', 238), ('PROBABLE_UNDERSTANDING', 315), ('INCOMPLETE_EVIDENCE', 324), ('FUTURE_WORK', 361)]	11	[('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('GO_0007565', 'female pregnancy', 102, 'pregnancy'), ('GO_0007565', 'female pregnancy', 275, 'prenatal'), ('CHEBI_27300', 'vitamin D', 284, 'vitamin D')]
S178-PMC5706533	PMC5706533	11/2017	S178-PMC5706533	['what is already known on THIS topic\nnumerous randomised trials and systematic reviews of Vitamin D supplementation during Pregnancy HAVE BEEN published, with CONFLICTING results and conclusions\nrecommendations regarding Vitamin D supplementation vary widely among medical and professional organisations, and who currently RECOMMENDS against routine Prenatal Vitamin D supplementation\n\nwhat THIS STUDY adds\nsystematic review and meta-analyses of 43 trials including 8406 participants SHOWED that Prenatal Vitamin D supplementation was ASSOCIATED with increased maternal and cord Serum 25-Hydroxyvitamin D concentrations, increased mean birth weight, reduced the risk of small for Gestational age, reduced the risk of wheeze in offspring, and increased infant length at one year of age\nthere was a LACK OF EVIDENCE OF benefits of Prenatal Vitamin D supplementation for maternal health conditions RELATED to Pregnancy, no effect on other Birth outcomes of PUBLIC HEALTH IMPORTANCE such as Preterm Birth, and SCANT EVIDENCE on safety outcomes\nFEW of the trials were designed to test the EFFECT of Vitamin D on clinical or functional outcomes, and most trials were SMALL and at overall high or UNCERTAIN risk of bias\nthirty five planned or ongoing Prenatal Vitamin D trials COULD contribute an additional 12\u2009530 participants to FUTURE systematic reviews\n\npubmed central:']	[('QUESTION_ANSWERED_BY_THIS_WORK', 25), ('INCOMPLETE_EVIDENCE', 132), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 158), ('FUTURE_WORK', 322), ('QUESTION_ANSWERED_BY_THIS_WORK', 390), ('INCOMPLETE_EVIDENCE', 483), ('SUPERFICIAL_RELATIONSHIP', 534), ('INCOMPLETE_EVIDENCE', 796), ('SUPERFICIAL_RELATIONSHIP', 894), ('IMPORTANT_CONSIDERATION', 953), ('IMPORTANT_CONSIDERATION', 967), ('INCOMPLETE_EVIDENCE', 1005), ('INCOMPLETE_EVIDENCE', 1039), ('SUPERFICIAL_RELATIONSHIP', 1083), ('INCOMPLETE_EVIDENCE', 1160), ('FULL_UNKNOWN', 1189), ('INCOMPLETE_EVIDENCE', 1269), ('FUTURE_WORK', 1323)]	18	[('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('GO_0007565', 'female pregnancy', 122, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 220, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 228, 'D'), ('GO_0007565', 'female pregnancy', 349, 'prenatal'), ('CHEBI_27300', 'vitamin D', 358, 'vitamin D'), ('GO_0007565', 'female pregnancy', 495, 'prenatal'), ('CHEBI_27300', 'vitamin D', 504, 'vitamin D'), ('UBERON_0001977', 'blood serum', 578, 'serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 584, '25-hydroxyvitamin D'), ('GO_0007565', 'female pregnancy', 679, 'gestational'), ('GO_0007565', 'female pregnancy', 828, 'prenatal'), ('CHEBI_27300', 'vitamin D', 837, 'vitamin D'), ('GO_0007565', 'female pregnancy', 905, 'pregnancy'), ('GO_0007567', 'parturition', 935, 'birth'), ('GO_0007565', 'female pregnancy', 986, 'preterm'), ('GO_0007567', 'parturition', 994, 'birth'), ('CHEBI_27300', 'vitamin D', 1093, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1243, 'prenatal'), ('CHEBI_27300', 'vitamin D', 1252, 'vitamin D')]
S176-PMC5707701	PMC5707701	11/2017	S176-PMC5707701	['PREVIOUS STUDIES [36,37,66] SUGGESTED Vitamins A and e in Human milk were ASSOCIATED with maternal stores, dietary supplements, fortified foods, and dietary intake.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 28), ('SUPERFICIAL_RELATIONSHIP', 74)]	3	[('CHEBI_27300', 'vitamin D', 38, 'vitamins A'), ('NCBITaxon_9606', 'Homo sapiens', 58, 'human')]
S99-PMC5732505	PMC5732505	12/2017	S99-PMC5732505	['MAJORITY (95%) of the mothers took Vitamin D supplements during Pregnancy, MOST of them were highly educated (75% had at least a bachelor level education), and 73% had normal weight before Pregnancy.']	[('PROBABLE_UNDERSTANDING', 0), ('PROBABLE_UNDERSTANDING', 75)]	2	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('GO_0007565', 'female pregnancy', 64, 'pregnancy'), ('GO_0007565', 'female pregnancy', 189, 'pregnancy')]
S104-PMC5732505	PMC5732505	12/2017	S104-PMC5732505	['NO DIFFERENCES between the groups were OBSERVED in SEVERAL other characteristics, including gwg, duration of Gestation, and supplemental Vitamin D intake.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 39), ('INCOMPLETE_EVIDENCE', 51)]	3	[('GO_0007565', 'female pregnancy', 109, 'gestation'), ('CHEBI_27300', 'vitamin D', 137, 'vitamin D')]
S151-PMC5732505	PMC5732505	12/2017	S151-PMC5732505	['ALTHOUGH a biological mechanism between low Vitamin D status and diabetes is PLAUSIBLE [29], ONLY a FEW INTERVENTIONS have been conducted, and these HAVE NOT proved an EFFECT of Vitamin D supplementation on RISK of gdm [30].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 77), ('INCOMPLETE_EVIDENCE', 93), ('INCOMPLETE_EVIDENCE', 100), ('SUPERFICIAL_RELATIONSHIP', 104), ('INCOMPLETE_EVIDENCE', 149), ('SUPERFICIAL_RELATIONSHIP', 168), ('IMPORTANT_CONSIDERATION', 207)]	8	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 178, 'vitamin D')]
S178-PMC5732505	PMC5732505	12/2017	S178-PMC5732505	['HOWEVER, randomised controlled TRIALS ARE REQUIRED in specific RISK groups of Vitamin D deficiency TO CLARIFY if Vitamin D supplementation AFFECTS the RISK of gdm.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('FUTURE_WORK', 31), ('IMPORTANT_CONSIDERATION', 63), ('FUTURE_WORK', 99), ('SUPERFICIAL_RELATIONSHIP', 139), ('IMPORTANT_CONSIDERATION', 151)]	6	[('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D')]
S14-PMC5738092	PMC5738092	12/2017	S14-PMC5738092	['in THIS PAPER, we illustrate the use of partial least squares (pls) regression analysis to quantify ASSOCIATIONS between materno-infant and household socioeconomic characteristics and multiple measures of newborn size, drawing on a large population cohort of infants whose mothers participated in a maternal Vitamin A and Beta-Carotene supplementation in rural, northern bangladesh [6].']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('SUPERFICIAL_RELATIONSHIP', 100)]	2	[('CHEBI_27300', 'vitamin D', 308, 'vitamin A'), ('CHEBI_17579', 'beta-carotene', 322, 'beta-carotene')]
S93-PMC5738092	PMC5738092	12/2017	S93-PMC5738092	['all the PREDICTORS except Vitamin A and Β-Carotene supplementation were significantly (p<0.05) CORRELATED with all the Birth size variables.']	[('SUPERFICIAL_RELATIONSHIP', 8), ('SUPERFICIAL_RELATIONSHIP', 95)]	2	[('CHEBI_27300', 'vitamin D', 26, 'vitamin A'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 40, 'β-carotene'), ('GO_0007567', 'parturition', 119, 'birth')]
S100-PMC5738092	PMC5738092	12/2017	S100-PMC5738092	['except the Prenatal supplementation of Vitamin A and Β-Carotene, all the variables had significant (p <0.001) ASSOCIATION with infant’s size at Birth.']	[('SUPERFICIAL_RELATIONSHIP', 110)]	1	[('GO_0007565', 'female pregnancy', 11, 'prenatal'), ('CHEBI_27300', 'vitamin D', 39, 'vitamin A'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 53, 'β-carotene'), ('GO_0007567', 'parturition', 144, 'birth')]
S123-PMC5738092	PMC5738092	12/2017	S123-PMC5738092	['OUR STUDY REVEALED that all the maternal variables EXAMINED, except Vitamin A and Β- Carotene supplement receipt during Pregnancy, were significantly ASSOCIATED with Birth size.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 10), ('QUESTION_ANSWERED_BY_THIS_WORK', 51), ('SUPERFICIAL_RELATIONSHIP', 150)]	4	[('CHEBI_27300', 'vitamin D', 68, 'vitamin A'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 82, 'β- carotene'), ('GO_0007565', 'female pregnancy', 120, 'pregnancy'), ('GO_0007567', 'parturition', 166, 'birth')]
S142-PMC5738092	PMC5738092	12/2017	S142-PMC5738092	['we did NOT FIND any effect of maternal Vitamin A and Β-Carotene supplementation on infant’s size at Birth and which is CONSISTENT with the result found by christian et al.']	[('INCOMPLETE_EVIDENCE', 7), ('INCOMPLETE_EVIDENCE', 119)]	2	[('CHEBI_27300', 'vitamin D', 39, 'vitamin A'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 53, 'β-carotene'), ('GO_0007567', 'parturition', 100, 'birth')]
S13-PMC5758521	PMC5758521	1/2018	S13-PMC5758521	['SURPRISINGLY, high-dose Vitamin E (Α-Tocopherol) supplementation HAS BEEN ASSOCIATED with increased risk of low Birth weight8– a condition LINKED to Insulin-Like Growth Factor I (Igf-I) insufficiency9.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 65), ('SUPERFICIAL_RELATIONSHIP', 74), ('SUPERFICIAL_RELATIONSHIP', 139)]	4	[('CHEBI_27300', 'vitamin D', 24, 'vitamin E'), ('CHEBI_27725', 'butin', 35, 'α-tocopherol'), ('GO_0007567', 'parturition', 112, 'birth'), ('PR_000045358', 'insulin family protein', 149, 'insulin'), ('PR_000009659', 'laminin subunit gamma-2', 157, 'like growth factor I'), ('PR_000008919', 'interferon alpha-6', 179, 'IGF-I')]
S144-PMC5758521	PMC5758521	1/2018	S144-PMC5758521	['REPORTED that maternal Α-Tocopherol concentrations were positively ASSOCIATED with Birth weight, BUT poston and colleagues FOUND that Prenatal supplementation with Α-Tocopherol and Vitamin C was ASSOCIATED with elevated risk of low Birth weight8.']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 67), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 97), ('ANOMALY_CURIOUS_FINDING', 97), ('INCOMPLETE_EVIDENCE', 123), ('SUPERFICIAL_RELATIONSHIP', 195)]	6	[('CHEBI_27725', 'butin', 23, 'α-tocopherol'), ('GO_0007567', 'parturition', 83, 'birth'), ('GO_0007565', 'female pregnancy', 134, 'prenatal'), ('CHEBI_27725', 'butin', 164, 'α-tocopherol'), ('CHEBI_27300', 'vitamin D', 181, 'vitamin C'), ('GO_0007567', 'parturition', 232, 'birth')]
S17-PMC5784894	PMC5784894	1/2018	S17-PMC5784894	['in a recent prospective randomised controlled STUDY, maternal Vitamin D supplementation increased bone mass at Birth in winter-Born infants.']	[('INCOMPLETE_EVIDENCE', 46)]	1	[('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('GO_0007567', 'parturition', 111, 'birth'), ('GO_0007567', 'parturition', 127, 'born')]
S159-PMC5784894	PMC5784894	1/2018	S159-PMC5784894	['the mavidos study, a randomised controlled trial of Vitamin D supplementation to Pregnant women RECENTLY REPORTED changes in bmc in babies Born during the winter months.']	[('INCOMPLETE_EVIDENCE', 96), ('INCOMPLETE_EVIDENCE', 105)]	2	[('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('GO_0007565', 'female pregnancy', 81, 'pregnant'), ('GO_0007567', 'parturition', 139, 'born')]
S191-PMC5784894	PMC5784894	1/2018	S191-PMC5784894	['THIS work THUS establishes Early Life Vitamin D deficiency as a FACTOR that CAN CONTRIBUTE to Adult osteoporosis; offers a POTENTIAL Solution–supplementation of Vitamin D during Pregnancy and infancy; and presents a MODEL system TO IDENTIFY pathways that COULD BE TARGETED in Adult Life to prevent or treat osteoporosis, a GLOBAL health PROBLEM.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('PROBABLE_UNDERSTANDING', 10), ('SUPERFICIAL_RELATIONSHIP', 64), ('INCOMPLETE_EVIDENCE', 76), ('SUPERFICIAL_RELATIONSHIP', 80), ('INCOMPLETE_EVIDENCE', 123), ('INCOMPLETE_EVIDENCE', 216), ('QUESTION_ANSWERED_BY_THIS_WORK', 229), ('INCOMPLETE_EVIDENCE', 255), ('FUTURE_WORK', 264), ('IMPORTANT_CONSIDERATION', 323), ('IMPORTANT_CONSIDERATION', 337)]	12	[('UBERON_0001847', 'lobule of pinna', 27, 'early life'), ('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('UBERON_0007023', 'adult organism', 94, 'adult'), ('CHEBI_75958', 'solution', 133, 'solution'), ('CHEBI_27300', 'vitamin D', 161, 'vitamin D'), ('GO_0007565', 'female pregnancy', 178, 'pregnancy'), ('UBERON_0000113', 'post-juvenile adult stage', 276, 'adult life')]
S73-PMC5812027	PMC5812027	2/2018	S73-PMC5812027	['tobacco use and Vitamin D supplement use were also INVESTIGATED as POTENTIAL CONFOUNDERS BUT did not show any confounding effect and were THUS not included in the final MODELS.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 51), ('INCOMPLETE_EVIDENCE', 67), ('PROBLEM_COMPLICATION', 77), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 89), ('PROBABLE_UNDERSTANDING', 138), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 169)]	6	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D')]
S116-PMC5812027	PMC5812027	2/2018	S116-PMC5812027	['we have PREVIOUSLY SHOWN that the DETERMINANTS of season-corrected change in 25Ohd during Pregnancy include origin, sun-exposure and dietary as well as supplementary Vitamin D Intake [18].']	[('INCOMPLETE_EVIDENCE', 8), ('SUPERFICIAL_RELATIONSHIP', 34)]	2	"[('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 77, '25OHD'), ('GO_0007565', 'female pregnancy', 90, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 166, 'vitamin D'), ('GO_0007631', 'feeding behavior', 176, 'intake')]"
S118-PMC5812027	PMC5812027	2/2018	S118-PMC5812027	['AS the results between change in 25Ohd and neonatal Birth size and Preterm Delivery REMAINED after adjustment for season of Conception, origin and Vitamin D supplementation, Vitamin D status trajectory CAN be SUSPECTED to play a ROLE in healthy Pregnancy.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 84), ('INCOMPLETE_EVIDENCE', 202), ('PROBABLE_UNDERSTANDING', 209), ('SUPERFICIAL_RELATIONSHIP', 229)]	5	"[('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 33, '25OHD'), ('GO_0007567', 'parturition', 52, 'birth'), ('GO_0007565', 'female pregnancy', 67, 'preterm'), ('GO_0007567', 'parturition', 75, 'delivery'), ('GO_0007620', 'copulation', 124, 'conception'), ('CHEBI_27300', 'vitamin D', 147, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 174, 'vitamin D'), ('GO_0007565', 'female pregnancy', 245, 'pregnancy')]"
S136-PMC5812027	PMC5812027	2/2018	S136-PMC5812027	['supplementation CAN THEREFORE ONLY PARTLY EXPLAIN the large proportion with high Vitamin D status, and OTHER LIKELY CONTRIBUTORS are Pregnancy associated Endocrine changes and POSSIBLY lifestyle FACTORS.']	[('INCOMPLETE_EVIDENCE', 16), ('PROBABLE_UNDERSTANDING', 20), ('INCOMPLETE_EVIDENCE', 30), ('INCOMPLETE_EVIDENCE', 35), ('PROBABLE_UNDERSTANDING', 42), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 103), ('PROBABLE_UNDERSTANDING', 109), ('SUPERFICIAL_RELATIONSHIP', 116), ('INCOMPLETE_EVIDENCE', 176), ('SUPERFICIAL_RELATIONSHIP', 195)]	10	[('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('GO_0007565', 'female pregnancy', 133, 'pregnancy'), ('GO_0006397', 'mRNA processing', 154, 'endocrine')]
S17-PMC5827025	PMC5827025	2/2018	S17-PMC5827025	['IN CONTRAST, the reports from randomized controlled trials INDICATE that Gestational Vitamin D supplementation CAN markedly decrease Pregnancy COMPLICATIONS including Preeclampsia and Pregnancy induced hypertension11.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 59), ('INCOMPLETE_EVIDENCE', 111), ('PROBLEM_COMPLICATION', 143)]	4	[('GO_0007565', 'female pregnancy', 73, 'gestational'), ('CHEBI_27300', 'vitamin D', 85, 'vitamin D'), ('GO_0007565', 'female pregnancy', 133, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 167, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 184, 'pregnancy')]
S101-PMC5827025	PMC5827025	2/2018	S101-PMC5827025	['follow-up, SEVERAL randomized TRIAL of Vitamin D supplementation FOUND that the rate of Preterm Delivery is significant more lower in Pregnant women with Serum 25(Oh)D ≥40\u2009ng/ml COMPARED TO those with Serum 25(Oh)D ≤20\u2009ng/ml, SUGGESTING higher 25(Oh)D concentration was ASSOCIATED with an decreased risk of Preterm Delivery35–38.']	[('INCOMPLETE_EVIDENCE', 11), ('INCOMPLETE_EVIDENCE', 65), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 178), ('INCOMPLETE_EVIDENCE', 226), ('SUPERFICIAL_RELATIONSHIP', 270)]	5	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('GO_0007565', 'female pregnancy', 88, 'preterm'), ('GO_0007567', 'parturition', 96, 'delivery'), ('GO_0007565', 'female pregnancy', 134, 'pregnant'), ('UBERON_0001977', 'blood serum', 154, 'serum'), ('CHEBI_63056', 'zinc cation', 160, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 166, 'D'), ('UBERON_0001977', 'blood serum', 201, 'serum'), ('CHEBI_71657', 'versiconol acetate', 207, '25(OH)D'), ('PR_000011614', 'opioid growth factor receptor', 210, 'OH'), ('PR_000006444', 'diacylglycerol kinase delta', 213, 'D'), ('CHEBI_71657', 'versiconol acetate', 244, '25(OH)D'), ('GO_0007565', 'female pregnancy', 307, 'preterm'), ('GO_0008219', 'cell death', 315, 'delivery35')]
S82-PMC5838372	PMC5838372	3/2018	S82-PMC5838372	['the SAFETY dose during Pregnancy is NOT CLEAR, but hollis et al (20) SHOWED that Vitamin D supplementation of 4000 iu/day for achieving adequate levels was SAFE and EFFECTIVE in Pregnant women.']	[('IMPORTANT_CONSIDERATION', 4), ('FULL_UNKNOWN', 36), ('INCOMPLETE_EVIDENCE', 69), ('IMPORTANT_CONSIDERATION', 156), ('SUPERFICIAL_RELATIONSHIP', 165)]	5	[('GO_0007565', 'female pregnancy', 23, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('GO_0007565', 'female pregnancy', 178, 'pregnant')]
S98-PMC5838372	PMC5838372	3/2018	S98-PMC5838372	['it should BE NOTED that all of these studies were conducted prior to the introduction of the national Pregnancy Vitamin D supplementation programme.']	[('ANOMALY_CURIOUS_FINDING', 10), ('ANOMALY_CURIOUS_FINDING', 13)]	2	[('GO_0007565', 'female pregnancy', 102, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 112, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 120, 'D')]
S101-PMC5838372	PMC5838372	3/2018	S101-PMC5838372	['all these data CONFIRM that Vitamin D deficiency continues to be a PROBLEM in Pregnant women and their infants in turkey, DESPITE the introduction of the supplementation programme.']	[('INCOMPLETE_EVIDENCE', 15), ('IMPORTANT_CONSIDERATION', 67), ('PROBLEM_COMPLICATION', 67), ('ANOMALY_CURIOUS_FINDING', 122)]	4	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('GO_0007565', 'female pregnancy', 78, 'pregnant')]
S102-PMC5838372	PMC5838372	3/2018	S102-PMC5838372	['ALTHOUGH the ministry of health has RECOMMENDED a Vitamin D intake of 1200 iu/day, we FOUND that 12.4% of mothers never used Vitamin D Supplements and 73.2% used irregular or low doses.']	[('ANOMALY_CURIOUS_FINDING', 0), ('FUTURE_WORK', 36), ('INCOMPLETE_EVIDENCE', 86)]	3	[('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 135, 'supplements')]
S104-PMC5838372	PMC5838372	3/2018	S104-PMC5838372	['Vitamin D levels were significantly lower in mothers who used low dose Vitamin D supplements COMPARED TO those who used recommended doses.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 93)]	1	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin D')]
S17-PMC5841533	PMC5841533	2/2018	S17-PMC5841533	['introduction\nan ESTIMATED 250\u2009million children GLOBALLY are denied the opportunity to reach their full developmental potential DUE TO the combined EFFECTS of poverty and undernutrition.1poor nutrition during Pregnancy CONTRIBUTES to maternal morbidity and mortality, increases the risks of low Birth weight and poor development, and exacerbates the risk of chronic disease in Adulthood.2 3many Pregnant women face Micronutrient deficiencies: an ESTIMATED 15.3% globally lack Vitamin A, 28.5% lack Iodine and 38% have iron-deficiency anaemia.1 4nutritional deprivation in Pregnancy CAN alter neural growth in the fetus and AFFECT Cognitive functioning, hindering children’s chances in school and CONTRIBUTING to the intergenerational transmission of poverty.5–9\nthe world health organisation (who) currently RECOMMENDS Iron and Folic Acid (ifa) supplementation in Pregnancy to improve maternal and Perinatal outcomes, BUT NOT multiple Micronutrient (mmn)supplementation.10–12could Antenatal Micronutrient supplementation improve children’s long-term Cognitive functioning?']	[('INCOMPLETE_EVIDENCE', 16), ('IMPORTANT_CONSIDERATION', 47), ('PROBLEM_COMPLICATION', 127), ('SUPERFICIAL_RELATIONSHIP', 147), ('SUPERFICIAL_RELATIONSHIP', 218), ('INCOMPLETE_EVIDENCE', 445), ('INCOMPLETE_EVIDENCE', 581), ('SUPERFICIAL_RELATIONSHIP', 622), ('SUPERFICIAL_RELATIONSHIP', 695), ('FUTURE_WORK', 807), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 917), ('ANOMALY_CURIOUS_FINDING', 917), ('EXPLICIT_QUESTION', 1070)]	13	[('GO_0007565', 'female pregnancy', 208, 'pregnancy'), ('GO_0007567', 'parturition', 294, 'birth'), ('UBERON_0000113', 'post-juvenile adult stage', 376, 'adulthood'), ('GO_0007565', 'female pregnancy', 394, 'pregnant'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 414, 'micronutrient'), ('CHEBI_27300', 'vitamin D', 475, 'vitamin A'), ('CHEBI_24859', 'iodine atom', 497, 'iodine'), ('GO_0007565', 'female pregnancy', 571, 'pregnancy'), ('GO_0050890', 'cognition', 629, 'cognitive'), ('CHEBI_24870', 'ion', 818, 'Iron'), ('CHEBI_30751', 'formic acid', 827, 'Folic Acid'), ('GO_0007565', 'female pregnancy', 863, 'pregnancy'), ('GO_0036268', 'swimming', 897, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 897, 'perinatal'), ('CHEBI_6956', 'Mitragynine', 934, 'Micronutrient'), ('GO_0007567', 'parturition', 980, 'antenatal'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 990, 'micronutrient'), ('GO_0050890', 'cognition', 1049, 'cognitive')]
S19-PMC5841533	PMC5841533	2/2018	S19-PMC5841533	['supplementation with single Micronutrients during Pregnancy APPEARS TO have little influence on children’s Cognitive outcomes: 10 trials conducted in high-income, middle-income and low-income settings FOUND no effects of Antenatal iron, zinc, Vitamin A or Choline supplementation on Cognitive functions.13–20supplementation with mmn, on the OTHER HAND, COULD AFFECT children’s Cognitive functions via three RELATED pathways.']	[('ANOMALY_CURIOUS_FINDING', 60), ('INCOMPLETE_EVIDENCE', 201), ('ANOMALY_CURIOUS_FINDING', 341), ('INCOMPLETE_EVIDENCE', 353), ('SUPERFICIAL_RELATIONSHIP', 359), ('SUPERFICIAL_RELATIONSHIP', 407)]	6	[('CHEBI_33839', 'macromolecule', 28, 'micronutrients'), ('GO_0007565', 'female pregnancy', 50, 'pregnancy'), ('GO_0050890', 'cognition', 107, 'cognitive'), ('GO_0007567', 'parturition', 221, 'antenatal'), ('CHEBI_27300', 'vitamin D', 243, 'vitamin A'), ('CHEBI_15354', 'choline', 256, 'choline'), ('GO_0050890', 'cognition', 283, 'cognitive'), ('GO_0050890', 'cognition', 377, 'cognitive')]
S4-PMC5941617	PMC5941617	5/2018	S4-PMC5941617	['AT PRESENT, the prevalence of Vitamin D deficiency is high in italian children and adolescents, and national RECOMMENDATIONS on Vitamin D supplementation during pediatric age are LACKING.']	[('INCOMPLETE_EVIDENCE', 0), ('FUTURE_WORK', 109), ('FULL_UNKNOWN', 179)]	3	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 128, 'vitamin D')]
S24-PMC5941617	PMC5941617	5/2018	S24-PMC5941617	['further literature search was performed focusing available international GUIDELINES on Vitamin D supplementation in children.']	[('PROBABLE_UNDERSTANDING', 73)]	1	[('CHEBI_27300', 'vitamin D', 87, 'vitamin D')]
S65-PMC5941617	PMC5941617	5/2018	S65-PMC5941617	['LIMITATIONS of the study include the fact that SOME of the studies mainly included children aged 7–11\xa0years, and that Vitamin D supplements, Food fortification or sun awareness campaigns COULD have INFLUENCED the ESTIMATES.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 47), ('INCOMPLETE_EVIDENCE', 187), ('SUPERFICIAL_RELATIONSHIP', 198), ('INCOMPLETE_EVIDENCE', 213)]	5	[('CHEBI_27300', 'vitamin D', 118, 'vitamin D'), ('CHEBI_33290', 'food', 141, 'food')]
S67-PMC5941617	PMC5941617	5/2018	S67-PMC5941617	['other italian data are present in literature, ALTHOUGH they SHOW SOME LIMITATIONS, regarding SMALL populations, analytic methods for 25(Oh)D, the season of recruitment, the prevalence of overweight/obesity, Vitamin D supplements, sunscreens, ethnicity, and uncovered areas of latitude.']	[('ANOMALY_CURIOUS_FINDING', 46), ('INCOMPLETE_EVIDENCE', 60), ('INCOMPLETE_EVIDENCE', 65), ('INCOMPLETE_EVIDENCE', 70), ('PROBLEM_COMPLICATION', 70), ('INCOMPLETE_EVIDENCE', 93)]	6	[('CHEBI_71657', 'versiconol acetate', 133, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 133, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 207, 'vitamin D')]
S92-PMC5941617	PMC5941617	5/2018	S92-PMC5941617	['THUS, during this period an adequate Vitamin D status can be maintained only from endogenous stores accumulated during previous summer or by exogenous supplementation.']	[('PROBABLE_UNDERSTANDING', 0)]	1	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D')]
S107-PMC5941617	PMC5941617	5/2018	S107-PMC5941617	['HOWEVER, various dietary reference values for Vitamin D are useful to guide local STRATEGIES for Vitamin D supplementation, but are not directly comparable.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('FUTURE_WORK', 82)]	2	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 97, 'vitamin D')]
S110-PMC5941617	PMC5941617	5/2018	S110-PMC5941617	['Vitamin D supplementation\n\n0–12\xa0months\nvitamin D supplementation in the first year of Life is ESSENTIAL to ensure an adequate Vitamin D status and to prevent nutritional rickets.']	[('IMPORTANT_CONSIDERATION', 94)]	1	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 47, 'D'), ('UBERON_0000104', 'life cycle', 86, 'life'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D')]
S114-PMC5941617	PMC5941617	5/2018	S114-PMC5941617	['the IMPORTANCE of Vitamin D supplementation during the first year of Life HAS BEEN CONFIRMED by the FINDING that children not receiving supplementation have reduced Serum 25(Oh)d levels, PARTICULARLY if exclusively Breastfed and during winter season [94–96].']	[('IMPORTANT_CONSIDERATION', 4), ('INCOMPLETE_EVIDENCE', 74), ('INCOMPLETE_EVIDENCE', 83), ('INCOMPLETE_EVIDENCE', 100), ('ANOMALY_CURIOUS_FINDING', 187)]	5	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('UBERON_0000104', 'life cycle', 69, 'life'), ('UBERON_0001977', 'blood serum', 165, 'serum'), ('CHEBI_30778', 'gallic acid', 171, '25(OH)'), ('GO_0007567', 'parturition', 215, 'breastfed')]
S115-PMC5941617	PMC5941617	5/2018	S115-PMC5941617	['SOME STUDIES evaluated the EFFECT of daily Vitamin D supplementation at variable dosages (ranging from 200 to 1600\xa0iu/day) on Vitamin D status in children during the first year of Life [52,62,97–107].']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 27)]	2	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D'), ('UBERON_0000104', 'life cycle', 180, 'life')]
S117-PMC5941617	PMC5941617	5/2018	S117-PMC5941617	['ON THE CONTRARY, Vitamin D supplementation at higher dosages SEEMED TO BE ASSOCIATED with increased RISK of hypervitaminosis D with hypercalciuria and hypercalcemia [62].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 7), ('ANOMALY_CURIOUS_FINDING', 7), ('ANOMALY_CURIOUS_FINDING', 61), ('SUPERFICIAL_RELATIONSHIP', 74), ('IMPORTANT_CONSIDERATION', 100)]	6	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 125, 'D')]
S119-PMC5941617	PMC5941617	5/2018	S119-PMC5941617	['ONLY FEW STUDIES evaluated the EFFICACY and SAFETY of intermittent Vitamin D supplementation during the first year of Life, particularly in cases with low compliance [109–111], THUS AT PRESENT daily supplementation REMAINS PREFERRED.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 5), ('SUPERFICIAL_RELATIONSHIP', 31), ('IMPORTANT_CONSIDERATION', 44), ('PROBABLE_UNDERSTANDING', 177), ('INCOMPLETE_EVIDENCE', 182), ('INCOMPLETE_EVIDENCE', 215), ('PROBABLE_UNDERSTANDING', 223)]	8	[('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('UBERON_0000104', 'life cycle', 118, 'life')]
S120-PMC5941617	PMC5941617	5/2018	S120-PMC5941617	['various international scientific societies agree to RECOMMEND Vitamin D supplementation during the first year of Life [9,12–15,19,20,22,23,27,28,30,112–116].']	[('FUTURE_WORK', 52)]	1	[('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('UBERON_0000104', 'life cycle', 113, 'life')]
S125-PMC5941617	PMC5941617	5/2018	S125-PMC5941617	['regarding the PREFERRED form of Vitamin D for supplementation, the national institute for health and care excellence GUIDELINE RECOMMENDED Vitamin D drops in infants and young children [114], WHILE other international scientific societies DID NOT make any SPECIFIC RECOMMENDATION.']	[('PROBABLE_UNDERSTANDING', 14), ('PROBABLE_UNDERSTANDING', 117), ('FUTURE_WORK', 127), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 192), ('INCOMPLETE_EVIDENCE', 239), ('FUTURE_WORK', 256), ('FUTURE_WORK', 265)]	7	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 139, 'vitamin D')]
S126-PMC5941617	PMC5941617	5/2018	S126-PMC5941617	['DESPITE this GLOBAL agreement on Vitamin D supplementation in the first year of Life, several barriers to adherence STILL exist, such as reluctance of mothers to give their children daily supplementation, lack OF knowledge about Vitamin D actions and the RISK of nutritional rickets, lack of awareness by health care professionals, ASSUMPTION that both breast milk and formula milk provide sufficient Vitamin D intake [116,117].']	[('ANOMALY_CURIOUS_FINDING', 0), ('IMPORTANT_CONSIDERATION', 13), ('IMPORTANT_CONSIDERATION', 116), ('ANOMALY_CURIOUS_FINDING', 210), ('IMPORTANT_CONSIDERATION', 255), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 332)]	6	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('UBERON_0000104', 'life cycle', 80, 'life'), ('CHEBI_27300', 'vitamin D', 229, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 401, 'vitamin D')]
S127-PMC5941617	PMC5941617	5/2018	S127-PMC5941617	['in the present consensus we RECOMMEND Vitamin D supplementation in all newborns independently of the type of Feeding, starting from Birth and continuing throughout the first year of Life.']	[('FUTURE_WORK', 28)]	1	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('GO_0007631', 'feeding behavior', 109, 'feeding'), ('GO_0007567', 'parturition', 132, 'birth'), ('UBERON_0000104', 'life cycle', 182, 'life')]
S129-PMC5941617	PMC5941617	5/2018	S129-PMC5941617	['we RECOMMEND against using Vitamin D Metabolites and their analogs (Calcifediol, Alfacalcidol, Calcitriol, and Dihydrotachysterol) for the routine Vitamin D supplementation, as the administration of these Compounds increases the RISK of hypercalcemia and is NOT ABLE to maintain and/or restore Vitamin D stores [118,119].']	[('FUTURE_WORK', 3), ('IMPORTANT_CONSIDERATION', 229), ('DIFFICULT_TASK', 258)]	3	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('CHEBI_25212', 'metabolite', 37, 'metabolites'), ('CHEBI_22975', 'cadinane sesquiterpenoid', 68, 'calcifediol'), ('CHEBI_31186', 'alfacalcidol', 81, 'alfacalcidol'), ('CHEBI_17823', 'calcitriol', 95, 'calcitriol'), ('CHEBI_4657', 'disopyramide', 111, 'dihydrotachysterol'), ('CHEBI_27300', 'vitamin D', 147, 'vitamin D'), ('CHEBI_36357', 'polyatomic entity', 205, 'compounds'), ('CHEBI_27300', 'vitamin D', 294, 'vitamin D')]
S134-PMC5941617	PMC5941617	5/2018	S134-PMC5941617	['Ketoconazole)• infants Born from mothers with multiple RISK FACTORS for Vitamin D deficiency, particularly in absence of Vitamin D supplementation during Pregnancy\n\npreterm\npreterm infants are AT RISK for Calcium-Phosphorus Metabolism alterations, with POSSIBLE development of osteopenia of prematurity [120].']	[('SUPERFICIAL_RELATIONSHIP', 55), ('IMPORTANT_CONSIDERATION', 193), ('INCOMPLETE_EVIDENCE', 253)]	3	[('CHEBI_47519', 'ketoconazole', 0, 'ketoconazole'), ('GO_0007567', 'parturition', 23, 'born'), ('CHEBI_27300', 'vitamin D', 72, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin D'), ('GO_0007565', 'female pregnancy', 154, 'pregnancy'), ('CHEBI_30272', 'arsonium', 205, 'calcium-phosphorus'), ('GO_0050655', 'dermatan sulfate proteoglycan metabolic process', 205, 'calcium-phosphorus metabolism')]
S140-PMC5941617	PMC5941617	5/2018	S140-PMC5941617	['RELATIVELY few international scientific societies gave RECOMMENDATIONS on Vitamin D supplementation in preterm infants.']	[('IMPORTANT_CONSIDERATION', 0), ('FUTURE_WORK', 55)]	2	[('CHEBI_27300', 'vitamin D', 74, 'vitamin D')]
S144-PMC5941617	PMC5941617	5/2018	S144-PMC5941617	['OTHER authors and GUIDELINES for central europe RECOMMENDED Vitamin D supplementation in preterm infants at higher dosages (400–1000\xa0iu/day) THAN those SUGGESTED for healthy term newborns [1,9,20,126], BUT such an intake SHOULD NOT BE prolonged over the THEORETICAL term (40\xa0weeks of post-Conceptional age) due to the POTENTIAL risk of Vitamin D intoxication [126].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('PROBABLE_UNDERSTANDING', 18), ('FUTURE_WORK', 48), ('INCOMPLETE_EVIDENCE', 48), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 141), ('INCOMPLETE_EVIDENCE', 152), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 202), ('FUTURE_WORK', 221), ('INCOMPLETE_EVIDENCE', 254), ('INCOMPLETE_EVIDENCE', 318)]	10	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('GO_0007620', 'copulation', 289, 'conceptional'), ('CHEBI_27300', 'vitamin D', 336, 'vitamin D')]
S145-PMC5941617	PMC5941617	5/2018	S145-PMC5941617	['preterm infants MAY receive Vitamin D from various sources, such as parenteral nutrition, fortified Human milk or preterm infant formula, but it HAS BEEN calculated that without supplementation they do not receive 400\xa0iu/day of Vitamin D until reaching a weight of 2–2.5 kg [123] or only 4\xa0weeks after Birth [127].']	[('INCOMPLETE_EVIDENCE', 16), ('INCOMPLETE_EVIDENCE', 145)]	2	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('NCBITaxon_9606', 'Homo sapiens', 100, 'human'), ('CHEBI_27300', 'vitamin D', 228, 'vitamin D'), ('GO_0007567', 'parturition', 302, 'birth')]
S146-PMC5941617	PMC5941617	5/2018	S146-PMC5941617	['HOWEVER, total Vitamin D intake from supplementation and Feeding SHOULD BE assessed to avoid excess, particularly in vlbw infants.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('FUTURE_WORK', 65)]	2	[('CHEBI_27300', 'vitamin D', 15, 'vitamin D'), ('GO_0007631', 'feeding behavior', 57, 'feeding')]
S147-PMC5941617	PMC5941617	5/2018	S147-PMC5941617	['SOME STUDIES evaluated the EFFECT of Vitamin D supplementation at DIFFERENT doses in preterm infants of various Gestational age and Birth weight [124,128–146].']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 27), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 66)]	3	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('GO_0007565', 'female pregnancy', 112, 'gestational'), ('GO_0007567', 'parturition', 132, 'birth')]
S149-PMC5941617	PMC5941617	5/2018	S149-PMC5941617	['studies that evaluated Vitamin D supplementation at 200\xa0iu/day gave CONFLICTING results [128,129,134].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 68)]	1	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D')]
S152-PMC5941617	PMC5941617	5/2018	S152-PMC5941617	['RECENTLY RECOMMENDED Vitamin D supplementation at 800\xa0iu/day to enhance Vitamin D status during early hospitalization in vlbw infants with Serum 25(Oh)D levels <\u200910\xa0ng/ml at Birth [142].']	[('INCOMPLETE_EVIDENCE', 0), ('FUTURE_WORK', 9)]	2	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 72, 'vitamin D'), ('UBERON_0001977', 'blood serum', 139, 'serum'), ('CHEBI_71657', 'versiconol acetate', 145, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 145, '25 ... OH ... D'), ('GO_0007567', 'parturition', 174, 'birth')]
S157-PMC5941617	PMC5941617	5/2018	S157-PMC5941617	['SUGGESTED for extremely low Gestational age newborns an initial Vitamin D supplementation at 800\xa0iu/day for 1–2\xa0weeks to restore Serum 25(Oh)D levels followed by a lower dosage (200\xa0iu/day) [143].']	[('INCOMPLETE_EVIDENCE', 0)]	1	[('GO_0007565', 'female pregnancy', 28, 'gestational'), ('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('UBERON_0001977', 'blood serum', 129, 'serum'), ('CHEBI_71657', 'versiconol acetate', 135, '25(OH)D')]
S158-PMC5941617	PMC5941617	5/2018	S158-PMC5941617	['in the present consensus we RECOMMEND a total daily Vitamin D intake of 200–400\xa0iu (including the amount administered through parenteral nutrition, fortified Breast Milk, and preterm formula) for preterm infants with a Birth weight\u2009<\u20091500\xa0g. Vitamin D supplementation at 400–800\xa0iu/day is RECOMMENDED for vlbw infants when they reach a weight\u2009≥\u20091500\xa0g and full enteral nutrition, and for preterm infants with a Birth weight\u2009≥\u20091500\xa0g. after a post-Conceptional age of 40\xa0weeks, RECOMMENDATIONS for Vitamin D supplementation are equal to those for healthy term infants.']	[('FUTURE_WORK', 28), ('FUTURE_WORK', 289), ('FUTURE_WORK', 477)]	3	[('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('UBERON_0000310', 'breast', 158, 'breast'), ('UBERON_0001913', 'milk', 165, 'milk'), ('GO_0007567', 'parturition', 219, 'birth'), ('CHEBI_28384', 'vitamin K', 242, 'Vitamin D'), ('GO_0007567', 'parturition', 411, 'birth'), ('GO_0007620', 'copulation', 447, 'conceptional'), ('CHEBI_27300', 'vitamin D', 497, 'vitamin D')]
S160-PMC5941617	PMC5941617	5/2018	S160-PMC5941617	['VARIOUS STUDIES evaluated DIFFERENT regimens of Vitamin D supplementation, BUT comparison of results is COMPLEX DUE TO HETEROGENEITY in Vitamin D administration (dose, interval, and length of supplementation) and population enrolled (age, gender, ethnicity, body mass index, latitude of the country of residence, season of enrolment, and basal Vitamin D status).']	[('INCOMPLETE_EVIDENCE', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 26), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 75), ('PROBLEM_COMPLICATION', 75), ('DIFFICULT_TASK', 104), ('PROBLEM_COMPLICATION', 112), ('DIFFICULT_TASK', 119)]	7	[('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 344, 'vitamin D')]
S162-PMC5941617	PMC5941617	5/2018	S162-PMC5941617	['supplementation at 400\xa0iu/day for variable length (up to 12\xa0months) was USUALLY INSUFFICIENT in raising Serum 25(Oh)D levels >\u200930\xa0ng/ml [78,147–149,151–153,160–162], particularly in subjects with Vitamin D deficiency.']	[('INCOMPLETE_EVIDENCE', 72), ('PROBLEM_COMPLICATION', 80)]	2	[('UBERON_0001977', 'blood serum', 104, 'serum'), ('CHEBI_71657', 'versiconol acetate', 110, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 110, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 196, 'vitamin D')]
S168-PMC5941617	PMC5941617	5/2018	S168-PMC5941617	['intermittent Vitamin D administration MAY BE CONSIDERED in case of reduced compliance with daily supplementation, BUT ACTUAL EVIDENCE IS INSUFFICIENT to RECOMMEND a PREFERRED doses and interval.']	[('INCOMPLETE_EVIDENCE', 38), ('FUTURE_WORK', 45), ('INCOMPLETE_EVIDENCE', 45), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 114), ('INCOMPLETE_EVIDENCE', 118), ('PROBLEM_COMPLICATION', 137), ('FUTURE_WORK', 153), ('PROBABLE_UNDERSTANDING', 165)]	8	[('CHEBI_27300', 'vitamin D', 13, 'vitamin D')]
S169-PMC5941617	PMC5941617	5/2018	S169-PMC5941617	['several international societies RECOMMENDED Vitamin D supplementation in children older than 1\xa0year and adolescents with RISK FACTORS for Vitamin D, such as reduced sun exposure or dark skin pigmentation [8,9,11,18,19,23,28,30,114].']	[('FUTURE_WORK', 32), ('SUPERFICIAL_RELATIONSHIP', 121)]	2	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 138, 'vitamin D')]
S171-PMC5941617	PMC5941617	5/2018	S171-PMC5941617	['moreover, pediatricians SHOULD periodically evaluate Vitamin D intake from diet and Supplements [23,28].']	[('FUTURE_WORK', 24), ('IMPORTANT_CONSIDERATION', 24)]	2	[('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 84, 'supplements')]
S173-PMC5941617	PMC5941617	5/2018	S173-PMC5941617	['ON THE CONTRARY, OTHER societies systematically RECOMMENDED Vitamin D supplementation in children and adolescents during winter months [13,20,115] or throughout the whole year IF reduced sun exposure during summer [20,115].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 7), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 17), ('FUTURE_WORK', 48), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 176)]	5	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D')]
S174-PMC5941617	PMC5941617	5/2018	S174-PMC5941617	['following the publication of sacn review of the EVIDENCE on Vitamin D and health [25], public health england advised that uk children aged 1 to 4\xa0years should receive Vitamin D supplementation at 400\xa0iu/day, and older children and adolescents SHOULD take a daily supplement containing 400\xa0iu of Vitamin D in autumn and winter to PROTECT bone and muscle health because it is DIFFICULT to meet this intake from dietary sources.']	[('INCOMPLETE_EVIDENCE', 48), ('FUTURE_WORK', 243), ('SUPERFICIAL_RELATIONSHIP', 329), ('DIFFICULT_TASK', 374)]	4	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 167, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 295, 'vitamin D')]
S175-PMC5941617	PMC5941617	5/2018	S175-PMC5941617	['public health england also RECOMMENDED that Individuals with darker skin and People with reduced sun exposure SHOULD receive Vitamin D supplementation throughout the year [115].']	[('FUTURE_WORK', 27), ('FUTURE_WORK', 110)]	2	[('NCBITaxon_1', 'root', 44, 'individuals'), ('NCBITaxon_10088', 'Mus <genus>', 77, 'people'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin D')]
S176-PMC5941617	PMC5941617	5/2018	S176-PMC5941617	['adolescents are at INCREASED RISK for Vitamin D deficiency [79], THUS the society for adolescent health and medicine RECOMMENDED continuous Vitamin D supplementation (600\xa0iu daily for healthy adolescents, and at LEAST 1000\xa0iu daily for adolescents at risk for Vitamin D deficiency or insufficiency) in addition to Vitamin D received through the diet or via sun exposure [21].']	[('IMPORTANT_CONSIDERATION', 19), ('PROBABLE_UNDERSTANDING', 65), ('FUTURE_WORK', 117), ('PROBABLE_UNDERSTANDING', 212)]	4	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 140, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 260, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 314, 'vitamin D')]
S179-PMC5941617	PMC5941617	5/2018	S179-PMC5941617	['for example, arab emirates GUIDELINES RECOMMENDED Vitamin D supplementation between may and october BECAUSE arabian People avoid sun exposure during summer due to excessive heat [27].']	[('PROBABLE_UNDERSTANDING', 27), ('FUTURE_WORK', 38), ('PROBABLE_UNDERSTANDING', 100)]	3	[('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 116, 'people')]
S181-PMC5941617	PMC5941617	5/2018	S181-PMC5941617	['subsequent italian cross sectional studies enrolling children and adolescents living in the north-western area of tuscany, central italy (latitude between 43°n and 44°n) not receiving Vitamin D supplementation CONFIRMED seasonal variability in Serum 25(Oh)D levels, with lower concentrations during late winter-early spring months (february–april), with negligible amount of Vitamin D obtained from diet [50,79], ACCORDING TO OTHER italian pediatric studies [70,76–78,83].']	[('INCOMPLETE_EVIDENCE', 210), ('INCOMPLETE_EVIDENCE', 413), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 426)]	3	[('CHEBI_27300', 'vitamin D', 184, 'vitamin D'), ('UBERON_0001977', 'blood serum', 244, 'serum'), ('CHEBI_71657', 'versiconol acetate', 250, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 250, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 375, 'vitamin D')]
S184-PMC5941617	PMC5941617	5/2018	S184-PMC5941617	['in the present consensus we RECOMMEND Vitamin D supplementation in children and adolescents with RISK FACTORS for Vitamin D deficiency (table\xa07), at doses ranging from 600\xa0iu/day (i.e.']	[('FUTURE_WORK', 28), ('SUPERFICIAL_RELATIONSHIP', 97)]	2	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D')]
S187-PMC5941617	PMC5941617	5/2018	S187-PMC5941617	['in cases of POOR compliance, supplementation with intermittent dosing (weekly or monthly doses for a cumulative monthly dose of 18000–30000\xa0iu of Vitamin D) can be CONSIDERED, starting from children aged 5–6\xa0years and PARTICULARLY during Adolescence.']	[('PROBLEM_COMPLICATION', 12), ('FUTURE_WORK', 164), ('IMPORTANT_CONSIDERATION', 218)]	3	[('CHEBI_27300', 'vitamin D', 146, 'vitamin D'), ('GO_0048848', 'neurohypophysis morphogenesis', 238, 'adolescence')]
S188-PMC5941617	PMC5941617	5/2018	S188-PMC5941617	['CONSIDERING the results of italian studies, we SUGGEST Vitamin D supplementation from the end of fall to the beginning of spring (november–april) in children and adolescents with reduced sun exposure during summer.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 47)]	2	[('CHEBI_27300', 'vitamin D', 55, 'vitamin D')]
S189-PMC5941617	PMC5941617	5/2018	S189-PMC5941617	['continuous supplementation SHOULD BE reserved to children with permanent RISK FACTORS for Vitamin D deficiency.']	[('FUTURE_WORK', 27), ('SUPERFICIAL_RELATIONSHIP', 73)]	2	[('CHEBI_27300', 'vitamin D', 90, 'vitamin D')]
S191-PMC5941617	PMC5941617	5/2018	S191-PMC5941617	['as REPORTED for infants in the first years of Life, we RECOMMEND against using Vitamin D Metabolites and their analogs (Calcifediol, Alfacalcidol, Calcitriol, and Dihydrotachysterol) for the routine Vitamin D supplementation.']	[('INCOMPLETE_EVIDENCE', 3), ('FUTURE_WORK', 55)]	2	[('UBERON_0000104', 'life cycle', 46, 'life'), ('CHEBI_27300', 'vitamin D', 79, 'vitamin D'), ('CHEBI_25212', 'metabolite', 89, 'metabolites'), ('CHEBI_22975', 'cadinane sesquiterpenoid', 120, 'calcifediol'), ('CHEBI_31186', 'alfacalcidol', 133, 'alfacalcidol'), ('CHEBI_17823', 'calcitriol', 147, 'calcitriol'), ('CHEBI_4657', 'disopyramide', 163, 'dihydrotachysterol'), ('CHEBI_27300', 'vitamin D', 199, 'vitamin D')]
S199-PMC5941617	PMC5941617	5/2018	S199-PMC5941617	['particularly, Vitamin D status SHOULD BE monitored AT LEAST yearly in subjects that REQUIRE supplementation during the whole year BECAUSE AFFECTED from pathological conditions or receiving Drugs AFFECTING vitamin D Metabolism (table\xa07) (see “Extraskeletal actions of Vitamin D” for specific RECOMMENDATIONS).']	[('FUTURE_WORK', 31), ('IMPORTANT_CONSIDERATION', 31), ('PROBABLE_UNDERSTANDING', 51), ('IMPORTANT_CONSIDERATION', 84), ('PROBABLE_UNDERSTANDING', 130), ('SUPERFICIAL_RELATIONSHIP', 138), ('SUPERFICIAL_RELATIONSHIP', 195), ('FUTURE_WORK', 291)]	8	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('CHEBI_23888', 'drug', 189, 'drugs'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 213, 'D'), ('GO_0018977', '1,1,1-trichloro-2,2-bis-(4-chlorophenyl)ethane metabolic process', 213, 'D metabolism'), ('UBERON_0001431', 'distal carpal bone 2', 242, 'Extraskeletal'), ('CHEBI_27300', 'vitamin D', 267, 'vitamin D')]
S205-PMC5941617	PMC5941617	5/2018	S205-PMC5941617	['tuberculosis)xxxxamenorrheaxcancer (DIFFERENT types)xfxxxhepatitis cgxxrecurrent acute Lower Respiratory Tract infectionsgxxatopic dermatitisgxxatopic asthmagxxautoimmune diseaseshxxixcardiovascular diseases (especially hypertension)xxmetabolic syndrome, type 2 diabetesx\npes pediatric endocrine society, Es endocrine society, fcn federal commission for nutrition (switzerland), sahm society for adolescent health and medicine, aap american academy of pediatrics, eap european academy of pediatrics\nasuggested to guide Vitamin D prescription in Individuals with underlying RISKS requiring continuing supplementation all year long, if NECESSARY\nbgenetic conditions (Osteogenesis imperfecta, idiopathic juvenile osteoporosis, turner syndrome), Endocrine conditions (cushing syndrome, hypogonadism, hyperthyroidism, hyperparathyroidism, growth hormone deficiency, diabetes mellitus) ASSOCIATED with reduced bone mass\ncliving at higher latitudes in the winter and spring months\ndafrican-american and hispanic children\neobese children with additional RISK factors/symptoms for Vitamin D deficiency\nfsome lymphomas\ngpatients admitted to hospital\nhmultiple sclerosis, psoriasis, rheumatoid arthritis, dermatomyositis, systemic lupus erythematosus\nisystemic lupus erythematosus, juvenile idiopathic arthritis, juvenile dermatomyositis as associated with reduced bone mass\n\nSkeletal actions of Vitamin D\n\nnutritional rickets\nrickets is characterized by defective Mineralization Of developing Bone Tissue and reduced or absent Endochondral Ossification of the growth plate, with subsequent deformation [183,184].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 36), ('IMPORTANT_CONSIDERATION', 573), ('IMPORTANT_CONSIDERATION', 634), ('SUPERFICIAL_RELATIONSHIP', 880), ('SUPERFICIAL_RELATIONSHIP', 1046)]	5	[('UBERON_0004905', 'articulation', 87, 'lower respiratory tract'), ('CL_0002322', 'embryonic stem cell', 305, 'ES'), ('CHEBI_27300', 'vitamin D', 519, 'vitamin D'), ('NCBITaxon_1', 'root', 545, 'individuals'), ('GO_0001503', 'ossification', 665, 'osteogenesis'), ('GO_0006397', 'mRNA processing', 742, 'endocrine'), ('CHEBI_27300', 'vitamin D', 1072, 'vitamin D'), ('UBERON_0004288', 'skeleton', 1365, 'Skeletal'), ('CHEBI_27300', 'vitamin D', 1385, 'vitamin D'), ('GO_0051217', 'molybdenum incorporation via L-aspartyl molybdenum bis(molybdopterin guanine dinucleotide)', 1454, 'mineralization of ...'), ('UBERON_0002481', 'bone tissue', 1483, 'bone tissue'), ('GO_0042695', 'thelarche', 1488, 'tissue'), ('GO_0001958', 'endochondral ossification', 1517, 'endochondral ossification'), ('UBERON_0010363', 'endochondral element', 1517, 'endochondral')]
S208-PMC5941617	PMC5941617	5/2018	S208-PMC5941617	['children of immigrants living in industrialized countries are at INCREASED RISK of rickets BECAUSE they USUALLY present several RISK FACTORS for Vitamin D deficiency such as prolonged breastfeeding without vitamin d supplementation, increased skin pigmentation, reduced sun exposure due to cultural habits (i.e.']	[('IMPORTANT_CONSIDERATION', 65), ('PROBABLE_UNDERSTANDING', 91), ('INCOMPLETE_EVIDENCE', 104), ('SUPERFICIAL_RELATIONSHIP', 128)]	4	[('CHEBI_27300', 'vitamin D', 145, 'vitamin D')]
S233-PMC5941617	PMC5941617	5/2018	S233-PMC5941617	['after rickets healing, Vitamin D supplementation SHOULD continue according to age (AT LEAST 400\xa0iu/day in the first year of Life and 600\xa0iu/day from 1 to 18\xa0years) [11,23,28,183,188].']	[('FUTURE_WORK', 49), ('PROBABLE_UNDERSTANDING', 83)]	2	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('UBERON_0000104', 'life cycle', 124, 'life')]
S239-PMC5941617	PMC5941617	5/2018	S239-PMC5941617	['Calcium supplementation is IMPORTANT to prevent “hungry-bone” syndrome (hypocalcemia secondary to an increase in Bone mineralization as pth levels normalize during Vitamin D treatment) [9].']	[('IMPORTANT_CONSIDERATION', 27)]	1	[('CHEBI_31341', 'calcium dihydroxide', 0, 'Calcium'), ('GO_0007567', 'parturition', 113, 'bone'), ('CHEBI_27300', 'vitamin D', 164, 'vitamin D')]
S249-PMC5941617	PMC5941617	5/2018	S249-PMC5941617	['as discussed before, Vitamin D supplementation during the first year of Life is ESSENTIAL to prevent nutritional rickets occurrence.']	[('IMPORTANT_CONSIDERATION', 80)]	1	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('UBERON_0000104', 'life cycle', 72, 'life')]
S251-PMC5941617	PMC5941617	5/2018	S251-PMC5941617	['among these, three italian STUDIES assessed bone Mineral status in infants using quantitative ultrasound [201–203], SUGGESTING that Vitamin D supplementation is IMPORTANT to provide an adequate Bone Development, PARTICULARLY in exclusively breastfed infants.']	[('INCOMPLETE_EVIDENCE', 27), ('INCOMPLETE_EVIDENCE', 116), ('IMPORTANT_CONSIDERATION', 161), ('ANOMALY_CURIOUS_FINDING', 212), ('IMPORTANT_CONSIDERATION', 212)]	5	[('CHEBI_46662', 'mineral', 49, 'mineral'), ('CHEBI_27300', 'vitamin D', 132, 'vitamin D'), ('GO_0048539', 'bone marrow development', 194, 'bone development')]
S253-PMC5941617	PMC5941617	5/2018	S253-PMC5941617	['moreover, studies comparing supplementation with placebo or different regimens of Vitamin D supplementation (up to 1600\xa0iu/day) did not FIND any difference in infant bone mass at 3\xa0months [104], 6\xa0months [97], 1\xa0year [62] or 3\xa0years of Life [204].']	[('INCOMPLETE_EVIDENCE', 136)]	1	[('CHEBI_27300', 'vitamin D', 82, 'vitamin D'), ('UBERON_0000104', 'life cycle', 236, 'life')]
S255-PMC5941617	PMC5941617	5/2018	S255-PMC5941617	['THUS, Vitamin D supplementation during infancy is IMPORTANT to optimize bone mass acquisition and body composition, but high doses are not RECOMMENDED.']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 50), ('FUTURE_WORK', 139)]	3	[('CHEBI_27300', 'vitamin D', 6, 'vitamin D')]
S263-PMC5941617	PMC5941617	5/2018	S263-PMC5941617	['overall, meta-analysis SHOWED a non-significant EFFECT of Vitamin D supplementation on bmd at any site.']	[('INCOMPLETE_EVIDENCE', 23), ('SUPERFICIAL_RELATIONSHIP', 48)]	2	[('CHEBI_27300', 'vitamin D', 58, 'vitamin D')]
S264-PMC5941617	PMC5941617	5/2018	S264-PMC5941617	['HOWEVER, the EFFECT of supplementation became significant on total body bmc and Lumbar Spine bmd by dividing the sample into two groups, depending on Vitamin D status [25(Oh)D levels <\u200914\xa0ng/ml vs. ≥ 14\xa0ng/ml], SUGGESTING that Vitamin D supplementation MAY result in a clinically significant increase in bone mass in subjects with Vitamin D deficiency.']	[('ANOMALY_CURIOUS_FINDING', 0), ('SUPERFICIAL_RELATIONSHIP', 13), ('INCOMPLETE_EVIDENCE', 211), ('INCOMPLETE_EVIDENCE', 253)]	4	[('UBERON_0006074', 'lumbar region of vertebral column', 80, 'lumbar spine'), ('CHEBI_27300', 'vitamin D', 150, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 168, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 168, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 227, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 331, 'vitamin D')]
S268-PMC5941617	PMC5941617	5/2018	S268-PMC5941617	['particularly, 4 rcts PROVIDE EVIDENCE for a beneficial EFFECT of Vitamin D supplementation on bone Mineral accrual [148,166,216,224], mainly in subjects with Vitamin D deficiency.']	[('INCOMPLETE_EVIDENCE', 21), ('INCOMPLETE_EVIDENCE', 29), ('SUPERFICIAL_RELATIONSHIP', 55)]	3	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('CHEBI_46662', 'mineral', 99, 'mineral'), ('CHEBI_27300', 'vitamin D', 158, 'vitamin D')]
S270-PMC5941617	PMC5941617	5/2018	S270-PMC5941617	['INTERESTINGLY, a RECENT STUDY showed that the beneficial EFFECT of Vitamin D on Hip bone mass in lebanese adolescent girls persisted 1\xa0year after discontinuation of supplementation [226].']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 17), ('SUPERFICIAL_RELATIONSHIP', 57)]	3	[('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('UBERON_0001464', 'hip', 80, 'hip')]
S271-PMC5941617	PMC5941617	5/2018	S271-PMC5941617	['at PRESENT, SOME UNANSWERED QUESTIONS REMAIN [CRITICAL times during which supplementation MAY BE most EFFECTIVE, regimen and length of supplementation (continuous or intermittent), gender difference] [227], THUS Vitamin D supplementation to optimize bone mass acquisition SHOULD BE reserved for children AT RISK for deficiency.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('INCOMPLETE_EVIDENCE', 12), ('ANOMALY_CURIOUS_FINDING', 17), ('EXPLICIT_QUESTION', 28), ('INCOMPLETE_EVIDENCE', 38), ('IMPORTANT_CONSIDERATION', 46), ('INCOMPLETE_EVIDENCE', 90), ('SUPERFICIAL_RELATIONSHIP', 102), ('PROBABLE_UNDERSTANDING', 207), ('FUTURE_WORK', 272), ('IMPORTANT_CONSIDERATION', 304)]	11	[('CHEBI_27300', 'vitamin D', 212, 'vitamin D')]
S276-PMC5941617	PMC5941617	5/2018	S276-PMC5941617	['moreover, Postnatal Vitamin D supplementation (follow-up 14\xa0months) MAY ONLY PARTLY eliminate the differences in bone variables induced by maternal Vitamin D status during the Fetal Period [231].']	[('INCOMPLETE_EVIDENCE', 68), ('INCOMPLETE_EVIDENCE', 72), ('INCOMPLETE_EVIDENCE', 77)]	3	[('GO_0007567', 'parturition', 10, 'postnatal'), ('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 148, 'vitamin D'), ('UBERON_0002375', 'cricoid cartilage', 176, 'fetal period')]
S277-PMC5941617	PMC5941617	5/2018	S277-PMC5941617	['RECENTLY an english rct (mavidos) failed to demonstrate an EFFECT of maternal Vitamin D supplementation (1000\xa0iu/day from 14\xa0week of Gestation until Delivery) on offspring bone mass assessed within 2\xa0weeks of Birth by dxa.']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 59)]	2	[('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('GO_0007565', 'female pregnancy', 133, 'gestation'), ('GO_0007567', 'parturition', 149, 'delivery'), ('GO_0007567', 'parturition', 209, 'birth')]
S280-PMC5941617	PMC5941617	5/2018	S280-PMC5941617	['another smaller rct on 50 newborns FAILED TO demonstrate an EFFECT of Vitamin D supplementation during Pregnancy (2000\xa0iu/day from 26 to 28\xa0weeks until Childbirth) on infant bone mass measured at 23\u2009±\u200910\xa0days by dxa [234].']	[('ANOMALY_CURIOUS_FINDING', 35), ('SUPERFICIAL_RELATIONSHIP', 60)]	2	[('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('GO_0007565', 'female pregnancy', 103, 'pregnancy'), ('GO_0007623', 'circadian rhythm', 152, 'childbirth')]
S282-PMC5941617	PMC5941617	5/2018	S282-PMC5941617	['several variables MAY justify this DISCREPANCY, such as DIFFERENT enrolled populations, various regimens of Vitamin D supplementation, and age at bone mass assessment.']	[('INCOMPLETE_EVIDENCE', 18), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 35), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 56)]	3	[('CHEBI_27300', 'vitamin D', 108, 'vitamin D')]
S303-PMC5941617	PMC5941617	5/2018	S303-PMC5941617	['SEVERAL STUDIES, mostly in Adults, have also addressed the QUESTION WHETHER Vitamin D supplementation CAN PREVENT OR reduce the severity of upper or lower Respiratory infections.']	[('INCOMPLETE_EVIDENCE', 0), ('EXPLICIT_QUESTION', 59), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 68), ('EXPLICIT_QUESTION', 68), ('INCOMPLETE_EVIDENCE', 102), ('SUPERFICIAL_RELATIONSHIP', 106), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 114)]	7	[('UBERON_0007023', 'adult organism', 27, 'adults'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 155, 'respiratory')]
S306-PMC5941617	PMC5941617	5/2018	S306-PMC5941617	['all BUT two [259,261] of the aforementioned reviews concluded that published studies do not INDICATE a PROTECTIVE EFFECT of Vitamin D supplementation on the PREVENTION of acute Respiratory infections in healthy Individuals.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 4), ('INCOMPLETE_EVIDENCE', 92), ('SUPERFICIAL_RELATIONSHIP', 103), ('SUPERFICIAL_RELATIONSHIP', 114), ('SUPERFICIAL_RELATIONSHIP', 157)]	5	[('CHEBI_27300', 'vitamin D', 124, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 177, 'respiratory'), ('NCBITaxon_1', 'root', 211, 'individuals')]
S309-PMC5941617	PMC5941617	5/2018	S309-PMC5941617	['a RECENT meta-analysis of 25 rcts (total 11,321 participants, aged 0–95\xa0years) SHOWED that Vitamin D supplementation was SAFE and protected against acute Respiratory Tract infections overall (adjusted odds ratio 0.88).']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 79), ('IMPORTANT_CONSIDERATION', 121)]	3	[('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('UBERON_0000065', 'respiratory tract', 154, 'respiratory tract')]
S311-PMC5941617	PMC5941617	5/2018	S311-PMC5941617	['indeed, a more RECENT canadian rct SHOWED that daily administration of 2000\xa0iu of Vitamin D did not reduce overall wintertime Upper Respiratory Tract infections among healthy children aged 1–5\xa0years compared with supplementation with 400\xa0iu/day.']	[('INCOMPLETE_EVIDENCE', 15), ('INCOMPLETE_EVIDENCE', 35)]	2	[('CHEBI_27300', 'vitamin D', 82, 'vitamin D'), ('UBERON_0001557', 'upper respiratory tract', 126, 'upper respiratory tract')]
S312-PMC5941617	PMC5941617	5/2018	S312-PMC5941617	['THUS, the results of this study do not SUPPORT the routine use of high-dose Vitamin D supplementation in children for the PREVENTION of Viral Upper Respiratory Tract infections [271].']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 39), ('SUPERFICIAL_RELATIONSHIP', 122)]	3	[('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('NCBITaxon_1', 'root', 136, 'viral'), ('UBERON_0001557', 'upper respiratory tract', 142, 'upper respiratory tract')]
S313-PMC5941617	PMC5941617	5/2018	S313-PMC5941617	['finally, LIMITED DATA are available on Vitamin D supplementation in Pregnancy and the RISK of Respiratory infections in the offspring [272,273].']	[('INCOMPLETE_EVIDENCE', 9), ('IMPORTANT_CONSIDERATION', 86)]	2	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('GO_0007565', 'female pregnancy', 68, 'pregnancy'), ('UBERON_0001004', 'respiratory system', 94, 'respiratory')]
S321-PMC5941617	PMC5941617	5/2018	S321-PMC5941617	['FEW REPORTS exist regarding the BENEFIT of Vitamin D supplementation in children with specific infections.']	[('INCOMPLETE_EVIDENCE', 0), ('IMPORTANT_CONSIDERATION', 32)]	2	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D')]
S322-PMC5941617	PMC5941617	5/2018	S322-PMC5941617	['in a large randomized study in afghanistan involving 3000 children with acute diarrhea Vitamin D supplementation HAS BEEN ASSOCIATED with improvement in clinical parameters [283].']	[('INCOMPLETE_EVIDENCE', 113), ('SUPERFICIAL_RELATIONSHIP', 122)]	2	[('CHEBI_27300', 'vitamin D', 87, 'vitamin D')]
S333-PMC5941617	PMC5941617	5/2018	S333-PMC5941617	['an italian rct was performed TO TEST WHETHER Vitamin D3Supplementation (oral 100000\xa0iu every 3\xa0months for 4 doses) COULD improve Vitamin D status and AFFECT the t-Cell phenotype in hiv-infected patients aged 8 to 26\xa0years with Serum 25(Oh) D\u2009<\u200930\xa0ng/ml.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 29), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 37), ('INCOMPLETE_EVIDENCE', 115), ('SUPERFICIAL_RELATIONSHIP', 150)]	4	[('CHEBI_52915', 'phosphatediyl group', 45, 'vitamin D3supplementation'), ('CHEBI_27300', 'vitamin D', 129, 'vitamin D'), ('CL_0000622', 'acinar cell', 162, '-cell'), ('UBERON_0001977', 'blood serum', 227, 'serum'), ('CHEBI_71657', 'versiconol acetate', 233, '25(OH) D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 233, '25(OH) D')]
S336-PMC5941617	PMC5941617	5/2018	S336-PMC5941617	['in a pilot study in botswana, Vitamin D3Supplementation (4000–7000\xa0iu/day for 12\xa0weeks) was SAFE and improved Vitamin D status, growth and hiv status [289].']	[('IMPORTANT_CONSIDERATION', 92)]	1	[('CHEBI_52915', 'phosphatediyl group', 30, 'vitamin D3supplementation'), ('PR_000006649', 'zinc finger protein neuro-d4', 38, 'D3supplementation'), ('CHEBI_27300', 'vitamin D', 110, 'vitamin D')]
S344-PMC5941617	PMC5941617	5/2018	S344-PMC5941617	['moreover, a large meta-analysis FAILED TO demonstrate that Vitamin D supplementation MAY BE beneficial in children with tubercular infection [300].']	[('ANOMALY_CURIOUS_FINDING', 32), ('DIFFICULT_TASK', 32), ('INCOMPLETE_EVIDENCE', 85)]	3	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D')]
S358-PMC5941617	PMC5941617	5/2018	S358-PMC5941617	['CONSEQUENTLY, SEVERAL STUDIES in vivo and in vitro SHOWED that Vitamin D supplementation inhibits the th2 Expression contrasting allergic diseases [309–314].']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 14), ('INCOMPLETE_EVIDENCE', 51)]	3	[('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('GO_0010467', 'gene expression', 106, 'expression')]
S377-PMC5941617	PMC5941617	5/2018	S377-PMC5941617	['a meta-analysis SHOWED a significant ASSOCIATION between Vitamin D supplementation and reduction of asthma exacerbations (17% vs. 46%, p \u2009<\u20090.029) [334].']	[('INCOMPLETE_EVIDENCE', 16), ('SUPERFICIAL_RELATIONSHIP', 37)]	2	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D')]
S378-PMC5941617	PMC5941617	5/2018	S378-PMC5941617	['RECENTLY, three studies SHOWED a positive CORRELATION between Vitamin D supplementation and the improvement of asthma Control [335–337], accordingly with two RECENT meta-analyses.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 24), ('SUPERFICIAL_RELATIONSHIP', 42), ('INCOMPLETE_EVIDENCE', 158)]	4	[('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('GO_0065007', 'biological regulation', 118, 'control')]
S386-PMC5941617	PMC5941617	5/2018	S386-PMC5941617	['two STUDIES in vitro SHOWED the IMPORTANCE of Vitamin D supplementation in patients affected by Corticosteroid-resistant asthma [315,343] BUT two other STUDIES DEMONSTRATED in vivo that lower 25(Oh)D levels were ASSOCIATED with an increase in Corticosteroids use and an IMPAIRED Lung function [344,345].']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 21), ('IMPORTANT_CONSIDERATION', 32), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 138), ('INCOMPLETE_EVIDENCE', 152), ('INCOMPLETE_EVIDENCE', 160), ('SUPERFICIAL_RELATIONSHIP', 212), ('IMPORTANT_CONSIDERATION', 270)]	8	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('CHEBI_36916', 'cation', 96, 'corticosteroid'), ('CHEBI_71657', 'versiconol acetate', 192, '25(OH)D'), ('CHEBI_50850', 'etabonate ester', 243, 'corticosteroids'), ('UBERON_0002048', 'lung', 279, 'lung')]
S393-PMC5941617	PMC5941617	5/2018	S393-PMC5941617	['it is STILL a matter for full DEBATE WHETHER supplementation with Vitamin D in pediatric ad is WORTH, PARTICULARLY in deficient patients.']	[('IMPORTANT_CONSIDERATION', 6), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 30), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 37), ('ANOMALY_CURIOUS_FINDING', 95), ('IMPORTANT_CONSIDERATION', 102)]	5	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D')]
S395-PMC5941617	PMC5941617	5/2018	S395-PMC5941617	['HOWEVER, there are also two reviews and meta-analyses, considering ad patients of all ages, SHOWING that Vitamin D supplementation is capable of a higher mean difference in severity of ad symptoms [350,351].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 92)]	2	[('CHEBI_27300', 'vitamin D', 105, 'vitamin D')]
S398-PMC5941617	PMC5941617	5/2018	S398-PMC5941617	['FOR THESE REASONS AT PRESENT Vitamin D supplementation as adjunctive standard therapy for ad cannot be RECOMMENDED in all the affected children [351].']	[('PROBABLE_UNDERSTANDING', 0), ('PROBABLE_UNDERSTANDING', 10), ('INCOMPLETE_EVIDENCE', 18), ('FUTURE_WORK', 103)]	4	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D')]
S400-PMC5941617	PMC5941617	5/2018	S400-PMC5941617	['HOWEVER, it HAS BEEN SUGGESTED that in patients with a more SEVERE ad, unresponsive to common therapy and with low Serum 25(Oh)D levels, a trial of Vitamin D supplementation CAN BE CONSIDERED [352].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 12), ('IMPORTANT_CONSIDERATION', 60), ('FUTURE_WORK', 174), ('FUTURE_WORK', 181)]	5	[('UBERON_0001977', 'blood serum', 115, 'serum'), ('CHEBI_71657', 'versiconol acetate', 121, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 127, 'D'), ('CHEBI_27300', 'vitamin D', 148, 'vitamin D')]
S405-PMC5941617	PMC5941617	5/2018	S405-PMC5941617	['furthermore, the use of Vitamin D supplementation for primary PREVENTION of allergic diseases REMAINS an attractive AREA OF STUDY, BUT CURRENT KNOWLEDGE and EVIDENCE DOES NOT ALLOW to RECOMMEND it in routine use.']	[('SUPERFICIAL_RELATIONSHIP', 62), ('INCOMPLETE_EVIDENCE', 94), ('FUTURE_WORK', 116), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 131), ('INCOMPLETE_EVIDENCE', 135), ('INCOMPLETE_EVIDENCE', 157), ('DIFFICULT_TASK', 166), ('FUTURE_WORK', 184)]	8	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D')]
S411-PMC5941617	PMC5941617	5/2018	S411-PMC5941617	['negative results were obtained in term of primary PREVENTION by Vitamin D supplementation in a RECENT meta-analysis and conclusions were that the EFFECTS of Vitamin D supplementation REMAIN UNCERTAIN [353].']	[('SUPERFICIAL_RELATIONSHIP', 50), ('INCOMPLETE_EVIDENCE', 95), ('SUPERFICIAL_RELATIONSHIP', 146), ('INCOMPLETE_EVIDENCE', 183), ('FULL_UNKNOWN', 190)]	5	[('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 157, 'vitamin D')]
S420-PMC5941617	PMC5941617	5/2018	S420-PMC5941617	['a meta-analysis of six case-control studies and two cohort-studies SHOWED a reduction of the RISK of t1dm in later Life (odds ratio: 0.71; 95% ci 0.51–0.98) in infants who were supplemented with Vitamin D compared with controls, ALTHOUGH the needed time of supplementation and the dose are STILL UNCLEAR [377–379].']	[('INCOMPLETE_EVIDENCE', 67), ('IMPORTANT_CONSIDERATION', 93), ('ANOMALY_CURIOUS_FINDING', 229), ('FULL_UNKNOWN', 290)]	4	[('UBERON_0000104', 'life cycle', 115, 'life'), ('CHEBI_27300', 'vitamin D', 195, 'vitamin D')]
S452-PMC5941617	PMC5941617	5/2018	S452-PMC5941617	['Vitamin D supplementation at 800–1000\xa0iu/day is SUGGESTED to maintain optimal Vitamin D status [403].']	[('INCOMPLETE_EVIDENCE', 48)]	1	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 78, 'vitamin D')]
S453-PMC5941617	PMC5941617	5/2018	S453-PMC5941617	['the endocrine society RECOMMENDS to treat Vitamin D deficiency in patients with malabsorption with Vitamin D at doses 2–3 times higher than those RECOMMENDED for otherwise healthy pediatric population for at least 6\xa0weeks, followed by Vitamin D supplementation at doses 2–3 times higher than those recommended for age [11].']	[('FUTURE_WORK', 22), ('FUTURE_WORK', 146)]	2	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 99, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 235, 'vitamin D')]
S461-PMC5941617	PMC5941617	5/2018	S461-PMC5941617	['ON THE CONTRARY, maternal Vitamin D supplementation, maternal and neonatal Vitamin D status were not related to the risk of childhood cd [415,416].']	[('ANOMALY_CURIOUS_FINDING', 0)]	1	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 75, 'vitamin D')]
S472-PMC5941617	PMC5941617	5/2018	S472-PMC5941617	['AS Vitamin D is an IMPORTANT KEY DETERMINANT of bone mass acquisition, SOME authors RECOMMENDED Vitamin D supplementation during winter and spring in all cd children and adolescents to optimize bone recovery [432].']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 19), ('IMPORTANT_CONSIDERATION', 29), ('SUPERFICIAL_RELATIONSHIP', 33), ('INCOMPLETE_EVIDENCE', 71), ('FUTURE_WORK', 84)]	6	[('CHEBI_27300', 'vitamin D', 3, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin D')]
S473-PMC5941617	PMC5941617	5/2018	S473-PMC5941617	['nice GUIDELINES ADVICE that People with cd MAY NEED to receive Calcium and Vitamin D supplementation if their dietary intake is insufficient [433].']	[('PROBABLE_UNDERSTANDING', 5), ('FUTURE_WORK', 16), ('INCOMPLETE_EVIDENCE', 43), ('IMPORTANT_CONSIDERATION', 47)]	4	[('NCBITaxon_10088', 'Mus <genus>', 28, 'people'), ('CHEBI_22313', 'alkaline earth metal atom', 63, 'calcium'), ('CHEBI_27300', 'vitamin D', 75, 'vitamin D')]
S474-PMC5941617	PMC5941617	5/2018	S474-PMC5941617	['other authors REINFORCE that Vitamin D supplementation SHOULD BE offered to cd patients AT LEAST during the first years of gluten free diet [423].']	[('INCOMPLETE_EVIDENCE', 14), ('FUTURE_WORK', 55), ('PROBABLE_UNDERSTANDING', 88)]	3	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D')]
S475-PMC5941617	PMC5941617	5/2018	S475-PMC5941617	['expert RECOMMENDATIONS for the management of cd in children RECOMMENDED to provide counselling on age-appropriate intake of Calcium and Vitamin D supplementation by a dietitian to cd children both at diagnosis and follow-up (grade of evidence high, strength of statement strong) [430].']	[('FUTURE_WORK', 7), ('FUTURE_WORK', 60)]	2	[('CHEBI_22313', 'alkaline earth metal atom', 124, 'calcium'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin D')]
S483-PMC5941617	PMC5941617	5/2018	S483-PMC5941617	['ON THE CONTRARY, two meta-analyses enrolling MAINLY Adults SHOWED that Vitamin D supplementation did not decrease adiposity [444,445].']	[('ANOMALY_CURIOUS_FINDING', 0), ('PROBABLE_UNDERSTANDING', 45), ('INCOMPLETE_EVIDENCE', 59)]	3	[('UBERON_0007023', 'adult organism', 52, 'adults'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin D')]
S495-PMC5941617	PMC5941617	5/2018	S495-PMC5941617	['several rcts HAVE BEEN conducted to evaluate the efficacy of Vitamin D supplementation as a POTENTIAL therapy for each component of Metabolic syndrome.']	[('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 92)]	2	[('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('GO_0008152', 'metabolic process', 132, 'metabolic')]
S497-PMC5941617	PMC5941617	5/2018	S497-PMC5941617	['other papers DESCRIBE a significant reduction of Insulin resistance index after Vitamin D supplementation [454,455].']	[('INCOMPLETE_EVIDENCE', 13)]	1	[('PR_000045358', 'insulin family protein', 49, 'insulin'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin D')]
S499-PMC5941617	PMC5941617	5/2018	S499-PMC5941617	['more RECENT FINDINGS have reported no influence of DIFFERENT Vitamin D supplementation schedules on Serum Lipid levels, Glucose Homeostasis, glycated hemoglobin and Pancreatic Insulin secretion [457–459].']	[('INCOMPLETE_EVIDENCE', 5), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 51)]	2	[('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('UBERON_0001977', 'blood serum', 100, 'serum'), ('CHEBI_18059', 'lipid', 106, 'lipid'), ('CHEBI_17234', 'glucose', 120, 'glucose'), ('GO_0042593', 'glucose homeostasis', 120, 'glucose homeostasis'), ('UBERON_0001264', 'pancreas', 165, 'pancreatic'), ('PR_000045358', 'insulin family protein', 176, 'insulin')]
S500-PMC5941617	PMC5941617	5/2018	S500-PMC5941617	['a RECENT italian rct SHOWED that supplementation with Vitamin D (800\xa0iu/day) plus Docosahexanoic Acid IMPROVED Insulin-resistance, Lipid profile, aminotransferases levels, and activity score in obese children with non alcoholic fatty Liver disease and Vitamin D deficiency [460].']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 21), ('SUPERFICIAL_RELATIONSHIP', 102)]	3	[('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('CHEBI_36006', 'icosapentaenoic acid', 82, 'docosahexanoic acid'), ('PR_000045358', 'insulin family protein', 111, 'insulin'), ('CHEBI_18059', 'lipid', 131, 'lipid'), ('UBERON_0002107', 'liver', 234, 'liver'), ('CHEBI_27300', 'vitamin D', 252, 'vitamin D')]
S501-PMC5941617	PMC5941617	5/2018	S501-PMC5941617	['finally, two RECENT meta-analyses SHOWED that Vitamin D supplementation had no significant effect on Glucose and Insulin Metabolism [461] and on changes in the concentrations of inflammatory BIOMARKERS (C-Reactive Protein, tumor necrosis factor alpha, Il-6) in obese and overweight adolescents and Adults [462].']	[('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 34), ('SUPERFICIAL_RELATIONSHIP', 191)]	3	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('CHEBI_17234', 'glucose', 101, 'glucose'), ('GO_0007369', 'gastrulation', 101, 'glucose ...'), ('GO_1901142', 'insulin metabolic process', 113, 'insulin metabolism'), ('PR_000045358', 'insulin family protein', 113, 'insulin'), ('PR_000005890', 'crooked neck-like protein 1', 203, 'C-reactive protein'), ('PR_000001470', 'interleukin-28B', 252, 'IL-6'), ('UBERON_0007023', 'adult organism', 298, 'adults')]
S505-PMC5941617	PMC5941617	5/2018	S505-PMC5941617	['DIFFERENT Vitamin D dose regimens HAVE BEEN PROPOSED in obese children and adolescents for both Vitamin D supplementation and treatment of deficiency [463–467].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 34), ('INCOMPLETE_EVIDENCE', 44)]	3	[('CHEBI_27300', 'vitamin D', 10, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin D')]
S506-PMC5941617	PMC5941617	5/2018	S506-PMC5941617	['the Endocrine society clinical practice guideline SUGGESTED in obese children Vitamin D supplementation at doses 2–3 times higher than those recommended for age to satisfy their body’s Vitamin D REQUIREMENT.']	[('INCOMPLETE_EVIDENCE', 50), ('IMPORTANT_CONSIDERATION', 195)]	2	[('UBERON_0005063', 'left ventricular compact myocardium', 4, 'Endocrine'), ('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 185, 'vitamin D')]
S508-PMC5941617	PMC5941617	5/2018	S508-PMC5941617	['similarly, guidelines for central europe RECOMMENDED in obese children Vitamin D supplementation (1200–2000\xa0iu/day depending on severity of obesity) between september and april, or throughout the whole year IF sufficient Skin Synthesis Of Vitamin D is not ensured in the summer [20].']	[('FUTURE_WORK', 41), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 207)]	2	[('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('GO_0034205', 'amyloid-beta formation', 221, 'skin synthesis of'), ('CHEBI_27300', 'vitamin D', 239, 'vitamin D')]
S509-PMC5941617	PMC5941617	5/2018	S509-PMC5941617	['regarding Adolescence, the society for adolescent health and medicine RECOMMENDED that obese adolescent without a 25(Oh)D measurement empirically receive Vitamin D supplementation at 1000\xa0iu/day [21].']	[('FUTURE_WORK', 70)]	1	[('GO_0048848', 'neurohypophysis morphogenesis', 10, 'adolescence'), ('CHEBI_71657', 'versiconol acetate', 114, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 120, 'D'), ('CHEBI_27300', 'vitamin D', 154, 'vitamin D')]
S510-PMC5941617	PMC5941617	5/2018	S510-PMC5941617	['more RECENTLY, united arab emirates GUIDELINES also RECOMMENDED Vitamin D supplementation in obese children and adolescents (1200–2000\xa0iu/day DEPENDING ON severity of obesity, season and sun exposure) throughout the year IF sufficient Skin Synthesis if Vitamin D is not ensured during winter [27].']	[('INCOMPLETE_EVIDENCE', 5), ('PROBABLE_UNDERSTANDING', 36), ('FUTURE_WORK', 52), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 142), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 221)]	5	[('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('GO_0009697', 'salicylic acid biosynthetic process', 235, 'skin synthesis'), ('CHEBI_27300', 'vitamin D', 253, 'vitamin D')]
S515-PMC5941617	PMC5941617	5/2018	S515-PMC5941617	['MORE rcts ARE NEEDED to evaluate the INFLUENCE of Vitamin D supplementation on Controlling Metabolic syndrome.']	[('FUTURE_WORK', 0), ('SUPERFICIAL_RELATIONSHIP', 37)]	2	[('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('GO_0065007', 'biological regulation', 79, 'controlling'), ('GO_0008152', 'metabolic process', 91, 'metabolic')]
S517-PMC5941617	PMC5941617	5/2018	S517-PMC5941617	['AT PRESENT, CONSIDERING that obese italian children have higher prevalence of Vitamin D deficiency and insufficiency then normal weight Individuals, we SUGGEST in obese children and adolescents vitamin D supplementation at higher doses THAN those RECOMMENDED for age (1000–1500\xa0iu/day) from the end of fall to the beginning of spring (november–april) to ensure an adequate Vitamin D status.']	[('INCOMPLETE_EVIDENCE', 0), ('PROBABLE_UNDERSTANDING', 12), ('INCOMPLETE_EVIDENCE', 152), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 236), ('FUTURE_WORK', 247)]	5	[('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('NCBITaxon_1', 'root', 136, 'individuals'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 202, 'D'), ('CHEBI_27300', 'vitamin D', 373, 'vitamin D')]
S518-PMC5941617	PMC5941617	5/2018	S518-PMC5941617	['obese subjects with reduced sun exposure during summer SHOULD receive Vitamin D supplementation throughout the year.']	[('FUTURE_WORK', 55)]	1	[('CHEBI_27300', 'vitamin D', 70, 'vitamin D')]
S524-PMC5941617	PMC5941617	5/2018	S524-PMC5941617	['FEW STUDIES or case reports SUGGESTED that Vitamin D supplementation CAN improve autism symptoms [481–484].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 28), ('INCOMPLETE_EVIDENCE', 69)]	3	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D')]
S525-PMC5941617	PMC5941617	5/2018	S525-PMC5941617	['NEVERTHELESS, a RECENT rct enrolled 42 children with autism spectrum disorders showing that Vitamin D supplementation (2000\xa0iu/day of Vitamin D3For 20\xa0weeks) had no EFFECT on the primary outcome (the stereotypic behaviour subscale from the aberrant behaviour checklist) in comparison with placebo [485].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 16), ('SUPERFICIAL_RELATIONSHIP', 165)]	3	[('CHEBI_27300', 'vitamin D', 92, 'vitamin D'), ('CHEBI_27364', 'zinc molecular entity', 134, 'vitamin D3for')]
S526-PMC5941617	PMC5941617	5/2018	S526-PMC5941617	['THEREFORE, FURTHER rcts ARE NEEDED before RECOMMENDING routine Vitamin D supplementation in children with autism.']	[('PROBABLE_UNDERSTANDING', 0), ('FUTURE_WORK', 11), ('FUTURE_WORK', 42)]	3	[('CHEBI_27300', 'vitamin D', 63, 'vitamin D')]
S536-PMC5941617	PMC5941617	5/2018	S536-PMC5941617	['meta-analyses assessing the EFFECT of Vitamin D supplementation in depressed Adults FOUNDED CONFLICTING results [495–497].']	[('SUPERFICIAL_RELATIONSHIP', 28), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 84), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 92)]	3	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('UBERON_0007023', 'adult organism', 77, 'adults')]
S554-PMC5941617	PMC5941617	5/2018	S554-PMC5941617	['supplementing Pregnant women with Vitamin D in a single or continued dose increases Serum 25(Oh)D at term and MAY reduce the RISK of Preeclampsia, low Birth weight and Preterm Birth.']	[('INCOMPLETE_EVIDENCE', 110), ('IMPORTANT_CONSIDERATION', 125)]	2	[('GO_0007565', 'female pregnancy', 14, 'pregnant'), ('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('UBERON_0001977', 'blood serum', 84, 'serum'), ('CHEBI_71657', 'versiconol acetate', 90, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 93, 'OH ... D'), ('GO_0007128', 'meiotic prophase I', 133, 'preeclampsia'), ('GO_0007567', 'parturition', 151, 'birth'), ('GO_0007565', 'female pregnancy', 168, 'preterm'), ('GO_0007567', 'parturition', 176, 'birth')]
S556-PMC5941617	PMC5941617	5/2018	S556-PMC5941617	['the royal college of obstetricians & gynaecoloists RECOMMENDED Vitamin D supplementation with 400\xa0iu/day for all Pregnant women.']	[('FUTURE_WORK', 51)]	1	[('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('GO_0007565', 'female pregnancy', 113, 'pregnant')]
S558-PMC5941617	PMC5941617	5/2018	S558-PMC5941617	['indeed, Vitamin D supplementation with 400\xa0iu/day HAS BEEN REPORTED insufficient in Pregnancy, PARTICULARLY for women at higher RISK of Vitamin D deficiency [512,513].']	[('INCOMPLETE_EVIDENCE', 50), ('ANOMALY_CURIOUS_FINDING', 95), ('IMPORTANT_CONSIDERATION', 128)]	3	[('CHEBI_27300', 'vitamin D', 8, 'vitamin D'), ('GO_0007565', 'female pregnancy', 84, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin D')]
S566-PMC5941617	PMC5941617	5/2018	S566-PMC5941617	['veiled women) and/or constant use of sunscreens• Malabsorption syndromes• chronic therapies AFFECTING Vitamin D Metabolism• obesity• risk of pre-eclampsia• Alcohol abuse• bone pain• hypocalcemia• a previous child with rickets• Pregnant adolescents\nin the present consensus we RECOMMEND Vitamin D supplementation in all Pregnant and breastfeeding women since the beginning of Pregnancy at a dose of 600\xa0iu/day.']	[('SUPERFICIAL_RELATIONSHIP', 92), ('FUTURE_WORK', 276)]	2	[('GO_0046661', 'male sex differentiation', 49, 'Malabsorption'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 102, 'vitamin D metabolism'), ('CHEBI_30879', 'alcohol', 156, 'Alcohol'), ('GO_0007565', 'female pregnancy', 227, 'Pregnant'), ('CHEBI_27300', 'vitamin D', 286, 'vitamin D'), ('GO_0007565', 'female pregnancy', 319, 'pregnant'), ('GO_0007565', 'female pregnancy', 375, 'pregnancy')]
S568-PMC5941617	PMC5941617	5/2018	S568-PMC5941617	['we do not RECOMMEND routine screening of Serum 25(Oh)D levels in all Pregnant and breastfeeding women, BUT we SUGGEST to CONSIDER Vitamin D testing in women with multiple RISK FACTORS for Vitamin D deficiency, PARTICULARLY if not receiving Vitamin D supplementation.']	[('FUTURE_WORK', 10), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 103), ('INCOMPLETE_EVIDENCE', 110), ('FUTURE_WORK', 121), ('SUPERFICIAL_RELATIONSHIP', 171), ('ANOMALY_CURIOUS_FINDING', 210), ('IMPORTANT_CONSIDERATION', 210)]	7	[('UBERON_0001977', 'blood serum', 41, 'serum'), ('CHEBI_71657', 'versiconol acetate', 47, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 47, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 69, 'pregnant'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 188, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 240, 'vitamin D')]
S605-PMC5941617	PMC5941617	5/2018	S605-PMC5941617	['the society for adolescent health and medicine RECOMMENDED to supplement Vitamin D insufficient with Vitamin D 1000\xa0iu/day for at least 3\xa0months [21].']	[('FUTURE_WORK', 47)]	1	[('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin D')]
S606-PMC5941617	PMC5941617	5/2018	S606-PMC5941617	['in the case of Vitamin D insufficiency, particularly in subjects AT RISK for Vitamin D deficiency, we RECOMMENDED starting Vitamin D supplementation according to the modalities and REQUIREMENTS RECOMMENDED for age.']	[('IMPORTANT_CONSIDERATION', 65), ('FUTURE_WORK', 102), ('IMPORTANT_CONSIDERATION', 181), ('FUTURE_WORK', 194)]	4	[('CHEBI_27300', 'vitamin D', 15, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 77, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 123, 'vitamin D')]
S610-PMC5941617	PMC5941617	5/2018	S610-PMC5941617	['the PRESENT consensus PAPER AIMS to give practical approach to Vitamin D supplementation for italian infants, children and adolescents.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 22), ('QUESTION_ANSWERED_BY_THIS_WORK', 28)]	3	[('CHEBI_27300', 'vitamin D', 63, 'vitamin D')]
S611-PMC5941617	PMC5941617	5/2018	S611-PMC5941617	['particularly, Vitamin D supplementation SHOULD BE RECOMMENDED in all infants in the first year of Life, independently of the type of Feeding.']	[('FUTURE_WORK', 40), ('FUTURE_WORK', 50)]	2	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('UBERON_0000104', 'life cycle', 98, 'life'), ('GO_0007631', 'feeding behavior', 133, 'feeding')]
S612-PMC5941617	PMC5941617	5/2018	S612-PMC5941617	['supplementation SHOULD BE subsequently individualized in terms of regimen and duration on the basis of the presence of RISK FACTORS for Vitamin D deficiency.']	[('FUTURE_WORK', 16), ('SUPERFICIAL_RELATIONSHIP', 119)]	2	[('CHEBI_27300', 'vitamin D', 136, 'vitamin D')]
S621-PMC5941617	PMC5941617	5/2018	S621-PMC5941617	['Vitamin D supplementation\n\n0–12\xa0months\n\nwe RECOMMEND Vitamin D supplementation in the first year of Life to ensure an adequate Vitamin D status and to prevent nutritional rickets.']	[('FUTURE_WORK', 43)]	1	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('UBERON_0000104', 'life cycle', 100, 'life'), ('CHEBI_27300', 'vitamin D', 127, 'vitamin D')]
S622-PMC5941617	PMC5941617	5/2018	S622-PMC5941617	['we RECOMMEND Vitamin D supplementation in all newborns independently of the type of Feeding.']	[('FUTURE_WORK', 3)]	1	[('CHEBI_27300', 'vitamin D', 13, 'vitamin D'), ('GO_0007631', 'feeding behavior', 84, 'feeding')]
S625-PMC5941617	PMC5941617	5/2018	S625-PMC5941617	['in the first year of Life we RECOMMEND daily administration of Vitamin D.\nwe RECOMMEND against using Vitamin D Metabolites and their analogs (Calcifediol, Alfacalcidol, Calcitriol, and Dihydrotachysterol) for the routine Vitamin D supplementation.']	[('FUTURE_WORK', 29), ('FUTURE_WORK', 77)]	2	[('UBERON_0000104', 'life cycle', 21, 'life'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('CHEBI_25212', 'metabolite', 111, 'metabolites'), ('CHEBI_22975', 'cadinane sesquiterpenoid', 142, 'calcifediol'), ('CHEBI_31186', 'alfacalcidol', 155, 'alfacalcidol'), ('CHEBI_17823', 'calcitriol', 169, 'calcitriol'), ('CHEBI_4657', 'disopyramide', 185, 'dihydrotachysterol'), ('CHEBI_27300', 'vitamin D', 221, 'vitamin D')]
S630-PMC5941617	PMC5941617	5/2018	S630-PMC5941617	['when vlbw infants reach a weight\u2009≥\u20091500\xa0g and full enteral nutrition we SUGGEST Vitamin D supplementation at 400–800\xa0iu/day.']	[('INCOMPLETE_EVIDENCE', 72)]	1	[('CHEBI_27300', 'vitamin D', 80, 'vitamin D')]
S631-PMC5941617	PMC5941617	5/2018	S631-PMC5941617	['we RECOMMEND Vitamin D supplementation at 400–800\xa0iu/day for preterm infants with Birth weight\u2009≥\u20091500\xa0g.\nafter a post-Conceptional age of 40\xa0weeks, RECOMMENDATIONS for Vitamin D supplementation are equal to those for healthy term infants.']	[('FUTURE_WORK', 3), ('FUTURE_WORK', 148)]	2	[('CHEBI_27300', 'vitamin D', 13, 'vitamin D'), ('GO_0007567', 'parturition', 82, 'birth'), ('GO_0007620', 'copulation', 118, 'conceptional'), ('CHEBI_27300', 'vitamin D', 168, 'vitamin D')]
S633-PMC5941617	PMC5941617	5/2018	S633-PMC5941617	['1–18\xa0years\n\nwe RECOMMEND Vitamin D supplementation in children and adolescents with RISK FACTORS for Vitamin D deficiency (table\xa07).']	[('FUTURE_WORK', 15), ('SUPERFICIAL_RELATIONSHIP', 84)]	2	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin D')]
S636-PMC5941617	PMC5941617	5/2018	S636-PMC5941617	['we RECOMMEND daily Vitamin D supplementation ranging from 600\xa0iu/day (i.e.']	[('FUTURE_WORK', 3)]	1	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D')]
S639-PMC5941617	PMC5941617	5/2018	S639-PMC5941617	['in cases of POOR compliance, supplementation with intermittent dosing (weekly or monthly doses for a cumulative monthly dose of 18000–30000\xa0iu of Vitamin D) can be CONSIDERED, starting from children aged 5–6\xa0years and PARTICULARLY during Adolescence.']	[('PROBLEM_COMPLICATION', 12), ('FUTURE_WORK', 164), ('IMPORTANT_CONSIDERATION', 218)]	3	[('CHEBI_27300', 'vitamin D', 146, 'vitamin D'), ('GO_0048848', 'neurohypophysis morphogenesis', 238, 'adolescence')]
S640-PMC5941617	PMC5941617	5/2018	S640-PMC5941617	['we SUGGEST Vitamin D supplementation from the end of fall to the beginning of spring (november–april) in children and adolescents with reduced sun exposure during summer.']	[('INCOMPLETE_EVIDENCE', 3)]	1	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D')]
S641-PMC5941617	PMC5941617	5/2018	S641-PMC5941617	['we SUGGEST continuous Vitamin D supplementation in cases of permanent RISK FACTORS for Vitamin D deficiency.']	[('INCOMPLETE_EVIDENCE', 3), ('SUPERFICIAL_RELATIONSHIP', 70)]	2	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 87, 'vitamin D')]
S644-PMC5941617	PMC5941617	5/2018	S644-PMC5941617	['we RECOMMEND against using Vitamin D Metabolites and their analogs (Calcifediol, Alfacalcidol, Calcitriol, and Dihydrotachysterol) for the routine Vitamin D supplementation.']	[('FUTURE_WORK', 3)]	1	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('CHEBI_25212', 'metabolite', 37, 'metabolites'), ('CHEBI_22975', 'cadinane sesquiterpenoid', 68, 'calcifediol'), ('CHEBI_31186', 'alfacalcidol', 81, 'alfacalcidol'), ('CHEBI_17823', 'calcitriol', 95, 'calcitriol'), ('CHEBI_4657', 'disopyramide', 111, 'dihydrotachysterol'), ('CHEBI_27300', 'vitamin D', 147, 'vitamin D')]
S648-PMC5941617	PMC5941617	5/2018	S648-PMC5941617	['Vitamin D status SHOULD BE monitored AT LEAST yearly in subjects that REQUIRE supplementation during the whole year BECAUSE AFFECTED from pathological conditions or receiving Drugs AFFECTING Vitamin D Metabolism (table\xa07).']	[('FUTURE_WORK', 17), ('IMPORTANT_CONSIDERATION', 17), ('PROBABLE_UNDERSTANDING', 37), ('IMPORTANT_CONSIDERATION', 70), ('PROBABLE_UNDERSTANDING', 116), ('SUPERFICIAL_RELATIONSHIP', 124), ('SUPERFICIAL_RELATIONSHIP', 181)]	7	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_23888', 'drug', 175, 'drugs'), ('CHEBI_27300', 'vitamin D', 191, 'vitamin D'), ('GO_0008152', 'metabolic process', 201, 'metabolism')]
S649-PMC5941617	PMC5941617	5/2018	S649-PMC5941617	['Skeletal actions of Vitamin D\n\nnutritional rickets\n\nchildren of immigrants living in industrialized countries are at INCREASED RISK of nutritional rickets BECAUSE they USUALLY present several risk FACTORS for vitamin d deficiency such as prolonged breastfeeding without Vitamin D supplementation, increased skin pigmentation, reduced sun exposure due to cultural habits (i.e.']	[('IMPORTANT_CONSIDERATION', 117), ('PROBABLE_UNDERSTANDING', 155), ('INCOMPLETE_EVIDENCE', 168), ('SUPERFICIAL_RELATIONSHIP', 197)]	4	[('UBERON_0004288', 'skeleton', 0, 'Skeletal'), ('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 270, 'vitamin D')]
S658-PMC5941617	PMC5941617	5/2018	S658-PMC5941617	['after rickets healing, we RECOMMEND to continue Vitamin D supplementation according to age (400–1000\xa0iu/day in the first year of Life and 600–1000\xa0iu/day from 1 to 18\xa0years).']	[('FUTURE_WORK', 26)]	1	[('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('UBERON_0000104', 'life cycle', 129, 'life')]
S660-PMC5941617	PMC5941617	5/2018	S660-PMC5941617	['AVAILABLE EVIDENCE SUGGESTS a positive EFFECT of Vitamin D supplementation on bone mass acquisition in children and adolescents with Vitamin D deficiency.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 19), ('SUPERFICIAL_RELATIONSHIP', 39)]	3	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 133, 'vitamin D')]
S665-PMC5941617	PMC5941617	5/2018	S665-PMC5941617	['NO DEFINITIVE EVIDENCE exists to RECOMMEND Vitamin D supplementation for PREVENTION of Respiratory infections (non-associated with wheezing) or recurrent Respiratory infections.']	[('INCOMPLETE_EVIDENCE', 0), ('FUTURE_WORK', 33), ('SUPERFICIAL_RELATIONSHIP', 73)]	3	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 87, 'respiratory'), ('UBERON_0001004', 'respiratory system', 154, 'respiratory')]
S668-PMC5941617	PMC5941617	5/2018	S668-PMC5941617	['a single rct SUGGESTED that Vitamin D supplementation MAY help in preventing non complicated acute otitis media.']	[('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 54)]	2	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D')]
S672-PMC5941617	PMC5941617	5/2018	S672-PMC5941617	['we SUGGEST the evaluation of Vitamin D status ONLY in patients affected by tuberculosis or hiv infection, AS they MAY BENEFIT from Vitamin D supplementation, in particular due to concomitant treatments that INFLUENCE Vitamin D Metabolism.']	[('FUTURE_WORK', 3), ('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 46), ('PROBABLE_UNDERSTANDING', 106), ('INCOMPLETE_EVIDENCE', 114), ('IMPORTANT_CONSIDERATION', 118), ('SUPERFICIAL_RELATIONSHIP', 207)]	7	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 217, 'vitamin D'), ('GO_0008152', 'metabolic process', 227, 'metabolism')]
S673-PMC5941617	PMC5941617	5/2018	S673-PMC5941617	['we RECOMMEND against Vitamin D supplementation to reduce incidence or severity of non-Respiratory infections in children.']	[('FUTURE_WORK', 3)]	1	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 86, 'respiratory')]
S674-PMC5941617	PMC5941617	5/2018	S674-PMC5941617	['HOWEVER, as FEW STUDIES SHOWED that Vitamin D supplementation improves clinical parameters in patients with active tuberculosis or hiv infection, MORE rigorous and extensive STUDIES ARE NEEDED to EVALUATE the ROLE of Vitamin D supplementation in infectious diseases, CONSIDERING also the setting of care, children’s age and nutritional status, POTENTIAL co-infections and compliance with Anti-infective therapy.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 24), ('ANOMALY_CURIOUS_FINDING', 146), ('FUTURE_WORK', 174), ('QUESTION_ANSWERED_BY_THIS_WORK', 196), ('SUPERFICIAL_RELATIONSHIP', 209), ('IMPORTANT_CONSIDERATION', 267), ('INCOMPLETE_EVIDENCE', 344)]	9	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 217, 'vitamin D'), ('CHEBI_59132', 'antigen', 388, 'anti')]
S678-PMC5941617	PMC5941617	5/2018	S678-PMC5941617	['recent meta-analyses SUGGEST that supplementation with Vitamin D (500–2000\xa0iu/day) MAY reduce the RISK of asthma exacerbation.']	[('INCOMPLETE_EVIDENCE', 21), ('INCOMPLETE_EVIDENCE', 83), ('IMPORTANT_CONSIDERATION', 98)]	3	[('CHEBI_27300', 'vitamin D', 55, 'vitamin D')]
S684-PMC5941617	PMC5941617	5/2018	S684-PMC5941617	['in pediatric population there is LIMITED EVIDENCE regarding a POSSIBLE favourable EFFECT of Vitamin D supplementation on several aspects of ad.']	[('INCOMPLETE_EVIDENCE', 33), ('INCOMPLETE_EVIDENCE', 62), ('SUPERFICIAL_RELATIONSHIP', 82)]	3	[('CHEBI_27300', 'vitamin D', 92, 'vitamin D')]
S685-PMC5941617	PMC5941617	5/2018	S685-PMC5941617	['a short trial of Vitamin D supplementation CAN be CONSIDERED in patients with SEVERE ad unresponsive to common therapy, especially in the late winter-early spring period.']	[('INCOMPLETE_EVIDENCE', 43), ('FUTURE_WORK', 50), ('IMPORTANT_CONSIDERATION', 78)]	3	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D')]
S686-PMC5941617	PMC5941617	5/2018	S686-PMC5941617	['in presence of documented Vitamin D deficiency, we RECOMMENDED adequate treatment to restore Vitamin D status, followed by supplementation at doses RECOMMENDED for age.']	[('FUTURE_WORK', 51), ('FUTURE_WORK', 148)]	2	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 93, 'vitamin D')]
S691-PMC5941617	PMC5941617	5/2018	S691-PMC5941617	['at PRESENT, there is NO EVIDENCE that Vitamin D supplementation MAY delay the development of t1dm or MAY ameliorate its clinical features.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('INCOMPLETE_EVIDENCE', 21), ('INCOMPLETE_EVIDENCE', 64), ('INCOMPLETE_EVIDENCE', 101)]	4	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D')]
S695-PMC5941617	PMC5941617	5/2018	S695-PMC5941617	['we RECOMMEND continuous Vitamin D supplementation at higher doses THAN those RECOMMENDED for age (AT LEAST 1000–1500\xa0iu/day).']	[('FUTURE_WORK', 3), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 66), ('FUTURE_WORK', 77), ('PROBABLE_UNDERSTANDING', 98)]	4	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D')]
S698-PMC5941617	PMC5941617	5/2018	S698-PMC5941617	['after achieving Vitamin D sufficiency, we RECOMMEND to continue with Vitamin D supplementation at higher doses than those RECOMMENDED for age (AT LEAST 1000–1500\xa0iu/day).']	[('FUTURE_WORK', 42), ('FUTURE_WORK', 122), ('PROBABLE_UNDERSTANDING', 143)]	3	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 69, 'vitamin D')]
S702-PMC5941617	PMC5941617	5/2018	S702-PMC5941617	['AS gluten-free diet restores normal Intestinal absorption, after treatment of deficiency we RECOMMEND Vitamin D supplementation according to the modalities and REQUIREMENTS for otherwise healthy children and adolescents.']	[('PROBABLE_UNDERSTANDING', 0), ('FUTURE_WORK', 92), ('IMPORTANT_CONSIDERATION', 160)]	3	[('UBERON_0000160', 'intestine', 36, 'intestinal'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin D')]
S707-PMC5941617	PMC5941617	5/2018	S707-PMC5941617	['we SUGGEST Vitamin D supplementation at higher doses THAN those RECOMMENDED for age (1000–1500\xa0iu/day) from the end of fall to the beginning of spring (november–april) in obese children and adolescents to ensure an adequate Vitamin D status.']	[('INCOMPLETE_EVIDENCE', 3), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 53), ('FUTURE_WORK', 64)]	3	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 224, 'vitamin D')]
S708-PMC5941617	PMC5941617	5/2018	S708-PMC5941617	['obese subjects with reduced sun exposure during summer SHOULD receive Vitamin D supplementation throughout the year.']	[('FUTURE_WORK', 55)]	1	[('CHEBI_27300', 'vitamin D', 70, 'vitamin D')]
S711-PMC5941617	PMC5941617	5/2018	S711-PMC5941617	['if an obese Individual does not receive Vitamin D supplementation and has a sedentary indoor lifestyle with consequent reduced sun exposure, Serum 25(Oh)D evaluation MAY BE CONSIDERED to confirm Vitamin D deficiency and start adequate treatment.']	[('INCOMPLETE_EVIDENCE', 166), ('ANOMALY_CURIOUS_FINDING', 170), ('FUTURE_WORK', 173), ('IMPORTANT_CONSIDERATION', 173)]	4	[('NCBITaxon_1', 'root', 12, 'individual'), ('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('UBERON_0001977', 'blood serum', 141, 'serum'), ('CHEBI_71657', 'versiconol acetate', 147, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 147, '25 ... OH ... D'), ('CHEBI_27300', 'vitamin D', 195, 'vitamin D')]
S720-PMC5941617	PMC5941617	5/2018	S720-PMC5941617	['we SUGGEST to CONSIDER serum 25(Oh)D testing in women with multiple RISK FACTORS for Vitamin D deficiency, PARTICULARLY if not receiving Vitamin D supplementation, and/or with specific conditions POSSIBLY AFFECTING Pregnancy course (table\xa09).']	[('INCOMPLETE_EVIDENCE', 3), ('FUTURE_WORK', 14), ('SUPERFICIAL_RELATIONSHIP', 68), ('ANOMALY_CURIOUS_FINDING', 107), ('IMPORTANT_CONSIDERATION', 107), ('INCOMPLETE_EVIDENCE', 196), ('SUPERFICIAL_RELATIONSHIP', 205)]	7	[('CHEBI_71657', 'versiconol acetate', 29, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 35, 'D'), ('CHEBI_27300', 'vitamin D', 85, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 137, 'vitamin D'), ('GO_0007565', 'female pregnancy', 215, 'pregnancy')]
S721-PMC5941617	PMC5941617	5/2018	S721-PMC5941617	['we RECOMMEND Vitamin D supplementation in all Pregnant and breastfeeding women at a dose of 600\xa0iu/day.']	[('FUTURE_WORK', 3)]	1	[('CHEBI_27300', 'vitamin D', 13, 'vitamin D'), ('GO_0007565', 'female pregnancy', 46, 'pregnant')]
S727-PMC5941617	PMC5941617	5/2018	S727-PMC5941617	['in presence of adequate Vitamin D status [25(Oh)D\u2009≥\u200930\xa0ng/ml], we RECOMMEND to continue Vitamin D supplementation as RECOMMENDED for age.']	[('FUTURE_WORK', 66), ('FUTURE_WORK', 117)]	2	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 42, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 42, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 88, 'vitamin D')]
S730-PMC5941617	PMC5941617	5/2018	S730-PMC5941617	['in case of detection of asymptomatic Vitamin D insufficiency [25(Oh)D between 20 and 29\xa0ng/ml], particularly in subjects AT RISK for vitamin d deficiency, we RECOMMENDED to start Vitamin D supplementation according to the modalities and REQUIREMENTS RECOMMENDED for age.']	[('IMPORTANT_CONSIDERATION', 121), ('FUTURE_WORK', 158), ('IMPORTANT_CONSIDERATION', 237), ('FUTURE_WORK', 250)]	4	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 62, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 179, 'vitamin D')]
S146-PMC5952272	PMC5952272	5/2018	S146-PMC5952272	['it is IMPORTANT TO MENTION in this context that the PREVALENCE of autism in somali children Born in sweden was FOUND TO BE 3 to 4 times higher than in the non-somali group (0.7% vs 0.19%).39as somalis have high levels of Melanin, during migration to northern latitudes, such as sweden, they would REQUIRE 5 to 10 times more uv-b exposure than light-skinned Individuals OR an ALTERNATIVE Vitamin D source, such as from the diet or supplementation.40moreover, saad et al41reported that 57% Vitamin D deficient and 30% insufficient patients who received Vitamin D3 (300\u2009iu/kg/day not to exceed 5000\u2009iu/day) for 3\u2009months SHOWED significant improved outcomes (80.72 %), which were MAINLY in the sections of the childhood autism rating scale (cars) and aberrant behaviour checklist subscales that measure behaviour, stereotypy, Eye contact, and attention span.']	[('IMPORTANT_CONSIDERATION', 6), ('IMPORTANT_CONSIDERATION', 52), ('ANOMALY_CURIOUS_FINDING', 111), ('FUTURE_WORK', 297), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 369), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 375), ('INCOMPLETE_EVIDENCE', 617), ('PROBABLE_UNDERSTANDING', 676)]	8	[('GO_0007567', 'parturition', 92, 'born'), ('CHEBI_25179', 'melanins', 221, 'melanin'), ('NCBITaxon_1', 'root', 357, 'individuals'), ('CHEBI_27300', 'vitamin D', 387, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 488, 'vitamin D'), ('CHEBI_33279', 'vitamin D5', 551, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 551, 'vitamin D3'), ('UBERON_0000970', 'eye', 822, 'eye')]
S147-PMC5952272	PMC5952272	5/2018	S147-PMC5952272	['experiment on Animal models SHOWED that 1,25 Dihydroxyvitamin D3 Prenatal supplementations were PROTECTIVE for offsprings against induced Maternal Immune Activation (mia).42maternal Immune Activation in experimental Animals Reproduces asd-like symptoms via significant increase of proinflammatory cytokines; however, administration of Vitamin D has blocked the emergence of asd-relevant deficits in social INTERACTION, stereotyped behaviour, and emotional Learning and Memory.42RECENTLY, sotodehasl et al43have reviewed 80 articles LINKING autism and Vitamin D. the authors found no significant DIFFERENCES between children with asd and neurotypical developed children.43this was also SUPPORTED by a canadian prospective cohort study that included 3852 children.44forty-one children were diagnosed with asd, who have no difference in the level of Vitamin D in their Serum compared with non-asd children.']	[('INCOMPLETE_EVIDENCE', 28), ('SUPERFICIAL_RELATIONSHIP', 96), ('SUPERFICIAL_RELATIONSHIP', 406), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 476), ('SUPERFICIAL_RELATIONSHIP', 532), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 595), ('INCOMPLETE_EVIDENCE', 685)]	7	[('NCBITaxon_33208', 'Metazoa', 14, 'animal'), ('CHEBI_63912', '19-hydroxyprostaglandin H2', 40, '1,25 dihydroxyvitamin D3'), ('PR_000001177', 'D(2) dopamine receptor', 62, 'D3'), ('GO_0007565', 'female pregnancy', 65, 'prenatal'), ('GO_0007618', 'mating', 138, 'maternal'), ('GO_0060819', 'inactivation of X chromosome by genetic imprinting', 147, 'immune activation'), ('UBERON_0002405', 'immune system', 147, 'immune'), ('GO_0060819', 'inactivation of X chromosome by genetic imprinting', 182, 'immune activation'), ('UBERON_0002405', 'immune system', 182, 'immune'), ('NCBITaxon_33208', 'Metazoa', 216, 'animals'), ('GO_0000003', 'reproduction', 224, 'reproduces'), ('CHEBI_27300', 'vitamin D', 335, 'vitamin D'), ('GO_0007612', 'learning', 456, 'learning'), ('GO_0007613', 'memory', 469, 'memory'), ('CHEBI_27300', 'vitamin D', 551, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 847, 'vitamin D'), ('UBERON_0001977', 'blood serum', 866, 'serum')]
S81-PMC5956785	PMC5956785	5/2018	S81-PMC5956785	['2008 37°n [54]children with arthritis n \u2009=\u2009183–1582.1\u2009±\u200938.7supplemental Vitamin D improved status, BUT supplemental Vitamin D or calcium did not improve bone mass.kansas, usa warady et al.']	[('ANOMALY_CURIOUS_FINDING', 100)]	1	[('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin D')]
S83-PMC5956785	PMC5956785	5/2018	S83-PMC5956785	['(10.9–18.0)70.1\u2009±\u200921.2children with rheumatic disease would BENEFIT from receiving Calcium and Vitamin D supplements.illinois, usa reed et al.']	[('IMPORTANT_CONSIDERATION', 60)]	1	[('CHEBI_22313', 'alkaline earth metal atom', 83, 'calcium'), ('CHEBI_27300', 'vitamin D', 95, 'vitamin D')]
S189-PMC5956785	PMC5956785	5/2018	S189-PMC5956785	['the authors QUESTIONED WHETHER jia patients with more SEVERE disease REQUIRE higher supplementation of Vitamin D to maintain normal 25(Oh) D concentrations.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 12), ('INCOMPLETE_EVIDENCE', 12), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 23), ('IMPORTANT_CONSIDERATION', 54), ('IMPORTANT_CONSIDERATION', 69)]	5	[('CHEBI_27300', 'vitamin D', 103, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 132, '25(OH) D')]
S199-PMC5956785	PMC5956785	5/2018	S199-PMC5956785	['two studies REPORTED Intake of Vitamin D supplements by study participants but neither had a mean 25(Oh)D that reached the OPTIMAL concentration [38,44].']	[('INCOMPLETE_EVIDENCE', 12), ('IMPORTANT_CONSIDERATION', 123)]	2	[('GO_0007631', 'feeding behavior', 21, 'intake'), ('CHEBI_27300', 'vitamin D', 31, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 98, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 104, 'D')]
S208-PMC5956785	PMC5956785	5/2018	S208-PMC5956785	['ADDITIONAL STUDIES investigating Vitamin D intake from all sources (both Food and supplements) are REQUIRED to determine IF children with chronic arthritis REQUIRE additional Vitamin D to maintain Serum concentrations in comparison to healthy children.']	[('FUTURE_WORK', 0), ('IMPORTANT_CONSIDERATION', 99), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 121), ('IMPORTANT_CONSIDERATION', 156)]	4	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('CHEBI_33290', 'food', 73, 'food'), ('CHEBI_27300', 'vitamin D', 175, 'vitamin D'), ('UBERON_0001977', 'blood serum', 197, 'serum')]
S28-PMC5995352	PMC5995352	6/2018	S28-PMC5995352	['this leaves the infant more SUSCEPTIBLE to developing Vitamin D deficiency rickets if not receiving adequate Vitamin D supplementation, AS the lower inborn Vitamin D stores will decrease to severely insufficient levels sooner IN ACCORDANCE WITH the half-life of 25Ohd.']	[('SUPERFICIAL_RELATIONSHIP', 28), ('PROBABLE_UNDERSTANDING', 136), ('INCOMPLETE_EVIDENCE', 226)]	3	"[('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 109, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 156, 'vitamin D'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 262, '25OHD')]"
S31-PMC5995352	PMC5995352	6/2018	S31-PMC5995352	['low foetal Vitamin D stores MAY THEREFORE further decrease to CRITICAL levels soon after Birth, in the absence of infant Vitamin D supplementation.']	[('INCOMPLETE_EVIDENCE', 28), ('PROBABLE_UNDERSTANDING', 32), ('IMPORTANT_CONSIDERATION', 62)]	3	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('GO_0007567', 'parturition', 89, 'birth'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin D')]
S38-PMC5995352	PMC5995352	6/2018	S38-PMC5995352	['IF low maternal or Cord 25Ohd is LINKED to diminished infant growth, especially of the Long Bones, DESPITE Vitamin D supplementation RECOMMENDATIONS, an IMPORTANT POTENTIAL for enforced PREVENTION STRATEGIES is SUGGESTED, EVEN in populations with low incidence of Vitamin D deficiency rickets.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('SUPERFICIAL_RELATIONSHIP', 33), ('ANOMALY_CURIOUS_FINDING', 99), ('FUTURE_WORK', 133), ('IMPORTANT_CONSIDERATION', 153), ('INCOMPLETE_EVIDENCE', 163), ('SUPERFICIAL_RELATIONSHIP', 186), ('FUTURE_WORK', 197), ('INCOMPLETE_EVIDENCE', 211), ('ANOMALY_CURIOUS_FINDING', 222)]	10	"[('UBERON_0002240', 'spinal cord', 19, 'cord'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 24, '25OHD'), ('UBERON_0002495', 'long bone', 87, 'long bones'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 264, 'vitamin D')]"
S64-PMC5995352	PMC5995352	6/2018	S64-PMC5995352	['dietary Intake of Calcium and Vitamin D intake were ESTIMATED by multiplying the frequency of self-reported Consumed Food with standard portion sizes [29] and information obtained from danish Food composition tables [30] the Intake of supplementary Vitamin D was calculated based on self-reported data on type and frequency of Supplements, and a database of all registered Supplements in denmark provided by the danish veterinary and Food administration [31].']	[('INCOMPLETE_EVIDENCE', 52), ('IMPORTANT_CONSIDERATION', 98)]	2	[('GO_0007631', 'feeding behavior', 8, 'intake'), ('CHEBI_22313', 'alkaline earth metal atom', 18, 'calcium'), ('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0007631', 'feeding behavior', 108, 'consumed'), ('CHEBI_33290', 'food', 117, 'food'), ('CHEBI_33290', 'food', 192, 'food'), ('GO_0007631', 'feeding behavior', 225, 'intake'), ('CHEBI_27300', 'vitamin D', 249, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 327, 'supplements'), ('CHEBI_33341', 'titanium atom', 373, 'supplements'), ('CHEBI_33290', 'food', 434, 'Food')]
S92-PMC5995352	PMC5995352	6/2018	S92-PMC5995352	['compared to children in the highest Cord 25Ohd quartile, children in the lowest quartile were more often Born during winter and spring and more LIKELY had mothers of non-western ethnicity, mothers with pre-Gestational bmi above 25 kg/m2, mothers with parity above three children, mothers who took less than the recommended Vitamin D supplement of 10 μg/day, or mothers who Smoked during Pregnancy,table 1.10.1371/journal.pone.0198724.t001\n\ncaption (table-wrap): table 1\nbasic characteristics of the 2010 participants.nquartiles of Cord 25Ohd, nmol/lp-value*< 30.730.8–45.145.2–60.6> 60.7 maternal characteristics maternal height, cm2010168.3 ± 6.51168.0 ± 6.6168.2 ± 6.1168.5 ± 6.10.7maternal pre-Gestational weight, kg201069 [60–80]266 [60–74]66 [59–75]65 [59–73]<0.001 Pregestational bmi, kg/m2201024.3 [21.8–28.1]23.3 [21.4–26.0]23.5 [21.1–26.2]22.8 [21.0–25.6]<0.001 Gestational weight gain, kg87315.1 ± 6.315.0 ± 5.615.5 ± 5.614.5 ± 5.20.4maternal age, y201029.8 ± 4.630.4 ± 4.330.3 ± 4.330.0 ± 4.60.1smoking in Pregnancy, n (%) <0.001 \u2003smoker9843 (8.6)18 (3.6)19 (3.8)18 (3.6)\u2003non-smoker1912460 (91.4)484 (96.4)484 (96.2)484 (96.4)maternal educational level, n (%)0.2\u2003lower25274 (19.5)64 (16.3)54 (13.7)60 (17.7)\u2003intermediate908218 (57.5)230 (58.7)245 (62.2)215 (63.2)\u2003higher34587 (23.0)98 (25.0)95 (24.1)65 (19.1)ethnicity, n (%) <0.001 \u2003western1918459 (93.2)482 (95.8)486 (98.6)491 (97.1)\u2003non-western9244 (6.8)20 (4.2)17 (1.4)11 (2.9)skin-type**, n (%)0.2\u2003i/ii white29986 (22.6)84 (21.3)66 (16.7)63 (18.4)\u2003iii darker white889207 (54.3)239 (60.5)249 (62.8)194 (56.7)\u2003iv brown30982 (21.5)67 (16.9)78 (19.7)82 (23.9)\u2003v/vi dark brown176 (1.6)5 (1.3)3 (0.6)3 (1.0)parity, n (%) <0.001 \u2003first child1109230 (45.7)282 (56.2)295 (58.7)302 (60.2)\u2003second child679204 (40.6)164 (32.7)156 (31.0)155 (30.9)\u2003third child or more22269 (13.7)56 (11.1)52 (10.3)45 (8.9)time spent outdoors, mother, n (%) 0.002 \u2003never/rarely3111 (2.9)7 (1.8)7 (1.8)6 (1.8)\u2003sometimes29595 (24.9)84 (21.2)62 (15.7)54 (15.8)\u2003often920204 (54.4)252 (63.6)256 (64.7)208 (60.8)\u2003most of the time27072 (18.8)53 (13.4)71 (17.8)74 (21.6)Vitamin D supplementation in Pregnancy, mother, n (%) <0.001 \u2003≤10 μg/day15764 (23.4)33 (10.7)36 (11.4)24 (8.5)\u2003>10 μg/day1023210 (76.6)275 (89.3)281 (88.6)257 (91.5) paternal characteristics paternal height, cm1223182.6 ± 6.7182.5 ± 7.0183.2± 6.6182.3± 6.70.3 child characteristics Gestational age (ga) at Birth, w201040 [39–41]40 [39–41]40 [39–41]40 [39–41]0.6season of Birth n (%) <0.001 \u2003winter (dec-feb)489190 (37.7)143 (28.5)107 (21.3)49 (9.8)\u2003spring (mar-may)496158 (31.4)144 (28.7)106 (21.1)88 (17.5)\u2003summer (jun-aug)47729 (5.8)78 (15.5)135 (26.8)235 (46.8)\u2003autumn (sep-nov)548126 (25.1)137 (27.3)155 (30.8)130 (25.9)child sex, n (%)0.6\u2003girls948241 (47.9)228 (45.4)247 (49.1)232 (46.2)\u2003boys1062262 (52.1)274 (54.6)256 (50.9)270 (53.8)child age at 18 months examination, m135018.7 [18.3–19.4]18.8 [18.2–19.4]18.0 [18.4–19.6]19.0 [18.4–19.5]0.03 duration of exclusive breastfeeding, w123018 [6–34]19 [11–24]20 [10–24]20 [12–24]0.06intake of infant formula after 8 weeks of age0.06\u2003yes9219 (6.5)21 (6.2)34 (10.3)18 (5.2)\u2003no1219275 (93.5)319 (93.8)297 (89.7)328 (94.8)dietary intake of Calcium, mg/day1243489 [213–756]495 [230–751]495 [224–757]489 [211–747]0.06dietary intake of Vitamin D, μg/day11851.14 ± 1.011.18 ± 1.661.04 ± 0.900.98 ± 1.00.2vitamin D supplementation, μg/day9433.47 ± 2.213.98 ± 1.363.88 ± 1.454.03 ± 1.59 0.002\nanova was used for comparing means of numerical, normally distributed variables.']	[('PROBABLE_UNDERSTANDING', 144)]	1	"[('UBERON_0002240', 'spinal cord', 36, 'cord'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 41, '25OHD'), ('GO_0007567', 'parturition', 105, 'born'), ('GO_0007565', 'female pregnancy', 206, 'gestational'), ('CHEBI_27300', 'vitamin D', 323, 'vitamin D'), ('GO_0007601', 'visual perception', 373, 'smoked'), ('GO_0007565', 'female pregnancy', 387, 'pregnancy'), ('UBERON_0002240', 'spinal cord', 531, 'cord'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 536, '25OHD'), ('GO_0007565', 'female pregnancy', 697, 'gestational'), ('GO_0007565', 'female pregnancy', 771, 'Pregestational'), ('GO_0007565', 'female pregnancy', 871, 'Gestational'), ('GO_0007565', 'female pregnancy', 1017, 'pregnancy'), ('CHEBI_28384', 'vitamin K', 2097, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 2126, 'pregnancy'), ('GO_0007565', 'female pregnancy', 2379, 'Gestational'), ('GO_0007567', 'parturition', 2403, 'birth'), ('GO_0007567', 'parturition', 2468, 'birth'), ('CHEBI_22313', 'alkaline earth metal atom', 3186, 'calcium'), ('CHEBI_27300', 'vitamin D', 3279, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 3354, 'D')]"
S145-PMC5995352	PMC5995352	6/2018	S145-PMC5995352	['covariates\nCord 25Ohd was RELATED with season of Birth, maternal ethnicity, pre-Gestational bmi, parity, maternal Vitamin D supplementation and smoking in Pregnancy, which is CONSISTENT with the literature [33–35].']	[('SUPERFICIAL_RELATIONSHIP', 26), ('INCOMPLETE_EVIDENCE', 175)]	2	"[('UBERON_0000948', 'heart', 11, 'Cord'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 16, '25OHD'), ('GO_0007567', 'parturition', 49, 'birth'), ('GO_0007565', 'female pregnancy', 80, 'gestational'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('GO_0007565', 'female pregnancy', 155, 'pregnancy')]"
S148-PMC5995352	PMC5995352	6/2018	S148-PMC5995352	['IN KEEPING WITH our results, longitudinal growth trajectories at age seven months were SIMILAR in Breast vs. formula Fed infants in an american cohort studying maternal Vitamin D supplementation during Lactation [37].']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 87)]	2	[('UBERON_0000310', 'breast', 98, 'breast'), ('GO_0007631', 'feeding behavior', 117, 'fed'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin D'), ('GO_0007595', 'lactation', 202, 'lactation')]
S113-PMC6011374	PMC6011374	6/2018	S113-PMC6011374	['high dose (>\u20092000\xa0iu) Vitamin D supplementation is ASSOCIATED with decreasing risk of Pregnancy complications [23–25].']	[('SUPERFICIAL_RELATIONSHIP', 51)]	1	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('GO_0007565', 'female pregnancy', 86, 'pregnancy')]
S115-PMC6011374	PMC6011374	6/2018	S115-PMC6011374	['furthermore, multivitamin supplements available during the study period contained very little (maximum 50\xa0iu), if any, Vitamin D and THUS are\xa0an UNLIKELY source of variation within the population.']	[('PROBABLE_UNDERSTANDING', 133), ('PROBABLE_UNDERSTANDING', 145)]	2	[('CHEBI_27300', 'vitamin D', 119, 'vitamin D')]
S260-PMC6039335	PMC6039335	7/2018	S260-PMC6039335	['the appropriate age for, and duration of, Vitamin A deple tion or supplementation have been SUGGESTED as IMPORTANT factors that AFFECT ms. oka et al [134] reported that restricting Vitamin A in 15-month-old cattle until the final finishing phase (29 months of age) increased ms, but not in 23-month-old cattle prior to finishing.']	[('INCOMPLETE_EVIDENCE', 92), ('IMPORTANT_CONSIDERATION', 105), ('SUPERFICIAL_RELATIONSHIP', 128)]	3	[('CHEBI_27300', 'vitamin D', 42, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 181, 'vitamin A')]
S272-PMC6039335	PMC6039335	7/2018	S272-PMC6039335	['a significant INTERACTION was detected between adh1c c.-64t>c genotype and Vitamin A supplementation for imf content in the lm.']	[('SUPERFICIAL_RELATIONSHIP', 14)]	1	[('CHEBI_27300', 'vitamin D', 75, 'vitamin A')]
S291-PMC6039335	PMC6039335	7/2018	S291-PMC6039335	['a Rumen-protected form of Vitamin C is PREFERRED as a dietary supplement because Vitamin C is MOST LIKELY degraded in the Rumen [146].']	[('PROBABLE_UNDERSTANDING', 39), ('PROBABLE_UNDERSTANDING', 94)]	2	[('UBERON_0007365', 'rumen', 2, 'rumen'), ('CHEBI_27300', 'vitamin D', 26, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 81, 'vitamin C'), ('UBERON_0007365', 'rumen', 122, 'rumen')]
S8-PMC6043562	PMC6043562	7/2018	S8-PMC6043562	['we IDENTIFIED a POTENTIAL synergistic INTERACTION (p\u2009=\u20090.02) between Vitamin E (Food\u2009+\u2009supplements) and Pm2.5; this exposure combination was ASSOCIATED with further increases in Feno levels.']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 16), ('SUPERFICIAL_RELATIONSHIP', 38), ('SUPERFICIAL_RELATIONSHIP', 141)]	4	[('CHEBI_27300', 'vitamin D', 69, 'vitamin E'), ('CHEBI_33290', 'food', 80, 'food'), ('CHEBI_8102', 'phenylmethanesulfonyl fluoride', 104, 'PM2'), ('CHEBI_32035', 'potassium hydroxide', 178, 'FeNO')]
S104-PMC5273824	PMC5273824	1/2017	S104-PMC5273824	['HOWEVER, ONLY four out of nineteen participants with supplement use who was also positive for Vitamin D2 received Vitamin D2-containing supplements.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 9)]	2	[('CHEBI_28934', 'vitamin D2', 94, 'Vitamin D2'), ('PR_000017279', 'testis-specific basic protein Y 1', 94, 'Vitamin D2'), ('CHEBI_28934', 'vitamin D2', 114, 'Vitamin D2'), ('PR_000017279', 'testis-specific basic protein Y 1', 114, 'Vitamin D2')]
S106-PMC5273824	PMC5273824	1/2017	S106-PMC5273824	['THEREFORE, Consumption of Vitamin D2-containing supplements is ASSOCIATED with higher Vitamin D2 DETECTION rate among Pregnant women.']	[('PROBABLE_UNDERSTANDING', 0), ('SUPERFICIAL_RELATIONSHIP', 63), ('INCOMPLETE_EVIDENCE', 97)]	3	[('GO_0007631', 'feeding behavior', 11, 'consumption'), ('CHEBI_28934', 'vitamin D2', 26, 'Vitamin D2'), ('PR_000017279', 'testis-specific basic protein Y 1', 26, 'Vitamin D2'), ('CHEBI_28934', 'vitamin D2', 86, 'Vitamin D2'), ('PR_000017279', 'testis-specific basic protein Y 1', 86, 'Vitamin D2'), ('GO_0007565', 'female pregnancy', 118, 'pregnant')]
S117-PMC5273824	PMC5273824	1/2017	S117-PMC5273824	['this group OFTEN uses dietary supplements containing Vitamin D. they also have a Vitamin D2 DETECTION rate of 19.4%, which CAN be EXPLAINED by Consuming edible Fungi or supplements containing Vitamin D2.']	[('PROBABLE_UNDERSTANDING', 11), ('INCOMPLETE_EVIDENCE', 92), ('INCOMPLETE_EVIDENCE', 123), ('PROBABLE_UNDERSTANDING', 130)]	4	[('CHEBI_28384', 'vitamin K', 53, 'Vitamin D'), ('CHEBI_28934', 'vitamin D2', 81, 'Vitamin D2'), ('PR_000017279', 'testis-specific basic protein Y 1', 81, 'Vitamin D2'), ('GO_0007631', 'feeding behavior', 143, 'consuming'), ('NCBITaxon_10088', 'Mus <genus>', 160, 'fungi'), ('CHEBI_28934', 'vitamin D2', 192, 'Vitamin D2'), ('PR_000017279', 'testis-specific basic protein Y 1', 192, 'Vitamin D2')]
